https://scielo.conicyt.cl/scielo.php?script=sci_arttext&pid=S0716-10182001000100002
Propiedades microbiológicas, clasificación y relación estructura-actividad de cefalosporinas e importancia de las cefalosporinas de cuarta generación

CONSIDERACIONES GENERALES 

Las cefalosporinas son agentes antibacterianos que pertenecen    al grupo de los ß-lactámicos, es decir, poseen un anillo ß-lactámico    fusionado con un anillo dihidrotiazínico constituyendo el núcleo    cefem del que derivan todas las cefalosporinas, a diferencia de las penicilinas    que también poseen el anillo ß-lactámico pero fusionado    a un anillo tiazolidínico de 5 miembros1-5.    Sobre la base de esta comparación, se puede entender que el núcleo    cefem presente ventajas con relación al núcleo penam. En    primer lugar, el núcleo de las cefalosporinas es intrínsecamente    resistente a muchas penicilinasas; así, bacterias que producen estas    enzimas permanecen susceptibles a las cefalosporinas; esta propiedad explica    el amplio espectro de actividad de las cefalosporinas, particularmente sobre    Staphylococcus spp. oxacilina-susceptibles3.    En segundo lugar, en el núcleo cefem son constantes la presencia de un    grupo carboxílico en C4 y una cadena lateral ß-acilamínica    en C7 (-R1); sin embargo, este núcleo también    permite la adición de distintos sustituyentes en C3 (-R2),    a diferencia del núcleo penam donde la mayor parte de las variaciones    químicas puede sólo realizarse en C6 (-R1)1-8    (Figuras 1 y 2). 

  

       Figura 1. Núcleo cefem (núcleo básico          de las cefalos-porinas).            

Figura 2. Núcleo penam (núcleo            básico de las penicilinas).      En términos microbiológicos, estos compuestos    se caracterizan por su actividad bactericida dependiente del tiempo (su máximo    efecto bactericida se logra cuando en una proporción importante del intervalo    interdosis la concentración plasmática del antibacteriano se encuentra    sobre la CIM), del inoculo bacteriano y de la fase de crecimiento bacteriana7,9-13;    amplio espectro de actividad que incluye bacterias Gram positivas, Gram negativas    y anaerobios (cefoxitina, cefotetan)3,6,14,15.    Debe enfatizarse que como característica de clase las cefalosporinas    no tienen actividad sobre Enterococcus spp., Staphylococcus spp.    resistente a meticilina, Corynebacterium jeikeium, Stenotrophomonas    maltophilia, Listeria monocytogenes, Legionella spp.,    Chlamydia spp. y Mycoplasma spp.3,6,7,14,15.    Por otra parte, dada la potente actividad bactericida, favorables parámetros    farmacocinéticos, adecuada penetración a diferentes parénquimas    alcanzando allí niveles bactericidas, baja toxicidad y sinergia con otros    antibacterianos, las cefalosporinas son utilizadas como agentes de primera elección    en el tratamiento de una serie de infecciones comunitarias y nosocomiales14,16-24.   Sin embargo, el uso creciente de esta clase de antibióticos    se ha asociado en forma progresiva al aislamiento de bacterias resistentes,    adquiriendo cada vez mayor importancia bacilos Gram negativos multiresistentes    hiperproductores de ß-lactamasas cromosomales (ß-lactamasas Amp    C), destacando en este grupo Serratia, Pseudomonas, Acinetobacter, Citrobacter,    Enterobacter, Morganella, Providencia y cepas de Proteus indol negativo25-27    o ß-lactamasas de espectro extendido (extended spectrum ß lactamases    ESBLs) de origen plasmidial, particularmente en cepas de Klebsiella pneumoniae    y Escherichia coli28-30.    En este contexto, el resultado final es la selección de cepas de bacilos    Gram negativos capaces de degradar cefalosporinas de tercera generación    (ya sea por ß-lactamasas cromo-somales y/o plasmidiales) lo que sumado    a la capacidad de albergar otros genes de resistencia y/o alteraciones en la    permeabilidad, explica la diseminación de bacterias Gram negativas multiresistentes    a varias familias de antimi-crobianos que incluye, entre otros, cefalosporinas    de tercera generación, aminoglucósidos, quinolonas e incluso carbapenémicos31-35.    Es en este marco donde se desarrollan las denominadas cefalosporinas de cuarta    generación, caracterizadas fundamentalmente por mantener un amplio espectro    de actividad que abarca desde Streptococcus pneumoniae, incluyendo cepas    resistentes a penicilina, hasta bacilos Gram negativos multiresistentes capaces    de degradar cefalosporinas de tercera generación25,36,37.   Estructura y función  El grupo activo básico de las cefalosporinas deriva    de la remoción de la cadena lateral de la cefalosporina C, producida    naturalmente por Acremonium chrysogenum (antes Cephalos-porium acremonium),    lo que da origen al anillo 7-amino-cefalosporánico (Figura    1)1-6.  A su vez, al grupo 7-amino-cefalosporánico se le han    incorporado por semisíntesis diversos grupos químicos especialmente    en los carbonos 3 y 7 (radicales R2 y R1, respectivamente).    En términos generales las sustituciones al nivel de R1 habitualmente    producen moléculas con mayor afinidad por PBPs, particularmente de bacilos    Gram negativos, y estabilidad frente ß-lactamasas, lo que clínicamente    permite obtener compuestos con mayor espectro de actividad y potencia; así,    el grupo 2-aminotiazolil en el carbono 7 (R1) presente históricamente    en moléculas como el cefotiam, permitió el desarrollo de moléculas    con elevada afinidad sobre PBPs de bacterias Gram negativas, particularmente    por PBPs 1A y PBP 34-6,8,38,    pero dada su inestabilidad frente a ß-lactamasas, la industria farmacéutica    fue capaz de desarrollar nuevas moléculas que manteniendo la capacidad    de unión a PBPs fueran resistentes a la degradación enzimática.    Así, la introducción del radical metoxi-imino sobre el carbono    a originó las metoxi-iminocefalosporinas, las que en términos    microbiológicos se caracterizan por su estabilidad frente a ß-lactamasas4-6,8.    Debe destacarse que uno de los grupos de moléculas de mayor uso, las    cefalosporinas de tercera generación, incorporaron simultáneamente    el grupo aminotiazolil y el radical metoxi-imino, lo que explica la elevada    actividad de estos compuestos sobre Enterobacteriaceae4-6,8,23.   Por otra parte, en términos generales, las sustituciones    en R2 producen cambios en las propiedades farmacocinéticas    de estas moléculas4-6,8,23,39.    Por ejemplo, el radical acetiloximetil, presente en cefalosporina C, también    se encuentra en cefalotina y cefotaxima; exhiben estos agentes una vida media    muy corta, dado que son rápidamente metabolizados en el organismo por    esterasas plasmáticas y hepáticas, dando origen a compuestos desacetilados    que, en general, son menos activos como anti infecciosos que la molécula    original8,40-42.    Además, la presencia de sustituyentes pequeños y exentos de carga    en R2 es una característica general de las cefalosporinas    de primera generación de uso oral; así cefalexina, cefradina y    cefadroxilo, presentan como característica un grupo metilo a este nivel,    interesantemente cefaclor presenta un cloro en R24-6,16,41.    Por otra parte, y también desde una perspectiva general, las cefalosporinas    de uso parenteral tienden a presentar vidas medias más prolongadas en    relación a la presencia de radicales acídicos y de mayor tamaño    en R2, como en ceftriaxona que presenta un anillo heterocíclico    de carácter ácido (1,2,5,6 - tetrahidro- 2-metil - 5,6-dioxo-    1,2,4 - triazin -3-il) que permite explicar niveles plasmáticos más    elevados y tiempo de vida media más prolongado que el resto de las aminotiazolil    metoxi-imino cefalospori-nas39,41,43.    Otro ejemplo al respecto es la comparación entre cefazolina (cefalosporina    con un anillo heterocíclico en R2) y cefalotina (acetiloximetilo    cefalosporina), presentando las primeras concentraciones plasmáticas    más elevadas y vida media más prolongada que la segunda5,8,41.    Otro grupo de importancia en este sustituyente es el radical N-metiltetrazol,    presente en: moxalactam, cefamandol, cefoperazona cefmenoxima, cefpiramida,    cefmetazol, cefotetan y cefbuperazona, que explica la presencia de efectos adversos    con el uso de estas moléculas, principalmente de tipo hematológico    con prolongación del tiempo de protrombina y efecto "de tipo disulfiram",    por alteración en la síntesis de vitamina K en el intestino e    inhibición del metabolismo del alcohol, respectivamente3,5-7,23.    Finalmente, otro grupo interesante a este nivel es el radical 3'mercaptotiazida,    presente en cefodizima, cefalosporina con favorables parámetros farmacocinéticos    y una peculiar actividad inmunomoduladora 44.  También, desde una perspectiva histórica, un    grupo muy interesante de moléculas en que se utilizaron sustituyentes    catecólicos en R1 y en menor medida en R2, fueron    las denominadas cefalosporinas catecólicas, que presentaban una favorable    penetración intracelular en bacilos Gram negativos, ya que eran activamente    transportadas a través de proteínas de membrana externa reguladas    por fierro (IROMPs)45-47.  Desde esta misma perspectiva, en el intento de lograr moléculas    con propiedades microbio-lógicas y/o farmacocinéticas superiores,    se sintetizaron compuestos experimentales cuya estructura química correspondía    a la asociación de una cefalosporina con una quinolona, las así    denominadas moléculas duales, destacando en este grupo Ro 24-6392, molécula    cuya estructura química derivaba de la asociación entre desacetilcefotaxima    y una sustitución 3' con ciprofloxacina y que exhibía una actividad    antimicrobiana comparable a la de ciprofloxacina sobre bacterias Gram negativas    y a la de cefotaxima sobre bacterias Gram positivas47.   En términos generales, la, adición de nuevos    sustituyentes permite:  • Ampliar el espectro de actividad  • Mejorar las características farmacocinéticas    • Ampliar la actividad a bacterias de difícil    tratamiento como Pseudomonas spp, Citrobacter spp, Serratia    spp, Enterobacter spp, etc.  • Aumentar la estabilidad frente a la hidrólisis    de ß-lactamasas   • Describir nuevas propiedades biológicas como    la inmunomodulación  Mecanismo de acción  Las cefalosporinas, al igual que el resto de los antibióticos    ß-lactámicos, ejercen su actividad antibacteriana inhibiendo la    síntesis del peptidoglicano, produciendo finalmente lisis bacteriana3,7,9,23.    El mecanismo de acción deriva de la unión covalente del ß-lactámico    al sitio activo de las enzimas denominadas PBPs. Esta reacción se explica    porque los ß-lactámicos poseen una estructura química similar    a los dos últimos aminoácidos del pentapéptido (D-alanina-D-alanina)    que une las moléculas de peptidoglicano. Por otra parte, las PBPs ejercen    actividad bioquímica de transglicosilasas (complejo PBP1), transpeptidasas    (PBP3) y carboxipeptidasas (PBP4, 5 y 6); además, este grupo de antimicrobianos    produce una activación de autolisinas bacterianas que destruyen el peptidoglicano5,49-51.    La activación de la actividad autolítica de la bacteria ha ido    adquiriendo mayor relevancia por la relación que se establecería    entre el desarrollo de tolerancia y la ausencia de activación de esta    vía51. Clásicamente se ha descrito    que con la unión de la cefalosporina a la PBP se bloquea la actividad    de transglicosilasa o transpeptidasa interrumpiéndose el ensamblaje de    las moléculas precursoras del peptidoglicano (N-acetilmurámico    + péptido y N-acetilglucosamina en bacilos Gram negativos o incluyendo    un pentapéptido de glicina en S. aureus), de esta manera se interrumpe    la síntesis de esta cubierta. Esto sumado a la activación autolítica    llevaría finalmente a la lisis osmótica y por tanto a la muerte    de la bacteria6,7,49,51.   En las bacterias Gram negativas las PBPs se disponen hacia    el espacio periplásmico por la presencia de la membrana externa (que    constituye una barrera al paso de una importante cantidad de moléculas);    a diferencia de las bacterias Gram positivas, donde las PBPs se encuentran en    la membrana citoplasmática expuestas al medio externo52.    Por tanto, para que una cefalosporina alcance su blanco (PBP) en un bacilo Gram    negativo debe poseer una adecuada penetración a través de las    porinas de la membrana externa (canales que permiten el ingreso de moléculas    desde el medio externo hacia el espacio periplásmico). En este contexto,    la mayor penetración intracelular es una característica microbiológica    de interés de las cefalosporinas de cuarta generación36,53.   Clasificación  Existe un número importante de clasificaciones, destaca    entre ellas la clasificación biológica de O'Callaghan, actualmente    de carácter histórico, que subdividió a estos antimicrobianos    en 7 grupos de acuerdo a su metabolismo y estabilidad a la degradación    por ß-lactamasas54. Otra clasificación,    de carácter químico, agrupa a las cefalosporinas de acuerdo a    los sustitu-yentes presentes en el carbono de la cadena lateral de C7,    distinguiéndose cuatro grupos: cefalosporinas sustituidas y no sustituidas    a este nivel; a- amino cefalosporinas y aril-oxi-imino cefalosporinas44.    Interesantemente, otra clasificación es sólo de carácter    farmacocinético, de acuerdo al tiempo de vida media, y aplicada fundamentalmente    a las cefalosporinas de uso parenteral, así en el grupo 1, se incluyen    aquellos compuestos que tienen vidas medias menores de 1 hora (cefalotina, cefradina,    cefapirina, cefoxitina); en el grupo 2 compuestos con vidas medias entre 1 y    3 horas (cefazolina, cefmetazol, cefuroxima, cefotaxima, ceftixozima, moxalactam,    cefmenoxima, cefoperazona, ceftazidima, cefpiroma, cefepime) y finalmente en    el grupo 3 aquellas cefalosporinas con tiempos de vida media mayores a 3 horas    (cefpiramide, ceftriaxona, cefodizima)23,55.    A su vez, dentro de cada uno de estos grupos las moléculas son subdivididas    según la ruta principal de eliminación (renal, biliar). Otras    clasificaciones subdividen a las cefalosporinas de acuerdo a sus propiedades    microbiológicas, principalmente el espectro de actividad. En los grupos    I y II, cefalosporinas de amplio espectro, se incluyen moléculas de primera    y segunda generación, respectivamente. En el grupo III, se incluyen moléculas    de tercera generación y oxacefems. En el grupo IV cefalosporinas de cuarta    generación. En el grupo V, o de cefalosporinas de reducido espectro,    se incluye a cefsulodina44.   Otra clasificación, más funcional en una perspectiva    microbiológica, fue desarrollada por J.D. Williams, quien agrupó    a estas moléculas de acuerdo a su espectro antibacteriano enfatizando    la cobertura sobre bacterias Gram positivas, Gram negativas, Pseudomonas    aeruginosa y anaerobias. Así el grupo I incluye a las moléculas    con mayor actividad sobre Gram positivos (cefradina, cefradoxilo, cefalexina,    cefalotina); el grupo II, a cefalosporinas con mayor actividad sobre Gram negativos    (cefuroxima, cefotaxima, ceftriaxona, ceftizoxima); el grupo III a compuestos    con actividad sobre P. aeruginosa (ceftazidima, cefoperazona) y el grupo    IV a moléculas con actividad sobre bacterias anaerobias (cefoxitina,    cefotetan, moxalactam)56.  Sin embargo, desde el punto de vista clínico, la clasificación    más utilizada agrupa a estos compuestos de acuerdo al desarrollo histórico    y algunas características microbiológicas y estructurales en común,    las denominadas generaciones de cefalosporinas3,4-6,14.    A las ya conocidas moléculas de primera, segunda y tercera generación    se agregan las denominadas cefalos-porinas de cuarta generación, destacando    en este grupo: cefepime y cefepiroma, aunque también se incluyen en este    grupo otras moléculas todavía en fase de desarrollo como: cefoselis,    cefclidin, cefozopram y cefluprenam57-62.   Dado que la clasificación en generaciones es la de mayor    uso, se discutirán algunas características relevantes de éstas:   Las cefalosporinas de primera generación presentan mejor    actividad sobre cocos Gram positivos como S. aureus susceptible a meticilina,    S. pyogenes y S. pneumoniae; sin embargo, como ya se comentó,    carecen de actividad sobre Enterococcus spp. Su actividad sobre bacilos    Gram negativos es limitada a cepas de E. coli, Klebsiella spp. y Proteus    mirabilis (no productoras de ß-lactamasas cromosomales y/o plasmidiales)3,7,14.    A pesar de la descripción de actividad in vitro sobre algunas    cepas de Salmonella y Shigella, las moléculas de este grupo    no son útiles para el tratamiento de infecciones producidas por estos    patógenos63-65. Además,    carecen de una actividad significativa sobre Haemophilus influenzae3,7,14,23.    En este grupo existen moléculas de uso oral y parenteral; desde un punto    de vista farmacológico se caracterizan por sus cortos tiempos de vida    media (aunque cefazolina y cefadroxilo presentan tiempos de eliminación    más prolongados que el resto de las moléculas del grupo), baja    penetración al LCR y excreción por vía urinaria alcanzando    adecuados niveles terapéuticos para el tratamiento de infecciones por    especies uropatógenas comunitarias susceptibles3,16,23,66.   La característica microbiológica definitiva de    las cefalosporinas de segunda generación es su actividad sobre H.    influenzae, Moraxella catarrhalis, Neisseria meningitidis y Neisseria gonorrhoeae.    En esta generación de cefalos-porinas, también se incluyen    otras moléculas que técnicamente corresponden a:    • Cefamicinas: químicamente son 7-alfa metoxi-cefalosporinas. Estas    moléculas - cefoxitina, cefotetan- presentan una potente actividad sobre    Bacteroides fragilis3,67,68.   • Carbacefems: químicamente estos compuestos se caracterizan porque    el azufre del anillo dihidrotiazínico del grupo cefem está sustituido    por un carbono (carba) de un grupo metileno (CH2). Así loracarbef    se diferencia de cefaclor sólo por el ambio estructural previamente señalado    (carbono en vez de azufre)69.  Por otra parte, la descripción de una mayor actividad    microbiológica de moléculas de este grupo sobre enterobacterias    resistentes a cefalotina - como cepas de Enterobacter, Serratia, Citrobacter,    Providencia y Proteus indol-positivos - carece de importancia microbiológica    y clínica, dados los actuales perfiles de susceptibilidad de los bacilos    Gram negativos26,30,70,71.   Debe enfatizarse que los antimicrobianos de esta generación    - incluyendo tanto a cefalosporinas, cefamicinas y carbacefems (o carbacefemas)-    carecen de actividad sobre P. aeruginosa; además, con la excepción    de cefamandol, son menos activos que sus congéneres de primera generación    sobre cepas de S. aureus susceptibles a oxacilina3,5,23,72.    Desde un punto de vista farmacológico no difieren en forma sustancial    de las moléculas de primera generación, excepto en su mejor penetración    al LCR; sin embargo, no se consideran agentes de elección en el tratamiento    de MBA debido a la menor eficacia clínica al compararlas con moléculas    de tercera generación, por ejemplo cefuroxima versus ceftriaxona20,73.   Las cefalosporinas de tercera generación constituyen    uno de los grupos de antimicrobianos de mayor uso en la actualidad. Los compuestos    de esta generación se caracterizan por presentar, al menos, dos de las    siguientes características:   • en C-7 del núcleo cefem, la presencia de un anillo 2-aminotiazolil    como cadena lateral  • amplio espectro de actividad  • elevada actividad sobre Enterobacteriaceae (excepto    sobre cepas hiperproductoras de cefalosporinasas y/o ESBLs), H. influenzae,    Neisseria spp., S. pyogenes y S. pneumoniae y actividad sobre    P. aeruginosa (ceftazidima y cefoperazona)42,74.   En este contexto es importante destacar que si bien ceftriaxona    y cefotaxima son agentes de elección en el tratamiento de MBA adquirida    en la comunidad, la descripción creciente de cepas de S. pneumoniae    resistentes a penicilina y cefalosporinas ha limitado en algunos centros, su    uso como monoterapia empírica para el tratamiento de infecciones meníngeas75.    Por otra parte, la actividad de estos agentes sobre S. aureus susceptible    a meticilina es menor que la de los congéneres de primera y segunda generación,    debiéndose considerar que ceftazidima y los agentes de uso oral cefixima    y ceftibuten carecen de una actividad microbiológica útil sobre    este patógeno7,23,76,77.    Desde una perspectiva farmacológica en este grupo existen moléculas    como ceftriaxona que presentan tiempos de vida media prolongados, permitiendo    su dosificación cada 12 o incluso cada 24 horas; además, cefotaxima    es metabolizada a una forma biológicamente activa (desacetilcefotaxima)    y por otra parte estos agentes alcanzan concentraciones útiles en una    serie de tejidos y parénquimas, entre ellos sangre, orina, bilis (particularmente    cefoperazona y ceftriaxona), pulmones, líquido peritoneal y meninges3,14,39,78.   Es interesante destacar que en los grupos analizados, cefalosporinas    de primera hasta tercera generación, hay agentes de uso oral, que en    términos generales mantienen las características microbiológicas    generales de las respectivas generaciones, por ejemplo, cefadroxilo, cefuroxima    y cefixima, respectivamente7,16,77.   CEFALOSPORINAS DE CUARTA GENERACION Las cefalosporinas de cuarta generación se caracterizan    químicamente por la presencia de un grupo metoxi-imino aminotiazolil    en R1 del núcleo cefem (similar al que presentan las moléculas    de tercera generación), excepto cefclidin (previamente E 1040) que presenta    un radical muy similar: aminotiadiazolil, y principalmente por la presencia    de un nitrógeno cuaternario en R2 (Figura    3). Este grupo se mantiene cargado positivamente tanto en condiciones de    pH ácido como alcalino. La asociación de esta carga neta positiva    con una carga negativa en C4 del núcleo cefem hace de estos    antibacterianos moléculas zwitteriónicas, es decir, moléculas    con un balance entre sus cargas positivas y negativas en los rangos de pH encontrados    in vivo (Figura 4)36,53,57,58,79.      

Figura 3. Estructura química de cefepime y cefpirome,          respectivamente.          

Figura 4. Estructura zwitteriónica            de las cefalosporinas de cuarta generación.      Esta característica químico-estructural explica    por qué estas cefalosporinas presentan una penetración a través    de las porinas, superior a sus congéneres de tercera generación,    lo que le permite alcanzar altas concentraciones en el espacio periplásmico    de bacilos Gram negativos79,80.    Experimentalmente se ha demostrado que cefpiroma, cefepima y cefclidin tienen    una velocidad de penetración intracelular, sobre cepas de E. coli    y E. cloacae, varias veces superior a la de cefotaxima y ceftazidi-ma79-81.    Esta propiedad se relacionaría con el balance de cargas químicas    de estos compuestos, ya que, si bien las cefalosporinas de cuarta generación    son moléculas de mayor tamaño que sus congéneres de tercera    generación, presentan en su estructura química una importante    carga positiva (a nivel del amonio cuaternario) y además son selectivamente    incorporadas a través de la porina Omp F36,58,79-81.    Ceftazidima, en cambio, tiene una carga neta negativa, a pesar de presentar    una carga positiva en C3. La penetración intracelular más    lenta de esta molécula puede explicarse entonces por el potencial de    Donnan de la bacteria (interior negativo)58,80.    Sin embargo, el solo aumento de la penetración intracelular, no explica    en forma exclusiva la importante actividad antibacteriana de estos compuestos,    particularmente sobre bacterias resistentes. Así, cefaloridina que estructuralmente    también es una molécula dipolar, sin carga neta, con un amonio    cuaternario en C3, presenta una penetración intracelular incluso    superior a las moléculas de cuarta generación; sin embargo, al    carecer del radical metoxi-imino no presenta una adecuada estabilidad frente    a beta-lactamasas, siendo rápidamente degradada5,36,58.   Por lo anterior otro aspecto relevante para explicar la mayor    actividad de estas cefalos-porinas sobre bacterias Gram negativas resistentes    a moléculas de tercera generación, es la estabilidad frente a    las ß-lactamasas tanto cromosomales como plasmidiales y su afinidad por    el sitio blanco: PBP´s36,58,80,82,83.    Así, la actividad sobre cepas hiperproductoras de ß-lactamasas    del grupo 1 de Bush (cefalospori-nasas cromosomales) se explica por la baja    afinidad de la ß-lactamasa por la cefalosporina (en general valores más    elevados para Km); habiéndose establecido que la afinidad    de estas enzimas por cefotaxima es 1.000 a 10.000 veces mayor que sobre cefepima    y del orden de 10 a 100 veces superior para ceftazidima en comparación    con cefepima36,58.  Por otra parte, el efecto final de los sustitu-yentes en la    relación estructura-actividad de estos compuestos, es decir, mantención    de sustituyentes con importante actividad sobre Gram negativos como metoxi-imino,    como la presencia en la misma molécula de radicales que incrementan la    actividad sobre cocáceas Gram positivas como amonio cuaternario, explican    la actividad microbiológica "más balanceada" de estos    antimicrobianos, ya que presentan una elevada actividad in vitro sobre    Gram positivos, particularmente, S. pneumonaie (incluyendo cepas resistentes    a penicilina), junto a una potente actividad inhibitoria y bactericida sobre    bacilos Gram negativos entéricos, incluyéndose, como ya se mencionó,    cepas multiresis-tentes capaces de degradar moléculas de tercera generación    (Tabla 1)36,84-86.     Tabla 1. Actividad inihibitoria de cefepime,    cefotaxima y ceftazidima, en presencia        y ausencia de ácido clavulánico, sobre 75 cepas de K. pneumoniae    y 12 cepas de E. coli     productoras de ESßLs aisladas de diferentes hospitales chilenos           CMI (ug/ml)      Antibiótico Microorganismo Rango 50 90 % resistencia   CFTX K. pneumoniae 4-256 32,0 64 100     E. coli 4-256 64,0 1280 092       CFTX + AC K. pneumoniae < 0,25-2 < 0,25 16 003     E. coli 1-32 20 32 025       CFZD K. pneumoniae 8- > 256 320, > 25600 100     E. coli 8- > 256 64,0 256, 100       CFZD + AC K. pneumoniae < 0,25-16 10 04 004     E. coli 2- > 32 40 32 025       CFPM K. pneumoniae < 0,25-128 < 0,25 16 000,2,6     E. coli < 0,25-256 < 0,25 32 025       CFPM + AC K. pneumoniae < 0,25-32 < 0,25 02 ,0,0     E. coli < 0,25-32 < 0,25 32 017     Cefotaxima (CFTX), Ceftazidima (CFZD), Cefepima (CFPM), Acido clavulánico          (AC)              *Cefalosporina: ácido clavulánico, 2:1       En forma general y práctica puede señalarse    que estos agentes despliegan una actividad superior a la de ceftriaxona y cefotaxima    sobre bacilos Gram negativos multiresistentes (Serratia, Citrobacter, Enterobacter,    Morganella, Providencia y cepas de Proteus indol negativo hiperproductoras    de cefalosporinasas y/o sobre de cepas de K. pneumoniae y E. coli    productoras de ESßLs ) y equivalente al de estos compuestos de tercera    generación sobre cepas de bacterias Gram negativos susceptibles y S.    pneumoniae36,58,84-86.    Con relación a su actividad sobre P. aeruginosa, estas moléculas    tienen una actividad antibacteriana comparable, pero no superior, a la de ceftazidima36,53,    57,58,82,83.   En este contexto, en nuestro laboratorio evaluamos la actividad    de cefepima, cefotaxima y ceftazidima sobre cepas de K. pneumoniae y    E. coli productoras de ESBLs aisladas de diferentes hospitales chilenos.    Es interesante destacar que de las cepas originalmente recibidas en nuestro    estudio, se determinó la producción de ESBLs en 43,9% de las cepas    de K. pneumoniae y en 8% de las cepas de E. coli. Cefepima demostró    ser el ß-lactámico de mayor actividad sobre las cepas ensayadas.    Así, 2,6% de los aislamientos de K. pneumoniae y 25% de las cepas    de E. coli fueron resistentes a este agente. Al analizar la Tabla    1 puede comprobarse también que con la asociación con ácido    clavulánico se produce un importante incremento en la susceptibilidad    de las bacterias en estudio a las cefalosporinas de tercera generación.    Este efecto fue más pronunciado sobre K. pneumoniae con disminución    de las frecuencias de resistencia de 100% (cefalos-porina) a 4% (cefalosporina    asociada a inhibidor de ß-lactamasa). La mayor susceptibilidad de las    bacterias a la asociación de cefalosporina de tercera generación    y ácido clavulánico (AC) se explica por la actividad hidrolizante    de ESßLs sobre las cefalosporinas. Por lo tanto, el escaso efecto sinergístico    de AC y cefepima sugiere una escasa actividad de ESßLs como mecanismo    de resistencia a esta cefalosporina de cuarta generación. De lo anterior    puede concluirse que cefepima es activa sobre una importante proporción    de cepas chilenas de K. pneumoniae y de E. coli productoras de    ESßLs.  Como última característica microbiológica    general, debe destacarse que estos compuestos son débiles inductores    de la producción de ß-lactamasas cromosomales, a diferencia de    lo que ocurre con carbapenémicos y cefamicinas, que característicamente    son potentes inductores de ß-lactamasas Amp C25,37.   Finalmente, basándonos en el aumento cada vez más    creciente de la resistencia bacteriana, la mayor sobrevida de huéspedes    susceptibles, el lento desarrollo de nuevas familias de antimicrobianos (con    excepción de las oxazolidinonas) y las propiedades microbiológicas    de las cefalosporinas de cuarta generación, debemos plantear que -de    acuerdo a los estudios de susceptibilidad locales- las cefalosporinas de cuarta    generación podrían representar una alternativa terapéutica    para el tratamiento de infecciones producidas por bacilos Gram negativos resistentes    a cefalosporinas de tercera generación87-91.   RESUMEN  Las cefalosporinas son uno de los grupos de mayor importancia    dentro de los ß-lactámicos. Existen diversas clasificaciones de    estas moléculas, siendo la más utilizada aquella que agrupa a    estos compuestos de acuerdo a propiedades estructurales, microbiológicas    y desarrollo histórico: primera a cuarta generación. Las cefalosporinas    de tercera generación han sido ampliamente utilizadas, pero la emergencia    de resistencia bacteriana fundamentalmente derivada de la producción    de ß-lactamasas tanto cromosomales como plasmidiales, ha limitado el uso    de estos compuestos. Las cefalosporinas de cuarta generación se caracterizan    por la presencia de un nitrógeno cuaternario en C3, además    de mantener el grupo metoxi-imino aminotiazolil en C7. Presentan    una elevada penetración intracelular a través de la membrana externa    de bacilos Gram negativos y tienen una baja afinidad por enzimas que degradan    cefalos-porinas de tercera generación. Cefepime, una cefalosporina de    cuarta generación, demostró una mayor actividad inhibitoria sobre    cepas chilenas de Klebsiella pneumoniae y Escherichia coli productoras    de ß-lactamasas de espectro extendido, que cefotaxima y ceftazidima.  Universidad de Concepción:      1 Departamento de Microbiología, Facultad de Ciencias Biológicas.         2 Departamento de Medicina Interna, Facultad de Medicina.      3 Facultad de Medicina. Universidad San Sebastián, Concepción.           Este trabajo fue financiado por el Proyecto Nº 1980109 del Fondo Nacional    de Desarrollo Científico y Tecnológico (FONDECYT)  BIBLIOGRAFIA  1.- ROLINSON G N. The influence of 6-aminopenicillanic    acid on antibiotic development. J Antimicrob Chemother 1988; 22: 5-14.         [ Links ]2.- ZEMELMAN R, NORAMBUENA R, VERGARA L, GACITUA    R. Los antibióticos ß-lactámicos: agrupación según    su estructura química y sus propiedades bacteriológicas. Rev Méd    Chile 1987; 115: 983-91.         [ Links ]3.- FRIED J S, HINTHORN D R. The cephalosporins.    Dis a Month 1985; 31: 1-60.         [ Links ]4.- NEU HC. Structure-activity relations of    new ß-lactam compounds and in vitro activity against common bacteria.    Rev Infect Dis 1983; 5 (suppl 2): S319-.         [ Links ]5.- NEU H C. Beta-lactam antibiotics structural    relationships affecting in vitro activity and pharmacological properties. Rev    Infect Dis 1986; 8 (Suppl 3): 237-59         [ Links ]6.- NEU H C. Relation of structural properties    of beta-lactam antibiotics to antibacterial activity. Am J Med 1985; 79 (Suppl    2 A): 2-13.         [ Links ]7.- SCHOLAR E M, PRATT W B (Eds). The inhibitors    of cell wall synthesis, II. The antimicrobial drugs. Oxford University Press.    2000 Nueva York. pp:         [ Links ]8.- LOPEZ F, GARRIDO J C. Química y    relación estructura-actividad de los antibióticos cefalosporínicos    (I). Rev Col Químico Farmacéutico 1988; 44: 110-22.         [ Links ]9.- TURNIDGE J D. The pharmacodynamics of        ß-lactams. Clin Infect Dis 1998; 27: 10-22.  10.- CRAIG W A. The future-can we learn from    the past? Diagn Microbiol Infect Dis 1997; 27: 49-53.         [ Links ]11.- DUDLEY M N. Pharmacodynamics and pharmacokinetics    of antibiotics with special reference to the fluoroquinolones. Am J Med 1991;    91 (Suppl 6 A): 6A-45S.         [ Links ]12.- NICOLAU D P, QUINTILIANI R, NIGHTINGALE    C H. Cinética y dinámica de los antibióticos para el clínico.    Clin Med Nort Am 1995; 79: 483-500.         [ Links ]13.- DRUSANO G L. Human pharmacodynamics of    beta-lactams, aminoglycosides and their combination. Scand J Infect Dis 1991    (Suppl); 74: 235-48.         [ Links ]14.- MARSHALL W F, BLAIR J E. The cephalosporins.    Mayo Clinic Proc 1999; 74: 187-95.         [ Links ]15.- DONOWIRZ G R, MANDELL G L. Beta-lactam    antibiotics. N Engl J Med 1988; 318: 490-500.         [ Links ]16.- PAYA E. Ventajas y desventajas de las    cefalosporinas orales de segunda y tercera generación. Rev Chil Infect    1997; 14: 233-8.         [ Links ]17.- AMERICAN THORACIC SOCIETY. Guidelines    for the initial management of adults with community-acquired pneumonia: diagnosis,    assessment of severity, and initial antimicrobial therapy. Am Rev Respir Dis    1993; 148: 1418-26.         [ Links ]18.- BARTLETT J G, BREIMAN R F, MANDELL L    A, FILE T M Jr. Community-acquired pneumonia in adults: guidelines for management.    The Infectious Diseases Society of America. Clin Infect Dis 1998: 26: 811-38.          [ Links ]19.- MARRIE T J. Community-acquired pneumonia:    epidemiology, etiology, treatment. Infect Dis Clin North Am 1998; 12: 723-40          [ Links ]20.- TUNKEL A R, SCHELD W M. Acute meningitis.    In: Mandell, Douglas & Bennett's. Principles and Practice of Infectious    Diseases. Mandell G L, Bennett J E, Dolin R, eds. Fifth edition. Philadelphia:    Editorial Churchill Livingstone 2000; 959-96.         [ Links ]21.- AMERICAN THORACIC SOCIETY. Hospital-acquired    pneumonia in adults: diagnosis, assessment of severity, initial antimicrobial    therapy, and preventive strategies. A consensus statement. Am J Respir Crit    Care Med 1996; 153: 1711-25.         [ Links ]22.- BARTLETT J G, DOWELL S F, MANDELL L A,    FILE T M, MUSHER D M, FINE M J. Practice guidelines for the management of community-acquired    pneumonia in adults. Clin Infect Dis. 2000; 31: 347-82         [ Links ]23.- KARCHMER A W. Cephalosporins. In: Mandell,    Douglas & Bennett's. Principles and Practice of Infectious Diseases. Mandell    G L, Bennett J E, Dolin R, eds. Fifth edition. Philadelphia: Churchill Livingstone    2000; 274-99.         [ Links ]24.- ADU A, ARMOUR C L. Drug utilisation review    (DUR) of the third generation cephalosporins. Drugs 1995; 50: 423-39.         [ Links ]25.- JONES R N. Important and emerging ß-lactamase    mediated resistances in hospital-based pathogens: the Amp C enzymes. Diagn Microbiol    Infect Dis 1998; 31: 461-6.         [ Links ]26.- JARVIS W R, MARTONE W J. Predominant    pathogens in hospital infections. J Antimicrob Chemother 1992; 29: 19-24.         [ Links ]27.- LIVERMORE D M. ß-lactamases in    laboratory and clinical resistance. Clin Microbiol Rev 1995; 8: 557-84.         [ Links ]28.- HERITAGE J, M'ZALI F H, GASCOYNE-BINZI    D, HAWKEY P M. Evolution and spread of SHV extended-spectrum ß-lactamases    in gram negative bacteria. J Antimicrob Chemother 1999; 44: 309-18.         [ Links ]29.- PODSCHUN R, ULLMAN U. Klebsiella spp.    as nosocomial pathogens: epidemiology, taxonomy, typing methods, and pathogenicity    factors. Clin Microbiol Rev 1998; 11: 589-603.         [ Links ]30.- PITOUT J D D, SANDERS C C, SANDERS W    E. Antimicrobial resistance with focus on ß-lactam resistance in Gram    negative bacilli. Am J Med 1997; 103: 51-9.         [ Links ]31.- HANBERGER H, GARCIA-RODRIGUEZ J A, GOBERNADO    et al. Antibiotic susceptibility among aerobic Gram negative bacilli in intensive    care units in 5 european countries. JAMA 1999; 281: 67-71.         [ Links ]32.- CHARREL R N, PAGES J M, DE MICCO P et    al. Prevalence of outer membrane porin alteration in ß-lactam-antibiotic-resistant    Enterobacter aerogenes. Antimicrob Agents Chemother 1996; 40: 2854-8.          [ Links ]33.- BRADFORD P A, URBAN C, MARIANO N, PROJAN    S J, RAHAL J J, BUSH K. Imipenem resistance in Klebsiella pneumoniae is    associated with the combination of ACT-1, a plasmid-mediated Amp C ß-lactamase,    and the loss of an outer membrane protein. Antimicrob Agents Chemother 1997;    41: 563-9.         [ Links ]34.- QUEENAN A M, TORRES-VIERA C, GOLD H et    al. SME-type carbapenem-hydrolizing class A ß-lactamases from geographically    diverse Serratia marcescens strains. Antimicrob Agents Chemother 2000;    44: 3035-9.         [ Links ]35.- COHEN S P, MC MURRY L M, HOOPER D C,    WOLFSON J S, LEVY S B. Cross-resistance to fluoroquinolones in multiple-antibiotic-resistance    (Mar) Escherichia coli selected by tetracycline resistance: decreased    drug accumulation asociated with membrane changes in addition to Omp F reduction.    Antimicrob Agents Chemother 1989; 33:1318-25.         [ Links ]36.- SANDERS C C. Cefepime: The next generation?    Clin Infect Dis 1993; 17: 369-79         [ Links ]37.- GARAU J. The clinical potential of fourth-generation    cephalosporins. Diagn Microbiol Infect Dis 1998; 31: 479-80.         [ Links ]38.- CURTIS N A C, ORR D C, ROSS G W, BOULTON    M G. Affinities of penicillins and cephalosporins for the penicillin-binding    proteins of Escherichia coli    K-12 and their antibacterial activity. Antimicrob Agents Chemother 1979; 16:    533-9.  39.- BALANT L, DAYER P, AUCKENTHALER R. Clinical    pharmacokinetics of the third generation cephalosporins. Clin Pharmacokinetics    1985; 10: 101-43.         [ Links ]40.- WHEELER W J. Cephalosporins and other    beta-lactam antibiotics. Lloydia. 1977; 40: 519-42.         [ Links ]41.- LOPEZ F, GARRIDO J C. Química    y relación estructura-actividad de los antibióticos cefalosporínicos.    Rev Col Químico Farmacéutico 1989; 41: 5-14.         [ Links ]42.- FU K P, ASWAPOKEE P, HO I, MATTHIJSSEN    C, NEU H C. Pharmacokinetics of cefotaxime. Antimicrob Agents Chemother 1979;16:    592-7.         [ Links ]43.- YUK J H, NIGHTINGALE C H, QUINTILIANI    R. Clinical pharmacokinetics of ceftriaxone. Clin Pharmacokinetic 1989; 17:    223-35.         [ Links ]44.- BRYSKIER A, PROCYK T, LABRO M T. Cefodizime,    a new 2-aminothiazolyl cephalosporin: physicochemical properties, toxicology    and structure-activity relationships. J Antimicrob Chemother 1990; 26 (Suppl    C): 1-8.         [ Links ]45.- CRITCHLEY I A, BASKER M J, EDMONDSON    R A, KNOTT S J. Uptake of catecholic cephalosporin by the iron transport system    of Escherichia coli. J Antimicrob Chemother 1991; 28: 377-88.         [ Links ]46.- CRITCHLEY I A. Catecholic ß-lactams:    facilitated transport. J Antimicrob Chemother 1990; 26: 733-7.         [ Links ]47.- JONES R N, ERWIN M E. In vitro evaluation    of Ro 09-1227, a novel catechol-substituted cephalosporin. Antimicrob Agents    Chemother 1992; 36: 233-8.         [ Links ]48.- JONES R N. In vitro activity of Ro 24-6392,    a novel ester-linked co-drug combining ciprofloxacin and desacetylcefotaxime.    Eur J Clin Microbiol Infect Dis 1990; 9: 435-8.         [ Links ]49.- TOMASZ A. Penicillin-binding proteins    and the antibacterial effectiveness of ß-lactam antibiotics. Rev Infect    Dis 1986 (Suppl 3); 8: 260-78.         [ Links ]50.- HOLM S E. Interaction between ß-lactam    and other antibiotics. Rev Infect Dis 1986 (Suppl 3); 8: 305-14.         [ Links ]51.- MC CULLERS J A, ENGLISH B K, NOVAK R.    Isolation and characterization of vancomycin-tolerant Streptococcus pneumoniae    from the cerebrospinal fluid of a patient who developed recrudescet meningitis.    J Infect Dis 2000; 181: 369-73.         [ Links ]52.- NIKAIDO H. Outer membrane barrier as    a mechanism of antimicrobial resistance. Antimicrob Agents Chemother 1989; 33:    1831-6.         [ Links ]53.- BARRADELL L B, BRYSON H M. Cefepime.    A review of its antibacterial activity, pharmacokinetic properties and therapeutic    use. Drugs 1994; 47: 471-505.         [ Links ]54.- O'CALLAGHAN C H 1979. Description and    classification of the newer cephalosporins and their relationship with the established    compounds. J Antimicrob Chemother 5: 635-71         [ Links ]55.- BRYSKIER A, PROCYK T, TREMBLAY D, LENFANT    B FOURTILLAN J B. The pharmacokinetics of cefodizime following intravenous and    intramuscular administration of a single dose of 1.0 g. J Antimicrob Chemother    1990; 26 (Suppl. C): 59-63.         [ Links ]56.- WILLIAMS J D. Classification of cephalosporins.    Drugs. 1987; 34 (Suppl 2): 15-22.         [ Links ]57.- WISEMAN L R, LAMB H M. Cefpirome. A review    of its antibacterial activity, pharmacokinetic properties and efficacy in the    treatment of severe nosocomial infections and febrile neutropenia. Drugs 1997;    57: 117-40.         [ Links ]58.- PECHERE J C, WILSON W, NEU H. Laboratory    assesment of antibacterial activity of zwitterionic 7-methoxyimino cephalosporins.    J Antimicrob Chemother 1995; 36: 757-71         [ Links ]59.- GIAMARELLOS-BOURBOULIS EJ, GRECKA P,    TSITSIKA A, TYMPANIDOU C, GIAMARELLOU H. In-vitro activity of FK 037 (cefoselis),    a novel 4 (th) generation cephalosporin, cefepime and cefpirome on nosocomial    staphylococci and gram-negative isolates. Diagn Microbiol infect Dis 2000; 36:    185-91.         [ Links ]60.- JONES R N, ERWIN M E, BARRETT M S, JOHNSON    D M, BRIGGS B M. Antimicrobial activity of E-1040, a novel thiadiazolyl cephalosporin    compare with parenteral cephems. Diagn Microbiol infect Dis 1991; 14: 301-9.          [ Links ]61.- IIZAWA Y, OKONOGI K, HAYASHI R, IWAHI    T, YAMAZAKI T, IMADA A. Therapeutic effect of cefozopran (SCE-2787), a new parenteral    cephalosporin in experimental infections in mice. Antimicrob Agents Chemother    1993; 37: 100-5.         [ Links ]62.- WATANABE N A. Newer antipseudomonal cephalosporins.    J Chemother 1996; 8 (Suppl 2): 48-56.         [ Links ]63.- ACTOR P, GUARINI J, URI J et al. Disk    susceptibility studies with cefazolin and cephalotin. Antimicrob Agents Chemother    1974; 5: 63-7.         [ Links ]64.- UWAYDAH M. Cefazolin in the treatment    of acute enteric fever. Antimicrob Agents Chemother 1976; 10: 52-6.         [ Links ]65.- JAMAL W Y, ROTIMI V O, CHUGH T D, PAL    T. Prevalence and susceptibility of Shigella to 11 antibiotics in a Kuwait    teaching hospital. J Chemother 1998; 10: 285-90.         [ Links ]66.- COX CE, SHERRILL M, COCCHETT DM. Evaluation    of cefuroxime axetil, cefaclor, and cephalexin in the treatment of urinary tract    infections in adults. Curr Ther Res 1987; 42: 124-37.         [ Links ]67.- SANDERS C W, GREENBERG R N, MARIER R    L. Cefamandole and cefoxitin. Ann Intern Med 1985; 103: 70-8.          [ Links ]68.- STAPLEY E P, JACKSON M, HERNANDEZ S et    al. Cephamycins, a new family of ß-lactam antibiotics I. Production actinomycetes,    including Streptomyces lactamdurans spp.n. Antimicrob Agents Chemother    1972; 2: 122-31.         [ Links ]69.- COOPER R D G. The carbacephems a new    ß-lactams class. Am J Med 1992; 92 (Suppl 6 A): 25-65.         [ Links ]70.- ZEMELMAN R, BELLO H, DOMINGUEZ M, GONZALEZ    G, MELLA S, GARCIA A. Activity of imipenem, third-generation cephalosporins,    aztreonam, and ciprofloxacin against multi-resistant Gram negative bacilli isolated    from Chilean hospitals. J Antimicrob Chemother 1993; 32: 413-9.         [ Links ]71.- MEDEIROS A A. Evolution and dissemination    of ß-lactamases accelerated by generation of ß-lactam antibiotics.    Clin Infect Dis 1997; 24 (Suppl. 1): 19-45.         [ Links ]72.- PERRY C M, BROGDEN R N. Cefuroxime axetil:    review of its antibacterial activity, pharmacokinetic properties and therapeutic    efficacy. Drugs 1996; 52: 125-58.         [ Links ]73.- SCHAAD U B, SUTER S, GIANELLA-BORRADORI    et al. A comparison of ceftriaxone and cefuroxime for the treatment of bacterial    meningitis in children. N Engl J Med 1990; 322: 141-7.         [ Links ]74.- KLEIN N C, CUNHA B A. Cefalosporinas de    la tercera generación. Clin Med Nort Am 1995; 79: 693-707.         [ Links ]75.- KLUGMAN K P, MADHI S A. Emergence of    drug resistance impact on bacterial meningitis. Infect Dis Clin North Am 1999;    13: 637-46.         [ Links ]76.- RICHARDS D M, BROGDEN R N. Ceftazidime.    A review of its antibacterial activity, pharmacokinetic properties and therapeutic    use. Drugs 1985; 29: 105-61.         [ Links ]77.- SCHATZ B S, KARAVOKIROS K T, TAEUBEL    M A, ITOKAZU G S. Comparison of cefprozil, cefpodoxime proxetil, loracarbef,    cefixime, and ceftibuten. Ann Pharmacother 1996; 30: 258-68.         [ Links ]78.- DALMAU D, LAYRARGUES G P, FENYVES D,    WILLEMS B, TURGEON F, TURGEON P. Cefotaxime, desacetyl-cefotaxime, and bactericidal    activity in spontaneous bacterial peritonitis. J Infect Dis 1999; 180: 1597-1602.          [ Links ]79.- NIKAIDO W, LIU W, ROSENBERG E Y. Outer    membrane permeability and ß-lactamase stability of dipolar ionic cephalosporins    containing methoxyimino substituents. Antimicrob Agents Chemother 1990; 34:    337-42.         [ Links ]80.- HANCOCK R E W, BELLIDO F. Factors involved    in the enhanced efficacy against gram-negative bacteria of fourth generation    cephalosporins. J Antimicrob Chemother 1992; 29(Suppl A): 1-6.         [ Links ]81.- BELLIDO F, PECHERE J C, HANCOCK REW.    Novel method for measurement of outer membrane permeability to new beta-lactams    in intact Enterobacter cloacae cells. Antimicrob Agents Chemother 1991;    35: 68-72.         [ Links ]82.- NEU H C, CHIN N X, JULES K, LABTHAVIKUL    P. The activity of BMY-28142, a new broad spectrum beta-lactamase stable cephalosporin.    J Antimicrob Chemother 1986; 17: 441-52.         [ Links ]83.- KOBAYASHI S, ARAI S, HAYASHI S, FUJIMOTO    K. ß-lactamase stability of cefpirome (HR 810), a new cephalosporin with    a broad antimicrobial spectrum. Antimicrob Agents Chemother 1986; 30: 713-8.          [ Links ]84.- GARAU J, WILSON W, WOOD M, CARLET J.    Fourth generation cephalosporins: a review of in vitro activity, pharmacokinetics,    pharmacodynamics, and clinical utility. Clin Microb Infect 1997; 3 (Suppl 1):    87-101.         [ Links ]85.- KESSLER R E, FUNG-TOMC J. Susceptibility    of bacterial isolates to beta-lactam antibiotics from U.S. clinical trials over    5-year period. Am J Med 1996; 24 (6 A): 13-9.         [ Links ]86.- PIERARD D, EMMERECHTS K, LAUWERS S. Comparative    in-vitro activity of cefpirome against isolates from intensive care and haematology/oncology    units. Belgian Multicentric Study Group. J Antimicrob Chemother 1998; 41: 443-50.          [ Links ]87.- JONES R N. Resistance patterns among    nosocomial pathogens: trends over the past few years. Chest 2001; 119 (Suppl    2): 397-404.         [ Links ]88.- LORBER B. Changing patterns of infectious    diseases. Am J Med 1988; 84: 569-78.         [ Links ]89.- MOELLERING R C. A novel antimicrobial    agent joins the battle against resistant bacteria. Ann Intern Med 1999; 130:    155-7.         [ Links ]90.- WILSON W R. The role of fourth-generation    cephalosporins in the treatment of serious infectious diseases in hospitalized    patients. Diagn Microbiol Infect Dis 1998; 31: 473-7.         [ Links ]Correspondencia a:        Sergio Mella Montecinos        Laboratorio de Antibióticos,        Departamento de Microbiología,        Facultad de Ciencias Biológicas        Casilla 160-C, Concepción        E-mail: pignatio@ctcinternet.cl  

Figura 1. Núcleo cefem (núcleo básico          de las cefalos-porinas).  

 

Figura 2. Núcleo penam (núcleo            básico de las penicilinas). 

 

En términos microbiológicos, estos compuestos    se caracterizan por su actividad bactericida dependiente del tiempo (su máximo    efecto bactericida se logra cuando en una proporción importante del intervalo    interdosis la concentración plasmática del antibacteriano se encuentra    sobre la CIM), del inoculo bacteriano y de la fase de crecimiento bacteriana7,9-13;    amplio espectro de actividad que incluye bacterias Gram positivas, Gram negativas    y anaerobios (cefoxitina, cefotetan)3,6,14,15.    Debe enfatizarse que como característica de clase las cefalosporinas    no tienen actividad sobre Enterococcus spp., Staphylococcus spp.    resistente a meticilina, Corynebacterium jeikeium, Stenotrophomonas    maltophilia, Listeria monocytogenes, Legionella spp.,    Chlamydia spp. y Mycoplasma spp.3,6,7,14,15.    Por otra parte, dada la potente actividad bactericida, favorables parámetros    farmacocinéticos, adecuada penetración a diferentes parénquimas    alcanzando allí niveles bactericidas, baja toxicidad y sinergia con otros    antibacterianos, las cefalosporinas son utilizadas como agentes de primera elección    en el tratamiento de una serie de infecciones comunitarias y nosocomiales14,16-24.  

Sin embargo, el uso creciente de esta clase de antibióticos    se ha asociado en forma progresiva al aislamiento de bacterias resistentes,    adquiriendo cada vez mayor importancia bacilos Gram negativos multiresistentes    hiperproductores de ß-lactamasas cromosomales (ß-lactamasas Amp    C), destacando en este grupo Serratia, Pseudomonas, Acinetobacter, Citrobacter,    Enterobacter, Morganella, Providencia y cepas de Proteus indol negativo25-27    o ß-lactamasas de espectro extendido (extended spectrum ß lactamases    ESBLs) de origen plasmidial, particularmente en cepas de Klebsiella pneumoniae    y Escherichia coli28-30.    En este contexto, el resultado final es la selección de cepas de bacilos    Gram negativos capaces de degradar cefalosporinas de tercera generación    (ya sea por ß-lactamasas cromo-somales y/o plasmidiales) lo que sumado    a la capacidad de albergar otros genes de resistencia y/o alteraciones en la    permeabilidad, explica la diseminación de bacterias Gram negativas multiresistentes    a varias familias de antimi-crobianos que incluye, entre otros, cefalosporinas    de tercera generación, aminoglucósidos, quinolonas e incluso carbapenémicos31-35.    Es en este marco donde se desarrollan las denominadas cefalosporinas de cuarta    generación, caracterizadas fundamentalmente por mantener un amplio espectro    de actividad que abarca desde Streptococcus pneumoniae, incluyendo cepas    resistentes a penicilina, hasta bacilos Gram negativos multiresistentes capaces    de degradar cefalosporinas de tercera generación25,36,37.  

Estructura y función 

El grupo activo básico de las cefalosporinas deriva    de la remoción de la cadena lateral de la cefalosporina C, producida    naturalmente por Acremonium chrysogenum (antes Cephalos-porium acremonium),    lo que da origen al anillo 7-amino-cefalosporánico (Figura    1)1-6. 

A su vez, al grupo 7-amino-cefalosporánico se le han    incorporado por semisíntesis diversos grupos químicos especialmente    en los carbonos 3 y 7 (radicales R2 y R1, respectivamente).    En términos generales las sustituciones al nivel de R1 habitualmente    producen moléculas con mayor afinidad por PBPs, particularmente de bacilos    Gram negativos, y estabilidad frente ß-lactamasas, lo que clínicamente    permite obtener compuestos con mayor espectro de actividad y potencia; así,    el grupo 2-aminotiazolil en el carbono 7 (R1) presente históricamente    en moléculas como el cefotiam, permitió el desarrollo de moléculas    con elevada afinidad sobre PBPs de bacterias Gram negativas, particularmente    por PBPs 1A y PBP 34-6,8,38,    pero dada su inestabilidad frente a ß-lactamasas, la industria farmacéutica    fue capaz de desarrollar nuevas moléculas que manteniendo la capacidad    de unión a PBPs fueran resistentes a la degradación enzimática.    Así, la introducción del radical metoxi-imino sobre el carbono    a originó las metoxi-iminocefalosporinas, las que en términos    microbiológicos se caracterizan por su estabilidad frente a ß-lactamasas4-6,8.    Debe destacarse que uno de los grupos de moléculas de mayor uso, las    cefalosporinas de tercera generación, incorporaron simultáneamente    el grupo aminotiazolil y el radical metoxi-imino, lo que explica la elevada    actividad de estos compuestos sobre Enterobacteriaceae4-6,8,23.  

Por otra parte, en términos generales, las sustituciones    en R2 producen cambios en las propiedades farmacocinéticas    de estas moléculas4-6,8,23,39.    Por ejemplo, el radical acetiloximetil, presente en cefalosporina C, también    se encuentra en cefalotina y cefotaxima; exhiben estos agentes una vida media    muy corta, dado que son rápidamente metabolizados en el organismo por    esterasas plasmáticas y hepáticas, dando origen a compuestos desacetilados    que, en general, son menos activos como anti infecciosos que la molécula    original8,40-42.    Además, la presencia de sustituyentes pequeños y exentos de carga    en R2 es una característica general de las cefalosporinas    de primera generación de uso oral; así cefalexina, cefradina y    cefadroxilo, presentan como característica un grupo metilo a este nivel,    interesantemente cefaclor presenta un cloro en R24-6,16,41.    Por otra parte, y también desde una perspectiva general, las cefalosporinas    de uso parenteral tienden a presentar vidas medias más prolongadas en    relación a la presencia de radicales acídicos y de mayor tamaño    en R2, como en ceftriaxona que presenta un anillo heterocíclico    de carácter ácido (1,2,5,6 - tetrahidro- 2-metil - 5,6-dioxo-    1,2,4 - triazin -3-il) que permite explicar niveles plasmáticos más    elevados y tiempo de vida media más prolongado que el resto de las aminotiazolil    metoxi-imino cefalospori-nas39,41,43.    Otro ejemplo al respecto es la comparación entre cefazolina (cefalosporina    con un anillo heterocíclico en R2) y cefalotina (acetiloximetilo    cefalosporina), presentando las primeras concentraciones plasmáticas    más elevadas y vida media más prolongada que la segunda5,8,41.    Otro grupo de importancia en este sustituyente es el radical N-metiltetrazol,    presente en: moxalactam, cefamandol, cefoperazona cefmenoxima, cefpiramida,    cefmetazol, cefotetan y cefbuperazona, que explica la presencia de efectos adversos    con el uso de estas moléculas, principalmente de tipo hematológico    con prolongación del tiempo de protrombina y efecto "de tipo disulfiram",    por alteración en la síntesis de vitamina K en el intestino e    inhibición del metabolismo del alcohol, respectivamente3,5-7,23.    Finalmente, otro grupo interesante a este nivel es el radical 3'mercaptotiazida,    presente en cefodizima, cefalosporina con favorables parámetros farmacocinéticos    y una peculiar actividad inmunomoduladora 44. 

También, desde una perspectiva histórica, un    grupo muy interesante de moléculas en que se utilizaron sustituyentes    catecólicos en R1 y en menor medida en R2, fueron    las denominadas cefalosporinas catecólicas, que presentaban una favorable    penetración intracelular en bacilos Gram negativos, ya que eran activamente    transportadas a través de proteínas de membrana externa reguladas    por fierro (IROMPs)45-47. 

Desde esta misma perspectiva, en el intento de lograr moléculas    con propiedades microbio-lógicas y/o farmacocinéticas superiores,    se sintetizaron compuestos experimentales cuya estructura química correspondía    a la asociación de una cefalosporina con una quinolona, las así    denominadas moléculas duales, destacando en este grupo Ro 24-6392, molécula    cuya estructura química derivaba de la asociación entre desacetilcefotaxima    y una sustitución 3' con ciprofloxacina y que exhibía una actividad    antimicrobiana comparable a la de ciprofloxacina sobre bacterias Gram negativas    y a la de cefotaxima sobre bacterias Gram positivas47.  

En términos generales, la, adición de nuevos    sustituyentes permite: 

• Ampliar el espectro de actividad

 • Mejorar las características farmacocinéticas  

 • Ampliar la actividad a bacterias de difícil    tratamiento como Pseudomonas spp, Citrobacter spp, Serratia    spp, Enterobacter spp, etc. 

• Aumentar la estabilidad frente a la hidrólisis    de ß-lactamasas 

 • Describir nuevas propiedades biológicas como    la inmunomodulación 

Mecanismo de acción 

Las cefalosporinas, al igual que el resto de los antibióticos    ß-lactámicos, ejercen su actividad antibacteriana inhibiendo la    síntesis del peptidoglicano, produciendo finalmente lisis bacteriana3,7,9,23.    El mecanismo de acción deriva de la unión covalente del ß-lactámico    al sitio activo de las enzimas denominadas PBPs. Esta reacción se explica    porque los ß-lactámicos poseen una estructura química similar    a los dos últimos aminoácidos del pentapéptido (D-alanina-D-alanina)    que une las moléculas de peptidoglicano. Por otra parte, las PBPs ejercen    actividad bioquímica de transglicosilasas (complejo PBP1), transpeptidasas    (PBP3) y carboxipeptidasas (PBP4, 5 y 6); además, este grupo de antimicrobianos    produce una activación de autolisinas bacterianas que destruyen el peptidoglicano5,49-51.    La activación de la actividad autolítica de la bacteria ha ido    adquiriendo mayor relevancia por la relación que se establecería    entre el desarrollo de tolerancia y la ausencia de activación de esta    vía51. Clásicamente se ha descrito    que con la unión de la cefalosporina a la PBP se bloquea la actividad    de transglicosilasa o transpeptidasa interrumpiéndose el ensamblaje de    las moléculas precursoras del peptidoglicano (N-acetilmurámico    + péptido y N-acetilglucosamina en bacilos Gram negativos o incluyendo    un pentapéptido de glicina en S. aureus), de esta manera se interrumpe    la síntesis de esta cubierta. Esto sumado a la activación autolítica    llevaría finalmente a la lisis osmótica y por tanto a la muerte    de la bacteria6,7,49,51.  

En las bacterias Gram negativas las PBPs se disponen hacia    el espacio periplásmico por la presencia de la membrana externa (que    constituye una barrera al paso de una importante cantidad de moléculas);    a diferencia de las bacterias Gram positivas, donde las PBPs se encuentran en    la membrana citoplasmática expuestas al medio externo52.    Por tanto, para que una cefalosporina alcance su blanco (PBP) en un bacilo Gram    negativo debe poseer una adecuada penetración a través de las    porinas de la membrana externa (canales que permiten el ingreso de moléculas    desde el medio externo hacia el espacio periplásmico). En este contexto,    la mayor penetración intracelular es una característica microbiológica    de interés de las cefalosporinas de cuarta generación36,53.  

Clasificación 

Existe un número importante de clasificaciones, destaca    entre ellas la clasificación biológica de O'Callaghan, actualmente    de carácter histórico, que subdividió a estos antimicrobianos    en 7 grupos de acuerdo a su metabolismo y estabilidad a la degradación    por ß-lactamasas54. Otra clasificación,    de carácter químico, agrupa a las cefalosporinas de acuerdo a    los sustitu-yentes presentes en el carbono de la cadena lateral de C7,    distinguiéndose cuatro grupos: cefalosporinas sustituidas y no sustituidas    a este nivel; a- amino cefalosporinas y aril-oxi-imino cefalosporinas44.    Interesantemente, otra clasificación es sólo de carácter    farmacocinético, de acuerdo al tiempo de vida media, y aplicada fundamentalmente    a las cefalosporinas de uso parenteral, así en el grupo 1, se incluyen    aquellos compuestos que tienen vidas medias menores de 1 hora (cefalotina, cefradina,    cefapirina, cefoxitina); en el grupo 2 compuestos con vidas medias entre 1 y    3 horas (cefazolina, cefmetazol, cefuroxima, cefotaxima, ceftixozima, moxalactam,    cefmenoxima, cefoperazona, ceftazidima, cefpiroma, cefepime) y finalmente en    el grupo 3 aquellas cefalosporinas con tiempos de vida media mayores a 3 horas    (cefpiramide, ceftriaxona, cefodizima)23,55.    A su vez, dentro de cada uno de estos grupos las moléculas son subdivididas    según la ruta principal de eliminación (renal, biliar). Otras    clasificaciones subdividen a las cefalosporinas de acuerdo a sus propiedades    microbiológicas, principalmente el espectro de actividad. En los grupos    I y II, cefalosporinas de amplio espectro, se incluyen moléculas de primera    y segunda generación, respectivamente. En el grupo III, se incluyen moléculas    de tercera generación y oxacefems. En el grupo IV cefalosporinas de cuarta    generación. En el grupo V, o de cefalosporinas de reducido espectro,    se incluye a cefsulodina44. 

 Otra clasificación, más funcional en una perspectiva    microbiológica, fue desarrollada por J.D. Williams, quien agrupó    a estas moléculas de acuerdo a su espectro antibacteriano enfatizando    la cobertura sobre bacterias Gram positivas, Gram negativas, Pseudomonas    aeruginosa y anaerobias. Así el grupo I incluye a las moléculas    con mayor actividad sobre Gram positivos (cefradina, cefradoxilo, cefalexina,    cefalotina); el grupo II, a cefalosporinas con mayor actividad sobre Gram negativos    (cefuroxima, cefotaxima, ceftriaxona, ceftizoxima); el grupo III a compuestos    con actividad sobre P. aeruginosa (ceftazidima, cefoperazona) y el grupo    IV a moléculas con actividad sobre bacterias anaerobias (cefoxitina,    cefotetan, moxalactam)56. 

Sin embargo, desde el punto de vista clínico, la clasificación    más utilizada agrupa a estos compuestos de acuerdo al desarrollo histórico    y algunas características microbiológicas y estructurales en común,    las denominadas generaciones de cefalosporinas3,4-6,14.    A las ya conocidas moléculas de primera, segunda y tercera generación    se agregan las denominadas cefalos-porinas de cuarta generación, destacando    en este grupo: cefepime y cefepiroma, aunque también se incluyen en este    grupo otras moléculas todavía en fase de desarrollo como: cefoselis,    cefclidin, cefozopram y cefluprenam57-62.  

Dado que la clasificación en generaciones es la de mayor    uso, se discutirán algunas características relevantes de éstas:  

Las cefalosporinas de primera generación presentan mejor    actividad sobre cocos Gram positivos como S. aureus susceptible a meticilina,    S. pyogenes y S. pneumoniae; sin embargo, como ya se comentó,    carecen de actividad sobre Enterococcus spp. Su actividad sobre bacilos    Gram negativos es limitada a cepas de E. coli, Klebsiella spp. y Proteus    mirabilis (no productoras de ß-lactamasas cromosomales y/o plasmidiales)3,7,14.    A pesar de la descripción de actividad in vitro sobre algunas    cepas de Salmonella y Shigella, las moléculas de este grupo    no son útiles para el tratamiento de infecciones producidas por estos    patógenos63-65. Además,    carecen de una actividad significativa sobre Haemophilus influenzae3,7,14,23.    En este grupo existen moléculas de uso oral y parenteral; desde un punto    de vista farmacológico se caracterizan por sus cortos tiempos de vida    media (aunque cefazolina y cefadroxilo presentan tiempos de eliminación    más prolongados que el resto de las moléculas del grupo), baja    penetración al LCR y excreción por vía urinaria alcanzando    adecuados niveles terapéuticos para el tratamiento de infecciones por    especies uropatógenas comunitarias susceptibles3,16,23,66.  

La característica microbiológica definitiva de    las cefalosporinas de segunda generación es su actividad sobre H.    influenzae, Moraxella catarrhalis, Neisseria meningitidis y Neisseria gonorrhoeae.    En esta generación de cefalos-porinas, también se incluyen    otras moléculas que técnicamente corresponden a: 

  • Cefamicinas: químicamente son 7-alfa metoxi-cefalosporinas. Estas    moléculas - cefoxitina, cefotetan- presentan una potente actividad sobre    Bacteroides fragilis3,67,68.   • Carbacefems: químicamente estos compuestos se caracterizan porque    el azufre del anillo dihidrotiazínico del grupo cefem está sustituido    por un carbono (carba) de un grupo metileno (CH2). Así loracarbef    se diferencia de cefaclor sólo por el ambio estructural previamente señalado    (carbono en vez de azufre)69.  Por otra parte, la descripción de una mayor actividad    microbiológica de moléculas de este grupo sobre enterobacterias    resistentes a cefalotina - como cepas de Enterobacter, Serratia, Citrobacter,    Providencia y Proteus indol-positivos - carece de importancia microbiológica    y clínica, dados los actuales perfiles de susceptibilidad de los bacilos    Gram negativos26,30,70,71.   Debe enfatizarse que los antimicrobianos de esta generación    - incluyendo tanto a cefalosporinas, cefamicinas y carbacefems (o carbacefemas)-    carecen de actividad sobre P. aeruginosa; además, con la excepción    de cefamandol, son menos activos que sus congéneres de primera generación    sobre cepas de S. aureus susceptibles a oxacilina3,5,23,72.    Desde un punto de vista farmacológico no difieren en forma sustancial    de las moléculas de primera generación, excepto en su mejor penetración    al LCR; sin embargo, no se consideran agentes de elección en el tratamiento    de MBA debido a la menor eficacia clínica al compararlas con moléculas    de tercera generación, por ejemplo cefuroxima versus ceftriaxona20,73.   Las cefalosporinas de tercera generación constituyen    uno de los grupos de antimicrobianos de mayor uso en la actualidad. Los compuestos    de esta generación se caracterizan por presentar, al menos, dos de las    siguientes características:   • en C-7 del núcleo cefem, la presencia de un anillo 2-aminotiazolil    como cadena lateral  • amplio espectro de actividad  • elevada actividad sobre Enterobacteriaceae (excepto    sobre cepas hiperproductoras de cefalosporinasas y/o ESBLs), H. influenzae,    Neisseria spp., S. pyogenes y S. pneumoniae y actividad sobre    P. aeruginosa (ceftazidima y cefoperazona)42,74.   En este contexto es importante destacar que si bien ceftriaxona    y cefotaxima son agentes de elección en el tratamiento de MBA adquirida    en la comunidad, la descripción creciente de cepas de S. pneumoniae    resistentes a penicilina y cefalosporinas ha limitado en algunos centros, su    uso como monoterapia empírica para el tratamiento de infecciones meníngeas75.    Por otra parte, la actividad de estos agentes sobre S. aureus susceptible    a meticilina es menor que la de los congéneres de primera y segunda generación,    debiéndose considerar que ceftazidima y los agentes de uso oral cefixima    y ceftibuten carecen de una actividad microbiológica útil sobre    este patógeno7,23,76,77.    Desde una perspectiva farmacológica en este grupo existen moléculas    como ceftriaxona que presentan tiempos de vida media prolongados, permitiendo    su dosificación cada 12 o incluso cada 24 horas; además, cefotaxima    es metabolizada a una forma biológicamente activa (desacetilcefotaxima)    y por otra parte estos agentes alcanzan concentraciones útiles en una    serie de tejidos y parénquimas, entre ellos sangre, orina, bilis (particularmente    cefoperazona y ceftriaxona), pulmones, líquido peritoneal y meninges3,14,39,78.   Es interesante destacar que en los grupos analizados, cefalosporinas    de primera hasta tercera generación, hay agentes de uso oral, que en    términos generales mantienen las características microbiológicas    generales de las respectivas generaciones, por ejemplo, cefadroxilo, cefuroxima    y cefixima, respectivamente7,16,77.   CEFALOSPORINAS DE CUARTA GENERACION Las cefalosporinas de cuarta generación se caracterizan    químicamente por la presencia de un grupo metoxi-imino aminotiazolil    en R1 del núcleo cefem (similar al que presentan las moléculas    de tercera generación), excepto cefclidin (previamente E 1040) que presenta    un radical muy similar: aminotiadiazolil, y principalmente por la presencia    de un nitrógeno cuaternario en R2 (Figura    3). Este grupo se mantiene cargado positivamente tanto en condiciones de    pH ácido como alcalino. La asociación de esta carga neta positiva    con una carga negativa en C4 del núcleo cefem hace de estos    antibacterianos moléculas zwitteriónicas, es decir, moléculas    con un balance entre sus cargas positivas y negativas en los rangos de pH encontrados    in vivo (Figura 4)36,53,57,58,79.      

Figura 3. Estructura química de cefepime y cefpirome,          respectivamente.          

Figura 4. Estructura zwitteriónica            de las cefalosporinas de cuarta generación.      Esta característica químico-estructural explica    por qué estas cefalosporinas presentan una penetración a través    de las porinas, superior a sus congéneres de tercera generación,    lo que le permite alcanzar altas concentraciones en el espacio periplásmico    de bacilos Gram negativos79,80.    Experimentalmente se ha demostrado que cefpiroma, cefepima y cefclidin tienen    una velocidad de penetración intracelular, sobre cepas de E. coli    y E. cloacae, varias veces superior a la de cefotaxima y ceftazidi-ma79-81.    Esta propiedad se relacionaría con el balance de cargas químicas    de estos compuestos, ya que, si bien las cefalosporinas de cuarta generación    son moléculas de mayor tamaño que sus congéneres de tercera    generación, presentan en su estructura química una importante    carga positiva (a nivel del amonio cuaternario) y además son selectivamente    incorporadas a través de la porina Omp F36,58,79-81.    Ceftazidima, en cambio, tiene una carga neta negativa, a pesar de presentar    una carga positiva en C3. La penetración intracelular más    lenta de esta molécula puede explicarse entonces por el potencial de    Donnan de la bacteria (interior negativo)58,80.    Sin embargo, el solo aumento de la penetración intracelular, no explica    en forma exclusiva la importante actividad antibacteriana de estos compuestos,    particularmente sobre bacterias resistentes. Así, cefaloridina que estructuralmente    también es una molécula dipolar, sin carga neta, con un amonio    cuaternario en C3, presenta una penetración intracelular incluso    superior a las moléculas de cuarta generación; sin embargo, al    carecer del radical metoxi-imino no presenta una adecuada estabilidad frente    a beta-lactamasas, siendo rápidamente degradada5,36,58.   Por lo anterior otro aspecto relevante para explicar la mayor    actividad de estas cefalos-porinas sobre bacterias Gram negativas resistentes    a moléculas de tercera generación, es la estabilidad frente a    las ß-lactamasas tanto cromosomales como plasmidiales y su afinidad por    el sitio blanco: PBP´s36,58,80,82,83.    Así, la actividad sobre cepas hiperproductoras de ß-lactamasas    del grupo 1 de Bush (cefalospori-nasas cromosomales) se explica por la baja    afinidad de la ß-lactamasa por la cefalosporina (en general valores más    elevados para Km); habiéndose establecido que la afinidad    de estas enzimas por cefotaxima es 1.000 a 10.000 veces mayor que sobre cefepima    y del orden de 10 a 100 veces superior para ceftazidima en comparación    con cefepima36,58.  Por otra parte, el efecto final de los sustitu-yentes en la    relación estructura-actividad de estos compuestos, es decir, mantención    de sustituyentes con importante actividad sobre Gram negativos como metoxi-imino,    como la presencia en la misma molécula de radicales que incrementan la    actividad sobre cocáceas Gram positivas como amonio cuaternario, explican    la actividad microbiológica "más balanceada" de estos    antimicrobianos, ya que presentan una elevada actividad in vitro sobre    Gram positivos, particularmente, S. pneumonaie (incluyendo cepas resistentes    a penicilina), junto a una potente actividad inhibitoria y bactericida sobre    bacilos Gram negativos entéricos, incluyéndose, como ya se mencionó,    cepas multiresis-tentes capaces de degradar moléculas de tercera generación    (Tabla 1)36,84-86.     Tabla 1. Actividad inihibitoria de cefepime,    cefotaxima y ceftazidima, en presencia        y ausencia de ácido clavulánico, sobre 75 cepas de K. pneumoniae    y 12 cepas de E. coli     productoras de ESßLs aisladas de diferentes hospitales chilenos           CMI (ug/ml)      Antibiótico Microorganismo Rango 50 90 % resistencia   CFTX K. pneumoniae 4-256 32,0 64 100     E. coli 4-256 64,0 1280 092       CFTX + AC K. pneumoniae < 0,25-2 < 0,25 16 003     E. coli 1-32 20 32 025       CFZD K. pneumoniae 8- > 256 320, > 25600 100     E. coli 8- > 256 64,0 256, 100       CFZD + AC K. pneumoniae < 0,25-16 10 04 004     E. coli 2- > 32 40 32 025       CFPM K. pneumoniae < 0,25-128 < 0,25 16 000,2,6     E. coli < 0,25-256 < 0,25 32 025       CFPM + AC K. pneumoniae < 0,25-32 < 0,25 02 ,0,0     E. coli < 0,25-32 < 0,25 32 017     Cefotaxima (CFTX), Ceftazidima (CFZD), Cefepima (CFPM), Acido clavulánico          (AC)              *Cefalosporina: ácido clavulánico, 2:1       En forma general y práctica puede señalarse    que estos agentes despliegan una actividad superior a la de ceftriaxona y cefotaxima    sobre bacilos Gram negativos multiresistentes (Serratia, Citrobacter, Enterobacter,    Morganella, Providencia y cepas de Proteus indol negativo hiperproductoras    de cefalosporinasas y/o sobre de cepas de K. pneumoniae y E. coli    productoras de ESßLs ) y equivalente al de estos compuestos de tercera    generación sobre cepas de bacterias Gram negativos susceptibles y S.    pneumoniae36,58,84-86.    Con relación a su actividad sobre P. aeruginosa, estas moléculas    tienen una actividad antibacteriana comparable, pero no superior, a la de ceftazidima36,53,    57,58,82,83.   En este contexto, en nuestro laboratorio evaluamos la actividad    de cefepima, cefotaxima y ceftazidima sobre cepas de K. pneumoniae y    E. coli productoras de ESBLs aisladas de diferentes hospitales chilenos.    Es interesante destacar que de las cepas originalmente recibidas en nuestro    estudio, se determinó la producción de ESBLs en 43,9% de las cepas    de K. pneumoniae y en 8% de las cepas de E. coli. Cefepima demostró    ser el ß-lactámico de mayor actividad sobre las cepas ensayadas.    Así, 2,6% de los aislamientos de K. pneumoniae y 25% de las cepas    de E. coli fueron resistentes a este agente. Al analizar la Tabla    1 puede comprobarse también que con la asociación con ácido    clavulánico se produce un importante incremento en la susceptibilidad    de las bacterias en estudio a las cefalosporinas de tercera generación.    Este efecto fue más pronunciado sobre K. pneumoniae con disminución    de las frecuencias de resistencia de 100% (cefalos-porina) a 4% (cefalosporina    asociada a inhibidor de ß-lactamasa). La mayor susceptibilidad de las    bacterias a la asociación de cefalosporina de tercera generación    y ácido clavulánico (AC) se explica por la actividad hidrolizante    de ESßLs sobre las cefalosporinas. Por lo tanto, el escaso efecto sinergístico    de AC y cefepima sugiere una escasa actividad de ESßLs como mecanismo    de resistencia a esta cefalosporina de cuarta generación. De lo anterior    puede concluirse que cefepima es activa sobre una importante proporción    de cepas chilenas de K. pneumoniae y de E. coli productoras de    ESßLs.  Como última característica microbiológica    general, debe destacarse que estos compuestos son débiles inductores    de la producción de ß-lactamasas cromosomales, a diferencia de    lo que ocurre con carbapenémicos y cefamicinas, que característicamente    son potentes inductores de ß-lactamasas Amp C25,37.   Finalmente, basándonos en el aumento cada vez más    creciente de la resistencia bacteriana, la mayor sobrevida de huéspedes    susceptibles, el lento desarrollo de nuevas familias de antimicrobianos (con    excepción de las oxazolidinonas) y las propiedades microbiológicas    de las cefalosporinas de cuarta generación, debemos plantear que -de    acuerdo a los estudios de susceptibilidad locales- las cefalosporinas de cuarta    generación podrían representar una alternativa terapéutica    para el tratamiento de infecciones producidas por bacilos Gram negativos resistentes    a cefalosporinas de tercera generación87-91.   RESUMEN  Las cefalosporinas son uno de los grupos de mayor importancia    dentro de los ß-lactámicos. Existen diversas clasificaciones de    estas moléculas, siendo la más utilizada aquella que agrupa a    estos compuestos de acuerdo a propiedades estructurales, microbiológicas    y desarrollo histórico: primera a cuarta generación. Las cefalosporinas    de tercera generación han sido ampliamente utilizadas, pero la emergencia    de resistencia bacteriana fundamentalmente derivada de la producción    de ß-lactamasas tanto cromosomales como plasmidiales, ha limitado el uso    de estos compuestos. Las cefalosporinas de cuarta generación se caracterizan    por la presencia de un nitrógeno cuaternario en C3, además    de mantener el grupo metoxi-imino aminotiazolil en C7. Presentan    una elevada penetración intracelular a través de la membrana externa    de bacilos Gram negativos y tienen una baja afinidad por enzimas que degradan    cefalos-porinas de tercera generación. Cefepime, una cefalosporina de    cuarta generación, demostró una mayor actividad inhibitoria sobre    cepas chilenas de Klebsiella pneumoniae y Escherichia coli productoras    de ß-lactamasas de espectro extendido, que cefotaxima y ceftazidima.  Universidad de Concepción:      1 Departamento de Microbiología, Facultad de Ciencias Biológicas.         2 Departamento de Medicina Interna, Facultad de Medicina.      3 Facultad de Medicina. Universidad San Sebastián, Concepción.           Este trabajo fue financiado por el Proyecto Nº 1980109 del Fondo Nacional    de Desarrollo Científico y Tecnológico (FONDECYT)  BIBLIOGRAFIA  1.- ROLINSON G N. The influence of 6-aminopenicillanic    acid on antibiotic development. J Antimicrob Chemother 1988; 22: 5-14.         [ Links ]2.- ZEMELMAN R, NORAMBUENA R, VERGARA L, GACITUA    R. Los antibióticos ß-lactámicos: agrupación según    su estructura química y sus propiedades bacteriológicas. Rev Méd    Chile 1987; 115: 983-91.         [ Links ]3.- FRIED J S, HINTHORN D R. The cephalosporins.    Dis a Month 1985; 31: 1-60.         [ Links ]4.- NEU HC. Structure-activity relations of    new ß-lactam compounds and in vitro activity against common bacteria.    Rev Infect Dis 1983; 5 (suppl 2): S319-.         [ Links ]5.- NEU H C. Beta-lactam antibiotics structural    relationships affecting in vitro activity and pharmacological properties. Rev    Infect Dis 1986; 8 (Suppl 3): 237-59         [ Links ]6.- NEU H C. Relation of structural properties    of beta-lactam antibiotics to antibacterial activity. Am J Med 1985; 79 (Suppl    2 A): 2-13.         [ Links ]7.- SCHOLAR E M, PRATT W B (Eds). The inhibitors    of cell wall synthesis, II. The antimicrobial drugs. Oxford University Press.    2000 Nueva York. pp:         [ Links ]8.- LOPEZ F, GARRIDO J C. Química y    relación estructura-actividad de los antibióticos cefalosporínicos    (I). Rev Col Químico Farmacéutico 1988; 44: 110-22.         [ Links ]9.- TURNIDGE J D. The pharmacodynamics of        ß-lactams. Clin Infect Dis 1998; 27: 10-22.  10.- CRAIG W A. The future-can we learn from    the past? Diagn Microbiol Infect Dis 1997; 27: 49-53.         [ Links ]11.- DUDLEY M N. Pharmacodynamics and pharmacokinetics    of antibiotics with special reference to the fluoroquinolones. Am J Med 1991;    91 (Suppl 6 A): 6A-45S.         [ Links ]12.- NICOLAU D P, QUINTILIANI R, NIGHTINGALE    C H. Cinética y dinámica de los antibióticos para el clínico.    Clin Med Nort Am 1995; 79: 483-500.         [ Links ]13.- DRUSANO G L. Human pharmacodynamics of    beta-lactams, aminoglycosides and their combination. Scand J Infect Dis 1991    (Suppl); 74: 235-48.         [ Links ]14.- MARSHALL W F, BLAIR J E. The cephalosporins.    Mayo Clinic Proc 1999; 74: 187-95.         [ Links ]15.- DONOWIRZ G R, MANDELL G L. Beta-lactam    antibiotics. N Engl J Med 1988; 318: 490-500.         [ Links ]16.- PAYA E. Ventajas y desventajas de las    cefalosporinas orales de segunda y tercera generación. Rev Chil Infect    1997; 14: 233-8.         [ Links ]17.- AMERICAN THORACIC SOCIETY. Guidelines    for the initial management of adults with community-acquired pneumonia: diagnosis,    assessment of severity, and initial antimicrobial therapy. Am Rev Respir Dis    1993; 148: 1418-26.         [ Links ]18.- BARTLETT J G, BREIMAN R F, MANDELL L    A, FILE T M Jr. Community-acquired pneumonia in adults: guidelines for management.    The Infectious Diseases Society of America. Clin Infect Dis 1998: 26: 811-38.          [ Links ]19.- MARRIE T J. Community-acquired pneumonia:    epidemiology, etiology, treatment. Infect Dis Clin North Am 1998; 12: 723-40          [ Links ]20.- TUNKEL A R, SCHELD W M. Acute meningitis.    In: Mandell, Douglas & Bennett's. Principles and Practice of Infectious    Diseases. Mandell G L, Bennett J E, Dolin R, eds. Fifth edition. Philadelphia:    Editorial Churchill Livingstone 2000; 959-96.         [ Links ]21.- AMERICAN THORACIC SOCIETY. Hospital-acquired    pneumonia in adults: diagnosis, assessment of severity, initial antimicrobial    therapy, and preventive strategies. A consensus statement. Am J Respir Crit    Care Med 1996; 153: 1711-25.         [ Links ]22.- BARTLETT J G, DOWELL S F, MANDELL L A,    FILE T M, MUSHER D M, FINE M J. Practice guidelines for the management of community-acquired    pneumonia in adults. Clin Infect Dis. 2000; 31: 347-82         [ Links ]23.- KARCHMER A W. Cephalosporins. In: Mandell,    Douglas & Bennett's. Principles and Practice of Infectious Diseases. Mandell    G L, Bennett J E, Dolin R, eds. Fifth edition. Philadelphia: Churchill Livingstone    2000; 274-99.         [ Links ]24.- ADU A, ARMOUR C L. Drug utilisation review    (DUR) of the third generation cephalosporins. Drugs 1995; 50: 423-39.         [ Links ]25.- JONES R N. Important and emerging ß-lactamase    mediated resistances in hospital-based pathogens: the Amp C enzymes. Diagn Microbiol    Infect Dis 1998; 31: 461-6.         [ Links ]26.- JARVIS W R, MARTONE W J. Predominant    pathogens in hospital infections. J Antimicrob Chemother 1992; 29: 19-24.         [ Links ]27.- LIVERMORE D M. ß-lactamases in    laboratory and clinical resistance. Clin Microbiol Rev 1995; 8: 557-84.         [ Links ]28.- HERITAGE J, M'ZALI F H, GASCOYNE-BINZI    D, HAWKEY P M. Evolution and spread of SHV extended-spectrum ß-lactamases    in gram negative bacteria. J Antimicrob Chemother 1999; 44: 309-18.         [ Links ]29.- PODSCHUN R, ULLMAN U. Klebsiella spp.    as nosocomial pathogens: epidemiology, taxonomy, typing methods, and pathogenicity    factors. Clin Microbiol Rev 1998; 11: 589-603.         [ Links ]30.- PITOUT J D D, SANDERS C C, SANDERS W    E. Antimicrobial resistance with focus on ß-lactam resistance in Gram    negative bacilli. Am J Med 1997; 103: 51-9.         [ Links ]31.- HANBERGER H, GARCIA-RODRIGUEZ J A, GOBERNADO    et al. Antibiotic susceptibility among aerobic Gram negative bacilli in intensive    care units in 5 european countries. JAMA 1999; 281: 67-71.         [ Links ]32.- CHARREL R N, PAGES J M, DE MICCO P et    al. Prevalence of outer membrane porin alteration in ß-lactam-antibiotic-resistant    Enterobacter aerogenes. Antimicrob Agents Chemother 1996; 40: 2854-8.          [ Links ]33.- BRADFORD P A, URBAN C, MARIANO N, PROJAN    S J, RAHAL J J, BUSH K. Imipenem resistance in Klebsiella pneumoniae is    associated with the combination of ACT-1, a plasmid-mediated Amp C ß-lactamase,    and the loss of an outer membrane protein. Antimicrob Agents Chemother 1997;    41: 563-9.         [ Links ]34.- QUEENAN A M, TORRES-VIERA C, GOLD H et    al. SME-type carbapenem-hydrolizing class A ß-lactamases from geographically    diverse Serratia marcescens strains. Antimicrob Agents Chemother 2000;    44: 3035-9.         [ Links ]35.- COHEN S P, MC MURRY L M, HOOPER D C,    WOLFSON J S, LEVY S B. Cross-resistance to fluoroquinolones in multiple-antibiotic-resistance    (Mar) Escherichia coli selected by tetracycline resistance: decreased    drug accumulation asociated with membrane changes in addition to Omp F reduction.    Antimicrob Agents Chemother 1989; 33:1318-25.         [ Links ]36.- SANDERS C C. Cefepime: The next generation?    Clin Infect Dis 1993; 17: 369-79         [ Links ]37.- GARAU J. The clinical potential of fourth-generation    cephalosporins. Diagn Microbiol Infect Dis 1998; 31: 479-80.         [ Links ]38.- CURTIS N A C, ORR D C, ROSS G W, BOULTON    M G. Affinities of penicillins and cephalosporins for the penicillin-binding    proteins of Escherichia coli    K-12 and their antibacterial activity. Antimicrob Agents Chemother 1979; 16:    533-9.  39.- BALANT L, DAYER P, AUCKENTHALER R. Clinical    pharmacokinetics of the third generation cephalosporins. Clin Pharmacokinetics    1985; 10: 101-43.         [ Links ]40.- WHEELER W J. Cephalosporins and other    beta-lactam antibiotics. Lloydia. 1977; 40: 519-42.         [ Links ]41.- LOPEZ F, GARRIDO J C. Química    y relación estructura-actividad de los antibióticos cefalosporínicos.    Rev Col Químico Farmacéutico 1989; 41: 5-14.         [ Links ]42.- FU K P, ASWAPOKEE P, HO I, MATTHIJSSEN    C, NEU H C. Pharmacokinetics of cefotaxime. Antimicrob Agents Chemother 1979;16:    592-7.         [ Links ]43.- YUK J H, NIGHTINGALE C H, QUINTILIANI    R. Clinical pharmacokinetics of ceftriaxone. Clin Pharmacokinetic 1989; 17:    223-35.         [ Links ]44.- BRYSKIER A, PROCYK T, LABRO M T. Cefodizime,    a new 2-aminothiazolyl cephalosporin: physicochemical properties, toxicology    and structure-activity relationships. J Antimicrob Chemother 1990; 26 (Suppl    C): 1-8.         [ Links ]45.- CRITCHLEY I A, BASKER M J, EDMONDSON    R A, KNOTT S J. Uptake of catecholic cephalosporin by the iron transport system    of Escherichia coli. J Antimicrob Chemother 1991; 28: 377-88.         [ Links ]46.- CRITCHLEY I A. Catecholic ß-lactams:    facilitated transport. J Antimicrob Chemother 1990; 26: 733-7.         [ Links ]47.- JONES R N, ERWIN M E. In vitro evaluation    of Ro 09-1227, a novel catechol-substituted cephalosporin. Antimicrob Agents    Chemother 1992; 36: 233-8.         [ Links ]48.- JONES R N. In vitro activity of Ro 24-6392,    a novel ester-linked co-drug combining ciprofloxacin and desacetylcefotaxime.    Eur J Clin Microbiol Infect Dis 1990; 9: 435-8.         [ Links ]49.- TOMASZ A. Penicillin-binding proteins    and the antibacterial effectiveness of ß-lactam antibiotics. Rev Infect    Dis 1986 (Suppl 3); 8: 260-78.         [ Links ]50.- HOLM S E. Interaction between ß-lactam    and other antibiotics. Rev Infect Dis 1986 (Suppl 3); 8: 305-14.         [ Links ]51.- MC CULLERS J A, ENGLISH B K, NOVAK R.    Isolation and characterization of vancomycin-tolerant Streptococcus pneumoniae    from the cerebrospinal fluid of a patient who developed recrudescet meningitis.    J Infect Dis 2000; 181: 369-73.         [ Links ]52.- NIKAIDO H. Outer membrane barrier as    a mechanism of antimicrobial resistance. Antimicrob Agents Chemother 1989; 33:    1831-6.         [ Links ]53.- BARRADELL L B, BRYSON H M. Cefepime.    A review of its antibacterial activity, pharmacokinetic properties and therapeutic    use. Drugs 1994; 47: 471-505.         [ Links ]54.- O'CALLAGHAN C H 1979. Description and    classification of the newer cephalosporins and their relationship with the established    compounds. J Antimicrob Chemother 5: 635-71         [ Links ]55.- BRYSKIER A, PROCYK T, TREMBLAY D, LENFANT    B FOURTILLAN J B. The pharmacokinetics of cefodizime following intravenous and    intramuscular administration of a single dose of 1.0 g. J Antimicrob Chemother    1990; 26 (Suppl. C): 59-63.         [ Links ]56.- WILLIAMS J D. Classification of cephalosporins.    Drugs. 1987; 34 (Suppl 2): 15-22.         [ Links ]57.- WISEMAN L R, LAMB H M. Cefpirome. A review    of its antibacterial activity, pharmacokinetic properties and efficacy in the    treatment of severe nosocomial infections and febrile neutropenia. Drugs 1997;    57: 117-40.         [ Links ]58.- PECHERE J C, WILSON W, NEU H. Laboratory    assesment of antibacterial activity of zwitterionic 7-methoxyimino cephalosporins.    J Antimicrob Chemother 1995; 36: 757-71         [ Links ]59.- GIAMARELLOS-BOURBOULIS EJ, GRECKA P,    TSITSIKA A, TYMPANIDOU C, GIAMARELLOU H. In-vitro activity of FK 037 (cefoselis),    a novel 4 (th) generation cephalosporin, cefepime and cefpirome on nosocomial    staphylococci and gram-negative isolates. Diagn Microbiol infect Dis 2000; 36:    185-91.         [ Links ]60.- JONES R N, ERWIN M E, BARRETT M S, JOHNSON    D M, BRIGGS B M. Antimicrobial activity of E-1040, a novel thiadiazolyl cephalosporin    compare with parenteral cephems. Diagn Microbiol infect Dis 1991; 14: 301-9.          [ Links ]61.- IIZAWA Y, OKONOGI K, HAYASHI R, IWAHI    T, YAMAZAKI T, IMADA A. Therapeutic effect of cefozopran (SCE-2787), a new parenteral    cephalosporin in experimental infections in mice. Antimicrob Agents Chemother    1993; 37: 100-5.         [ Links ]62.- WATANABE N A. Newer antipseudomonal cephalosporins.    J Chemother 1996; 8 (Suppl 2): 48-56.         [ Links ]63.- ACTOR P, GUARINI J, URI J et al. Disk    susceptibility studies with cefazolin and cephalotin. Antimicrob Agents Chemother    1974; 5: 63-7.         [ Links ]64.- UWAYDAH M. Cefazolin in the treatment    of acute enteric fever. Antimicrob Agents Chemother 1976; 10: 52-6.         [ Links ]65.- JAMAL W Y, ROTIMI V O, CHUGH T D, PAL    T. Prevalence and susceptibility of Shigella to 11 antibiotics in a Kuwait    teaching hospital. J Chemother 1998; 10: 285-90.         [ Links ]66.- COX CE, SHERRILL M, COCCHETT DM. Evaluation    of cefuroxime axetil, cefaclor, and cephalexin in the treatment of urinary tract    infections in adults. Curr Ther Res 1987; 42: 124-37.         [ Links ]67.- SANDERS C W, GREENBERG R N, MARIER R    L. Cefamandole and cefoxitin. Ann Intern Med 1985; 103: 70-8.          [ Links ]68.- STAPLEY E P, JACKSON M, HERNANDEZ S et    al. Cephamycins, a new family of ß-lactam antibiotics I. Production actinomycetes,    including Streptomyces lactamdurans spp.n. Antimicrob Agents Chemother    1972; 2: 122-31.         [ Links ]69.- COOPER R D G. The carbacephems a new    ß-lactams class. Am J Med 1992; 92 (Suppl 6 A): 25-65.         [ Links ]70.- ZEMELMAN R, BELLO H, DOMINGUEZ M, GONZALEZ    G, MELLA S, GARCIA A. Activity of imipenem, third-generation cephalosporins,    aztreonam, and ciprofloxacin against multi-resistant Gram negative bacilli isolated    from Chilean hospitals. J Antimicrob Chemother 1993; 32: 413-9.         [ Links ]71.- MEDEIROS A A. Evolution and dissemination    of ß-lactamases accelerated by generation of ß-lactam antibiotics.    Clin Infect Dis 1997; 24 (Suppl. 1): 19-45.         [ Links ]72.- PERRY C M, BROGDEN R N. Cefuroxime axetil:    review of its antibacterial activity, pharmacokinetic properties and therapeutic    efficacy. Drugs 1996; 52: 125-58.         [ Links ]73.- SCHAAD U B, SUTER S, GIANELLA-BORRADORI    et al. A comparison of ceftriaxone and cefuroxime for the treatment of bacterial    meningitis in children. N Engl J Med 1990; 322: 141-7.         [ Links ]74.- KLEIN N C, CUNHA B A. Cefalosporinas de    la tercera generación. Clin Med Nort Am 1995; 79: 693-707.         [ Links ]75.- KLUGMAN K P, MADHI S A. Emergence of    drug resistance impact on bacterial meningitis. Infect Dis Clin North Am 1999;    13: 637-46.         [ Links ]76.- RICHARDS D M, BROGDEN R N. Ceftazidime.    A review of its antibacterial activity, pharmacokinetic properties and therapeutic    use. Drugs 1985; 29: 105-61.         [ Links ]77.- SCHATZ B S, KARAVOKIROS K T, TAEUBEL    M A, ITOKAZU G S. Comparison of cefprozil, cefpodoxime proxetil, loracarbef,    cefixime, and ceftibuten. Ann Pharmacother 1996; 30: 258-68.         [ Links ]78.- DALMAU D, LAYRARGUES G P, FENYVES D,    WILLEMS B, TURGEON F, TURGEON P. Cefotaxime, desacetyl-cefotaxime, and bactericidal    activity in spontaneous bacterial peritonitis. J Infect Dis 1999; 180: 1597-1602.          [ Links ]79.- NIKAIDO W, LIU W, ROSENBERG E Y. Outer    membrane permeability and ß-lactamase stability of dipolar ionic cephalosporins    containing methoxyimino substituents. Antimicrob Agents Chemother 1990; 34:    337-42.         [ Links ]80.- HANCOCK R E W, BELLIDO F. Factors involved    in the enhanced efficacy against gram-negative bacteria of fourth generation    cephalosporins. J Antimicrob Chemother 1992; 29(Suppl A): 1-6.         [ Links ]81.- BELLIDO F, PECHERE J C, HANCOCK REW.    Novel method for measurement of outer membrane permeability to new beta-lactams    in intact Enterobacter cloacae cells. Antimicrob Agents Chemother 1991;    35: 68-72.         [ Links ]82.- NEU H C, CHIN N X, JULES K, LABTHAVIKUL    P. The activity of BMY-28142, a new broad spectrum beta-lactamase stable cephalosporin.    J Antimicrob Chemother 1986; 17: 441-52.         [ Links ]83.- KOBAYASHI S, ARAI S, HAYASHI S, FUJIMOTO    K. ß-lactamase stability of cefpirome (HR 810), a new cephalosporin with    a broad antimicrobial spectrum. Antimicrob Agents Chemother 1986; 30: 713-8.          [ Links ]84.- GARAU J, WILSON W, WOOD M, CARLET J.    Fourth generation cephalosporins: a review of in vitro activity, pharmacokinetics,    pharmacodynamics, and clinical utility. Clin Microb Infect 1997; 3 (Suppl 1):    87-101.         [ Links ]85.- KESSLER R E, FUNG-TOMC J. Susceptibility    of bacterial isolates to beta-lactam antibiotics from U.S. clinical trials over    5-year period. Am J Med 1996; 24 (6 A): 13-9.         [ Links ]86.- PIERARD D, EMMERECHTS K, LAUWERS S. Comparative    in-vitro activity of cefpirome against isolates from intensive care and haematology/oncology    units. Belgian Multicentric Study Group. J Antimicrob Chemother 1998; 41: 443-50.          [ Links ]87.- JONES R N. Resistance patterns among    nosocomial pathogens: trends over the past few years. Chest 2001; 119 (Suppl    2): 397-404.         [ Links ]88.- LORBER B. Changing patterns of infectious    diseases. Am J Med 1988; 84: 569-78.         [ Links ]89.- MOELLERING R C. A novel antimicrobial    agent joins the battle against resistant bacteria. Ann Intern Med 1999; 130:    155-7.         [ Links ]90.- WILSON W R. The role of fourth-generation    cephalosporins in the treatment of serious infectious diseases in hospitalized    patients. Diagn Microbiol Infect Dis 1998; 31: 473-7.         [ Links ]Correspondencia a:        Sergio Mella Montecinos        Laboratorio de Antibióticos,        Departamento de Microbiología,        Facultad de Ciencias Biológicas        Casilla 160-C, Concepción        E-mail: pignatio@ctcinternet.cl  

 • Cefamicinas: químicamente son 7-alfa metoxi-cefalosporinas. Estas    moléculas - cefoxitina, cefotetan- presentan una potente actividad sobre    Bacteroides fragilis3,67,68.   • Carbacefems: químicamente estos compuestos se caracterizan porque    el azufre del anillo dihidrotiazínico del grupo cefem está sustituido    por un carbono (carba) de un grupo metileno (CH2). Así loracarbef    se diferencia de cefaclor sólo por el ambio estructural previamente señalado    (carbono en vez de azufre)69.  Por otra parte, la descripción de una mayor actividad    microbiológica de moléculas de este grupo sobre enterobacterias    resistentes a cefalotina - como cepas de Enterobacter, Serratia, Citrobacter,    Providencia y Proteus indol-positivos - carece de importancia microbiológica    y clínica, dados los actuales perfiles de susceptibilidad de los bacilos    Gram negativos26,30,70,71.   Debe enfatizarse que los antimicrobianos de esta generación    - incluyendo tanto a cefalosporinas, cefamicinas y carbacefems (o carbacefemas)-    carecen de actividad sobre P. aeruginosa; además, con la excepción    de cefamandol, son menos activos que sus congéneres de primera generación    sobre cepas de S. aureus susceptibles a oxacilina3,5,23,72.    Desde un punto de vista farmacológico no difieren en forma sustancial    de las moléculas de primera generación, excepto en su mejor penetración    al LCR; sin embargo, no se consideran agentes de elección en el tratamiento    de MBA debido a la menor eficacia clínica al compararlas con moléculas    de tercera generación, por ejemplo cefuroxima versus ceftriaxona20,73.   Las cefalosporinas de tercera generación constituyen    uno de los grupos de antimicrobianos de mayor uso en la actualidad. Los compuestos    de esta generación se caracterizan por presentar, al menos, dos de las    siguientes características:   • en C-7 del núcleo cefem, la presencia de un anillo 2-aminotiazolil    como cadena lateral  • amplio espectro de actividad  • elevada actividad sobre Enterobacteriaceae (excepto    sobre cepas hiperproductoras de cefalosporinasas y/o ESBLs), H. influenzae,    Neisseria spp., S. pyogenes y S. pneumoniae y actividad sobre    P. aeruginosa (ceftazidima y cefoperazona)42,74.   En este contexto es importante destacar que si bien ceftriaxona    y cefotaxima son agentes de elección en el tratamiento de MBA adquirida    en la comunidad, la descripción creciente de cepas de S. pneumoniae    resistentes a penicilina y cefalosporinas ha limitado en algunos centros, su    uso como monoterapia empírica para el tratamiento de infecciones meníngeas75.    Por otra parte, la actividad de estos agentes sobre S. aureus susceptible    a meticilina es menor que la de los congéneres de primera y segunda generación,    debiéndose considerar que ceftazidima y los agentes de uso oral cefixima    y ceftibuten carecen de una actividad microbiológica útil sobre    este patógeno7,23,76,77.    Desde una perspectiva farmacológica en este grupo existen moléculas    como ceftriaxona que presentan tiempos de vida media prolongados, permitiendo    su dosificación cada 12 o incluso cada 24 horas; además, cefotaxima    es metabolizada a una forma biológicamente activa (desacetilcefotaxima)    y por otra parte estos agentes alcanzan concentraciones útiles en una    serie de tejidos y parénquimas, entre ellos sangre, orina, bilis (particularmente    cefoperazona y ceftriaxona), pulmones, líquido peritoneal y meninges3,14,39,78.   Es interesante destacar que en los grupos analizados, cefalosporinas    de primera hasta tercera generación, hay agentes de uso oral, que en    términos generales mantienen las características microbiológicas    generales de las respectivas generaciones, por ejemplo, cefadroxilo, cefuroxima    y cefixima, respectivamente7,16,77.   CEFALOSPORINAS DE CUARTA GENERACION Las cefalosporinas de cuarta generación se caracterizan    químicamente por la presencia de un grupo metoxi-imino aminotiazolil    en R1 del núcleo cefem (similar al que presentan las moléculas    de tercera generación), excepto cefclidin (previamente E 1040) que presenta    un radical muy similar: aminotiadiazolil, y principalmente por la presencia    de un nitrógeno cuaternario en R2 (Figura    3). Este grupo se mantiene cargado positivamente tanto en condiciones de    pH ácido como alcalino. La asociación de esta carga neta positiva    con una carga negativa en C4 del núcleo cefem hace de estos    antibacterianos moléculas zwitteriónicas, es decir, moléculas    con un balance entre sus cargas positivas y negativas en los rangos de pH encontrados    in vivo (Figura 4)36,53,57,58,79.      

Figura 3. Estructura química de cefepime y cefpirome,          respectivamente.          

Figura 4. Estructura zwitteriónica            de las cefalosporinas de cuarta generación.      Esta característica químico-estructural explica    por qué estas cefalosporinas presentan una penetración a través    de las porinas, superior a sus congéneres de tercera generación,    lo que le permite alcanzar altas concentraciones en el espacio periplásmico    de bacilos Gram negativos79,80.    Experimentalmente se ha demostrado que cefpiroma, cefepima y cefclidin tienen    una velocidad de penetración intracelular, sobre cepas de E. coli    y E. cloacae, varias veces superior a la de cefotaxima y ceftazidi-ma79-81.    Esta propiedad se relacionaría con el balance de cargas químicas    de estos compuestos, ya que, si bien las cefalosporinas de cuarta generación    son moléculas de mayor tamaño que sus congéneres de tercera    generación, presentan en su estructura química una importante    carga positiva (a nivel del amonio cuaternario) y además son selectivamente    incorporadas a través de la porina Omp F36,58,79-81.    Ceftazidima, en cambio, tiene una carga neta negativa, a pesar de presentar    una carga positiva en C3. La penetración intracelular más    lenta de esta molécula puede explicarse entonces por el potencial de    Donnan de la bacteria (interior negativo)58,80.    Sin embargo, el solo aumento de la penetración intracelular, no explica    en forma exclusiva la importante actividad antibacteriana de estos compuestos,    particularmente sobre bacterias resistentes. Así, cefaloridina que estructuralmente    también es una molécula dipolar, sin carga neta, con un amonio    cuaternario en C3, presenta una penetración intracelular incluso    superior a las moléculas de cuarta generación; sin embargo, al    carecer del radical metoxi-imino no presenta una adecuada estabilidad frente    a beta-lactamasas, siendo rápidamente degradada5,36,58.   Por lo anterior otro aspecto relevante para explicar la mayor    actividad de estas cefalos-porinas sobre bacterias Gram negativas resistentes    a moléculas de tercera generación, es la estabilidad frente a    las ß-lactamasas tanto cromosomales como plasmidiales y su afinidad por    el sitio blanco: PBP´s36,58,80,82,83.    Así, la actividad sobre cepas hiperproductoras de ß-lactamasas    del grupo 1 de Bush (cefalospori-nasas cromosomales) se explica por la baja    afinidad de la ß-lactamasa por la cefalosporina (en general valores más    elevados para Km); habiéndose establecido que la afinidad    de estas enzimas por cefotaxima es 1.000 a 10.000 veces mayor que sobre cefepima    y del orden de 10 a 100 veces superior para ceftazidima en comparación    con cefepima36,58.  Por otra parte, el efecto final de los sustitu-yentes en la    relación estructura-actividad de estos compuestos, es decir, mantención    de sustituyentes con importante actividad sobre Gram negativos como metoxi-imino,    como la presencia en la misma molécula de radicales que incrementan la    actividad sobre cocáceas Gram positivas como amonio cuaternario, explican    la actividad microbiológica "más balanceada" de estos    antimicrobianos, ya que presentan una elevada actividad in vitro sobre    Gram positivos, particularmente, S. pneumonaie (incluyendo cepas resistentes    a penicilina), junto a una potente actividad inhibitoria y bactericida sobre    bacilos Gram negativos entéricos, incluyéndose, como ya se mencionó,    cepas multiresis-tentes capaces de degradar moléculas de tercera generación    (Tabla 1)36,84-86.     Tabla 1. Actividad inihibitoria de cefepime,    cefotaxima y ceftazidima, en presencia        y ausencia de ácido clavulánico, sobre 75 cepas de K. pneumoniae    y 12 cepas de E. coli     productoras de ESßLs aisladas de diferentes hospitales chilenos           CMI (ug/ml)      Antibiótico Microorganismo Rango 50 90 % resistencia   CFTX K. pneumoniae 4-256 32,0 64 100     E. coli 4-256 64,0 1280 092       CFTX + AC K. pneumoniae < 0,25-2 < 0,25 16 003     E. coli 1-32 20 32 025       CFZD K. pneumoniae 8- > 256 320, > 25600 100     E. coli 8- > 256 64,0 256, 100       CFZD + AC K. pneumoniae < 0,25-16 10 04 004     E. coli 2- > 32 40 32 025       CFPM K. pneumoniae < 0,25-128 < 0,25 16 000,2,6     E. coli < 0,25-256 < 0,25 32 025       CFPM + AC K. pneumoniae < 0,25-32 < 0,25 02 ,0,0     E. coli < 0,25-32 < 0,25 32 017     Cefotaxima (CFTX), Ceftazidima (CFZD), Cefepima (CFPM), Acido clavulánico          (AC)              *Cefalosporina: ácido clavulánico, 2:1       En forma general y práctica puede señalarse    que estos agentes despliegan una actividad superior a la de ceftriaxona y cefotaxima    sobre bacilos Gram negativos multiresistentes (Serratia, Citrobacter, Enterobacter,    Morganella, Providencia y cepas de Proteus indol negativo hiperproductoras    de cefalosporinasas y/o sobre de cepas de K. pneumoniae y E. coli    productoras de ESßLs ) y equivalente al de estos compuestos de tercera    generación sobre cepas de bacterias Gram negativos susceptibles y S.    pneumoniae36,58,84-86.    Con relación a su actividad sobre P. aeruginosa, estas moléculas    tienen una actividad antibacteriana comparable, pero no superior, a la de ceftazidima36,53,    57,58,82,83.   En este contexto, en nuestro laboratorio evaluamos la actividad    de cefepima, cefotaxima y ceftazidima sobre cepas de K. pneumoniae y    E. coli productoras de ESBLs aisladas de diferentes hospitales chilenos.    Es interesante destacar que de las cepas originalmente recibidas en nuestro    estudio, se determinó la producción de ESBLs en 43,9% de las cepas    de K. pneumoniae y en 8% de las cepas de E. coli. Cefepima demostró    ser el ß-lactámico de mayor actividad sobre las cepas ensayadas.    Así, 2,6% de los aislamientos de K. pneumoniae y 25% de las cepas    de E. coli fueron resistentes a este agente. Al analizar la Tabla    1 puede comprobarse también que con la asociación con ácido    clavulánico se produce un importante incremento en la susceptibilidad    de las bacterias en estudio a las cefalosporinas de tercera generación.    Este efecto fue más pronunciado sobre K. pneumoniae con disminución    de las frecuencias de resistencia de 100% (cefalos-porina) a 4% (cefalosporina    asociada a inhibidor de ß-lactamasa). La mayor susceptibilidad de las    bacterias a la asociación de cefalosporina de tercera generación    y ácido clavulánico (AC) se explica por la actividad hidrolizante    de ESßLs sobre las cefalosporinas. Por lo tanto, el escaso efecto sinergístico    de AC y cefepima sugiere una escasa actividad de ESßLs como mecanismo    de resistencia a esta cefalosporina de cuarta generación. De lo anterior    puede concluirse que cefepima es activa sobre una importante proporción    de cepas chilenas de K. pneumoniae y de E. coli productoras de    ESßLs.  Como última característica microbiológica    general, debe destacarse que estos compuestos son débiles inductores    de la producción de ß-lactamasas cromosomales, a diferencia de    lo que ocurre con carbapenémicos y cefamicinas, que característicamente    son potentes inductores de ß-lactamasas Amp C25,37.   Finalmente, basándonos en el aumento cada vez más    creciente de la resistencia bacteriana, la mayor sobrevida de huéspedes    susceptibles, el lento desarrollo de nuevas familias de antimicrobianos (con    excepción de las oxazolidinonas) y las propiedades microbiológicas    de las cefalosporinas de cuarta generación, debemos plantear que -de    acuerdo a los estudios de susceptibilidad locales- las cefalosporinas de cuarta    generación podrían representar una alternativa terapéutica    para el tratamiento de infecciones producidas por bacilos Gram negativos resistentes    a cefalosporinas de tercera generación87-91.   RESUMEN  Las cefalosporinas son uno de los grupos de mayor importancia    dentro de los ß-lactámicos. Existen diversas clasificaciones de    estas moléculas, siendo la más utilizada aquella que agrupa a    estos compuestos de acuerdo a propiedades estructurales, microbiológicas    y desarrollo histórico: primera a cuarta generación. Las cefalosporinas    de tercera generación han sido ampliamente utilizadas, pero la emergencia    de resistencia bacteriana fundamentalmente derivada de la producción    de ß-lactamasas tanto cromosomales como plasmidiales, ha limitado el uso    de estos compuestos. Las cefalosporinas de cuarta generación se caracterizan    por la presencia de un nitrógeno cuaternario en C3, además    de mantener el grupo metoxi-imino aminotiazolil en C7. Presentan    una elevada penetración intracelular a través de la membrana externa    de bacilos Gram negativos y tienen una baja afinidad por enzimas que degradan    cefalos-porinas de tercera generación. Cefepime, una cefalosporina de    cuarta generación, demostró una mayor actividad inhibitoria sobre    cepas chilenas de Klebsiella pneumoniae y Escherichia coli productoras    de ß-lactamasas de espectro extendido, que cefotaxima y ceftazidima.  Universidad de Concepción:      1 Departamento de Microbiología, Facultad de Ciencias Biológicas.         2 Departamento de Medicina Interna, Facultad de Medicina.      3 Facultad de Medicina. Universidad San Sebastián, Concepción.           Este trabajo fue financiado por el Proyecto Nº 1980109 del Fondo Nacional    de Desarrollo Científico y Tecnológico (FONDECYT)  BIBLIOGRAFIA  1.- ROLINSON G N. The influence of 6-aminopenicillanic    acid on antibiotic development. J Antimicrob Chemother 1988; 22: 5-14.         [ Links ]2.- ZEMELMAN R, NORAMBUENA R, VERGARA L, GACITUA    R. Los antibióticos ß-lactámicos: agrupación según    su estructura química y sus propiedades bacteriológicas. Rev Méd    Chile 1987; 115: 983-91.         [ Links ]3.- FRIED J S, HINTHORN D R. The cephalosporins.    Dis a Month 1985; 31: 1-60.         [ Links ]4.- NEU HC. Structure-activity relations of    new ß-lactam compounds and in vitro activity against common bacteria.    Rev Infect Dis 1983; 5 (suppl 2): S319-.         [ Links ]5.- NEU H C. Beta-lactam antibiotics structural    relationships affecting in vitro activity and pharmacological properties. Rev    Infect Dis 1986; 8 (Suppl 3): 237-59         [ Links ]6.- NEU H C. Relation of structural properties    of beta-lactam antibiotics to antibacterial activity. Am J Med 1985; 79 (Suppl    2 A): 2-13.         [ Links ]7.- SCHOLAR E M, PRATT W B (Eds). The inhibitors    of cell wall synthesis, II. The antimicrobial drugs. Oxford University Press.    2000 Nueva York. pp:         [ Links ]8.- LOPEZ F, GARRIDO J C. Química y    relación estructura-actividad de los antibióticos cefalosporínicos    (I). Rev Col Químico Farmacéutico 1988; 44: 110-22.         [ Links ]9.- TURNIDGE J D. The pharmacodynamics of        ß-lactams. Clin Infect Dis 1998; 27: 10-22.  10.- CRAIG W A. The future-can we learn from    the past? Diagn Microbiol Infect Dis 1997; 27: 49-53.         [ Links ]11.- DUDLEY M N. Pharmacodynamics and pharmacokinetics    of antibiotics with special reference to the fluoroquinolones. Am J Med 1991;    91 (Suppl 6 A): 6A-45S.         [ Links ]12.- NICOLAU D P, QUINTILIANI R, NIGHTINGALE    C H. Cinética y dinámica de los antibióticos para el clínico.    Clin Med Nort Am 1995; 79: 483-500.         [ Links ]13.- DRUSANO G L. Human pharmacodynamics of    beta-lactams, aminoglycosides and their combination. Scand J Infect Dis 1991    (Suppl); 74: 235-48.         [ Links ]14.- MARSHALL W F, BLAIR J E. The cephalosporins.    Mayo Clinic Proc 1999; 74: 187-95.         [ Links ]15.- DONOWIRZ G R, MANDELL G L. Beta-lactam    antibiotics. N Engl J Med 1988; 318: 490-500.         [ Links ]16.- PAYA E. Ventajas y desventajas de las    cefalosporinas orales de segunda y tercera generación. Rev Chil Infect    1997; 14: 233-8.         [ Links ]17.- AMERICAN THORACIC SOCIETY. Guidelines    for the initial management of adults with community-acquired pneumonia: diagnosis,    assessment of severity, and initial antimicrobial therapy. Am Rev Respir Dis    1993; 148: 1418-26.         [ Links ]18.- BARTLETT J G, BREIMAN R F, MANDELL L    A, FILE T M Jr. Community-acquired pneumonia in adults: guidelines for management.    The Infectious Diseases Society of America. Clin Infect Dis 1998: 26: 811-38.          [ Links ]19.- MARRIE T J. Community-acquired pneumonia:    epidemiology, etiology, treatment. Infect Dis Clin North Am 1998; 12: 723-40          [ Links ]20.- TUNKEL A R, SCHELD W M. Acute meningitis.    In: Mandell, Douglas & Bennett's. Principles and Practice of Infectious    Diseases. Mandell G L, Bennett J E, Dolin R, eds. Fifth edition. Philadelphia:    Editorial Churchill Livingstone 2000; 959-96.         [ Links ]21.- AMERICAN THORACIC SOCIETY. Hospital-acquired    pneumonia in adults: diagnosis, assessment of severity, initial antimicrobial    therapy, and preventive strategies. A consensus statement. Am J Respir Crit    Care Med 1996; 153: 1711-25.         [ Links ]22.- BARTLETT J G, DOWELL S F, MANDELL L A,    FILE T M, MUSHER D M, FINE M J. Practice guidelines for the management of community-acquired    pneumonia in adults. Clin Infect Dis. 2000; 31: 347-82         [ Links ]23.- KARCHMER A W. Cephalosporins. In: Mandell,    Douglas & Bennett's. Principles and Practice of Infectious Diseases. Mandell    G L, Bennett J E, Dolin R, eds. Fifth edition. Philadelphia: Churchill Livingstone    2000; 274-99.         [ Links ]24.- ADU A, ARMOUR C L. Drug utilisation review    (DUR) of the third generation cephalosporins. Drugs 1995; 50: 423-39.         [ Links ]25.- JONES R N. Important and emerging ß-lactamase    mediated resistances in hospital-based pathogens: the Amp C enzymes. Diagn Microbiol    Infect Dis 1998; 31: 461-6.         [ Links ]26.- JARVIS W R, MARTONE W J. Predominant    pathogens in hospital infections. J Antimicrob Chemother 1992; 29: 19-24.         [ Links ]27.- LIVERMORE D M. ß-lactamases in    laboratory and clinical resistance. Clin Microbiol Rev 1995; 8: 557-84.         [ Links ]28.- HERITAGE J, M'ZALI F H, GASCOYNE-BINZI    D, HAWKEY P M. Evolution and spread of SHV extended-spectrum ß-lactamases    in gram negative bacteria. J Antimicrob Chemother 1999; 44: 309-18.         [ Links ]29.- PODSCHUN R, ULLMAN U. Klebsiella spp.    as nosocomial pathogens: epidemiology, taxonomy, typing methods, and pathogenicity    factors. Clin Microbiol Rev 1998; 11: 589-603.         [ Links ]30.- PITOUT J D D, SANDERS C C, SANDERS W    E. Antimicrobial resistance with focus on ß-lactam resistance in Gram    negative bacilli. Am J Med 1997; 103: 51-9.         [ Links ]31.- HANBERGER H, GARCIA-RODRIGUEZ J A, GOBERNADO    et al. Antibiotic susceptibility among aerobic Gram negative bacilli in intensive    care units in 5 european countries. JAMA 1999; 281: 67-71.         [ Links ]32.- CHARREL R N, PAGES J M, DE MICCO P et    al. Prevalence of outer membrane porin alteration in ß-lactam-antibiotic-resistant    Enterobacter aerogenes. Antimicrob Agents Chemother 1996; 40: 2854-8.          [ Links ]33.- BRADFORD P A, URBAN C, MARIANO N, PROJAN    S J, RAHAL J J, BUSH K. Imipenem resistance in Klebsiella pneumoniae is    associated with the combination of ACT-1, a plasmid-mediated Amp C ß-lactamase,    and the loss of an outer membrane protein. Antimicrob Agents Chemother 1997;    41: 563-9.         [ Links ]34.- QUEENAN A M, TORRES-VIERA C, GOLD H et    al. SME-type carbapenem-hydrolizing class A ß-lactamases from geographically    diverse Serratia marcescens strains. Antimicrob Agents Chemother 2000;    44: 3035-9.         [ Links ]35.- COHEN S P, MC MURRY L M, HOOPER D C,    WOLFSON J S, LEVY S B. Cross-resistance to fluoroquinolones in multiple-antibiotic-resistance    (Mar) Escherichia coli selected by tetracycline resistance: decreased    drug accumulation asociated with membrane changes in addition to Omp F reduction.    Antimicrob Agents Chemother 1989; 33:1318-25.         [ Links ]36.- SANDERS C C. Cefepime: The next generation?    Clin Infect Dis 1993; 17: 369-79         [ Links ]37.- GARAU J. The clinical potential of fourth-generation    cephalosporins. Diagn Microbiol Infect Dis 1998; 31: 479-80.         [ Links ]38.- CURTIS N A C, ORR D C, ROSS G W, BOULTON    M G. Affinities of penicillins and cephalosporins for the penicillin-binding    proteins of Escherichia coli    K-12 and their antibacterial activity. Antimicrob Agents Chemother 1979; 16:    533-9.  39.- BALANT L, DAYER P, AUCKENTHALER R. Clinical    pharmacokinetics of the third generation cephalosporins. Clin Pharmacokinetics    1985; 10: 101-43.         [ Links ]40.- WHEELER W J. Cephalosporins and other    beta-lactam antibiotics. Lloydia. 1977; 40: 519-42.         [ Links ]41.- LOPEZ F, GARRIDO J C. Química    y relación estructura-actividad de los antibióticos cefalosporínicos.    Rev Col Químico Farmacéutico 1989; 41: 5-14.         [ Links ]42.- FU K P, ASWAPOKEE P, HO I, MATTHIJSSEN    C, NEU H C. Pharmacokinetics of cefotaxime. Antimicrob Agents Chemother 1979;16:    592-7.         [ Links ]43.- YUK J H, NIGHTINGALE C H, QUINTILIANI    R. Clinical pharmacokinetics of ceftriaxone. Clin Pharmacokinetic 1989; 17:    223-35.         [ Links ]44.- BRYSKIER A, PROCYK T, LABRO M T. Cefodizime,    a new 2-aminothiazolyl cephalosporin: physicochemical properties, toxicology    and structure-activity relationships. J Antimicrob Chemother 1990; 26 (Suppl    C): 1-8.         [ Links ]45.- CRITCHLEY I A, BASKER M J, EDMONDSON    R A, KNOTT S J. Uptake of catecholic cephalosporin by the iron transport system    of Escherichia coli. J Antimicrob Chemother 1991; 28: 377-88.         [ Links ]46.- CRITCHLEY I A. Catecholic ß-lactams:    facilitated transport. J Antimicrob Chemother 1990; 26: 733-7.         [ Links ]47.- JONES R N, ERWIN M E. In vitro evaluation    of Ro 09-1227, a novel catechol-substituted cephalosporin. Antimicrob Agents    Chemother 1992; 36: 233-8.         [ Links ]48.- JONES R N. In vitro activity of Ro 24-6392,    a novel ester-linked co-drug combining ciprofloxacin and desacetylcefotaxime.    Eur J Clin Microbiol Infect Dis 1990; 9: 435-8.         [ Links ]49.- TOMASZ A. Penicillin-binding proteins    and the antibacterial effectiveness of ß-lactam antibiotics. Rev Infect    Dis 1986 (Suppl 3); 8: 260-78.         [ Links ]50.- HOLM S E. Interaction between ß-lactam    and other antibiotics. Rev Infect Dis 1986 (Suppl 3); 8: 305-14.         [ Links ]51.- MC CULLERS J A, ENGLISH B K, NOVAK R.    Isolation and characterization of vancomycin-tolerant Streptococcus pneumoniae    from the cerebrospinal fluid of a patient who developed recrudescet meningitis.    J Infect Dis 2000; 181: 369-73.         [ Links ]52.- NIKAIDO H. Outer membrane barrier as    a mechanism of antimicrobial resistance. Antimicrob Agents Chemother 1989; 33:    1831-6.         [ Links ]53.- BARRADELL L B, BRYSON H M. Cefepime.    A review of its antibacterial activity, pharmacokinetic properties and therapeutic    use. Drugs 1994; 47: 471-505.         [ Links ]54.- O'CALLAGHAN C H 1979. Description and    classification of the newer cephalosporins and their relationship with the established    compounds. J Antimicrob Chemother 5: 635-71         [ Links ]55.- BRYSKIER A, PROCYK T, TREMBLAY D, LENFANT    B FOURTILLAN J B. The pharmacokinetics of cefodizime following intravenous and    intramuscular administration of a single dose of 1.0 g. J Antimicrob Chemother    1990; 26 (Suppl. C): 59-63.         [ Links ]56.- WILLIAMS J D. Classification of cephalosporins.    Drugs. 1987; 34 (Suppl 2): 15-22.         [ Links ]57.- WISEMAN L R, LAMB H M. Cefpirome. A review    of its antibacterial activity, pharmacokinetic properties and efficacy in the    treatment of severe nosocomial infections and febrile neutropenia. Drugs 1997;    57: 117-40.         [ Links ]58.- PECHERE J C, WILSON W, NEU H. Laboratory    assesment of antibacterial activity of zwitterionic 7-methoxyimino cephalosporins.    J Antimicrob Chemother 1995; 36: 757-71         [ Links ]59.- GIAMARELLOS-BOURBOULIS EJ, GRECKA P,    TSITSIKA A, TYMPANIDOU C, GIAMARELLOU H. In-vitro activity of FK 037 (cefoselis),    a novel 4 (th) generation cephalosporin, cefepime and cefpirome on nosocomial    staphylococci and gram-negative isolates. Diagn Microbiol infect Dis 2000; 36:    185-91.         [ Links ]60.- JONES R N, ERWIN M E, BARRETT M S, JOHNSON    D M, BRIGGS B M. Antimicrobial activity of E-1040, a novel thiadiazolyl cephalosporin    compare with parenteral cephems. Diagn Microbiol infect Dis 1991; 14: 301-9.          [ Links ]61.- IIZAWA Y, OKONOGI K, HAYASHI R, IWAHI    T, YAMAZAKI T, IMADA A. Therapeutic effect of cefozopran (SCE-2787), a new parenteral    cephalosporin in experimental infections in mice. Antimicrob Agents Chemother    1993; 37: 100-5.         [ Links ]62.- WATANABE N A. Newer antipseudomonal cephalosporins.    J Chemother 1996; 8 (Suppl 2): 48-56.         [ Links ]63.- ACTOR P, GUARINI J, URI J et al. Disk    susceptibility studies with cefazolin and cephalotin. Antimicrob Agents Chemother    1974; 5: 63-7.         [ Links ]64.- UWAYDAH M. Cefazolin in the treatment    of acute enteric fever. Antimicrob Agents Chemother 1976; 10: 52-6.         [ Links ]65.- JAMAL W Y, ROTIMI V O, CHUGH T D, PAL    T. Prevalence and susceptibility of Shigella to 11 antibiotics in a Kuwait    teaching hospital. J Chemother 1998; 10: 285-90.         [ Links ]66.- COX CE, SHERRILL M, COCCHETT DM. Evaluation    of cefuroxime axetil, cefaclor, and cephalexin in the treatment of urinary tract    infections in adults. Curr Ther Res 1987; 42: 124-37.         [ Links ]67.- SANDERS C W, GREENBERG R N, MARIER R    L. Cefamandole and cefoxitin. Ann Intern Med 1985; 103: 70-8.          [ Links ]68.- STAPLEY E P, JACKSON M, HERNANDEZ S et    al. Cephamycins, a new family of ß-lactam antibiotics I. Production actinomycetes,    including Streptomyces lactamdurans spp.n. Antimicrob Agents Chemother    1972; 2: 122-31.         [ Links ]69.- COOPER R D G. The carbacephems a new    ß-lactams class. Am J Med 1992; 92 (Suppl 6 A): 25-65.         [ Links ]70.- ZEMELMAN R, BELLO H, DOMINGUEZ M, GONZALEZ    G, MELLA S, GARCIA A. Activity of imipenem, third-generation cephalosporins,    aztreonam, and ciprofloxacin against multi-resistant Gram negative bacilli isolated    from Chilean hospitals. J Antimicrob Chemother 1993; 32: 413-9.         [ Links ]71.- MEDEIROS A A. Evolution and dissemination    of ß-lactamases accelerated by generation of ß-lactam antibiotics.    Clin Infect Dis 1997; 24 (Suppl. 1): 19-45.         [ Links ]72.- PERRY C M, BROGDEN R N. Cefuroxime axetil:    review of its antibacterial activity, pharmacokinetic properties and therapeutic    efficacy. Drugs 1996; 52: 125-58.         [ Links ]73.- SCHAAD U B, SUTER S, GIANELLA-BORRADORI    et al. A comparison of ceftriaxone and cefuroxime for the treatment of bacterial    meningitis in children. N Engl J Med 1990; 322: 141-7.         [ Links ]74.- KLEIN N C, CUNHA B A. Cefalosporinas de    la tercera generación. Clin Med Nort Am 1995; 79: 693-707.         [ Links ]75.- KLUGMAN K P, MADHI S A. Emergence of    drug resistance impact on bacterial meningitis. Infect Dis Clin North Am 1999;    13: 637-46.         [ Links ]76.- RICHARDS D M, BROGDEN R N. Ceftazidime.    A review of its antibacterial activity, pharmacokinetic properties and therapeutic    use. Drugs 1985; 29: 105-61.         [ Links ]77.- SCHATZ B S, KARAVOKIROS K T, TAEUBEL    M A, ITOKAZU G S. Comparison of cefprozil, cefpodoxime proxetil, loracarbef,    cefixime, and ceftibuten. Ann Pharmacother 1996; 30: 258-68.         [ Links ]78.- DALMAU D, LAYRARGUES G P, FENYVES D,    WILLEMS B, TURGEON F, TURGEON P. Cefotaxime, desacetyl-cefotaxime, and bactericidal    activity in spontaneous bacterial peritonitis. J Infect Dis 1999; 180: 1597-1602.          [ Links ]79.- NIKAIDO W, LIU W, ROSENBERG E Y. Outer    membrane permeability and ß-lactamase stability of dipolar ionic cephalosporins    containing methoxyimino substituents. Antimicrob Agents Chemother 1990; 34:    337-42.         [ Links ]80.- HANCOCK R E W, BELLIDO F. Factors involved    in the enhanced efficacy against gram-negative bacteria of fourth generation    cephalosporins. J Antimicrob Chemother 1992; 29(Suppl A): 1-6.         [ Links ]81.- BELLIDO F, PECHERE J C, HANCOCK REW.    Novel method for measurement of outer membrane permeability to new beta-lactams    in intact Enterobacter cloacae cells. Antimicrob Agents Chemother 1991;    35: 68-72.         [ Links ]82.- NEU H C, CHIN N X, JULES K, LABTHAVIKUL    P. The activity of BMY-28142, a new broad spectrum beta-lactamase stable cephalosporin.    J Antimicrob Chemother 1986; 17: 441-52.         [ Links ]83.- KOBAYASHI S, ARAI S, HAYASHI S, FUJIMOTO    K. ß-lactamase stability of cefpirome (HR 810), a new cephalosporin with    a broad antimicrobial spectrum. Antimicrob Agents Chemother 1986; 30: 713-8.          [ Links ]84.- GARAU J, WILSON W, WOOD M, CARLET J.    Fourth generation cephalosporins: a review of in vitro activity, pharmacokinetics,    pharmacodynamics, and clinical utility. Clin Microb Infect 1997; 3 (Suppl 1):    87-101.         [ Links ]85.- KESSLER R E, FUNG-TOMC J. Susceptibility    of bacterial isolates to beta-lactam antibiotics from U.S. clinical trials over    5-year period. Am J Med 1996; 24 (6 A): 13-9.         [ Links ]86.- PIERARD D, EMMERECHTS K, LAUWERS S. Comparative    in-vitro activity of cefpirome against isolates from intensive care and haematology/oncology    units. Belgian Multicentric Study Group. J Antimicrob Chemother 1998; 41: 443-50.          [ Links ]87.- JONES R N. Resistance patterns among    nosocomial pathogens: trends over the past few years. Chest 2001; 119 (Suppl    2): 397-404.         [ Links ]88.- LORBER B. Changing patterns of infectious    diseases. Am J Med 1988; 84: 569-78.         [ Links ]89.- MOELLERING R C. A novel antimicrobial    agent joins the battle against resistant bacteria. Ann Intern Med 1999; 130:    155-7.         [ Links ]90.- WILSON W R. The role of fourth-generation    cephalosporins in the treatment of serious infectious diseases in hospitalized    patients. Diagn Microbiol Infect Dis 1998; 31: 473-7.         [ Links ]Correspondencia a:        Sergio Mella Montecinos        Laboratorio de Antibióticos,        Departamento de Microbiología,        Facultad de Ciencias Biológicas        Casilla 160-C, Concepción        E-mail: pignatio@ctcinternet.cl  

• Cefamicinas: químicamente son 7-alfa metoxi-cefalosporinas. Estas    moléculas - cefoxitina, cefotetan- presentan una potente actividad sobre    Bacteroides fragilis3,67,68.  

• Carbacefems: químicamente estos compuestos se caracterizan porque    el azufre del anillo dihidrotiazínico del grupo cefem está sustituido    por un carbono (carba) de un grupo metileno (CH2). Así loracarbef    se diferencia de cefaclor sólo por el ambio estructural previamente señalado    (carbono en vez de azufre)69. 

Por otra parte, la descripción de una mayor actividad    microbiológica de moléculas de este grupo sobre enterobacterias    resistentes a cefalotina - como cepas de Enterobacter, Serratia, Citrobacter,    Providencia y Proteus indol-positivos - carece de importancia microbiológica    y clínica, dados los actuales perfiles de susceptibilidad de los bacilos    Gram negativos26,30,70,71.  

Debe enfatizarse que los antimicrobianos de esta generación    - incluyendo tanto a cefalosporinas, cefamicinas y carbacefems (o carbacefemas)-    carecen de actividad sobre P. aeruginosa; además, con la excepción    de cefamandol, son menos activos que sus congéneres de primera generación    sobre cepas de S. aureus susceptibles a oxacilina3,5,23,72.    Desde un punto de vista farmacológico no difieren en forma sustancial    de las moléculas de primera generación, excepto en su mejor penetración    al LCR; sin embargo, no se consideran agentes de elección en el tratamiento    de MBA debido a la menor eficacia clínica al compararlas con moléculas    de tercera generación, por ejemplo cefuroxima versus ceftriaxona20,73.  

Las cefalosporinas de tercera generación constituyen    uno de los grupos de antimicrobianos de mayor uso en la actualidad. Los compuestos    de esta generación se caracterizan por presentar, al menos, dos de las    siguientes características: 

 • en C-7 del núcleo cefem, la presencia de un anillo 2-aminotiazolil    como cadena lateral 

• amplio espectro de actividad 

• elevada actividad sobre Enterobacteriaceae (excepto    sobre cepas hiperproductoras de cefalosporinasas y/o ESBLs), H. influenzae,    Neisseria spp., S. pyogenes y S. pneumoniae y actividad sobre    P. aeruginosa (ceftazidima y cefoperazona)42,74.  

En este contexto es importante destacar que si bien ceftriaxona    y cefotaxima son agentes de elección en el tratamiento de MBA adquirida    en la comunidad, la descripción creciente de cepas de S. pneumoniae    resistentes a penicilina y cefalosporinas ha limitado en algunos centros, su    uso como monoterapia empírica para el tratamiento de infecciones meníngeas75.    Por otra parte, la actividad de estos agentes sobre S. aureus susceptible    a meticilina es menor que la de los congéneres de primera y segunda generación,    debiéndose considerar que ceftazidima y los agentes de uso oral cefixima    y ceftibuten carecen de una actividad microbiológica útil sobre    este patógeno7,23,76,77.    Desde una perspectiva farmacológica en este grupo existen moléculas    como ceftriaxona que presentan tiempos de vida media prolongados, permitiendo    su dosificación cada 12 o incluso cada 24 horas; además, cefotaxima    es metabolizada a una forma biológicamente activa (desacetilcefotaxima)    y por otra parte estos agentes alcanzan concentraciones útiles en una    serie de tejidos y parénquimas, entre ellos sangre, orina, bilis (particularmente    cefoperazona y ceftriaxona), pulmones, líquido peritoneal y meninges3,14,39,78.  

Es interesante destacar que en los grupos analizados, cefalosporinas    de primera hasta tercera generación, hay agentes de uso oral, que en    términos generales mantienen las características microbiológicas    generales de las respectivas generaciones, por ejemplo, cefadroxilo, cefuroxima    y cefixima, respectivamente7,16,77.  

CEFALOSPORINAS DE CUARTA GENERACION

Las cefalosporinas de cuarta generación se caracterizan    químicamente por la presencia de un grupo metoxi-imino aminotiazolil    en R1 del núcleo cefem (similar al que presentan las moléculas    de tercera generación), excepto cefclidin (previamente E 1040) que presenta    un radical muy similar: aminotiadiazolil, y principalmente por la presencia    de un nitrógeno cuaternario en R2 (Figura    3). Este grupo se mantiene cargado positivamente tanto en condiciones de    pH ácido como alcalino. La asociación de esta carga neta positiva    con una carga negativa en C4 del núcleo cefem hace de estos    antibacterianos moléculas zwitteriónicas, es decir, moléculas    con un balance entre sus cargas positivas y negativas en los rangos de pH encontrados    in vivo (Figura 4)36,53,57,58,79.

Figura 3. Estructura química de cefepime y cefpirome,          respectivamente.

 

Figura 4. Estructura zwitteriónica            de las cefalosporinas de cuarta generación. 

 

Esta característica químico-estructural explica    por qué estas cefalosporinas presentan una penetración a través    de las porinas, superior a sus congéneres de tercera generación,    lo que le permite alcanzar altas concentraciones en el espacio periplásmico    de bacilos Gram negativos79,80.    Experimentalmente se ha demostrado que cefpiroma, cefepima y cefclidin tienen    una velocidad de penetración intracelular, sobre cepas de E. coli    y E. cloacae, varias veces superior a la de cefotaxima y ceftazidi-ma79-81.    Esta propiedad se relacionaría con el balance de cargas químicas    de estos compuestos, ya que, si bien las cefalosporinas de cuarta generación    son moléculas de mayor tamaño que sus congéneres de tercera    generación, presentan en su estructura química una importante    carga positiva (a nivel del amonio cuaternario) y además son selectivamente    incorporadas a través de la porina Omp F36,58,79-81.    Ceftazidima, en cambio, tiene una carga neta negativa, a pesar de presentar    una carga positiva en C3. La penetración intracelular más    lenta de esta molécula puede explicarse entonces por el potencial de    Donnan de la bacteria (interior negativo)58,80.    Sin embargo, el solo aumento de la penetración intracelular, no explica    en forma exclusiva la importante actividad antibacteriana de estos compuestos,    particularmente sobre bacterias resistentes. Así, cefaloridina que estructuralmente    también es una molécula dipolar, sin carga neta, con un amonio    cuaternario en C3, presenta una penetración intracelular incluso    superior a las moléculas de cuarta generación; sin embargo, al    carecer del radical metoxi-imino no presenta una adecuada estabilidad frente    a beta-lactamasas, siendo rápidamente degradada5,36,58.  

Por lo anterior otro aspecto relevante para explicar la mayor    actividad de estas cefalos-porinas sobre bacterias Gram negativas resistentes    a moléculas de tercera generación, es la estabilidad frente a    las ß-lactamasas tanto cromosomales como plasmidiales y su afinidad por    el sitio blanco: PBP´s36,58,80,82,83.    Así, la actividad sobre cepas hiperproductoras de ß-lactamasas    del grupo 1 de Bush (cefalospori-nasas cromosomales) se explica por la baja    afinidad de la ß-lactamasa por la cefalosporina (en general valores más    elevados para Km); habiéndose establecido que la afinidad    de estas enzimas por cefotaxima es 1.000 a 10.000 veces mayor que sobre cefepima    y del orden de 10 a 100 veces superior para ceftazidima en comparación    con cefepima36,58. 

Por otra parte, el efecto final de los sustitu-yentes en la    relación estructura-actividad de estos compuestos, es decir, mantención    de sustituyentes con importante actividad sobre Gram negativos como metoxi-imino,    como la presencia en la misma molécula de radicales que incrementan la    actividad sobre cocáceas Gram positivas como amonio cuaternario, explican    la actividad microbiológica "más balanceada" de estos    antimicrobianos, ya que presentan una elevada actividad in vitro sobre    Gram positivos, particularmente, S. pneumonaie (incluyendo cepas resistentes    a penicilina), junto a una potente actividad inhibitoria y bactericida sobre    bacilos Gram negativos entéricos, incluyéndose, como ya se mencionó,    cepas multiresis-tentes capaces de degradar moléculas de tercera generación    (Tabla 1)36,84-86.    

Tabla 1. Actividad inihibitoria de cefepime,    cefotaxima y ceftazidima, en presencia        y ausencia de ácido clavulánico, sobre 75 cepas de K. pneumoniae    y 12 cepas de E. coli     productoras de ESßLs aisladas de diferentes hospitales chilenos 

 

 En forma general y práctica puede señalarse    que estos agentes despliegan una actividad superior a la de ceftriaxona y cefotaxima    sobre bacilos Gram negativos multiresistentes (Serratia, Citrobacter, Enterobacter,    Morganella, Providencia y cepas de Proteus indol negativo hiperproductoras    de cefalosporinasas y/o sobre de cepas de K. pneumoniae y E. coli    productoras de ESßLs ) y equivalente al de estos compuestos de tercera    generación sobre cepas de bacterias Gram negativos susceptibles y S.    pneumoniae36,58,84-86.    Con relación a su actividad sobre P. aeruginosa, estas moléculas    tienen una actividad antibacteriana comparable, pero no superior, a la de ceftazidima36,53,    57,58,82,83.  

En este contexto, en nuestro laboratorio evaluamos la actividad    de cefepima, cefotaxima y ceftazidima sobre cepas de K. pneumoniae y    E. coli productoras de ESBLs aisladas de diferentes hospitales chilenos.    Es interesante destacar que de las cepas originalmente recibidas en nuestro    estudio, se determinó la producción de ESBLs en 43,9% de las cepas    de K. pneumoniae y en 8% de las cepas de E. coli. Cefepima demostró    ser el ß-lactámico de mayor actividad sobre las cepas ensayadas.    Así, 2,6% de los aislamientos de K. pneumoniae y 25% de las cepas    de E. coli fueron resistentes a este agente. Al analizar la Tabla    1 puede comprobarse también que con la asociación con ácido    clavulánico se produce un importante incremento en la susceptibilidad    de las bacterias en estudio a las cefalosporinas de tercera generación.    Este efecto fue más pronunciado sobre K. pneumoniae con disminución    de las frecuencias de resistencia de 100% (cefalos-porina) a 4% (cefalosporina    asociada a inhibidor de ß-lactamasa). La mayor susceptibilidad de las    bacterias a la asociación de cefalosporina de tercera generación    y ácido clavulánico (AC) se explica por la actividad hidrolizante    de ESßLs sobre las cefalosporinas. Por lo tanto, el escaso efecto sinergístico    de AC y cefepima sugiere una escasa actividad de ESßLs como mecanismo    de resistencia a esta cefalosporina de cuarta generación. De lo anterior    puede concluirse que cefepima es activa sobre una importante proporción    de cepas chilenas de K. pneumoniae y de E. coli productoras de    ESßLs. 

Como última característica microbiológica    general, debe destacarse que estos compuestos son débiles inductores    de la producción de ß-lactamasas cromosomales, a diferencia de    lo que ocurre con carbapenémicos y cefamicinas, que característicamente    son potentes inductores de ß-lactamasas Amp C25,37.  

Finalmente, basándonos en el aumento cada vez más    creciente de la resistencia bacteriana, la mayor sobrevida de huéspedes    susceptibles, el lento desarrollo de nuevas familias de antimicrobianos (con    excepción de las oxazolidinonas) y las propiedades microbiológicas    de las cefalosporinas de cuarta generación, debemos plantear que -de    acuerdo a los estudios de susceptibilidad locales- las cefalosporinas de cuarta    generación podrían representar una alternativa terapéutica    para el tratamiento de infecciones producidas por bacilos Gram negativos resistentes    a cefalosporinas de tercera generación87-91.  

RESUMEN 

Las cefalosporinas son uno de los grupos de mayor importancia    dentro de los ß-lactámicos. Existen diversas clasificaciones de    estas moléculas, siendo la más utilizada aquella que agrupa a    estos compuestos de acuerdo a propiedades estructurales, microbiológicas    y desarrollo histórico: primera a cuarta generación. Las cefalosporinas    de tercera generación han sido ampliamente utilizadas, pero la emergencia    de resistencia bacteriana fundamentalmente derivada de la producción    de ß-lactamasas tanto cromosomales como plasmidiales, ha limitado el uso    de estos compuestos. Las cefalosporinas de cuarta generación se caracterizan    por la presencia de un nitrógeno cuaternario en C3, además    de mantener el grupo metoxi-imino aminotiazolil en C7. Presentan    una elevada penetración intracelular a través de la membrana externa    de bacilos Gram negativos y tienen una baja afinidad por enzimas que degradan    cefalos-porinas de tercera generación. Cefepime, una cefalosporina de    cuarta generación, demostró una mayor actividad inhibitoria sobre    cepas chilenas de Klebsiella pneumoniae y Escherichia coli productoras    de ß-lactamasas de espectro extendido, que cefotaxima y ceftazidima. 

Universidad de Concepción:      1 Departamento de Microbiología, Facultad de Ciencias Biológicas.         2 Departamento de Medicina Interna, Facultad de Medicina.      3 Facultad de Medicina. Universidad San Sebastián, Concepción.           Este trabajo fue financiado por el Proyecto Nº 1980109 del Fondo Nacional    de Desarrollo Científico y Tecnológico (FONDECYT) 

BIBLIOGRAFIA 

1.- ROLINSON G N. The influence of 6-aminopenicillanic    acid on antibiotic development. J Antimicrob Chemother 1988; 22: 5-14.         [ Links ]2.- ZEMELMAN R, NORAMBUENA R, VERGARA L, GACITUA    R. Los antibióticos ß-lactámicos: agrupación según    su estructura química y sus propiedades bacteriológicas. Rev Méd    Chile 1987; 115: 983-91.         [ Links ]3.- FRIED J S, HINTHORN D R. The cephalosporins.    Dis a Month 1985; 31: 1-60.         [ Links ]4.- NEU HC. Structure-activity relations of    new ß-lactam compounds and in vitro activity against common bacteria.    Rev Infect Dis 1983; 5 (suppl 2): S319-.         [ Links ]5.- NEU H C. Beta-lactam antibiotics structural    relationships affecting in vitro activity and pharmacological properties. Rev    Infect Dis 1986; 8 (Suppl 3): 237-59         [ Links ]6.- NEU H C. Relation of structural properties    of beta-lactam antibiotics to antibacterial activity. Am J Med 1985; 79 (Suppl    2 A): 2-13.         [ Links ]7.- SCHOLAR E M, PRATT W B (Eds). The inhibitors    of cell wall synthesis, II. The antimicrobial drugs. Oxford University Press.    2000 Nueva York. pp:         [ Links ]8.- LOPEZ F, GARRIDO J C. Química y    relación estructura-actividad de los antibióticos cefalosporínicos    (I). Rev Col Químico Farmacéutico 1988; 44: 110-22.         [ Links ]9.- TURNIDGE J D. The pharmacodynamics of        ß-lactams. Clin Infect Dis 1998; 27: 10-22.  10.- CRAIG W A. The future-can we learn from    the past? Diagn Microbiol Infect Dis 1997; 27: 49-53.         [ Links ]11.- DUDLEY M N. Pharmacodynamics and pharmacokinetics    of antibiotics with special reference to the fluoroquinolones. Am J Med 1991;    91 (Suppl 6 A): 6A-45S.         [ Links ]12.- NICOLAU D P, QUINTILIANI R, NIGHTINGALE    C H. Cinética y dinámica de los antibióticos para el clínico.    Clin Med Nort Am 1995; 79: 483-500.         [ Links ]13.- DRUSANO G L. Human pharmacodynamics of    beta-lactams, aminoglycosides and their combination. Scand J Infect Dis 1991    (Suppl); 74: 235-48.         [ Links ]14.- MARSHALL W F, BLAIR J E. The cephalosporins.    Mayo Clinic Proc 1999; 74: 187-95.         [ Links ]15.- DONOWIRZ G R, MANDELL G L. Beta-lactam    antibiotics. N Engl J Med 1988; 318: 490-500.         [ Links ]16.- PAYA E. Ventajas y desventajas de las    cefalosporinas orales de segunda y tercera generación. Rev Chil Infect    1997; 14: 233-8.         [ Links ]17.- AMERICAN THORACIC SOCIETY. Guidelines    for the initial management of adults with community-acquired pneumonia: diagnosis,    assessment of severity, and initial antimicrobial therapy. Am Rev Respir Dis    1993; 148: 1418-26.         [ Links ]18.- BARTLETT J G, BREIMAN R F, MANDELL L    A, FILE T M Jr. Community-acquired pneumonia in adults: guidelines for management.    The Infectious Diseases Society of America. Clin Infect Dis 1998: 26: 811-38.          [ Links ]19.- MARRIE T J. Community-acquired pneumonia:    epidemiology, etiology, treatment. Infect Dis Clin North Am 1998; 12: 723-40          [ Links ]20.- TUNKEL A R, SCHELD W M. Acute meningitis.    In: Mandell, Douglas & Bennett's. Principles and Practice of Infectious    Diseases. Mandell G L, Bennett J E, Dolin R, eds. Fifth edition. Philadelphia:    Editorial Churchill Livingstone 2000; 959-96.         [ Links ]21.- AMERICAN THORACIC SOCIETY. Hospital-acquired    pneumonia in adults: diagnosis, assessment of severity, initial antimicrobial    therapy, and preventive strategies. A consensus statement. Am J Respir Crit    Care Med 1996; 153: 1711-25.         [ Links ]22.- BARTLETT J G, DOWELL S F, MANDELL L A,    FILE T M, MUSHER D M, FINE M J. Practice guidelines for the management of community-acquired    pneumonia in adults. Clin Infect Dis. 2000; 31: 347-82         [ Links ]23.- KARCHMER A W. Cephalosporins. In: Mandell,    Douglas & Bennett's. Principles and Practice of Infectious Diseases. Mandell    G L, Bennett J E, Dolin R, eds. Fifth edition. Philadelphia: Churchill Livingstone    2000; 274-99.         [ Links ]24.- ADU A, ARMOUR C L. Drug utilisation review    (DUR) of the third generation cephalosporins. Drugs 1995; 50: 423-39.         [ Links ]25.- JONES R N. Important and emerging ß-lactamase    mediated resistances in hospital-based pathogens: the Amp C enzymes. Diagn Microbiol    Infect Dis 1998; 31: 461-6.         [ Links ]26.- JARVIS W R, MARTONE W J. Predominant    pathogens in hospital infections. J Antimicrob Chemother 1992; 29: 19-24.         [ Links ]27.- LIVERMORE D M. ß-lactamases in    laboratory and clinical resistance. Clin Microbiol Rev 1995; 8: 557-84.         [ Links ]28.- HERITAGE J, M'ZALI F H, GASCOYNE-BINZI    D, HAWKEY P M. Evolution and spread of SHV extended-spectrum ß-lactamases    in gram negative bacteria. J Antimicrob Chemother 1999; 44: 309-18.         [ Links ]29.- PODSCHUN R, ULLMAN U. Klebsiella spp.    as nosocomial pathogens: epidemiology, taxonomy, typing methods, and pathogenicity    factors. Clin Microbiol Rev 1998; 11: 589-603.         [ Links ]30.- PITOUT J D D, SANDERS C C, SANDERS W    E. Antimicrobial resistance with focus on ß-lactam resistance in Gram    negative bacilli. Am J Med 1997; 103: 51-9.         [ Links ]31.- HANBERGER H, GARCIA-RODRIGUEZ J A, GOBERNADO    et al. Antibiotic susceptibility among aerobic Gram negative bacilli in intensive    care units in 5 european countries. JAMA 1999; 281: 67-71.         [ Links ]32.- CHARREL R N, PAGES J M, DE MICCO P et    al. Prevalence of outer membrane porin alteration in ß-lactam-antibiotic-resistant    Enterobacter aerogenes. Antimicrob Agents Chemother 1996; 40: 2854-8.          [ Links ]33.- BRADFORD P A, URBAN C, MARIANO N, PROJAN    S J, RAHAL J J, BUSH K. Imipenem resistance in Klebsiella pneumoniae is    associated with the combination of ACT-1, a plasmid-mediated Amp C ß-lactamase,    and the loss of an outer membrane protein. Antimicrob Agents Chemother 1997;    41: 563-9.         [ Links ]34.- QUEENAN A M, TORRES-VIERA C, GOLD H et    al. SME-type carbapenem-hydrolizing class A ß-lactamases from geographically    diverse Serratia marcescens strains. Antimicrob Agents Chemother 2000;    44: 3035-9.         [ Links ]35.- COHEN S P, MC MURRY L M, HOOPER D C,    WOLFSON J S, LEVY S B. Cross-resistance to fluoroquinolones in multiple-antibiotic-resistance    (Mar) Escherichia coli selected by tetracycline resistance: decreased    drug accumulation asociated with membrane changes in addition to Omp F reduction.    Antimicrob Agents Chemother 1989; 33:1318-25.         [ Links ]36.- SANDERS C C. Cefepime: The next generation?    Clin Infect Dis 1993; 17: 369-79         [ Links ]37.- GARAU J. The clinical potential of fourth-generation    cephalosporins. Diagn Microbiol Infect Dis 1998; 31: 479-80.         [ Links ]38.- CURTIS N A C, ORR D C, ROSS G W, BOULTON    M G. Affinities of penicillins and cephalosporins for the penicillin-binding    proteins of Escherichia coli    K-12 and their antibacterial activity. Antimicrob Agents Chemother 1979; 16:    533-9.  39.- BALANT L, DAYER P, AUCKENTHALER R. Clinical    pharmacokinetics of the third generation cephalosporins. Clin Pharmacokinetics    1985; 10: 101-43.         [ Links ]40.- WHEELER W J. Cephalosporins and other    beta-lactam antibiotics. Lloydia. 1977; 40: 519-42.         [ Links ]41.- LOPEZ F, GARRIDO J C. Química    y relación estructura-actividad de los antibióticos cefalosporínicos.    Rev Col Químico Farmacéutico 1989; 41: 5-14.         [ Links ]42.- FU K P, ASWAPOKEE P, HO I, MATTHIJSSEN    C, NEU H C. Pharmacokinetics of cefotaxime. Antimicrob Agents Chemother 1979;16:    592-7.         [ Links ]43.- YUK J H, NIGHTINGALE C H, QUINTILIANI    R. Clinical pharmacokinetics of ceftriaxone. Clin Pharmacokinetic 1989; 17:    223-35.         [ Links ]44.- BRYSKIER A, PROCYK T, LABRO M T. Cefodizime,    a new 2-aminothiazolyl cephalosporin: physicochemical properties, toxicology    and structure-activity relationships. J Antimicrob Chemother 1990; 26 (Suppl    C): 1-8.         [ Links ]45.- CRITCHLEY I A, BASKER M J, EDMONDSON    R A, KNOTT S J. Uptake of catecholic cephalosporin by the iron transport system    of Escherichia coli. J Antimicrob Chemother 1991; 28: 377-88.         [ Links ]46.- CRITCHLEY I A. Catecholic ß-lactams:    facilitated transport. J Antimicrob Chemother 1990; 26: 733-7.         [ Links ]47.- JONES R N, ERWIN M E. In vitro evaluation    of Ro 09-1227, a novel catechol-substituted cephalosporin. Antimicrob Agents    Chemother 1992; 36: 233-8.         [ Links ]48.- JONES R N. In vitro activity of Ro 24-6392,    a novel ester-linked co-drug combining ciprofloxacin and desacetylcefotaxime.    Eur J Clin Microbiol Infect Dis 1990; 9: 435-8.         [ Links ]49.- TOMASZ A. Penicillin-binding proteins    and the antibacterial effectiveness of ß-lactam antibiotics. Rev Infect    Dis 1986 (Suppl 3); 8: 260-78.         [ Links ]50.- HOLM S E. Interaction between ß-lactam    and other antibiotics. Rev Infect Dis 1986 (Suppl 3); 8: 305-14.         [ Links ]51.- MC CULLERS J A, ENGLISH B K, NOVAK R.    Isolation and characterization of vancomycin-tolerant Streptococcus pneumoniae    from the cerebrospinal fluid of a patient who developed recrudescet meningitis.    J Infect Dis 2000; 181: 369-73.         [ Links ]52.- NIKAIDO H. Outer membrane barrier as    a mechanism of antimicrobial resistance. Antimicrob Agents Chemother 1989; 33:    1831-6.         [ Links ]53.- BARRADELL L B, BRYSON H M. Cefepime.    A review of its antibacterial activity, pharmacokinetic properties and therapeutic    use. Drugs 1994; 47: 471-505.         [ Links ]54.- O'CALLAGHAN C H 1979. Description and    classification of the newer cephalosporins and their relationship with the established    compounds. J Antimicrob Chemother 5: 635-71         [ Links ]55.- BRYSKIER A, PROCYK T, TREMBLAY D, LENFANT    B FOURTILLAN J B. The pharmacokinetics of cefodizime following intravenous and    intramuscular administration of a single dose of 1.0 g. J Antimicrob Chemother    1990; 26 (Suppl. C): 59-63.         [ Links ]56.- WILLIAMS J D. Classification of cephalosporins.    Drugs. 1987; 34 (Suppl 2): 15-22.         [ Links ]57.- WISEMAN L R, LAMB H M. Cefpirome. A review    of its antibacterial activity, pharmacokinetic properties and efficacy in the    treatment of severe nosocomial infections and febrile neutropenia. Drugs 1997;    57: 117-40.         [ Links ]58.- PECHERE J C, WILSON W, NEU H. Laboratory    assesment of antibacterial activity of zwitterionic 7-methoxyimino cephalosporins.    J Antimicrob Chemother 1995; 36: 757-71         [ Links ]59.- GIAMARELLOS-BOURBOULIS EJ, GRECKA P,    TSITSIKA A, TYMPANIDOU C, GIAMARELLOU H. In-vitro activity of FK 037 (cefoselis),    a novel 4 (th) generation cephalosporin, cefepime and cefpirome on nosocomial    staphylococci and gram-negative isolates. Diagn Microbiol infect Dis 2000; 36:    185-91.         [ Links ]60.- JONES R N, ERWIN M E, BARRETT M S, JOHNSON    D M, BRIGGS B M. Antimicrobial activity of E-1040, a novel thiadiazolyl cephalosporin    compare with parenteral cephems. Diagn Microbiol infect Dis 1991; 14: 301-9.          [ Links ]61.- IIZAWA Y, OKONOGI K, HAYASHI R, IWAHI    T, YAMAZAKI T, IMADA A. Therapeutic effect of cefozopran (SCE-2787), a new parenteral    cephalosporin in experimental infections in mice. Antimicrob Agents Chemother    1993; 37: 100-5.         [ Links ]62.- WATANABE N A. Newer antipseudomonal cephalosporins.    J Chemother 1996; 8 (Suppl 2): 48-56.         [ Links ]63.- ACTOR P, GUARINI J, URI J et al. Disk    susceptibility studies with cefazolin and cephalotin. Antimicrob Agents Chemother    1974; 5: 63-7.         [ Links ]64.- UWAYDAH M. Cefazolin in the treatment    of acute enteric fever. Antimicrob Agents Chemother 1976; 10: 52-6.         [ Links ]65.- JAMAL W Y, ROTIMI V O, CHUGH T D, PAL    T. Prevalence and susceptibility of Shigella to 11 antibiotics in a Kuwait    teaching hospital. J Chemother 1998; 10: 285-90.         [ Links ]66.- COX CE, SHERRILL M, COCCHETT DM. Evaluation    of cefuroxime axetil, cefaclor, and cephalexin in the treatment of urinary tract    infections in adults. Curr Ther Res 1987; 42: 124-37.         [ Links ]67.- SANDERS C W, GREENBERG R N, MARIER R    L. Cefamandole and cefoxitin. Ann Intern Med 1985; 103: 70-8.          [ Links ]68.- STAPLEY E P, JACKSON M, HERNANDEZ S et    al. Cephamycins, a new family of ß-lactam antibiotics I. Production actinomycetes,    including Streptomyces lactamdurans spp.n. Antimicrob Agents Chemother    1972; 2: 122-31.         [ Links ]69.- COOPER R D G. The carbacephems a new    ß-lactams class. Am J Med 1992; 92 (Suppl 6 A): 25-65.         [ Links ]70.- ZEMELMAN R, BELLO H, DOMINGUEZ M, GONZALEZ    G, MELLA S, GARCIA A. Activity of imipenem, third-generation cephalosporins,    aztreonam, and ciprofloxacin against multi-resistant Gram negative bacilli isolated    from Chilean hospitals. J Antimicrob Chemother 1993; 32: 413-9.         [ Links ]71.- MEDEIROS A A. Evolution and dissemination    of ß-lactamases accelerated by generation of ß-lactam antibiotics.    Clin Infect Dis 1997; 24 (Suppl. 1): 19-45.         [ Links ]72.- PERRY C M, BROGDEN R N. Cefuroxime axetil:    review of its antibacterial activity, pharmacokinetic properties and therapeutic    efficacy. Drugs 1996; 52: 125-58.         [ Links ]73.- SCHAAD U B, SUTER S, GIANELLA-BORRADORI    et al. A comparison of ceftriaxone and cefuroxime for the treatment of bacterial    meningitis in children. N Engl J Med 1990; 322: 141-7.         [ Links ]74.- KLEIN N C, CUNHA B A. Cefalosporinas de    la tercera generación. Clin Med Nort Am 1995; 79: 693-707.         [ Links ]75.- KLUGMAN K P, MADHI S A. Emergence of    drug resistance impact on bacterial meningitis. Infect Dis Clin North Am 1999;    13: 637-46.         [ Links ]76.- RICHARDS D M, BROGDEN R N. Ceftazidime.    A review of its antibacterial activity, pharmacokinetic properties and therapeutic    use. Drugs 1985; 29: 105-61.         [ Links ]77.- SCHATZ B S, KARAVOKIROS K T, TAEUBEL    M A, ITOKAZU G S. Comparison of cefprozil, cefpodoxime proxetil, loracarbef,    cefixime, and ceftibuten. Ann Pharmacother 1996; 30: 258-68.         [ Links ]78.- DALMAU D, LAYRARGUES G P, FENYVES D,    WILLEMS B, TURGEON F, TURGEON P. Cefotaxime, desacetyl-cefotaxime, and bactericidal    activity in spontaneous bacterial peritonitis. J Infect Dis 1999; 180: 1597-1602.          [ Links ]79.- NIKAIDO W, LIU W, ROSENBERG E Y. Outer    membrane permeability and ß-lactamase stability of dipolar ionic cephalosporins    containing methoxyimino substituents. Antimicrob Agents Chemother 1990; 34:    337-42.         [ Links ]80.- HANCOCK R E W, BELLIDO F. Factors involved    in the enhanced efficacy against gram-negative bacteria of fourth generation    cephalosporins. J Antimicrob Chemother 1992; 29(Suppl A): 1-6.         [ Links ]81.- BELLIDO F, PECHERE J C, HANCOCK REW.    Novel method for measurement of outer membrane permeability to new beta-lactams    in intact Enterobacter cloacae cells. Antimicrob Agents Chemother 1991;    35: 68-72.         [ Links ]82.- NEU H C, CHIN N X, JULES K, LABTHAVIKUL    P. The activity of BMY-28142, a new broad spectrum beta-lactamase stable cephalosporin.    J Antimicrob Chemother 1986; 17: 441-52.         [ Links ]83.- KOBAYASHI S, ARAI S, HAYASHI S, FUJIMOTO    K. ß-lactamase stability of cefpirome (HR 810), a new cephalosporin with    a broad antimicrobial spectrum. Antimicrob Agents Chemother 1986; 30: 713-8.          [ Links ]84.- GARAU J, WILSON W, WOOD M, CARLET J.    Fourth generation cephalosporins: a review of in vitro activity, pharmacokinetics,    pharmacodynamics, and clinical utility. Clin Microb Infect 1997; 3 (Suppl 1):    87-101.         [ Links ]85.- KESSLER R E, FUNG-TOMC J. Susceptibility    of bacterial isolates to beta-lactam antibiotics from U.S. clinical trials over    5-year period. Am J Med 1996; 24 (6 A): 13-9.         [ Links ]86.- PIERARD D, EMMERECHTS K, LAUWERS S. Comparative    in-vitro activity of cefpirome against isolates from intensive care and haematology/oncology    units. Belgian Multicentric Study Group. J Antimicrob Chemother 1998; 41: 443-50.          [ Links ]87.- JONES R N. Resistance patterns among    nosocomial pathogens: trends over the past few years. Chest 2001; 119 (Suppl    2): 397-404.         [ Links ]88.- LORBER B. Changing patterns of infectious    diseases. Am J Med 1988; 84: 569-78.         [ Links ]89.- MOELLERING R C. A novel antimicrobial    agent joins the battle against resistant bacteria. Ann Intern Med 1999; 130:    155-7.         [ Links ]90.- WILSON W R. The role of fourth-generation    cephalosporins in the treatment of serious infectious diseases in hospitalized    patients. Diagn Microbiol Infect Dis 1998; 31: 473-7.         [ Links ]Correspondencia a:        Sergio Mella Montecinos        Laboratorio de Antibióticos,        Departamento de Microbiología,        Facultad de Ciencias Biológicas        Casilla 160-C, Concepción        E-mail: pignatio@ctcinternet.cl  

2.- ZEMELMAN R, NORAMBUENA R, VERGARA L, GACITUA    R. Los antibióticos ß-lactámicos: agrupación según    su estructura química y sus propiedades bacteriológicas. Rev Méd    Chile 1987; 115: 983-91.         [ Links ]3.- FRIED J S, HINTHORN D R. The cephalosporins.    Dis a Month 1985; 31: 1-60.         [ Links ]4.- NEU HC. Structure-activity relations of    new ß-lactam compounds and in vitro activity against common bacteria.    Rev Infect Dis 1983; 5 (suppl 2): S319-.         [ Links ]5.- NEU H C. Beta-lactam antibiotics structural    relationships affecting in vitro activity and pharmacological properties. Rev    Infect Dis 1986; 8 (Suppl 3): 237-59         [ Links ]6.- NEU H C. Relation of structural properties    of beta-lactam antibiotics to antibacterial activity. Am J Med 1985; 79 (Suppl    2 A): 2-13.         [ Links ]7.- SCHOLAR E M, PRATT W B (Eds). The inhibitors    of cell wall synthesis, II. The antimicrobial drugs. Oxford University Press.    2000 Nueva York. pp:         [ Links ]8.- LOPEZ F, GARRIDO J C. Química y    relación estructura-actividad de los antibióticos cefalosporínicos    (I). Rev Col Químico Farmacéutico 1988; 44: 110-22.         [ Links ]9.- TURNIDGE J D. The pharmacodynamics of        ß-lactams. Clin Infect Dis 1998; 27: 10-22.  10.- CRAIG W A. The future-can we learn from    the past? Diagn Microbiol Infect Dis 1997; 27: 49-53.         [ Links ]11.- DUDLEY M N. Pharmacodynamics and pharmacokinetics    of antibiotics with special reference to the fluoroquinolones. Am J Med 1991;    91 (Suppl 6 A): 6A-45S.         [ Links ]12.- NICOLAU D P, QUINTILIANI R, NIGHTINGALE    C H. Cinética y dinámica de los antibióticos para el clínico.    Clin Med Nort Am 1995; 79: 483-500.         [ Links ]13.- DRUSANO G L. Human pharmacodynamics of    beta-lactams, aminoglycosides and their combination. Scand J Infect Dis 1991    (Suppl); 74: 235-48.         [ Links ]14.- MARSHALL W F, BLAIR J E. The cephalosporins.    Mayo Clinic Proc 1999; 74: 187-95.         [ Links ]15.- DONOWIRZ G R, MANDELL G L. Beta-lactam    antibiotics. N Engl J Med 1988; 318: 490-500.         [ Links ]16.- PAYA E. Ventajas y desventajas de las    cefalosporinas orales de segunda y tercera generación. Rev Chil Infect    1997; 14: 233-8.         [ Links ]17.- AMERICAN THORACIC SOCIETY. Guidelines    for the initial management of adults with community-acquired pneumonia: diagnosis,    assessment of severity, and initial antimicrobial therapy. Am Rev Respir Dis    1993; 148: 1418-26.         [ Links ]18.- BARTLETT J G, BREIMAN R F, MANDELL L    A, FILE T M Jr. Community-acquired pneumonia in adults: guidelines for management.    The Infectious Diseases Society of America. Clin Infect Dis 1998: 26: 811-38.          [ Links ]19.- MARRIE T J. Community-acquired pneumonia:    epidemiology, etiology, treatment. Infect Dis Clin North Am 1998; 12: 723-40          [ Links ]20.- TUNKEL A R, SCHELD W M. Acute meningitis.    In: Mandell, Douglas & Bennett's. Principles and Practice of Infectious    Diseases. Mandell G L, Bennett J E, Dolin R, eds. Fifth edition. Philadelphia:    Editorial Churchill Livingstone 2000; 959-96.         [ Links ]21.- AMERICAN THORACIC SOCIETY. Hospital-acquired    pneumonia in adults: diagnosis, assessment of severity, initial antimicrobial    therapy, and preventive strategies. A consensus statement. Am J Respir Crit    Care Med 1996; 153: 1711-25.         [ Links ]22.- BARTLETT J G, DOWELL S F, MANDELL L A,    FILE T M, MUSHER D M, FINE M J. Practice guidelines for the management of community-acquired    pneumonia in adults. Clin Infect Dis. 2000; 31: 347-82         [ Links ]23.- KARCHMER A W. Cephalosporins. In: Mandell,    Douglas & Bennett's. Principles and Practice of Infectious Diseases. Mandell    G L, Bennett J E, Dolin R, eds. Fifth edition. Philadelphia: Churchill Livingstone    2000; 274-99.         [ Links ]24.- ADU A, ARMOUR C L. Drug utilisation review    (DUR) of the third generation cephalosporins. Drugs 1995; 50: 423-39.         [ Links ]25.- JONES R N. Important and emerging ß-lactamase    mediated resistances in hospital-based pathogens: the Amp C enzymes. Diagn Microbiol    Infect Dis 1998; 31: 461-6.         [ Links ]26.- JARVIS W R, MARTONE W J. Predominant    pathogens in hospital infections. J Antimicrob Chemother 1992; 29: 19-24.         [ Links ]27.- LIVERMORE D M. ß-lactamases in    laboratory and clinical resistance. Clin Microbiol Rev 1995; 8: 557-84.         [ Links ]28.- HERITAGE J, M'ZALI F H, GASCOYNE-BINZI    D, HAWKEY P M. Evolution and spread of SHV extended-spectrum ß-lactamases    in gram negative bacteria. J Antimicrob Chemother 1999; 44: 309-18.         [ Links ]29.- PODSCHUN R, ULLMAN U. Klebsiella spp.    as nosocomial pathogens: epidemiology, taxonomy, typing methods, and pathogenicity    factors. Clin Microbiol Rev 1998; 11: 589-603.         [ Links ]30.- PITOUT J D D, SANDERS C C, SANDERS W    E. Antimicrobial resistance with focus on ß-lactam resistance in Gram    negative bacilli. Am J Med 1997; 103: 51-9.         [ Links ]31.- HANBERGER H, GARCIA-RODRIGUEZ J A, GOBERNADO    et al. Antibiotic susceptibility among aerobic Gram negative bacilli in intensive    care units in 5 european countries. JAMA 1999; 281: 67-71.         [ Links ]32.- CHARREL R N, PAGES J M, DE MICCO P et    al. Prevalence of outer membrane porin alteration in ß-lactam-antibiotic-resistant    Enterobacter aerogenes. Antimicrob Agents Chemother 1996; 40: 2854-8.          [ Links ]33.- BRADFORD P A, URBAN C, MARIANO N, PROJAN    S J, RAHAL J J, BUSH K. Imipenem resistance in Klebsiella pneumoniae is    associated with the combination of ACT-1, a plasmid-mediated Amp C ß-lactamase,    and the loss of an outer membrane protein. Antimicrob Agents Chemother 1997;    41: 563-9.         [ Links ]34.- QUEENAN A M, TORRES-VIERA C, GOLD H et    al. SME-type carbapenem-hydrolizing class A ß-lactamases from geographically    diverse Serratia marcescens strains. Antimicrob Agents Chemother 2000;    44: 3035-9.         [ Links ]35.- COHEN S P, MC MURRY L M, HOOPER D C,    WOLFSON J S, LEVY S B. Cross-resistance to fluoroquinolones in multiple-antibiotic-resistance    (Mar) Escherichia coli selected by tetracycline resistance: decreased    drug accumulation asociated with membrane changes in addition to Omp F reduction.    Antimicrob Agents Chemother 1989; 33:1318-25.         [ Links ]36.- SANDERS C C. Cefepime: The next generation?    Clin Infect Dis 1993; 17: 369-79         [ Links ]37.- GARAU J. The clinical potential of fourth-generation    cephalosporins. Diagn Microbiol Infect Dis 1998; 31: 479-80.         [ Links ]38.- CURTIS N A C, ORR D C, ROSS G W, BOULTON    M G. Affinities of penicillins and cephalosporins for the penicillin-binding    proteins of Escherichia coli    K-12 and their antibacterial activity. Antimicrob Agents Chemother 1979; 16:    533-9.  39.- BALANT L, DAYER P, AUCKENTHALER R. Clinical    pharmacokinetics of the third generation cephalosporins. Clin Pharmacokinetics    1985; 10: 101-43.         [ Links ]40.- WHEELER W J. Cephalosporins and other    beta-lactam antibiotics. Lloydia. 1977; 40: 519-42.         [ Links ]41.- LOPEZ F, GARRIDO J C. Química    y relación estructura-actividad de los antibióticos cefalosporínicos.    Rev Col Químico Farmacéutico 1989; 41: 5-14.         [ Links ]42.- FU K P, ASWAPOKEE P, HO I, MATTHIJSSEN    C, NEU H C. Pharmacokinetics of cefotaxime. Antimicrob Agents Chemother 1979;16:    592-7.         [ Links ]43.- YUK J H, NIGHTINGALE C H, QUINTILIANI    R. Clinical pharmacokinetics of ceftriaxone. Clin Pharmacokinetic 1989; 17:    223-35.         [ Links ]44.- BRYSKIER A, PROCYK T, LABRO M T. Cefodizime,    a new 2-aminothiazolyl cephalosporin: physicochemical properties, toxicology    and structure-activity relationships. J Antimicrob Chemother 1990; 26 (Suppl    C): 1-8.         [ Links ]45.- CRITCHLEY I A, BASKER M J, EDMONDSON    R A, KNOTT S J. Uptake of catecholic cephalosporin by the iron transport system    of Escherichia coli. J Antimicrob Chemother 1991; 28: 377-88.         [ Links ]46.- CRITCHLEY I A. Catecholic ß-lactams:    facilitated transport. J Antimicrob Chemother 1990; 26: 733-7.         [ Links ]47.- JONES R N, ERWIN M E. In vitro evaluation    of Ro 09-1227, a novel catechol-substituted cephalosporin. Antimicrob Agents    Chemother 1992; 36: 233-8.         [ Links ]48.- JONES R N. In vitro activity of Ro 24-6392,    a novel ester-linked co-drug combining ciprofloxacin and desacetylcefotaxime.    Eur J Clin Microbiol Infect Dis 1990; 9: 435-8.         [ Links ]49.- TOMASZ A. Penicillin-binding proteins    and the antibacterial effectiveness of ß-lactam antibiotics. Rev Infect    Dis 1986 (Suppl 3); 8: 260-78.         [ Links ]50.- HOLM S E. Interaction between ß-lactam    and other antibiotics. Rev Infect Dis 1986 (Suppl 3); 8: 305-14.         [ Links ]51.- MC CULLERS J A, ENGLISH B K, NOVAK R.    Isolation and characterization of vancomycin-tolerant Streptococcus pneumoniae    from the cerebrospinal fluid of a patient who developed recrudescet meningitis.    J Infect Dis 2000; 181: 369-73.         [ Links ]52.- NIKAIDO H. Outer membrane barrier as    a mechanism of antimicrobial resistance. Antimicrob Agents Chemother 1989; 33:    1831-6.         [ Links ]53.- BARRADELL L B, BRYSON H M. Cefepime.    A review of its antibacterial activity, pharmacokinetic properties and therapeutic    use. Drugs 1994; 47: 471-505.         [ Links ]54.- O'CALLAGHAN C H 1979. Description and    classification of the newer cephalosporins and their relationship with the established    compounds. J Antimicrob Chemother 5: 635-71         [ Links ]55.- BRYSKIER A, PROCYK T, TREMBLAY D, LENFANT    B FOURTILLAN J B. The pharmacokinetics of cefodizime following intravenous and    intramuscular administration of a single dose of 1.0 g. J Antimicrob Chemother    1990; 26 (Suppl. C): 59-63.         [ Links ]56.- WILLIAMS J D. Classification of cephalosporins.    Drugs. 1987; 34 (Suppl 2): 15-22.         [ Links ]57.- WISEMAN L R, LAMB H M. Cefpirome. A review    of its antibacterial activity, pharmacokinetic properties and efficacy in the    treatment of severe nosocomial infections and febrile neutropenia. Drugs 1997;    57: 117-40.         [ Links ]58.- PECHERE J C, WILSON W, NEU H. Laboratory    assesment of antibacterial activity of zwitterionic 7-methoxyimino cephalosporins.    J Antimicrob Chemother 1995; 36: 757-71         [ Links ]59.- GIAMARELLOS-BOURBOULIS EJ, GRECKA P,    TSITSIKA A, TYMPANIDOU C, GIAMARELLOU H. In-vitro activity of FK 037 (cefoselis),    a novel 4 (th) generation cephalosporin, cefepime and cefpirome on nosocomial    staphylococci and gram-negative isolates. Diagn Microbiol infect Dis 2000; 36:    185-91.         [ Links ]60.- JONES R N, ERWIN M E, BARRETT M S, JOHNSON    D M, BRIGGS B M. Antimicrobial activity of E-1040, a novel thiadiazolyl cephalosporin    compare with parenteral cephems. Diagn Microbiol infect Dis 1991; 14: 301-9.          [ Links ]61.- IIZAWA Y, OKONOGI K, HAYASHI R, IWAHI    T, YAMAZAKI T, IMADA A. Therapeutic effect of cefozopran (SCE-2787), a new parenteral    cephalosporin in experimental infections in mice. Antimicrob Agents Chemother    1993; 37: 100-5.         [ Links ]62.- WATANABE N A. Newer antipseudomonal cephalosporins.    J Chemother 1996; 8 (Suppl 2): 48-56.         [ Links ]63.- ACTOR P, GUARINI J, URI J et al. Disk    susceptibility studies with cefazolin and cephalotin. Antimicrob Agents Chemother    1974; 5: 63-7.         [ Links ]64.- UWAYDAH M. Cefazolin in the treatment    of acute enteric fever. Antimicrob Agents Chemother 1976; 10: 52-6.         [ Links ]65.- JAMAL W Y, ROTIMI V O, CHUGH T D, PAL    T. Prevalence and susceptibility of Shigella to 11 antibiotics in a Kuwait    teaching hospital. J Chemother 1998; 10: 285-90.         [ Links ]66.- COX CE, SHERRILL M, COCCHETT DM. Evaluation    of cefuroxime axetil, cefaclor, and cephalexin in the treatment of urinary tract    infections in adults. Curr Ther Res 1987; 42: 124-37.         [ Links ]67.- SANDERS C W, GREENBERG R N, MARIER R    L. Cefamandole and cefoxitin. Ann Intern Med 1985; 103: 70-8.          [ Links ]68.- STAPLEY E P, JACKSON M, HERNANDEZ S et    al. Cephamycins, a new family of ß-lactam antibiotics I. Production actinomycetes,    including Streptomyces lactamdurans spp.n. Antimicrob Agents Chemother    1972; 2: 122-31.         [ Links ]69.- COOPER R D G. The carbacephems a new    ß-lactams class. Am J Med 1992; 92 (Suppl 6 A): 25-65.         [ Links ]70.- ZEMELMAN R, BELLO H, DOMINGUEZ M, GONZALEZ    G, MELLA S, GARCIA A. Activity of imipenem, third-generation cephalosporins,    aztreonam, and ciprofloxacin against multi-resistant Gram negative bacilli isolated    from Chilean hospitals. J Antimicrob Chemother 1993; 32: 413-9.         [ Links ]71.- MEDEIROS A A. Evolution and dissemination    of ß-lactamases accelerated by generation of ß-lactam antibiotics.    Clin Infect Dis 1997; 24 (Suppl. 1): 19-45.         [ Links ]72.- PERRY C M, BROGDEN R N. Cefuroxime axetil:    review of its antibacterial activity, pharmacokinetic properties and therapeutic    efficacy. Drugs 1996; 52: 125-58.         [ Links ]73.- SCHAAD U B, SUTER S, GIANELLA-BORRADORI    et al. A comparison of ceftriaxone and cefuroxime for the treatment of bacterial    meningitis in children. N Engl J Med 1990; 322: 141-7.         [ Links ]74.- KLEIN N C, CUNHA B A. Cefalosporinas de    la tercera generación. Clin Med Nort Am 1995; 79: 693-707.         [ Links ]75.- KLUGMAN K P, MADHI S A. Emergence of    drug resistance impact on bacterial meningitis. Infect Dis Clin North Am 1999;    13: 637-46.         [ Links ]76.- RICHARDS D M, BROGDEN R N. Ceftazidime.    A review of its antibacterial activity, pharmacokinetic properties and therapeutic    use. Drugs 1985; 29: 105-61.         [ Links ]77.- SCHATZ B S, KARAVOKIROS K T, TAEUBEL    M A, ITOKAZU G S. Comparison of cefprozil, cefpodoxime proxetil, loracarbef,    cefixime, and ceftibuten. Ann Pharmacother 1996; 30: 258-68.         [ Links ]78.- DALMAU D, LAYRARGUES G P, FENYVES D,    WILLEMS B, TURGEON F, TURGEON P. Cefotaxime, desacetyl-cefotaxime, and bactericidal    activity in spontaneous bacterial peritonitis. J Infect Dis 1999; 180: 1597-1602.          [ Links ]79.- NIKAIDO W, LIU W, ROSENBERG E Y. Outer    membrane permeability and ß-lactamase stability of dipolar ionic cephalosporins    containing methoxyimino substituents. Antimicrob Agents Chemother 1990; 34:    337-42.         [ Links ]80.- HANCOCK R E W, BELLIDO F. Factors involved    in the enhanced efficacy against gram-negative bacteria of fourth generation    cephalosporins. J Antimicrob Chemother 1992; 29(Suppl A): 1-6.         [ Links ]81.- BELLIDO F, PECHERE J C, HANCOCK REW.    Novel method for measurement of outer membrane permeability to new beta-lactams    in intact Enterobacter cloacae cells. Antimicrob Agents Chemother 1991;    35: 68-72.         [ Links ]82.- NEU H C, CHIN N X, JULES K, LABTHAVIKUL    P. The activity of BMY-28142, a new broad spectrum beta-lactamase stable cephalosporin.    J Antimicrob Chemother 1986; 17: 441-52.         [ Links ]83.- KOBAYASHI S, ARAI S, HAYASHI S, FUJIMOTO    K. ß-lactamase stability of cefpirome (HR 810), a new cephalosporin with    a broad antimicrobial spectrum. Antimicrob Agents Chemother 1986; 30: 713-8.          [ Links ]84.- GARAU J, WILSON W, WOOD M, CARLET J.    Fourth generation cephalosporins: a review of in vitro activity, pharmacokinetics,    pharmacodynamics, and clinical utility. Clin Microb Infect 1997; 3 (Suppl 1):    87-101.         [ Links ]85.- KESSLER R E, FUNG-TOMC J. Susceptibility    of bacterial isolates to beta-lactam antibiotics from U.S. clinical trials over    5-year period. Am J Med 1996; 24 (6 A): 13-9.         [ Links ]86.- PIERARD D, EMMERECHTS K, LAUWERS S. Comparative    in-vitro activity of cefpirome against isolates from intensive care and haematology/oncology    units. Belgian Multicentric Study Group. J Antimicrob Chemother 1998; 41: 443-50.          [ Links ]87.- JONES R N. Resistance patterns among    nosocomial pathogens: trends over the past few years. Chest 2001; 119 (Suppl    2): 397-404.         [ Links ]88.- LORBER B. Changing patterns of infectious    diseases. Am J Med 1988; 84: 569-78.         [ Links ]89.- MOELLERING R C. A novel antimicrobial    agent joins the battle against resistant bacteria. Ann Intern Med 1999; 130:    155-7.         [ Links ]90.- WILSON W R. The role of fourth-generation    cephalosporins in the treatment of serious infectious diseases in hospitalized    patients. Diagn Microbiol Infect Dis 1998; 31: 473-7.         [ Links ]Correspondencia a:        Sergio Mella Montecinos        Laboratorio de Antibióticos,        Departamento de Microbiología,        Facultad de Ciencias Biológicas        Casilla 160-C, Concepción        E-mail: pignatio@ctcinternet.cl  

3.- FRIED J S, HINTHORN D R. The cephalosporins.    Dis a Month 1985; 31: 1-60.         [ Links ]4.- NEU HC. Structure-activity relations of    new ß-lactam compounds and in vitro activity against common bacteria.    Rev Infect Dis 1983; 5 (suppl 2): S319-.         [ Links ]5.- NEU H C. Beta-lactam antibiotics structural    relationships affecting in vitro activity and pharmacological properties. Rev    Infect Dis 1986; 8 (Suppl 3): 237-59         [ Links ]6.- NEU H C. Relation of structural properties    of beta-lactam antibiotics to antibacterial activity. Am J Med 1985; 79 (Suppl    2 A): 2-13.         [ Links ]7.- SCHOLAR E M, PRATT W B (Eds). The inhibitors    of cell wall synthesis, II. The antimicrobial drugs. Oxford University Press.    2000 Nueva York. pp:         [ Links ]8.- LOPEZ F, GARRIDO J C. Química y    relación estructura-actividad de los antibióticos cefalosporínicos    (I). Rev Col Químico Farmacéutico 1988; 44: 110-22.         [ Links ]9.- TURNIDGE J D. The pharmacodynamics of        ß-lactams. Clin Infect Dis 1998; 27: 10-22.  10.- CRAIG W A. The future-can we learn from    the past? Diagn Microbiol Infect Dis 1997; 27: 49-53.         [ Links ]11.- DUDLEY M N. Pharmacodynamics and pharmacokinetics    of antibiotics with special reference to the fluoroquinolones. Am J Med 1991;    91 (Suppl 6 A): 6A-45S.         [ Links ]12.- NICOLAU D P, QUINTILIANI R, NIGHTINGALE    C H. Cinética y dinámica de los antibióticos para el clínico.    Clin Med Nort Am 1995; 79: 483-500.         [ Links ]13.- DRUSANO G L. Human pharmacodynamics of    beta-lactams, aminoglycosides and their combination. Scand J Infect Dis 1991    (Suppl); 74: 235-48.         [ Links ]14.- MARSHALL W F, BLAIR J E. The cephalosporins.    Mayo Clinic Proc 1999; 74: 187-95.         [ Links ]15.- DONOWIRZ G R, MANDELL G L. Beta-lactam    antibiotics. N Engl J Med 1988; 318: 490-500.         [ Links ]16.- PAYA E. Ventajas y desventajas de las    cefalosporinas orales de segunda y tercera generación. Rev Chil Infect    1997; 14: 233-8.         [ Links ]17.- AMERICAN THORACIC SOCIETY. Guidelines    for the initial management of adults with community-acquired pneumonia: diagnosis,    assessment of severity, and initial antimicrobial therapy. Am Rev Respir Dis    1993; 148: 1418-26.         [ Links ]18.- BARTLETT J G, BREIMAN R F, MANDELL L    A, FILE T M Jr. Community-acquired pneumonia in adults: guidelines for management.    The Infectious Diseases Society of America. Clin Infect Dis 1998: 26: 811-38.          [ Links ]19.- MARRIE T J. Community-acquired pneumonia:    epidemiology, etiology, treatment. Infect Dis Clin North Am 1998; 12: 723-40          [ Links ]20.- TUNKEL A R, SCHELD W M. Acute meningitis.    In: Mandell, Douglas & Bennett's. Principles and Practice of Infectious    Diseases. Mandell G L, Bennett J E, Dolin R, eds. Fifth edition. Philadelphia:    Editorial Churchill Livingstone 2000; 959-96.         [ Links ]21.- AMERICAN THORACIC SOCIETY. Hospital-acquired    pneumonia in adults: diagnosis, assessment of severity, initial antimicrobial    therapy, and preventive strategies. A consensus statement. Am J Respir Crit    Care Med 1996; 153: 1711-25.         [ Links ]22.- BARTLETT J G, DOWELL S F, MANDELL L A,    FILE T M, MUSHER D M, FINE M J. Practice guidelines for the management of community-acquired    pneumonia in adults. Clin Infect Dis. 2000; 31: 347-82         [ Links ]23.- KARCHMER A W. Cephalosporins. In: Mandell,    Douglas & Bennett's. Principles and Practice of Infectious Diseases. Mandell    G L, Bennett J E, Dolin R, eds. Fifth edition. Philadelphia: Churchill Livingstone    2000; 274-99.         [ Links ]24.- ADU A, ARMOUR C L. Drug utilisation review    (DUR) of the third generation cephalosporins. Drugs 1995; 50: 423-39.         [ Links ]25.- JONES R N. Important and emerging ß-lactamase    mediated resistances in hospital-based pathogens: the Amp C enzymes. Diagn Microbiol    Infect Dis 1998; 31: 461-6.         [ Links ]26.- JARVIS W R, MARTONE W J. Predominant    pathogens in hospital infections. J Antimicrob Chemother 1992; 29: 19-24.         [ Links ]27.- LIVERMORE D M. ß-lactamases in    laboratory and clinical resistance. Clin Microbiol Rev 1995; 8: 557-84.         [ Links ]28.- HERITAGE J, M'ZALI F H, GASCOYNE-BINZI    D, HAWKEY P M. Evolution and spread of SHV extended-spectrum ß-lactamases    in gram negative bacteria. J Antimicrob Chemother 1999; 44: 309-18.         [ Links ]29.- PODSCHUN R, ULLMAN U. Klebsiella spp.    as nosocomial pathogens: epidemiology, taxonomy, typing methods, and pathogenicity    factors. Clin Microbiol Rev 1998; 11: 589-603.         [ Links ]30.- PITOUT J D D, SANDERS C C, SANDERS W    E. Antimicrobial resistance with focus on ß-lactam resistance in Gram    negative bacilli. Am J Med 1997; 103: 51-9.         [ Links ]31.- HANBERGER H, GARCIA-RODRIGUEZ J A, GOBERNADO    et al. Antibiotic susceptibility among aerobic Gram negative bacilli in intensive    care units in 5 european countries. JAMA 1999; 281: 67-71.         [ Links ]32.- CHARREL R N, PAGES J M, DE MICCO P et    al. Prevalence of outer membrane porin alteration in ß-lactam-antibiotic-resistant    Enterobacter aerogenes. Antimicrob Agents Chemother 1996; 40: 2854-8.          [ Links ]33.- BRADFORD P A, URBAN C, MARIANO N, PROJAN    S J, RAHAL J J, BUSH K. Imipenem resistance in Klebsiella pneumoniae is    associated with the combination of ACT-1, a plasmid-mediated Amp C ß-lactamase,    and the loss of an outer membrane protein. Antimicrob Agents Chemother 1997;    41: 563-9.         [ Links ]34.- QUEENAN A M, TORRES-VIERA C, GOLD H et    al. SME-type carbapenem-hydrolizing class A ß-lactamases from geographically    diverse Serratia marcescens strains. Antimicrob Agents Chemother 2000;    44: 3035-9.         [ Links ]35.- COHEN S P, MC MURRY L M, HOOPER D C,    WOLFSON J S, LEVY S B. Cross-resistance to fluoroquinolones in multiple-antibiotic-resistance    (Mar) Escherichia coli selected by tetracycline resistance: decreased    drug accumulation asociated with membrane changes in addition to Omp F reduction.    Antimicrob Agents Chemother 1989; 33:1318-25.         [ Links ]36.- SANDERS C C. Cefepime: The next generation?    Clin Infect Dis 1993; 17: 369-79         [ Links ]37.- GARAU J. The clinical potential of fourth-generation    cephalosporins. Diagn Microbiol Infect Dis 1998; 31: 479-80.         [ Links ]38.- CURTIS N A C, ORR D C, ROSS G W, BOULTON    M G. Affinities of penicillins and cephalosporins for the penicillin-binding    proteins of Escherichia coli    K-12 and their antibacterial activity. Antimicrob Agents Chemother 1979; 16:    533-9.  39.- BALANT L, DAYER P, AUCKENTHALER R. Clinical    pharmacokinetics of the third generation cephalosporins. Clin Pharmacokinetics    1985; 10: 101-43.         [ Links ]40.- WHEELER W J. Cephalosporins and other    beta-lactam antibiotics. Lloydia. 1977; 40: 519-42.         [ Links ]41.- LOPEZ F, GARRIDO J C. Química    y relación estructura-actividad de los antibióticos cefalosporínicos.    Rev Col Químico Farmacéutico 1989; 41: 5-14.         [ Links ]42.- FU K P, ASWAPOKEE P, HO I, MATTHIJSSEN    C, NEU H C. Pharmacokinetics of cefotaxime. Antimicrob Agents Chemother 1979;16:    592-7.         [ Links ]43.- YUK J H, NIGHTINGALE C H, QUINTILIANI    R. Clinical pharmacokinetics of ceftriaxone. Clin Pharmacokinetic 1989; 17:    223-35.         [ Links ]44.- BRYSKIER A, PROCYK T, LABRO M T. Cefodizime,    a new 2-aminothiazolyl cephalosporin: physicochemical properties, toxicology    and structure-activity relationships. J Antimicrob Chemother 1990; 26 (Suppl    C): 1-8.         [ Links ]45.- CRITCHLEY I A, BASKER M J, EDMONDSON    R A, KNOTT S J. Uptake of catecholic cephalosporin by the iron transport system    of Escherichia coli. J Antimicrob Chemother 1991; 28: 377-88.         [ Links ]46.- CRITCHLEY I A. Catecholic ß-lactams:    facilitated transport. J Antimicrob Chemother 1990; 26: 733-7.         [ Links ]47.- JONES R N, ERWIN M E. In vitro evaluation    of Ro 09-1227, a novel catechol-substituted cephalosporin. Antimicrob Agents    Chemother 1992; 36: 233-8.         [ Links ]48.- JONES R N. In vitro activity of Ro 24-6392,    a novel ester-linked co-drug combining ciprofloxacin and desacetylcefotaxime.    Eur J Clin Microbiol Infect Dis 1990; 9: 435-8.         [ Links ]49.- TOMASZ A. Penicillin-binding proteins    and the antibacterial effectiveness of ß-lactam antibiotics. Rev Infect    Dis 1986 (Suppl 3); 8: 260-78.         [ Links ]50.- HOLM S E. Interaction between ß-lactam    and other antibiotics. Rev Infect Dis 1986 (Suppl 3); 8: 305-14.         [ Links ]51.- MC CULLERS J A, ENGLISH B K, NOVAK R.    Isolation and characterization of vancomycin-tolerant Streptococcus pneumoniae    from the cerebrospinal fluid of a patient who developed recrudescet meningitis.    J Infect Dis 2000; 181: 369-73.         [ Links ]52.- NIKAIDO H. Outer membrane barrier as    a mechanism of antimicrobial resistance. Antimicrob Agents Chemother 1989; 33:    1831-6.         [ Links ]53.- BARRADELL L B, BRYSON H M. Cefepime.    A review of its antibacterial activity, pharmacokinetic properties and therapeutic    use. Drugs 1994; 47: 471-505.         [ Links ]54.- O'CALLAGHAN C H 1979. Description and    classification of the newer cephalosporins and their relationship with the established    compounds. J Antimicrob Chemother 5: 635-71         [ Links ]55.- BRYSKIER A, PROCYK T, TREMBLAY D, LENFANT    B FOURTILLAN J B. The pharmacokinetics of cefodizime following intravenous and    intramuscular administration of a single dose of 1.0 g. J Antimicrob Chemother    1990; 26 (Suppl. C): 59-63.         [ Links ]56.- WILLIAMS J D. Classification of cephalosporins.    Drugs. 1987; 34 (Suppl 2): 15-22.         [ Links ]57.- WISEMAN L R, LAMB H M. Cefpirome. A review    of its antibacterial activity, pharmacokinetic properties and efficacy in the    treatment of severe nosocomial infections and febrile neutropenia. Drugs 1997;    57: 117-40.         [ Links ]58.- PECHERE J C, WILSON W, NEU H. Laboratory    assesment of antibacterial activity of zwitterionic 7-methoxyimino cephalosporins.    J Antimicrob Chemother 1995; 36: 757-71         [ Links ]59.- GIAMARELLOS-BOURBOULIS EJ, GRECKA P,    TSITSIKA A, TYMPANIDOU C, GIAMARELLOU H. In-vitro activity of FK 037 (cefoselis),    a novel 4 (th) generation cephalosporin, cefepime and cefpirome on nosocomial    staphylococci and gram-negative isolates. Diagn Microbiol infect Dis 2000; 36:    185-91.         [ Links ]60.- JONES R N, ERWIN M E, BARRETT M S, JOHNSON    D M, BRIGGS B M. Antimicrobial activity of E-1040, a novel thiadiazolyl cephalosporin    compare with parenteral cephems. Diagn Microbiol infect Dis 1991; 14: 301-9.          [ Links ]61.- IIZAWA Y, OKONOGI K, HAYASHI R, IWAHI    T, YAMAZAKI T, IMADA A. Therapeutic effect of cefozopran (SCE-2787), a new parenteral    cephalosporin in experimental infections in mice. Antimicrob Agents Chemother    1993; 37: 100-5.         [ Links ]62.- WATANABE N A. Newer antipseudomonal cephalosporins.    J Chemother 1996; 8 (Suppl 2): 48-56.         [ Links ]63.- ACTOR P, GUARINI J, URI J et al. Disk    susceptibility studies with cefazolin and cephalotin. Antimicrob Agents Chemother    1974; 5: 63-7.         [ Links ]64.- UWAYDAH M. Cefazolin in the treatment    of acute enteric fever. Antimicrob Agents Chemother 1976; 10: 52-6.         [ Links ]65.- JAMAL W Y, ROTIMI V O, CHUGH T D, PAL    T. Prevalence and susceptibility of Shigella to 11 antibiotics in a Kuwait    teaching hospital. J Chemother 1998; 10: 285-90.         [ Links ]66.- COX CE, SHERRILL M, COCCHETT DM. Evaluation    of cefuroxime axetil, cefaclor, and cephalexin in the treatment of urinary tract    infections in adults. Curr Ther Res 1987; 42: 124-37.         [ Links ]67.- SANDERS C W, GREENBERG R N, MARIER R    L. Cefamandole and cefoxitin. Ann Intern Med 1985; 103: 70-8.          [ Links ]68.- STAPLEY E P, JACKSON M, HERNANDEZ S et    al. Cephamycins, a new family of ß-lactam antibiotics I. Production actinomycetes,    including Streptomyces lactamdurans spp.n. Antimicrob Agents Chemother    1972; 2: 122-31.         [ Links ]69.- COOPER R D G. The carbacephems a new    ß-lactams class. Am J Med 1992; 92 (Suppl 6 A): 25-65.         [ Links ]70.- ZEMELMAN R, BELLO H, DOMINGUEZ M, GONZALEZ    G, MELLA S, GARCIA A. Activity of imipenem, third-generation cephalosporins,    aztreonam, and ciprofloxacin against multi-resistant Gram negative bacilli isolated    from Chilean hospitals. J Antimicrob Chemother 1993; 32: 413-9.         [ Links ]71.- MEDEIROS A A. Evolution and dissemination    of ß-lactamases accelerated by generation of ß-lactam antibiotics.    Clin Infect Dis 1997; 24 (Suppl. 1): 19-45.         [ Links ]72.- PERRY C M, BROGDEN R N. Cefuroxime axetil:    review of its antibacterial activity, pharmacokinetic properties and therapeutic    efficacy. Drugs 1996; 52: 125-58.         [ Links ]73.- SCHAAD U B, SUTER S, GIANELLA-BORRADORI    et al. A comparison of ceftriaxone and cefuroxime for the treatment of bacterial    meningitis in children. N Engl J Med 1990; 322: 141-7.         [ Links ]74.- KLEIN N C, CUNHA B A. Cefalosporinas de    la tercera generación. Clin Med Nort Am 1995; 79: 693-707.         [ Links ]75.- KLUGMAN K P, MADHI S A. Emergence of    drug resistance impact on bacterial meningitis. Infect Dis Clin North Am 1999;    13: 637-46.         [ Links ]76.- RICHARDS D M, BROGDEN R N. Ceftazidime.    A review of its antibacterial activity, pharmacokinetic properties and therapeutic    use. Drugs 1985; 29: 105-61.         [ Links ]77.- SCHATZ B S, KARAVOKIROS K T, TAEUBEL    M A, ITOKAZU G S. Comparison of cefprozil, cefpodoxime proxetil, loracarbef,    cefixime, and ceftibuten. Ann Pharmacother 1996; 30: 258-68.         [ Links ]78.- DALMAU D, LAYRARGUES G P, FENYVES D,    WILLEMS B, TURGEON F, TURGEON P. Cefotaxime, desacetyl-cefotaxime, and bactericidal    activity in spontaneous bacterial peritonitis. J Infect Dis 1999; 180: 1597-1602.          [ Links ]79.- NIKAIDO W, LIU W, ROSENBERG E Y. Outer    membrane permeability and ß-lactamase stability of dipolar ionic cephalosporins    containing methoxyimino substituents. Antimicrob Agents Chemother 1990; 34:    337-42.         [ Links ]80.- HANCOCK R E W, BELLIDO F. Factors involved    in the enhanced efficacy against gram-negative bacteria of fourth generation    cephalosporins. J Antimicrob Chemother 1992; 29(Suppl A): 1-6.         [ Links ]81.- BELLIDO F, PECHERE J C, HANCOCK REW.    Novel method for measurement of outer membrane permeability to new beta-lactams    in intact Enterobacter cloacae cells. Antimicrob Agents Chemother 1991;    35: 68-72.         [ Links ]82.- NEU H C, CHIN N X, JULES K, LABTHAVIKUL    P. The activity of BMY-28142, a new broad spectrum beta-lactamase stable cephalosporin.    J Antimicrob Chemother 1986; 17: 441-52.         [ Links ]83.- KOBAYASHI S, ARAI S, HAYASHI S, FUJIMOTO    K. ß-lactamase stability of cefpirome (HR 810), a new cephalosporin with    a broad antimicrobial spectrum. Antimicrob Agents Chemother 1986; 30: 713-8.          [ Links ]84.- GARAU J, WILSON W, WOOD M, CARLET J.    Fourth generation cephalosporins: a review of in vitro activity, pharmacokinetics,    pharmacodynamics, and clinical utility. Clin Microb Infect 1997; 3 (Suppl 1):    87-101.         [ Links ]85.- KESSLER R E, FUNG-TOMC J. Susceptibility    of bacterial isolates to beta-lactam antibiotics from U.S. clinical trials over    5-year period. Am J Med 1996; 24 (6 A): 13-9.         [ Links ]86.- PIERARD D, EMMERECHTS K, LAUWERS S. Comparative    in-vitro activity of cefpirome against isolates from intensive care and haematology/oncology    units. Belgian Multicentric Study Group. J Antimicrob Chemother 1998; 41: 443-50.          [ Links ]87.- JONES R N. Resistance patterns among    nosocomial pathogens: trends over the past few years. Chest 2001; 119 (Suppl    2): 397-404.         [ Links ]88.- LORBER B. Changing patterns of infectious    diseases. Am J Med 1988; 84: 569-78.         [ Links ]89.- MOELLERING R C. A novel antimicrobial    agent joins the battle against resistant bacteria. Ann Intern Med 1999; 130:    155-7.         [ Links ]90.- WILSON W R. The role of fourth-generation    cephalosporins in the treatment of serious infectious diseases in hospitalized    patients. Diagn Microbiol Infect Dis 1998; 31: 473-7.         [ Links ]Correspondencia a:        Sergio Mella Montecinos        Laboratorio de Antibióticos,        Departamento de Microbiología,        Facultad de Ciencias Biológicas        Casilla 160-C, Concepción        E-mail: pignatio@ctcinternet.cl  

4.- NEU HC. Structure-activity relations of    new ß-lactam compounds and in vitro activity against common bacteria.    Rev Infect Dis 1983; 5 (suppl 2): S319-.         [ Links ]5.- NEU H C. Beta-lactam antibiotics structural    relationships affecting in vitro activity and pharmacological properties. Rev    Infect Dis 1986; 8 (Suppl 3): 237-59         [ Links ]6.- NEU H C. Relation of structural properties    of beta-lactam antibiotics to antibacterial activity. Am J Med 1985; 79 (Suppl    2 A): 2-13.         [ Links ]7.- SCHOLAR E M, PRATT W B (Eds). The inhibitors    of cell wall synthesis, II. The antimicrobial drugs. Oxford University Press.    2000 Nueva York. pp:         [ Links ]8.- LOPEZ F, GARRIDO J C. Química y    relación estructura-actividad de los antibióticos cefalosporínicos    (I). Rev Col Químico Farmacéutico 1988; 44: 110-22.         [ Links ]9.- TURNIDGE J D. The pharmacodynamics of        ß-lactams. Clin Infect Dis 1998; 27: 10-22.  10.- CRAIG W A. The future-can we learn from    the past? Diagn Microbiol Infect Dis 1997; 27: 49-53.         [ Links ]11.- DUDLEY M N. Pharmacodynamics and pharmacokinetics    of antibiotics with special reference to the fluoroquinolones. Am J Med 1991;    91 (Suppl 6 A): 6A-45S.         [ Links ]12.- NICOLAU D P, QUINTILIANI R, NIGHTINGALE    C H. Cinética y dinámica de los antibióticos para el clínico.    Clin Med Nort Am 1995; 79: 483-500.         [ Links ]13.- DRUSANO G L. Human pharmacodynamics of    beta-lactams, aminoglycosides and their combination. Scand J Infect Dis 1991    (Suppl); 74: 235-48.         [ Links ]14.- MARSHALL W F, BLAIR J E. The cephalosporins.    Mayo Clinic Proc 1999; 74: 187-95.         [ Links ]15.- DONOWIRZ G R, MANDELL G L. Beta-lactam    antibiotics. N Engl J Med 1988; 318: 490-500.         [ Links ]16.- PAYA E. Ventajas y desventajas de las    cefalosporinas orales de segunda y tercera generación. Rev Chil Infect    1997; 14: 233-8.         [ Links ]17.- AMERICAN THORACIC SOCIETY. Guidelines    for the initial management of adults with community-acquired pneumonia: diagnosis,    assessment of severity, and initial antimicrobial therapy. Am Rev Respir Dis    1993; 148: 1418-26.         [ Links ]18.- BARTLETT J G, BREIMAN R F, MANDELL L    A, FILE T M Jr. Community-acquired pneumonia in adults: guidelines for management.    The Infectious Diseases Society of America. Clin Infect Dis 1998: 26: 811-38.          [ Links ]19.- MARRIE T J. Community-acquired pneumonia:    epidemiology, etiology, treatment. Infect Dis Clin North Am 1998; 12: 723-40          [ Links ]20.- TUNKEL A R, SCHELD W M. Acute meningitis.    In: Mandell, Douglas & Bennett's. Principles and Practice of Infectious    Diseases. Mandell G L, Bennett J E, Dolin R, eds. Fifth edition. Philadelphia:    Editorial Churchill Livingstone 2000; 959-96.         [ Links ]21.- AMERICAN THORACIC SOCIETY. Hospital-acquired    pneumonia in adults: diagnosis, assessment of severity, initial antimicrobial    therapy, and preventive strategies. A consensus statement. Am J Respir Crit    Care Med 1996; 153: 1711-25.         [ Links ]22.- BARTLETT J G, DOWELL S F, MANDELL L A,    FILE T M, MUSHER D M, FINE M J. Practice guidelines for the management of community-acquired    pneumonia in adults. Clin Infect Dis. 2000; 31: 347-82         [ Links ]23.- KARCHMER A W. Cephalosporins. In: Mandell,    Douglas & Bennett's. Principles and Practice of Infectious Diseases. Mandell    G L, Bennett J E, Dolin R, eds. Fifth edition. Philadelphia: Churchill Livingstone    2000; 274-99.         [ Links ]24.- ADU A, ARMOUR C L. Drug utilisation review    (DUR) of the third generation cephalosporins. Drugs 1995; 50: 423-39.         [ Links ]25.- JONES R N. Important and emerging ß-lactamase    mediated resistances in hospital-based pathogens: the Amp C enzymes. Diagn Microbiol    Infect Dis 1998; 31: 461-6.         [ Links ]26.- JARVIS W R, MARTONE W J. Predominant    pathogens in hospital infections. J Antimicrob Chemother 1992; 29: 19-24.         [ Links ]27.- LIVERMORE D M. ß-lactamases in    laboratory and clinical resistance. Clin Microbiol Rev 1995; 8: 557-84.         [ Links ]28.- HERITAGE J, M'ZALI F H, GASCOYNE-BINZI    D, HAWKEY P M. Evolution and spread of SHV extended-spectrum ß-lactamases    in gram negative bacteria. J Antimicrob Chemother 1999; 44: 309-18.         [ Links ]29.- PODSCHUN R, ULLMAN U. Klebsiella spp.    as nosocomial pathogens: epidemiology, taxonomy, typing methods, and pathogenicity    factors. Clin Microbiol Rev 1998; 11: 589-603.         [ Links ]30.- PITOUT J D D, SANDERS C C, SANDERS W    E. Antimicrobial resistance with focus on ß-lactam resistance in Gram    negative bacilli. Am J Med 1997; 103: 51-9.         [ Links ]31.- HANBERGER H, GARCIA-RODRIGUEZ J A, GOBERNADO    et al. Antibiotic susceptibility among aerobic Gram negative bacilli in intensive    care units in 5 european countries. JAMA 1999; 281: 67-71.         [ Links ]32.- CHARREL R N, PAGES J M, DE MICCO P et    al. Prevalence of outer membrane porin alteration in ß-lactam-antibiotic-resistant    Enterobacter aerogenes. Antimicrob Agents Chemother 1996; 40: 2854-8.          [ Links ]33.- BRADFORD P A, URBAN C, MARIANO N, PROJAN    S J, RAHAL J J, BUSH K. Imipenem resistance in Klebsiella pneumoniae is    associated with the combination of ACT-1, a plasmid-mediated Amp C ß-lactamase,    and the loss of an outer membrane protein. Antimicrob Agents Chemother 1997;    41: 563-9.         [ Links ]34.- QUEENAN A M, TORRES-VIERA C, GOLD H et    al. SME-type carbapenem-hydrolizing class A ß-lactamases from geographically    diverse Serratia marcescens strains. Antimicrob Agents Chemother 2000;    44: 3035-9.         [ Links ]35.- COHEN S P, MC MURRY L M, HOOPER D C,    WOLFSON J S, LEVY S B. Cross-resistance to fluoroquinolones in multiple-antibiotic-resistance    (Mar) Escherichia coli selected by tetracycline resistance: decreased    drug accumulation asociated with membrane changes in addition to Omp F reduction.    Antimicrob Agents Chemother 1989; 33:1318-25.         [ Links ]36.- SANDERS C C. Cefepime: The next generation?    Clin Infect Dis 1993; 17: 369-79         [ Links ]37.- GARAU J. The clinical potential of fourth-generation    cephalosporins. Diagn Microbiol Infect Dis 1998; 31: 479-80.         [ Links ]38.- CURTIS N A C, ORR D C, ROSS G W, BOULTON    M G. Affinities of penicillins and cephalosporins for the penicillin-binding    proteins of Escherichia coli    K-12 and their antibacterial activity. Antimicrob Agents Chemother 1979; 16:    533-9.  39.- BALANT L, DAYER P, AUCKENTHALER R. Clinical    pharmacokinetics of the third generation cephalosporins. Clin Pharmacokinetics    1985; 10: 101-43.         [ Links ]40.- WHEELER W J. Cephalosporins and other    beta-lactam antibiotics. Lloydia. 1977; 40: 519-42.         [ Links ]41.- LOPEZ F, GARRIDO J C. Química    y relación estructura-actividad de los antibióticos cefalosporínicos.    Rev Col Químico Farmacéutico 1989; 41: 5-14.         [ Links ]42.- FU K P, ASWAPOKEE P, HO I, MATTHIJSSEN    C, NEU H C. Pharmacokinetics of cefotaxime. Antimicrob Agents Chemother 1979;16:    592-7.         [ Links ]43.- YUK J H, NIGHTINGALE C H, QUINTILIANI    R. Clinical pharmacokinetics of ceftriaxone. Clin Pharmacokinetic 1989; 17:    223-35.         [ Links ]44.- BRYSKIER A, PROCYK T, LABRO M T. Cefodizime,    a new 2-aminothiazolyl cephalosporin: physicochemical properties, toxicology    and structure-activity relationships. J Antimicrob Chemother 1990; 26 (Suppl    C): 1-8.         [ Links ]45.- CRITCHLEY I A, BASKER M J, EDMONDSON    R A, KNOTT S J. Uptake of catecholic cephalosporin by the iron transport system    of Escherichia coli. J Antimicrob Chemother 1991; 28: 377-88.         [ Links ]46.- CRITCHLEY I A. Catecholic ß-lactams:    facilitated transport. J Antimicrob Chemother 1990; 26: 733-7.         [ Links ]47.- JONES R N, ERWIN M E. In vitro evaluation    of Ro 09-1227, a novel catechol-substituted cephalosporin. Antimicrob Agents    Chemother 1992; 36: 233-8.         [ Links ]48.- JONES R N. In vitro activity of Ro 24-6392,    a novel ester-linked co-drug combining ciprofloxacin and desacetylcefotaxime.    Eur J Clin Microbiol Infect Dis 1990; 9: 435-8.         [ Links ]49.- TOMASZ A. Penicillin-binding proteins    and the antibacterial effectiveness of ß-lactam antibiotics. Rev Infect    Dis 1986 (Suppl 3); 8: 260-78.         [ Links ]50.- HOLM S E. Interaction between ß-lactam    and other antibiotics. Rev Infect Dis 1986 (Suppl 3); 8: 305-14.         [ Links ]51.- MC CULLERS J A, ENGLISH B K, NOVAK R.    Isolation and characterization of vancomycin-tolerant Streptococcus pneumoniae    from the cerebrospinal fluid of a patient who developed recrudescet meningitis.    J Infect Dis 2000; 181: 369-73.         [ Links ]52.- NIKAIDO H. Outer membrane barrier as    a mechanism of antimicrobial resistance. Antimicrob Agents Chemother 1989; 33:    1831-6.         [ Links ]53.- BARRADELL L B, BRYSON H M. Cefepime.    A review of its antibacterial activity, pharmacokinetic properties and therapeutic    use. Drugs 1994; 47: 471-505.         [ Links ]54.- O'CALLAGHAN C H 1979. Description and    classification of the newer cephalosporins and their relationship with the established    compounds. J Antimicrob Chemother 5: 635-71         [ Links ]55.- BRYSKIER A, PROCYK T, TREMBLAY D, LENFANT    B FOURTILLAN J B. The pharmacokinetics of cefodizime following intravenous and    intramuscular administration of a single dose of 1.0 g. J Antimicrob Chemother    1990; 26 (Suppl. C): 59-63.         [ Links ]56.- WILLIAMS J D. Classification of cephalosporins.    Drugs. 1987; 34 (Suppl 2): 15-22.         [ Links ]57.- WISEMAN L R, LAMB H M. Cefpirome. A review    of its antibacterial activity, pharmacokinetic properties and efficacy in the    treatment of severe nosocomial infections and febrile neutropenia. Drugs 1997;    57: 117-40.         [ Links ]58.- PECHERE J C, WILSON W, NEU H. Laboratory    assesment of antibacterial activity of zwitterionic 7-methoxyimino cephalosporins.    J Antimicrob Chemother 1995; 36: 757-71         [ Links ]59.- GIAMARELLOS-BOURBOULIS EJ, GRECKA P,    TSITSIKA A, TYMPANIDOU C, GIAMARELLOU H. In-vitro activity of FK 037 (cefoselis),    a novel 4 (th) generation cephalosporin, cefepime and cefpirome on nosocomial    staphylococci and gram-negative isolates. Diagn Microbiol infect Dis 2000; 36:    185-91.         [ Links ]60.- JONES R N, ERWIN M E, BARRETT M S, JOHNSON    D M, BRIGGS B M. Antimicrobial activity of E-1040, a novel thiadiazolyl cephalosporin    compare with parenteral cephems. Diagn Microbiol infect Dis 1991; 14: 301-9.          [ Links ]61.- IIZAWA Y, OKONOGI K, HAYASHI R, IWAHI    T, YAMAZAKI T, IMADA A. Therapeutic effect of cefozopran (SCE-2787), a new parenteral    cephalosporin in experimental infections in mice. Antimicrob Agents Chemother    1993; 37: 100-5.         [ Links ]62.- WATANABE N A. Newer antipseudomonal cephalosporins.    J Chemother 1996; 8 (Suppl 2): 48-56.         [ Links ]63.- ACTOR P, GUARINI J, URI J et al. Disk    susceptibility studies with cefazolin and cephalotin. Antimicrob Agents Chemother    1974; 5: 63-7.         [ Links ]64.- UWAYDAH M. Cefazolin in the treatment    of acute enteric fever. Antimicrob Agents Chemother 1976; 10: 52-6.         [ Links ]65.- JAMAL W Y, ROTIMI V O, CHUGH T D, PAL    T. Prevalence and susceptibility of Shigella to 11 antibiotics in a Kuwait    teaching hospital. J Chemother 1998; 10: 285-90.         [ Links ]66.- COX CE, SHERRILL M, COCCHETT DM. Evaluation    of cefuroxime axetil, cefaclor, and cephalexin in the treatment of urinary tract    infections in adults. Curr Ther Res 1987; 42: 124-37.         [ Links ]67.- SANDERS C W, GREENBERG R N, MARIER R    L. Cefamandole and cefoxitin. Ann Intern Med 1985; 103: 70-8.          [ Links ]68.- STAPLEY E P, JACKSON M, HERNANDEZ S et    al. Cephamycins, a new family of ß-lactam antibiotics I. Production actinomycetes,    including Streptomyces lactamdurans spp.n. Antimicrob Agents Chemother    1972; 2: 122-31.         [ Links ]69.- COOPER R D G. The carbacephems a new    ß-lactams class. Am J Med 1992; 92 (Suppl 6 A): 25-65.         [ Links ]70.- ZEMELMAN R, BELLO H, DOMINGUEZ M, GONZALEZ    G, MELLA S, GARCIA A. Activity of imipenem, third-generation cephalosporins,    aztreonam, and ciprofloxacin against multi-resistant Gram negative bacilli isolated    from Chilean hospitals. J Antimicrob Chemother 1993; 32: 413-9.         [ Links ]71.- MEDEIROS A A. Evolution and dissemination    of ß-lactamases accelerated by generation of ß-lactam antibiotics.    Clin Infect Dis 1997; 24 (Suppl. 1): 19-45.         [ Links ]72.- PERRY C M, BROGDEN R N. Cefuroxime axetil:    review of its antibacterial activity, pharmacokinetic properties and therapeutic    efficacy. Drugs 1996; 52: 125-58.         [ Links ]73.- SCHAAD U B, SUTER S, GIANELLA-BORRADORI    et al. A comparison of ceftriaxone and cefuroxime for the treatment of bacterial    meningitis in children. N Engl J Med 1990; 322: 141-7.         [ Links ]74.- KLEIN N C, CUNHA B A. Cefalosporinas de    la tercera generación. Clin Med Nort Am 1995; 79: 693-707.         [ Links ]75.- KLUGMAN K P, MADHI S A. Emergence of    drug resistance impact on bacterial meningitis. Infect Dis Clin North Am 1999;    13: 637-46.         [ Links ]76.- RICHARDS D M, BROGDEN R N. Ceftazidime.    A review of its antibacterial activity, pharmacokinetic properties and therapeutic    use. Drugs 1985; 29: 105-61.         [ Links ]77.- SCHATZ B S, KARAVOKIROS K T, TAEUBEL    M A, ITOKAZU G S. Comparison of cefprozil, cefpodoxime proxetil, loracarbef,    cefixime, and ceftibuten. Ann Pharmacother 1996; 30: 258-68.         [ Links ]78.- DALMAU D, LAYRARGUES G P, FENYVES D,    WILLEMS B, TURGEON F, TURGEON P. Cefotaxime, desacetyl-cefotaxime, and bactericidal    activity in spontaneous bacterial peritonitis. J Infect Dis 1999; 180: 1597-1602.          [ Links ]79.- NIKAIDO W, LIU W, ROSENBERG E Y. Outer    membrane permeability and ß-lactamase stability of dipolar ionic cephalosporins    containing methoxyimino substituents. Antimicrob Agents Chemother 1990; 34:    337-42.         [ Links ]80.- HANCOCK R E W, BELLIDO F. Factors involved    in the enhanced efficacy against gram-negative bacteria of fourth generation    cephalosporins. J Antimicrob Chemother 1992; 29(Suppl A): 1-6.         [ Links ]81.- BELLIDO F, PECHERE J C, HANCOCK REW.    Novel method for measurement of outer membrane permeability to new beta-lactams    in intact Enterobacter cloacae cells. Antimicrob Agents Chemother 1991;    35: 68-72.         [ Links ]82.- NEU H C, CHIN N X, JULES K, LABTHAVIKUL    P. The activity of BMY-28142, a new broad spectrum beta-lactamase stable cephalosporin.    J Antimicrob Chemother 1986; 17: 441-52.         [ Links ]83.- KOBAYASHI S, ARAI S, HAYASHI S, FUJIMOTO    K. ß-lactamase stability of cefpirome (HR 810), a new cephalosporin with    a broad antimicrobial spectrum. Antimicrob Agents Chemother 1986; 30: 713-8.          [ Links ]84.- GARAU J, WILSON W, WOOD M, CARLET J.    Fourth generation cephalosporins: a review of in vitro activity, pharmacokinetics,    pharmacodynamics, and clinical utility. Clin Microb Infect 1997; 3 (Suppl 1):    87-101.         [ Links ]85.- KESSLER R E, FUNG-TOMC J. Susceptibility    of bacterial isolates to beta-lactam antibiotics from U.S. clinical trials over    5-year period. Am J Med 1996; 24 (6 A): 13-9.         [ Links ]86.- PIERARD D, EMMERECHTS K, LAUWERS S. Comparative    in-vitro activity of cefpirome against isolates from intensive care and haematology/oncology    units. Belgian Multicentric Study Group. J Antimicrob Chemother 1998; 41: 443-50.          [ Links ]87.- JONES R N. Resistance patterns among    nosocomial pathogens: trends over the past few years. Chest 2001; 119 (Suppl    2): 397-404.         [ Links ]88.- LORBER B. Changing patterns of infectious    diseases. Am J Med 1988; 84: 569-78.         [ Links ]89.- MOELLERING R C. A novel antimicrobial    agent joins the battle against resistant bacteria. Ann Intern Med 1999; 130:    155-7.         [ Links ]90.- WILSON W R. The role of fourth-generation    cephalosporins in the treatment of serious infectious diseases in hospitalized    patients. Diagn Microbiol Infect Dis 1998; 31: 473-7.         [ Links ]Correspondencia a:        Sergio Mella Montecinos        Laboratorio de Antibióticos,        Departamento de Microbiología,        Facultad de Ciencias Biológicas        Casilla 160-C, Concepción        E-mail: pignatio@ctcinternet.cl  

5.- NEU H C. Beta-lactam antibiotics structural    relationships affecting in vitro activity and pharmacological properties. Rev    Infect Dis 1986; 8 (Suppl 3): 237-59         [ Links ]6.- NEU H C. Relation of structural properties    of beta-lactam antibiotics to antibacterial activity. Am J Med 1985; 79 (Suppl    2 A): 2-13.         [ Links ]7.- SCHOLAR E M, PRATT W B (Eds). The inhibitors    of cell wall synthesis, II. The antimicrobial drugs. Oxford University Press.    2000 Nueva York. pp:         [ Links ]8.- LOPEZ F, GARRIDO J C. Química y    relación estructura-actividad de los antibióticos cefalosporínicos    (I). Rev Col Químico Farmacéutico 1988; 44: 110-22.         [ Links ]9.- TURNIDGE J D. The pharmacodynamics of        ß-lactams. Clin Infect Dis 1998; 27: 10-22.  10.- CRAIG W A. The future-can we learn from    the past? Diagn Microbiol Infect Dis 1997; 27: 49-53.         [ Links ]11.- DUDLEY M N. Pharmacodynamics and pharmacokinetics    of antibiotics with special reference to the fluoroquinolones. Am J Med 1991;    91 (Suppl 6 A): 6A-45S.         [ Links ]12.- NICOLAU D P, QUINTILIANI R, NIGHTINGALE    C H. Cinética y dinámica de los antibióticos para el clínico.    Clin Med Nort Am 1995; 79: 483-500.         [ Links ]13.- DRUSANO G L. Human pharmacodynamics of    beta-lactams, aminoglycosides and their combination. Scand J Infect Dis 1991    (Suppl); 74: 235-48.         [ Links ]14.- MARSHALL W F, BLAIR J E. The cephalosporins.    Mayo Clinic Proc 1999; 74: 187-95.         [ Links ]15.- DONOWIRZ G R, MANDELL G L. Beta-lactam    antibiotics. N Engl J Med 1988; 318: 490-500.         [ Links ]16.- PAYA E. Ventajas y desventajas de las    cefalosporinas orales de segunda y tercera generación. Rev Chil Infect    1997; 14: 233-8.         [ Links ]17.- AMERICAN THORACIC SOCIETY. Guidelines    for the initial management of adults with community-acquired pneumonia: diagnosis,    assessment of severity, and initial antimicrobial therapy. Am Rev Respir Dis    1993; 148: 1418-26.         [ Links ]18.- BARTLETT J G, BREIMAN R F, MANDELL L    A, FILE T M Jr. Community-acquired pneumonia in adults: guidelines for management.    The Infectious Diseases Society of America. Clin Infect Dis 1998: 26: 811-38.          [ Links ]19.- MARRIE T J. Community-acquired pneumonia:    epidemiology, etiology, treatment. Infect Dis Clin North Am 1998; 12: 723-40          [ Links ]20.- TUNKEL A R, SCHELD W M. Acute meningitis.    In: Mandell, Douglas & Bennett's. Principles and Practice of Infectious    Diseases. Mandell G L, Bennett J E, Dolin R, eds. Fifth edition. Philadelphia:    Editorial Churchill Livingstone 2000; 959-96.         [ Links ]21.- AMERICAN THORACIC SOCIETY. Hospital-acquired    pneumonia in adults: diagnosis, assessment of severity, initial antimicrobial    therapy, and preventive strategies. A consensus statement. Am J Respir Crit    Care Med 1996; 153: 1711-25.         [ Links ]22.- BARTLETT J G, DOWELL S F, MANDELL L A,    FILE T M, MUSHER D M, FINE M J. Practice guidelines for the management of community-acquired    pneumonia in adults. Clin Infect Dis. 2000; 31: 347-82         [ Links ]23.- KARCHMER A W. Cephalosporins. In: Mandell,    Douglas & Bennett's. Principles and Practice of Infectious Diseases. Mandell    G L, Bennett J E, Dolin R, eds. Fifth edition. Philadelphia: Churchill Livingstone    2000; 274-99.         [ Links ]24.- ADU A, ARMOUR C L. Drug utilisation review    (DUR) of the third generation cephalosporins. Drugs 1995; 50: 423-39.         [ Links ]25.- JONES R N. Important and emerging ß-lactamase    mediated resistances in hospital-based pathogens: the Amp C enzymes. Diagn Microbiol    Infect Dis 1998; 31: 461-6.         [ Links ]26.- JARVIS W R, MARTONE W J. Predominant    pathogens in hospital infections. J Antimicrob Chemother 1992; 29: 19-24.         [ Links ]27.- LIVERMORE D M. ß-lactamases in    laboratory and clinical resistance. Clin Microbiol Rev 1995; 8: 557-84.         [ Links ]28.- HERITAGE J, M'ZALI F H, GASCOYNE-BINZI    D, HAWKEY P M. Evolution and spread of SHV extended-spectrum ß-lactamases    in gram negative bacteria. J Antimicrob Chemother 1999; 44: 309-18.         [ Links ]29.- PODSCHUN R, ULLMAN U. Klebsiella spp.    as nosocomial pathogens: epidemiology, taxonomy, typing methods, and pathogenicity    factors. Clin Microbiol Rev 1998; 11: 589-603.         [ Links ]30.- PITOUT J D D, SANDERS C C, SANDERS W    E. Antimicrobial resistance with focus on ß-lactam resistance in Gram    negative bacilli. Am J Med 1997; 103: 51-9.         [ Links ]31.- HANBERGER H, GARCIA-RODRIGUEZ J A, GOBERNADO    et al. Antibiotic susceptibility among aerobic Gram negative bacilli in intensive    care units in 5 european countries. JAMA 1999; 281: 67-71.         [ Links ]32.- CHARREL R N, PAGES J M, DE MICCO P et    al. Prevalence of outer membrane porin alteration in ß-lactam-antibiotic-resistant    Enterobacter aerogenes. Antimicrob Agents Chemother 1996; 40: 2854-8.          [ Links ]33.- BRADFORD P A, URBAN C, MARIANO N, PROJAN    S J, RAHAL J J, BUSH K. Imipenem resistance in Klebsiella pneumoniae is    associated with the combination of ACT-1, a plasmid-mediated Amp C ß-lactamase,    and the loss of an outer membrane protein. Antimicrob Agents Chemother 1997;    41: 563-9.         [ Links ]34.- QUEENAN A M, TORRES-VIERA C, GOLD H et    al. SME-type carbapenem-hydrolizing class A ß-lactamases from geographically    diverse Serratia marcescens strains. Antimicrob Agents Chemother 2000;    44: 3035-9.         [ Links ]35.- COHEN S P, MC MURRY L M, HOOPER D C,    WOLFSON J S, LEVY S B. Cross-resistance to fluoroquinolones in multiple-antibiotic-resistance    (Mar) Escherichia coli selected by tetracycline resistance: decreased    drug accumulation asociated with membrane changes in addition to Omp F reduction.    Antimicrob Agents Chemother 1989; 33:1318-25.         [ Links ]36.- SANDERS C C. Cefepime: The next generation?    Clin Infect Dis 1993; 17: 369-79         [ Links ]37.- GARAU J. The clinical potential of fourth-generation    cephalosporins. Diagn Microbiol Infect Dis 1998; 31: 479-80.         [ Links ]38.- CURTIS N A C, ORR D C, ROSS G W, BOULTON    M G. Affinities of penicillins and cephalosporins for the penicillin-binding    proteins of Escherichia coli    K-12 and their antibacterial activity. Antimicrob Agents Chemother 1979; 16:    533-9.  39.- BALANT L, DAYER P, AUCKENTHALER R. Clinical    pharmacokinetics of the third generation cephalosporins. Clin Pharmacokinetics    1985; 10: 101-43.         [ Links ]40.- WHEELER W J. Cephalosporins and other    beta-lactam antibiotics. Lloydia. 1977; 40: 519-42.         [ Links ]41.- LOPEZ F, GARRIDO J C. Química    y relación estructura-actividad de los antibióticos cefalosporínicos.    Rev Col Químico Farmacéutico 1989; 41: 5-14.         [ Links ]42.- FU K P, ASWAPOKEE P, HO I, MATTHIJSSEN    C, NEU H C. Pharmacokinetics of cefotaxime. Antimicrob Agents Chemother 1979;16:    592-7.         [ Links ]43.- YUK J H, NIGHTINGALE C H, QUINTILIANI    R. Clinical pharmacokinetics of ceftriaxone. Clin Pharmacokinetic 1989; 17:    223-35.         [ Links ]44.- BRYSKIER A, PROCYK T, LABRO M T. Cefodizime,    a new 2-aminothiazolyl cephalosporin: physicochemical properties, toxicology    and structure-activity relationships. J Antimicrob Chemother 1990; 26 (Suppl    C): 1-8.         [ Links ]45.- CRITCHLEY I A, BASKER M J, EDMONDSON    R A, KNOTT S J. Uptake of catecholic cephalosporin by the iron transport system    of Escherichia coli. J Antimicrob Chemother 1991; 28: 377-88.         [ Links ]46.- CRITCHLEY I A. Catecholic ß-lactams:    facilitated transport. J Antimicrob Chemother 1990; 26: 733-7.         [ Links ]47.- JONES R N, ERWIN M E. In vitro evaluation    of Ro 09-1227, a novel catechol-substituted cephalosporin. Antimicrob Agents    Chemother 1992; 36: 233-8.         [ Links ]48.- JONES R N. In vitro activity of Ro 24-6392,    a novel ester-linked co-drug combining ciprofloxacin and desacetylcefotaxime.    Eur J Clin Microbiol Infect Dis 1990; 9: 435-8.         [ Links ]49.- TOMASZ A. Penicillin-binding proteins    and the antibacterial effectiveness of ß-lactam antibiotics. Rev Infect    Dis 1986 (Suppl 3); 8: 260-78.         [ Links ]50.- HOLM S E. Interaction between ß-lactam    and other antibiotics. Rev Infect Dis 1986 (Suppl 3); 8: 305-14.         [ Links ]51.- MC CULLERS J A, ENGLISH B K, NOVAK R.    Isolation and characterization of vancomycin-tolerant Streptococcus pneumoniae    from the cerebrospinal fluid of a patient who developed recrudescet meningitis.    J Infect Dis 2000; 181: 369-73.         [ Links ]52.- NIKAIDO H. Outer membrane barrier as    a mechanism of antimicrobial resistance. Antimicrob Agents Chemother 1989; 33:    1831-6.         [ Links ]53.- BARRADELL L B, BRYSON H M. Cefepime.    A review of its antibacterial activity, pharmacokinetic properties and therapeutic    use. Drugs 1994; 47: 471-505.         [ Links ]54.- O'CALLAGHAN C H 1979. Description and    classification of the newer cephalosporins and their relationship with the established    compounds. J Antimicrob Chemother 5: 635-71         [ Links ]55.- BRYSKIER A, PROCYK T, TREMBLAY D, LENFANT    B FOURTILLAN J B. The pharmacokinetics of cefodizime following intravenous and    intramuscular administration of a single dose of 1.0 g. J Antimicrob Chemother    1990; 26 (Suppl. C): 59-63.         [ Links ]56.- WILLIAMS J D. Classification of cephalosporins.    Drugs. 1987; 34 (Suppl 2): 15-22.         [ Links ]57.- WISEMAN L R, LAMB H M. Cefpirome. A review    of its antibacterial activity, pharmacokinetic properties and efficacy in the    treatment of severe nosocomial infections and febrile neutropenia. Drugs 1997;    57: 117-40.         [ Links ]58.- PECHERE J C, WILSON W, NEU H. Laboratory    assesment of antibacterial activity of zwitterionic 7-methoxyimino cephalosporins.    J Antimicrob Chemother 1995; 36: 757-71         [ Links ]59.- GIAMARELLOS-BOURBOULIS EJ, GRECKA P,    TSITSIKA A, TYMPANIDOU C, GIAMARELLOU H. In-vitro activity of FK 037 (cefoselis),    a novel 4 (th) generation cephalosporin, cefepime and cefpirome on nosocomial    staphylococci and gram-negative isolates. Diagn Microbiol infect Dis 2000; 36:    185-91.         [ Links ]60.- JONES R N, ERWIN M E, BARRETT M S, JOHNSON    D M, BRIGGS B M. Antimicrobial activity of E-1040, a novel thiadiazolyl cephalosporin    compare with parenteral cephems. Diagn Microbiol infect Dis 1991; 14: 301-9.          [ Links ]61.- IIZAWA Y, OKONOGI K, HAYASHI R, IWAHI    T, YAMAZAKI T, IMADA A. Therapeutic effect of cefozopran (SCE-2787), a new parenteral    cephalosporin in experimental infections in mice. Antimicrob Agents Chemother    1993; 37: 100-5.         [ Links ]62.- WATANABE N A. Newer antipseudomonal cephalosporins.    J Chemother 1996; 8 (Suppl 2): 48-56.         [ Links ]63.- ACTOR P, GUARINI J, URI J et al. Disk    susceptibility studies with cefazolin and cephalotin. Antimicrob Agents Chemother    1974; 5: 63-7.         [ Links ]64.- UWAYDAH M. Cefazolin in the treatment    of acute enteric fever. Antimicrob Agents Chemother 1976; 10: 52-6.         [ Links ]65.- JAMAL W Y, ROTIMI V O, CHUGH T D, PAL    T. Prevalence and susceptibility of Shigella to 11 antibiotics in a Kuwait    teaching hospital. J Chemother 1998; 10: 285-90.         [ Links ]66.- COX CE, SHERRILL M, COCCHETT DM. Evaluation    of cefuroxime axetil, cefaclor, and cephalexin in the treatment of urinary tract    infections in adults. Curr Ther Res 1987; 42: 124-37.         [ Links ]67.- SANDERS C W, GREENBERG R N, MARIER R    L. Cefamandole and cefoxitin. Ann Intern Med 1985; 103: 70-8.          [ Links ]68.- STAPLEY E P, JACKSON M, HERNANDEZ S et    al. Cephamycins, a new family of ß-lactam antibiotics I. Production actinomycetes,    including Streptomyces lactamdurans spp.n. Antimicrob Agents Chemother    1972; 2: 122-31.         [ Links ]69.- COOPER R D G. The carbacephems a new    ß-lactams class. Am J Med 1992; 92 (Suppl 6 A): 25-65.         [ Links ]70.- ZEMELMAN R, BELLO H, DOMINGUEZ M, GONZALEZ    G, MELLA S, GARCIA A. Activity of imipenem, third-generation cephalosporins,    aztreonam, and ciprofloxacin against multi-resistant Gram negative bacilli isolated    from Chilean hospitals. J Antimicrob Chemother 1993; 32: 413-9.         [ Links ]71.- MEDEIROS A A. Evolution and dissemination    of ß-lactamases accelerated by generation of ß-lactam antibiotics.    Clin Infect Dis 1997; 24 (Suppl. 1): 19-45.         [ Links ]72.- PERRY C M, BROGDEN R N. Cefuroxime axetil:    review of its antibacterial activity, pharmacokinetic properties and therapeutic    efficacy. Drugs 1996; 52: 125-58.         [ Links ]73.- SCHAAD U B, SUTER S, GIANELLA-BORRADORI    et al. A comparison of ceftriaxone and cefuroxime for the treatment of bacterial    meningitis in children. N Engl J Med 1990; 322: 141-7.         [ Links ]74.- KLEIN N C, CUNHA B A. Cefalosporinas de    la tercera generación. Clin Med Nort Am 1995; 79: 693-707.         [ Links ]75.- KLUGMAN K P, MADHI S A. Emergence of    drug resistance impact on bacterial meningitis. Infect Dis Clin North Am 1999;    13: 637-46.         [ Links ]76.- RICHARDS D M, BROGDEN R N. Ceftazidime.    A review of its antibacterial activity, pharmacokinetic properties and therapeutic    use. Drugs 1985; 29: 105-61.         [ Links ]77.- SCHATZ B S, KARAVOKIROS K T, TAEUBEL    M A, ITOKAZU G S. Comparison of cefprozil, cefpodoxime proxetil, loracarbef,    cefixime, and ceftibuten. Ann Pharmacother 1996; 30: 258-68.         [ Links ]78.- DALMAU D, LAYRARGUES G P, FENYVES D,    WILLEMS B, TURGEON F, TURGEON P. Cefotaxime, desacetyl-cefotaxime, and bactericidal    activity in spontaneous bacterial peritonitis. J Infect Dis 1999; 180: 1597-1602.          [ Links ]79.- NIKAIDO W, LIU W, ROSENBERG E Y. Outer    membrane permeability and ß-lactamase stability of dipolar ionic cephalosporins    containing methoxyimino substituents. Antimicrob Agents Chemother 1990; 34:    337-42.         [ Links ]80.- HANCOCK R E W, BELLIDO F. Factors involved    in the enhanced efficacy against gram-negative bacteria of fourth generation    cephalosporins. J Antimicrob Chemother 1992; 29(Suppl A): 1-6.         [ Links ]81.- BELLIDO F, PECHERE J C, HANCOCK REW.    Novel method for measurement of outer membrane permeability to new beta-lactams    in intact Enterobacter cloacae cells. Antimicrob Agents Chemother 1991;    35: 68-72.         [ Links ]82.- NEU H C, CHIN N X, JULES K, LABTHAVIKUL    P. The activity of BMY-28142, a new broad spectrum beta-lactamase stable cephalosporin.    J Antimicrob Chemother 1986; 17: 441-52.         [ Links ]83.- KOBAYASHI S, ARAI S, HAYASHI S, FUJIMOTO    K. ß-lactamase stability of cefpirome (HR 810), a new cephalosporin with    a broad antimicrobial spectrum. Antimicrob Agents Chemother 1986; 30: 713-8.          [ Links ]84.- GARAU J, WILSON W, WOOD M, CARLET J.    Fourth generation cephalosporins: a review of in vitro activity, pharmacokinetics,    pharmacodynamics, and clinical utility. Clin Microb Infect 1997; 3 (Suppl 1):    87-101.         [ Links ]85.- KESSLER R E, FUNG-TOMC J. Susceptibility    of bacterial isolates to beta-lactam antibiotics from U.S. clinical trials over    5-year period. Am J Med 1996; 24 (6 A): 13-9.         [ Links ]86.- PIERARD D, EMMERECHTS K, LAUWERS S. Comparative    in-vitro activity of cefpirome against isolates from intensive care and haematology/oncology    units. Belgian Multicentric Study Group. J Antimicrob Chemother 1998; 41: 443-50.          [ Links ]87.- JONES R N. Resistance patterns among    nosocomial pathogens: trends over the past few years. Chest 2001; 119 (Suppl    2): 397-404.         [ Links ]88.- LORBER B. Changing patterns of infectious    diseases. Am J Med 1988; 84: 569-78.         [ Links ]89.- MOELLERING R C. A novel antimicrobial    agent joins the battle against resistant bacteria. Ann Intern Med 1999; 130:    155-7.         [ Links ]90.- WILSON W R. The role of fourth-generation    cephalosporins in the treatment of serious infectious diseases in hospitalized    patients. Diagn Microbiol Infect Dis 1998; 31: 473-7.         [ Links ]Correspondencia a:        Sergio Mella Montecinos        Laboratorio de Antibióticos,        Departamento de Microbiología,        Facultad de Ciencias Biológicas        Casilla 160-C, Concepción        E-mail: pignatio@ctcinternet.cl  

6.- NEU H C. Relation of structural properties    of beta-lactam antibiotics to antibacterial activity. Am J Med 1985; 79 (Suppl    2 A): 2-13.         [ Links ]7.- SCHOLAR E M, PRATT W B (Eds). The inhibitors    of cell wall synthesis, II. The antimicrobial drugs. Oxford University Press.    2000 Nueva York. pp:         [ Links ]8.- LOPEZ F, GARRIDO J C. Química y    relación estructura-actividad de los antibióticos cefalosporínicos    (I). Rev Col Químico Farmacéutico 1988; 44: 110-22.         [ Links ]9.- TURNIDGE J D. The pharmacodynamics of        ß-lactams. Clin Infect Dis 1998; 27: 10-22.  10.- CRAIG W A. The future-can we learn from    the past? Diagn Microbiol Infect Dis 1997; 27: 49-53.         [ Links ]11.- DUDLEY M N. Pharmacodynamics and pharmacokinetics    of antibiotics with special reference to the fluoroquinolones. Am J Med 1991;    91 (Suppl 6 A): 6A-45S.         [ Links ]12.- NICOLAU D P, QUINTILIANI R, NIGHTINGALE    C H. Cinética y dinámica de los antibióticos para el clínico.    Clin Med Nort Am 1995; 79: 483-500.         [ Links ]13.- DRUSANO G L. Human pharmacodynamics of    beta-lactams, aminoglycosides and their combination. Scand J Infect Dis 1991    (Suppl); 74: 235-48.         [ Links ]14.- MARSHALL W F, BLAIR J E. The cephalosporins.    Mayo Clinic Proc 1999; 74: 187-95.         [ Links ]15.- DONOWIRZ G R, MANDELL G L. Beta-lactam    antibiotics. N Engl J Med 1988; 318: 490-500.         [ Links ]16.- PAYA E. Ventajas y desventajas de las    cefalosporinas orales de segunda y tercera generación. Rev Chil Infect    1997; 14: 233-8.         [ Links ]17.- AMERICAN THORACIC SOCIETY. Guidelines    for the initial management of adults with community-acquired pneumonia: diagnosis,    assessment of severity, and initial antimicrobial therapy. Am Rev Respir Dis    1993; 148: 1418-26.         [ Links ]18.- BARTLETT J G, BREIMAN R F, MANDELL L    A, FILE T M Jr. Community-acquired pneumonia in adults: guidelines for management.    The Infectious Diseases Society of America. Clin Infect Dis 1998: 26: 811-38.          [ Links ]19.- MARRIE T J. Community-acquired pneumonia:    epidemiology, etiology, treatment. Infect Dis Clin North Am 1998; 12: 723-40          [ Links ]20.- TUNKEL A R, SCHELD W M. Acute meningitis.    In: Mandell, Douglas & Bennett's. Principles and Practice of Infectious    Diseases. Mandell G L, Bennett J E, Dolin R, eds. Fifth edition. Philadelphia:    Editorial Churchill Livingstone 2000; 959-96.         [ Links ]21.- AMERICAN THORACIC SOCIETY. Hospital-acquired    pneumonia in adults: diagnosis, assessment of severity, initial antimicrobial    therapy, and preventive strategies. A consensus statement. Am J Respir Crit    Care Med 1996; 153: 1711-25.         [ Links ]22.- BARTLETT J G, DOWELL S F, MANDELL L A,    FILE T M, MUSHER D M, FINE M J. Practice guidelines for the management of community-acquired    pneumonia in adults. Clin Infect Dis. 2000; 31: 347-82         [ Links ]23.- KARCHMER A W. Cephalosporins. In: Mandell,    Douglas & Bennett's. Principles and Practice of Infectious Diseases. Mandell    G L, Bennett J E, Dolin R, eds. Fifth edition. Philadelphia: Churchill Livingstone    2000; 274-99.         [ Links ]24.- ADU A, ARMOUR C L. Drug utilisation review    (DUR) of the third generation cephalosporins. Drugs 1995; 50: 423-39.         [ Links ]25.- JONES R N. Important and emerging ß-lactamase    mediated resistances in hospital-based pathogens: the Amp C enzymes. Diagn Microbiol    Infect Dis 1998; 31: 461-6.         [ Links ]26.- JARVIS W R, MARTONE W J. Predominant    pathogens in hospital infections. J Antimicrob Chemother 1992; 29: 19-24.         [ Links ]27.- LIVERMORE D M. ß-lactamases in    laboratory and clinical resistance. Clin Microbiol Rev 1995; 8: 557-84.         [ Links ]28.- HERITAGE J, M'ZALI F H, GASCOYNE-BINZI    D, HAWKEY P M. Evolution and spread of SHV extended-spectrum ß-lactamases    in gram negative bacteria. J Antimicrob Chemother 1999; 44: 309-18.         [ Links ]29.- PODSCHUN R, ULLMAN U. Klebsiella spp.    as nosocomial pathogens: epidemiology, taxonomy, typing methods, and pathogenicity    factors. Clin Microbiol Rev 1998; 11: 589-603.         [ Links ]30.- PITOUT J D D, SANDERS C C, SANDERS W    E. Antimicrobial resistance with focus on ß-lactam resistance in Gram    negative bacilli. Am J Med 1997; 103: 51-9.         [ Links ]31.- HANBERGER H, GARCIA-RODRIGUEZ J A, GOBERNADO    et al. Antibiotic susceptibility among aerobic Gram negative bacilli in intensive    care units in 5 european countries. JAMA 1999; 281: 67-71.         [ Links ]32.- CHARREL R N, PAGES J M, DE MICCO P et    al. Prevalence of outer membrane porin alteration in ß-lactam-antibiotic-resistant    Enterobacter aerogenes. Antimicrob Agents Chemother 1996; 40: 2854-8.          [ Links ]33.- BRADFORD P A, URBAN C, MARIANO N, PROJAN    S J, RAHAL J J, BUSH K. Imipenem resistance in Klebsiella pneumoniae is    associated with the combination of ACT-1, a plasmid-mediated Amp C ß-lactamase,    and the loss of an outer membrane protein. Antimicrob Agents Chemother 1997;    41: 563-9.         [ Links ]34.- QUEENAN A M, TORRES-VIERA C, GOLD H et    al. SME-type carbapenem-hydrolizing class A ß-lactamases from geographically    diverse Serratia marcescens strains. Antimicrob Agents Chemother 2000;    44: 3035-9.         [ Links ]35.- COHEN S P, MC MURRY L M, HOOPER D C,    WOLFSON J S, LEVY S B. Cross-resistance to fluoroquinolones in multiple-antibiotic-resistance    (Mar) Escherichia coli selected by tetracycline resistance: decreased    drug accumulation asociated with membrane changes in addition to Omp F reduction.    Antimicrob Agents Chemother 1989; 33:1318-25.         [ Links ]36.- SANDERS C C. Cefepime: The next generation?    Clin Infect Dis 1993; 17: 369-79         [ Links ]37.- GARAU J. The clinical potential of fourth-generation    cephalosporins. Diagn Microbiol Infect Dis 1998; 31: 479-80.         [ Links ]38.- CURTIS N A C, ORR D C, ROSS G W, BOULTON    M G. Affinities of penicillins and cephalosporins for the penicillin-binding    proteins of Escherichia coli    K-12 and their antibacterial activity. Antimicrob Agents Chemother 1979; 16:    533-9.  39.- BALANT L, DAYER P, AUCKENTHALER R. Clinical    pharmacokinetics of the third generation cephalosporins. Clin Pharmacokinetics    1985; 10: 101-43.         [ Links ]40.- WHEELER W J. Cephalosporins and other    beta-lactam antibiotics. Lloydia. 1977; 40: 519-42.         [ Links ]41.- LOPEZ F, GARRIDO J C. Química    y relación estructura-actividad de los antibióticos cefalosporínicos.    Rev Col Químico Farmacéutico 1989; 41: 5-14.         [ Links ]42.- FU K P, ASWAPOKEE P, HO I, MATTHIJSSEN    C, NEU H C. Pharmacokinetics of cefotaxime. Antimicrob Agents Chemother 1979;16:    592-7.         [ Links ]43.- YUK J H, NIGHTINGALE C H, QUINTILIANI    R. Clinical pharmacokinetics of ceftriaxone. Clin Pharmacokinetic 1989; 17:    223-35.         [ Links ]44.- BRYSKIER A, PROCYK T, LABRO M T. Cefodizime,    a new 2-aminothiazolyl cephalosporin: physicochemical properties, toxicology    and structure-activity relationships. J Antimicrob Chemother 1990; 26 (Suppl    C): 1-8.         [ Links ]45.- CRITCHLEY I A, BASKER M J, EDMONDSON    R A, KNOTT S J. Uptake of catecholic cephalosporin by the iron transport system    of Escherichia coli. J Antimicrob Chemother 1991; 28: 377-88.         [ Links ]46.- CRITCHLEY I A. Catecholic ß-lactams:    facilitated transport. J Antimicrob Chemother 1990; 26: 733-7.         [ Links ]47.- JONES R N, ERWIN M E. In vitro evaluation    of Ro 09-1227, a novel catechol-substituted cephalosporin. Antimicrob Agents    Chemother 1992; 36: 233-8.         [ Links ]48.- JONES R N. In vitro activity of Ro 24-6392,    a novel ester-linked co-drug combining ciprofloxacin and desacetylcefotaxime.    Eur J Clin Microbiol Infect Dis 1990; 9: 435-8.         [ Links ]49.- TOMASZ A. Penicillin-binding proteins    and the antibacterial effectiveness of ß-lactam antibiotics. Rev Infect    Dis 1986 (Suppl 3); 8: 260-78.         [ Links ]50.- HOLM S E. Interaction between ß-lactam    and other antibiotics. Rev Infect Dis 1986 (Suppl 3); 8: 305-14.         [ Links ]51.- MC CULLERS J A, ENGLISH B K, NOVAK R.    Isolation and characterization of vancomycin-tolerant Streptococcus pneumoniae    from the cerebrospinal fluid of a patient who developed recrudescet meningitis.    J Infect Dis 2000; 181: 369-73.         [ Links ]52.- NIKAIDO H. Outer membrane barrier as    a mechanism of antimicrobial resistance. Antimicrob Agents Chemother 1989; 33:    1831-6.         [ Links ]53.- BARRADELL L B, BRYSON H M. Cefepime.    A review of its antibacterial activity, pharmacokinetic properties and therapeutic    use. Drugs 1994; 47: 471-505.         [ Links ]54.- O'CALLAGHAN C H 1979. Description and    classification of the newer cephalosporins and their relationship with the established    compounds. J Antimicrob Chemother 5: 635-71         [ Links ]55.- BRYSKIER A, PROCYK T, TREMBLAY D, LENFANT    B FOURTILLAN J B. The pharmacokinetics of cefodizime following intravenous and    intramuscular administration of a single dose of 1.0 g. J Antimicrob Chemother    1990; 26 (Suppl. C): 59-63.         [ Links ]56.- WILLIAMS J D. Classification of cephalosporins.    Drugs. 1987; 34 (Suppl 2): 15-22.         [ Links ]57.- WISEMAN L R, LAMB H M. Cefpirome. A review    of its antibacterial activity, pharmacokinetic properties and efficacy in the    treatment of severe nosocomial infections and febrile neutropenia. Drugs 1997;    57: 117-40.         [ Links ]58.- PECHERE J C, WILSON W, NEU H. Laboratory    assesment of antibacterial activity of zwitterionic 7-methoxyimino cephalosporins.    J Antimicrob Chemother 1995; 36: 757-71         [ Links ]59.- GIAMARELLOS-BOURBOULIS EJ, GRECKA P,    TSITSIKA A, TYMPANIDOU C, GIAMARELLOU H. In-vitro activity of FK 037 (cefoselis),    a novel 4 (th) generation cephalosporin, cefepime and cefpirome on nosocomial    staphylococci and gram-negative isolates. Diagn Microbiol infect Dis 2000; 36:    185-91.         [ Links ]60.- JONES R N, ERWIN M E, BARRETT M S, JOHNSON    D M, BRIGGS B M. Antimicrobial activity of E-1040, a novel thiadiazolyl cephalosporin    compare with parenteral cephems. Diagn Microbiol infect Dis 1991; 14: 301-9.          [ Links ]61.- IIZAWA Y, OKONOGI K, HAYASHI R, IWAHI    T, YAMAZAKI T, IMADA A. Therapeutic effect of cefozopran (SCE-2787), a new parenteral    cephalosporin in experimental infections in mice. Antimicrob Agents Chemother    1993; 37: 100-5.         [ Links ]62.- WATANABE N A. Newer antipseudomonal cephalosporins.    J Chemother 1996; 8 (Suppl 2): 48-56.         [ Links ]63.- ACTOR P, GUARINI J, URI J et al. Disk    susceptibility studies with cefazolin and cephalotin. Antimicrob Agents Chemother    1974; 5: 63-7.         [ Links ]64.- UWAYDAH M. Cefazolin in the treatment    of acute enteric fever. Antimicrob Agents Chemother 1976; 10: 52-6.         [ Links ]65.- JAMAL W Y, ROTIMI V O, CHUGH T D, PAL    T. Prevalence and susceptibility of Shigella to 11 antibiotics in a Kuwait    teaching hospital. J Chemother 1998; 10: 285-90.         [ Links ]66.- COX CE, SHERRILL M, COCCHETT DM. Evaluation    of cefuroxime axetil, cefaclor, and cephalexin in the treatment of urinary tract    infections in adults. Curr Ther Res 1987; 42: 124-37.         [ Links ]67.- SANDERS C W, GREENBERG R N, MARIER R    L. Cefamandole and cefoxitin. Ann Intern Med 1985; 103: 70-8.          [ Links ]68.- STAPLEY E P, JACKSON M, HERNANDEZ S et    al. Cephamycins, a new family of ß-lactam antibiotics I. Production actinomycetes,    including Streptomyces lactamdurans spp.n. Antimicrob Agents Chemother    1972; 2: 122-31.         [ Links ]69.- COOPER R D G. The carbacephems a new    ß-lactams class. Am J Med 1992; 92 (Suppl 6 A): 25-65.         [ Links ]70.- ZEMELMAN R, BELLO H, DOMINGUEZ M, GONZALEZ    G, MELLA S, GARCIA A. Activity of imipenem, third-generation cephalosporins,    aztreonam, and ciprofloxacin against multi-resistant Gram negative bacilli isolated    from Chilean hospitals. J Antimicrob Chemother 1993; 32: 413-9.         [ Links ]71.- MEDEIROS A A. Evolution and dissemination    of ß-lactamases accelerated by generation of ß-lactam antibiotics.    Clin Infect Dis 1997; 24 (Suppl. 1): 19-45.         [ Links ]72.- PERRY C M, BROGDEN R N. Cefuroxime axetil:    review of its antibacterial activity, pharmacokinetic properties and therapeutic    efficacy. Drugs 1996; 52: 125-58.         [ Links ]73.- SCHAAD U B, SUTER S, GIANELLA-BORRADORI    et al. A comparison of ceftriaxone and cefuroxime for the treatment of bacterial    meningitis in children. N Engl J Med 1990; 322: 141-7.         [ Links ]74.- KLEIN N C, CUNHA B A. Cefalosporinas de    la tercera generación. Clin Med Nort Am 1995; 79: 693-707.         [ Links ]75.- KLUGMAN K P, MADHI S A. Emergence of    drug resistance impact on bacterial meningitis. Infect Dis Clin North Am 1999;    13: 637-46.         [ Links ]76.- RICHARDS D M, BROGDEN R N. Ceftazidime.    A review of its antibacterial activity, pharmacokinetic properties and therapeutic    use. Drugs 1985; 29: 105-61.         [ Links ]77.- SCHATZ B S, KARAVOKIROS K T, TAEUBEL    M A, ITOKAZU G S. Comparison of cefprozil, cefpodoxime proxetil, loracarbef,    cefixime, and ceftibuten. Ann Pharmacother 1996; 30: 258-68.         [ Links ]78.- DALMAU D, LAYRARGUES G P, FENYVES D,    WILLEMS B, TURGEON F, TURGEON P. Cefotaxime, desacetyl-cefotaxime, and bactericidal    activity in spontaneous bacterial peritonitis. J Infect Dis 1999; 180: 1597-1602.          [ Links ]79.- NIKAIDO W, LIU W, ROSENBERG E Y. Outer    membrane permeability and ß-lactamase stability of dipolar ionic cephalosporins    containing methoxyimino substituents. Antimicrob Agents Chemother 1990; 34:    337-42.         [ Links ]80.- HANCOCK R E W, BELLIDO F. Factors involved    in the enhanced efficacy against gram-negative bacteria of fourth generation    cephalosporins. J Antimicrob Chemother 1992; 29(Suppl A): 1-6.         [ Links ]81.- BELLIDO F, PECHERE J C, HANCOCK REW.    Novel method for measurement of outer membrane permeability to new beta-lactams    in intact Enterobacter cloacae cells. Antimicrob Agents Chemother 1991;    35: 68-72.         [ Links ]82.- NEU H C, CHIN N X, JULES K, LABTHAVIKUL    P. The activity of BMY-28142, a new broad spectrum beta-lactamase stable cephalosporin.    J Antimicrob Chemother 1986; 17: 441-52.         [ Links ]83.- KOBAYASHI S, ARAI S, HAYASHI S, FUJIMOTO    K. ß-lactamase stability of cefpirome (HR 810), a new cephalosporin with    a broad antimicrobial spectrum. Antimicrob Agents Chemother 1986; 30: 713-8.          [ Links ]84.- GARAU J, WILSON W, WOOD M, CARLET J.    Fourth generation cephalosporins: a review of in vitro activity, pharmacokinetics,    pharmacodynamics, and clinical utility. Clin Microb Infect 1997; 3 (Suppl 1):    87-101.         [ Links ]85.- KESSLER R E, FUNG-TOMC J. Susceptibility    of bacterial isolates to beta-lactam antibiotics from U.S. clinical trials over    5-year period. Am J Med 1996; 24 (6 A): 13-9.         [ Links ]86.- PIERARD D, EMMERECHTS K, LAUWERS S. Comparative    in-vitro activity of cefpirome against isolates from intensive care and haematology/oncology    units. Belgian Multicentric Study Group. J Antimicrob Chemother 1998; 41: 443-50.          [ Links ]87.- JONES R N. Resistance patterns among    nosocomial pathogens: trends over the past few years. Chest 2001; 119 (Suppl    2): 397-404.         [ Links ]88.- LORBER B. Changing patterns of infectious    diseases. Am J Med 1988; 84: 569-78.         [ Links ]89.- MOELLERING R C. A novel antimicrobial    agent joins the battle against resistant bacteria. Ann Intern Med 1999; 130:    155-7.         [ Links ]90.- WILSON W R. The role of fourth-generation    cephalosporins in the treatment of serious infectious diseases in hospitalized    patients. Diagn Microbiol Infect Dis 1998; 31: 473-7.         [ Links ]Correspondencia a:        Sergio Mella Montecinos        Laboratorio de Antibióticos,        Departamento de Microbiología,        Facultad de Ciencias Biológicas        Casilla 160-C, Concepción        E-mail: pignatio@ctcinternet.cl  

7.- SCHOLAR E M, PRATT W B (Eds). The inhibitors    of cell wall synthesis, II. The antimicrobial drugs. Oxford University Press.    2000 Nueva York. pp:         [ Links ]8.- LOPEZ F, GARRIDO J C. Química y    relación estructura-actividad de los antibióticos cefalosporínicos    (I). Rev Col Químico Farmacéutico 1988; 44: 110-22.         [ Links ]9.- TURNIDGE J D. The pharmacodynamics of        ß-lactams. Clin Infect Dis 1998; 27: 10-22.  10.- CRAIG W A. The future-can we learn from    the past? Diagn Microbiol Infect Dis 1997; 27: 49-53.         [ Links ]11.- DUDLEY M N. Pharmacodynamics and pharmacokinetics    of antibiotics with special reference to the fluoroquinolones. Am J Med 1991;    91 (Suppl 6 A): 6A-45S.         [ Links ]12.- NICOLAU D P, QUINTILIANI R, NIGHTINGALE    C H. Cinética y dinámica de los antibióticos para el clínico.    Clin Med Nort Am 1995; 79: 483-500.         [ Links ]13.- DRUSANO G L. Human pharmacodynamics of    beta-lactams, aminoglycosides and their combination. Scand J Infect Dis 1991    (Suppl); 74: 235-48.         [ Links ]14.- MARSHALL W F, BLAIR J E. The cephalosporins.    Mayo Clinic Proc 1999; 74: 187-95.         [ Links ]15.- DONOWIRZ G R, MANDELL G L. Beta-lactam    antibiotics. N Engl J Med 1988; 318: 490-500.         [ Links ]16.- PAYA E. Ventajas y desventajas de las    cefalosporinas orales de segunda y tercera generación. Rev Chil Infect    1997; 14: 233-8.         [ Links ]17.- AMERICAN THORACIC SOCIETY. Guidelines    for the initial management of adults with community-acquired pneumonia: diagnosis,    assessment of severity, and initial antimicrobial therapy. Am Rev Respir Dis    1993; 148: 1418-26.         [ Links ]18.- BARTLETT J G, BREIMAN R F, MANDELL L    A, FILE T M Jr. Community-acquired pneumonia in adults: guidelines for management.    The Infectious Diseases Society of America. Clin Infect Dis 1998: 26: 811-38.          [ Links ]19.- MARRIE T J. Community-acquired pneumonia:    epidemiology, etiology, treatment. Infect Dis Clin North Am 1998; 12: 723-40          [ Links ]20.- TUNKEL A R, SCHELD W M. Acute meningitis.    In: Mandell, Douglas & Bennett's. Principles and Practice of Infectious    Diseases. Mandell G L, Bennett J E, Dolin R, eds. Fifth edition. Philadelphia:    Editorial Churchill Livingstone 2000; 959-96.         [ Links ]21.- AMERICAN THORACIC SOCIETY. Hospital-acquired    pneumonia in adults: diagnosis, assessment of severity, initial antimicrobial    therapy, and preventive strategies. A consensus statement. Am J Respir Crit    Care Med 1996; 153: 1711-25.         [ Links ]22.- BARTLETT J G, DOWELL S F, MANDELL L A,    FILE T M, MUSHER D M, FINE M J. Practice guidelines for the management of community-acquired    pneumonia in adults. Clin Infect Dis. 2000; 31: 347-82         [ Links ]23.- KARCHMER A W. Cephalosporins. In: Mandell,    Douglas & Bennett's. Principles and Practice of Infectious Diseases. Mandell    G L, Bennett J E, Dolin R, eds. Fifth edition. Philadelphia: Churchill Livingstone    2000; 274-99.         [ Links ]24.- ADU A, ARMOUR C L. Drug utilisation review    (DUR) of the third generation cephalosporins. Drugs 1995; 50: 423-39.         [ Links ]25.- JONES R N. Important and emerging ß-lactamase    mediated resistances in hospital-based pathogens: the Amp C enzymes. Diagn Microbiol    Infect Dis 1998; 31: 461-6.         [ Links ]26.- JARVIS W R, MARTONE W J. Predominant    pathogens in hospital infections. J Antimicrob Chemother 1992; 29: 19-24.         [ Links ]27.- LIVERMORE D M. ß-lactamases in    laboratory and clinical resistance. Clin Microbiol Rev 1995; 8: 557-84.         [ Links ]28.- HERITAGE J, M'ZALI F H, GASCOYNE-BINZI    D, HAWKEY P M. Evolution and spread of SHV extended-spectrum ß-lactamases    in gram negative bacteria. J Antimicrob Chemother 1999; 44: 309-18.         [ Links ]29.- PODSCHUN R, ULLMAN U. Klebsiella spp.    as nosocomial pathogens: epidemiology, taxonomy, typing methods, and pathogenicity    factors. Clin Microbiol Rev 1998; 11: 589-603.         [ Links ]30.- PITOUT J D D, SANDERS C C, SANDERS W    E. Antimicrobial resistance with focus on ß-lactam resistance in Gram    negative bacilli. Am J Med 1997; 103: 51-9.         [ Links ]31.- HANBERGER H, GARCIA-RODRIGUEZ J A, GOBERNADO    et al. Antibiotic susceptibility among aerobic Gram negative bacilli in intensive    care units in 5 european countries. JAMA 1999; 281: 67-71.         [ Links ]32.- CHARREL R N, PAGES J M, DE MICCO P et    al. Prevalence of outer membrane porin alteration in ß-lactam-antibiotic-resistant    Enterobacter aerogenes. Antimicrob Agents Chemother 1996; 40: 2854-8.          [ Links ]33.- BRADFORD P A, URBAN C, MARIANO N, PROJAN    S J, RAHAL J J, BUSH K. Imipenem resistance in Klebsiella pneumoniae is    associated with the combination of ACT-1, a plasmid-mediated Amp C ß-lactamase,    and the loss of an outer membrane protein. Antimicrob Agents Chemother 1997;    41: 563-9.         [ Links ]34.- QUEENAN A M, TORRES-VIERA C, GOLD H et    al. SME-type carbapenem-hydrolizing class A ß-lactamases from geographically    diverse Serratia marcescens strains. Antimicrob Agents Chemother 2000;    44: 3035-9.         [ Links ]35.- COHEN S P, MC MURRY L M, HOOPER D C,    WOLFSON J S, LEVY S B. Cross-resistance to fluoroquinolones in multiple-antibiotic-resistance    (Mar) Escherichia coli selected by tetracycline resistance: decreased    drug accumulation asociated with membrane changes in addition to Omp F reduction.    Antimicrob Agents Chemother 1989; 33:1318-25.         [ Links ]36.- SANDERS C C. Cefepime: The next generation?    Clin Infect Dis 1993; 17: 369-79         [ Links ]37.- GARAU J. The clinical potential of fourth-generation    cephalosporins. Diagn Microbiol Infect Dis 1998; 31: 479-80.         [ Links ]38.- CURTIS N A C, ORR D C, ROSS G W, BOULTON    M G. Affinities of penicillins and cephalosporins for the penicillin-binding    proteins of Escherichia coli    K-12 and their antibacterial activity. Antimicrob Agents Chemother 1979; 16:    533-9.  39.- BALANT L, DAYER P, AUCKENTHALER R. Clinical    pharmacokinetics of the third generation cephalosporins. Clin Pharmacokinetics    1985; 10: 101-43.         [ Links ]40.- WHEELER W J. Cephalosporins and other    beta-lactam antibiotics. Lloydia. 1977; 40: 519-42.         [ Links ]41.- LOPEZ F, GARRIDO J C. Química    y relación estructura-actividad de los antibióticos cefalosporínicos.    Rev Col Químico Farmacéutico 1989; 41: 5-14.         [ Links ]42.- FU K P, ASWAPOKEE P, HO I, MATTHIJSSEN    C, NEU H C. Pharmacokinetics of cefotaxime. Antimicrob Agents Chemother 1979;16:    592-7.         [ Links ]43.- YUK J H, NIGHTINGALE C H, QUINTILIANI    R. Clinical pharmacokinetics of ceftriaxone. Clin Pharmacokinetic 1989; 17:    223-35.         [ Links ]44.- BRYSKIER A, PROCYK T, LABRO M T. Cefodizime,    a new 2-aminothiazolyl cephalosporin: physicochemical properties, toxicology    and structure-activity relationships. J Antimicrob Chemother 1990; 26 (Suppl    C): 1-8.         [ Links ]45.- CRITCHLEY I A, BASKER M J, EDMONDSON    R A, KNOTT S J. Uptake of catecholic cephalosporin by the iron transport system    of Escherichia coli. J Antimicrob Chemother 1991; 28: 377-88.         [ Links ]46.- CRITCHLEY I A. Catecholic ß-lactams:    facilitated transport. J Antimicrob Chemother 1990; 26: 733-7.         [ Links ]47.- JONES R N, ERWIN M E. In vitro evaluation    of Ro 09-1227, a novel catechol-substituted cephalosporin. Antimicrob Agents    Chemother 1992; 36: 233-8.         [ Links ]48.- JONES R N. In vitro activity of Ro 24-6392,    a novel ester-linked co-drug combining ciprofloxacin and desacetylcefotaxime.    Eur J Clin Microbiol Infect Dis 1990; 9: 435-8.         [ Links ]49.- TOMASZ A. Penicillin-binding proteins    and the antibacterial effectiveness of ß-lactam antibiotics. Rev Infect    Dis 1986 (Suppl 3); 8: 260-78.         [ Links ]50.- HOLM S E. Interaction between ß-lactam    and other antibiotics. Rev Infect Dis 1986 (Suppl 3); 8: 305-14.         [ Links ]51.- MC CULLERS J A, ENGLISH B K, NOVAK R.    Isolation and characterization of vancomycin-tolerant Streptococcus pneumoniae    from the cerebrospinal fluid of a patient who developed recrudescet meningitis.    J Infect Dis 2000; 181: 369-73.         [ Links ]52.- NIKAIDO H. Outer membrane barrier as    a mechanism of antimicrobial resistance. Antimicrob Agents Chemother 1989; 33:    1831-6.         [ Links ]53.- BARRADELL L B, BRYSON H M. Cefepime.    A review of its antibacterial activity, pharmacokinetic properties and therapeutic    use. Drugs 1994; 47: 471-505.         [ Links ]54.- O'CALLAGHAN C H 1979. Description and    classification of the newer cephalosporins and their relationship with the established    compounds. J Antimicrob Chemother 5: 635-71         [ Links ]55.- BRYSKIER A, PROCYK T, TREMBLAY D, LENFANT    B FOURTILLAN J B. The pharmacokinetics of cefodizime following intravenous and    intramuscular administration of a single dose of 1.0 g. J Antimicrob Chemother    1990; 26 (Suppl. C): 59-63.         [ Links ]56.- WILLIAMS J D. Classification of cephalosporins.    Drugs. 1987; 34 (Suppl 2): 15-22.         [ Links ]57.- WISEMAN L R, LAMB H M. Cefpirome. A review    of its antibacterial activity, pharmacokinetic properties and efficacy in the    treatment of severe nosocomial infections and febrile neutropenia. Drugs 1997;    57: 117-40.         [ Links ]58.- PECHERE J C, WILSON W, NEU H. Laboratory    assesment of antibacterial activity of zwitterionic 7-methoxyimino cephalosporins.    J Antimicrob Chemother 1995; 36: 757-71         [ Links ]59.- GIAMARELLOS-BOURBOULIS EJ, GRECKA P,    TSITSIKA A, TYMPANIDOU C, GIAMARELLOU H. In-vitro activity of FK 037 (cefoselis),    a novel 4 (th) generation cephalosporin, cefepime and cefpirome on nosocomial    staphylococci and gram-negative isolates. Diagn Microbiol infect Dis 2000; 36:    185-91.         [ Links ]60.- JONES R N, ERWIN M E, BARRETT M S, JOHNSON    D M, BRIGGS B M. Antimicrobial activity of E-1040, a novel thiadiazolyl cephalosporin    compare with parenteral cephems. Diagn Microbiol infect Dis 1991; 14: 301-9.          [ Links ]61.- IIZAWA Y, OKONOGI K, HAYASHI R, IWAHI    T, YAMAZAKI T, IMADA A. Therapeutic effect of cefozopran (SCE-2787), a new parenteral    cephalosporin in experimental infections in mice. Antimicrob Agents Chemother    1993; 37: 100-5.         [ Links ]62.- WATANABE N A. Newer antipseudomonal cephalosporins.    J Chemother 1996; 8 (Suppl 2): 48-56.         [ Links ]63.- ACTOR P, GUARINI J, URI J et al. Disk    susceptibility studies with cefazolin and cephalotin. Antimicrob Agents Chemother    1974; 5: 63-7.         [ Links ]64.- UWAYDAH M. Cefazolin in the treatment    of acute enteric fever. Antimicrob Agents Chemother 1976; 10: 52-6.         [ Links ]65.- JAMAL W Y, ROTIMI V O, CHUGH T D, PAL    T. Prevalence and susceptibility of Shigella to 11 antibiotics in a Kuwait    teaching hospital. J Chemother 1998; 10: 285-90.         [ Links ]66.- COX CE, SHERRILL M, COCCHETT DM. Evaluation    of cefuroxime axetil, cefaclor, and cephalexin in the treatment of urinary tract    infections in adults. Curr Ther Res 1987; 42: 124-37.         [ Links ]67.- SANDERS C W, GREENBERG R N, MARIER R    L. Cefamandole and cefoxitin. Ann Intern Med 1985; 103: 70-8.          [ Links ]68.- STAPLEY E P, JACKSON M, HERNANDEZ S et    al. Cephamycins, a new family of ß-lactam antibiotics I. Production actinomycetes,    including Streptomyces lactamdurans spp.n. Antimicrob Agents Chemother    1972; 2: 122-31.         [ Links ]69.- COOPER R D G. The carbacephems a new    ß-lactams class. Am J Med 1992; 92 (Suppl 6 A): 25-65.         [ Links ]70.- ZEMELMAN R, BELLO H, DOMINGUEZ M, GONZALEZ    G, MELLA S, GARCIA A. Activity of imipenem, third-generation cephalosporins,    aztreonam, and ciprofloxacin against multi-resistant Gram negative bacilli isolated    from Chilean hospitals. J Antimicrob Chemother 1993; 32: 413-9.         [ Links ]71.- MEDEIROS A A. Evolution and dissemination    of ß-lactamases accelerated by generation of ß-lactam antibiotics.    Clin Infect Dis 1997; 24 (Suppl. 1): 19-45.         [ Links ]72.- PERRY C M, BROGDEN R N. Cefuroxime axetil:    review of its antibacterial activity, pharmacokinetic properties and therapeutic    efficacy. Drugs 1996; 52: 125-58.         [ Links ]73.- SCHAAD U B, SUTER S, GIANELLA-BORRADORI    et al. A comparison of ceftriaxone and cefuroxime for the treatment of bacterial    meningitis in children. N Engl J Med 1990; 322: 141-7.         [ Links ]74.- KLEIN N C, CUNHA B A. Cefalosporinas de    la tercera generación. Clin Med Nort Am 1995; 79: 693-707.         [ Links ]75.- KLUGMAN K P, MADHI S A. Emergence of    drug resistance impact on bacterial meningitis. Infect Dis Clin North Am 1999;    13: 637-46.         [ Links ]76.- RICHARDS D M, BROGDEN R N. Ceftazidime.    A review of its antibacterial activity, pharmacokinetic properties and therapeutic    use. Drugs 1985; 29: 105-61.         [ Links ]77.- SCHATZ B S, KARAVOKIROS K T, TAEUBEL    M A, ITOKAZU G S. Comparison of cefprozil, cefpodoxime proxetil, loracarbef,    cefixime, and ceftibuten. Ann Pharmacother 1996; 30: 258-68.         [ Links ]78.- DALMAU D, LAYRARGUES G P, FENYVES D,    WILLEMS B, TURGEON F, TURGEON P. Cefotaxime, desacetyl-cefotaxime, and bactericidal    activity in spontaneous bacterial peritonitis. J Infect Dis 1999; 180: 1597-1602.          [ Links ]79.- NIKAIDO W, LIU W, ROSENBERG E Y. Outer    membrane permeability and ß-lactamase stability of dipolar ionic cephalosporins    containing methoxyimino substituents. Antimicrob Agents Chemother 1990; 34:    337-42.         [ Links ]80.- HANCOCK R E W, BELLIDO F. Factors involved    in the enhanced efficacy against gram-negative bacteria of fourth generation    cephalosporins. J Antimicrob Chemother 1992; 29(Suppl A): 1-6.         [ Links ]81.- BELLIDO F, PECHERE J C, HANCOCK REW.    Novel method for measurement of outer membrane permeability to new beta-lactams    in intact Enterobacter cloacae cells. Antimicrob Agents Chemother 1991;    35: 68-72.         [ Links ]82.- NEU H C, CHIN N X, JULES K, LABTHAVIKUL    P. The activity of BMY-28142, a new broad spectrum beta-lactamase stable cephalosporin.    J Antimicrob Chemother 1986; 17: 441-52.         [ Links ]83.- KOBAYASHI S, ARAI S, HAYASHI S, FUJIMOTO    K. ß-lactamase stability of cefpirome (HR 810), a new cephalosporin with    a broad antimicrobial spectrum. Antimicrob Agents Chemother 1986; 30: 713-8.          [ Links ]84.- GARAU J, WILSON W, WOOD M, CARLET J.    Fourth generation cephalosporins: a review of in vitro activity, pharmacokinetics,    pharmacodynamics, and clinical utility. Clin Microb Infect 1997; 3 (Suppl 1):    87-101.         [ Links ]85.- KESSLER R E, FUNG-TOMC J. Susceptibility    of bacterial isolates to beta-lactam antibiotics from U.S. clinical trials over    5-year period. Am J Med 1996; 24 (6 A): 13-9.         [ Links ]86.- PIERARD D, EMMERECHTS K, LAUWERS S. Comparative    in-vitro activity of cefpirome against isolates from intensive care and haematology/oncology    units. Belgian Multicentric Study Group. J Antimicrob Chemother 1998; 41: 443-50.          [ Links ]87.- JONES R N. Resistance patterns among    nosocomial pathogens: trends over the past few years. Chest 2001; 119 (Suppl    2): 397-404.         [ Links ]88.- LORBER B. Changing patterns of infectious    diseases. Am J Med 1988; 84: 569-78.         [ Links ]89.- MOELLERING R C. A novel antimicrobial    agent joins the battle against resistant bacteria. Ann Intern Med 1999; 130:    155-7.         [ Links ]90.- WILSON W R. The role of fourth-generation    cephalosporins in the treatment of serious infectious diseases in hospitalized    patients. Diagn Microbiol Infect Dis 1998; 31: 473-7.         [ Links ]Correspondencia a:        Sergio Mella Montecinos        Laboratorio de Antibióticos,        Departamento de Microbiología,        Facultad de Ciencias Biológicas        Casilla 160-C, Concepción        E-mail: pignatio@ctcinternet.cl  

8.- LOPEZ F, GARRIDO J C. Química y    relación estructura-actividad de los antibióticos cefalosporínicos    (I). Rev Col Químico Farmacéutico 1988; 44: 110-22.         [ Links ]9.- TURNIDGE J D. The pharmacodynamics of        ß-lactams. Clin Infect Dis 1998; 27: 10-22.  10.- CRAIG W A. The future-can we learn from    the past? Diagn Microbiol Infect Dis 1997; 27: 49-53.         [ Links ]11.- DUDLEY M N. Pharmacodynamics and pharmacokinetics    of antibiotics with special reference to the fluoroquinolones. Am J Med 1991;    91 (Suppl 6 A): 6A-45S.         [ Links ]12.- NICOLAU D P, QUINTILIANI R, NIGHTINGALE    C H. Cinética y dinámica de los antibióticos para el clínico.    Clin Med Nort Am 1995; 79: 483-500.         [ Links ]13.- DRUSANO G L. Human pharmacodynamics of    beta-lactams, aminoglycosides and their combination. Scand J Infect Dis 1991    (Suppl); 74: 235-48.         [ Links ]14.- MARSHALL W F, BLAIR J E. The cephalosporins.    Mayo Clinic Proc 1999; 74: 187-95.         [ Links ]15.- DONOWIRZ G R, MANDELL G L. Beta-lactam    antibiotics. N Engl J Med 1988; 318: 490-500.         [ Links ]16.- PAYA E. Ventajas y desventajas de las    cefalosporinas orales de segunda y tercera generación. Rev Chil Infect    1997; 14: 233-8.         [ Links ]17.- AMERICAN THORACIC SOCIETY. Guidelines    for the initial management of adults with community-acquired pneumonia: diagnosis,    assessment of severity, and initial antimicrobial therapy. Am Rev Respir Dis    1993; 148: 1418-26.         [ Links ]18.- BARTLETT J G, BREIMAN R F, MANDELL L    A, FILE T M Jr. Community-acquired pneumonia in adults: guidelines for management.    The Infectious Diseases Society of America. Clin Infect Dis 1998: 26: 811-38.          [ Links ]19.- MARRIE T J. Community-acquired pneumonia:    epidemiology, etiology, treatment. Infect Dis Clin North Am 1998; 12: 723-40          [ Links ]20.- TUNKEL A R, SCHELD W M. Acute meningitis.    In: Mandell, Douglas & Bennett's. Principles and Practice of Infectious    Diseases. Mandell G L, Bennett J E, Dolin R, eds. Fifth edition. Philadelphia:    Editorial Churchill Livingstone 2000; 959-96.         [ Links ]21.- AMERICAN THORACIC SOCIETY. Hospital-acquired    pneumonia in adults: diagnosis, assessment of severity, initial antimicrobial    therapy, and preventive strategies. A consensus statement. Am J Respir Crit    Care Med 1996; 153: 1711-25.         [ Links ]22.- BARTLETT J G, DOWELL S F, MANDELL L A,    FILE T M, MUSHER D M, FINE M J. Practice guidelines for the management of community-acquired    pneumonia in adults. Clin Infect Dis. 2000; 31: 347-82         [ Links ]23.- KARCHMER A W. Cephalosporins. In: Mandell,    Douglas & Bennett's. Principles and Practice of Infectious Diseases. Mandell    G L, Bennett J E, Dolin R, eds. Fifth edition. Philadelphia: Churchill Livingstone    2000; 274-99.         [ Links ]24.- ADU A, ARMOUR C L. Drug utilisation review    (DUR) of the third generation cephalosporins. Drugs 1995; 50: 423-39.         [ Links ]25.- JONES R N. Important and emerging ß-lactamase    mediated resistances in hospital-based pathogens: the Amp C enzymes. Diagn Microbiol    Infect Dis 1998; 31: 461-6.         [ Links ]26.- JARVIS W R, MARTONE W J. Predominant    pathogens in hospital infections. J Antimicrob Chemother 1992; 29: 19-24.         [ Links ]27.- LIVERMORE D M. ß-lactamases in    laboratory and clinical resistance. Clin Microbiol Rev 1995; 8: 557-84.         [ Links ]28.- HERITAGE J, M'ZALI F H, GASCOYNE-BINZI    D, HAWKEY P M. Evolution and spread of SHV extended-spectrum ß-lactamases    in gram negative bacteria. J Antimicrob Chemother 1999; 44: 309-18.         [ Links ]29.- PODSCHUN R, ULLMAN U. Klebsiella spp.    as nosocomial pathogens: epidemiology, taxonomy, typing methods, and pathogenicity    factors. Clin Microbiol Rev 1998; 11: 589-603.         [ Links ]30.- PITOUT J D D, SANDERS C C, SANDERS W    E. Antimicrobial resistance with focus on ß-lactam resistance in Gram    negative bacilli. Am J Med 1997; 103: 51-9.         [ Links ]31.- HANBERGER H, GARCIA-RODRIGUEZ J A, GOBERNADO    et al. Antibiotic susceptibility among aerobic Gram negative bacilli in intensive    care units in 5 european countries. JAMA 1999; 281: 67-71.         [ Links ]32.- CHARREL R N, PAGES J M, DE MICCO P et    al. Prevalence of outer membrane porin alteration in ß-lactam-antibiotic-resistant    Enterobacter aerogenes. Antimicrob Agents Chemother 1996; 40: 2854-8.          [ Links ]33.- BRADFORD P A, URBAN C, MARIANO N, PROJAN    S J, RAHAL J J, BUSH K. Imipenem resistance in Klebsiella pneumoniae is    associated with the combination of ACT-1, a plasmid-mediated Amp C ß-lactamase,    and the loss of an outer membrane protein. Antimicrob Agents Chemother 1997;    41: 563-9.         [ Links ]34.- QUEENAN A M, TORRES-VIERA C, GOLD H et    al. SME-type carbapenem-hydrolizing class A ß-lactamases from geographically    diverse Serratia marcescens strains. Antimicrob Agents Chemother 2000;    44: 3035-9.         [ Links ]35.- COHEN S P, MC MURRY L M, HOOPER D C,    WOLFSON J S, LEVY S B. Cross-resistance to fluoroquinolones in multiple-antibiotic-resistance    (Mar) Escherichia coli selected by tetracycline resistance: decreased    drug accumulation asociated with membrane changes in addition to Omp F reduction.    Antimicrob Agents Chemother 1989; 33:1318-25.         [ Links ]36.- SANDERS C C. Cefepime: The next generation?    Clin Infect Dis 1993; 17: 369-79         [ Links ]37.- GARAU J. The clinical potential of fourth-generation    cephalosporins. Diagn Microbiol Infect Dis 1998; 31: 479-80.         [ Links ]38.- CURTIS N A C, ORR D C, ROSS G W, BOULTON    M G. Affinities of penicillins and cephalosporins for the penicillin-binding    proteins of Escherichia coli    K-12 and their antibacterial activity. Antimicrob Agents Chemother 1979; 16:    533-9.  39.- BALANT L, DAYER P, AUCKENTHALER R. Clinical    pharmacokinetics of the third generation cephalosporins. Clin Pharmacokinetics    1985; 10: 101-43.         [ Links ]40.- WHEELER W J. Cephalosporins and other    beta-lactam antibiotics. Lloydia. 1977; 40: 519-42.         [ Links ]41.- LOPEZ F, GARRIDO J C. Química    y relación estructura-actividad de los antibióticos cefalosporínicos.    Rev Col Químico Farmacéutico 1989; 41: 5-14.         [ Links ]42.- FU K P, ASWAPOKEE P, HO I, MATTHIJSSEN    C, NEU H C. Pharmacokinetics of cefotaxime. Antimicrob Agents Chemother 1979;16:    592-7.         [ Links ]43.- YUK J H, NIGHTINGALE C H, QUINTILIANI    R. Clinical pharmacokinetics of ceftriaxone. Clin Pharmacokinetic 1989; 17:    223-35.         [ Links ]44.- BRYSKIER A, PROCYK T, LABRO M T. Cefodizime,    a new 2-aminothiazolyl cephalosporin: physicochemical properties, toxicology    and structure-activity relationships. J Antimicrob Chemother 1990; 26 (Suppl    C): 1-8.         [ Links ]45.- CRITCHLEY I A, BASKER M J, EDMONDSON    R A, KNOTT S J. Uptake of catecholic cephalosporin by the iron transport system    of Escherichia coli. J Antimicrob Chemother 1991; 28: 377-88.         [ Links ]46.- CRITCHLEY I A. Catecholic ß-lactams:    facilitated transport. J Antimicrob Chemother 1990; 26: 733-7.         [ Links ]47.- JONES R N, ERWIN M E. In vitro evaluation    of Ro 09-1227, a novel catechol-substituted cephalosporin. Antimicrob Agents    Chemother 1992; 36: 233-8.         [ Links ]48.- JONES R N. In vitro activity of Ro 24-6392,    a novel ester-linked co-drug combining ciprofloxacin and desacetylcefotaxime.    Eur J Clin Microbiol Infect Dis 1990; 9: 435-8.         [ Links ]49.- TOMASZ A. Penicillin-binding proteins    and the antibacterial effectiveness of ß-lactam antibiotics. Rev Infect    Dis 1986 (Suppl 3); 8: 260-78.         [ Links ]50.- HOLM S E. Interaction between ß-lactam    and other antibiotics. Rev Infect Dis 1986 (Suppl 3); 8: 305-14.         [ Links ]51.- MC CULLERS J A, ENGLISH B K, NOVAK R.    Isolation and characterization of vancomycin-tolerant Streptococcus pneumoniae    from the cerebrospinal fluid of a patient who developed recrudescet meningitis.    J Infect Dis 2000; 181: 369-73.         [ Links ]52.- NIKAIDO H. Outer membrane barrier as    a mechanism of antimicrobial resistance. Antimicrob Agents Chemother 1989; 33:    1831-6.         [ Links ]53.- BARRADELL L B, BRYSON H M. Cefepime.    A review of its antibacterial activity, pharmacokinetic properties and therapeutic    use. Drugs 1994; 47: 471-505.         [ Links ]54.- O'CALLAGHAN C H 1979. Description and    classification of the newer cephalosporins and their relationship with the established    compounds. J Antimicrob Chemother 5: 635-71         [ Links ]55.- BRYSKIER A, PROCYK T, TREMBLAY D, LENFANT    B FOURTILLAN J B. The pharmacokinetics of cefodizime following intravenous and    intramuscular administration of a single dose of 1.0 g. J Antimicrob Chemother    1990; 26 (Suppl. C): 59-63.         [ Links ]56.- WILLIAMS J D. Classification of cephalosporins.    Drugs. 1987; 34 (Suppl 2): 15-22.         [ Links ]57.- WISEMAN L R, LAMB H M. Cefpirome. A review    of its antibacterial activity, pharmacokinetic properties and efficacy in the    treatment of severe nosocomial infections and febrile neutropenia. Drugs 1997;    57: 117-40.         [ Links ]58.- PECHERE J C, WILSON W, NEU H. Laboratory    assesment of antibacterial activity of zwitterionic 7-methoxyimino cephalosporins.    J Antimicrob Chemother 1995; 36: 757-71         [ Links ]59.- GIAMARELLOS-BOURBOULIS EJ, GRECKA P,    TSITSIKA A, TYMPANIDOU C, GIAMARELLOU H. In-vitro activity of FK 037 (cefoselis),    a novel 4 (th) generation cephalosporin, cefepime and cefpirome on nosocomial    staphylococci and gram-negative isolates. Diagn Microbiol infect Dis 2000; 36:    185-91.         [ Links ]60.- JONES R N, ERWIN M E, BARRETT M S, JOHNSON    D M, BRIGGS B M. Antimicrobial activity of E-1040, a novel thiadiazolyl cephalosporin    compare with parenteral cephems. Diagn Microbiol infect Dis 1991; 14: 301-9.          [ Links ]61.- IIZAWA Y, OKONOGI K, HAYASHI R, IWAHI    T, YAMAZAKI T, IMADA A. Therapeutic effect of cefozopran (SCE-2787), a new parenteral    cephalosporin in experimental infections in mice. Antimicrob Agents Chemother    1993; 37: 100-5.         [ Links ]62.- WATANABE N A. Newer antipseudomonal cephalosporins.    J Chemother 1996; 8 (Suppl 2): 48-56.         [ Links ]63.- ACTOR P, GUARINI J, URI J et al. Disk    susceptibility studies with cefazolin and cephalotin. Antimicrob Agents Chemother    1974; 5: 63-7.         [ Links ]64.- UWAYDAH M. Cefazolin in the treatment    of acute enteric fever. Antimicrob Agents Chemother 1976; 10: 52-6.         [ Links ]65.- JAMAL W Y, ROTIMI V O, CHUGH T D, PAL    T. Prevalence and susceptibility of Shigella to 11 antibiotics in a Kuwait    teaching hospital. J Chemother 1998; 10: 285-90.         [ Links ]66.- COX CE, SHERRILL M, COCCHETT DM. Evaluation    of cefuroxime axetil, cefaclor, and cephalexin in the treatment of urinary tract    infections in adults. Curr Ther Res 1987; 42: 124-37.         [ Links ]67.- SANDERS C W, GREENBERG R N, MARIER R    L. Cefamandole and cefoxitin. Ann Intern Med 1985; 103: 70-8.          [ Links ]68.- STAPLEY E P, JACKSON M, HERNANDEZ S et    al. Cephamycins, a new family of ß-lactam antibiotics I. Production actinomycetes,    including Streptomyces lactamdurans spp.n. Antimicrob Agents Chemother    1972; 2: 122-31.         [ Links ]69.- COOPER R D G. The carbacephems a new    ß-lactams class. Am J Med 1992; 92 (Suppl 6 A): 25-65.         [ Links ]70.- ZEMELMAN R, BELLO H, DOMINGUEZ M, GONZALEZ    G, MELLA S, GARCIA A. Activity of imipenem, third-generation cephalosporins,    aztreonam, and ciprofloxacin against multi-resistant Gram negative bacilli isolated    from Chilean hospitals. J Antimicrob Chemother 1993; 32: 413-9.         [ Links ]71.- MEDEIROS A A. Evolution and dissemination    of ß-lactamases accelerated by generation of ß-lactam antibiotics.    Clin Infect Dis 1997; 24 (Suppl. 1): 19-45.         [ Links ]72.- PERRY C M, BROGDEN R N. Cefuroxime axetil:    review of its antibacterial activity, pharmacokinetic properties and therapeutic    efficacy. Drugs 1996; 52: 125-58.         [ Links ]73.- SCHAAD U B, SUTER S, GIANELLA-BORRADORI    et al. A comparison of ceftriaxone and cefuroxime for the treatment of bacterial    meningitis in children. N Engl J Med 1990; 322: 141-7.         [ Links ]74.- KLEIN N C, CUNHA B A. Cefalosporinas de    la tercera generación. Clin Med Nort Am 1995; 79: 693-707.         [ Links ]75.- KLUGMAN K P, MADHI S A. Emergence of    drug resistance impact on bacterial meningitis. Infect Dis Clin North Am 1999;    13: 637-46.         [ Links ]76.- RICHARDS D M, BROGDEN R N. Ceftazidime.    A review of its antibacterial activity, pharmacokinetic properties and therapeutic    use. Drugs 1985; 29: 105-61.         [ Links ]77.- SCHATZ B S, KARAVOKIROS K T, TAEUBEL    M A, ITOKAZU G S. Comparison of cefprozil, cefpodoxime proxetil, loracarbef,    cefixime, and ceftibuten. Ann Pharmacother 1996; 30: 258-68.         [ Links ]78.- DALMAU D, LAYRARGUES G P, FENYVES D,    WILLEMS B, TURGEON F, TURGEON P. Cefotaxime, desacetyl-cefotaxime, and bactericidal    activity in spontaneous bacterial peritonitis. J Infect Dis 1999; 180: 1597-1602.          [ Links ]79.- NIKAIDO W, LIU W, ROSENBERG E Y. Outer    membrane permeability and ß-lactamase stability of dipolar ionic cephalosporins    containing methoxyimino substituents. Antimicrob Agents Chemother 1990; 34:    337-42.         [ Links ]80.- HANCOCK R E W, BELLIDO F. Factors involved    in the enhanced efficacy against gram-negative bacteria of fourth generation    cephalosporins. J Antimicrob Chemother 1992; 29(Suppl A): 1-6.         [ Links ]81.- BELLIDO F, PECHERE J C, HANCOCK REW.    Novel method for measurement of outer membrane permeability to new beta-lactams    in intact Enterobacter cloacae cells. Antimicrob Agents Chemother 1991;    35: 68-72.         [ Links ]82.- NEU H C, CHIN N X, JULES K, LABTHAVIKUL    P. The activity of BMY-28142, a new broad spectrum beta-lactamase stable cephalosporin.    J Antimicrob Chemother 1986; 17: 441-52.         [ Links ]83.- KOBAYASHI S, ARAI S, HAYASHI S, FUJIMOTO    K. ß-lactamase stability of cefpirome (HR 810), a new cephalosporin with    a broad antimicrobial spectrum. Antimicrob Agents Chemother 1986; 30: 713-8.          [ Links ]84.- GARAU J, WILSON W, WOOD M, CARLET J.    Fourth generation cephalosporins: a review of in vitro activity, pharmacokinetics,    pharmacodynamics, and clinical utility. Clin Microb Infect 1997; 3 (Suppl 1):    87-101.         [ Links ]85.- KESSLER R E, FUNG-TOMC J. Susceptibility    of bacterial isolates to beta-lactam antibiotics from U.S. clinical trials over    5-year period. Am J Med 1996; 24 (6 A): 13-9.         [ Links ]86.- PIERARD D, EMMERECHTS K, LAUWERS S. Comparative    in-vitro activity of cefpirome against isolates from intensive care and haematology/oncology    units. Belgian Multicentric Study Group. J Antimicrob Chemother 1998; 41: 443-50.          [ Links ]87.- JONES R N. Resistance patterns among    nosocomial pathogens: trends over the past few years. Chest 2001; 119 (Suppl    2): 397-404.         [ Links ]88.- LORBER B. Changing patterns of infectious    diseases. Am J Med 1988; 84: 569-78.         [ Links ]89.- MOELLERING R C. A novel antimicrobial    agent joins the battle against resistant bacteria. Ann Intern Med 1999; 130:    155-7.         [ Links ]90.- WILSON W R. The role of fourth-generation    cephalosporins in the treatment of serious infectious diseases in hospitalized    patients. Diagn Microbiol Infect Dis 1998; 31: 473-7.         [ Links ]Correspondencia a:        Sergio Mella Montecinos        Laboratorio de Antibióticos,        Departamento de Microbiología,        Facultad de Ciencias Biológicas        Casilla 160-C, Concepción        E-mail: pignatio@ctcinternet.cl  

9.- TURNIDGE J D. The pharmacodynamics of        ß-lactams. Clin Infect Dis 1998; 27: 10-22. 

10.- CRAIG W A. The future-can we learn from    the past? Diagn Microbiol Infect Dis 1997; 27: 49-53.         [ Links ]11.- DUDLEY M N. Pharmacodynamics and pharmacokinetics    of antibiotics with special reference to the fluoroquinolones. Am J Med 1991;    91 (Suppl 6 A): 6A-45S.         [ Links ]12.- NICOLAU D P, QUINTILIANI R, NIGHTINGALE    C H. Cinética y dinámica de los antibióticos para el clínico.    Clin Med Nort Am 1995; 79: 483-500.         [ Links ]13.- DRUSANO G L. Human pharmacodynamics of    beta-lactams, aminoglycosides and their combination. Scand J Infect Dis 1991    (Suppl); 74: 235-48.         [ Links ]14.- MARSHALL W F, BLAIR J E. The cephalosporins.    Mayo Clinic Proc 1999; 74: 187-95.         [ Links ]15.- DONOWIRZ G R, MANDELL G L. Beta-lactam    antibiotics. N Engl J Med 1988; 318: 490-500.         [ Links ]16.- PAYA E. Ventajas y desventajas de las    cefalosporinas orales de segunda y tercera generación. Rev Chil Infect    1997; 14: 233-8.         [ Links ]17.- AMERICAN THORACIC SOCIETY. Guidelines    for the initial management of adults with community-acquired pneumonia: diagnosis,    assessment of severity, and initial antimicrobial therapy. Am Rev Respir Dis    1993; 148: 1418-26.         [ Links ]18.- BARTLETT J G, BREIMAN R F, MANDELL L    A, FILE T M Jr. Community-acquired pneumonia in adults: guidelines for management.    The Infectious Diseases Society of America. Clin Infect Dis 1998: 26: 811-38.          [ Links ]19.- MARRIE T J. Community-acquired pneumonia:    epidemiology, etiology, treatment. Infect Dis Clin North Am 1998; 12: 723-40          [ Links ]20.- TUNKEL A R, SCHELD W M. Acute meningitis.    In: Mandell, Douglas & Bennett's. Principles and Practice of Infectious    Diseases. Mandell G L, Bennett J E, Dolin R, eds. Fifth edition. Philadelphia:    Editorial Churchill Livingstone 2000; 959-96.         [ Links ]21.- AMERICAN THORACIC SOCIETY. Hospital-acquired    pneumonia in adults: diagnosis, assessment of severity, initial antimicrobial    therapy, and preventive strategies. A consensus statement. Am J Respir Crit    Care Med 1996; 153: 1711-25.         [ Links ]22.- BARTLETT J G, DOWELL S F, MANDELL L A,    FILE T M, MUSHER D M, FINE M J. Practice guidelines for the management of community-acquired    pneumonia in adults. Clin Infect Dis. 2000; 31: 347-82         [ Links ]23.- KARCHMER A W. Cephalosporins. In: Mandell,    Douglas & Bennett's. Principles and Practice of Infectious Diseases. Mandell    G L, Bennett J E, Dolin R, eds. Fifth edition. Philadelphia: Churchill Livingstone    2000; 274-99.         [ Links ]24.- ADU A, ARMOUR C L. Drug utilisation review    (DUR) of the third generation cephalosporins. Drugs 1995; 50: 423-39.         [ Links ]25.- JONES R N. Important and emerging ß-lactamase    mediated resistances in hospital-based pathogens: the Amp C enzymes. Diagn Microbiol    Infect Dis 1998; 31: 461-6.         [ Links ]26.- JARVIS W R, MARTONE W J. Predominant    pathogens in hospital infections. J Antimicrob Chemother 1992; 29: 19-24.         [ Links ]27.- LIVERMORE D M. ß-lactamases in    laboratory and clinical resistance. Clin Microbiol Rev 1995; 8: 557-84.         [ Links ]28.- HERITAGE J, M'ZALI F H, GASCOYNE-BINZI    D, HAWKEY P M. Evolution and spread of SHV extended-spectrum ß-lactamases    in gram negative bacteria. J Antimicrob Chemother 1999; 44: 309-18.         [ Links ]29.- PODSCHUN R, ULLMAN U. Klebsiella spp.    as nosocomial pathogens: epidemiology, taxonomy, typing methods, and pathogenicity    factors. Clin Microbiol Rev 1998; 11: 589-603.         [ Links ]30.- PITOUT J D D, SANDERS C C, SANDERS W    E. Antimicrobial resistance with focus on ß-lactam resistance in Gram    negative bacilli. Am J Med 1997; 103: 51-9.         [ Links ]31.- HANBERGER H, GARCIA-RODRIGUEZ J A, GOBERNADO    et al. Antibiotic susceptibility among aerobic Gram negative bacilli in intensive    care units in 5 european countries. JAMA 1999; 281: 67-71.         [ Links ]32.- CHARREL R N, PAGES J M, DE MICCO P et    al. Prevalence of outer membrane porin alteration in ß-lactam-antibiotic-resistant    Enterobacter aerogenes. Antimicrob Agents Chemother 1996; 40: 2854-8.          [ Links ]33.- BRADFORD P A, URBAN C, MARIANO N, PROJAN    S J, RAHAL J J, BUSH K. Imipenem resistance in Klebsiella pneumoniae is    associated with the combination of ACT-1, a plasmid-mediated Amp C ß-lactamase,    and the loss of an outer membrane protein. Antimicrob Agents Chemother 1997;    41: 563-9.         [ Links ]34.- QUEENAN A M, TORRES-VIERA C, GOLD H et    al. SME-type carbapenem-hydrolizing class A ß-lactamases from geographically    diverse Serratia marcescens strains. Antimicrob Agents Chemother 2000;    44: 3035-9.         [ Links ]35.- COHEN S P, MC MURRY L M, HOOPER D C,    WOLFSON J S, LEVY S B. Cross-resistance to fluoroquinolones in multiple-antibiotic-resistance    (Mar) Escherichia coli selected by tetracycline resistance: decreased    drug accumulation asociated with membrane changes in addition to Omp F reduction.    Antimicrob Agents Chemother 1989; 33:1318-25.         [ Links ]36.- SANDERS C C. Cefepime: The next generation?    Clin Infect Dis 1993; 17: 369-79         [ Links ]37.- GARAU J. The clinical potential of fourth-generation    cephalosporins. Diagn Microbiol Infect Dis 1998; 31: 479-80.         [ Links ]38.- CURTIS N A C, ORR D C, ROSS G W, BOULTON    M G. Affinities of penicillins and cephalosporins for the penicillin-binding    proteins of Escherichia coli    K-12 and their antibacterial activity. Antimicrob Agents Chemother 1979; 16:    533-9.  39.- BALANT L, DAYER P, AUCKENTHALER R. Clinical    pharmacokinetics of the third generation cephalosporins. Clin Pharmacokinetics    1985; 10: 101-43.         [ Links ]40.- WHEELER W J. Cephalosporins and other    beta-lactam antibiotics. Lloydia. 1977; 40: 519-42.         [ Links ]41.- LOPEZ F, GARRIDO J C. Química    y relación estructura-actividad de los antibióticos cefalosporínicos.    Rev Col Químico Farmacéutico 1989; 41: 5-14.         [ Links ]42.- FU K P, ASWAPOKEE P, HO I, MATTHIJSSEN    C, NEU H C. Pharmacokinetics of cefotaxime. Antimicrob Agents Chemother 1979;16:    592-7.         [ Links ]43.- YUK J H, NIGHTINGALE C H, QUINTILIANI    R. Clinical pharmacokinetics of ceftriaxone. Clin Pharmacokinetic 1989; 17:    223-35.         [ Links ]44.- BRYSKIER A, PROCYK T, LABRO M T. Cefodizime,    a new 2-aminothiazolyl cephalosporin: physicochemical properties, toxicology    and structure-activity relationships. J Antimicrob Chemother 1990; 26 (Suppl    C): 1-8.         [ Links ]45.- CRITCHLEY I A, BASKER M J, EDMONDSON    R A, KNOTT S J. Uptake of catecholic cephalosporin by the iron transport system    of Escherichia coli. J Antimicrob Chemother 1991; 28: 377-88.         [ Links ]46.- CRITCHLEY I A. Catecholic ß-lactams:    facilitated transport. J Antimicrob Chemother 1990; 26: 733-7.         [ Links ]47.- JONES R N, ERWIN M E. In vitro evaluation    of Ro 09-1227, a novel catechol-substituted cephalosporin. Antimicrob Agents    Chemother 1992; 36: 233-8.         [ Links ]48.- JONES R N. In vitro activity of Ro 24-6392,    a novel ester-linked co-drug combining ciprofloxacin and desacetylcefotaxime.    Eur J Clin Microbiol Infect Dis 1990; 9: 435-8.         [ Links ]49.- TOMASZ A. Penicillin-binding proteins    and the antibacterial effectiveness of ß-lactam antibiotics. Rev Infect    Dis 1986 (Suppl 3); 8: 260-78.         [ Links ]50.- HOLM S E. Interaction between ß-lactam    and other antibiotics. Rev Infect Dis 1986 (Suppl 3); 8: 305-14.         [ Links ]51.- MC CULLERS J A, ENGLISH B K, NOVAK R.    Isolation and characterization of vancomycin-tolerant Streptococcus pneumoniae    from the cerebrospinal fluid of a patient who developed recrudescet meningitis.    J Infect Dis 2000; 181: 369-73.         [ Links ]52.- NIKAIDO H. Outer membrane barrier as    a mechanism of antimicrobial resistance. Antimicrob Agents Chemother 1989; 33:    1831-6.         [ Links ]53.- BARRADELL L B, BRYSON H M. Cefepime.    A review of its antibacterial activity, pharmacokinetic properties and therapeutic    use. Drugs 1994; 47: 471-505.         [ Links ]54.- O'CALLAGHAN C H 1979. Description and    classification of the newer cephalosporins and their relationship with the established    compounds. J Antimicrob Chemother 5: 635-71         [ Links ]55.- BRYSKIER A, PROCYK T, TREMBLAY D, LENFANT    B FOURTILLAN J B. The pharmacokinetics of cefodizime following intravenous and    intramuscular administration of a single dose of 1.0 g. J Antimicrob Chemother    1990; 26 (Suppl. C): 59-63.         [ Links ]56.- WILLIAMS J D. Classification of cephalosporins.    Drugs. 1987; 34 (Suppl 2): 15-22.         [ Links ]57.- WISEMAN L R, LAMB H M. Cefpirome. A review    of its antibacterial activity, pharmacokinetic properties and efficacy in the    treatment of severe nosocomial infections and febrile neutropenia. Drugs 1997;    57: 117-40.         [ Links ]58.- PECHERE J C, WILSON W, NEU H. Laboratory    assesment of antibacterial activity of zwitterionic 7-methoxyimino cephalosporins.    J Antimicrob Chemother 1995; 36: 757-71         [ Links ]59.- GIAMARELLOS-BOURBOULIS EJ, GRECKA P,    TSITSIKA A, TYMPANIDOU C, GIAMARELLOU H. In-vitro activity of FK 037 (cefoselis),    a novel 4 (th) generation cephalosporin, cefepime and cefpirome on nosocomial    staphylococci and gram-negative isolates. Diagn Microbiol infect Dis 2000; 36:    185-91.         [ Links ]60.- JONES R N, ERWIN M E, BARRETT M S, JOHNSON    D M, BRIGGS B M. Antimicrobial activity of E-1040, a novel thiadiazolyl cephalosporin    compare with parenteral cephems. Diagn Microbiol infect Dis 1991; 14: 301-9.          [ Links ]61.- IIZAWA Y, OKONOGI K, HAYASHI R, IWAHI    T, YAMAZAKI T, IMADA A. Therapeutic effect of cefozopran (SCE-2787), a new parenteral    cephalosporin in experimental infections in mice. Antimicrob Agents Chemother    1993; 37: 100-5.         [ Links ]62.- WATANABE N A. Newer antipseudomonal cephalosporins.    J Chemother 1996; 8 (Suppl 2): 48-56.         [ Links ]63.- ACTOR P, GUARINI J, URI J et al. Disk    susceptibility studies with cefazolin and cephalotin. Antimicrob Agents Chemother    1974; 5: 63-7.         [ Links ]64.- UWAYDAH M. Cefazolin in the treatment    of acute enteric fever. Antimicrob Agents Chemother 1976; 10: 52-6.         [ Links ]65.- JAMAL W Y, ROTIMI V O, CHUGH T D, PAL    T. Prevalence and susceptibility of Shigella to 11 antibiotics in a Kuwait    teaching hospital. J Chemother 1998; 10: 285-90.         [ Links ]66.- COX CE, SHERRILL M, COCCHETT DM. Evaluation    of cefuroxime axetil, cefaclor, and cephalexin in the treatment of urinary tract    infections in adults. Curr Ther Res 1987; 42: 124-37.         [ Links ]67.- SANDERS C W, GREENBERG R N, MARIER R    L. Cefamandole and cefoxitin. Ann Intern Med 1985; 103: 70-8.          [ Links ]68.- STAPLEY E P, JACKSON M, HERNANDEZ S et    al. Cephamycins, a new family of ß-lactam antibiotics I. Production actinomycetes,    including Streptomyces lactamdurans spp.n. Antimicrob Agents Chemother    1972; 2: 122-31.         [ Links ]69.- COOPER R D G. The carbacephems a new    ß-lactams class. Am J Med 1992; 92 (Suppl 6 A): 25-65.         [ Links ]70.- ZEMELMAN R, BELLO H, DOMINGUEZ M, GONZALEZ    G, MELLA S, GARCIA A. Activity of imipenem, third-generation cephalosporins,    aztreonam, and ciprofloxacin against multi-resistant Gram negative bacilli isolated    from Chilean hospitals. J Antimicrob Chemother 1993; 32: 413-9.         [ Links ]71.- MEDEIROS A A. Evolution and dissemination    of ß-lactamases accelerated by generation of ß-lactam antibiotics.    Clin Infect Dis 1997; 24 (Suppl. 1): 19-45.         [ Links ]72.- PERRY C M, BROGDEN R N. Cefuroxime axetil:    review of its antibacterial activity, pharmacokinetic properties and therapeutic    efficacy. Drugs 1996; 52: 125-58.         [ Links ]73.- SCHAAD U B, SUTER S, GIANELLA-BORRADORI    et al. A comparison of ceftriaxone and cefuroxime for the treatment of bacterial    meningitis in children. N Engl J Med 1990; 322: 141-7.         [ Links ]74.- KLEIN N C, CUNHA B A. Cefalosporinas de    la tercera generación. Clin Med Nort Am 1995; 79: 693-707.         [ Links ]75.- KLUGMAN K P, MADHI S A. Emergence of    drug resistance impact on bacterial meningitis. Infect Dis Clin North Am 1999;    13: 637-46.         [ Links ]76.- RICHARDS D M, BROGDEN R N. Ceftazidime.    A review of its antibacterial activity, pharmacokinetic properties and therapeutic    use. Drugs 1985; 29: 105-61.         [ Links ]77.- SCHATZ B S, KARAVOKIROS K T, TAEUBEL    M A, ITOKAZU G S. Comparison of cefprozil, cefpodoxime proxetil, loracarbef,    cefixime, and ceftibuten. Ann Pharmacother 1996; 30: 258-68.         [ Links ]78.- DALMAU D, LAYRARGUES G P, FENYVES D,    WILLEMS B, TURGEON F, TURGEON P. Cefotaxime, desacetyl-cefotaxime, and bactericidal    activity in spontaneous bacterial peritonitis. J Infect Dis 1999; 180: 1597-1602.          [ Links ]79.- NIKAIDO W, LIU W, ROSENBERG E Y. Outer    membrane permeability and ß-lactamase stability of dipolar ionic cephalosporins    containing methoxyimino substituents. Antimicrob Agents Chemother 1990; 34:    337-42.         [ Links ]80.- HANCOCK R E W, BELLIDO F. Factors involved    in the enhanced efficacy against gram-negative bacteria of fourth generation    cephalosporins. J Antimicrob Chemother 1992; 29(Suppl A): 1-6.         [ Links ]81.- BELLIDO F, PECHERE J C, HANCOCK REW.    Novel method for measurement of outer membrane permeability to new beta-lactams    in intact Enterobacter cloacae cells. Antimicrob Agents Chemother 1991;    35: 68-72.         [ Links ]82.- NEU H C, CHIN N X, JULES K, LABTHAVIKUL    P. The activity of BMY-28142, a new broad spectrum beta-lactamase stable cephalosporin.    J Antimicrob Chemother 1986; 17: 441-52.         [ Links ]83.- KOBAYASHI S, ARAI S, HAYASHI S, FUJIMOTO    K. ß-lactamase stability of cefpirome (HR 810), a new cephalosporin with    a broad antimicrobial spectrum. Antimicrob Agents Chemother 1986; 30: 713-8.          [ Links ]84.- GARAU J, WILSON W, WOOD M, CARLET J.    Fourth generation cephalosporins: a review of in vitro activity, pharmacokinetics,    pharmacodynamics, and clinical utility. Clin Microb Infect 1997; 3 (Suppl 1):    87-101.         [ Links ]85.- KESSLER R E, FUNG-TOMC J. Susceptibility    of bacterial isolates to beta-lactam antibiotics from U.S. clinical trials over    5-year period. Am J Med 1996; 24 (6 A): 13-9.         [ Links ]86.- PIERARD D, EMMERECHTS K, LAUWERS S. Comparative    in-vitro activity of cefpirome against isolates from intensive care and haematology/oncology    units. Belgian Multicentric Study Group. J Antimicrob Chemother 1998; 41: 443-50.          [ Links ]87.- JONES R N. Resistance patterns among    nosocomial pathogens: trends over the past few years. Chest 2001; 119 (Suppl    2): 397-404.         [ Links ]88.- LORBER B. Changing patterns of infectious    diseases. Am J Med 1988; 84: 569-78.         [ Links ]89.- MOELLERING R C. A novel antimicrobial    agent joins the battle against resistant bacteria. Ann Intern Med 1999; 130:    155-7.         [ Links ]90.- WILSON W R. The role of fourth-generation    cephalosporins in the treatment of serious infectious diseases in hospitalized    patients. Diagn Microbiol Infect Dis 1998; 31: 473-7.         [ Links ]Correspondencia a:        Sergio Mella Montecinos        Laboratorio de Antibióticos,        Departamento de Microbiología,        Facultad de Ciencias Biológicas        Casilla 160-C, Concepción        E-mail: pignatio@ctcinternet.cl  

11.- DUDLEY M N. Pharmacodynamics and pharmacokinetics    of antibiotics with special reference to the fluoroquinolones. Am J Med 1991;    91 (Suppl 6 A): 6A-45S.         [ Links ]12.- NICOLAU D P, QUINTILIANI R, NIGHTINGALE    C H. Cinética y dinámica de los antibióticos para el clínico.    Clin Med Nort Am 1995; 79: 483-500.         [ Links ]13.- DRUSANO G L. Human pharmacodynamics of    beta-lactams, aminoglycosides and their combination. Scand J Infect Dis 1991    (Suppl); 74: 235-48.         [ Links ]14.- MARSHALL W F, BLAIR J E. The cephalosporins.    Mayo Clinic Proc 1999; 74: 187-95.         [ Links ]15.- DONOWIRZ G R, MANDELL G L. Beta-lactam    antibiotics. N Engl J Med 1988; 318: 490-500.         [ Links ]16.- PAYA E. Ventajas y desventajas de las    cefalosporinas orales de segunda y tercera generación. Rev Chil Infect    1997; 14: 233-8.         [ Links ]17.- AMERICAN THORACIC SOCIETY. Guidelines    for the initial management of adults with community-acquired pneumonia: diagnosis,    assessment of severity, and initial antimicrobial therapy. Am Rev Respir Dis    1993; 148: 1418-26.         [ Links ]18.- BARTLETT J G, BREIMAN R F, MANDELL L    A, FILE T M Jr. Community-acquired pneumonia in adults: guidelines for management.    The Infectious Diseases Society of America. Clin Infect Dis 1998: 26: 811-38.          [ Links ]19.- MARRIE T J. Community-acquired pneumonia:    epidemiology, etiology, treatment. Infect Dis Clin North Am 1998; 12: 723-40          [ Links ]20.- TUNKEL A R, SCHELD W M. Acute meningitis.    In: Mandell, Douglas & Bennett's. Principles and Practice of Infectious    Diseases. Mandell G L, Bennett J E, Dolin R, eds. Fifth edition. Philadelphia:    Editorial Churchill Livingstone 2000; 959-96.         [ Links ]21.- AMERICAN THORACIC SOCIETY. Hospital-acquired    pneumonia in adults: diagnosis, assessment of severity, initial antimicrobial    therapy, and preventive strategies. A consensus statement. Am J Respir Crit    Care Med 1996; 153: 1711-25.         [ Links ]22.- BARTLETT J G, DOWELL S F, MANDELL L A,    FILE T M, MUSHER D M, FINE M J. Practice guidelines for the management of community-acquired    pneumonia in adults. Clin Infect Dis. 2000; 31: 347-82         [ Links ]23.- KARCHMER A W. Cephalosporins. In: Mandell,    Douglas & Bennett's. Principles and Practice of Infectious Diseases. Mandell    G L, Bennett J E, Dolin R, eds. Fifth edition. Philadelphia: Churchill Livingstone    2000; 274-99.         [ Links ]24.- ADU A, ARMOUR C L. Drug utilisation review    (DUR) of the third generation cephalosporins. Drugs 1995; 50: 423-39.         [ Links ]25.- JONES R N. Important and emerging ß-lactamase    mediated resistances in hospital-based pathogens: the Amp C enzymes. Diagn Microbiol    Infect Dis 1998; 31: 461-6.         [ Links ]26.- JARVIS W R, MARTONE W J. Predominant    pathogens in hospital infections. J Antimicrob Chemother 1992; 29: 19-24.         [ Links ]27.- LIVERMORE D M. ß-lactamases in    laboratory and clinical resistance. Clin Microbiol Rev 1995; 8: 557-84.         [ Links ]28.- HERITAGE J, M'ZALI F H, GASCOYNE-BINZI    D, HAWKEY P M. Evolution and spread of SHV extended-spectrum ß-lactamases    in gram negative bacteria. J Antimicrob Chemother 1999; 44: 309-18.         [ Links ]29.- PODSCHUN R, ULLMAN U. Klebsiella spp.    as nosocomial pathogens: epidemiology, taxonomy, typing methods, and pathogenicity    factors. Clin Microbiol Rev 1998; 11: 589-603.         [ Links ]30.- PITOUT J D D, SANDERS C C, SANDERS W    E. Antimicrobial resistance with focus on ß-lactam resistance in Gram    negative bacilli. Am J Med 1997; 103: 51-9.         [ Links ]31.- HANBERGER H, GARCIA-RODRIGUEZ J A, GOBERNADO    et al. Antibiotic susceptibility among aerobic Gram negative bacilli in intensive    care units in 5 european countries. JAMA 1999; 281: 67-71.         [ Links ]32.- CHARREL R N, PAGES J M, DE MICCO P et    al. Prevalence of outer membrane porin alteration in ß-lactam-antibiotic-resistant    Enterobacter aerogenes. Antimicrob Agents Chemother 1996; 40: 2854-8.          [ Links ]33.- BRADFORD P A, URBAN C, MARIANO N, PROJAN    S J, RAHAL J J, BUSH K. Imipenem resistance in Klebsiella pneumoniae is    associated with the combination of ACT-1, a plasmid-mediated Amp C ß-lactamase,    and the loss of an outer membrane protein. Antimicrob Agents Chemother 1997;    41: 563-9.         [ Links ]34.- QUEENAN A M, TORRES-VIERA C, GOLD H et    al. SME-type carbapenem-hydrolizing class A ß-lactamases from geographically    diverse Serratia marcescens strains. Antimicrob Agents Chemother 2000;    44: 3035-9.         [ Links ]35.- COHEN S P, MC MURRY L M, HOOPER D C,    WOLFSON J S, LEVY S B. Cross-resistance to fluoroquinolones in multiple-antibiotic-resistance    (Mar) Escherichia coli selected by tetracycline resistance: decreased    drug accumulation asociated with membrane changes in addition to Omp F reduction.    Antimicrob Agents Chemother 1989; 33:1318-25.         [ Links ]36.- SANDERS C C. Cefepime: The next generation?    Clin Infect Dis 1993; 17: 369-79         [ Links ]37.- GARAU J. The clinical potential of fourth-generation    cephalosporins. Diagn Microbiol Infect Dis 1998; 31: 479-80.         [ Links ]38.- CURTIS N A C, ORR D C, ROSS G W, BOULTON    M G. Affinities of penicillins and cephalosporins for the penicillin-binding    proteins of Escherichia coli    K-12 and their antibacterial activity. Antimicrob Agents Chemother 1979; 16:    533-9.  39.- BALANT L, DAYER P, AUCKENTHALER R. Clinical    pharmacokinetics of the third generation cephalosporins. Clin Pharmacokinetics    1985; 10: 101-43.         [ Links ]40.- WHEELER W J. Cephalosporins and other    beta-lactam antibiotics. Lloydia. 1977; 40: 519-42.         [ Links ]41.- LOPEZ F, GARRIDO J C. Química    y relación estructura-actividad de los antibióticos cefalosporínicos.    Rev Col Químico Farmacéutico 1989; 41: 5-14.         [ Links ]42.- FU K P, ASWAPOKEE P, HO I, MATTHIJSSEN    C, NEU H C. Pharmacokinetics of cefotaxime. Antimicrob Agents Chemother 1979;16:    592-7.         [ Links ]43.- YUK J H, NIGHTINGALE C H, QUINTILIANI    R. Clinical pharmacokinetics of ceftriaxone. Clin Pharmacokinetic 1989; 17:    223-35.         [ Links ]44.- BRYSKIER A, PROCYK T, LABRO M T. Cefodizime,    a new 2-aminothiazolyl cephalosporin: physicochemical properties, toxicology    and structure-activity relationships. J Antimicrob Chemother 1990; 26 (Suppl    C): 1-8.         [ Links ]45.- CRITCHLEY I A, BASKER M J, EDMONDSON    R A, KNOTT S J. Uptake of catecholic cephalosporin by the iron transport system    of Escherichia coli. J Antimicrob Chemother 1991; 28: 377-88.         [ Links ]46.- CRITCHLEY I A. Catecholic ß-lactams:    facilitated transport. J Antimicrob Chemother 1990; 26: 733-7.         [ Links ]47.- JONES R N, ERWIN M E. In vitro evaluation    of Ro 09-1227, a novel catechol-substituted cephalosporin. Antimicrob Agents    Chemother 1992; 36: 233-8.         [ Links ]48.- JONES R N. In vitro activity of Ro 24-6392,    a novel ester-linked co-drug combining ciprofloxacin and desacetylcefotaxime.    Eur J Clin Microbiol Infect Dis 1990; 9: 435-8.         [ Links ]49.- TOMASZ A. Penicillin-binding proteins    and the antibacterial effectiveness of ß-lactam antibiotics. Rev Infect    Dis 1986 (Suppl 3); 8: 260-78.         [ Links ]50.- HOLM S E. Interaction between ß-lactam    and other antibiotics. Rev Infect Dis 1986 (Suppl 3); 8: 305-14.         [ Links ]51.- MC CULLERS J A, ENGLISH B K, NOVAK R.    Isolation and characterization of vancomycin-tolerant Streptococcus pneumoniae    from the cerebrospinal fluid of a patient who developed recrudescet meningitis.    J Infect Dis 2000; 181: 369-73.         [ Links ]52.- NIKAIDO H. Outer membrane barrier as    a mechanism of antimicrobial resistance. Antimicrob Agents Chemother 1989; 33:    1831-6.         [ Links ]53.- BARRADELL L B, BRYSON H M. Cefepime.    A review of its antibacterial activity, pharmacokinetic properties and therapeutic    use. Drugs 1994; 47: 471-505.         [ Links ]54.- O'CALLAGHAN C H 1979. Description and    classification of the newer cephalosporins and their relationship with the established    compounds. J Antimicrob Chemother 5: 635-71         [ Links ]55.- BRYSKIER A, PROCYK T, TREMBLAY D, LENFANT    B FOURTILLAN J B. The pharmacokinetics of cefodizime following intravenous and    intramuscular administration of a single dose of 1.0 g. J Antimicrob Chemother    1990; 26 (Suppl. C): 59-63.         [ Links ]56.- WILLIAMS J D. Classification of cephalosporins.    Drugs. 1987; 34 (Suppl 2): 15-22.         [ Links ]57.- WISEMAN L R, LAMB H M. Cefpirome. A review    of its antibacterial activity, pharmacokinetic properties and efficacy in the    treatment of severe nosocomial infections and febrile neutropenia. Drugs 1997;    57: 117-40.         [ Links ]58.- PECHERE J C, WILSON W, NEU H. Laboratory    assesment of antibacterial activity of zwitterionic 7-methoxyimino cephalosporins.    J Antimicrob Chemother 1995; 36: 757-71         [ Links ]59.- GIAMARELLOS-BOURBOULIS EJ, GRECKA P,    TSITSIKA A, TYMPANIDOU C, GIAMARELLOU H. In-vitro activity of FK 037 (cefoselis),    a novel 4 (th) generation cephalosporin, cefepime and cefpirome on nosocomial    staphylococci and gram-negative isolates. Diagn Microbiol infect Dis 2000; 36:    185-91.         [ Links ]60.- JONES R N, ERWIN M E, BARRETT M S, JOHNSON    D M, BRIGGS B M. Antimicrobial activity of E-1040, a novel thiadiazolyl cephalosporin    compare with parenteral cephems. Diagn Microbiol infect Dis 1991; 14: 301-9.          [ Links ]61.- IIZAWA Y, OKONOGI K, HAYASHI R, IWAHI    T, YAMAZAKI T, IMADA A. Therapeutic effect of cefozopran (SCE-2787), a new parenteral    cephalosporin in experimental infections in mice. Antimicrob Agents Chemother    1993; 37: 100-5.         [ Links ]62.- WATANABE N A. Newer antipseudomonal cephalosporins.    J Chemother 1996; 8 (Suppl 2): 48-56.         [ Links ]63.- ACTOR P, GUARINI J, URI J et al. Disk    susceptibility studies with cefazolin and cephalotin. Antimicrob Agents Chemother    1974; 5: 63-7.         [ Links ]64.- UWAYDAH M. Cefazolin in the treatment    of acute enteric fever. Antimicrob Agents Chemother 1976; 10: 52-6.         [ Links ]65.- JAMAL W Y, ROTIMI V O, CHUGH T D, PAL    T. Prevalence and susceptibility of Shigella to 11 antibiotics in a Kuwait    teaching hospital. J Chemother 1998; 10: 285-90.         [ Links ]66.- COX CE, SHERRILL M, COCCHETT DM. Evaluation    of cefuroxime axetil, cefaclor, and cephalexin in the treatment of urinary tract    infections in adults. Curr Ther Res 1987; 42: 124-37.         [ Links ]67.- SANDERS C W, GREENBERG R N, MARIER R    L. Cefamandole and cefoxitin. Ann Intern Med 1985; 103: 70-8.          [ Links ]68.- STAPLEY E P, JACKSON M, HERNANDEZ S et    al. Cephamycins, a new family of ß-lactam antibiotics I. Production actinomycetes,    including Streptomyces lactamdurans spp.n. Antimicrob Agents Chemother    1972; 2: 122-31.         [ Links ]69.- COOPER R D G. The carbacephems a new    ß-lactams class. Am J Med 1992; 92 (Suppl 6 A): 25-65.         [ Links ]70.- ZEMELMAN R, BELLO H, DOMINGUEZ M, GONZALEZ    G, MELLA S, GARCIA A. Activity of imipenem, third-generation cephalosporins,    aztreonam, and ciprofloxacin against multi-resistant Gram negative bacilli isolated    from Chilean hospitals. J Antimicrob Chemother 1993; 32: 413-9.         [ Links ]71.- MEDEIROS A A. Evolution and dissemination    of ß-lactamases accelerated by generation of ß-lactam antibiotics.    Clin Infect Dis 1997; 24 (Suppl. 1): 19-45.         [ Links ]72.- PERRY C M, BROGDEN R N. Cefuroxime axetil:    review of its antibacterial activity, pharmacokinetic properties and therapeutic    efficacy. Drugs 1996; 52: 125-58.         [ Links ]73.- SCHAAD U B, SUTER S, GIANELLA-BORRADORI    et al. A comparison of ceftriaxone and cefuroxime for the treatment of bacterial    meningitis in children. N Engl J Med 1990; 322: 141-7.         [ Links ]74.- KLEIN N C, CUNHA B A. Cefalosporinas de    la tercera generación. Clin Med Nort Am 1995; 79: 693-707.         [ Links ]75.- KLUGMAN K P, MADHI S A. Emergence of    drug resistance impact on bacterial meningitis. Infect Dis Clin North Am 1999;    13: 637-46.         [ Links ]76.- RICHARDS D M, BROGDEN R N. Ceftazidime.    A review of its antibacterial activity, pharmacokinetic properties and therapeutic    use. Drugs 1985; 29: 105-61.         [ Links ]77.- SCHATZ B S, KARAVOKIROS K T, TAEUBEL    M A, ITOKAZU G S. Comparison of cefprozil, cefpodoxime proxetil, loracarbef,    cefixime, and ceftibuten. Ann Pharmacother 1996; 30: 258-68.         [ Links ]78.- DALMAU D, LAYRARGUES G P, FENYVES D,    WILLEMS B, TURGEON F, TURGEON P. Cefotaxime, desacetyl-cefotaxime, and bactericidal    activity in spontaneous bacterial peritonitis. J Infect Dis 1999; 180: 1597-1602.          [ Links ]79.- NIKAIDO W, LIU W, ROSENBERG E Y. Outer    membrane permeability and ß-lactamase stability of dipolar ionic cephalosporins    containing methoxyimino substituents. Antimicrob Agents Chemother 1990; 34:    337-42.         [ Links ]80.- HANCOCK R E W, BELLIDO F. Factors involved    in the enhanced efficacy against gram-negative bacteria of fourth generation    cephalosporins. J Antimicrob Chemother 1992; 29(Suppl A): 1-6.         [ Links ]81.- BELLIDO F, PECHERE J C, HANCOCK REW.    Novel method for measurement of outer membrane permeability to new beta-lactams    in intact Enterobacter cloacae cells. Antimicrob Agents Chemother 1991;    35: 68-72.         [ Links ]82.- NEU H C, CHIN N X, JULES K, LABTHAVIKUL    P. The activity of BMY-28142, a new broad spectrum beta-lactamase stable cephalosporin.    J Antimicrob Chemother 1986; 17: 441-52.         [ Links ]83.- KOBAYASHI S, ARAI S, HAYASHI S, FUJIMOTO    K. ß-lactamase stability of cefpirome (HR 810), a new cephalosporin with    a broad antimicrobial spectrum. Antimicrob Agents Chemother 1986; 30: 713-8.          [ Links ]84.- GARAU J, WILSON W, WOOD M, CARLET J.    Fourth generation cephalosporins: a review of in vitro activity, pharmacokinetics,    pharmacodynamics, and clinical utility. Clin Microb Infect 1997; 3 (Suppl 1):    87-101.         [ Links ]85.- KESSLER R E, FUNG-TOMC J. Susceptibility    of bacterial isolates to beta-lactam antibiotics from U.S. clinical trials over    5-year period. Am J Med 1996; 24 (6 A): 13-9.         [ Links ]86.- PIERARD D, EMMERECHTS K, LAUWERS S. Comparative    in-vitro activity of cefpirome against isolates from intensive care and haematology/oncology    units. Belgian Multicentric Study Group. J Antimicrob Chemother 1998; 41: 443-50.          [ Links ]87.- JONES R N. Resistance patterns among    nosocomial pathogens: trends over the past few years. Chest 2001; 119 (Suppl    2): 397-404.         [ Links ]88.- LORBER B. Changing patterns of infectious    diseases. Am J Med 1988; 84: 569-78.         [ Links ]89.- MOELLERING R C. A novel antimicrobial    agent joins the battle against resistant bacteria. Ann Intern Med 1999; 130:    155-7.         [ Links ]90.- WILSON W R. The role of fourth-generation    cephalosporins in the treatment of serious infectious diseases in hospitalized    patients. Diagn Microbiol Infect Dis 1998; 31: 473-7.         [ Links ]Correspondencia a:        Sergio Mella Montecinos        Laboratorio de Antibióticos,        Departamento de Microbiología,        Facultad de Ciencias Biológicas        Casilla 160-C, Concepción        E-mail: pignatio@ctcinternet.cl  

12.- NICOLAU D P, QUINTILIANI R, NIGHTINGALE    C H. Cinética y dinámica de los antibióticos para el clínico.    Clin Med Nort Am 1995; 79: 483-500.         [ Links ]13.- DRUSANO G L. Human pharmacodynamics of    beta-lactams, aminoglycosides and their combination. Scand J Infect Dis 1991    (Suppl); 74: 235-48.         [ Links ]14.- MARSHALL W F, BLAIR J E. The cephalosporins.    Mayo Clinic Proc 1999; 74: 187-95.         [ Links ]15.- DONOWIRZ G R, MANDELL G L. Beta-lactam    antibiotics. N Engl J Med 1988; 318: 490-500.         [ Links ]16.- PAYA E. Ventajas y desventajas de las    cefalosporinas orales de segunda y tercera generación. Rev Chil Infect    1997; 14: 233-8.         [ Links ]17.- AMERICAN THORACIC SOCIETY. Guidelines    for the initial management of adults with community-acquired pneumonia: diagnosis,    assessment of severity, and initial antimicrobial therapy. Am Rev Respir Dis    1993; 148: 1418-26.         [ Links ]18.- BARTLETT J G, BREIMAN R F, MANDELL L    A, FILE T M Jr. Community-acquired pneumonia in adults: guidelines for management.    The Infectious Diseases Society of America. Clin Infect Dis 1998: 26: 811-38.          [ Links ]19.- MARRIE T J. Community-acquired pneumonia:    epidemiology, etiology, treatment. Infect Dis Clin North Am 1998; 12: 723-40          [ Links ]20.- TUNKEL A R, SCHELD W M. Acute meningitis.    In: Mandell, Douglas & Bennett's. Principles and Practice of Infectious    Diseases. Mandell G L, Bennett J E, Dolin R, eds. Fifth edition. Philadelphia:    Editorial Churchill Livingstone 2000; 959-96.         [ Links ]21.- AMERICAN THORACIC SOCIETY. Hospital-acquired    pneumonia in adults: diagnosis, assessment of severity, initial antimicrobial    therapy, and preventive strategies. A consensus statement. Am J Respir Crit    Care Med 1996; 153: 1711-25.         [ Links ]22.- BARTLETT J G, DOWELL S F, MANDELL L A,    FILE T M, MUSHER D M, FINE M J. Practice guidelines for the management of community-acquired    pneumonia in adults. Clin Infect Dis. 2000; 31: 347-82         [ Links ]23.- KARCHMER A W. Cephalosporins. In: Mandell,    Douglas & Bennett's. Principles and Practice of Infectious Diseases. Mandell    G L, Bennett J E, Dolin R, eds. Fifth edition. Philadelphia: Churchill Livingstone    2000; 274-99.         [ Links ]24.- ADU A, ARMOUR C L. Drug utilisation review    (DUR) of the third generation cephalosporins. Drugs 1995; 50: 423-39.         [ Links ]25.- JONES R N. Important and emerging ß-lactamase    mediated resistances in hospital-based pathogens: the Amp C enzymes. Diagn Microbiol    Infect Dis 1998; 31: 461-6.         [ Links ]26.- JARVIS W R, MARTONE W J. Predominant    pathogens in hospital infections. J Antimicrob Chemother 1992; 29: 19-24.         [ Links ]27.- LIVERMORE D M. ß-lactamases in    laboratory and clinical resistance. Clin Microbiol Rev 1995; 8: 557-84.         [ Links ]28.- HERITAGE J, M'ZALI F H, GASCOYNE-BINZI    D, HAWKEY P M. Evolution and spread of SHV extended-spectrum ß-lactamases    in gram negative bacteria. J Antimicrob Chemother 1999; 44: 309-18.         [ Links ]29.- PODSCHUN R, ULLMAN U. Klebsiella spp.    as nosocomial pathogens: epidemiology, taxonomy, typing methods, and pathogenicity    factors. Clin Microbiol Rev 1998; 11: 589-603.         [ Links ]30.- PITOUT J D D, SANDERS C C, SANDERS W    E. Antimicrobial resistance with focus on ß-lactam resistance in Gram    negative bacilli. Am J Med 1997; 103: 51-9.         [ Links ]31.- HANBERGER H, GARCIA-RODRIGUEZ J A, GOBERNADO    et al. Antibiotic susceptibility among aerobic Gram negative bacilli in intensive    care units in 5 european countries. JAMA 1999; 281: 67-71.         [ Links ]32.- CHARREL R N, PAGES J M, DE MICCO P et    al. Prevalence of outer membrane porin alteration in ß-lactam-antibiotic-resistant    Enterobacter aerogenes. Antimicrob Agents Chemother 1996; 40: 2854-8.          [ Links ]33.- BRADFORD P A, URBAN C, MARIANO N, PROJAN    S J, RAHAL J J, BUSH K. Imipenem resistance in Klebsiella pneumoniae is    associated with the combination of ACT-1, a plasmid-mediated Amp C ß-lactamase,    and the loss of an outer membrane protein. Antimicrob Agents Chemother 1997;    41: 563-9.         [ Links ]34.- QUEENAN A M, TORRES-VIERA C, GOLD H et    al. SME-type carbapenem-hydrolizing class A ß-lactamases from geographically    diverse Serratia marcescens strains. Antimicrob Agents Chemother 2000;    44: 3035-9.         [ Links ]35.- COHEN S P, MC MURRY L M, HOOPER D C,    WOLFSON J S, LEVY S B. Cross-resistance to fluoroquinolones in multiple-antibiotic-resistance    (Mar) Escherichia coli selected by tetracycline resistance: decreased    drug accumulation asociated with membrane changes in addition to Omp F reduction.    Antimicrob Agents Chemother 1989; 33:1318-25.         [ Links ]36.- SANDERS C C. Cefepime: The next generation?    Clin Infect Dis 1993; 17: 369-79         [ Links ]37.- GARAU J. The clinical potential of fourth-generation    cephalosporins. Diagn Microbiol Infect Dis 1998; 31: 479-80.         [ Links ]38.- CURTIS N A C, ORR D C, ROSS G W, BOULTON    M G. Affinities of penicillins and cephalosporins for the penicillin-binding    proteins of Escherichia coli    K-12 and their antibacterial activity. Antimicrob Agents Chemother 1979; 16:    533-9.  39.- BALANT L, DAYER P, AUCKENTHALER R. Clinical    pharmacokinetics of the third generation cephalosporins. Clin Pharmacokinetics    1985; 10: 101-43.         [ Links ]40.- WHEELER W J. Cephalosporins and other    beta-lactam antibiotics. Lloydia. 1977; 40: 519-42.         [ Links ]41.- LOPEZ F, GARRIDO J C. Química    y relación estructura-actividad de los antibióticos cefalosporínicos.    Rev Col Químico Farmacéutico 1989; 41: 5-14.         [ Links ]42.- FU K P, ASWAPOKEE P, HO I, MATTHIJSSEN    C, NEU H C. Pharmacokinetics of cefotaxime. Antimicrob Agents Chemother 1979;16:    592-7.         [ Links ]43.- YUK J H, NIGHTINGALE C H, QUINTILIANI    R. Clinical pharmacokinetics of ceftriaxone. Clin Pharmacokinetic 1989; 17:    223-35.         [ Links ]44.- BRYSKIER A, PROCYK T, LABRO M T. Cefodizime,    a new 2-aminothiazolyl cephalosporin: physicochemical properties, toxicology    and structure-activity relationships. J Antimicrob Chemother 1990; 26 (Suppl    C): 1-8.         [ Links ]45.- CRITCHLEY I A, BASKER M J, EDMONDSON    R A, KNOTT S J. Uptake of catecholic cephalosporin by the iron transport system    of Escherichia coli. J Antimicrob Chemother 1991; 28: 377-88.         [ Links ]46.- CRITCHLEY I A. Catecholic ß-lactams:    facilitated transport. J Antimicrob Chemother 1990; 26: 733-7.         [ Links ]47.- JONES R N, ERWIN M E. In vitro evaluation    of Ro 09-1227, a novel catechol-substituted cephalosporin. Antimicrob Agents    Chemother 1992; 36: 233-8.         [ Links ]48.- JONES R N. In vitro activity of Ro 24-6392,    a novel ester-linked co-drug combining ciprofloxacin and desacetylcefotaxime.    Eur J Clin Microbiol Infect Dis 1990; 9: 435-8.         [ Links ]49.- TOMASZ A. Penicillin-binding proteins    and the antibacterial effectiveness of ß-lactam antibiotics. Rev Infect    Dis 1986 (Suppl 3); 8: 260-78.         [ Links ]50.- HOLM S E. Interaction between ß-lactam    and other antibiotics. Rev Infect Dis 1986 (Suppl 3); 8: 305-14.         [ Links ]51.- MC CULLERS J A, ENGLISH B K, NOVAK R.    Isolation and characterization of vancomycin-tolerant Streptococcus pneumoniae    from the cerebrospinal fluid of a patient who developed recrudescet meningitis.    J Infect Dis 2000; 181: 369-73.         [ Links ]52.- NIKAIDO H. Outer membrane barrier as    a mechanism of antimicrobial resistance. Antimicrob Agents Chemother 1989; 33:    1831-6.         [ Links ]53.- BARRADELL L B, BRYSON H M. Cefepime.    A review of its antibacterial activity, pharmacokinetic properties and therapeutic    use. Drugs 1994; 47: 471-505.         [ Links ]54.- O'CALLAGHAN C H 1979. Description and    classification of the newer cephalosporins and their relationship with the established    compounds. J Antimicrob Chemother 5: 635-71         [ Links ]55.- BRYSKIER A, PROCYK T, TREMBLAY D, LENFANT    B FOURTILLAN J B. The pharmacokinetics of cefodizime following intravenous and    intramuscular administration of a single dose of 1.0 g. J Antimicrob Chemother    1990; 26 (Suppl. C): 59-63.         [ Links ]56.- WILLIAMS J D. Classification of cephalosporins.    Drugs. 1987; 34 (Suppl 2): 15-22.         [ Links ]57.- WISEMAN L R, LAMB H M. Cefpirome. A review    of its antibacterial activity, pharmacokinetic properties and efficacy in the    treatment of severe nosocomial infections and febrile neutropenia. Drugs 1997;    57: 117-40.         [ Links ]58.- PECHERE J C, WILSON W, NEU H. Laboratory    assesment of antibacterial activity of zwitterionic 7-methoxyimino cephalosporins.    J Antimicrob Chemother 1995; 36: 757-71         [ Links ]59.- GIAMARELLOS-BOURBOULIS EJ, GRECKA P,    TSITSIKA A, TYMPANIDOU C, GIAMARELLOU H. In-vitro activity of FK 037 (cefoselis),    a novel 4 (th) generation cephalosporin, cefepime and cefpirome on nosocomial    staphylococci and gram-negative isolates. Diagn Microbiol infect Dis 2000; 36:    185-91.         [ Links ]60.- JONES R N, ERWIN M E, BARRETT M S, JOHNSON    D M, BRIGGS B M. Antimicrobial activity of E-1040, a novel thiadiazolyl cephalosporin    compare with parenteral cephems. Diagn Microbiol infect Dis 1991; 14: 301-9.          [ Links ]61.- IIZAWA Y, OKONOGI K, HAYASHI R, IWAHI    T, YAMAZAKI T, IMADA A. Therapeutic effect of cefozopran (SCE-2787), a new parenteral    cephalosporin in experimental infections in mice. Antimicrob Agents Chemother    1993; 37: 100-5.         [ Links ]62.- WATANABE N A. Newer antipseudomonal cephalosporins.    J Chemother 1996; 8 (Suppl 2): 48-56.         [ Links ]63.- ACTOR P, GUARINI J, URI J et al. Disk    susceptibility studies with cefazolin and cephalotin. Antimicrob Agents Chemother    1974; 5: 63-7.         [ Links ]64.- UWAYDAH M. Cefazolin in the treatment    of acute enteric fever. Antimicrob Agents Chemother 1976; 10: 52-6.         [ Links ]65.- JAMAL W Y, ROTIMI V O, CHUGH T D, PAL    T. Prevalence and susceptibility of Shigella to 11 antibiotics in a Kuwait    teaching hospital. J Chemother 1998; 10: 285-90.         [ Links ]66.- COX CE, SHERRILL M, COCCHETT DM. Evaluation    of cefuroxime axetil, cefaclor, and cephalexin in the treatment of urinary tract    infections in adults. Curr Ther Res 1987; 42: 124-37.         [ Links ]67.- SANDERS C W, GREENBERG R N, MARIER R    L. Cefamandole and cefoxitin. Ann Intern Med 1985; 103: 70-8.          [ Links ]68.- STAPLEY E P, JACKSON M, HERNANDEZ S et    al. Cephamycins, a new family of ß-lactam antibiotics I. Production actinomycetes,    including Streptomyces lactamdurans spp.n. Antimicrob Agents Chemother    1972; 2: 122-31.         [ Links ]69.- COOPER R D G. The carbacephems a new    ß-lactams class. Am J Med 1992; 92 (Suppl 6 A): 25-65.         [ Links ]70.- ZEMELMAN R, BELLO H, DOMINGUEZ M, GONZALEZ    G, MELLA S, GARCIA A. Activity of imipenem, third-generation cephalosporins,    aztreonam, and ciprofloxacin against multi-resistant Gram negative bacilli isolated    from Chilean hospitals. J Antimicrob Chemother 1993; 32: 413-9.         [ Links ]71.- MEDEIROS A A. Evolution and dissemination    of ß-lactamases accelerated by generation of ß-lactam antibiotics.    Clin Infect Dis 1997; 24 (Suppl. 1): 19-45.         [ Links ]72.- PERRY C M, BROGDEN R N. Cefuroxime axetil:    review of its antibacterial activity, pharmacokinetic properties and therapeutic    efficacy. Drugs 1996; 52: 125-58.         [ Links ]73.- SCHAAD U B, SUTER S, GIANELLA-BORRADORI    et al. A comparison of ceftriaxone and cefuroxime for the treatment of bacterial    meningitis in children. N Engl J Med 1990; 322: 141-7.         [ Links ]74.- KLEIN N C, CUNHA B A. Cefalosporinas de    la tercera generación. Clin Med Nort Am 1995; 79: 693-707.         [ Links ]75.- KLUGMAN K P, MADHI S A. Emergence of    drug resistance impact on bacterial meningitis. Infect Dis Clin North Am 1999;    13: 637-46.         [ Links ]76.- RICHARDS D M, BROGDEN R N. Ceftazidime.    A review of its antibacterial activity, pharmacokinetic properties and therapeutic    use. Drugs 1985; 29: 105-61.         [ Links ]77.- SCHATZ B S, KARAVOKIROS K T, TAEUBEL    M A, ITOKAZU G S. Comparison of cefprozil, cefpodoxime proxetil, loracarbef,    cefixime, and ceftibuten. Ann Pharmacother 1996; 30: 258-68.         [ Links ]78.- DALMAU D, LAYRARGUES G P, FENYVES D,    WILLEMS B, TURGEON F, TURGEON P. Cefotaxime, desacetyl-cefotaxime, and bactericidal    activity in spontaneous bacterial peritonitis. J Infect Dis 1999; 180: 1597-1602.          [ Links ]79.- NIKAIDO W, LIU W, ROSENBERG E Y. Outer    membrane permeability and ß-lactamase stability of dipolar ionic cephalosporins    containing methoxyimino substituents. Antimicrob Agents Chemother 1990; 34:    337-42.         [ Links ]80.- HANCOCK R E W, BELLIDO F. Factors involved    in the enhanced efficacy against gram-negative bacteria of fourth generation    cephalosporins. J Antimicrob Chemother 1992; 29(Suppl A): 1-6.         [ Links ]81.- BELLIDO F, PECHERE J C, HANCOCK REW.    Novel method for measurement of outer membrane permeability to new beta-lactams    in intact Enterobacter cloacae cells. Antimicrob Agents Chemother 1991;    35: 68-72.         [ Links ]82.- NEU H C, CHIN N X, JULES K, LABTHAVIKUL    P. The activity of BMY-28142, a new broad spectrum beta-lactamase stable cephalosporin.    J Antimicrob Chemother 1986; 17: 441-52.         [ Links ]83.- KOBAYASHI S, ARAI S, HAYASHI S, FUJIMOTO    K. ß-lactamase stability of cefpirome (HR 810), a new cephalosporin with    a broad antimicrobial spectrum. Antimicrob Agents Chemother 1986; 30: 713-8.          [ Links ]84.- GARAU J, WILSON W, WOOD M, CARLET J.    Fourth generation cephalosporins: a review of in vitro activity, pharmacokinetics,    pharmacodynamics, and clinical utility. Clin Microb Infect 1997; 3 (Suppl 1):    87-101.         [ Links ]85.- KESSLER R E, FUNG-TOMC J. Susceptibility    of bacterial isolates to beta-lactam antibiotics from U.S. clinical trials over    5-year period. Am J Med 1996; 24 (6 A): 13-9.         [ Links ]86.- PIERARD D, EMMERECHTS K, LAUWERS S. Comparative    in-vitro activity of cefpirome against isolates from intensive care and haematology/oncology    units. Belgian Multicentric Study Group. J Antimicrob Chemother 1998; 41: 443-50.          [ Links ]87.- JONES R N. Resistance patterns among    nosocomial pathogens: trends over the past few years. Chest 2001; 119 (Suppl    2): 397-404.         [ Links ]88.- LORBER B. Changing patterns of infectious    diseases. Am J Med 1988; 84: 569-78.         [ Links ]89.- MOELLERING R C. A novel antimicrobial    agent joins the battle against resistant bacteria. Ann Intern Med 1999; 130:    155-7.         [ Links ]90.- WILSON W R. The role of fourth-generation    cephalosporins in the treatment of serious infectious diseases in hospitalized    patients. Diagn Microbiol Infect Dis 1998; 31: 473-7.         [ Links ]Correspondencia a:        Sergio Mella Montecinos        Laboratorio de Antibióticos,        Departamento de Microbiología,        Facultad de Ciencias Biológicas        Casilla 160-C, Concepción        E-mail: pignatio@ctcinternet.cl  

13.- DRUSANO G L. Human pharmacodynamics of    beta-lactams, aminoglycosides and their combination. Scand J Infect Dis 1991    (Suppl); 74: 235-48.         [ Links ]14.- MARSHALL W F, BLAIR J E. The cephalosporins.    Mayo Clinic Proc 1999; 74: 187-95.         [ Links ]15.- DONOWIRZ G R, MANDELL G L. Beta-lactam    antibiotics. N Engl J Med 1988; 318: 490-500.         [ Links ]16.- PAYA E. Ventajas y desventajas de las    cefalosporinas orales de segunda y tercera generación. Rev Chil Infect    1997; 14: 233-8.         [ Links ]17.- AMERICAN THORACIC SOCIETY. Guidelines    for the initial management of adults with community-acquired pneumonia: diagnosis,    assessment of severity, and initial antimicrobial therapy. Am Rev Respir Dis    1993; 148: 1418-26.         [ Links ]18.- BARTLETT J G, BREIMAN R F, MANDELL L    A, FILE T M Jr. Community-acquired pneumonia in adults: guidelines for management.    The Infectious Diseases Society of America. Clin Infect Dis 1998: 26: 811-38.          [ Links ]19.- MARRIE T J. Community-acquired pneumonia:    epidemiology, etiology, treatment. Infect Dis Clin North Am 1998; 12: 723-40          [ Links ]20.- TUNKEL A R, SCHELD W M. Acute meningitis.    In: Mandell, Douglas & Bennett's. Principles and Practice of Infectious    Diseases. Mandell G L, Bennett J E, Dolin R, eds. Fifth edition. Philadelphia:    Editorial Churchill Livingstone 2000; 959-96.         [ Links ]21.- AMERICAN THORACIC SOCIETY. Hospital-acquired    pneumonia in adults: diagnosis, assessment of severity, initial antimicrobial    therapy, and preventive strategies. A consensus statement. Am J Respir Crit    Care Med 1996; 153: 1711-25.         [ Links ]22.- BARTLETT J G, DOWELL S F, MANDELL L A,    FILE T M, MUSHER D M, FINE M J. Practice guidelines for the management of community-acquired    pneumonia in adults. Clin Infect Dis. 2000; 31: 347-82         [ Links ]23.- KARCHMER A W. Cephalosporins. In: Mandell,    Douglas & Bennett's. Principles and Practice of Infectious Diseases. Mandell    G L, Bennett J E, Dolin R, eds. Fifth edition. Philadelphia: Churchill Livingstone    2000; 274-99.         [ Links ]24.- ADU A, ARMOUR C L. Drug utilisation review    (DUR) of the third generation cephalosporins. Drugs 1995; 50: 423-39.         [ Links ]25.- JONES R N. Important and emerging ß-lactamase    mediated resistances in hospital-based pathogens: the Amp C enzymes. Diagn Microbiol    Infect Dis 1998; 31: 461-6.         [ Links ]26.- JARVIS W R, MARTONE W J. Predominant    pathogens in hospital infections. J Antimicrob Chemother 1992; 29: 19-24.         [ Links ]27.- LIVERMORE D M. ß-lactamases in    laboratory and clinical resistance. Clin Microbiol Rev 1995; 8: 557-84.         [ Links ]28.- HERITAGE J, M'ZALI F H, GASCOYNE-BINZI    D, HAWKEY P M. Evolution and spread of SHV extended-spectrum ß-lactamases    in gram negative bacteria. J Antimicrob Chemother 1999; 44: 309-18.         [ Links ]29.- PODSCHUN R, ULLMAN U. Klebsiella spp.    as nosocomial pathogens: epidemiology, taxonomy, typing methods, and pathogenicity    factors. Clin Microbiol Rev 1998; 11: 589-603.         [ Links ]30.- PITOUT J D D, SANDERS C C, SANDERS W    E. Antimicrobial resistance with focus on ß-lactam resistance in Gram    negative bacilli. Am J Med 1997; 103: 51-9.         [ Links ]31.- HANBERGER H, GARCIA-RODRIGUEZ J A, GOBERNADO    et al. Antibiotic susceptibility among aerobic Gram negative bacilli in intensive    care units in 5 european countries. JAMA 1999; 281: 67-71.         [ Links ]32.- CHARREL R N, PAGES J M, DE MICCO P et    al. Prevalence of outer membrane porin alteration in ß-lactam-antibiotic-resistant    Enterobacter aerogenes. Antimicrob Agents Chemother 1996; 40: 2854-8.          [ Links ]33.- BRADFORD P A, URBAN C, MARIANO N, PROJAN    S J, RAHAL J J, BUSH K. Imipenem resistance in Klebsiella pneumoniae is    associated with the combination of ACT-1, a plasmid-mediated Amp C ß-lactamase,    and the loss of an outer membrane protein. Antimicrob Agents Chemother 1997;    41: 563-9.         [ Links ]34.- QUEENAN A M, TORRES-VIERA C, GOLD H et    al. SME-type carbapenem-hydrolizing class A ß-lactamases from geographically    diverse Serratia marcescens strains. Antimicrob Agents Chemother 2000;    44: 3035-9.         [ Links ]35.- COHEN S P, MC MURRY L M, HOOPER D C,    WOLFSON J S, LEVY S B. Cross-resistance to fluoroquinolones in multiple-antibiotic-resistance    (Mar) Escherichia coli selected by tetracycline resistance: decreased    drug accumulation asociated with membrane changes in addition to Omp F reduction.    Antimicrob Agents Chemother 1989; 33:1318-25.         [ Links ]36.- SANDERS C C. Cefepime: The next generation?    Clin Infect Dis 1993; 17: 369-79         [ Links ]37.- GARAU J. The clinical potential of fourth-generation    cephalosporins. Diagn Microbiol Infect Dis 1998; 31: 479-80.         [ Links ]38.- CURTIS N A C, ORR D C, ROSS G W, BOULTON    M G. Affinities of penicillins and cephalosporins for the penicillin-binding    proteins of Escherichia coli    K-12 and their antibacterial activity. Antimicrob Agents Chemother 1979; 16:    533-9.  39.- BALANT L, DAYER P, AUCKENTHALER R. Clinical    pharmacokinetics of the third generation cephalosporins. Clin Pharmacokinetics    1985; 10: 101-43.         [ Links ]40.- WHEELER W J. Cephalosporins and other    beta-lactam antibiotics. Lloydia. 1977; 40: 519-42.         [ Links ]41.- LOPEZ F, GARRIDO J C. Química    y relación estructura-actividad de los antibióticos cefalosporínicos.    Rev Col Químico Farmacéutico 1989; 41: 5-14.         [ Links ]42.- FU K P, ASWAPOKEE P, HO I, MATTHIJSSEN    C, NEU H C. Pharmacokinetics of cefotaxime. Antimicrob Agents Chemother 1979;16:    592-7.         [ Links ]43.- YUK J H, NIGHTINGALE C H, QUINTILIANI    R. Clinical pharmacokinetics of ceftriaxone. Clin Pharmacokinetic 1989; 17:    223-35.         [ Links ]44.- BRYSKIER A, PROCYK T, LABRO M T. Cefodizime,    a new 2-aminothiazolyl cephalosporin: physicochemical properties, toxicology    and structure-activity relationships. J Antimicrob Chemother 1990; 26 (Suppl    C): 1-8.         [ Links ]45.- CRITCHLEY I A, BASKER M J, EDMONDSON    R A, KNOTT S J. Uptake of catecholic cephalosporin by the iron transport system    of Escherichia coli. J Antimicrob Chemother 1991; 28: 377-88.         [ Links ]46.- CRITCHLEY I A. Catecholic ß-lactams:    facilitated transport. J Antimicrob Chemother 1990; 26: 733-7.         [ Links ]47.- JONES R N, ERWIN M E. In vitro evaluation    of Ro 09-1227, a novel catechol-substituted cephalosporin. Antimicrob Agents    Chemother 1992; 36: 233-8.         [ Links ]48.- JONES R N. In vitro activity of Ro 24-6392,    a novel ester-linked co-drug combining ciprofloxacin and desacetylcefotaxime.    Eur J Clin Microbiol Infect Dis 1990; 9: 435-8.         [ Links ]49.- TOMASZ A. Penicillin-binding proteins    and the antibacterial effectiveness of ß-lactam antibiotics. Rev Infect    Dis 1986 (Suppl 3); 8: 260-78.         [ Links ]50.- HOLM S E. Interaction between ß-lactam    and other antibiotics. Rev Infect Dis 1986 (Suppl 3); 8: 305-14.         [ Links ]51.- MC CULLERS J A, ENGLISH B K, NOVAK R.    Isolation and characterization of vancomycin-tolerant Streptococcus pneumoniae    from the cerebrospinal fluid of a patient who developed recrudescet meningitis.    J Infect Dis 2000; 181: 369-73.         [ Links ]52.- NIKAIDO H. Outer membrane barrier as    a mechanism of antimicrobial resistance. Antimicrob Agents Chemother 1989; 33:    1831-6.         [ Links ]53.- BARRADELL L B, BRYSON H M. Cefepime.    A review of its antibacterial activity, pharmacokinetic properties and therapeutic    use. Drugs 1994; 47: 471-505.         [ Links ]54.- O'CALLAGHAN C H 1979. Description and    classification of the newer cephalosporins and their relationship with the established    compounds. J Antimicrob Chemother 5: 635-71         [ Links ]55.- BRYSKIER A, PROCYK T, TREMBLAY D, LENFANT    B FOURTILLAN J B. The pharmacokinetics of cefodizime following intravenous and    intramuscular administration of a single dose of 1.0 g. J Antimicrob Chemother    1990; 26 (Suppl. C): 59-63.         [ Links ]56.- WILLIAMS J D. Classification of cephalosporins.    Drugs. 1987; 34 (Suppl 2): 15-22.         [ Links ]57.- WISEMAN L R, LAMB H M. Cefpirome. A review    of its antibacterial activity, pharmacokinetic properties and efficacy in the    treatment of severe nosocomial infections and febrile neutropenia. Drugs 1997;    57: 117-40.         [ Links ]58.- PECHERE J C, WILSON W, NEU H. Laboratory    assesment of antibacterial activity of zwitterionic 7-methoxyimino cephalosporins.    J Antimicrob Chemother 1995; 36: 757-71         [ Links ]59.- GIAMARELLOS-BOURBOULIS EJ, GRECKA P,    TSITSIKA A, TYMPANIDOU C, GIAMARELLOU H. In-vitro activity of FK 037 (cefoselis),    a novel 4 (th) generation cephalosporin, cefepime and cefpirome on nosocomial    staphylococci and gram-negative isolates. Diagn Microbiol infect Dis 2000; 36:    185-91.         [ Links ]60.- JONES R N, ERWIN M E, BARRETT M S, JOHNSON    D M, BRIGGS B M. Antimicrobial activity of E-1040, a novel thiadiazolyl cephalosporin    compare with parenteral cephems. Diagn Microbiol infect Dis 1991; 14: 301-9.          [ Links ]61.- IIZAWA Y, OKONOGI K, HAYASHI R, IWAHI    T, YAMAZAKI T, IMADA A. Therapeutic effect of cefozopran (SCE-2787), a new parenteral    cephalosporin in experimental infections in mice. Antimicrob Agents Chemother    1993; 37: 100-5.         [ Links ]62.- WATANABE N A. Newer antipseudomonal cephalosporins.    J Chemother 1996; 8 (Suppl 2): 48-56.         [ Links ]63.- ACTOR P, GUARINI J, URI J et al. Disk    susceptibility studies with cefazolin and cephalotin. Antimicrob Agents Chemother    1974; 5: 63-7.         [ Links ]64.- UWAYDAH M. Cefazolin in the treatment    of acute enteric fever. Antimicrob Agents Chemother 1976; 10: 52-6.         [ Links ]65.- JAMAL W Y, ROTIMI V O, CHUGH T D, PAL    T. Prevalence and susceptibility of Shigella to 11 antibiotics in a Kuwait    teaching hospital. J Chemother 1998; 10: 285-90.         [ Links ]66.- COX CE, SHERRILL M, COCCHETT DM. Evaluation    of cefuroxime axetil, cefaclor, and cephalexin in the treatment of urinary tract    infections in adults. Curr Ther Res 1987; 42: 124-37.         [ Links ]67.- SANDERS C W, GREENBERG R N, MARIER R    L. Cefamandole and cefoxitin. Ann Intern Med 1985; 103: 70-8.          [ Links ]68.- STAPLEY E P, JACKSON M, HERNANDEZ S et    al. Cephamycins, a new family of ß-lactam antibiotics I. Production actinomycetes,    including Streptomyces lactamdurans spp.n. Antimicrob Agents Chemother    1972; 2: 122-31.         [ Links ]69.- COOPER R D G. The carbacephems a new    ß-lactams class. Am J Med 1992; 92 (Suppl 6 A): 25-65.         [ Links ]70.- ZEMELMAN R, BELLO H, DOMINGUEZ M, GONZALEZ    G, MELLA S, GARCIA A. Activity of imipenem, third-generation cephalosporins,    aztreonam, and ciprofloxacin against multi-resistant Gram negative bacilli isolated    from Chilean hospitals. J Antimicrob Chemother 1993; 32: 413-9.         [ Links ]71.- MEDEIROS A A. Evolution and dissemination    of ß-lactamases accelerated by generation of ß-lactam antibiotics.    Clin Infect Dis 1997; 24 (Suppl. 1): 19-45.         [ Links ]72.- PERRY C M, BROGDEN R N. Cefuroxime axetil:    review of its antibacterial activity, pharmacokinetic properties and therapeutic    efficacy. Drugs 1996; 52: 125-58.         [ Links ]73.- SCHAAD U B, SUTER S, GIANELLA-BORRADORI    et al. A comparison of ceftriaxone and cefuroxime for the treatment of bacterial    meningitis in children. N Engl J Med 1990; 322: 141-7.         [ Links ]74.- KLEIN N C, CUNHA B A. Cefalosporinas de    la tercera generación. Clin Med Nort Am 1995; 79: 693-707.         [ Links ]75.- KLUGMAN K P, MADHI S A. Emergence of    drug resistance impact on bacterial meningitis. Infect Dis Clin North Am 1999;    13: 637-46.         [ Links ]76.- RICHARDS D M, BROGDEN R N. Ceftazidime.    A review of its antibacterial activity, pharmacokinetic properties and therapeutic    use. Drugs 1985; 29: 105-61.         [ Links ]77.- SCHATZ B S, KARAVOKIROS K T, TAEUBEL    M A, ITOKAZU G S. Comparison of cefprozil, cefpodoxime proxetil, loracarbef,    cefixime, and ceftibuten. Ann Pharmacother 1996; 30: 258-68.         [ Links ]78.- DALMAU D, LAYRARGUES G P, FENYVES D,    WILLEMS B, TURGEON F, TURGEON P. Cefotaxime, desacetyl-cefotaxime, and bactericidal    activity in spontaneous bacterial peritonitis. J Infect Dis 1999; 180: 1597-1602.          [ Links ]79.- NIKAIDO W, LIU W, ROSENBERG E Y. Outer    membrane permeability and ß-lactamase stability of dipolar ionic cephalosporins    containing methoxyimino substituents. Antimicrob Agents Chemother 1990; 34:    337-42.         [ Links ]80.- HANCOCK R E W, BELLIDO F. Factors involved    in the enhanced efficacy against gram-negative bacteria of fourth generation    cephalosporins. J Antimicrob Chemother 1992; 29(Suppl A): 1-6.         [ Links ]81.- BELLIDO F, PECHERE J C, HANCOCK REW.    Novel method for measurement of outer membrane permeability to new beta-lactams    in intact Enterobacter cloacae cells. Antimicrob Agents Chemother 1991;    35: 68-72.         [ Links ]82.- NEU H C, CHIN N X, JULES K, LABTHAVIKUL    P. The activity of BMY-28142, a new broad spectrum beta-lactamase stable cephalosporin.    J Antimicrob Chemother 1986; 17: 441-52.         [ Links ]83.- KOBAYASHI S, ARAI S, HAYASHI S, FUJIMOTO    K. ß-lactamase stability of cefpirome (HR 810), a new cephalosporin with    a broad antimicrobial spectrum. Antimicrob Agents Chemother 1986; 30: 713-8.          [ Links ]84.- GARAU J, WILSON W, WOOD M, CARLET J.    Fourth generation cephalosporins: a review of in vitro activity, pharmacokinetics,    pharmacodynamics, and clinical utility. Clin Microb Infect 1997; 3 (Suppl 1):    87-101.         [ Links ]85.- KESSLER R E, FUNG-TOMC J. Susceptibility    of bacterial isolates to beta-lactam antibiotics from U.S. clinical trials over    5-year period. Am J Med 1996; 24 (6 A): 13-9.         [ Links ]86.- PIERARD D, EMMERECHTS K, LAUWERS S. Comparative    in-vitro activity of cefpirome against isolates from intensive care and haematology/oncology    units. Belgian Multicentric Study Group. J Antimicrob Chemother 1998; 41: 443-50.          [ Links ]87.- JONES R N. Resistance patterns among    nosocomial pathogens: trends over the past few years. Chest 2001; 119 (Suppl    2): 397-404.         [ Links ]88.- LORBER B. Changing patterns of infectious    diseases. Am J Med 1988; 84: 569-78.         [ Links ]89.- MOELLERING R C. A novel antimicrobial    agent joins the battle against resistant bacteria. Ann Intern Med 1999; 130:    155-7.         [ Links ]90.- WILSON W R. The role of fourth-generation    cephalosporins in the treatment of serious infectious diseases in hospitalized    patients. Diagn Microbiol Infect Dis 1998; 31: 473-7.         [ Links ]Correspondencia a:        Sergio Mella Montecinos        Laboratorio de Antibióticos,        Departamento de Microbiología,        Facultad de Ciencias Biológicas        Casilla 160-C, Concepción        E-mail: pignatio@ctcinternet.cl  

14.- MARSHALL W F, BLAIR J E. The cephalosporins.    Mayo Clinic Proc 1999; 74: 187-95.         [ Links ]15.- DONOWIRZ G R, MANDELL G L. Beta-lactam    antibiotics. N Engl J Med 1988; 318: 490-500.         [ Links ]16.- PAYA E. Ventajas y desventajas de las    cefalosporinas orales de segunda y tercera generación. Rev Chil Infect    1997; 14: 233-8.         [ Links ]17.- AMERICAN THORACIC SOCIETY. Guidelines    for the initial management of adults with community-acquired pneumonia: diagnosis,    assessment of severity, and initial antimicrobial therapy. Am Rev Respir Dis    1993; 148: 1418-26.         [ Links ]18.- BARTLETT J G, BREIMAN R F, MANDELL L    A, FILE T M Jr. Community-acquired pneumonia in adults: guidelines for management.    The Infectious Diseases Society of America. Clin Infect Dis 1998: 26: 811-38.          [ Links ]19.- MARRIE T J. Community-acquired pneumonia:    epidemiology, etiology, treatment. Infect Dis Clin North Am 1998; 12: 723-40          [ Links ]20.- TUNKEL A R, SCHELD W M. Acute meningitis.    In: Mandell, Douglas & Bennett's. Principles and Practice of Infectious    Diseases. Mandell G L, Bennett J E, Dolin R, eds. Fifth edition. Philadelphia:    Editorial Churchill Livingstone 2000; 959-96.         [ Links ]21.- AMERICAN THORACIC SOCIETY. Hospital-acquired    pneumonia in adults: diagnosis, assessment of severity, initial antimicrobial    therapy, and preventive strategies. A consensus statement. Am J Respir Crit    Care Med 1996; 153: 1711-25.         [ Links ]22.- BARTLETT J G, DOWELL S F, MANDELL L A,    FILE T M, MUSHER D M, FINE M J. Practice guidelines for the management of community-acquired    pneumonia in adults. Clin Infect Dis. 2000; 31: 347-82         [ Links ]23.- KARCHMER A W. Cephalosporins. In: Mandell,    Douglas & Bennett's. Principles and Practice of Infectious Diseases. Mandell    G L, Bennett J E, Dolin R, eds. Fifth edition. Philadelphia: Churchill Livingstone    2000; 274-99.         [ Links ]24.- ADU A, ARMOUR C L. Drug utilisation review    (DUR) of the third generation cephalosporins. Drugs 1995; 50: 423-39.         [ Links ]25.- JONES R N. Important and emerging ß-lactamase    mediated resistances in hospital-based pathogens: the Amp C enzymes. Diagn Microbiol    Infect Dis 1998; 31: 461-6.         [ Links ]26.- JARVIS W R, MARTONE W J. Predominant    pathogens in hospital infections. J Antimicrob Chemother 1992; 29: 19-24.         [ Links ]27.- LIVERMORE D M. ß-lactamases in    laboratory and clinical resistance. Clin Microbiol Rev 1995; 8: 557-84.         [ Links ]28.- HERITAGE J, M'ZALI F H, GASCOYNE-BINZI    D, HAWKEY P M. Evolution and spread of SHV extended-spectrum ß-lactamases    in gram negative bacteria. J Antimicrob Chemother 1999; 44: 309-18.         [ Links ]29.- PODSCHUN R, ULLMAN U. Klebsiella spp.    as nosocomial pathogens: epidemiology, taxonomy, typing methods, and pathogenicity    factors. Clin Microbiol Rev 1998; 11: 589-603.         [ Links ]30.- PITOUT J D D, SANDERS C C, SANDERS W    E. Antimicrobial resistance with focus on ß-lactam resistance in Gram    negative bacilli. Am J Med 1997; 103: 51-9.         [ Links ]31.- HANBERGER H, GARCIA-RODRIGUEZ J A, GOBERNADO    et al. Antibiotic susceptibility among aerobic Gram negative bacilli in intensive    care units in 5 european countries. JAMA 1999; 281: 67-71.         [ Links ]32.- CHARREL R N, PAGES J M, DE MICCO P et    al. Prevalence of outer membrane porin alteration in ß-lactam-antibiotic-resistant    Enterobacter aerogenes. Antimicrob Agents Chemother 1996; 40: 2854-8.          [ Links ]33.- BRADFORD P A, URBAN C, MARIANO N, PROJAN    S J, RAHAL J J, BUSH K. Imipenem resistance in Klebsiella pneumoniae is    associated with the combination of ACT-1, a plasmid-mediated Amp C ß-lactamase,    and the loss of an outer membrane protein. Antimicrob Agents Chemother 1997;    41: 563-9.         [ Links ]34.- QUEENAN A M, TORRES-VIERA C, GOLD H et    al. SME-type carbapenem-hydrolizing class A ß-lactamases from geographically    diverse Serratia marcescens strains. Antimicrob Agents Chemother 2000;    44: 3035-9.         [ Links ]35.- COHEN S P, MC MURRY L M, HOOPER D C,    WOLFSON J S, LEVY S B. Cross-resistance to fluoroquinolones in multiple-antibiotic-resistance    (Mar) Escherichia coli selected by tetracycline resistance: decreased    drug accumulation asociated with membrane changes in addition to Omp F reduction.    Antimicrob Agents Chemother 1989; 33:1318-25.         [ Links ]36.- SANDERS C C. Cefepime: The next generation?    Clin Infect Dis 1993; 17: 369-79         [ Links ]37.- GARAU J. The clinical potential of fourth-generation    cephalosporins. Diagn Microbiol Infect Dis 1998; 31: 479-80.         [ Links ]38.- CURTIS N A C, ORR D C, ROSS G W, BOULTON    M G. Affinities of penicillins and cephalosporins for the penicillin-binding    proteins of Escherichia coli    K-12 and their antibacterial activity. Antimicrob Agents Chemother 1979; 16:    533-9.  39.- BALANT L, DAYER P, AUCKENTHALER R. Clinical    pharmacokinetics of the third generation cephalosporins. Clin Pharmacokinetics    1985; 10: 101-43.         [ Links ]40.- WHEELER W J. Cephalosporins and other    beta-lactam antibiotics. Lloydia. 1977; 40: 519-42.         [ Links ]41.- LOPEZ F, GARRIDO J C. Química    y relación estructura-actividad de los antibióticos cefalosporínicos.    Rev Col Químico Farmacéutico 1989; 41: 5-14.         [ Links ]42.- FU K P, ASWAPOKEE P, HO I, MATTHIJSSEN    C, NEU H C. Pharmacokinetics of cefotaxime. Antimicrob Agents Chemother 1979;16:    592-7.         [ Links ]43.- YUK J H, NIGHTINGALE C H, QUINTILIANI    R. Clinical pharmacokinetics of ceftriaxone. Clin Pharmacokinetic 1989; 17:    223-35.         [ Links ]44.- BRYSKIER A, PROCYK T, LABRO M T. Cefodizime,    a new 2-aminothiazolyl cephalosporin: physicochemical properties, toxicology    and structure-activity relationships. J Antimicrob Chemother 1990; 26 (Suppl    C): 1-8.         [ Links ]45.- CRITCHLEY I A, BASKER M J, EDMONDSON    R A, KNOTT S J. Uptake of catecholic cephalosporin by the iron transport system    of Escherichia coli. J Antimicrob Chemother 1991; 28: 377-88.         [ Links ]46.- CRITCHLEY I A. Catecholic ß-lactams:    facilitated transport. J Antimicrob Chemother 1990; 26: 733-7.         [ Links ]47.- JONES R N, ERWIN M E. In vitro evaluation    of Ro 09-1227, a novel catechol-substituted cephalosporin. Antimicrob Agents    Chemother 1992; 36: 233-8.         [ Links ]48.- JONES R N. In vitro activity of Ro 24-6392,    a novel ester-linked co-drug combining ciprofloxacin and desacetylcefotaxime.    Eur J Clin Microbiol Infect Dis 1990; 9: 435-8.         [ Links ]49.- TOMASZ A. Penicillin-binding proteins    and the antibacterial effectiveness of ß-lactam antibiotics. Rev Infect    Dis 1986 (Suppl 3); 8: 260-78.         [ Links ]50.- HOLM S E. Interaction between ß-lactam    and other antibiotics. Rev Infect Dis 1986 (Suppl 3); 8: 305-14.         [ Links ]51.- MC CULLERS J A, ENGLISH B K, NOVAK R.    Isolation and characterization of vancomycin-tolerant Streptococcus pneumoniae    from the cerebrospinal fluid of a patient who developed recrudescet meningitis.    J Infect Dis 2000; 181: 369-73.         [ Links ]52.- NIKAIDO H. Outer membrane barrier as    a mechanism of antimicrobial resistance. Antimicrob Agents Chemother 1989; 33:    1831-6.         [ Links ]53.- BARRADELL L B, BRYSON H M. Cefepime.    A review of its antibacterial activity, pharmacokinetic properties and therapeutic    use. Drugs 1994; 47: 471-505.         [ Links ]54.- O'CALLAGHAN C H 1979. Description and    classification of the newer cephalosporins and their relationship with the established    compounds. J Antimicrob Chemother 5: 635-71         [ Links ]55.- BRYSKIER A, PROCYK T, TREMBLAY D, LENFANT    B FOURTILLAN J B. The pharmacokinetics of cefodizime following intravenous and    intramuscular administration of a single dose of 1.0 g. J Antimicrob Chemother    1990; 26 (Suppl. C): 59-63.         [ Links ]56.- WILLIAMS J D. Classification of cephalosporins.    Drugs. 1987; 34 (Suppl 2): 15-22.         [ Links ]57.- WISEMAN L R, LAMB H M. Cefpirome. A review    of its antibacterial activity, pharmacokinetic properties and efficacy in the    treatment of severe nosocomial infections and febrile neutropenia. Drugs 1997;    57: 117-40.         [ Links ]58.- PECHERE J C, WILSON W, NEU H. Laboratory    assesment of antibacterial activity of zwitterionic 7-methoxyimino cephalosporins.    J Antimicrob Chemother 1995; 36: 757-71         [ Links ]59.- GIAMARELLOS-BOURBOULIS EJ, GRECKA P,    TSITSIKA A, TYMPANIDOU C, GIAMARELLOU H. In-vitro activity of FK 037 (cefoselis),    a novel 4 (th) generation cephalosporin, cefepime and cefpirome on nosocomial    staphylococci and gram-negative isolates. Diagn Microbiol infect Dis 2000; 36:    185-91.         [ Links ]60.- JONES R N, ERWIN M E, BARRETT M S, JOHNSON    D M, BRIGGS B M. Antimicrobial activity of E-1040, a novel thiadiazolyl cephalosporin    compare with parenteral cephems. Diagn Microbiol infect Dis 1991; 14: 301-9.          [ Links ]61.- IIZAWA Y, OKONOGI K, HAYASHI R, IWAHI    T, YAMAZAKI T, IMADA A. Therapeutic effect of cefozopran (SCE-2787), a new parenteral    cephalosporin in experimental infections in mice. Antimicrob Agents Chemother    1993; 37: 100-5.         [ Links ]62.- WATANABE N A. Newer antipseudomonal cephalosporins.    J Chemother 1996; 8 (Suppl 2): 48-56.         [ Links ]63.- ACTOR P, GUARINI J, URI J et al. Disk    susceptibility studies with cefazolin and cephalotin. Antimicrob Agents Chemother    1974; 5: 63-7.         [ Links ]64.- UWAYDAH M. Cefazolin in the treatment    of acute enteric fever. Antimicrob Agents Chemother 1976; 10: 52-6.         [ Links ]65.- JAMAL W Y, ROTIMI V O, CHUGH T D, PAL    T. Prevalence and susceptibility of Shigella to 11 antibiotics in a Kuwait    teaching hospital. J Chemother 1998; 10: 285-90.         [ Links ]66.- COX CE, SHERRILL M, COCCHETT DM. Evaluation    of cefuroxime axetil, cefaclor, and cephalexin in the treatment of urinary tract    infections in adults. Curr Ther Res 1987; 42: 124-37.         [ Links ]67.- SANDERS C W, GREENBERG R N, MARIER R    L. Cefamandole and cefoxitin. Ann Intern Med 1985; 103: 70-8.          [ Links ]68.- STAPLEY E P, JACKSON M, HERNANDEZ S et    al. Cephamycins, a new family of ß-lactam antibiotics I. Production actinomycetes,    including Streptomyces lactamdurans spp.n. Antimicrob Agents Chemother    1972; 2: 122-31.         [ Links ]69.- COOPER R D G. The carbacephems a new    ß-lactams class. Am J Med 1992; 92 (Suppl 6 A): 25-65.         [ Links ]70.- ZEMELMAN R, BELLO H, DOMINGUEZ M, GONZALEZ    G, MELLA S, GARCIA A. Activity of imipenem, third-generation cephalosporins,    aztreonam, and ciprofloxacin against multi-resistant Gram negative bacilli isolated    from Chilean hospitals. J Antimicrob Chemother 1993; 32: 413-9.         [ Links ]71.- MEDEIROS A A. Evolution and dissemination    of ß-lactamases accelerated by generation of ß-lactam antibiotics.    Clin Infect Dis 1997; 24 (Suppl. 1): 19-45.         [ Links ]72.- PERRY C M, BROGDEN R N. Cefuroxime axetil:    review of its antibacterial activity, pharmacokinetic properties and therapeutic    efficacy. Drugs 1996; 52: 125-58.         [ Links ]73.- SCHAAD U B, SUTER S, GIANELLA-BORRADORI    et al. A comparison of ceftriaxone and cefuroxime for the treatment of bacterial    meningitis in children. N Engl J Med 1990; 322: 141-7.         [ Links ]74.- KLEIN N C, CUNHA B A. Cefalosporinas de    la tercera generación. Clin Med Nort Am 1995; 79: 693-707.         [ Links ]75.- KLUGMAN K P, MADHI S A. Emergence of    drug resistance impact on bacterial meningitis. Infect Dis Clin North Am 1999;    13: 637-46.         [ Links ]76.- RICHARDS D M, BROGDEN R N. Ceftazidime.    A review of its antibacterial activity, pharmacokinetic properties and therapeutic    use. Drugs 1985; 29: 105-61.         [ Links ]77.- SCHATZ B S, KARAVOKIROS K T, TAEUBEL    M A, ITOKAZU G S. Comparison of cefprozil, cefpodoxime proxetil, loracarbef,    cefixime, and ceftibuten. Ann Pharmacother 1996; 30: 258-68.         [ Links ]78.- DALMAU D, LAYRARGUES G P, FENYVES D,    WILLEMS B, TURGEON F, TURGEON P. Cefotaxime, desacetyl-cefotaxime, and bactericidal    activity in spontaneous bacterial peritonitis. J Infect Dis 1999; 180: 1597-1602.          [ Links ]79.- NIKAIDO W, LIU W, ROSENBERG E Y. Outer    membrane permeability and ß-lactamase stability of dipolar ionic cephalosporins    containing methoxyimino substituents. Antimicrob Agents Chemother 1990; 34:    337-42.         [ Links ]80.- HANCOCK R E W, BELLIDO F. Factors involved    in the enhanced efficacy against gram-negative bacteria of fourth generation    cephalosporins. J Antimicrob Chemother 1992; 29(Suppl A): 1-6.         [ Links ]81.- BELLIDO F, PECHERE J C, HANCOCK REW.    Novel method for measurement of outer membrane permeability to new beta-lactams    in intact Enterobacter cloacae cells. Antimicrob Agents Chemother 1991;    35: 68-72.         [ Links ]82.- NEU H C, CHIN N X, JULES K, LABTHAVIKUL    P. The activity of BMY-28142, a new broad spectrum beta-lactamase stable cephalosporin.    J Antimicrob Chemother 1986; 17: 441-52.         [ Links ]83.- KOBAYASHI S, ARAI S, HAYASHI S, FUJIMOTO    K. ß-lactamase stability of cefpirome (HR 810), a new cephalosporin with    a broad antimicrobial spectrum. Antimicrob Agents Chemother 1986; 30: 713-8.          [ Links ]84.- GARAU J, WILSON W, WOOD M, CARLET J.    Fourth generation cephalosporins: a review of in vitro activity, pharmacokinetics,    pharmacodynamics, and clinical utility. Clin Microb Infect 1997; 3 (Suppl 1):    87-101.         [ Links ]85.- KESSLER R E, FUNG-TOMC J. Susceptibility    of bacterial isolates to beta-lactam antibiotics from U.S. clinical trials over    5-year period. Am J Med 1996; 24 (6 A): 13-9.         [ Links ]86.- PIERARD D, EMMERECHTS K, LAUWERS S. Comparative    in-vitro activity of cefpirome against isolates from intensive care and haematology/oncology    units. Belgian Multicentric Study Group. J Antimicrob Chemother 1998; 41: 443-50.          [ Links ]87.- JONES R N. Resistance patterns among    nosocomial pathogens: trends over the past few years. Chest 2001; 119 (Suppl    2): 397-404.         [ Links ]88.- LORBER B. Changing patterns of infectious    diseases. Am J Med 1988; 84: 569-78.         [ Links ]89.- MOELLERING R C. A novel antimicrobial    agent joins the battle against resistant bacteria. Ann Intern Med 1999; 130:    155-7.         [ Links ]90.- WILSON W R. The role of fourth-generation    cephalosporins in the treatment of serious infectious diseases in hospitalized    patients. Diagn Microbiol Infect Dis 1998; 31: 473-7.         [ Links ]Correspondencia a:        Sergio Mella Montecinos        Laboratorio de Antibióticos,        Departamento de Microbiología,        Facultad de Ciencias Biológicas        Casilla 160-C, Concepción        E-mail: pignatio@ctcinternet.cl  

15.- DONOWIRZ G R, MANDELL G L. Beta-lactam    antibiotics. N Engl J Med 1988; 318: 490-500.         [ Links ]16.- PAYA E. Ventajas y desventajas de las    cefalosporinas orales de segunda y tercera generación. Rev Chil Infect    1997; 14: 233-8.         [ Links ]17.- AMERICAN THORACIC SOCIETY. Guidelines    for the initial management of adults with community-acquired pneumonia: diagnosis,    assessment of severity, and initial antimicrobial therapy. Am Rev Respir Dis    1993; 148: 1418-26.         [ Links ]18.- BARTLETT J G, BREIMAN R F, MANDELL L    A, FILE T M Jr. Community-acquired pneumonia in adults: guidelines for management.    The Infectious Diseases Society of America. Clin Infect Dis 1998: 26: 811-38.          [ Links ]19.- MARRIE T J. Community-acquired pneumonia:    epidemiology, etiology, treatment. Infect Dis Clin North Am 1998; 12: 723-40          [ Links ]20.- TUNKEL A R, SCHELD W M. Acute meningitis.    In: Mandell, Douglas & Bennett's. Principles and Practice of Infectious    Diseases. Mandell G L, Bennett J E, Dolin R, eds. Fifth edition. Philadelphia:    Editorial Churchill Livingstone 2000; 959-96.         [ Links ]21.- AMERICAN THORACIC SOCIETY. Hospital-acquired    pneumonia in adults: diagnosis, assessment of severity, initial antimicrobial    therapy, and preventive strategies. A consensus statement. Am J Respir Crit    Care Med 1996; 153: 1711-25.         [ Links ]22.- BARTLETT J G, DOWELL S F, MANDELL L A,    FILE T M, MUSHER D M, FINE M J. Practice guidelines for the management of community-acquired    pneumonia in adults. Clin Infect Dis. 2000; 31: 347-82         [ Links ]23.- KARCHMER A W. Cephalosporins. In: Mandell,    Douglas & Bennett's. Principles and Practice of Infectious Diseases. Mandell    G L, Bennett J E, Dolin R, eds. Fifth edition. Philadelphia: Churchill Livingstone    2000; 274-99.         [ Links ]24.- ADU A, ARMOUR C L. Drug utilisation review    (DUR) of the third generation cephalosporins. Drugs 1995; 50: 423-39.         [ Links ]25.- JONES R N. Important and emerging ß-lactamase    mediated resistances in hospital-based pathogens: the Amp C enzymes. Diagn Microbiol    Infect Dis 1998; 31: 461-6.         [ Links ]26.- JARVIS W R, MARTONE W J. Predominant    pathogens in hospital infections. J Antimicrob Chemother 1992; 29: 19-24.         [ Links ]27.- LIVERMORE D M. ß-lactamases in    laboratory and clinical resistance. Clin Microbiol Rev 1995; 8: 557-84.         [ Links ]28.- HERITAGE J, M'ZALI F H, GASCOYNE-BINZI    D, HAWKEY P M. Evolution and spread of SHV extended-spectrum ß-lactamases    in gram negative bacteria. J Antimicrob Chemother 1999; 44: 309-18.         [ Links ]29.- PODSCHUN R, ULLMAN U. Klebsiella spp.    as nosocomial pathogens: epidemiology, taxonomy, typing methods, and pathogenicity    factors. Clin Microbiol Rev 1998; 11: 589-603.         [ Links ]30.- PITOUT J D D, SANDERS C C, SANDERS W    E. Antimicrobial resistance with focus on ß-lactam resistance in Gram    negative bacilli. Am J Med 1997; 103: 51-9.         [ Links ]31.- HANBERGER H, GARCIA-RODRIGUEZ J A, GOBERNADO    et al. Antibiotic susceptibility among aerobic Gram negative bacilli in intensive    care units in 5 european countries. JAMA 1999; 281: 67-71.         [ Links ]32.- CHARREL R N, PAGES J M, DE MICCO P et    al. Prevalence of outer membrane porin alteration in ß-lactam-antibiotic-resistant    Enterobacter aerogenes. Antimicrob Agents Chemother 1996; 40: 2854-8.          [ Links ]33.- BRADFORD P A, URBAN C, MARIANO N, PROJAN    S J, RAHAL J J, BUSH K. Imipenem resistance in Klebsiella pneumoniae is    associated with the combination of ACT-1, a plasmid-mediated Amp C ß-lactamase,    and the loss of an outer membrane protein. Antimicrob Agents Chemother 1997;    41: 563-9.         [ Links ]34.- QUEENAN A M, TORRES-VIERA C, GOLD H et    al. SME-type carbapenem-hydrolizing class A ß-lactamases from geographically    diverse Serratia marcescens strains. Antimicrob Agents Chemother 2000;    44: 3035-9.         [ Links ]35.- COHEN S P, MC MURRY L M, HOOPER D C,    WOLFSON J S, LEVY S B. Cross-resistance to fluoroquinolones in multiple-antibiotic-resistance    (Mar) Escherichia coli selected by tetracycline resistance: decreased    drug accumulation asociated with membrane changes in addition to Omp F reduction.    Antimicrob Agents Chemother 1989; 33:1318-25.         [ Links ]36.- SANDERS C C. Cefepime: The next generation?    Clin Infect Dis 1993; 17: 369-79         [ Links ]37.- GARAU J. The clinical potential of fourth-generation    cephalosporins. Diagn Microbiol Infect Dis 1998; 31: 479-80.         [ Links ]38.- CURTIS N A C, ORR D C, ROSS G W, BOULTON    M G. Affinities of penicillins and cephalosporins for the penicillin-binding    proteins of Escherichia coli    K-12 and their antibacterial activity. Antimicrob Agents Chemother 1979; 16:    533-9.  39.- BALANT L, DAYER P, AUCKENTHALER R. Clinical    pharmacokinetics of the third generation cephalosporins. Clin Pharmacokinetics    1985; 10: 101-43.         [ Links ]40.- WHEELER W J. Cephalosporins and other    beta-lactam antibiotics. Lloydia. 1977; 40: 519-42.         [ Links ]41.- LOPEZ F, GARRIDO J C. Química    y relación estructura-actividad de los antibióticos cefalosporínicos.    Rev Col Químico Farmacéutico 1989; 41: 5-14.         [ Links ]42.- FU K P, ASWAPOKEE P, HO I, MATTHIJSSEN    C, NEU H C. Pharmacokinetics of cefotaxime. Antimicrob Agents Chemother 1979;16:    592-7.         [ Links ]43.- YUK J H, NIGHTINGALE C H, QUINTILIANI    R. Clinical pharmacokinetics of ceftriaxone. Clin Pharmacokinetic 1989; 17:    223-35.         [ Links ]44.- BRYSKIER A, PROCYK T, LABRO M T. Cefodizime,    a new 2-aminothiazolyl cephalosporin: physicochemical properties, toxicology    and structure-activity relationships. J Antimicrob Chemother 1990; 26 (Suppl    C): 1-8.         [ Links ]45.- CRITCHLEY I A, BASKER M J, EDMONDSON    R A, KNOTT S J. Uptake of catecholic cephalosporin by the iron transport system    of Escherichia coli. J Antimicrob Chemother 1991; 28: 377-88.         [ Links ]46.- CRITCHLEY I A. Catecholic ß-lactams:    facilitated transport. J Antimicrob Chemother 1990; 26: 733-7.         [ Links ]47.- JONES R N, ERWIN M E. In vitro evaluation    of Ro 09-1227, a novel catechol-substituted cephalosporin. Antimicrob Agents    Chemother 1992; 36: 233-8.         [ Links ]48.- JONES R N. In vitro activity of Ro 24-6392,    a novel ester-linked co-drug combining ciprofloxacin and desacetylcefotaxime.    Eur J Clin Microbiol Infect Dis 1990; 9: 435-8.         [ Links ]49.- TOMASZ A. Penicillin-binding proteins    and the antibacterial effectiveness of ß-lactam antibiotics. Rev Infect    Dis 1986 (Suppl 3); 8: 260-78.         [ Links ]50.- HOLM S E. Interaction between ß-lactam    and other antibiotics. Rev Infect Dis 1986 (Suppl 3); 8: 305-14.         [ Links ]51.- MC CULLERS J A, ENGLISH B K, NOVAK R.    Isolation and characterization of vancomycin-tolerant Streptococcus pneumoniae    from the cerebrospinal fluid of a patient who developed recrudescet meningitis.    J Infect Dis 2000; 181: 369-73.         [ Links ]52.- NIKAIDO H. Outer membrane barrier as    a mechanism of antimicrobial resistance. Antimicrob Agents Chemother 1989; 33:    1831-6.         [ Links ]53.- BARRADELL L B, BRYSON H M. Cefepime.    A review of its antibacterial activity, pharmacokinetic properties and therapeutic    use. Drugs 1994; 47: 471-505.         [ Links ]54.- O'CALLAGHAN C H 1979. Description and    classification of the newer cephalosporins and their relationship with the established    compounds. J Antimicrob Chemother 5: 635-71         [ Links ]55.- BRYSKIER A, PROCYK T, TREMBLAY D, LENFANT    B FOURTILLAN J B. The pharmacokinetics of cefodizime following intravenous and    intramuscular administration of a single dose of 1.0 g. J Antimicrob Chemother    1990; 26 (Suppl. C): 59-63.         [ Links ]56.- WILLIAMS J D. Classification of cephalosporins.    Drugs. 1987; 34 (Suppl 2): 15-22.         [ Links ]57.- WISEMAN L R, LAMB H M. Cefpirome. A review    of its antibacterial activity, pharmacokinetic properties and efficacy in the    treatment of severe nosocomial infections and febrile neutropenia. Drugs 1997;    57: 117-40.         [ Links ]58.- PECHERE J C, WILSON W, NEU H. Laboratory    assesment of antibacterial activity of zwitterionic 7-methoxyimino cephalosporins.    J Antimicrob Chemother 1995; 36: 757-71         [ Links ]59.- GIAMARELLOS-BOURBOULIS EJ, GRECKA P,    TSITSIKA A, TYMPANIDOU C, GIAMARELLOU H. In-vitro activity of FK 037 (cefoselis),    a novel 4 (th) generation cephalosporin, cefepime and cefpirome on nosocomial    staphylococci and gram-negative isolates. Diagn Microbiol infect Dis 2000; 36:    185-91.         [ Links ]60.- JONES R N, ERWIN M E, BARRETT M S, JOHNSON    D M, BRIGGS B M. Antimicrobial activity of E-1040, a novel thiadiazolyl cephalosporin    compare with parenteral cephems. Diagn Microbiol infect Dis 1991; 14: 301-9.          [ Links ]61.- IIZAWA Y, OKONOGI K, HAYASHI R, IWAHI    T, YAMAZAKI T, IMADA A. Therapeutic effect of cefozopran (SCE-2787), a new parenteral    cephalosporin in experimental infections in mice. Antimicrob Agents Chemother    1993; 37: 100-5.         [ Links ]62.- WATANABE N A. Newer antipseudomonal cephalosporins.    J Chemother 1996; 8 (Suppl 2): 48-56.         [ Links ]63.- ACTOR P, GUARINI J, URI J et al. Disk    susceptibility studies with cefazolin and cephalotin. Antimicrob Agents Chemother    1974; 5: 63-7.         [ Links ]64.- UWAYDAH M. Cefazolin in the treatment    of acute enteric fever. Antimicrob Agents Chemother 1976; 10: 52-6.         [ Links ]65.- JAMAL W Y, ROTIMI V O, CHUGH T D, PAL    T. Prevalence and susceptibility of Shigella to 11 antibiotics in a Kuwait    teaching hospital. J Chemother 1998; 10: 285-90.         [ Links ]66.- COX CE, SHERRILL M, COCCHETT DM. Evaluation    of cefuroxime axetil, cefaclor, and cephalexin in the treatment of urinary tract    infections in adults. Curr Ther Res 1987; 42: 124-37.         [ Links ]67.- SANDERS C W, GREENBERG R N, MARIER R    L. Cefamandole and cefoxitin. Ann Intern Med 1985; 103: 70-8.          [ Links ]68.- STAPLEY E P, JACKSON M, HERNANDEZ S et    al. Cephamycins, a new family of ß-lactam antibiotics I. Production actinomycetes,    including Streptomyces lactamdurans spp.n. Antimicrob Agents Chemother    1972; 2: 122-31.         [ Links ]69.- COOPER R D G. The carbacephems a new    ß-lactams class. Am J Med 1992; 92 (Suppl 6 A): 25-65.         [ Links ]70.- ZEMELMAN R, BELLO H, DOMINGUEZ M, GONZALEZ    G, MELLA S, GARCIA A. Activity of imipenem, third-generation cephalosporins,    aztreonam, and ciprofloxacin against multi-resistant Gram negative bacilli isolated    from Chilean hospitals. J Antimicrob Chemother 1993; 32: 413-9.         [ Links ]71.- MEDEIROS A A. Evolution and dissemination    of ß-lactamases accelerated by generation of ß-lactam antibiotics.    Clin Infect Dis 1997; 24 (Suppl. 1): 19-45.         [ Links ]72.- PERRY C M, BROGDEN R N. Cefuroxime axetil:    review of its antibacterial activity, pharmacokinetic properties and therapeutic    efficacy. Drugs 1996; 52: 125-58.         [ Links ]73.- SCHAAD U B, SUTER S, GIANELLA-BORRADORI    et al. A comparison of ceftriaxone and cefuroxime for the treatment of bacterial    meningitis in children. N Engl J Med 1990; 322: 141-7.         [ Links ]74.- KLEIN N C, CUNHA B A. Cefalosporinas de    la tercera generación. Clin Med Nort Am 1995; 79: 693-707.         [ Links ]75.- KLUGMAN K P, MADHI S A. Emergence of    drug resistance impact on bacterial meningitis. Infect Dis Clin North Am 1999;    13: 637-46.         [ Links ]76.- RICHARDS D M, BROGDEN R N. Ceftazidime.    A review of its antibacterial activity, pharmacokinetic properties and therapeutic    use. Drugs 1985; 29: 105-61.         [ Links ]77.- SCHATZ B S, KARAVOKIROS K T, TAEUBEL    M A, ITOKAZU G S. Comparison of cefprozil, cefpodoxime proxetil, loracarbef,    cefixime, and ceftibuten. Ann Pharmacother 1996; 30: 258-68.         [ Links ]78.- DALMAU D, LAYRARGUES G P, FENYVES D,    WILLEMS B, TURGEON F, TURGEON P. Cefotaxime, desacetyl-cefotaxime, and bactericidal    activity in spontaneous bacterial peritonitis. J Infect Dis 1999; 180: 1597-1602.          [ Links ]79.- NIKAIDO W, LIU W, ROSENBERG E Y. Outer    membrane permeability and ß-lactamase stability of dipolar ionic cephalosporins    containing methoxyimino substituents. Antimicrob Agents Chemother 1990; 34:    337-42.         [ Links ]80.- HANCOCK R E W, BELLIDO F. Factors involved    in the enhanced efficacy against gram-negative bacteria of fourth generation    cephalosporins. J Antimicrob Chemother 1992; 29(Suppl A): 1-6.         [ Links ]81.- BELLIDO F, PECHERE J C, HANCOCK REW.    Novel method for measurement of outer membrane permeability to new beta-lactams    in intact Enterobacter cloacae cells. Antimicrob Agents Chemother 1991;    35: 68-72.         [ Links ]82.- NEU H C, CHIN N X, JULES K, LABTHAVIKUL    P. The activity of BMY-28142, a new broad spectrum beta-lactamase stable cephalosporin.    J Antimicrob Chemother 1986; 17: 441-52.         [ Links ]83.- KOBAYASHI S, ARAI S, HAYASHI S, FUJIMOTO    K. ß-lactamase stability of cefpirome (HR 810), a new cephalosporin with    a broad antimicrobial spectrum. Antimicrob Agents Chemother 1986; 30: 713-8.          [ Links ]84.- GARAU J, WILSON W, WOOD M, CARLET J.    Fourth generation cephalosporins: a review of in vitro activity, pharmacokinetics,    pharmacodynamics, and clinical utility. Clin Microb Infect 1997; 3 (Suppl 1):    87-101.         [ Links ]85.- KESSLER R E, FUNG-TOMC J. Susceptibility    of bacterial isolates to beta-lactam antibiotics from U.S. clinical trials over    5-year period. Am J Med 1996; 24 (6 A): 13-9.         [ Links ]86.- PIERARD D, EMMERECHTS K, LAUWERS S. Comparative    in-vitro activity of cefpirome against isolates from intensive care and haematology/oncology    units. Belgian Multicentric Study Group. J Antimicrob Chemother 1998; 41: 443-50.          [ Links ]87.- JONES R N. Resistance patterns among    nosocomial pathogens: trends over the past few years. Chest 2001; 119 (Suppl    2): 397-404.         [ Links ]88.- LORBER B. Changing patterns of infectious    diseases. Am J Med 1988; 84: 569-78.         [ Links ]89.- MOELLERING R C. A novel antimicrobial    agent joins the battle against resistant bacteria. Ann Intern Med 1999; 130:    155-7.         [ Links ]90.- WILSON W R. The role of fourth-generation    cephalosporins in the treatment of serious infectious diseases in hospitalized    patients. Diagn Microbiol Infect Dis 1998; 31: 473-7.         [ Links ]Correspondencia a:        Sergio Mella Montecinos        Laboratorio de Antibióticos,        Departamento de Microbiología,        Facultad de Ciencias Biológicas        Casilla 160-C, Concepción        E-mail: pignatio@ctcinternet.cl  

16.- PAYA E. Ventajas y desventajas de las    cefalosporinas orales de segunda y tercera generación. Rev Chil Infect    1997; 14: 233-8.         [ Links ]17.- AMERICAN THORACIC SOCIETY. Guidelines    for the initial management of adults with community-acquired pneumonia: diagnosis,    assessment of severity, and initial antimicrobial therapy. Am Rev Respir Dis    1993; 148: 1418-26.         [ Links ]18.- BARTLETT J G, BREIMAN R F, MANDELL L    A, FILE T M Jr. Community-acquired pneumonia in adults: guidelines for management.    The Infectious Diseases Society of America. Clin Infect Dis 1998: 26: 811-38.          [ Links ]19.- MARRIE T J. Community-acquired pneumonia:    epidemiology, etiology, treatment. Infect Dis Clin North Am 1998; 12: 723-40          [ Links ]20.- TUNKEL A R, SCHELD W M. Acute meningitis.    In: Mandell, Douglas & Bennett's. Principles and Practice of Infectious    Diseases. Mandell G L, Bennett J E, Dolin R, eds. Fifth edition. Philadelphia:    Editorial Churchill Livingstone 2000; 959-96.         [ Links ]21.- AMERICAN THORACIC SOCIETY. Hospital-acquired    pneumonia in adults: diagnosis, assessment of severity, initial antimicrobial    therapy, and preventive strategies. A consensus statement. Am J Respir Crit    Care Med 1996; 153: 1711-25.         [ Links ]22.- BARTLETT J G, DOWELL S F, MANDELL L A,    FILE T M, MUSHER D M, FINE M J. Practice guidelines for the management of community-acquired    pneumonia in adults. Clin Infect Dis. 2000; 31: 347-82         [ Links ]23.- KARCHMER A W. Cephalosporins. In: Mandell,    Douglas & Bennett's. Principles and Practice of Infectious Diseases. Mandell    G L, Bennett J E, Dolin R, eds. Fifth edition. Philadelphia: Churchill Livingstone    2000; 274-99.         [ Links ]24.- ADU A, ARMOUR C L. Drug utilisation review    (DUR) of the third generation cephalosporins. Drugs 1995; 50: 423-39.         [ Links ]25.- JONES R N. Important and emerging ß-lactamase    mediated resistances in hospital-based pathogens: the Amp C enzymes. Diagn Microbiol    Infect Dis 1998; 31: 461-6.         [ Links ]26.- JARVIS W R, MARTONE W J. Predominant    pathogens in hospital infections. J Antimicrob Chemother 1992; 29: 19-24.         [ Links ]27.- LIVERMORE D M. ß-lactamases in    laboratory and clinical resistance. Clin Microbiol Rev 1995; 8: 557-84.         [ Links ]28.- HERITAGE J, M'ZALI F H, GASCOYNE-BINZI    D, HAWKEY P M. Evolution and spread of SHV extended-spectrum ß-lactamases    in gram negative bacteria. J Antimicrob Chemother 1999; 44: 309-18.         [ Links ]29.- PODSCHUN R, ULLMAN U. Klebsiella spp.    as nosocomial pathogens: epidemiology, taxonomy, typing methods, and pathogenicity    factors. Clin Microbiol Rev 1998; 11: 589-603.         [ Links ]30.- PITOUT J D D, SANDERS C C, SANDERS W    E. Antimicrobial resistance with focus on ß-lactam resistance in Gram    negative bacilli. Am J Med 1997; 103: 51-9.         [ Links ]31.- HANBERGER H, GARCIA-RODRIGUEZ J A, GOBERNADO    et al. Antibiotic susceptibility among aerobic Gram negative bacilli in intensive    care units in 5 european countries. JAMA 1999; 281: 67-71.         [ Links ]32.- CHARREL R N, PAGES J M, DE MICCO P et    al. Prevalence of outer membrane porin alteration in ß-lactam-antibiotic-resistant    Enterobacter aerogenes. Antimicrob Agents Chemother 1996; 40: 2854-8.          [ Links ]33.- BRADFORD P A, URBAN C, MARIANO N, PROJAN    S J, RAHAL J J, BUSH K. Imipenem resistance in Klebsiella pneumoniae is    associated with the combination of ACT-1, a plasmid-mediated Amp C ß-lactamase,    and the loss of an outer membrane protein. Antimicrob Agents Chemother 1997;    41: 563-9.         [ Links ]34.- QUEENAN A M, TORRES-VIERA C, GOLD H et    al. SME-type carbapenem-hydrolizing class A ß-lactamases from geographically    diverse Serratia marcescens strains. Antimicrob Agents Chemother 2000;    44: 3035-9.         [ Links ]35.- COHEN S P, MC MURRY L M, HOOPER D C,    WOLFSON J S, LEVY S B. Cross-resistance to fluoroquinolones in multiple-antibiotic-resistance    (Mar) Escherichia coli selected by tetracycline resistance: decreased    drug accumulation asociated with membrane changes in addition to Omp F reduction.    Antimicrob Agents Chemother 1989; 33:1318-25.         [ Links ]36.- SANDERS C C. Cefepime: The next generation?    Clin Infect Dis 1993; 17: 369-79         [ Links ]37.- GARAU J. The clinical potential of fourth-generation    cephalosporins. Diagn Microbiol Infect Dis 1998; 31: 479-80.         [ Links ]38.- CURTIS N A C, ORR D C, ROSS G W, BOULTON    M G. Affinities of penicillins and cephalosporins for the penicillin-binding    proteins of Escherichia coli    K-12 and their antibacterial activity. Antimicrob Agents Chemother 1979; 16:    533-9.  39.- BALANT L, DAYER P, AUCKENTHALER R. Clinical    pharmacokinetics of the third generation cephalosporins. Clin Pharmacokinetics    1985; 10: 101-43.         [ Links ]40.- WHEELER W J. Cephalosporins and other    beta-lactam antibiotics. Lloydia. 1977; 40: 519-42.         [ Links ]41.- LOPEZ F, GARRIDO J C. Química    y relación estructura-actividad de los antibióticos cefalosporínicos.    Rev Col Químico Farmacéutico 1989; 41: 5-14.         [ Links ]42.- FU K P, ASWAPOKEE P, HO I, MATTHIJSSEN    C, NEU H C. Pharmacokinetics of cefotaxime. Antimicrob Agents Chemother 1979;16:    592-7.         [ Links ]43.- YUK J H, NIGHTINGALE C H, QUINTILIANI    R. Clinical pharmacokinetics of ceftriaxone. Clin Pharmacokinetic 1989; 17:    223-35.         [ Links ]44.- BRYSKIER A, PROCYK T, LABRO M T. Cefodizime,    a new 2-aminothiazolyl cephalosporin: physicochemical properties, toxicology    and structure-activity relationships. J Antimicrob Chemother 1990; 26 (Suppl    C): 1-8.         [ Links ]45.- CRITCHLEY I A, BASKER M J, EDMONDSON    R A, KNOTT S J. Uptake of catecholic cephalosporin by the iron transport system    of Escherichia coli. J Antimicrob Chemother 1991; 28: 377-88.         [ Links ]46.- CRITCHLEY I A. Catecholic ß-lactams:    facilitated transport. J Antimicrob Chemother 1990; 26: 733-7.         [ Links ]47.- JONES R N, ERWIN M E. In vitro evaluation    of Ro 09-1227, a novel catechol-substituted cephalosporin. Antimicrob Agents    Chemother 1992; 36: 233-8.         [ Links ]48.- JONES R N. In vitro activity of Ro 24-6392,    a novel ester-linked co-drug combining ciprofloxacin and desacetylcefotaxime.    Eur J Clin Microbiol Infect Dis 1990; 9: 435-8.         [ Links ]49.- TOMASZ A. Penicillin-binding proteins    and the antibacterial effectiveness of ß-lactam antibiotics. Rev Infect    Dis 1986 (Suppl 3); 8: 260-78.         [ Links ]50.- HOLM S E. Interaction between ß-lactam    and other antibiotics. Rev Infect Dis 1986 (Suppl 3); 8: 305-14.         [ Links ]51.- MC CULLERS J A, ENGLISH B K, NOVAK R.    Isolation and characterization of vancomycin-tolerant Streptococcus pneumoniae    from the cerebrospinal fluid of a patient who developed recrudescet meningitis.    J Infect Dis 2000; 181: 369-73.         [ Links ]52.- NIKAIDO H. Outer membrane barrier as    a mechanism of antimicrobial resistance. Antimicrob Agents Chemother 1989; 33:    1831-6.         [ Links ]53.- BARRADELL L B, BRYSON H M. Cefepime.    A review of its antibacterial activity, pharmacokinetic properties and therapeutic    use. Drugs 1994; 47: 471-505.         [ Links ]54.- O'CALLAGHAN C H 1979. Description and    classification of the newer cephalosporins and their relationship with the established    compounds. J Antimicrob Chemother 5: 635-71         [ Links ]55.- BRYSKIER A, PROCYK T, TREMBLAY D, LENFANT    B FOURTILLAN J B. The pharmacokinetics of cefodizime following intravenous and    intramuscular administration of a single dose of 1.0 g. J Antimicrob Chemother    1990; 26 (Suppl. C): 59-63.         [ Links ]56.- WILLIAMS J D. Classification of cephalosporins.    Drugs. 1987; 34 (Suppl 2): 15-22.         [ Links ]57.- WISEMAN L R, LAMB H M. Cefpirome. A review    of its antibacterial activity, pharmacokinetic properties and efficacy in the    treatment of severe nosocomial infections and febrile neutropenia. Drugs 1997;    57: 117-40.         [ Links ]58.- PECHERE J C, WILSON W, NEU H. Laboratory    assesment of antibacterial activity of zwitterionic 7-methoxyimino cephalosporins.    J Antimicrob Chemother 1995; 36: 757-71         [ Links ]59.- GIAMARELLOS-BOURBOULIS EJ, GRECKA P,    TSITSIKA A, TYMPANIDOU C, GIAMARELLOU H. In-vitro activity of FK 037 (cefoselis),    a novel 4 (th) generation cephalosporin, cefepime and cefpirome on nosocomial    staphylococci and gram-negative isolates. Diagn Microbiol infect Dis 2000; 36:    185-91.         [ Links ]60.- JONES R N, ERWIN M E, BARRETT M S, JOHNSON    D M, BRIGGS B M. Antimicrobial activity of E-1040, a novel thiadiazolyl cephalosporin    compare with parenteral cephems. Diagn Microbiol infect Dis 1991; 14: 301-9.          [ Links ]61.- IIZAWA Y, OKONOGI K, HAYASHI R, IWAHI    T, YAMAZAKI T, IMADA A. Therapeutic effect of cefozopran (SCE-2787), a new parenteral    cephalosporin in experimental infections in mice. Antimicrob Agents Chemother    1993; 37: 100-5.         [ Links ]62.- WATANABE N A. Newer antipseudomonal cephalosporins.    J Chemother 1996; 8 (Suppl 2): 48-56.         [ Links ]63.- ACTOR P, GUARINI J, URI J et al. Disk    susceptibility studies with cefazolin and cephalotin. Antimicrob Agents Chemother    1974; 5: 63-7.         [ Links ]64.- UWAYDAH M. Cefazolin in the treatment    of acute enteric fever. Antimicrob Agents Chemother 1976; 10: 52-6.         [ Links ]65.- JAMAL W Y, ROTIMI V O, CHUGH T D, PAL    T. Prevalence and susceptibility of Shigella to 11 antibiotics in a Kuwait    teaching hospital. J Chemother 1998; 10: 285-90.         [ Links ]66.- COX CE, SHERRILL M, COCCHETT DM. Evaluation    of cefuroxime axetil, cefaclor, and cephalexin in the treatment of urinary tract    infections in adults. Curr Ther Res 1987; 42: 124-37.         [ Links ]67.- SANDERS C W, GREENBERG R N, MARIER R    L. Cefamandole and cefoxitin. Ann Intern Med 1985; 103: 70-8.          [ Links ]68.- STAPLEY E P, JACKSON M, HERNANDEZ S et    al. Cephamycins, a new family of ß-lactam antibiotics I. Production actinomycetes,    including Streptomyces lactamdurans spp.n. Antimicrob Agents Chemother    1972; 2: 122-31.         [ Links ]69.- COOPER R D G. The carbacephems a new    ß-lactams class. Am J Med 1992; 92 (Suppl 6 A): 25-65.         [ Links ]70.- ZEMELMAN R, BELLO H, DOMINGUEZ M, GONZALEZ    G, MELLA S, GARCIA A. Activity of imipenem, third-generation cephalosporins,    aztreonam, and ciprofloxacin against multi-resistant Gram negative bacilli isolated    from Chilean hospitals. J Antimicrob Chemother 1993; 32: 413-9.         [ Links ]71.- MEDEIROS A A. Evolution and dissemination    of ß-lactamases accelerated by generation of ß-lactam antibiotics.    Clin Infect Dis 1997; 24 (Suppl. 1): 19-45.         [ Links ]72.- PERRY C M, BROGDEN R N. Cefuroxime axetil:    review of its antibacterial activity, pharmacokinetic properties and therapeutic    efficacy. Drugs 1996; 52: 125-58.         [ Links ]73.- SCHAAD U B, SUTER S, GIANELLA-BORRADORI    et al. A comparison of ceftriaxone and cefuroxime for the treatment of bacterial    meningitis in children. N Engl J Med 1990; 322: 141-7.         [ Links ]74.- KLEIN N C, CUNHA B A. Cefalosporinas de    la tercera generación. Clin Med Nort Am 1995; 79: 693-707.         [ Links ]75.- KLUGMAN K P, MADHI S A. Emergence of    drug resistance impact on bacterial meningitis. Infect Dis Clin North Am 1999;    13: 637-46.         [ Links ]76.- RICHARDS D M, BROGDEN R N. Ceftazidime.    A review of its antibacterial activity, pharmacokinetic properties and therapeutic    use. Drugs 1985; 29: 105-61.         [ Links ]77.- SCHATZ B S, KARAVOKIROS K T, TAEUBEL    M A, ITOKAZU G S. Comparison of cefprozil, cefpodoxime proxetil, loracarbef,    cefixime, and ceftibuten. Ann Pharmacother 1996; 30: 258-68.         [ Links ]78.- DALMAU D, LAYRARGUES G P, FENYVES D,    WILLEMS B, TURGEON F, TURGEON P. Cefotaxime, desacetyl-cefotaxime, and bactericidal    activity in spontaneous bacterial peritonitis. J Infect Dis 1999; 180: 1597-1602.          [ Links ]79.- NIKAIDO W, LIU W, ROSENBERG E Y. Outer    membrane permeability and ß-lactamase stability of dipolar ionic cephalosporins    containing methoxyimino substituents. Antimicrob Agents Chemother 1990; 34:    337-42.         [ Links ]80.- HANCOCK R E W, BELLIDO F. Factors involved    in the enhanced efficacy against gram-negative bacteria of fourth generation    cephalosporins. J Antimicrob Chemother 1992; 29(Suppl A): 1-6.         [ Links ]81.- BELLIDO F, PECHERE J C, HANCOCK REW.    Novel method for measurement of outer membrane permeability to new beta-lactams    in intact Enterobacter cloacae cells. Antimicrob Agents Chemother 1991;    35: 68-72.         [ Links ]82.- NEU H C, CHIN N X, JULES K, LABTHAVIKUL    P. The activity of BMY-28142, a new broad spectrum beta-lactamase stable cephalosporin.    J Antimicrob Chemother 1986; 17: 441-52.         [ Links ]83.- KOBAYASHI S, ARAI S, HAYASHI S, FUJIMOTO    K. ß-lactamase stability of cefpirome (HR 810), a new cephalosporin with    a broad antimicrobial spectrum. Antimicrob Agents Chemother 1986; 30: 713-8.          [ Links ]84.- GARAU J, WILSON W, WOOD M, CARLET J.    Fourth generation cephalosporins: a review of in vitro activity, pharmacokinetics,    pharmacodynamics, and clinical utility. Clin Microb Infect 1997; 3 (Suppl 1):    87-101.         [ Links ]85.- KESSLER R E, FUNG-TOMC J. Susceptibility    of bacterial isolates to beta-lactam antibiotics from U.S. clinical trials over    5-year period. Am J Med 1996; 24 (6 A): 13-9.         [ Links ]86.- PIERARD D, EMMERECHTS K, LAUWERS S. Comparative    in-vitro activity of cefpirome against isolates from intensive care and haematology/oncology    units. Belgian Multicentric Study Group. J Antimicrob Chemother 1998; 41: 443-50.          [ Links ]87.- JONES R N. Resistance patterns among    nosocomial pathogens: trends over the past few years. Chest 2001; 119 (Suppl    2): 397-404.         [ Links ]88.- LORBER B. Changing patterns of infectious    diseases. Am J Med 1988; 84: 569-78.         [ Links ]89.- MOELLERING R C. A novel antimicrobial    agent joins the battle against resistant bacteria. Ann Intern Med 1999; 130:    155-7.         [ Links ]90.- WILSON W R. The role of fourth-generation    cephalosporins in the treatment of serious infectious diseases in hospitalized    patients. Diagn Microbiol Infect Dis 1998; 31: 473-7.         [ Links ]Correspondencia a:        Sergio Mella Montecinos        Laboratorio de Antibióticos,        Departamento de Microbiología,        Facultad de Ciencias Biológicas        Casilla 160-C, Concepción        E-mail: pignatio@ctcinternet.cl  

17.- AMERICAN THORACIC SOCIETY. Guidelines    for the initial management of adults with community-acquired pneumonia: diagnosis,    assessment of severity, and initial antimicrobial therapy. Am Rev Respir Dis    1993; 148: 1418-26.         [ Links ]18.- BARTLETT J G, BREIMAN R F, MANDELL L    A, FILE T M Jr. Community-acquired pneumonia in adults: guidelines for management.    The Infectious Diseases Society of America. Clin Infect Dis 1998: 26: 811-38.          [ Links ]19.- MARRIE T J. Community-acquired pneumonia:    epidemiology, etiology, treatment. Infect Dis Clin North Am 1998; 12: 723-40          [ Links ]20.- TUNKEL A R, SCHELD W M. Acute meningitis.    In: Mandell, Douglas & Bennett's. Principles and Practice of Infectious    Diseases. Mandell G L, Bennett J E, Dolin R, eds. Fifth edition. Philadelphia:    Editorial Churchill Livingstone 2000; 959-96.         [ Links ]21.- AMERICAN THORACIC SOCIETY. Hospital-acquired    pneumonia in adults: diagnosis, assessment of severity, initial antimicrobial    therapy, and preventive strategies. A consensus statement. Am J Respir Crit    Care Med 1996; 153: 1711-25.         [ Links ]22.- BARTLETT J G, DOWELL S F, MANDELL L A,    FILE T M, MUSHER D M, FINE M J. Practice guidelines for the management of community-acquired    pneumonia in adults. Clin Infect Dis. 2000; 31: 347-82         [ Links ]23.- KARCHMER A W. Cephalosporins. In: Mandell,    Douglas & Bennett's. Principles and Practice of Infectious Diseases. Mandell    G L, Bennett J E, Dolin R, eds. Fifth edition. Philadelphia: Churchill Livingstone    2000; 274-99.         [ Links ]24.- ADU A, ARMOUR C L. Drug utilisation review    (DUR) of the third generation cephalosporins. Drugs 1995; 50: 423-39.         [ Links ]25.- JONES R N. Important and emerging ß-lactamase    mediated resistances in hospital-based pathogens: the Amp C enzymes. Diagn Microbiol    Infect Dis 1998; 31: 461-6.         [ Links ]26.- JARVIS W R, MARTONE W J. Predominant    pathogens in hospital infections. J Antimicrob Chemother 1992; 29: 19-24.         [ Links ]27.- LIVERMORE D M. ß-lactamases in    laboratory and clinical resistance. Clin Microbiol Rev 1995; 8: 557-84.         [ Links ]28.- HERITAGE J, M'ZALI F H, GASCOYNE-BINZI    D, HAWKEY P M. Evolution and spread of SHV extended-spectrum ß-lactamases    in gram negative bacteria. J Antimicrob Chemother 1999; 44: 309-18.         [ Links ]29.- PODSCHUN R, ULLMAN U. Klebsiella spp.    as nosocomial pathogens: epidemiology, taxonomy, typing methods, and pathogenicity    factors. Clin Microbiol Rev 1998; 11: 589-603.         [ Links ]30.- PITOUT J D D, SANDERS C C, SANDERS W    E. Antimicrobial resistance with focus on ß-lactam resistance in Gram    negative bacilli. Am J Med 1997; 103: 51-9.         [ Links ]31.- HANBERGER H, GARCIA-RODRIGUEZ J A, GOBERNADO    et al. Antibiotic susceptibility among aerobic Gram negative bacilli in intensive    care units in 5 european countries. JAMA 1999; 281: 67-71.         [ Links ]32.- CHARREL R N, PAGES J M, DE MICCO P et    al. Prevalence of outer membrane porin alteration in ß-lactam-antibiotic-resistant    Enterobacter aerogenes. Antimicrob Agents Chemother 1996; 40: 2854-8.          [ Links ]33.- BRADFORD P A, URBAN C, MARIANO N, PROJAN    S J, RAHAL J J, BUSH K. Imipenem resistance in Klebsiella pneumoniae is    associated with the combination of ACT-1, a plasmid-mediated Amp C ß-lactamase,    and the loss of an outer membrane protein. Antimicrob Agents Chemother 1997;    41: 563-9.         [ Links ]34.- QUEENAN A M, TORRES-VIERA C, GOLD H et    al. SME-type carbapenem-hydrolizing class A ß-lactamases from geographically    diverse Serratia marcescens strains. Antimicrob Agents Chemother 2000;    44: 3035-9.         [ Links ]35.- COHEN S P, MC MURRY L M, HOOPER D C,    WOLFSON J S, LEVY S B. Cross-resistance to fluoroquinolones in multiple-antibiotic-resistance    (Mar) Escherichia coli selected by tetracycline resistance: decreased    drug accumulation asociated with membrane changes in addition to Omp F reduction.    Antimicrob Agents Chemother 1989; 33:1318-25.         [ Links ]36.- SANDERS C C. Cefepime: The next generation?    Clin Infect Dis 1993; 17: 369-79         [ Links ]37.- GARAU J. The clinical potential of fourth-generation    cephalosporins. Diagn Microbiol Infect Dis 1998; 31: 479-80.         [ Links ]38.- CURTIS N A C, ORR D C, ROSS G W, BOULTON    M G. Affinities of penicillins and cephalosporins for the penicillin-binding    proteins of Escherichia coli    K-12 and their antibacterial activity. Antimicrob Agents Chemother 1979; 16:    533-9.  39.- BALANT L, DAYER P, AUCKENTHALER R. Clinical    pharmacokinetics of the third generation cephalosporins. Clin Pharmacokinetics    1985; 10: 101-43.         [ Links ]40.- WHEELER W J. Cephalosporins and other    beta-lactam antibiotics. Lloydia. 1977; 40: 519-42.         [ Links ]41.- LOPEZ F, GARRIDO J C. Química    y relación estructura-actividad de los antibióticos cefalosporínicos.    Rev Col Químico Farmacéutico 1989; 41: 5-14.         [ Links ]42.- FU K P, ASWAPOKEE P, HO I, MATTHIJSSEN    C, NEU H C. Pharmacokinetics of cefotaxime. Antimicrob Agents Chemother 1979;16:    592-7.         [ Links ]43.- YUK J H, NIGHTINGALE C H, QUINTILIANI    R. Clinical pharmacokinetics of ceftriaxone. Clin Pharmacokinetic 1989; 17:    223-35.         [ Links ]44.- BRYSKIER A, PROCYK T, LABRO M T. Cefodizime,    a new 2-aminothiazolyl cephalosporin: physicochemical properties, toxicology    and structure-activity relationships. J Antimicrob Chemother 1990; 26 (Suppl    C): 1-8.         [ Links ]45.- CRITCHLEY I A, BASKER M J, EDMONDSON    R A, KNOTT S J. Uptake of catecholic cephalosporin by the iron transport system    of Escherichia coli. J Antimicrob Chemother 1991; 28: 377-88.         [ Links ]46.- CRITCHLEY I A. Catecholic ß-lactams:    facilitated transport. J Antimicrob Chemother 1990; 26: 733-7.         [ Links ]47.- JONES R N, ERWIN M E. In vitro evaluation    of Ro 09-1227, a novel catechol-substituted cephalosporin. Antimicrob Agents    Chemother 1992; 36: 233-8.         [ Links ]48.- JONES R N. In vitro activity of Ro 24-6392,    a novel ester-linked co-drug combining ciprofloxacin and desacetylcefotaxime.    Eur J Clin Microbiol Infect Dis 1990; 9: 435-8.         [ Links ]49.- TOMASZ A. Penicillin-binding proteins    and the antibacterial effectiveness of ß-lactam antibiotics. Rev Infect    Dis 1986 (Suppl 3); 8: 260-78.         [ Links ]50.- HOLM S E. Interaction between ß-lactam    and other antibiotics. Rev Infect Dis 1986 (Suppl 3); 8: 305-14.         [ Links ]51.- MC CULLERS J A, ENGLISH B K, NOVAK R.    Isolation and characterization of vancomycin-tolerant Streptococcus pneumoniae    from the cerebrospinal fluid of a patient who developed recrudescet meningitis.    J Infect Dis 2000; 181: 369-73.         [ Links ]52.- NIKAIDO H. Outer membrane barrier as    a mechanism of antimicrobial resistance. Antimicrob Agents Chemother 1989; 33:    1831-6.         [ Links ]53.- BARRADELL L B, BRYSON H M. Cefepime.    A review of its antibacterial activity, pharmacokinetic properties and therapeutic    use. Drugs 1994; 47: 471-505.         [ Links ]54.- O'CALLAGHAN C H 1979. Description and    classification of the newer cephalosporins and their relationship with the established    compounds. J Antimicrob Chemother 5: 635-71         [ Links ]55.- BRYSKIER A, PROCYK T, TREMBLAY D, LENFANT    B FOURTILLAN J B. The pharmacokinetics of cefodizime following intravenous and    intramuscular administration of a single dose of 1.0 g. J Antimicrob Chemother    1990; 26 (Suppl. C): 59-63.         [ Links ]56.- WILLIAMS J D. Classification of cephalosporins.    Drugs. 1987; 34 (Suppl 2): 15-22.         [ Links ]57.- WISEMAN L R, LAMB H M. Cefpirome. A review    of its antibacterial activity, pharmacokinetic properties and efficacy in the    treatment of severe nosocomial infections and febrile neutropenia. Drugs 1997;    57: 117-40.         [ Links ]58.- PECHERE J C, WILSON W, NEU H. Laboratory    assesment of antibacterial activity of zwitterionic 7-methoxyimino cephalosporins.    J Antimicrob Chemother 1995; 36: 757-71         [ Links ]59.- GIAMARELLOS-BOURBOULIS EJ, GRECKA P,    TSITSIKA A, TYMPANIDOU C, GIAMARELLOU H. In-vitro activity of FK 037 (cefoselis),    a novel 4 (th) generation cephalosporin, cefepime and cefpirome on nosocomial    staphylococci and gram-negative isolates. Diagn Microbiol infect Dis 2000; 36:    185-91.         [ Links ]60.- JONES R N, ERWIN M E, BARRETT M S, JOHNSON    D M, BRIGGS B M. Antimicrobial activity of E-1040, a novel thiadiazolyl cephalosporin    compare with parenteral cephems. Diagn Microbiol infect Dis 1991; 14: 301-9.          [ Links ]61.- IIZAWA Y, OKONOGI K, HAYASHI R, IWAHI    T, YAMAZAKI T, IMADA A. Therapeutic effect of cefozopran (SCE-2787), a new parenteral    cephalosporin in experimental infections in mice. Antimicrob Agents Chemother    1993; 37: 100-5.         [ Links ]62.- WATANABE N A. Newer antipseudomonal cephalosporins.    J Chemother 1996; 8 (Suppl 2): 48-56.         [ Links ]63.- ACTOR P, GUARINI J, URI J et al. Disk    susceptibility studies with cefazolin and cephalotin. Antimicrob Agents Chemother    1974; 5: 63-7.         [ Links ]64.- UWAYDAH M. Cefazolin in the treatment    of acute enteric fever. Antimicrob Agents Chemother 1976; 10: 52-6.         [ Links ]65.- JAMAL W Y, ROTIMI V O, CHUGH T D, PAL    T. Prevalence and susceptibility of Shigella to 11 antibiotics in a Kuwait    teaching hospital. J Chemother 1998; 10: 285-90.         [ Links ]66.- COX CE, SHERRILL M, COCCHETT DM. Evaluation    of cefuroxime axetil, cefaclor, and cephalexin in the treatment of urinary tract    infections in adults. Curr Ther Res 1987; 42: 124-37.         [ Links ]67.- SANDERS C W, GREENBERG R N, MARIER R    L. Cefamandole and cefoxitin. Ann Intern Med 1985; 103: 70-8.          [ Links ]68.- STAPLEY E P, JACKSON M, HERNANDEZ S et    al. Cephamycins, a new family of ß-lactam antibiotics I. Production actinomycetes,    including Streptomyces lactamdurans spp.n. Antimicrob Agents Chemother    1972; 2: 122-31.         [ Links ]69.- COOPER R D G. The carbacephems a new    ß-lactams class. Am J Med 1992; 92 (Suppl 6 A): 25-65.         [ Links ]70.- ZEMELMAN R, BELLO H, DOMINGUEZ M, GONZALEZ    G, MELLA S, GARCIA A. Activity of imipenem, third-generation cephalosporins,    aztreonam, and ciprofloxacin against multi-resistant Gram negative bacilli isolated    from Chilean hospitals. J Antimicrob Chemother 1993; 32: 413-9.         [ Links ]71.- MEDEIROS A A. Evolution and dissemination    of ß-lactamases accelerated by generation of ß-lactam antibiotics.    Clin Infect Dis 1997; 24 (Suppl. 1): 19-45.         [ Links ]72.- PERRY C M, BROGDEN R N. Cefuroxime axetil:    review of its antibacterial activity, pharmacokinetic properties and therapeutic    efficacy. Drugs 1996; 52: 125-58.         [ Links ]73.- SCHAAD U B, SUTER S, GIANELLA-BORRADORI    et al. A comparison of ceftriaxone and cefuroxime for the treatment of bacterial    meningitis in children. N Engl J Med 1990; 322: 141-7.         [ Links ]74.- KLEIN N C, CUNHA B A. Cefalosporinas de    la tercera generación. Clin Med Nort Am 1995; 79: 693-707.         [ Links ]75.- KLUGMAN K P, MADHI S A. Emergence of    drug resistance impact on bacterial meningitis. Infect Dis Clin North Am 1999;    13: 637-46.         [ Links ]76.- RICHARDS D M, BROGDEN R N. Ceftazidime.    A review of its antibacterial activity, pharmacokinetic properties and therapeutic    use. Drugs 1985; 29: 105-61.         [ Links ]77.- SCHATZ B S, KARAVOKIROS K T, TAEUBEL    M A, ITOKAZU G S. Comparison of cefprozil, cefpodoxime proxetil, loracarbef,    cefixime, and ceftibuten. Ann Pharmacother 1996; 30: 258-68.         [ Links ]78.- DALMAU D, LAYRARGUES G P, FENYVES D,    WILLEMS B, TURGEON F, TURGEON P. Cefotaxime, desacetyl-cefotaxime, and bactericidal    activity in spontaneous bacterial peritonitis. J Infect Dis 1999; 180: 1597-1602.          [ Links ]79.- NIKAIDO W, LIU W, ROSENBERG E Y. Outer    membrane permeability and ß-lactamase stability of dipolar ionic cephalosporins    containing methoxyimino substituents. Antimicrob Agents Chemother 1990; 34:    337-42.         [ Links ]80.- HANCOCK R E W, BELLIDO F. Factors involved    in the enhanced efficacy against gram-negative bacteria of fourth generation    cephalosporins. J Antimicrob Chemother 1992; 29(Suppl A): 1-6.         [ Links ]81.- BELLIDO F, PECHERE J C, HANCOCK REW.    Novel method for measurement of outer membrane permeability to new beta-lactams    in intact Enterobacter cloacae cells. Antimicrob Agents Chemother 1991;    35: 68-72.         [ Links ]82.- NEU H C, CHIN N X, JULES K, LABTHAVIKUL    P. The activity of BMY-28142, a new broad spectrum beta-lactamase stable cephalosporin.    J Antimicrob Chemother 1986; 17: 441-52.         [ Links ]83.- KOBAYASHI S, ARAI S, HAYASHI S, FUJIMOTO    K. ß-lactamase stability of cefpirome (HR 810), a new cephalosporin with    a broad antimicrobial spectrum. Antimicrob Agents Chemother 1986; 30: 713-8.          [ Links ]84.- GARAU J, WILSON W, WOOD M, CARLET J.    Fourth generation cephalosporins: a review of in vitro activity, pharmacokinetics,    pharmacodynamics, and clinical utility. Clin Microb Infect 1997; 3 (Suppl 1):    87-101.         [ Links ]85.- KESSLER R E, FUNG-TOMC J. Susceptibility    of bacterial isolates to beta-lactam antibiotics from U.S. clinical trials over    5-year period. Am J Med 1996; 24 (6 A): 13-9.         [ Links ]86.- PIERARD D, EMMERECHTS K, LAUWERS S. Comparative    in-vitro activity of cefpirome against isolates from intensive care and haematology/oncology    units. Belgian Multicentric Study Group. J Antimicrob Chemother 1998; 41: 443-50.          [ Links ]87.- JONES R N. Resistance patterns among    nosocomial pathogens: trends over the past few years. Chest 2001; 119 (Suppl    2): 397-404.         [ Links ]88.- LORBER B. Changing patterns of infectious    diseases. Am J Med 1988; 84: 569-78.         [ Links ]89.- MOELLERING R C. A novel antimicrobial    agent joins the battle against resistant bacteria. Ann Intern Med 1999; 130:    155-7.         [ Links ]90.- WILSON W R. The role of fourth-generation    cephalosporins in the treatment of serious infectious diseases in hospitalized    patients. Diagn Microbiol Infect Dis 1998; 31: 473-7.         [ Links ]Correspondencia a:        Sergio Mella Montecinos        Laboratorio de Antibióticos,        Departamento de Microbiología,        Facultad de Ciencias Biológicas        Casilla 160-C, Concepción        E-mail: pignatio@ctcinternet.cl  

18.- BARTLETT J G, BREIMAN R F, MANDELL L    A, FILE T M Jr. Community-acquired pneumonia in adults: guidelines for management.    The Infectious Diseases Society of America. Clin Infect Dis 1998: 26: 811-38.          [ Links ]19.- MARRIE T J. Community-acquired pneumonia:    epidemiology, etiology, treatment. Infect Dis Clin North Am 1998; 12: 723-40          [ Links ]20.- TUNKEL A R, SCHELD W M. Acute meningitis.    In: Mandell, Douglas & Bennett's. Principles and Practice of Infectious    Diseases. Mandell G L, Bennett J E, Dolin R, eds. Fifth edition. Philadelphia:    Editorial Churchill Livingstone 2000; 959-96.         [ Links ]21.- AMERICAN THORACIC SOCIETY. Hospital-acquired    pneumonia in adults: diagnosis, assessment of severity, initial antimicrobial    therapy, and preventive strategies. A consensus statement. Am J Respir Crit    Care Med 1996; 153: 1711-25.         [ Links ]22.- BARTLETT J G, DOWELL S F, MANDELL L A,    FILE T M, MUSHER D M, FINE M J. Practice guidelines for the management of community-acquired    pneumonia in adults. Clin Infect Dis. 2000; 31: 347-82         [ Links ]23.- KARCHMER A W. Cephalosporins. In: Mandell,    Douglas & Bennett's. Principles and Practice of Infectious Diseases. Mandell    G L, Bennett J E, Dolin R, eds. Fifth edition. Philadelphia: Churchill Livingstone    2000; 274-99.         [ Links ]24.- ADU A, ARMOUR C L. Drug utilisation review    (DUR) of the third generation cephalosporins. Drugs 1995; 50: 423-39.         [ Links ]25.- JONES R N. Important and emerging ß-lactamase    mediated resistances in hospital-based pathogens: the Amp C enzymes. Diagn Microbiol    Infect Dis 1998; 31: 461-6.         [ Links ]26.- JARVIS W R, MARTONE W J. Predominant    pathogens in hospital infections. J Antimicrob Chemother 1992; 29: 19-24.         [ Links ]27.- LIVERMORE D M. ß-lactamases in    laboratory and clinical resistance. Clin Microbiol Rev 1995; 8: 557-84.         [ Links ]28.- HERITAGE J, M'ZALI F H, GASCOYNE-BINZI    D, HAWKEY P M. Evolution and spread of SHV extended-spectrum ß-lactamases    in gram negative bacteria. J Antimicrob Chemother 1999; 44: 309-18.         [ Links ]29.- PODSCHUN R, ULLMAN U. Klebsiella spp.    as nosocomial pathogens: epidemiology, taxonomy, typing methods, and pathogenicity    factors. Clin Microbiol Rev 1998; 11: 589-603.         [ Links ]30.- PITOUT J D D, SANDERS C C, SANDERS W    E. Antimicrobial resistance with focus on ß-lactam resistance in Gram    negative bacilli. Am J Med 1997; 103: 51-9.         [ Links ]31.- HANBERGER H, GARCIA-RODRIGUEZ J A, GOBERNADO    et al. Antibiotic susceptibility among aerobic Gram negative bacilli in intensive    care units in 5 european countries. JAMA 1999; 281: 67-71.         [ Links ]32.- CHARREL R N, PAGES J M, DE MICCO P et    al. Prevalence of outer membrane porin alteration in ß-lactam-antibiotic-resistant    Enterobacter aerogenes. Antimicrob Agents Chemother 1996; 40: 2854-8.          [ Links ]33.- BRADFORD P A, URBAN C, MARIANO N, PROJAN    S J, RAHAL J J, BUSH K. Imipenem resistance in Klebsiella pneumoniae is    associated with the combination of ACT-1, a plasmid-mediated Amp C ß-lactamase,    and the loss of an outer membrane protein. Antimicrob Agents Chemother 1997;    41: 563-9.         [ Links ]34.- QUEENAN A M, TORRES-VIERA C, GOLD H et    al. SME-type carbapenem-hydrolizing class A ß-lactamases from geographically    diverse Serratia marcescens strains. Antimicrob Agents Chemother 2000;    44: 3035-9.         [ Links ]35.- COHEN S P, MC MURRY L M, HOOPER D C,    WOLFSON J S, LEVY S B. Cross-resistance to fluoroquinolones in multiple-antibiotic-resistance    (Mar) Escherichia coli selected by tetracycline resistance: decreased    drug accumulation asociated with membrane changes in addition to Omp F reduction.    Antimicrob Agents Chemother 1989; 33:1318-25.         [ Links ]36.- SANDERS C C. Cefepime: The next generation?    Clin Infect Dis 1993; 17: 369-79         [ Links ]37.- GARAU J. The clinical potential of fourth-generation    cephalosporins. Diagn Microbiol Infect Dis 1998; 31: 479-80.         [ Links ]38.- CURTIS N A C, ORR D C, ROSS G W, BOULTON    M G. Affinities of penicillins and cephalosporins for the penicillin-binding    proteins of Escherichia coli    K-12 and their antibacterial activity. Antimicrob Agents Chemother 1979; 16:    533-9.  39.- BALANT L, DAYER P, AUCKENTHALER R. Clinical    pharmacokinetics of the third generation cephalosporins. Clin Pharmacokinetics    1985; 10: 101-43.         [ Links ]40.- WHEELER W J. Cephalosporins and other    beta-lactam antibiotics. Lloydia. 1977; 40: 519-42.         [ Links ]41.- LOPEZ F, GARRIDO J C. Química    y relación estructura-actividad de los antibióticos cefalosporínicos.    Rev Col Químico Farmacéutico 1989; 41: 5-14.         [ Links ]42.- FU K P, ASWAPOKEE P, HO I, MATTHIJSSEN    C, NEU H C. Pharmacokinetics of cefotaxime. Antimicrob Agents Chemother 1979;16:    592-7.         [ Links ]43.- YUK J H, NIGHTINGALE C H, QUINTILIANI    R. Clinical pharmacokinetics of ceftriaxone. Clin Pharmacokinetic 1989; 17:    223-35.         [ Links ]44.- BRYSKIER A, PROCYK T, LABRO M T. Cefodizime,    a new 2-aminothiazolyl cephalosporin: physicochemical properties, toxicology    and structure-activity relationships. J Antimicrob Chemother 1990; 26 (Suppl    C): 1-8.         [ Links ]45.- CRITCHLEY I A, BASKER M J, EDMONDSON    R A, KNOTT S J. Uptake of catecholic cephalosporin by the iron transport system    of Escherichia coli. J Antimicrob Chemother 1991; 28: 377-88.         [ Links ]46.- CRITCHLEY I A. Catecholic ß-lactams:    facilitated transport. J Antimicrob Chemother 1990; 26: 733-7.         [ Links ]47.- JONES R N, ERWIN M E. In vitro evaluation    of Ro 09-1227, a novel catechol-substituted cephalosporin. Antimicrob Agents    Chemother 1992; 36: 233-8.         [ Links ]48.- JONES R N. In vitro activity of Ro 24-6392,    a novel ester-linked co-drug combining ciprofloxacin and desacetylcefotaxime.    Eur J Clin Microbiol Infect Dis 1990; 9: 435-8.         [ Links ]49.- TOMASZ A. Penicillin-binding proteins    and the antibacterial effectiveness of ß-lactam antibiotics. Rev Infect    Dis 1986 (Suppl 3); 8: 260-78.         [ Links ]50.- HOLM S E. Interaction between ß-lactam    and other antibiotics. Rev Infect Dis 1986 (Suppl 3); 8: 305-14.         [ Links ]51.- MC CULLERS J A, ENGLISH B K, NOVAK R.    Isolation and characterization of vancomycin-tolerant Streptococcus pneumoniae    from the cerebrospinal fluid of a patient who developed recrudescet meningitis.    J Infect Dis 2000; 181: 369-73.         [ Links ]52.- NIKAIDO H. Outer membrane barrier as    a mechanism of antimicrobial resistance. Antimicrob Agents Chemother 1989; 33:    1831-6.         [ Links ]53.- BARRADELL L B, BRYSON H M. Cefepime.    A review of its antibacterial activity, pharmacokinetic properties and therapeutic    use. Drugs 1994; 47: 471-505.         [ Links ]54.- O'CALLAGHAN C H 1979. Description and    classification of the newer cephalosporins and their relationship with the established    compounds. J Antimicrob Chemother 5: 635-71         [ Links ]55.- BRYSKIER A, PROCYK T, TREMBLAY D, LENFANT    B FOURTILLAN J B. The pharmacokinetics of cefodizime following intravenous and    intramuscular administration of a single dose of 1.0 g. J Antimicrob Chemother    1990; 26 (Suppl. C): 59-63.         [ Links ]56.- WILLIAMS J D. Classification of cephalosporins.    Drugs. 1987; 34 (Suppl 2): 15-22.         [ Links ]57.- WISEMAN L R, LAMB H M. Cefpirome. A review    of its antibacterial activity, pharmacokinetic properties and efficacy in the    treatment of severe nosocomial infections and febrile neutropenia. Drugs 1997;    57: 117-40.         [ Links ]58.- PECHERE J C, WILSON W, NEU H. Laboratory    assesment of antibacterial activity of zwitterionic 7-methoxyimino cephalosporins.    J Antimicrob Chemother 1995; 36: 757-71         [ Links ]59.- GIAMARELLOS-BOURBOULIS EJ, GRECKA P,    TSITSIKA A, TYMPANIDOU C, GIAMARELLOU H. In-vitro activity of FK 037 (cefoselis),    a novel 4 (th) generation cephalosporin, cefepime and cefpirome on nosocomial    staphylococci and gram-negative isolates. Diagn Microbiol infect Dis 2000; 36:    185-91.         [ Links ]60.- JONES R N, ERWIN M E, BARRETT M S, JOHNSON    D M, BRIGGS B M. Antimicrobial activity of E-1040, a novel thiadiazolyl cephalosporin    compare with parenteral cephems. Diagn Microbiol infect Dis 1991; 14: 301-9.          [ Links ]61.- IIZAWA Y, OKONOGI K, HAYASHI R, IWAHI    T, YAMAZAKI T, IMADA A. Therapeutic effect of cefozopran (SCE-2787), a new parenteral    cephalosporin in experimental infections in mice. Antimicrob Agents Chemother    1993; 37: 100-5.         [ Links ]62.- WATANABE N A. Newer antipseudomonal cephalosporins.    J Chemother 1996; 8 (Suppl 2): 48-56.         [ Links ]63.- ACTOR P, GUARINI J, URI J et al. Disk    susceptibility studies with cefazolin and cephalotin. Antimicrob Agents Chemother    1974; 5: 63-7.         [ Links ]64.- UWAYDAH M. Cefazolin in the treatment    of acute enteric fever. Antimicrob Agents Chemother 1976; 10: 52-6.         [ Links ]65.- JAMAL W Y, ROTIMI V O, CHUGH T D, PAL    T. Prevalence and susceptibility of Shigella to 11 antibiotics in a Kuwait    teaching hospital. J Chemother 1998; 10: 285-90.         [ Links ]66.- COX CE, SHERRILL M, COCCHETT DM. Evaluation    of cefuroxime axetil, cefaclor, and cephalexin in the treatment of urinary tract    infections in adults. Curr Ther Res 1987; 42: 124-37.         [ Links ]67.- SANDERS C W, GREENBERG R N, MARIER R    L. Cefamandole and cefoxitin. Ann Intern Med 1985; 103: 70-8.          [ Links ]68.- STAPLEY E P, JACKSON M, HERNANDEZ S et    al. Cephamycins, a new family of ß-lactam antibiotics I. Production actinomycetes,    including Streptomyces lactamdurans spp.n. Antimicrob Agents Chemother    1972; 2: 122-31.         [ Links ]69.- COOPER R D G. The carbacephems a new    ß-lactams class. Am J Med 1992; 92 (Suppl 6 A): 25-65.         [ Links ]70.- ZEMELMAN R, BELLO H, DOMINGUEZ M, GONZALEZ    G, MELLA S, GARCIA A. Activity of imipenem, third-generation cephalosporins,    aztreonam, and ciprofloxacin against multi-resistant Gram negative bacilli isolated    from Chilean hospitals. J Antimicrob Chemother 1993; 32: 413-9.         [ Links ]71.- MEDEIROS A A. Evolution and dissemination    of ß-lactamases accelerated by generation of ß-lactam antibiotics.    Clin Infect Dis 1997; 24 (Suppl. 1): 19-45.         [ Links ]72.- PERRY C M, BROGDEN R N. Cefuroxime axetil:    review of its antibacterial activity, pharmacokinetic properties and therapeutic    efficacy. Drugs 1996; 52: 125-58.         [ Links ]73.- SCHAAD U B, SUTER S, GIANELLA-BORRADORI    et al. A comparison of ceftriaxone and cefuroxime for the treatment of bacterial    meningitis in children. N Engl J Med 1990; 322: 141-7.         [ Links ]74.- KLEIN N C, CUNHA B A. Cefalosporinas de    la tercera generación. Clin Med Nort Am 1995; 79: 693-707.         [ Links ]75.- KLUGMAN K P, MADHI S A. Emergence of    drug resistance impact on bacterial meningitis. Infect Dis Clin North Am 1999;    13: 637-46.         [ Links ]76.- RICHARDS D M, BROGDEN R N. Ceftazidime.    A review of its antibacterial activity, pharmacokinetic properties and therapeutic    use. Drugs 1985; 29: 105-61.         [ Links ]77.- SCHATZ B S, KARAVOKIROS K T, TAEUBEL    M A, ITOKAZU G S. Comparison of cefprozil, cefpodoxime proxetil, loracarbef,    cefixime, and ceftibuten. Ann Pharmacother 1996; 30: 258-68.         [ Links ]78.- DALMAU D, LAYRARGUES G P, FENYVES D,    WILLEMS B, TURGEON F, TURGEON P. Cefotaxime, desacetyl-cefotaxime, and bactericidal    activity in spontaneous bacterial peritonitis. J Infect Dis 1999; 180: 1597-1602.          [ Links ]79.- NIKAIDO W, LIU W, ROSENBERG E Y. Outer    membrane permeability and ß-lactamase stability of dipolar ionic cephalosporins    containing methoxyimino substituents. Antimicrob Agents Chemother 1990; 34:    337-42.         [ Links ]80.- HANCOCK R E W, BELLIDO F. Factors involved    in the enhanced efficacy against gram-negative bacteria of fourth generation    cephalosporins. J Antimicrob Chemother 1992; 29(Suppl A): 1-6.         [ Links ]81.- BELLIDO F, PECHERE J C, HANCOCK REW.    Novel method for measurement of outer membrane permeability to new beta-lactams    in intact Enterobacter cloacae cells. Antimicrob Agents Chemother 1991;    35: 68-72.         [ Links ]82.- NEU H C, CHIN N X, JULES K, LABTHAVIKUL    P. The activity of BMY-28142, a new broad spectrum beta-lactamase stable cephalosporin.    J Antimicrob Chemother 1986; 17: 441-52.         [ Links ]83.- KOBAYASHI S, ARAI S, HAYASHI S, FUJIMOTO    K. ß-lactamase stability of cefpirome (HR 810), a new cephalosporin with    a broad antimicrobial spectrum. Antimicrob Agents Chemother 1986; 30: 713-8.          [ Links ]84.- GARAU J, WILSON W, WOOD M, CARLET J.    Fourth generation cephalosporins: a review of in vitro activity, pharmacokinetics,    pharmacodynamics, and clinical utility. Clin Microb Infect 1997; 3 (Suppl 1):    87-101.         [ Links ]85.- KESSLER R E, FUNG-TOMC J. Susceptibility    of bacterial isolates to beta-lactam antibiotics from U.S. clinical trials over    5-year period. Am J Med 1996; 24 (6 A): 13-9.         [ Links ]86.- PIERARD D, EMMERECHTS K, LAUWERS S. Comparative    in-vitro activity of cefpirome against isolates from intensive care and haematology/oncology    units. Belgian Multicentric Study Group. J Antimicrob Chemother 1998; 41: 443-50.          [ Links ]87.- JONES R N. Resistance patterns among    nosocomial pathogens: trends over the past few years. Chest 2001; 119 (Suppl    2): 397-404.         [ Links ]88.- LORBER B. Changing patterns of infectious    diseases. Am J Med 1988; 84: 569-78.         [ Links ]89.- MOELLERING R C. A novel antimicrobial    agent joins the battle against resistant bacteria. Ann Intern Med 1999; 130:    155-7.         [ Links ]90.- WILSON W R. The role of fourth-generation    cephalosporins in the treatment of serious infectious diseases in hospitalized    patients. Diagn Microbiol Infect Dis 1998; 31: 473-7.         [ Links ]Correspondencia a:        Sergio Mella Montecinos        Laboratorio de Antibióticos,        Departamento de Microbiología,        Facultad de Ciencias Biológicas        Casilla 160-C, Concepción        E-mail: pignatio@ctcinternet.cl  

19.- MARRIE T J. Community-acquired pneumonia:    epidemiology, etiology, treatment. Infect Dis Clin North Am 1998; 12: 723-40          [ Links ]20.- TUNKEL A R, SCHELD W M. Acute meningitis.    In: Mandell, Douglas & Bennett's. Principles and Practice of Infectious    Diseases. Mandell G L, Bennett J E, Dolin R, eds. Fifth edition. Philadelphia:    Editorial Churchill Livingstone 2000; 959-96.         [ Links ]21.- AMERICAN THORACIC SOCIETY. Hospital-acquired    pneumonia in adults: diagnosis, assessment of severity, initial antimicrobial    therapy, and preventive strategies. A consensus statement. Am J Respir Crit    Care Med 1996; 153: 1711-25.         [ Links ]22.- BARTLETT J G, DOWELL S F, MANDELL L A,    FILE T M, MUSHER D M, FINE M J. Practice guidelines for the management of community-acquired    pneumonia in adults. Clin Infect Dis. 2000; 31: 347-82         [ Links ]23.- KARCHMER A W. Cephalosporins. In: Mandell,    Douglas & Bennett's. Principles and Practice of Infectious Diseases. Mandell    G L, Bennett J E, Dolin R, eds. Fifth edition. Philadelphia: Churchill Livingstone    2000; 274-99.         [ Links ]24.- ADU A, ARMOUR C L. Drug utilisation review    (DUR) of the third generation cephalosporins. Drugs 1995; 50: 423-39.         [ Links ]25.- JONES R N. Important and emerging ß-lactamase    mediated resistances in hospital-based pathogens: the Amp C enzymes. Diagn Microbiol    Infect Dis 1998; 31: 461-6.         [ Links ]26.- JARVIS W R, MARTONE W J. Predominant    pathogens in hospital infections. J Antimicrob Chemother 1992; 29: 19-24.         [ Links ]27.- LIVERMORE D M. ß-lactamases in    laboratory and clinical resistance. Clin Microbiol Rev 1995; 8: 557-84.         [ Links ]28.- HERITAGE J, M'ZALI F H, GASCOYNE-BINZI    D, HAWKEY P M. Evolution and spread of SHV extended-spectrum ß-lactamases    in gram negative bacteria. J Antimicrob Chemother 1999; 44: 309-18.         [ Links ]29.- PODSCHUN R, ULLMAN U. Klebsiella spp.    as nosocomial pathogens: epidemiology, taxonomy, typing methods, and pathogenicity    factors. Clin Microbiol Rev 1998; 11: 589-603.         [ Links ]30.- PITOUT J D D, SANDERS C C, SANDERS W    E. Antimicrobial resistance with focus on ß-lactam resistance in Gram    negative bacilli. Am J Med 1997; 103: 51-9.         [ Links ]31.- HANBERGER H, GARCIA-RODRIGUEZ J A, GOBERNADO    et al. Antibiotic susceptibility among aerobic Gram negative bacilli in intensive    care units in 5 european countries. JAMA 1999; 281: 67-71.         [ Links ]32.- CHARREL R N, PAGES J M, DE MICCO P et    al. Prevalence of outer membrane porin alteration in ß-lactam-antibiotic-resistant    Enterobacter aerogenes. Antimicrob Agents Chemother 1996; 40: 2854-8.          [ Links ]33.- BRADFORD P A, URBAN C, MARIANO N, PROJAN    S J, RAHAL J J, BUSH K. Imipenem resistance in Klebsiella pneumoniae is    associated with the combination of ACT-1, a plasmid-mediated Amp C ß-lactamase,    and the loss of an outer membrane protein. Antimicrob Agents Chemother 1997;    41: 563-9.         [ Links ]34.- QUEENAN A M, TORRES-VIERA C, GOLD H et    al. SME-type carbapenem-hydrolizing class A ß-lactamases from geographically    diverse Serratia marcescens strains. Antimicrob Agents Chemother 2000;    44: 3035-9.         [ Links ]35.- COHEN S P, MC MURRY L M, HOOPER D C,    WOLFSON J S, LEVY S B. Cross-resistance to fluoroquinolones in multiple-antibiotic-resistance    (Mar) Escherichia coli selected by tetracycline resistance: decreased    drug accumulation asociated with membrane changes in addition to Omp F reduction.    Antimicrob Agents Chemother 1989; 33:1318-25.         [ Links ]36.- SANDERS C C. Cefepime: The next generation?    Clin Infect Dis 1993; 17: 369-79         [ Links ]37.- GARAU J. The clinical potential of fourth-generation    cephalosporins. Diagn Microbiol Infect Dis 1998; 31: 479-80.         [ Links ]38.- CURTIS N A C, ORR D C, ROSS G W, BOULTON    M G. Affinities of penicillins and cephalosporins for the penicillin-binding    proteins of Escherichia coli    K-12 and their antibacterial activity. Antimicrob Agents Chemother 1979; 16:    533-9.  39.- BALANT L, DAYER P, AUCKENTHALER R. Clinical    pharmacokinetics of the third generation cephalosporins. Clin Pharmacokinetics    1985; 10: 101-43.         [ Links ]40.- WHEELER W J. Cephalosporins and other    beta-lactam antibiotics. Lloydia. 1977; 40: 519-42.         [ Links ]41.- LOPEZ F, GARRIDO J C. Química    y relación estructura-actividad de los antibióticos cefalosporínicos.    Rev Col Químico Farmacéutico 1989; 41: 5-14.         [ Links ]42.- FU K P, ASWAPOKEE P, HO I, MATTHIJSSEN    C, NEU H C. Pharmacokinetics of cefotaxime. Antimicrob Agents Chemother 1979;16:    592-7.         [ Links ]43.- YUK J H, NIGHTINGALE C H, QUINTILIANI    R. Clinical pharmacokinetics of ceftriaxone. Clin Pharmacokinetic 1989; 17:    223-35.         [ Links ]44.- BRYSKIER A, PROCYK T, LABRO M T. Cefodizime,    a new 2-aminothiazolyl cephalosporin: physicochemical properties, toxicology    and structure-activity relationships. J Antimicrob Chemother 1990; 26 (Suppl    C): 1-8.         [ Links ]45.- CRITCHLEY I A, BASKER M J, EDMONDSON    R A, KNOTT S J. Uptake of catecholic cephalosporin by the iron transport system    of Escherichia coli. J Antimicrob Chemother 1991; 28: 377-88.         [ Links ]46.- CRITCHLEY I A. Catecholic ß-lactams:    facilitated transport. J Antimicrob Chemother 1990; 26: 733-7.         [ Links ]47.- JONES R N, ERWIN M E. In vitro evaluation    of Ro 09-1227, a novel catechol-substituted cephalosporin. Antimicrob Agents    Chemother 1992; 36: 233-8.         [ Links ]48.- JONES R N. In vitro activity of Ro 24-6392,    a novel ester-linked co-drug combining ciprofloxacin and desacetylcefotaxime.    Eur J Clin Microbiol Infect Dis 1990; 9: 435-8.         [ Links ]49.- TOMASZ A. Penicillin-binding proteins    and the antibacterial effectiveness of ß-lactam antibiotics. Rev Infect    Dis 1986 (Suppl 3); 8: 260-78.         [ Links ]50.- HOLM S E. Interaction between ß-lactam    and other antibiotics. Rev Infect Dis 1986 (Suppl 3); 8: 305-14.         [ Links ]51.- MC CULLERS J A, ENGLISH B K, NOVAK R.    Isolation and characterization of vancomycin-tolerant Streptococcus pneumoniae    from the cerebrospinal fluid of a patient who developed recrudescet meningitis.    J Infect Dis 2000; 181: 369-73.         [ Links ]52.- NIKAIDO H. Outer membrane barrier as    a mechanism of antimicrobial resistance. Antimicrob Agents Chemother 1989; 33:    1831-6.         [ Links ]53.- BARRADELL L B, BRYSON H M. Cefepime.    A review of its antibacterial activity, pharmacokinetic properties and therapeutic    use. Drugs 1994; 47: 471-505.         [ Links ]54.- O'CALLAGHAN C H 1979. Description and    classification of the newer cephalosporins and their relationship with the established    compounds. J Antimicrob Chemother 5: 635-71         [ Links ]55.- BRYSKIER A, PROCYK T, TREMBLAY D, LENFANT    B FOURTILLAN J B. The pharmacokinetics of cefodizime following intravenous and    intramuscular administration of a single dose of 1.0 g. J Antimicrob Chemother    1990; 26 (Suppl. C): 59-63.         [ Links ]56.- WILLIAMS J D. Classification of cephalosporins.    Drugs. 1987; 34 (Suppl 2): 15-22.         [ Links ]57.- WISEMAN L R, LAMB H M. Cefpirome. A review    of its antibacterial activity, pharmacokinetic properties and efficacy in the    treatment of severe nosocomial infections and febrile neutropenia. Drugs 1997;    57: 117-40.         [ Links ]58.- PECHERE J C, WILSON W, NEU H. Laboratory    assesment of antibacterial activity of zwitterionic 7-methoxyimino cephalosporins.    J Antimicrob Chemother 1995; 36: 757-71         [ Links ]59.- GIAMARELLOS-BOURBOULIS EJ, GRECKA P,    TSITSIKA A, TYMPANIDOU C, GIAMARELLOU H. In-vitro activity of FK 037 (cefoselis),    a novel 4 (th) generation cephalosporin, cefepime and cefpirome on nosocomial    staphylococci and gram-negative isolates. Diagn Microbiol infect Dis 2000; 36:    185-91.         [ Links ]60.- JONES R N, ERWIN M E, BARRETT M S, JOHNSON    D M, BRIGGS B M. Antimicrobial activity of E-1040, a novel thiadiazolyl cephalosporin    compare with parenteral cephems. Diagn Microbiol infect Dis 1991; 14: 301-9.          [ Links ]61.- IIZAWA Y, OKONOGI K, HAYASHI R, IWAHI    T, YAMAZAKI T, IMADA A. Therapeutic effect of cefozopran (SCE-2787), a new parenteral    cephalosporin in experimental infections in mice. Antimicrob Agents Chemother    1993; 37: 100-5.         [ Links ]62.- WATANABE N A. Newer antipseudomonal cephalosporins.    J Chemother 1996; 8 (Suppl 2): 48-56.         [ Links ]63.- ACTOR P, GUARINI J, URI J et al. Disk    susceptibility studies with cefazolin and cephalotin. Antimicrob Agents Chemother    1974; 5: 63-7.         [ Links ]64.- UWAYDAH M. Cefazolin in the treatment    of acute enteric fever. Antimicrob Agents Chemother 1976; 10: 52-6.         [ Links ]65.- JAMAL W Y, ROTIMI V O, CHUGH T D, PAL    T. Prevalence and susceptibility of Shigella to 11 antibiotics in a Kuwait    teaching hospital. J Chemother 1998; 10: 285-90.         [ Links ]66.- COX CE, SHERRILL M, COCCHETT DM. Evaluation    of cefuroxime axetil, cefaclor, and cephalexin in the treatment of urinary tract    infections in adults. Curr Ther Res 1987; 42: 124-37.         [ Links ]67.- SANDERS C W, GREENBERG R N, MARIER R    L. Cefamandole and cefoxitin. Ann Intern Med 1985; 103: 70-8.          [ Links ]68.- STAPLEY E P, JACKSON M, HERNANDEZ S et    al. Cephamycins, a new family of ß-lactam antibiotics I. Production actinomycetes,    including Streptomyces lactamdurans spp.n. Antimicrob Agents Chemother    1972; 2: 122-31.         [ Links ]69.- COOPER R D G. The carbacephems a new    ß-lactams class. Am J Med 1992; 92 (Suppl 6 A): 25-65.         [ Links ]70.- ZEMELMAN R, BELLO H, DOMINGUEZ M, GONZALEZ    G, MELLA S, GARCIA A. Activity of imipenem, third-generation cephalosporins,    aztreonam, and ciprofloxacin against multi-resistant Gram negative bacilli isolated    from Chilean hospitals. J Antimicrob Chemother 1993; 32: 413-9.         [ Links ]71.- MEDEIROS A A. Evolution and dissemination    of ß-lactamases accelerated by generation of ß-lactam antibiotics.    Clin Infect Dis 1997; 24 (Suppl. 1): 19-45.         [ Links ]72.- PERRY C M, BROGDEN R N. Cefuroxime axetil:    review of its antibacterial activity, pharmacokinetic properties and therapeutic    efficacy. Drugs 1996; 52: 125-58.         [ Links ]73.- SCHAAD U B, SUTER S, GIANELLA-BORRADORI    et al. A comparison of ceftriaxone and cefuroxime for the treatment of bacterial    meningitis in children. N Engl J Med 1990; 322: 141-7.         [ Links ]74.- KLEIN N C, CUNHA B A. Cefalosporinas de    la tercera generación. Clin Med Nort Am 1995; 79: 693-707.         [ Links ]75.- KLUGMAN K P, MADHI S A. Emergence of    drug resistance impact on bacterial meningitis. Infect Dis Clin North Am 1999;    13: 637-46.         [ Links ]76.- RICHARDS D M, BROGDEN R N. Ceftazidime.    A review of its antibacterial activity, pharmacokinetic properties and therapeutic    use. Drugs 1985; 29: 105-61.         [ Links ]77.- SCHATZ B S, KARAVOKIROS K T, TAEUBEL    M A, ITOKAZU G S. Comparison of cefprozil, cefpodoxime proxetil, loracarbef,    cefixime, and ceftibuten. Ann Pharmacother 1996; 30: 258-68.         [ Links ]78.- DALMAU D, LAYRARGUES G P, FENYVES D,    WILLEMS B, TURGEON F, TURGEON P. Cefotaxime, desacetyl-cefotaxime, and bactericidal    activity in spontaneous bacterial peritonitis. J Infect Dis 1999; 180: 1597-1602.          [ Links ]79.- NIKAIDO W, LIU W, ROSENBERG E Y. Outer    membrane permeability and ß-lactamase stability of dipolar ionic cephalosporins    containing methoxyimino substituents. Antimicrob Agents Chemother 1990; 34:    337-42.         [ Links ]80.- HANCOCK R E W, BELLIDO F. Factors involved    in the enhanced efficacy against gram-negative bacteria of fourth generation    cephalosporins. J Antimicrob Chemother 1992; 29(Suppl A): 1-6.         [ Links ]81.- BELLIDO F, PECHERE J C, HANCOCK REW.    Novel method for measurement of outer membrane permeability to new beta-lactams    in intact Enterobacter cloacae cells. Antimicrob Agents Chemother 1991;    35: 68-72.         [ Links ]82.- NEU H C, CHIN N X, JULES K, LABTHAVIKUL    P. The activity of BMY-28142, a new broad spectrum beta-lactamase stable cephalosporin.    J Antimicrob Chemother 1986; 17: 441-52.         [ Links ]83.- KOBAYASHI S, ARAI S, HAYASHI S, FUJIMOTO    K. ß-lactamase stability of cefpirome (HR 810), a new cephalosporin with    a broad antimicrobial spectrum. Antimicrob Agents Chemother 1986; 30: 713-8.          [ Links ]84.- GARAU J, WILSON W, WOOD M, CARLET J.    Fourth generation cephalosporins: a review of in vitro activity, pharmacokinetics,    pharmacodynamics, and clinical utility. Clin Microb Infect 1997; 3 (Suppl 1):    87-101.         [ Links ]85.- KESSLER R E, FUNG-TOMC J. Susceptibility    of bacterial isolates to beta-lactam antibiotics from U.S. clinical trials over    5-year period. Am J Med 1996; 24 (6 A): 13-9.         [ Links ]86.- PIERARD D, EMMERECHTS K, LAUWERS S. Comparative    in-vitro activity of cefpirome against isolates from intensive care and haematology/oncology    units. Belgian Multicentric Study Group. J Antimicrob Chemother 1998; 41: 443-50.          [ Links ]87.- JONES R N. Resistance patterns among    nosocomial pathogens: trends over the past few years. Chest 2001; 119 (Suppl    2): 397-404.         [ Links ]88.- LORBER B. Changing patterns of infectious    diseases. Am J Med 1988; 84: 569-78.         [ Links ]89.- MOELLERING R C. A novel antimicrobial    agent joins the battle against resistant bacteria. Ann Intern Med 1999; 130:    155-7.         [ Links ]90.- WILSON W R. The role of fourth-generation    cephalosporins in the treatment of serious infectious diseases in hospitalized    patients. Diagn Microbiol Infect Dis 1998; 31: 473-7.         [ Links ]Correspondencia a:        Sergio Mella Montecinos        Laboratorio de Antibióticos,        Departamento de Microbiología,        Facultad de Ciencias Biológicas        Casilla 160-C, Concepción        E-mail: pignatio@ctcinternet.cl  

20.- TUNKEL A R, SCHELD W M. Acute meningitis.    In: Mandell, Douglas & Bennett's. Principles and Practice of Infectious    Diseases. Mandell G L, Bennett J E, Dolin R, eds. Fifth edition. Philadelphia:    Editorial Churchill Livingstone 2000; 959-96.         [ Links ]21.- AMERICAN THORACIC SOCIETY. Hospital-acquired    pneumonia in adults: diagnosis, assessment of severity, initial antimicrobial    therapy, and preventive strategies. A consensus statement. Am J Respir Crit    Care Med 1996; 153: 1711-25.         [ Links ]22.- BARTLETT J G, DOWELL S F, MANDELL L A,    FILE T M, MUSHER D M, FINE M J. Practice guidelines for the management of community-acquired    pneumonia in adults. Clin Infect Dis. 2000; 31: 347-82         [ Links ]23.- KARCHMER A W. Cephalosporins. In: Mandell,    Douglas & Bennett's. Principles and Practice of Infectious Diseases. Mandell    G L, Bennett J E, Dolin R, eds. Fifth edition. Philadelphia: Churchill Livingstone    2000; 274-99.         [ Links ]24.- ADU A, ARMOUR C L. Drug utilisation review    (DUR) of the third generation cephalosporins. Drugs 1995; 50: 423-39.         [ Links ]25.- JONES R N. Important and emerging ß-lactamase    mediated resistances in hospital-based pathogens: the Amp C enzymes. Diagn Microbiol    Infect Dis 1998; 31: 461-6.         [ Links ]26.- JARVIS W R, MARTONE W J. Predominant    pathogens in hospital infections. J Antimicrob Chemother 1992; 29: 19-24.         [ Links ]27.- LIVERMORE D M. ß-lactamases in    laboratory and clinical resistance. Clin Microbiol Rev 1995; 8: 557-84.         [ Links ]28.- HERITAGE J, M'ZALI F H, GASCOYNE-BINZI    D, HAWKEY P M. Evolution and spread of SHV extended-spectrum ß-lactamases    in gram negative bacteria. J Antimicrob Chemother 1999; 44: 309-18.         [ Links ]29.- PODSCHUN R, ULLMAN U. Klebsiella spp.    as nosocomial pathogens: epidemiology, taxonomy, typing methods, and pathogenicity    factors. Clin Microbiol Rev 1998; 11: 589-603.         [ Links ]30.- PITOUT J D D, SANDERS C C, SANDERS W    E. Antimicrobial resistance with focus on ß-lactam resistance in Gram    negative bacilli. Am J Med 1997; 103: 51-9.         [ Links ]31.- HANBERGER H, GARCIA-RODRIGUEZ J A, GOBERNADO    et al. Antibiotic susceptibility among aerobic Gram negative bacilli in intensive    care units in 5 european countries. JAMA 1999; 281: 67-71.         [ Links ]32.- CHARREL R N, PAGES J M, DE MICCO P et    al. Prevalence of outer membrane porin alteration in ß-lactam-antibiotic-resistant    Enterobacter aerogenes. Antimicrob Agents Chemother 1996; 40: 2854-8.          [ Links ]33.- BRADFORD P A, URBAN C, MARIANO N, PROJAN    S J, RAHAL J J, BUSH K. Imipenem resistance in Klebsiella pneumoniae is    associated with the combination of ACT-1, a plasmid-mediated Amp C ß-lactamase,    and the loss of an outer membrane protein. Antimicrob Agents Chemother 1997;    41: 563-9.         [ Links ]34.- QUEENAN A M, TORRES-VIERA C, GOLD H et    al. SME-type carbapenem-hydrolizing class A ß-lactamases from geographically    diverse Serratia marcescens strains. Antimicrob Agents Chemother 2000;    44: 3035-9.         [ Links ]35.- COHEN S P, MC MURRY L M, HOOPER D C,    WOLFSON J S, LEVY S B. Cross-resistance to fluoroquinolones in multiple-antibiotic-resistance    (Mar) Escherichia coli selected by tetracycline resistance: decreased    drug accumulation asociated with membrane changes in addition to Omp F reduction.    Antimicrob Agents Chemother 1989; 33:1318-25.         [ Links ]36.- SANDERS C C. Cefepime: The next generation?    Clin Infect Dis 1993; 17: 369-79         [ Links ]37.- GARAU J. The clinical potential of fourth-generation    cephalosporins. Diagn Microbiol Infect Dis 1998; 31: 479-80.         [ Links ]38.- CURTIS N A C, ORR D C, ROSS G W, BOULTON    M G. Affinities of penicillins and cephalosporins for the penicillin-binding    proteins of Escherichia coli    K-12 and their antibacterial activity. Antimicrob Agents Chemother 1979; 16:    533-9.  39.- BALANT L, DAYER P, AUCKENTHALER R. Clinical    pharmacokinetics of the third generation cephalosporins. Clin Pharmacokinetics    1985; 10: 101-43.         [ Links ]40.- WHEELER W J. Cephalosporins and other    beta-lactam antibiotics. Lloydia. 1977; 40: 519-42.         [ Links ]41.- LOPEZ F, GARRIDO J C. Química    y relación estructura-actividad de los antibióticos cefalosporínicos.    Rev Col Químico Farmacéutico 1989; 41: 5-14.         [ Links ]42.- FU K P, ASWAPOKEE P, HO I, MATTHIJSSEN    C, NEU H C. Pharmacokinetics of cefotaxime. Antimicrob Agents Chemother 1979;16:    592-7.         [ Links ]43.- YUK J H, NIGHTINGALE C H, QUINTILIANI    R. Clinical pharmacokinetics of ceftriaxone. Clin Pharmacokinetic 1989; 17:    223-35.         [ Links ]44.- BRYSKIER A, PROCYK T, LABRO M T. Cefodizime,    a new 2-aminothiazolyl cephalosporin: physicochemical properties, toxicology    and structure-activity relationships. J Antimicrob Chemother 1990; 26 (Suppl    C): 1-8.         [ Links ]45.- CRITCHLEY I A, BASKER M J, EDMONDSON    R A, KNOTT S J. Uptake of catecholic cephalosporin by the iron transport system    of Escherichia coli. J Antimicrob Chemother 1991; 28: 377-88.         [ Links ]46.- CRITCHLEY I A. Catecholic ß-lactams:    facilitated transport. J Antimicrob Chemother 1990; 26: 733-7.         [ Links ]47.- JONES R N, ERWIN M E. In vitro evaluation    of Ro 09-1227, a novel catechol-substituted cephalosporin. Antimicrob Agents    Chemother 1992; 36: 233-8.         [ Links ]48.- JONES R N. In vitro activity of Ro 24-6392,    a novel ester-linked co-drug combining ciprofloxacin and desacetylcefotaxime.    Eur J Clin Microbiol Infect Dis 1990; 9: 435-8.         [ Links ]49.- TOMASZ A. Penicillin-binding proteins    and the antibacterial effectiveness of ß-lactam antibiotics. Rev Infect    Dis 1986 (Suppl 3); 8: 260-78.         [ Links ]50.- HOLM S E. Interaction between ß-lactam    and other antibiotics. Rev Infect Dis 1986 (Suppl 3); 8: 305-14.         [ Links ]51.- MC CULLERS J A, ENGLISH B K, NOVAK R.    Isolation and characterization of vancomycin-tolerant Streptococcus pneumoniae    from the cerebrospinal fluid of a patient who developed recrudescet meningitis.    J Infect Dis 2000; 181: 369-73.         [ Links ]52.- NIKAIDO H. Outer membrane barrier as    a mechanism of antimicrobial resistance. Antimicrob Agents Chemother 1989; 33:    1831-6.         [ Links ]53.- BARRADELL L B, BRYSON H M. Cefepime.    A review of its antibacterial activity, pharmacokinetic properties and therapeutic    use. Drugs 1994; 47: 471-505.         [ Links ]54.- O'CALLAGHAN C H 1979. Description and    classification of the newer cephalosporins and their relationship with the established    compounds. J Antimicrob Chemother 5: 635-71         [ Links ]55.- BRYSKIER A, PROCYK T, TREMBLAY D, LENFANT    B FOURTILLAN J B. The pharmacokinetics of cefodizime following intravenous and    intramuscular administration of a single dose of 1.0 g. J Antimicrob Chemother    1990; 26 (Suppl. C): 59-63.         [ Links ]56.- WILLIAMS J D. Classification of cephalosporins.    Drugs. 1987; 34 (Suppl 2): 15-22.         [ Links ]57.- WISEMAN L R, LAMB H M. Cefpirome. A review    of its antibacterial activity, pharmacokinetic properties and efficacy in the    treatment of severe nosocomial infections and febrile neutropenia. Drugs 1997;    57: 117-40.         [ Links ]58.- PECHERE J C, WILSON W, NEU H. Laboratory    assesment of antibacterial activity of zwitterionic 7-methoxyimino cephalosporins.    J Antimicrob Chemother 1995; 36: 757-71         [ Links ]59.- GIAMARELLOS-BOURBOULIS EJ, GRECKA P,    TSITSIKA A, TYMPANIDOU C, GIAMARELLOU H. In-vitro activity of FK 037 (cefoselis),    a novel 4 (th) generation cephalosporin, cefepime and cefpirome on nosocomial    staphylococci and gram-negative isolates. Diagn Microbiol infect Dis 2000; 36:    185-91.         [ Links ]60.- JONES R N, ERWIN M E, BARRETT M S, JOHNSON    D M, BRIGGS B M. Antimicrobial activity of E-1040, a novel thiadiazolyl cephalosporin    compare with parenteral cephems. Diagn Microbiol infect Dis 1991; 14: 301-9.          [ Links ]61.- IIZAWA Y, OKONOGI K, HAYASHI R, IWAHI    T, YAMAZAKI T, IMADA A. Therapeutic effect of cefozopran (SCE-2787), a new parenteral    cephalosporin in experimental infections in mice. Antimicrob Agents Chemother    1993; 37: 100-5.         [ Links ]62.- WATANABE N A. Newer antipseudomonal cephalosporins.    J Chemother 1996; 8 (Suppl 2): 48-56.         [ Links ]63.- ACTOR P, GUARINI J, URI J et al. Disk    susceptibility studies with cefazolin and cephalotin. Antimicrob Agents Chemother    1974; 5: 63-7.         [ Links ]64.- UWAYDAH M. Cefazolin in the treatment    of acute enteric fever. Antimicrob Agents Chemother 1976; 10: 52-6.         [ Links ]65.- JAMAL W Y, ROTIMI V O, CHUGH T D, PAL    T. Prevalence and susceptibility of Shigella to 11 antibiotics in a Kuwait    teaching hospital. J Chemother 1998; 10: 285-90.         [ Links ]66.- COX CE, SHERRILL M, COCCHETT DM. Evaluation    of cefuroxime axetil, cefaclor, and cephalexin in the treatment of urinary tract    infections in adults. Curr Ther Res 1987; 42: 124-37.         [ Links ]67.- SANDERS C W, GREENBERG R N, MARIER R    L. Cefamandole and cefoxitin. Ann Intern Med 1985; 103: 70-8.          [ Links ]68.- STAPLEY E P, JACKSON M, HERNANDEZ S et    al. Cephamycins, a new family of ß-lactam antibiotics I. Production actinomycetes,    including Streptomyces lactamdurans spp.n. Antimicrob Agents Chemother    1972; 2: 122-31.         [ Links ]69.- COOPER R D G. The carbacephems a new    ß-lactams class. Am J Med 1992; 92 (Suppl 6 A): 25-65.         [ Links ]70.- ZEMELMAN R, BELLO H, DOMINGUEZ M, GONZALEZ    G, MELLA S, GARCIA A. Activity of imipenem, third-generation cephalosporins,    aztreonam, and ciprofloxacin against multi-resistant Gram negative bacilli isolated    from Chilean hospitals. J Antimicrob Chemother 1993; 32: 413-9.         [ Links ]71.- MEDEIROS A A. Evolution and dissemination    of ß-lactamases accelerated by generation of ß-lactam antibiotics.    Clin Infect Dis 1997; 24 (Suppl. 1): 19-45.         [ Links ]72.- PERRY C M, BROGDEN R N. Cefuroxime axetil:    review of its antibacterial activity, pharmacokinetic properties and therapeutic    efficacy. Drugs 1996; 52: 125-58.         [ Links ]73.- SCHAAD U B, SUTER S, GIANELLA-BORRADORI    et al. A comparison of ceftriaxone and cefuroxime for the treatment of bacterial    meningitis in children. N Engl J Med 1990; 322: 141-7.         [ Links ]74.- KLEIN N C, CUNHA B A. Cefalosporinas de    la tercera generación. Clin Med Nort Am 1995; 79: 693-707.         [ Links ]75.- KLUGMAN K P, MADHI S A. Emergence of    drug resistance impact on bacterial meningitis. Infect Dis Clin North Am 1999;    13: 637-46.         [ Links ]76.- RICHARDS D M, BROGDEN R N. Ceftazidime.    A review of its antibacterial activity, pharmacokinetic properties and therapeutic    use. Drugs 1985; 29: 105-61.         [ Links ]77.- SCHATZ B S, KARAVOKIROS K T, TAEUBEL    M A, ITOKAZU G S. Comparison of cefprozil, cefpodoxime proxetil, loracarbef,    cefixime, and ceftibuten. Ann Pharmacother 1996; 30: 258-68.         [ Links ]78.- DALMAU D, LAYRARGUES G P, FENYVES D,    WILLEMS B, TURGEON F, TURGEON P. Cefotaxime, desacetyl-cefotaxime, and bactericidal    activity in spontaneous bacterial peritonitis. J Infect Dis 1999; 180: 1597-1602.          [ Links ]79.- NIKAIDO W, LIU W, ROSENBERG E Y. Outer    membrane permeability and ß-lactamase stability of dipolar ionic cephalosporins    containing methoxyimino substituents. Antimicrob Agents Chemother 1990; 34:    337-42.         [ Links ]80.- HANCOCK R E W, BELLIDO F. Factors involved    in the enhanced efficacy against gram-negative bacteria of fourth generation    cephalosporins. J Antimicrob Chemother 1992; 29(Suppl A): 1-6.         [ Links ]81.- BELLIDO F, PECHERE J C, HANCOCK REW.    Novel method for measurement of outer membrane permeability to new beta-lactams    in intact Enterobacter cloacae cells. Antimicrob Agents Chemother 1991;    35: 68-72.         [ Links ]82.- NEU H C, CHIN N X, JULES K, LABTHAVIKUL    P. The activity of BMY-28142, a new broad spectrum beta-lactamase stable cephalosporin.    J Antimicrob Chemother 1986; 17: 441-52.         [ Links ]83.- KOBAYASHI S, ARAI S, HAYASHI S, FUJIMOTO    K. ß-lactamase stability of cefpirome (HR 810), a new cephalosporin with    a broad antimicrobial spectrum. Antimicrob Agents Chemother 1986; 30: 713-8.          [ Links ]84.- GARAU J, WILSON W, WOOD M, CARLET J.    Fourth generation cephalosporins: a review of in vitro activity, pharmacokinetics,    pharmacodynamics, and clinical utility. Clin Microb Infect 1997; 3 (Suppl 1):    87-101.         [ Links ]85.- KESSLER R E, FUNG-TOMC J. Susceptibility    of bacterial isolates to beta-lactam antibiotics from U.S. clinical trials over    5-year period. Am J Med 1996; 24 (6 A): 13-9.         [ Links ]86.- PIERARD D, EMMERECHTS K, LAUWERS S. Comparative    in-vitro activity of cefpirome against isolates from intensive care and haematology/oncology    units. Belgian Multicentric Study Group. J Antimicrob Chemother 1998; 41: 443-50.          [ Links ]87.- JONES R N. Resistance patterns among    nosocomial pathogens: trends over the past few years. Chest 2001; 119 (Suppl    2): 397-404.         [ Links ]88.- LORBER B. Changing patterns of infectious    diseases. Am J Med 1988; 84: 569-78.         [ Links ]89.- MOELLERING R C. A novel antimicrobial    agent joins the battle against resistant bacteria. Ann Intern Med 1999; 130:    155-7.         [ Links ]90.- WILSON W R. The role of fourth-generation    cephalosporins in the treatment of serious infectious diseases in hospitalized    patients. Diagn Microbiol Infect Dis 1998; 31: 473-7.         [ Links ]Correspondencia a:        Sergio Mella Montecinos        Laboratorio de Antibióticos,        Departamento de Microbiología,        Facultad de Ciencias Biológicas        Casilla 160-C, Concepción        E-mail: pignatio@ctcinternet.cl  

21.- AMERICAN THORACIC SOCIETY. Hospital-acquired    pneumonia in adults: diagnosis, assessment of severity, initial antimicrobial    therapy, and preventive strategies. A consensus statement. Am J Respir Crit    Care Med 1996; 153: 1711-25.         [ Links ]22.- BARTLETT J G, DOWELL S F, MANDELL L A,    FILE T M, MUSHER D M, FINE M J. Practice guidelines for the management of community-acquired    pneumonia in adults. Clin Infect Dis. 2000; 31: 347-82         [ Links ]23.- KARCHMER A W. Cephalosporins. In: Mandell,    Douglas & Bennett's. Principles and Practice of Infectious Diseases. Mandell    G L, Bennett J E, Dolin R, eds. Fifth edition. Philadelphia: Churchill Livingstone    2000; 274-99.         [ Links ]24.- ADU A, ARMOUR C L. Drug utilisation review    (DUR) of the third generation cephalosporins. Drugs 1995; 50: 423-39.         [ Links ]25.- JONES R N. Important and emerging ß-lactamase    mediated resistances in hospital-based pathogens: the Amp C enzymes. Diagn Microbiol    Infect Dis 1998; 31: 461-6.         [ Links ]26.- JARVIS W R, MARTONE W J. Predominant    pathogens in hospital infections. J Antimicrob Chemother 1992; 29: 19-24.         [ Links ]27.- LIVERMORE D M. ß-lactamases in    laboratory and clinical resistance. Clin Microbiol Rev 1995; 8: 557-84.         [ Links ]28.- HERITAGE J, M'ZALI F H, GASCOYNE-BINZI    D, HAWKEY P M. Evolution and spread of SHV extended-spectrum ß-lactamases    in gram negative bacteria. J Antimicrob Chemother 1999; 44: 309-18.         [ Links ]29.- PODSCHUN R, ULLMAN U. Klebsiella spp.    as nosocomial pathogens: epidemiology, taxonomy, typing methods, and pathogenicity    factors. Clin Microbiol Rev 1998; 11: 589-603.         [ Links ]30.- PITOUT J D D, SANDERS C C, SANDERS W    E. Antimicrobial resistance with focus on ß-lactam resistance in Gram    negative bacilli. Am J Med 1997; 103: 51-9.         [ Links ]31.- HANBERGER H, GARCIA-RODRIGUEZ J A, GOBERNADO    et al. Antibiotic susceptibility among aerobic Gram negative bacilli in intensive    care units in 5 european countries. JAMA 1999; 281: 67-71.         [ Links ]32.- CHARREL R N, PAGES J M, DE MICCO P et    al. Prevalence of outer membrane porin alteration in ß-lactam-antibiotic-resistant    Enterobacter aerogenes. Antimicrob Agents Chemother 1996; 40: 2854-8.          [ Links ]33.- BRADFORD P A, URBAN C, MARIANO N, PROJAN    S J, RAHAL J J, BUSH K. Imipenem resistance in Klebsiella pneumoniae is    associated with the combination of ACT-1, a plasmid-mediated Amp C ß-lactamase,    and the loss of an outer membrane protein. Antimicrob Agents Chemother 1997;    41: 563-9.         [ Links ]34.- QUEENAN A M, TORRES-VIERA C, GOLD H et    al. SME-type carbapenem-hydrolizing class A ß-lactamases from geographically    diverse Serratia marcescens strains. Antimicrob Agents Chemother 2000;    44: 3035-9.         [ Links ]35.- COHEN S P, MC MURRY L M, HOOPER D C,    WOLFSON J S, LEVY S B. Cross-resistance to fluoroquinolones in multiple-antibiotic-resistance    (Mar) Escherichia coli selected by tetracycline resistance: decreased    drug accumulation asociated with membrane changes in addition to Omp F reduction.    Antimicrob Agents Chemother 1989; 33:1318-25.         [ Links ]36.- SANDERS C C. Cefepime: The next generation?    Clin Infect Dis 1993; 17: 369-79         [ Links ]37.- GARAU J. The clinical potential of fourth-generation    cephalosporins. Diagn Microbiol Infect Dis 1998; 31: 479-80.         [ Links ]38.- CURTIS N A C, ORR D C, ROSS G W, BOULTON    M G. Affinities of penicillins and cephalosporins for the penicillin-binding    proteins of Escherichia coli    K-12 and their antibacterial activity. Antimicrob Agents Chemother 1979; 16:    533-9.  39.- BALANT L, DAYER P, AUCKENTHALER R. Clinical    pharmacokinetics of the third generation cephalosporins. Clin Pharmacokinetics    1985; 10: 101-43.         [ Links ]40.- WHEELER W J. Cephalosporins and other    beta-lactam antibiotics. Lloydia. 1977; 40: 519-42.         [ Links ]41.- LOPEZ F, GARRIDO J C. Química    y relación estructura-actividad de los antibióticos cefalosporínicos.    Rev Col Químico Farmacéutico 1989; 41: 5-14.         [ Links ]42.- FU K P, ASWAPOKEE P, HO I, MATTHIJSSEN    C, NEU H C. Pharmacokinetics of cefotaxime. Antimicrob Agents Chemother 1979;16:    592-7.         [ Links ]43.- YUK J H, NIGHTINGALE C H, QUINTILIANI    R. Clinical pharmacokinetics of ceftriaxone. Clin Pharmacokinetic 1989; 17:    223-35.         [ Links ]44.- BRYSKIER A, PROCYK T, LABRO M T. Cefodizime,    a new 2-aminothiazolyl cephalosporin: physicochemical properties, toxicology    and structure-activity relationships. J Antimicrob Chemother 1990; 26 (Suppl    C): 1-8.         [ Links ]45.- CRITCHLEY I A, BASKER M J, EDMONDSON    R A, KNOTT S J. Uptake of catecholic cephalosporin by the iron transport system    of Escherichia coli. J Antimicrob Chemother 1991; 28: 377-88.         [ Links ]46.- CRITCHLEY I A. Catecholic ß-lactams:    facilitated transport. J Antimicrob Chemother 1990; 26: 733-7.         [ Links ]47.- JONES R N, ERWIN M E. In vitro evaluation    of Ro 09-1227, a novel catechol-substituted cephalosporin. Antimicrob Agents    Chemother 1992; 36: 233-8.         [ Links ]48.- JONES R N. In vitro activity of Ro 24-6392,    a novel ester-linked co-drug combining ciprofloxacin and desacetylcefotaxime.    Eur J Clin Microbiol Infect Dis 1990; 9: 435-8.         [ Links ]49.- TOMASZ A. Penicillin-binding proteins    and the antibacterial effectiveness of ß-lactam antibiotics. Rev Infect    Dis 1986 (Suppl 3); 8: 260-78.         [ Links ]50.- HOLM S E. Interaction between ß-lactam    and other antibiotics. Rev Infect Dis 1986 (Suppl 3); 8: 305-14.         [ Links ]51.- MC CULLERS J A, ENGLISH B K, NOVAK R.    Isolation and characterization of vancomycin-tolerant Streptococcus pneumoniae    from the cerebrospinal fluid of a patient who developed recrudescet meningitis.    J Infect Dis 2000; 181: 369-73.         [ Links ]52.- NIKAIDO H. Outer membrane barrier as    a mechanism of antimicrobial resistance. Antimicrob Agents Chemother 1989; 33:    1831-6.         [ Links ]53.- BARRADELL L B, BRYSON H M. Cefepime.    A review of its antibacterial activity, pharmacokinetic properties and therapeutic    use. Drugs 1994; 47: 471-505.         [ Links ]54.- O'CALLAGHAN C H 1979. Description and    classification of the newer cephalosporins and their relationship with the established    compounds. J Antimicrob Chemother 5: 635-71         [ Links ]55.- BRYSKIER A, PROCYK T, TREMBLAY D, LENFANT    B FOURTILLAN J B. The pharmacokinetics of cefodizime following intravenous and    intramuscular administration of a single dose of 1.0 g. J Antimicrob Chemother    1990; 26 (Suppl. C): 59-63.         [ Links ]56.- WILLIAMS J D. Classification of cephalosporins.    Drugs. 1987; 34 (Suppl 2): 15-22.         [ Links ]57.- WISEMAN L R, LAMB H M. Cefpirome. A review    of its antibacterial activity, pharmacokinetic properties and efficacy in the    treatment of severe nosocomial infections and febrile neutropenia. Drugs 1997;    57: 117-40.         [ Links ]58.- PECHERE J C, WILSON W, NEU H. Laboratory    assesment of antibacterial activity of zwitterionic 7-methoxyimino cephalosporins.    J Antimicrob Chemother 1995; 36: 757-71         [ Links ]59.- GIAMARELLOS-BOURBOULIS EJ, GRECKA P,    TSITSIKA A, TYMPANIDOU C, GIAMARELLOU H. In-vitro activity of FK 037 (cefoselis),    a novel 4 (th) generation cephalosporin, cefepime and cefpirome on nosocomial    staphylococci and gram-negative isolates. Diagn Microbiol infect Dis 2000; 36:    185-91.         [ Links ]60.- JONES R N, ERWIN M E, BARRETT M S, JOHNSON    D M, BRIGGS B M. Antimicrobial activity of E-1040, a novel thiadiazolyl cephalosporin    compare with parenteral cephems. Diagn Microbiol infect Dis 1991; 14: 301-9.          [ Links ]61.- IIZAWA Y, OKONOGI K, HAYASHI R, IWAHI    T, YAMAZAKI T, IMADA A. Therapeutic effect of cefozopran (SCE-2787), a new parenteral    cephalosporin in experimental infections in mice. Antimicrob Agents Chemother    1993; 37: 100-5.         [ Links ]62.- WATANABE N A. Newer antipseudomonal cephalosporins.    J Chemother 1996; 8 (Suppl 2): 48-56.         [ Links ]63.- ACTOR P, GUARINI J, URI J et al. Disk    susceptibility studies with cefazolin and cephalotin. Antimicrob Agents Chemother    1974; 5: 63-7.         [ Links ]64.- UWAYDAH M. Cefazolin in the treatment    of acute enteric fever. Antimicrob Agents Chemother 1976; 10: 52-6.         [ Links ]65.- JAMAL W Y, ROTIMI V O, CHUGH T D, PAL    T. Prevalence and susceptibility of Shigella to 11 antibiotics in a Kuwait    teaching hospital. J Chemother 1998; 10: 285-90.         [ Links ]66.- COX CE, SHERRILL M, COCCHETT DM. Evaluation    of cefuroxime axetil, cefaclor, and cephalexin in the treatment of urinary tract    infections in adults. Curr Ther Res 1987; 42: 124-37.         [ Links ]67.- SANDERS C W, GREENBERG R N, MARIER R    L. Cefamandole and cefoxitin. Ann Intern Med 1985; 103: 70-8.          [ Links ]68.- STAPLEY E P, JACKSON M, HERNANDEZ S et    al. Cephamycins, a new family of ß-lactam antibiotics I. Production actinomycetes,    including Streptomyces lactamdurans spp.n. Antimicrob Agents Chemother    1972; 2: 122-31.         [ Links ]69.- COOPER R D G. The carbacephems a new    ß-lactams class. Am J Med 1992; 92 (Suppl 6 A): 25-65.         [ Links ]70.- ZEMELMAN R, BELLO H, DOMINGUEZ M, GONZALEZ    G, MELLA S, GARCIA A. Activity of imipenem, third-generation cephalosporins,    aztreonam, and ciprofloxacin against multi-resistant Gram negative bacilli isolated    from Chilean hospitals. J Antimicrob Chemother 1993; 32: 413-9.         [ Links ]71.- MEDEIROS A A. Evolution and dissemination    of ß-lactamases accelerated by generation of ß-lactam antibiotics.    Clin Infect Dis 1997; 24 (Suppl. 1): 19-45.         [ Links ]72.- PERRY C M, BROGDEN R N. Cefuroxime axetil:    review of its antibacterial activity, pharmacokinetic properties and therapeutic    efficacy. Drugs 1996; 52: 125-58.         [ Links ]73.- SCHAAD U B, SUTER S, GIANELLA-BORRADORI    et al. A comparison of ceftriaxone and cefuroxime for the treatment of bacterial    meningitis in children. N Engl J Med 1990; 322: 141-7.         [ Links ]74.- KLEIN N C, CUNHA B A. Cefalosporinas de    la tercera generación. Clin Med Nort Am 1995; 79: 693-707.         [ Links ]75.- KLUGMAN K P, MADHI S A. Emergence of    drug resistance impact on bacterial meningitis. Infect Dis Clin North Am 1999;    13: 637-46.         [ Links ]76.- RICHARDS D M, BROGDEN R N. Ceftazidime.    A review of its antibacterial activity, pharmacokinetic properties and therapeutic    use. Drugs 1985; 29: 105-61.         [ Links ]77.- SCHATZ B S, KARAVOKIROS K T, TAEUBEL    M A, ITOKAZU G S. Comparison of cefprozil, cefpodoxime proxetil, loracarbef,    cefixime, and ceftibuten. Ann Pharmacother 1996; 30: 258-68.         [ Links ]78.- DALMAU D, LAYRARGUES G P, FENYVES D,    WILLEMS B, TURGEON F, TURGEON P. Cefotaxime, desacetyl-cefotaxime, and bactericidal    activity in spontaneous bacterial peritonitis. J Infect Dis 1999; 180: 1597-1602.          [ Links ]79.- NIKAIDO W, LIU W, ROSENBERG E Y. Outer    membrane permeability and ß-lactamase stability of dipolar ionic cephalosporins    containing methoxyimino substituents. Antimicrob Agents Chemother 1990; 34:    337-42.         [ Links ]80.- HANCOCK R E W, BELLIDO F. Factors involved    in the enhanced efficacy against gram-negative bacteria of fourth generation    cephalosporins. J Antimicrob Chemother 1992; 29(Suppl A): 1-6.         [ Links ]81.- BELLIDO F, PECHERE J C, HANCOCK REW.    Novel method for measurement of outer membrane permeability to new beta-lactams    in intact Enterobacter cloacae cells. Antimicrob Agents Chemother 1991;    35: 68-72.         [ Links ]82.- NEU H C, CHIN N X, JULES K, LABTHAVIKUL    P. The activity of BMY-28142, a new broad spectrum beta-lactamase stable cephalosporin.    J Antimicrob Chemother 1986; 17: 441-52.         [ Links ]83.- KOBAYASHI S, ARAI S, HAYASHI S, FUJIMOTO    K. ß-lactamase stability of cefpirome (HR 810), a new cephalosporin with    a broad antimicrobial spectrum. Antimicrob Agents Chemother 1986; 30: 713-8.          [ Links ]84.- GARAU J, WILSON W, WOOD M, CARLET J.    Fourth generation cephalosporins: a review of in vitro activity, pharmacokinetics,    pharmacodynamics, and clinical utility. Clin Microb Infect 1997; 3 (Suppl 1):    87-101.         [ Links ]85.- KESSLER R E, FUNG-TOMC J. Susceptibility    of bacterial isolates to beta-lactam antibiotics from U.S. clinical trials over    5-year period. Am J Med 1996; 24 (6 A): 13-9.         [ Links ]86.- PIERARD D, EMMERECHTS K, LAUWERS S. Comparative    in-vitro activity of cefpirome against isolates from intensive care and haematology/oncology    units. Belgian Multicentric Study Group. J Antimicrob Chemother 1998; 41: 443-50.          [ Links ]87.- JONES R N. Resistance patterns among    nosocomial pathogens: trends over the past few years. Chest 2001; 119 (Suppl    2): 397-404.         [ Links ]88.- LORBER B. Changing patterns of infectious    diseases. Am J Med 1988; 84: 569-78.         [ Links ]89.- MOELLERING R C. A novel antimicrobial    agent joins the battle against resistant bacteria. Ann Intern Med 1999; 130:    155-7.         [ Links ]90.- WILSON W R. The role of fourth-generation    cephalosporins in the treatment of serious infectious diseases in hospitalized    patients. Diagn Microbiol Infect Dis 1998; 31: 473-7.         [ Links ]Correspondencia a:        Sergio Mella Montecinos        Laboratorio de Antibióticos,        Departamento de Microbiología,        Facultad de Ciencias Biológicas        Casilla 160-C, Concepción        E-mail: pignatio@ctcinternet.cl  

22.- BARTLETT J G, DOWELL S F, MANDELL L A,    FILE T M, MUSHER D M, FINE M J. Practice guidelines for the management of community-acquired    pneumonia in adults. Clin Infect Dis. 2000; 31: 347-82         [ Links ]23.- KARCHMER A W. Cephalosporins. In: Mandell,    Douglas & Bennett's. Principles and Practice of Infectious Diseases. Mandell    G L, Bennett J E, Dolin R, eds. Fifth edition. Philadelphia: Churchill Livingstone    2000; 274-99.         [ Links ]24.- ADU A, ARMOUR C L. Drug utilisation review    (DUR) of the third generation cephalosporins. Drugs 1995; 50: 423-39.         [ Links ]25.- JONES R N. Important and emerging ß-lactamase    mediated resistances in hospital-based pathogens: the Amp C enzymes. Diagn Microbiol    Infect Dis 1998; 31: 461-6.         [ Links ]26.- JARVIS W R, MARTONE W J. Predominant    pathogens in hospital infections. J Antimicrob Chemother 1992; 29: 19-24.         [ Links ]27.- LIVERMORE D M. ß-lactamases in    laboratory and clinical resistance. Clin Microbiol Rev 1995; 8: 557-84.         [ Links ]28.- HERITAGE J, M'ZALI F H, GASCOYNE-BINZI    D, HAWKEY P M. Evolution and spread of SHV extended-spectrum ß-lactamases    in gram negative bacteria. J Antimicrob Chemother 1999; 44: 309-18.         [ Links ]29.- PODSCHUN R, ULLMAN U. Klebsiella spp.    as nosocomial pathogens: epidemiology, taxonomy, typing methods, and pathogenicity    factors. Clin Microbiol Rev 1998; 11: 589-603.         [ Links ]30.- PITOUT J D D, SANDERS C C, SANDERS W    E. Antimicrobial resistance with focus on ß-lactam resistance in Gram    negative bacilli. Am J Med 1997; 103: 51-9.         [ Links ]31.- HANBERGER H, GARCIA-RODRIGUEZ J A, GOBERNADO    et al. Antibiotic susceptibility among aerobic Gram negative bacilli in intensive    care units in 5 european countries. JAMA 1999; 281: 67-71.         [ Links ]32.- CHARREL R N, PAGES J M, DE MICCO P et    al. Prevalence of outer membrane porin alteration in ß-lactam-antibiotic-resistant    Enterobacter aerogenes. Antimicrob Agents Chemother 1996; 40: 2854-8.          [ Links ]33.- BRADFORD P A, URBAN C, MARIANO N, PROJAN    S J, RAHAL J J, BUSH K. Imipenem resistance in Klebsiella pneumoniae is    associated with the combination of ACT-1, a plasmid-mediated Amp C ß-lactamase,    and the loss of an outer membrane protein. Antimicrob Agents Chemother 1997;    41: 563-9.         [ Links ]34.- QUEENAN A M, TORRES-VIERA C, GOLD H et    al. SME-type carbapenem-hydrolizing class A ß-lactamases from geographically    diverse Serratia marcescens strains. Antimicrob Agents Chemother 2000;    44: 3035-9.         [ Links ]35.- COHEN S P, MC MURRY L M, HOOPER D C,    WOLFSON J S, LEVY S B. Cross-resistance to fluoroquinolones in multiple-antibiotic-resistance    (Mar) Escherichia coli selected by tetracycline resistance: decreased    drug accumulation asociated with membrane changes in addition to Omp F reduction.    Antimicrob Agents Chemother 1989; 33:1318-25.         [ Links ]36.- SANDERS C C. Cefepime: The next generation?    Clin Infect Dis 1993; 17: 369-79         [ Links ]37.- GARAU J. The clinical potential of fourth-generation    cephalosporins. Diagn Microbiol Infect Dis 1998; 31: 479-80.         [ Links ]38.- CURTIS N A C, ORR D C, ROSS G W, BOULTON    M G. Affinities of penicillins and cephalosporins for the penicillin-binding    proteins of Escherichia coli    K-12 and their antibacterial activity. Antimicrob Agents Chemother 1979; 16:    533-9.  39.- BALANT L, DAYER P, AUCKENTHALER R. Clinical    pharmacokinetics of the third generation cephalosporins. Clin Pharmacokinetics    1985; 10: 101-43.         [ Links ]40.- WHEELER W J. Cephalosporins and other    beta-lactam antibiotics. Lloydia. 1977; 40: 519-42.         [ Links ]41.- LOPEZ F, GARRIDO J C. Química    y relación estructura-actividad de los antibióticos cefalosporínicos.    Rev Col Químico Farmacéutico 1989; 41: 5-14.         [ Links ]42.- FU K P, ASWAPOKEE P, HO I, MATTHIJSSEN    C, NEU H C. Pharmacokinetics of cefotaxime. Antimicrob Agents Chemother 1979;16:    592-7.         [ Links ]43.- YUK J H, NIGHTINGALE C H, QUINTILIANI    R. Clinical pharmacokinetics of ceftriaxone. Clin Pharmacokinetic 1989; 17:    223-35.         [ Links ]44.- BRYSKIER A, PROCYK T, LABRO M T. Cefodizime,    a new 2-aminothiazolyl cephalosporin: physicochemical properties, toxicology    and structure-activity relationships. J Antimicrob Chemother 1990; 26 (Suppl    C): 1-8.         [ Links ]45.- CRITCHLEY I A, BASKER M J, EDMONDSON    R A, KNOTT S J. Uptake of catecholic cephalosporin by the iron transport system    of Escherichia coli. J Antimicrob Chemother 1991; 28: 377-88.         [ Links ]46.- CRITCHLEY I A. Catecholic ß-lactams:    facilitated transport. J Antimicrob Chemother 1990; 26: 733-7.         [ Links ]47.- JONES R N, ERWIN M E. In vitro evaluation    of Ro 09-1227, a novel catechol-substituted cephalosporin. Antimicrob Agents    Chemother 1992; 36: 233-8.         [ Links ]48.- JONES R N. In vitro activity of Ro 24-6392,    a novel ester-linked co-drug combining ciprofloxacin and desacetylcefotaxime.    Eur J Clin Microbiol Infect Dis 1990; 9: 435-8.         [ Links ]49.- TOMASZ A. Penicillin-binding proteins    and the antibacterial effectiveness of ß-lactam antibiotics. Rev Infect    Dis 1986 (Suppl 3); 8: 260-78.         [ Links ]50.- HOLM S E. Interaction between ß-lactam    and other antibiotics. Rev Infect Dis 1986 (Suppl 3); 8: 305-14.         [ Links ]51.- MC CULLERS J A, ENGLISH B K, NOVAK R.    Isolation and characterization of vancomycin-tolerant Streptococcus pneumoniae    from the cerebrospinal fluid of a patient who developed recrudescet meningitis.    J Infect Dis 2000; 181: 369-73.         [ Links ]52.- NIKAIDO H. Outer membrane barrier as    a mechanism of antimicrobial resistance. Antimicrob Agents Chemother 1989; 33:    1831-6.         [ Links ]53.- BARRADELL L B, BRYSON H M. Cefepime.    A review of its antibacterial activity, pharmacokinetic properties and therapeutic    use. Drugs 1994; 47: 471-505.         [ Links ]54.- O'CALLAGHAN C H 1979. Description and    classification of the newer cephalosporins and their relationship with the established    compounds. J Antimicrob Chemother 5: 635-71         [ Links ]55.- BRYSKIER A, PROCYK T, TREMBLAY D, LENFANT    B FOURTILLAN J B. The pharmacokinetics of cefodizime following intravenous and    intramuscular administration of a single dose of 1.0 g. J Antimicrob Chemother    1990; 26 (Suppl. C): 59-63.         [ Links ]56.- WILLIAMS J D. Classification of cephalosporins.    Drugs. 1987; 34 (Suppl 2): 15-22.         [ Links ]57.- WISEMAN L R, LAMB H M. Cefpirome. A review    of its antibacterial activity, pharmacokinetic properties and efficacy in the    treatment of severe nosocomial infections and febrile neutropenia. Drugs 1997;    57: 117-40.         [ Links ]58.- PECHERE J C, WILSON W, NEU H. Laboratory    assesment of antibacterial activity of zwitterionic 7-methoxyimino cephalosporins.    J Antimicrob Chemother 1995; 36: 757-71         [ Links ]59.- GIAMARELLOS-BOURBOULIS EJ, GRECKA P,    TSITSIKA A, TYMPANIDOU C, GIAMARELLOU H. In-vitro activity of FK 037 (cefoselis),    a novel 4 (th) generation cephalosporin, cefepime and cefpirome on nosocomial    staphylococci and gram-negative isolates. Diagn Microbiol infect Dis 2000; 36:    185-91.         [ Links ]60.- JONES R N, ERWIN M E, BARRETT M S, JOHNSON    D M, BRIGGS B M. Antimicrobial activity of E-1040, a novel thiadiazolyl cephalosporin    compare with parenteral cephems. Diagn Microbiol infect Dis 1991; 14: 301-9.          [ Links ]61.- IIZAWA Y, OKONOGI K, HAYASHI R, IWAHI    T, YAMAZAKI T, IMADA A. Therapeutic effect of cefozopran (SCE-2787), a new parenteral    cephalosporin in experimental infections in mice. Antimicrob Agents Chemother    1993; 37: 100-5.         [ Links ]62.- WATANABE N A. Newer antipseudomonal cephalosporins.    J Chemother 1996; 8 (Suppl 2): 48-56.         [ Links ]63.- ACTOR P, GUARINI J, URI J et al. Disk    susceptibility studies with cefazolin and cephalotin. Antimicrob Agents Chemother    1974; 5: 63-7.         [ Links ]64.- UWAYDAH M. Cefazolin in the treatment    of acute enteric fever. Antimicrob Agents Chemother 1976; 10: 52-6.         [ Links ]65.- JAMAL W Y, ROTIMI V O, CHUGH T D, PAL    T. Prevalence and susceptibility of Shigella to 11 antibiotics in a Kuwait    teaching hospital. J Chemother 1998; 10: 285-90.         [ Links ]66.- COX CE, SHERRILL M, COCCHETT DM. Evaluation    of cefuroxime axetil, cefaclor, and cephalexin in the treatment of urinary tract    infections in adults. Curr Ther Res 1987; 42: 124-37.         [ Links ]67.- SANDERS C W, GREENBERG R N, MARIER R    L. Cefamandole and cefoxitin. Ann Intern Med 1985; 103: 70-8.          [ Links ]68.- STAPLEY E P, JACKSON M, HERNANDEZ S et    al. Cephamycins, a new family of ß-lactam antibiotics I. Production actinomycetes,    including Streptomyces lactamdurans spp.n. Antimicrob Agents Chemother    1972; 2: 122-31.         [ Links ]69.- COOPER R D G. The carbacephems a new    ß-lactams class. Am J Med 1992; 92 (Suppl 6 A): 25-65.         [ Links ]70.- ZEMELMAN R, BELLO H, DOMINGUEZ M, GONZALEZ    G, MELLA S, GARCIA A. Activity of imipenem, third-generation cephalosporins,    aztreonam, and ciprofloxacin against multi-resistant Gram negative bacilli isolated    from Chilean hospitals. J Antimicrob Chemother 1993; 32: 413-9.         [ Links ]71.- MEDEIROS A A. Evolution and dissemination    of ß-lactamases accelerated by generation of ß-lactam antibiotics.    Clin Infect Dis 1997; 24 (Suppl. 1): 19-45.         [ Links ]72.- PERRY C M, BROGDEN R N. Cefuroxime axetil:    review of its antibacterial activity, pharmacokinetic properties and therapeutic    efficacy. Drugs 1996; 52: 125-58.         [ Links ]73.- SCHAAD U B, SUTER S, GIANELLA-BORRADORI    et al. A comparison of ceftriaxone and cefuroxime for the treatment of bacterial    meningitis in children. N Engl J Med 1990; 322: 141-7.         [ Links ]74.- KLEIN N C, CUNHA B A. Cefalosporinas de    la tercera generación. Clin Med Nort Am 1995; 79: 693-707.         [ Links ]75.- KLUGMAN K P, MADHI S A. Emergence of    drug resistance impact on bacterial meningitis. Infect Dis Clin North Am 1999;    13: 637-46.         [ Links ]76.- RICHARDS D M, BROGDEN R N. Ceftazidime.    A review of its antibacterial activity, pharmacokinetic properties and therapeutic    use. Drugs 1985; 29: 105-61.         [ Links ]77.- SCHATZ B S, KARAVOKIROS K T, TAEUBEL    M A, ITOKAZU G S. Comparison of cefprozil, cefpodoxime proxetil, loracarbef,    cefixime, and ceftibuten. Ann Pharmacother 1996; 30: 258-68.         [ Links ]78.- DALMAU D, LAYRARGUES G P, FENYVES D,    WILLEMS B, TURGEON F, TURGEON P. Cefotaxime, desacetyl-cefotaxime, and bactericidal    activity in spontaneous bacterial peritonitis. J Infect Dis 1999; 180: 1597-1602.          [ Links ]79.- NIKAIDO W, LIU W, ROSENBERG E Y. Outer    membrane permeability and ß-lactamase stability of dipolar ionic cephalosporins    containing methoxyimino substituents. Antimicrob Agents Chemother 1990; 34:    337-42.         [ Links ]80.- HANCOCK R E W, BELLIDO F. Factors involved    in the enhanced efficacy against gram-negative bacteria of fourth generation    cephalosporins. J Antimicrob Chemother 1992; 29(Suppl A): 1-6.         [ Links ]81.- BELLIDO F, PECHERE J C, HANCOCK REW.    Novel method for measurement of outer membrane permeability to new beta-lactams    in intact Enterobacter cloacae cells. Antimicrob Agents Chemother 1991;    35: 68-72.         [ Links ]82.- NEU H C, CHIN N X, JULES K, LABTHAVIKUL    P. The activity of BMY-28142, a new broad spectrum beta-lactamase stable cephalosporin.    J Antimicrob Chemother 1986; 17: 441-52.         [ Links ]83.- KOBAYASHI S, ARAI S, HAYASHI S, FUJIMOTO    K. ß-lactamase stability of cefpirome (HR 810), a new cephalosporin with    a broad antimicrobial spectrum. Antimicrob Agents Chemother 1986; 30: 713-8.          [ Links ]84.- GARAU J, WILSON W, WOOD M, CARLET J.    Fourth generation cephalosporins: a review of in vitro activity, pharmacokinetics,    pharmacodynamics, and clinical utility. Clin Microb Infect 1997; 3 (Suppl 1):    87-101.         [ Links ]85.- KESSLER R E, FUNG-TOMC J. Susceptibility    of bacterial isolates to beta-lactam antibiotics from U.S. clinical trials over    5-year period. Am J Med 1996; 24 (6 A): 13-9.         [ Links ]86.- PIERARD D, EMMERECHTS K, LAUWERS S. Comparative    in-vitro activity of cefpirome against isolates from intensive care and haematology/oncology    units. Belgian Multicentric Study Group. J Antimicrob Chemother 1998; 41: 443-50.          [ Links ]87.- JONES R N. Resistance patterns among    nosocomial pathogens: trends over the past few years. Chest 2001; 119 (Suppl    2): 397-404.         [ Links ]88.- LORBER B. Changing patterns of infectious    diseases. Am J Med 1988; 84: 569-78.         [ Links ]89.- MOELLERING R C. A novel antimicrobial    agent joins the battle against resistant bacteria. Ann Intern Med 1999; 130:    155-7.         [ Links ]90.- WILSON W R. The role of fourth-generation    cephalosporins in the treatment of serious infectious diseases in hospitalized    patients. Diagn Microbiol Infect Dis 1998; 31: 473-7.         [ Links ]Correspondencia a:        Sergio Mella Montecinos        Laboratorio de Antibióticos,        Departamento de Microbiología,        Facultad de Ciencias Biológicas        Casilla 160-C, Concepción        E-mail: pignatio@ctcinternet.cl  

23.- KARCHMER A W. Cephalosporins. In: Mandell,    Douglas & Bennett's. Principles and Practice of Infectious Diseases. Mandell    G L, Bennett J E, Dolin R, eds. Fifth edition. Philadelphia: Churchill Livingstone    2000; 274-99.         [ Links ]24.- ADU A, ARMOUR C L. Drug utilisation review    (DUR) of the third generation cephalosporins. Drugs 1995; 50: 423-39.         [ Links ]25.- JONES R N. Important and emerging ß-lactamase    mediated resistances in hospital-based pathogens: the Amp C enzymes. Diagn Microbiol    Infect Dis 1998; 31: 461-6.         [ Links ]26.- JARVIS W R, MARTONE W J. Predominant    pathogens in hospital infections. J Antimicrob Chemother 1992; 29: 19-24.         [ Links ]27.- LIVERMORE D M. ß-lactamases in    laboratory and clinical resistance. Clin Microbiol Rev 1995; 8: 557-84.         [ Links ]28.- HERITAGE J, M'ZALI F H, GASCOYNE-BINZI    D, HAWKEY P M. Evolution and spread of SHV extended-spectrum ß-lactamases    in gram negative bacteria. J Antimicrob Chemother 1999; 44: 309-18.         [ Links ]29.- PODSCHUN R, ULLMAN U. Klebsiella spp.    as nosocomial pathogens: epidemiology, taxonomy, typing methods, and pathogenicity    factors. Clin Microbiol Rev 1998; 11: 589-603.         [ Links ]30.- PITOUT J D D, SANDERS C C, SANDERS W    E. Antimicrobial resistance with focus on ß-lactam resistance in Gram    negative bacilli. Am J Med 1997; 103: 51-9.         [ Links ]31.- HANBERGER H, GARCIA-RODRIGUEZ J A, GOBERNADO    et al. Antibiotic susceptibility among aerobic Gram negative bacilli in intensive    care units in 5 european countries. JAMA 1999; 281: 67-71.         [ Links ]32.- CHARREL R N, PAGES J M, DE MICCO P et    al. Prevalence of outer membrane porin alteration in ß-lactam-antibiotic-resistant    Enterobacter aerogenes. Antimicrob Agents Chemother 1996; 40: 2854-8.          [ Links ]33.- BRADFORD P A, URBAN C, MARIANO N, PROJAN    S J, RAHAL J J, BUSH K. Imipenem resistance in Klebsiella pneumoniae is    associated with the combination of ACT-1, a plasmid-mediated Amp C ß-lactamase,    and the loss of an outer membrane protein. Antimicrob Agents Chemother 1997;    41: 563-9.         [ Links ]34.- QUEENAN A M, TORRES-VIERA C, GOLD H et    al. SME-type carbapenem-hydrolizing class A ß-lactamases from geographically    diverse Serratia marcescens strains. Antimicrob Agents Chemother 2000;    44: 3035-9.         [ Links ]35.- COHEN S P, MC MURRY L M, HOOPER D C,    WOLFSON J S, LEVY S B. Cross-resistance to fluoroquinolones in multiple-antibiotic-resistance    (Mar) Escherichia coli selected by tetracycline resistance: decreased    drug accumulation asociated with membrane changes in addition to Omp F reduction.    Antimicrob Agents Chemother 1989; 33:1318-25.         [ Links ]36.- SANDERS C C. Cefepime: The next generation?    Clin Infect Dis 1993; 17: 369-79         [ Links ]37.- GARAU J. The clinical potential of fourth-generation    cephalosporins. Diagn Microbiol Infect Dis 1998; 31: 479-80.         [ Links ]38.- CURTIS N A C, ORR D C, ROSS G W, BOULTON    M G. Affinities of penicillins and cephalosporins for the penicillin-binding    proteins of Escherichia coli    K-12 and their antibacterial activity. Antimicrob Agents Chemother 1979; 16:    533-9.  39.- BALANT L, DAYER P, AUCKENTHALER R. Clinical    pharmacokinetics of the third generation cephalosporins. Clin Pharmacokinetics    1985; 10: 101-43.         [ Links ]40.- WHEELER W J. Cephalosporins and other    beta-lactam antibiotics. Lloydia. 1977; 40: 519-42.         [ Links ]41.- LOPEZ F, GARRIDO J C. Química    y relación estructura-actividad de los antibióticos cefalosporínicos.    Rev Col Químico Farmacéutico 1989; 41: 5-14.         [ Links ]42.- FU K P, ASWAPOKEE P, HO I, MATTHIJSSEN    C, NEU H C. Pharmacokinetics of cefotaxime. Antimicrob Agents Chemother 1979;16:    592-7.         [ Links ]43.- YUK J H, NIGHTINGALE C H, QUINTILIANI    R. Clinical pharmacokinetics of ceftriaxone. Clin Pharmacokinetic 1989; 17:    223-35.         [ Links ]44.- BRYSKIER A, PROCYK T, LABRO M T. Cefodizime,    a new 2-aminothiazolyl cephalosporin: physicochemical properties, toxicology    and structure-activity relationships. J Antimicrob Chemother 1990; 26 (Suppl    C): 1-8.         [ Links ]45.- CRITCHLEY I A, BASKER M J, EDMONDSON    R A, KNOTT S J. Uptake of catecholic cephalosporin by the iron transport system    of Escherichia coli. J Antimicrob Chemother 1991; 28: 377-88.         [ Links ]46.- CRITCHLEY I A. Catecholic ß-lactams:    facilitated transport. J Antimicrob Chemother 1990; 26: 733-7.         [ Links ]47.- JONES R N, ERWIN M E. In vitro evaluation    of Ro 09-1227, a novel catechol-substituted cephalosporin. Antimicrob Agents    Chemother 1992; 36: 233-8.         [ Links ]48.- JONES R N. In vitro activity of Ro 24-6392,    a novel ester-linked co-drug combining ciprofloxacin and desacetylcefotaxime.    Eur J Clin Microbiol Infect Dis 1990; 9: 435-8.         [ Links ]49.- TOMASZ A. Penicillin-binding proteins    and the antibacterial effectiveness of ß-lactam antibiotics. Rev Infect    Dis 1986 (Suppl 3); 8: 260-78.         [ Links ]50.- HOLM S E. Interaction between ß-lactam    and other antibiotics. Rev Infect Dis 1986 (Suppl 3); 8: 305-14.         [ Links ]51.- MC CULLERS J A, ENGLISH B K, NOVAK R.    Isolation and characterization of vancomycin-tolerant Streptococcus pneumoniae    from the cerebrospinal fluid of a patient who developed recrudescet meningitis.    J Infect Dis 2000; 181: 369-73.         [ Links ]52.- NIKAIDO H. Outer membrane barrier as    a mechanism of antimicrobial resistance. Antimicrob Agents Chemother 1989; 33:    1831-6.         [ Links ]53.- BARRADELL L B, BRYSON H M. Cefepime.    A review of its antibacterial activity, pharmacokinetic properties and therapeutic    use. Drugs 1994; 47: 471-505.         [ Links ]54.- O'CALLAGHAN C H 1979. Description and    classification of the newer cephalosporins and their relationship with the established    compounds. J Antimicrob Chemother 5: 635-71         [ Links ]55.- BRYSKIER A, PROCYK T, TREMBLAY D, LENFANT    B FOURTILLAN J B. The pharmacokinetics of cefodizime following intravenous and    intramuscular administration of a single dose of 1.0 g. J Antimicrob Chemother    1990; 26 (Suppl. C): 59-63.         [ Links ]56.- WILLIAMS J D. Classification of cephalosporins.    Drugs. 1987; 34 (Suppl 2): 15-22.         [ Links ]57.- WISEMAN L R, LAMB H M. Cefpirome. A review    of its antibacterial activity, pharmacokinetic properties and efficacy in the    treatment of severe nosocomial infections and febrile neutropenia. Drugs 1997;    57: 117-40.         [ Links ]58.- PECHERE J C, WILSON W, NEU H. Laboratory    assesment of antibacterial activity of zwitterionic 7-methoxyimino cephalosporins.    J Antimicrob Chemother 1995; 36: 757-71         [ Links ]59.- GIAMARELLOS-BOURBOULIS EJ, GRECKA P,    TSITSIKA A, TYMPANIDOU C, GIAMARELLOU H. In-vitro activity of FK 037 (cefoselis),    a novel 4 (th) generation cephalosporin, cefepime and cefpirome on nosocomial    staphylococci and gram-negative isolates. Diagn Microbiol infect Dis 2000; 36:    185-91.         [ Links ]60.- JONES R N, ERWIN M E, BARRETT M S, JOHNSON    D M, BRIGGS B M. Antimicrobial activity of E-1040, a novel thiadiazolyl cephalosporin    compare with parenteral cephems. Diagn Microbiol infect Dis 1991; 14: 301-9.          [ Links ]61.- IIZAWA Y, OKONOGI K, HAYASHI R, IWAHI    T, YAMAZAKI T, IMADA A. Therapeutic effect of cefozopran (SCE-2787), a new parenteral    cephalosporin in experimental infections in mice. Antimicrob Agents Chemother    1993; 37: 100-5.         [ Links ]62.- WATANABE N A. Newer antipseudomonal cephalosporins.    J Chemother 1996; 8 (Suppl 2): 48-56.         [ Links ]63.- ACTOR P, GUARINI J, URI J et al. Disk    susceptibility studies with cefazolin and cephalotin. Antimicrob Agents Chemother    1974; 5: 63-7.         [ Links ]64.- UWAYDAH M. Cefazolin in the treatment    of acute enteric fever. Antimicrob Agents Chemother 1976; 10: 52-6.         [ Links ]65.- JAMAL W Y, ROTIMI V O, CHUGH T D, PAL    T. Prevalence and susceptibility of Shigella to 11 antibiotics in a Kuwait    teaching hospital. J Chemother 1998; 10: 285-90.         [ Links ]66.- COX CE, SHERRILL M, COCCHETT DM. Evaluation    of cefuroxime axetil, cefaclor, and cephalexin in the treatment of urinary tract    infections in adults. Curr Ther Res 1987; 42: 124-37.         [ Links ]67.- SANDERS C W, GREENBERG R N, MARIER R    L. Cefamandole and cefoxitin. Ann Intern Med 1985; 103: 70-8.          [ Links ]68.- STAPLEY E P, JACKSON M, HERNANDEZ S et    al. Cephamycins, a new family of ß-lactam antibiotics I. Production actinomycetes,    including Streptomyces lactamdurans spp.n. Antimicrob Agents Chemother    1972; 2: 122-31.         [ Links ]69.- COOPER R D G. The carbacephems a new    ß-lactams class. Am J Med 1992; 92 (Suppl 6 A): 25-65.         [ Links ]70.- ZEMELMAN R, BELLO H, DOMINGUEZ M, GONZALEZ    G, MELLA S, GARCIA A. Activity of imipenem, third-generation cephalosporins,    aztreonam, and ciprofloxacin against multi-resistant Gram negative bacilli isolated    from Chilean hospitals. J Antimicrob Chemother 1993; 32: 413-9.         [ Links ]71.- MEDEIROS A A. Evolution and dissemination    of ß-lactamases accelerated by generation of ß-lactam antibiotics.    Clin Infect Dis 1997; 24 (Suppl. 1): 19-45.         [ Links ]72.- PERRY C M, BROGDEN R N. Cefuroxime axetil:    review of its antibacterial activity, pharmacokinetic properties and therapeutic    efficacy. Drugs 1996; 52: 125-58.         [ Links ]73.- SCHAAD U B, SUTER S, GIANELLA-BORRADORI    et al. A comparison of ceftriaxone and cefuroxime for the treatment of bacterial    meningitis in children. N Engl J Med 1990; 322: 141-7.         [ Links ]74.- KLEIN N C, CUNHA B A. Cefalosporinas de    la tercera generación. Clin Med Nort Am 1995; 79: 693-707.         [ Links ]75.- KLUGMAN K P, MADHI S A. Emergence of    drug resistance impact on bacterial meningitis. Infect Dis Clin North Am 1999;    13: 637-46.         [ Links ]76.- RICHARDS D M, BROGDEN R N. Ceftazidime.    A review of its antibacterial activity, pharmacokinetic properties and therapeutic    use. Drugs 1985; 29: 105-61.         [ Links ]77.- SCHATZ B S, KARAVOKIROS K T, TAEUBEL    M A, ITOKAZU G S. Comparison of cefprozil, cefpodoxime proxetil, loracarbef,    cefixime, and ceftibuten. Ann Pharmacother 1996; 30: 258-68.         [ Links ]78.- DALMAU D, LAYRARGUES G P, FENYVES D,    WILLEMS B, TURGEON F, TURGEON P. Cefotaxime, desacetyl-cefotaxime, and bactericidal    activity in spontaneous bacterial peritonitis. J Infect Dis 1999; 180: 1597-1602.          [ Links ]79.- NIKAIDO W, LIU W, ROSENBERG E Y. Outer    membrane permeability and ß-lactamase stability of dipolar ionic cephalosporins    containing methoxyimino substituents. Antimicrob Agents Chemother 1990; 34:    337-42.         [ Links ]80.- HANCOCK R E W, BELLIDO F. Factors involved    in the enhanced efficacy against gram-negative bacteria of fourth generation    cephalosporins. J Antimicrob Chemother 1992; 29(Suppl A): 1-6.         [ Links ]81.- BELLIDO F, PECHERE J C, HANCOCK REW.    Novel method for measurement of outer membrane permeability to new beta-lactams    in intact Enterobacter cloacae cells. Antimicrob Agents Chemother 1991;    35: 68-72.         [ Links ]82.- NEU H C, CHIN N X, JULES K, LABTHAVIKUL    P. The activity of BMY-28142, a new broad spectrum beta-lactamase stable cephalosporin.    J Antimicrob Chemother 1986; 17: 441-52.         [ Links ]83.- KOBAYASHI S, ARAI S, HAYASHI S, FUJIMOTO    K. ß-lactamase stability of cefpirome (HR 810), a new cephalosporin with    a broad antimicrobial spectrum. Antimicrob Agents Chemother 1986; 30: 713-8.          [ Links ]84.- GARAU J, WILSON W, WOOD M, CARLET J.    Fourth generation cephalosporins: a review of in vitro activity, pharmacokinetics,    pharmacodynamics, and clinical utility. Clin Microb Infect 1997; 3 (Suppl 1):    87-101.         [ Links ]85.- KESSLER R E, FUNG-TOMC J. Susceptibility    of bacterial isolates to beta-lactam antibiotics from U.S. clinical trials over    5-year period. Am J Med 1996; 24 (6 A): 13-9.         [ Links ]86.- PIERARD D, EMMERECHTS K, LAUWERS S. Comparative    in-vitro activity of cefpirome against isolates from intensive care and haematology/oncology    units. Belgian Multicentric Study Group. J Antimicrob Chemother 1998; 41: 443-50.          [ Links ]87.- JONES R N. Resistance patterns among    nosocomial pathogens: trends over the past few years. Chest 2001; 119 (Suppl    2): 397-404.         [ Links ]88.- LORBER B. Changing patterns of infectious    diseases. Am J Med 1988; 84: 569-78.         [ Links ]89.- MOELLERING R C. A novel antimicrobial    agent joins the battle against resistant bacteria. Ann Intern Med 1999; 130:    155-7.         [ Links ]90.- WILSON W R. The role of fourth-generation    cephalosporins in the treatment of serious infectious diseases in hospitalized    patients. Diagn Microbiol Infect Dis 1998; 31: 473-7.         [ Links ]Correspondencia a:        Sergio Mella Montecinos        Laboratorio de Antibióticos,        Departamento de Microbiología,        Facultad de Ciencias Biológicas        Casilla 160-C, Concepción        E-mail: pignatio@ctcinternet.cl  

24.- ADU A, ARMOUR C L. Drug utilisation review    (DUR) of the third generation cephalosporins. Drugs 1995; 50: 423-39.         [ Links ]25.- JONES R N. Important and emerging ß-lactamase    mediated resistances in hospital-based pathogens: the Amp C enzymes. Diagn Microbiol    Infect Dis 1998; 31: 461-6.         [ Links ]26.- JARVIS W R, MARTONE W J. Predominant    pathogens in hospital infections. J Antimicrob Chemother 1992; 29: 19-24.         [ Links ]27.- LIVERMORE D M. ß-lactamases in    laboratory and clinical resistance. Clin Microbiol Rev 1995; 8: 557-84.         [ Links ]28.- HERITAGE J, M'ZALI F H, GASCOYNE-BINZI    D, HAWKEY P M. Evolution and spread of SHV extended-spectrum ß-lactamases    in gram negative bacteria. J Antimicrob Chemother 1999; 44: 309-18.         [ Links ]29.- PODSCHUN R, ULLMAN U. Klebsiella spp.    as nosocomial pathogens: epidemiology, taxonomy, typing methods, and pathogenicity    factors. Clin Microbiol Rev 1998; 11: 589-603.         [ Links ]30.- PITOUT J D D, SANDERS C C, SANDERS W    E. Antimicrobial resistance with focus on ß-lactam resistance in Gram    negative bacilli. Am J Med 1997; 103: 51-9.         [ Links ]31.- HANBERGER H, GARCIA-RODRIGUEZ J A, GOBERNADO    et al. Antibiotic susceptibility among aerobic Gram negative bacilli in intensive    care units in 5 european countries. JAMA 1999; 281: 67-71.         [ Links ]32.- CHARREL R N, PAGES J M, DE MICCO P et    al. Prevalence of outer membrane porin alteration in ß-lactam-antibiotic-resistant    Enterobacter aerogenes. Antimicrob Agents Chemother 1996; 40: 2854-8.          [ Links ]33.- BRADFORD P A, URBAN C, MARIANO N, PROJAN    S J, RAHAL J J, BUSH K. Imipenem resistance in Klebsiella pneumoniae is    associated with the combination of ACT-1, a plasmid-mediated Amp C ß-lactamase,    and the loss of an outer membrane protein. Antimicrob Agents Chemother 1997;    41: 563-9.         [ Links ]34.- QUEENAN A M, TORRES-VIERA C, GOLD H et    al. SME-type carbapenem-hydrolizing class A ß-lactamases from geographically    diverse Serratia marcescens strains. Antimicrob Agents Chemother 2000;    44: 3035-9.         [ Links ]35.- COHEN S P, MC MURRY L M, HOOPER D C,    WOLFSON J S, LEVY S B. Cross-resistance to fluoroquinolones in multiple-antibiotic-resistance    (Mar) Escherichia coli selected by tetracycline resistance: decreased    drug accumulation asociated with membrane changes in addition to Omp F reduction.    Antimicrob Agents Chemother 1989; 33:1318-25.         [ Links ]36.- SANDERS C C. Cefepime: The next generation?    Clin Infect Dis 1993; 17: 369-79         [ Links ]37.- GARAU J. The clinical potential of fourth-generation    cephalosporins. Diagn Microbiol Infect Dis 1998; 31: 479-80.         [ Links ]38.- CURTIS N A C, ORR D C, ROSS G W, BOULTON    M G. Affinities of penicillins and cephalosporins for the penicillin-binding    proteins of Escherichia coli    K-12 and their antibacterial activity. Antimicrob Agents Chemother 1979; 16:    533-9.  39.- BALANT L, DAYER P, AUCKENTHALER R. Clinical    pharmacokinetics of the third generation cephalosporins. Clin Pharmacokinetics    1985; 10: 101-43.         [ Links ]40.- WHEELER W J. Cephalosporins and other    beta-lactam antibiotics. Lloydia. 1977; 40: 519-42.         [ Links ]41.- LOPEZ F, GARRIDO J C. Química    y relación estructura-actividad de los antibióticos cefalosporínicos.    Rev Col Químico Farmacéutico 1989; 41: 5-14.         [ Links ]42.- FU K P, ASWAPOKEE P, HO I, MATTHIJSSEN    C, NEU H C. Pharmacokinetics of cefotaxime. Antimicrob Agents Chemother 1979;16:    592-7.         [ Links ]43.- YUK J H, NIGHTINGALE C H, QUINTILIANI    R. Clinical pharmacokinetics of ceftriaxone. Clin Pharmacokinetic 1989; 17:    223-35.         [ Links ]44.- BRYSKIER A, PROCYK T, LABRO M T. Cefodizime,    a new 2-aminothiazolyl cephalosporin: physicochemical properties, toxicology    and structure-activity relationships. J Antimicrob Chemother 1990; 26 (Suppl    C): 1-8.         [ Links ]45.- CRITCHLEY I A, BASKER M J, EDMONDSON    R A, KNOTT S J. Uptake of catecholic cephalosporin by the iron transport system    of Escherichia coli. J Antimicrob Chemother 1991; 28: 377-88.         [ Links ]46.- CRITCHLEY I A. Catecholic ß-lactams:    facilitated transport. J Antimicrob Chemother 1990; 26: 733-7.         [ Links ]47.- JONES R N, ERWIN M E. In vitro evaluation    of Ro 09-1227, a novel catechol-substituted cephalosporin. Antimicrob Agents    Chemother 1992; 36: 233-8.         [ Links ]48.- JONES R N. In vitro activity of Ro 24-6392,    a novel ester-linked co-drug combining ciprofloxacin and desacetylcefotaxime.    Eur J Clin Microbiol Infect Dis 1990; 9: 435-8.         [ Links ]49.- TOMASZ A. Penicillin-binding proteins    and the antibacterial effectiveness of ß-lactam antibiotics. Rev Infect    Dis 1986 (Suppl 3); 8: 260-78.         [ Links ]50.- HOLM S E. Interaction between ß-lactam    and other antibiotics. Rev Infect Dis 1986 (Suppl 3); 8: 305-14.         [ Links ]51.- MC CULLERS J A, ENGLISH B K, NOVAK R.    Isolation and characterization of vancomycin-tolerant Streptococcus pneumoniae    from the cerebrospinal fluid of a patient who developed recrudescet meningitis.    J Infect Dis 2000; 181: 369-73.         [ Links ]52.- NIKAIDO H. Outer membrane barrier as    a mechanism of antimicrobial resistance. Antimicrob Agents Chemother 1989; 33:    1831-6.         [ Links ]53.- BARRADELL L B, BRYSON H M. Cefepime.    A review of its antibacterial activity, pharmacokinetic properties and therapeutic    use. Drugs 1994; 47: 471-505.         [ Links ]54.- O'CALLAGHAN C H 1979. Description and    classification of the newer cephalosporins and their relationship with the established    compounds. J Antimicrob Chemother 5: 635-71         [ Links ]55.- BRYSKIER A, PROCYK T, TREMBLAY D, LENFANT    B FOURTILLAN J B. The pharmacokinetics of cefodizime following intravenous and    intramuscular administration of a single dose of 1.0 g. J Antimicrob Chemother    1990; 26 (Suppl. C): 59-63.         [ Links ]56.- WILLIAMS J D. Classification of cephalosporins.    Drugs. 1987; 34 (Suppl 2): 15-22.         [ Links ]57.- WISEMAN L R, LAMB H M. Cefpirome. A review    of its antibacterial activity, pharmacokinetic properties and efficacy in the    treatment of severe nosocomial infections and febrile neutropenia. Drugs 1997;    57: 117-40.         [ Links ]58.- PECHERE J C, WILSON W, NEU H. Laboratory    assesment of antibacterial activity of zwitterionic 7-methoxyimino cephalosporins.    J Antimicrob Chemother 1995; 36: 757-71         [ Links ]59.- GIAMARELLOS-BOURBOULIS EJ, GRECKA P,    TSITSIKA A, TYMPANIDOU C, GIAMARELLOU H. In-vitro activity of FK 037 (cefoselis),    a novel 4 (th) generation cephalosporin, cefepime and cefpirome on nosocomial    staphylococci and gram-negative isolates. Diagn Microbiol infect Dis 2000; 36:    185-91.         [ Links ]60.- JONES R N, ERWIN M E, BARRETT M S, JOHNSON    D M, BRIGGS B M. Antimicrobial activity of E-1040, a novel thiadiazolyl cephalosporin    compare with parenteral cephems. Diagn Microbiol infect Dis 1991; 14: 301-9.          [ Links ]61.- IIZAWA Y, OKONOGI K, HAYASHI R, IWAHI    T, YAMAZAKI T, IMADA A. Therapeutic effect of cefozopran (SCE-2787), a new parenteral    cephalosporin in experimental infections in mice. Antimicrob Agents Chemother    1993; 37: 100-5.         [ Links ]62.- WATANABE N A. Newer antipseudomonal cephalosporins.    J Chemother 1996; 8 (Suppl 2): 48-56.         [ Links ]63.- ACTOR P, GUARINI J, URI J et al. Disk    susceptibility studies with cefazolin and cephalotin. Antimicrob Agents Chemother    1974; 5: 63-7.         [ Links ]64.- UWAYDAH M. Cefazolin in the treatment    of acute enteric fever. Antimicrob Agents Chemother 1976; 10: 52-6.         [ Links ]65.- JAMAL W Y, ROTIMI V O, CHUGH T D, PAL    T. Prevalence and susceptibility of Shigella to 11 antibiotics in a Kuwait    teaching hospital. J Chemother 1998; 10: 285-90.         [ Links ]66.- COX CE, SHERRILL M, COCCHETT DM. Evaluation    of cefuroxime axetil, cefaclor, and cephalexin in the treatment of urinary tract    infections in adults. Curr Ther Res 1987; 42: 124-37.         [ Links ]67.- SANDERS C W, GREENBERG R N, MARIER R    L. Cefamandole and cefoxitin. Ann Intern Med 1985; 103: 70-8.          [ Links ]68.- STAPLEY E P, JACKSON M, HERNANDEZ S et    al. Cephamycins, a new family of ß-lactam antibiotics I. Production actinomycetes,    including Streptomyces lactamdurans spp.n. Antimicrob Agents Chemother    1972; 2: 122-31.         [ Links ]69.- COOPER R D G. The carbacephems a new    ß-lactams class. Am J Med 1992; 92 (Suppl 6 A): 25-65.         [ Links ]70.- ZEMELMAN R, BELLO H, DOMINGUEZ M, GONZALEZ    G, MELLA S, GARCIA A. Activity of imipenem, third-generation cephalosporins,    aztreonam, and ciprofloxacin against multi-resistant Gram negative bacilli isolated    from Chilean hospitals. J Antimicrob Chemother 1993; 32: 413-9.         [ Links ]71.- MEDEIROS A A. Evolution and dissemination    of ß-lactamases accelerated by generation of ß-lactam antibiotics.    Clin Infect Dis 1997; 24 (Suppl. 1): 19-45.         [ Links ]72.- PERRY C M, BROGDEN R N. Cefuroxime axetil:    review of its antibacterial activity, pharmacokinetic properties and therapeutic    efficacy. Drugs 1996; 52: 125-58.         [ Links ]73.- SCHAAD U B, SUTER S, GIANELLA-BORRADORI    et al. A comparison of ceftriaxone and cefuroxime for the treatment of bacterial    meningitis in children. N Engl J Med 1990; 322: 141-7.         [ Links ]74.- KLEIN N C, CUNHA B A. Cefalosporinas de    la tercera generación. Clin Med Nort Am 1995; 79: 693-707.         [ Links ]75.- KLUGMAN K P, MADHI S A. Emergence of    drug resistance impact on bacterial meningitis. Infect Dis Clin North Am 1999;    13: 637-46.         [ Links ]76.- RICHARDS D M, BROGDEN R N. Ceftazidime.    A review of its antibacterial activity, pharmacokinetic properties and therapeutic    use. Drugs 1985; 29: 105-61.         [ Links ]77.- SCHATZ B S, KARAVOKIROS K T, TAEUBEL    M A, ITOKAZU G S. Comparison of cefprozil, cefpodoxime proxetil, loracarbef,    cefixime, and ceftibuten. Ann Pharmacother 1996; 30: 258-68.         [ Links ]78.- DALMAU D, LAYRARGUES G P, FENYVES D,    WILLEMS B, TURGEON F, TURGEON P. Cefotaxime, desacetyl-cefotaxime, and bactericidal    activity in spontaneous bacterial peritonitis. J Infect Dis 1999; 180: 1597-1602.          [ Links ]79.- NIKAIDO W, LIU W, ROSENBERG E Y. Outer    membrane permeability and ß-lactamase stability of dipolar ionic cephalosporins    containing methoxyimino substituents. Antimicrob Agents Chemother 1990; 34:    337-42.         [ Links ]80.- HANCOCK R E W, BELLIDO F. Factors involved    in the enhanced efficacy against gram-negative bacteria of fourth generation    cephalosporins. J Antimicrob Chemother 1992; 29(Suppl A): 1-6.         [ Links ]81.- BELLIDO F, PECHERE J C, HANCOCK REW.    Novel method for measurement of outer membrane permeability to new beta-lactams    in intact Enterobacter cloacae cells. Antimicrob Agents Chemother 1991;    35: 68-72.         [ Links ]82.- NEU H C, CHIN N X, JULES K, LABTHAVIKUL    P. The activity of BMY-28142, a new broad spectrum beta-lactamase stable cephalosporin.    J Antimicrob Chemother 1986; 17: 441-52.         [ Links ]83.- KOBAYASHI S, ARAI S, HAYASHI S, FUJIMOTO    K. ß-lactamase stability of cefpirome (HR 810), a new cephalosporin with    a broad antimicrobial spectrum. Antimicrob Agents Chemother 1986; 30: 713-8.          [ Links ]84.- GARAU J, WILSON W, WOOD M, CARLET J.    Fourth generation cephalosporins: a review of in vitro activity, pharmacokinetics,    pharmacodynamics, and clinical utility. Clin Microb Infect 1997; 3 (Suppl 1):    87-101.         [ Links ]85.- KESSLER R E, FUNG-TOMC J. Susceptibility    of bacterial isolates to beta-lactam antibiotics from U.S. clinical trials over    5-year period. Am J Med 1996; 24 (6 A): 13-9.         [ Links ]86.- PIERARD D, EMMERECHTS K, LAUWERS S. Comparative    in-vitro activity of cefpirome against isolates from intensive care and haematology/oncology    units. Belgian Multicentric Study Group. J Antimicrob Chemother 1998; 41: 443-50.          [ Links ]87.- JONES R N. Resistance patterns among    nosocomial pathogens: trends over the past few years. Chest 2001; 119 (Suppl    2): 397-404.         [ Links ]88.- LORBER B. Changing patterns of infectious    diseases. Am J Med 1988; 84: 569-78.         [ Links ]89.- MOELLERING R C. A novel antimicrobial    agent joins the battle against resistant bacteria. Ann Intern Med 1999; 130:    155-7.         [ Links ]90.- WILSON W R. The role of fourth-generation    cephalosporins in the treatment of serious infectious diseases in hospitalized    patients. Diagn Microbiol Infect Dis 1998; 31: 473-7.         [ Links ]Correspondencia a:        Sergio Mella Montecinos        Laboratorio de Antibióticos,        Departamento de Microbiología,        Facultad de Ciencias Biológicas        Casilla 160-C, Concepción        E-mail: pignatio@ctcinternet.cl  

25.- JONES R N. Important and emerging ß-lactamase    mediated resistances in hospital-based pathogens: the Amp C enzymes. Diagn Microbiol    Infect Dis 1998; 31: 461-6.         [ Links ]26.- JARVIS W R, MARTONE W J. Predominant    pathogens in hospital infections. J Antimicrob Chemother 1992; 29: 19-24.         [ Links ]27.- LIVERMORE D M. ß-lactamases in    laboratory and clinical resistance. Clin Microbiol Rev 1995; 8: 557-84.         [ Links ]28.- HERITAGE J, M'ZALI F H, GASCOYNE-BINZI    D, HAWKEY P M. Evolution and spread of SHV extended-spectrum ß-lactamases    in gram negative bacteria. J Antimicrob Chemother 1999; 44: 309-18.         [ Links ]29.- PODSCHUN R, ULLMAN U. Klebsiella spp.    as nosocomial pathogens: epidemiology, taxonomy, typing methods, and pathogenicity    factors. Clin Microbiol Rev 1998; 11: 589-603.         [ Links ]30.- PITOUT J D D, SANDERS C C, SANDERS W    E. Antimicrobial resistance with focus on ß-lactam resistance in Gram    negative bacilli. Am J Med 1997; 103: 51-9.         [ Links ]31.- HANBERGER H, GARCIA-RODRIGUEZ J A, GOBERNADO    et al. Antibiotic susceptibility among aerobic Gram negative bacilli in intensive    care units in 5 european countries. JAMA 1999; 281: 67-71.         [ Links ]32.- CHARREL R N, PAGES J M, DE MICCO P et    al. Prevalence of outer membrane porin alteration in ß-lactam-antibiotic-resistant    Enterobacter aerogenes. Antimicrob Agents Chemother 1996; 40: 2854-8.          [ Links ]33.- BRADFORD P A, URBAN C, MARIANO N, PROJAN    S J, RAHAL J J, BUSH K. Imipenem resistance in Klebsiella pneumoniae is    associated with the combination of ACT-1, a plasmid-mediated Amp C ß-lactamase,    and the loss of an outer membrane protein. Antimicrob Agents Chemother 1997;    41: 563-9.         [ Links ]34.- QUEENAN A M, TORRES-VIERA C, GOLD H et    al. SME-type carbapenem-hydrolizing class A ß-lactamases from geographically    diverse Serratia marcescens strains. Antimicrob Agents Chemother 2000;    44: 3035-9.         [ Links ]35.- COHEN S P, MC MURRY L M, HOOPER D C,    WOLFSON J S, LEVY S B. Cross-resistance to fluoroquinolones in multiple-antibiotic-resistance    (Mar) Escherichia coli selected by tetracycline resistance: decreased    drug accumulation asociated with membrane changes in addition to Omp F reduction.    Antimicrob Agents Chemother 1989; 33:1318-25.         [ Links ]36.- SANDERS C C. Cefepime: The next generation?    Clin Infect Dis 1993; 17: 369-79         [ Links ]37.- GARAU J. The clinical potential of fourth-generation    cephalosporins. Diagn Microbiol Infect Dis 1998; 31: 479-80.         [ Links ]38.- CURTIS N A C, ORR D C, ROSS G W, BOULTON    M G. Affinities of penicillins and cephalosporins for the penicillin-binding    proteins of Escherichia coli    K-12 and their antibacterial activity. Antimicrob Agents Chemother 1979; 16:    533-9.  39.- BALANT L, DAYER P, AUCKENTHALER R. Clinical    pharmacokinetics of the third generation cephalosporins. Clin Pharmacokinetics    1985; 10: 101-43.         [ Links ]40.- WHEELER W J. Cephalosporins and other    beta-lactam antibiotics. Lloydia. 1977; 40: 519-42.         [ Links ]41.- LOPEZ F, GARRIDO J C. Química    y relación estructura-actividad de los antibióticos cefalosporínicos.    Rev Col Químico Farmacéutico 1989; 41: 5-14.         [ Links ]42.- FU K P, ASWAPOKEE P, HO I, MATTHIJSSEN    C, NEU H C. Pharmacokinetics of cefotaxime. Antimicrob Agents Chemother 1979;16:    592-7.         [ Links ]43.- YUK J H, NIGHTINGALE C H, QUINTILIANI    R. Clinical pharmacokinetics of ceftriaxone. Clin Pharmacokinetic 1989; 17:    223-35.         [ Links ]44.- BRYSKIER A, PROCYK T, LABRO M T. Cefodizime,    a new 2-aminothiazolyl cephalosporin: physicochemical properties, toxicology    and structure-activity relationships. J Antimicrob Chemother 1990; 26 (Suppl    C): 1-8.         [ Links ]45.- CRITCHLEY I A, BASKER M J, EDMONDSON    R A, KNOTT S J. Uptake of catecholic cephalosporin by the iron transport system    of Escherichia coli. J Antimicrob Chemother 1991; 28: 377-88.         [ Links ]46.- CRITCHLEY I A. Catecholic ß-lactams:    facilitated transport. J Antimicrob Chemother 1990; 26: 733-7.         [ Links ]47.- JONES R N, ERWIN M E. In vitro evaluation    of Ro 09-1227, a novel catechol-substituted cephalosporin. Antimicrob Agents    Chemother 1992; 36: 233-8.         [ Links ]48.- JONES R N. In vitro activity of Ro 24-6392,    a novel ester-linked co-drug combining ciprofloxacin and desacetylcefotaxime.    Eur J Clin Microbiol Infect Dis 1990; 9: 435-8.         [ Links ]49.- TOMASZ A. Penicillin-binding proteins    and the antibacterial effectiveness of ß-lactam antibiotics. Rev Infect    Dis 1986 (Suppl 3); 8: 260-78.         [ Links ]50.- HOLM S E. Interaction between ß-lactam    and other antibiotics. Rev Infect Dis 1986 (Suppl 3); 8: 305-14.         [ Links ]51.- MC CULLERS J A, ENGLISH B K, NOVAK R.    Isolation and characterization of vancomycin-tolerant Streptococcus pneumoniae    from the cerebrospinal fluid of a patient who developed recrudescet meningitis.    J Infect Dis 2000; 181: 369-73.         [ Links ]52.- NIKAIDO H. Outer membrane barrier as    a mechanism of antimicrobial resistance. Antimicrob Agents Chemother 1989; 33:    1831-6.         [ Links ]53.- BARRADELL L B, BRYSON H M. Cefepime.    A review of its antibacterial activity, pharmacokinetic properties and therapeutic    use. Drugs 1994; 47: 471-505.         [ Links ]54.- O'CALLAGHAN C H 1979. Description and    classification of the newer cephalosporins and their relationship with the established    compounds. J Antimicrob Chemother 5: 635-71         [ Links ]55.- BRYSKIER A, PROCYK T, TREMBLAY D, LENFANT    B FOURTILLAN J B. The pharmacokinetics of cefodizime following intravenous and    intramuscular administration of a single dose of 1.0 g. J Antimicrob Chemother    1990; 26 (Suppl. C): 59-63.         [ Links ]56.- WILLIAMS J D. Classification of cephalosporins.    Drugs. 1987; 34 (Suppl 2): 15-22.         [ Links ]57.- WISEMAN L R, LAMB H M. Cefpirome. A review    of its antibacterial activity, pharmacokinetic properties and efficacy in the    treatment of severe nosocomial infections and febrile neutropenia. Drugs 1997;    57: 117-40.         [ Links ]58.- PECHERE J C, WILSON W, NEU H. Laboratory    assesment of antibacterial activity of zwitterionic 7-methoxyimino cephalosporins.    J Antimicrob Chemother 1995; 36: 757-71         [ Links ]59.- GIAMARELLOS-BOURBOULIS EJ, GRECKA P,    TSITSIKA A, TYMPANIDOU C, GIAMARELLOU H. In-vitro activity of FK 037 (cefoselis),    a novel 4 (th) generation cephalosporin, cefepime and cefpirome on nosocomial    staphylococci and gram-negative isolates. Diagn Microbiol infect Dis 2000; 36:    185-91.         [ Links ]60.- JONES R N, ERWIN M E, BARRETT M S, JOHNSON    D M, BRIGGS B M. Antimicrobial activity of E-1040, a novel thiadiazolyl cephalosporin    compare with parenteral cephems. Diagn Microbiol infect Dis 1991; 14: 301-9.          [ Links ]61.- IIZAWA Y, OKONOGI K, HAYASHI R, IWAHI    T, YAMAZAKI T, IMADA A. Therapeutic effect of cefozopran (SCE-2787), a new parenteral    cephalosporin in experimental infections in mice. Antimicrob Agents Chemother    1993; 37: 100-5.         [ Links ]62.- WATANABE N A. Newer antipseudomonal cephalosporins.    J Chemother 1996; 8 (Suppl 2): 48-56.         [ Links ]63.- ACTOR P, GUARINI J, URI J et al. Disk    susceptibility studies with cefazolin and cephalotin. Antimicrob Agents Chemother    1974; 5: 63-7.         [ Links ]64.- UWAYDAH M. Cefazolin in the treatment    of acute enteric fever. Antimicrob Agents Chemother 1976; 10: 52-6.         [ Links ]65.- JAMAL W Y, ROTIMI V O, CHUGH T D, PAL    T. Prevalence and susceptibility of Shigella to 11 antibiotics in a Kuwait    teaching hospital. J Chemother 1998; 10: 285-90.         [ Links ]66.- COX CE, SHERRILL M, COCCHETT DM. Evaluation    of cefuroxime axetil, cefaclor, and cephalexin in the treatment of urinary tract    infections in adults. Curr Ther Res 1987; 42: 124-37.         [ Links ]67.- SANDERS C W, GREENBERG R N, MARIER R    L. Cefamandole and cefoxitin. Ann Intern Med 1985; 103: 70-8.          [ Links ]68.- STAPLEY E P, JACKSON M, HERNANDEZ S et    al. Cephamycins, a new family of ß-lactam antibiotics I. Production actinomycetes,    including Streptomyces lactamdurans spp.n. Antimicrob Agents Chemother    1972; 2: 122-31.         [ Links ]69.- COOPER R D G. The carbacephems a new    ß-lactams class. Am J Med 1992; 92 (Suppl 6 A): 25-65.         [ Links ]70.- ZEMELMAN R, BELLO H, DOMINGUEZ M, GONZALEZ    G, MELLA S, GARCIA A. Activity of imipenem, third-generation cephalosporins,    aztreonam, and ciprofloxacin against multi-resistant Gram negative bacilli isolated    from Chilean hospitals. J Antimicrob Chemother 1993; 32: 413-9.         [ Links ]71.- MEDEIROS A A. Evolution and dissemination    of ß-lactamases accelerated by generation of ß-lactam antibiotics.    Clin Infect Dis 1997; 24 (Suppl. 1): 19-45.         [ Links ]72.- PERRY C M, BROGDEN R N. Cefuroxime axetil:    review of its antibacterial activity, pharmacokinetic properties and therapeutic    efficacy. Drugs 1996; 52: 125-58.         [ Links ]73.- SCHAAD U B, SUTER S, GIANELLA-BORRADORI    et al. A comparison of ceftriaxone and cefuroxime for the treatment of bacterial    meningitis in children. N Engl J Med 1990; 322: 141-7.         [ Links ]74.- KLEIN N C, CUNHA B A. Cefalosporinas de    la tercera generación. Clin Med Nort Am 1995; 79: 693-707.         [ Links ]75.- KLUGMAN K P, MADHI S A. Emergence of    drug resistance impact on bacterial meningitis. Infect Dis Clin North Am 1999;    13: 637-46.         [ Links ]76.- RICHARDS D M, BROGDEN R N. Ceftazidime.    A review of its antibacterial activity, pharmacokinetic properties and therapeutic    use. Drugs 1985; 29: 105-61.         [ Links ]77.- SCHATZ B S, KARAVOKIROS K T, TAEUBEL    M A, ITOKAZU G S. Comparison of cefprozil, cefpodoxime proxetil, loracarbef,    cefixime, and ceftibuten. Ann Pharmacother 1996; 30: 258-68.         [ Links ]78.- DALMAU D, LAYRARGUES G P, FENYVES D,    WILLEMS B, TURGEON F, TURGEON P. Cefotaxime, desacetyl-cefotaxime, and bactericidal    activity in spontaneous bacterial peritonitis. J Infect Dis 1999; 180: 1597-1602.          [ Links ]79.- NIKAIDO W, LIU W, ROSENBERG E Y. Outer    membrane permeability and ß-lactamase stability of dipolar ionic cephalosporins    containing methoxyimino substituents. Antimicrob Agents Chemother 1990; 34:    337-42.         [ Links ]80.- HANCOCK R E W, BELLIDO F. Factors involved    in the enhanced efficacy against gram-negative bacteria of fourth generation    cephalosporins. J Antimicrob Chemother 1992; 29(Suppl A): 1-6.         [ Links ]81.- BELLIDO F, PECHERE J C, HANCOCK REW.    Novel method for measurement of outer membrane permeability to new beta-lactams    in intact Enterobacter cloacae cells. Antimicrob Agents Chemother 1991;    35: 68-72.         [ Links ]82.- NEU H C, CHIN N X, JULES K, LABTHAVIKUL    P. The activity of BMY-28142, a new broad spectrum beta-lactamase stable cephalosporin.    J Antimicrob Chemother 1986; 17: 441-52.         [ Links ]83.- KOBAYASHI S, ARAI S, HAYASHI S, FUJIMOTO    K. ß-lactamase stability of cefpirome (HR 810), a new cephalosporin with    a broad antimicrobial spectrum. Antimicrob Agents Chemother 1986; 30: 713-8.          [ Links ]84.- GARAU J, WILSON W, WOOD M, CARLET J.    Fourth generation cephalosporins: a review of in vitro activity, pharmacokinetics,    pharmacodynamics, and clinical utility. Clin Microb Infect 1997; 3 (Suppl 1):    87-101.         [ Links ]85.- KESSLER R E, FUNG-TOMC J. Susceptibility    of bacterial isolates to beta-lactam antibiotics from U.S. clinical trials over    5-year period. Am J Med 1996; 24 (6 A): 13-9.         [ Links ]86.- PIERARD D, EMMERECHTS K, LAUWERS S. Comparative    in-vitro activity of cefpirome against isolates from intensive care and haematology/oncology    units. Belgian Multicentric Study Group. J Antimicrob Chemother 1998; 41: 443-50.          [ Links ]87.- JONES R N. Resistance patterns among    nosocomial pathogens: trends over the past few years. Chest 2001; 119 (Suppl    2): 397-404.         [ Links ]88.- LORBER B. Changing patterns of infectious    diseases. Am J Med 1988; 84: 569-78.         [ Links ]89.- MOELLERING R C. A novel antimicrobial    agent joins the battle against resistant bacteria. Ann Intern Med 1999; 130:    155-7.         [ Links ]90.- WILSON W R. The role of fourth-generation    cephalosporins in the treatment of serious infectious diseases in hospitalized    patients. Diagn Microbiol Infect Dis 1998; 31: 473-7.         [ Links ]Correspondencia a:        Sergio Mella Montecinos        Laboratorio de Antibióticos,        Departamento de Microbiología,        Facultad de Ciencias Biológicas        Casilla 160-C, Concepción        E-mail: pignatio@ctcinternet.cl  

26.- JARVIS W R, MARTONE W J. Predominant    pathogens in hospital infections. J Antimicrob Chemother 1992; 29: 19-24.         [ Links ]27.- LIVERMORE D M. ß-lactamases in    laboratory and clinical resistance. Clin Microbiol Rev 1995; 8: 557-84.         [ Links ]28.- HERITAGE J, M'ZALI F H, GASCOYNE-BINZI    D, HAWKEY P M. Evolution and spread of SHV extended-spectrum ß-lactamases    in gram negative bacteria. J Antimicrob Chemother 1999; 44: 309-18.         [ Links ]29.- PODSCHUN R, ULLMAN U. Klebsiella spp.    as nosocomial pathogens: epidemiology, taxonomy, typing methods, and pathogenicity    factors. Clin Microbiol Rev 1998; 11: 589-603.         [ Links ]30.- PITOUT J D D, SANDERS C C, SANDERS W    E. Antimicrobial resistance with focus on ß-lactam resistance in Gram    negative bacilli. Am J Med 1997; 103: 51-9.         [ Links ]31.- HANBERGER H, GARCIA-RODRIGUEZ J A, GOBERNADO    et al. Antibiotic susceptibility among aerobic Gram negative bacilli in intensive    care units in 5 european countries. JAMA 1999; 281: 67-71.         [ Links ]32.- CHARREL R N, PAGES J M, DE MICCO P et    al. Prevalence of outer membrane porin alteration in ß-lactam-antibiotic-resistant    Enterobacter aerogenes. Antimicrob Agents Chemother 1996; 40: 2854-8.          [ Links ]33.- BRADFORD P A, URBAN C, MARIANO N, PROJAN    S J, RAHAL J J, BUSH K. Imipenem resistance in Klebsiella pneumoniae is    associated with the combination of ACT-1, a plasmid-mediated Amp C ß-lactamase,    and the loss of an outer membrane protein. Antimicrob Agents Chemother 1997;    41: 563-9.         [ Links ]34.- QUEENAN A M, TORRES-VIERA C, GOLD H et    al. SME-type carbapenem-hydrolizing class A ß-lactamases from geographically    diverse Serratia marcescens strains. Antimicrob Agents Chemother 2000;    44: 3035-9.         [ Links ]35.- COHEN S P, MC MURRY L M, HOOPER D C,    WOLFSON J S, LEVY S B. Cross-resistance to fluoroquinolones in multiple-antibiotic-resistance    (Mar) Escherichia coli selected by tetracycline resistance: decreased    drug accumulation asociated with membrane changes in addition to Omp F reduction.    Antimicrob Agents Chemother 1989; 33:1318-25.         [ Links ]36.- SANDERS C C. Cefepime: The next generation?    Clin Infect Dis 1993; 17: 369-79         [ Links ]37.- GARAU J. The clinical potential of fourth-generation    cephalosporins. Diagn Microbiol Infect Dis 1998; 31: 479-80.         [ Links ]38.- CURTIS N A C, ORR D C, ROSS G W, BOULTON    M G. Affinities of penicillins and cephalosporins for the penicillin-binding    proteins of Escherichia coli    K-12 and their antibacterial activity. Antimicrob Agents Chemother 1979; 16:    533-9.  39.- BALANT L, DAYER P, AUCKENTHALER R. Clinical    pharmacokinetics of the third generation cephalosporins. Clin Pharmacokinetics    1985; 10: 101-43.         [ Links ]40.- WHEELER W J. Cephalosporins and other    beta-lactam antibiotics. Lloydia. 1977; 40: 519-42.         [ Links ]41.- LOPEZ F, GARRIDO J C. Química    y relación estructura-actividad de los antibióticos cefalosporínicos.    Rev Col Químico Farmacéutico 1989; 41: 5-14.         [ Links ]42.- FU K P, ASWAPOKEE P, HO I, MATTHIJSSEN    C, NEU H C. Pharmacokinetics of cefotaxime. Antimicrob Agents Chemother 1979;16:    592-7.         [ Links ]43.- YUK J H, NIGHTINGALE C H, QUINTILIANI    R. Clinical pharmacokinetics of ceftriaxone. Clin Pharmacokinetic 1989; 17:    223-35.         [ Links ]44.- BRYSKIER A, PROCYK T, LABRO M T. Cefodizime,    a new 2-aminothiazolyl cephalosporin: physicochemical properties, toxicology    and structure-activity relationships. J Antimicrob Chemother 1990; 26 (Suppl    C): 1-8.         [ Links ]45.- CRITCHLEY I A, BASKER M J, EDMONDSON    R A, KNOTT S J. Uptake of catecholic cephalosporin by the iron transport system    of Escherichia coli. J Antimicrob Chemother 1991; 28: 377-88.         [ Links ]46.- CRITCHLEY I A. Catecholic ß-lactams:    facilitated transport. J Antimicrob Chemother 1990; 26: 733-7.         [ Links ]47.- JONES R N, ERWIN M E. In vitro evaluation    of Ro 09-1227, a novel catechol-substituted cephalosporin. Antimicrob Agents    Chemother 1992; 36: 233-8.         [ Links ]48.- JONES R N. In vitro activity of Ro 24-6392,    a novel ester-linked co-drug combining ciprofloxacin and desacetylcefotaxime.    Eur J Clin Microbiol Infect Dis 1990; 9: 435-8.         [ Links ]49.- TOMASZ A. Penicillin-binding proteins    and the antibacterial effectiveness of ß-lactam antibiotics. Rev Infect    Dis 1986 (Suppl 3); 8: 260-78.         [ Links ]50.- HOLM S E. Interaction between ß-lactam    and other antibiotics. Rev Infect Dis 1986 (Suppl 3); 8: 305-14.         [ Links ]51.- MC CULLERS J A, ENGLISH B K, NOVAK R.    Isolation and characterization of vancomycin-tolerant Streptococcus pneumoniae    from the cerebrospinal fluid of a patient who developed recrudescet meningitis.    J Infect Dis 2000; 181: 369-73.         [ Links ]52.- NIKAIDO H. Outer membrane barrier as    a mechanism of antimicrobial resistance. Antimicrob Agents Chemother 1989; 33:    1831-6.         [ Links ]53.- BARRADELL L B, BRYSON H M. Cefepime.    A review of its antibacterial activity, pharmacokinetic properties and therapeutic    use. Drugs 1994; 47: 471-505.         [ Links ]54.- O'CALLAGHAN C H 1979. Description and    classification of the newer cephalosporins and their relationship with the established    compounds. J Antimicrob Chemother 5: 635-71         [ Links ]55.- BRYSKIER A, PROCYK T, TREMBLAY D, LENFANT    B FOURTILLAN J B. The pharmacokinetics of cefodizime following intravenous and    intramuscular administration of a single dose of 1.0 g. J Antimicrob Chemother    1990; 26 (Suppl. C): 59-63.         [ Links ]56.- WILLIAMS J D. Classification of cephalosporins.    Drugs. 1987; 34 (Suppl 2): 15-22.         [ Links ]57.- WISEMAN L R, LAMB H M. Cefpirome. A review    of its antibacterial activity, pharmacokinetic properties and efficacy in the    treatment of severe nosocomial infections and febrile neutropenia. Drugs 1997;    57: 117-40.         [ Links ]58.- PECHERE J C, WILSON W, NEU H. Laboratory    assesment of antibacterial activity of zwitterionic 7-methoxyimino cephalosporins.    J Antimicrob Chemother 1995; 36: 757-71         [ Links ]59.- GIAMARELLOS-BOURBOULIS EJ, GRECKA P,    TSITSIKA A, TYMPANIDOU C, GIAMARELLOU H. In-vitro activity of FK 037 (cefoselis),    a novel 4 (th) generation cephalosporin, cefepime and cefpirome on nosocomial    staphylococci and gram-negative isolates. Diagn Microbiol infect Dis 2000; 36:    185-91.         [ Links ]60.- JONES R N, ERWIN M E, BARRETT M S, JOHNSON    D M, BRIGGS B M. Antimicrobial activity of E-1040, a novel thiadiazolyl cephalosporin    compare with parenteral cephems. Diagn Microbiol infect Dis 1991; 14: 301-9.          [ Links ]61.- IIZAWA Y, OKONOGI K, HAYASHI R, IWAHI    T, YAMAZAKI T, IMADA A. Therapeutic effect of cefozopran (SCE-2787), a new parenteral    cephalosporin in experimental infections in mice. Antimicrob Agents Chemother    1993; 37: 100-5.         [ Links ]62.- WATANABE N A. Newer antipseudomonal cephalosporins.    J Chemother 1996; 8 (Suppl 2): 48-56.         [ Links ]63.- ACTOR P, GUARINI J, URI J et al. Disk    susceptibility studies with cefazolin and cephalotin. Antimicrob Agents Chemother    1974; 5: 63-7.         [ Links ]64.- UWAYDAH M. Cefazolin in the treatment    of acute enteric fever. Antimicrob Agents Chemother 1976; 10: 52-6.         [ Links ]65.- JAMAL W Y, ROTIMI V O, CHUGH T D, PAL    T. Prevalence and susceptibility of Shigella to 11 antibiotics in a Kuwait    teaching hospital. J Chemother 1998; 10: 285-90.         [ Links ]66.- COX CE, SHERRILL M, COCCHETT DM. Evaluation    of cefuroxime axetil, cefaclor, and cephalexin in the treatment of urinary tract    infections in adults. Curr Ther Res 1987; 42: 124-37.         [ Links ]67.- SANDERS C W, GREENBERG R N, MARIER R    L. Cefamandole and cefoxitin. Ann Intern Med 1985; 103: 70-8.          [ Links ]68.- STAPLEY E P, JACKSON M, HERNANDEZ S et    al. Cephamycins, a new family of ß-lactam antibiotics I. Production actinomycetes,    including Streptomyces lactamdurans spp.n. Antimicrob Agents Chemother    1972; 2: 122-31.         [ Links ]69.- COOPER R D G. The carbacephems a new    ß-lactams class. Am J Med 1992; 92 (Suppl 6 A): 25-65.         [ Links ]70.- ZEMELMAN R, BELLO H, DOMINGUEZ M, GONZALEZ    G, MELLA S, GARCIA A. Activity of imipenem, third-generation cephalosporins,    aztreonam, and ciprofloxacin against multi-resistant Gram negative bacilli isolated    from Chilean hospitals. J Antimicrob Chemother 1993; 32: 413-9.         [ Links ]71.- MEDEIROS A A. Evolution and dissemination    of ß-lactamases accelerated by generation of ß-lactam antibiotics.    Clin Infect Dis 1997; 24 (Suppl. 1): 19-45.         [ Links ]72.- PERRY C M, BROGDEN R N. Cefuroxime axetil:    review of its antibacterial activity, pharmacokinetic properties and therapeutic    efficacy. Drugs 1996; 52: 125-58.         [ Links ]73.- SCHAAD U B, SUTER S, GIANELLA-BORRADORI    et al. A comparison of ceftriaxone and cefuroxime for the treatment of bacterial    meningitis in children. N Engl J Med 1990; 322: 141-7.         [ Links ]74.- KLEIN N C, CUNHA B A. Cefalosporinas de    la tercera generación. Clin Med Nort Am 1995; 79: 693-707.         [ Links ]75.- KLUGMAN K P, MADHI S A. Emergence of    drug resistance impact on bacterial meningitis. Infect Dis Clin North Am 1999;    13: 637-46.         [ Links ]76.- RICHARDS D M, BROGDEN R N. Ceftazidime.    A review of its antibacterial activity, pharmacokinetic properties and therapeutic    use. Drugs 1985; 29: 105-61.         [ Links ]77.- SCHATZ B S, KARAVOKIROS K T, TAEUBEL    M A, ITOKAZU G S. Comparison of cefprozil, cefpodoxime proxetil, loracarbef,    cefixime, and ceftibuten. Ann Pharmacother 1996; 30: 258-68.         [ Links ]78.- DALMAU D, LAYRARGUES G P, FENYVES D,    WILLEMS B, TURGEON F, TURGEON P. Cefotaxime, desacetyl-cefotaxime, and bactericidal    activity in spontaneous bacterial peritonitis. J Infect Dis 1999; 180: 1597-1602.          [ Links ]79.- NIKAIDO W, LIU W, ROSENBERG E Y. Outer    membrane permeability and ß-lactamase stability of dipolar ionic cephalosporins    containing methoxyimino substituents. Antimicrob Agents Chemother 1990; 34:    337-42.         [ Links ]80.- HANCOCK R E W, BELLIDO F. Factors involved    in the enhanced efficacy against gram-negative bacteria of fourth generation    cephalosporins. J Antimicrob Chemother 1992; 29(Suppl A): 1-6.         [ Links ]81.- BELLIDO F, PECHERE J C, HANCOCK REW.    Novel method for measurement of outer membrane permeability to new beta-lactams    in intact Enterobacter cloacae cells. Antimicrob Agents Chemother 1991;    35: 68-72.         [ Links ]82.- NEU H C, CHIN N X, JULES K, LABTHAVIKUL    P. The activity of BMY-28142, a new broad spectrum beta-lactamase stable cephalosporin.    J Antimicrob Chemother 1986; 17: 441-52.         [ Links ]83.- KOBAYASHI S, ARAI S, HAYASHI S, FUJIMOTO    K. ß-lactamase stability of cefpirome (HR 810), a new cephalosporin with    a broad antimicrobial spectrum. Antimicrob Agents Chemother 1986; 30: 713-8.          [ Links ]84.- GARAU J, WILSON W, WOOD M, CARLET J.    Fourth generation cephalosporins: a review of in vitro activity, pharmacokinetics,    pharmacodynamics, and clinical utility. Clin Microb Infect 1997; 3 (Suppl 1):    87-101.         [ Links ]85.- KESSLER R E, FUNG-TOMC J. Susceptibility    of bacterial isolates to beta-lactam antibiotics from U.S. clinical trials over    5-year period. Am J Med 1996; 24 (6 A): 13-9.         [ Links ]86.- PIERARD D, EMMERECHTS K, LAUWERS S. Comparative    in-vitro activity of cefpirome against isolates from intensive care and haematology/oncology    units. Belgian Multicentric Study Group. J Antimicrob Chemother 1998; 41: 443-50.          [ Links ]87.- JONES R N. Resistance patterns among    nosocomial pathogens: trends over the past few years. Chest 2001; 119 (Suppl    2): 397-404.         [ Links ]88.- LORBER B. Changing patterns of infectious    diseases. Am J Med 1988; 84: 569-78.         [ Links ]89.- MOELLERING R C. A novel antimicrobial    agent joins the battle against resistant bacteria. Ann Intern Med 1999; 130:    155-7.         [ Links ]90.- WILSON W R. The role of fourth-generation    cephalosporins in the treatment of serious infectious diseases in hospitalized    patients. Diagn Microbiol Infect Dis 1998; 31: 473-7.         [ Links ]Correspondencia a:        Sergio Mella Montecinos        Laboratorio de Antibióticos,        Departamento de Microbiología,        Facultad de Ciencias Biológicas        Casilla 160-C, Concepción        E-mail: pignatio@ctcinternet.cl  

27.- LIVERMORE D M. ß-lactamases in    laboratory and clinical resistance. Clin Microbiol Rev 1995; 8: 557-84.         [ Links ]28.- HERITAGE J, M'ZALI F H, GASCOYNE-BINZI    D, HAWKEY P M. Evolution and spread of SHV extended-spectrum ß-lactamases    in gram negative bacteria. J Antimicrob Chemother 1999; 44: 309-18.         [ Links ]29.- PODSCHUN R, ULLMAN U. Klebsiella spp.    as nosocomial pathogens: epidemiology, taxonomy, typing methods, and pathogenicity    factors. Clin Microbiol Rev 1998; 11: 589-603.         [ Links ]30.- PITOUT J D D, SANDERS C C, SANDERS W    E. Antimicrobial resistance with focus on ß-lactam resistance in Gram    negative bacilli. Am J Med 1997; 103: 51-9.         [ Links ]31.- HANBERGER H, GARCIA-RODRIGUEZ J A, GOBERNADO    et al. Antibiotic susceptibility among aerobic Gram negative bacilli in intensive    care units in 5 european countries. JAMA 1999; 281: 67-71.         [ Links ]32.- CHARREL R N, PAGES J M, DE MICCO P et    al. Prevalence of outer membrane porin alteration in ß-lactam-antibiotic-resistant    Enterobacter aerogenes. Antimicrob Agents Chemother 1996; 40: 2854-8.          [ Links ]33.- BRADFORD P A, URBAN C, MARIANO N, PROJAN    S J, RAHAL J J, BUSH K. Imipenem resistance in Klebsiella pneumoniae is    associated with the combination of ACT-1, a plasmid-mediated Amp C ß-lactamase,    and the loss of an outer membrane protein. Antimicrob Agents Chemother 1997;    41: 563-9.         [ Links ]34.- QUEENAN A M, TORRES-VIERA C, GOLD H et    al. SME-type carbapenem-hydrolizing class A ß-lactamases from geographically    diverse Serratia marcescens strains. Antimicrob Agents Chemother 2000;    44: 3035-9.         [ Links ]35.- COHEN S P, MC MURRY L M, HOOPER D C,    WOLFSON J S, LEVY S B. Cross-resistance to fluoroquinolones in multiple-antibiotic-resistance    (Mar) Escherichia coli selected by tetracycline resistance: decreased    drug accumulation asociated with membrane changes in addition to Omp F reduction.    Antimicrob Agents Chemother 1989; 33:1318-25.         [ Links ]36.- SANDERS C C. Cefepime: The next generation?    Clin Infect Dis 1993; 17: 369-79         [ Links ]37.- GARAU J. The clinical potential of fourth-generation    cephalosporins. Diagn Microbiol Infect Dis 1998; 31: 479-80.         [ Links ]38.- CURTIS N A C, ORR D C, ROSS G W, BOULTON    M G. Affinities of penicillins and cephalosporins for the penicillin-binding    proteins of Escherichia coli    K-12 and their antibacterial activity. Antimicrob Agents Chemother 1979; 16:    533-9.  39.- BALANT L, DAYER P, AUCKENTHALER R. Clinical    pharmacokinetics of the third generation cephalosporins. Clin Pharmacokinetics    1985; 10: 101-43.         [ Links ]40.- WHEELER W J. Cephalosporins and other    beta-lactam antibiotics. Lloydia. 1977; 40: 519-42.         [ Links ]41.- LOPEZ F, GARRIDO J C. Química    y relación estructura-actividad de los antibióticos cefalosporínicos.    Rev Col Químico Farmacéutico 1989; 41: 5-14.         [ Links ]42.- FU K P, ASWAPOKEE P, HO I, MATTHIJSSEN    C, NEU H C. Pharmacokinetics of cefotaxime. Antimicrob Agents Chemother 1979;16:    592-7.         [ Links ]43.- YUK J H, NIGHTINGALE C H, QUINTILIANI    R. Clinical pharmacokinetics of ceftriaxone. Clin Pharmacokinetic 1989; 17:    223-35.         [ Links ]44.- BRYSKIER A, PROCYK T, LABRO M T. Cefodizime,    a new 2-aminothiazolyl cephalosporin: physicochemical properties, toxicology    and structure-activity relationships. J Antimicrob Chemother 1990; 26 (Suppl    C): 1-8.         [ Links ]45.- CRITCHLEY I A, BASKER M J, EDMONDSON    R A, KNOTT S J. Uptake of catecholic cephalosporin by the iron transport system    of Escherichia coli. J Antimicrob Chemother 1991; 28: 377-88.         [ Links ]46.- CRITCHLEY I A. Catecholic ß-lactams:    facilitated transport. J Antimicrob Chemother 1990; 26: 733-7.         [ Links ]47.- JONES R N, ERWIN M E. In vitro evaluation    of Ro 09-1227, a novel catechol-substituted cephalosporin. Antimicrob Agents    Chemother 1992; 36: 233-8.         [ Links ]48.- JONES R N. In vitro activity of Ro 24-6392,    a novel ester-linked co-drug combining ciprofloxacin and desacetylcefotaxime.    Eur J Clin Microbiol Infect Dis 1990; 9: 435-8.         [ Links ]49.- TOMASZ A. Penicillin-binding proteins    and the antibacterial effectiveness of ß-lactam antibiotics. Rev Infect    Dis 1986 (Suppl 3); 8: 260-78.         [ Links ]50.- HOLM S E. Interaction between ß-lactam    and other antibiotics. Rev Infect Dis 1986 (Suppl 3); 8: 305-14.         [ Links ]51.- MC CULLERS J A, ENGLISH B K, NOVAK R.    Isolation and characterization of vancomycin-tolerant Streptococcus pneumoniae    from the cerebrospinal fluid of a patient who developed recrudescet meningitis.    J Infect Dis 2000; 181: 369-73.         [ Links ]52.- NIKAIDO H. Outer membrane barrier as    a mechanism of antimicrobial resistance. Antimicrob Agents Chemother 1989; 33:    1831-6.         [ Links ]53.- BARRADELL L B, BRYSON H M. Cefepime.    A review of its antibacterial activity, pharmacokinetic properties and therapeutic    use. Drugs 1994; 47: 471-505.         [ Links ]54.- O'CALLAGHAN C H 1979. Description and    classification of the newer cephalosporins and their relationship with the established    compounds. J Antimicrob Chemother 5: 635-71         [ Links ]55.- BRYSKIER A, PROCYK T, TREMBLAY D, LENFANT    B FOURTILLAN J B. The pharmacokinetics of cefodizime following intravenous and    intramuscular administration of a single dose of 1.0 g. J Antimicrob Chemother    1990; 26 (Suppl. C): 59-63.         [ Links ]56.- WILLIAMS J D. Classification of cephalosporins.    Drugs. 1987; 34 (Suppl 2): 15-22.         [ Links ]57.- WISEMAN L R, LAMB H M. Cefpirome. A review    of its antibacterial activity, pharmacokinetic properties and efficacy in the    treatment of severe nosocomial infections and febrile neutropenia. Drugs 1997;    57: 117-40.         [ Links ]58.- PECHERE J C, WILSON W, NEU H. Laboratory    assesment of antibacterial activity of zwitterionic 7-methoxyimino cephalosporins.    J Antimicrob Chemother 1995; 36: 757-71         [ Links ]59.- GIAMARELLOS-BOURBOULIS EJ, GRECKA P,    TSITSIKA A, TYMPANIDOU C, GIAMARELLOU H. In-vitro activity of FK 037 (cefoselis),    a novel 4 (th) generation cephalosporin, cefepime and cefpirome on nosocomial    staphylococci and gram-negative isolates. Diagn Microbiol infect Dis 2000; 36:    185-91.         [ Links ]60.- JONES R N, ERWIN M E, BARRETT M S, JOHNSON    D M, BRIGGS B M. Antimicrobial activity of E-1040, a novel thiadiazolyl cephalosporin    compare with parenteral cephems. Diagn Microbiol infect Dis 1991; 14: 301-9.          [ Links ]61.- IIZAWA Y, OKONOGI K, HAYASHI R, IWAHI    T, YAMAZAKI T, IMADA A. Therapeutic effect of cefozopran (SCE-2787), a new parenteral    cephalosporin in experimental infections in mice. Antimicrob Agents Chemother    1993; 37: 100-5.         [ Links ]62.- WATANABE N A. Newer antipseudomonal cephalosporins.    J Chemother 1996; 8 (Suppl 2): 48-56.         [ Links ]63.- ACTOR P, GUARINI J, URI J et al. Disk    susceptibility studies with cefazolin and cephalotin. Antimicrob Agents Chemother    1974; 5: 63-7.         [ Links ]64.- UWAYDAH M. Cefazolin in the treatment    of acute enteric fever. Antimicrob Agents Chemother 1976; 10: 52-6.         [ Links ]65.- JAMAL W Y, ROTIMI V O, CHUGH T D, PAL    T. Prevalence and susceptibility of Shigella to 11 antibiotics in a Kuwait    teaching hospital. J Chemother 1998; 10: 285-90.         [ Links ]66.- COX CE, SHERRILL M, COCCHETT DM. Evaluation    of cefuroxime axetil, cefaclor, and cephalexin in the treatment of urinary tract    infections in adults. Curr Ther Res 1987; 42: 124-37.         [ Links ]67.- SANDERS C W, GREENBERG R N, MARIER R    L. Cefamandole and cefoxitin. Ann Intern Med 1985; 103: 70-8.          [ Links ]68.- STAPLEY E P, JACKSON M, HERNANDEZ S et    al. Cephamycins, a new family of ß-lactam antibiotics I. Production actinomycetes,    including Streptomyces lactamdurans spp.n. Antimicrob Agents Chemother    1972; 2: 122-31.         [ Links ]69.- COOPER R D G. The carbacephems a new    ß-lactams class. Am J Med 1992; 92 (Suppl 6 A): 25-65.         [ Links ]70.- ZEMELMAN R, BELLO H, DOMINGUEZ M, GONZALEZ    G, MELLA S, GARCIA A. Activity of imipenem, third-generation cephalosporins,    aztreonam, and ciprofloxacin against multi-resistant Gram negative bacilli isolated    from Chilean hospitals. J Antimicrob Chemother 1993; 32: 413-9.         [ Links ]71.- MEDEIROS A A. Evolution and dissemination    of ß-lactamases accelerated by generation of ß-lactam antibiotics.    Clin Infect Dis 1997; 24 (Suppl. 1): 19-45.         [ Links ]72.- PERRY C M, BROGDEN R N. Cefuroxime axetil:    review of its antibacterial activity, pharmacokinetic properties and therapeutic    efficacy. Drugs 1996; 52: 125-58.         [ Links ]73.- SCHAAD U B, SUTER S, GIANELLA-BORRADORI    et al. A comparison of ceftriaxone and cefuroxime for the treatment of bacterial    meningitis in children. N Engl J Med 1990; 322: 141-7.         [ Links ]74.- KLEIN N C, CUNHA B A. Cefalosporinas de    la tercera generación. Clin Med Nort Am 1995; 79: 693-707.         [ Links ]75.- KLUGMAN K P, MADHI S A. Emergence of    drug resistance impact on bacterial meningitis. Infect Dis Clin North Am 1999;    13: 637-46.         [ Links ]76.- RICHARDS D M, BROGDEN R N. Ceftazidime.    A review of its antibacterial activity, pharmacokinetic properties and therapeutic    use. Drugs 1985; 29: 105-61.         [ Links ]77.- SCHATZ B S, KARAVOKIROS K T, TAEUBEL    M A, ITOKAZU G S. Comparison of cefprozil, cefpodoxime proxetil, loracarbef,    cefixime, and ceftibuten. Ann Pharmacother 1996; 30: 258-68.         [ Links ]78.- DALMAU D, LAYRARGUES G P, FENYVES D,    WILLEMS B, TURGEON F, TURGEON P. Cefotaxime, desacetyl-cefotaxime, and bactericidal    activity in spontaneous bacterial peritonitis. J Infect Dis 1999; 180: 1597-1602.          [ Links ]79.- NIKAIDO W, LIU W, ROSENBERG E Y. Outer    membrane permeability and ß-lactamase stability of dipolar ionic cephalosporins    containing methoxyimino substituents. Antimicrob Agents Chemother 1990; 34:    337-42.         [ Links ]80.- HANCOCK R E W, BELLIDO F. Factors involved    in the enhanced efficacy against gram-negative bacteria of fourth generation    cephalosporins. J Antimicrob Chemother 1992; 29(Suppl A): 1-6.         [ Links ]81.- BELLIDO F, PECHERE J C, HANCOCK REW.    Novel method for measurement of outer membrane permeability to new beta-lactams    in intact Enterobacter cloacae cells. Antimicrob Agents Chemother 1991;    35: 68-72.         [ Links ]82.- NEU H C, CHIN N X, JULES K, LABTHAVIKUL    P. The activity of BMY-28142, a new broad spectrum beta-lactamase stable cephalosporin.    J Antimicrob Chemother 1986; 17: 441-52.         [ Links ]83.- KOBAYASHI S, ARAI S, HAYASHI S, FUJIMOTO    K. ß-lactamase stability of cefpirome (HR 810), a new cephalosporin with    a broad antimicrobial spectrum. Antimicrob Agents Chemother 1986; 30: 713-8.          [ Links ]84.- GARAU J, WILSON W, WOOD M, CARLET J.    Fourth generation cephalosporins: a review of in vitro activity, pharmacokinetics,    pharmacodynamics, and clinical utility. Clin Microb Infect 1997; 3 (Suppl 1):    87-101.         [ Links ]85.- KESSLER R E, FUNG-TOMC J. Susceptibility    of bacterial isolates to beta-lactam antibiotics from U.S. clinical trials over    5-year period. Am J Med 1996; 24 (6 A): 13-9.         [ Links ]86.- PIERARD D, EMMERECHTS K, LAUWERS S. Comparative    in-vitro activity of cefpirome against isolates from intensive care and haematology/oncology    units. Belgian Multicentric Study Group. J Antimicrob Chemother 1998; 41: 443-50.          [ Links ]87.- JONES R N. Resistance patterns among    nosocomial pathogens: trends over the past few years. Chest 2001; 119 (Suppl    2): 397-404.         [ Links ]88.- LORBER B. Changing patterns of infectious    diseases. Am J Med 1988; 84: 569-78.         [ Links ]89.- MOELLERING R C. A novel antimicrobial    agent joins the battle against resistant bacteria. Ann Intern Med 1999; 130:    155-7.         [ Links ]90.- WILSON W R. The role of fourth-generation    cephalosporins in the treatment of serious infectious diseases in hospitalized    patients. Diagn Microbiol Infect Dis 1998; 31: 473-7.         [ Links ]Correspondencia a:        Sergio Mella Montecinos        Laboratorio de Antibióticos,        Departamento de Microbiología,        Facultad de Ciencias Biológicas        Casilla 160-C, Concepción        E-mail: pignatio@ctcinternet.cl  

28.- HERITAGE J, M'ZALI F H, GASCOYNE-BINZI    D, HAWKEY P M. Evolution and spread of SHV extended-spectrum ß-lactamases    in gram negative bacteria. J Antimicrob Chemother 1999; 44: 309-18.         [ Links ]29.- PODSCHUN R, ULLMAN U. Klebsiella spp.    as nosocomial pathogens: epidemiology, taxonomy, typing methods, and pathogenicity    factors. Clin Microbiol Rev 1998; 11: 589-603.         [ Links ]30.- PITOUT J D D, SANDERS C C, SANDERS W    E. Antimicrobial resistance with focus on ß-lactam resistance in Gram    negative bacilli. Am J Med 1997; 103: 51-9.         [ Links ]31.- HANBERGER H, GARCIA-RODRIGUEZ J A, GOBERNADO    et al. Antibiotic susceptibility among aerobic Gram negative bacilli in intensive    care units in 5 european countries. JAMA 1999; 281: 67-71.         [ Links ]32.- CHARREL R N, PAGES J M, DE MICCO P et    al. Prevalence of outer membrane porin alteration in ß-lactam-antibiotic-resistant    Enterobacter aerogenes. Antimicrob Agents Chemother 1996; 40: 2854-8.          [ Links ]33.- BRADFORD P A, URBAN C, MARIANO N, PROJAN    S J, RAHAL J J, BUSH K. Imipenem resistance in Klebsiella pneumoniae is    associated with the combination of ACT-1, a plasmid-mediated Amp C ß-lactamase,    and the loss of an outer membrane protein. Antimicrob Agents Chemother 1997;    41: 563-9.         [ Links ]34.- QUEENAN A M, TORRES-VIERA C, GOLD H et    al. SME-type carbapenem-hydrolizing class A ß-lactamases from geographically    diverse Serratia marcescens strains. Antimicrob Agents Chemother 2000;    44: 3035-9.         [ Links ]35.- COHEN S P, MC MURRY L M, HOOPER D C,    WOLFSON J S, LEVY S B. Cross-resistance to fluoroquinolones in multiple-antibiotic-resistance    (Mar) Escherichia coli selected by tetracycline resistance: decreased    drug accumulation asociated with membrane changes in addition to Omp F reduction.    Antimicrob Agents Chemother 1989; 33:1318-25.         [ Links ]36.- SANDERS C C. Cefepime: The next generation?    Clin Infect Dis 1993; 17: 369-79         [ Links ]37.- GARAU J. The clinical potential of fourth-generation    cephalosporins. Diagn Microbiol Infect Dis 1998; 31: 479-80.         [ Links ]38.- CURTIS N A C, ORR D C, ROSS G W, BOULTON    M G. Affinities of penicillins and cephalosporins for the penicillin-binding    proteins of Escherichia coli    K-12 and their antibacterial activity. Antimicrob Agents Chemother 1979; 16:    533-9.  39.- BALANT L, DAYER P, AUCKENTHALER R. Clinical    pharmacokinetics of the third generation cephalosporins. Clin Pharmacokinetics    1985; 10: 101-43.         [ Links ]40.- WHEELER W J. Cephalosporins and other    beta-lactam antibiotics. Lloydia. 1977; 40: 519-42.         [ Links ]41.- LOPEZ F, GARRIDO J C. Química    y relación estructura-actividad de los antibióticos cefalosporínicos.    Rev Col Químico Farmacéutico 1989; 41: 5-14.         [ Links ]42.- FU K P, ASWAPOKEE P, HO I, MATTHIJSSEN    C, NEU H C. Pharmacokinetics of cefotaxime. Antimicrob Agents Chemother 1979;16:    592-7.         [ Links ]43.- YUK J H, NIGHTINGALE C H, QUINTILIANI    R. Clinical pharmacokinetics of ceftriaxone. Clin Pharmacokinetic 1989; 17:    223-35.         [ Links ]44.- BRYSKIER A, PROCYK T, LABRO M T. Cefodizime,    a new 2-aminothiazolyl cephalosporin: physicochemical properties, toxicology    and structure-activity relationships. J Antimicrob Chemother 1990; 26 (Suppl    C): 1-8.         [ Links ]45.- CRITCHLEY I A, BASKER M J, EDMONDSON    R A, KNOTT S J. Uptake of catecholic cephalosporin by the iron transport system    of Escherichia coli. J Antimicrob Chemother 1991; 28: 377-88.         [ Links ]46.- CRITCHLEY I A. Catecholic ß-lactams:    facilitated transport. J Antimicrob Chemother 1990; 26: 733-7.         [ Links ]47.- JONES R N, ERWIN M E. In vitro evaluation    of Ro 09-1227, a novel catechol-substituted cephalosporin. Antimicrob Agents    Chemother 1992; 36: 233-8.         [ Links ]48.- JONES R N. In vitro activity of Ro 24-6392,    a novel ester-linked co-drug combining ciprofloxacin and desacetylcefotaxime.    Eur J Clin Microbiol Infect Dis 1990; 9: 435-8.         [ Links ]49.- TOMASZ A. Penicillin-binding proteins    and the antibacterial effectiveness of ß-lactam antibiotics. Rev Infect    Dis 1986 (Suppl 3); 8: 260-78.         [ Links ]50.- HOLM S E. Interaction between ß-lactam    and other antibiotics. Rev Infect Dis 1986 (Suppl 3); 8: 305-14.         [ Links ]51.- MC CULLERS J A, ENGLISH B K, NOVAK R.    Isolation and characterization of vancomycin-tolerant Streptococcus pneumoniae    from the cerebrospinal fluid of a patient who developed recrudescet meningitis.    J Infect Dis 2000; 181: 369-73.         [ Links ]52.- NIKAIDO H. Outer membrane barrier as    a mechanism of antimicrobial resistance. Antimicrob Agents Chemother 1989; 33:    1831-6.         [ Links ]53.- BARRADELL L B, BRYSON H M. Cefepime.    A review of its antibacterial activity, pharmacokinetic properties and therapeutic    use. Drugs 1994; 47: 471-505.         [ Links ]54.- O'CALLAGHAN C H 1979. Description and    classification of the newer cephalosporins and their relationship with the established    compounds. J Antimicrob Chemother 5: 635-71         [ Links ]55.- BRYSKIER A, PROCYK T, TREMBLAY D, LENFANT    B FOURTILLAN J B. The pharmacokinetics of cefodizime following intravenous and    intramuscular administration of a single dose of 1.0 g. J Antimicrob Chemother    1990; 26 (Suppl. C): 59-63.         [ Links ]56.- WILLIAMS J D. Classification of cephalosporins.    Drugs. 1987; 34 (Suppl 2): 15-22.         [ Links ]57.- WISEMAN L R, LAMB H M. Cefpirome. A review    of its antibacterial activity, pharmacokinetic properties and efficacy in the    treatment of severe nosocomial infections and febrile neutropenia. Drugs 1997;    57: 117-40.         [ Links ]58.- PECHERE J C, WILSON W, NEU H. Laboratory    assesment of antibacterial activity of zwitterionic 7-methoxyimino cephalosporins.    J Antimicrob Chemother 1995; 36: 757-71         [ Links ]59.- GIAMARELLOS-BOURBOULIS EJ, GRECKA P,    TSITSIKA A, TYMPANIDOU C, GIAMARELLOU H. In-vitro activity of FK 037 (cefoselis),    a novel 4 (th) generation cephalosporin, cefepime and cefpirome on nosocomial    staphylococci and gram-negative isolates. Diagn Microbiol infect Dis 2000; 36:    185-91.         [ Links ]60.- JONES R N, ERWIN M E, BARRETT M S, JOHNSON    D M, BRIGGS B M. Antimicrobial activity of E-1040, a novel thiadiazolyl cephalosporin    compare with parenteral cephems. Diagn Microbiol infect Dis 1991; 14: 301-9.          [ Links ]61.- IIZAWA Y, OKONOGI K, HAYASHI R, IWAHI    T, YAMAZAKI T, IMADA A. Therapeutic effect of cefozopran (SCE-2787), a new parenteral    cephalosporin in experimental infections in mice. Antimicrob Agents Chemother    1993; 37: 100-5.         [ Links ]62.- WATANABE N A. Newer antipseudomonal cephalosporins.    J Chemother 1996; 8 (Suppl 2): 48-56.         [ Links ]63.- ACTOR P, GUARINI J, URI J et al. Disk    susceptibility studies with cefazolin and cephalotin. Antimicrob Agents Chemother    1974; 5: 63-7.         [ Links ]64.- UWAYDAH M. Cefazolin in the treatment    of acute enteric fever. Antimicrob Agents Chemother 1976; 10: 52-6.         [ Links ]65.- JAMAL W Y, ROTIMI V O, CHUGH T D, PAL    T. Prevalence and susceptibility of Shigella to 11 antibiotics in a Kuwait    teaching hospital. J Chemother 1998; 10: 285-90.         [ Links ]66.- COX CE, SHERRILL M, COCCHETT DM. Evaluation    of cefuroxime axetil, cefaclor, and cephalexin in the treatment of urinary tract    infections in adults. Curr Ther Res 1987; 42: 124-37.         [ Links ]67.- SANDERS C W, GREENBERG R N, MARIER R    L. Cefamandole and cefoxitin. Ann Intern Med 1985; 103: 70-8.          [ Links ]68.- STAPLEY E P, JACKSON M, HERNANDEZ S et    al. Cephamycins, a new family of ß-lactam antibiotics I. Production actinomycetes,    including Streptomyces lactamdurans spp.n. Antimicrob Agents Chemother    1972; 2: 122-31.         [ Links ]69.- COOPER R D G. The carbacephems a new    ß-lactams class. Am J Med 1992; 92 (Suppl 6 A): 25-65.         [ Links ]70.- ZEMELMAN R, BELLO H, DOMINGUEZ M, GONZALEZ    G, MELLA S, GARCIA A. Activity of imipenem, third-generation cephalosporins,    aztreonam, and ciprofloxacin against multi-resistant Gram negative bacilli isolated    from Chilean hospitals. J Antimicrob Chemother 1993; 32: 413-9.         [ Links ]71.- MEDEIROS A A. Evolution and dissemination    of ß-lactamases accelerated by generation of ß-lactam antibiotics.    Clin Infect Dis 1997; 24 (Suppl. 1): 19-45.         [ Links ]72.- PERRY C M, BROGDEN R N. Cefuroxime axetil:    review of its antibacterial activity, pharmacokinetic properties and therapeutic    efficacy. Drugs 1996; 52: 125-58.         [ Links ]73.- SCHAAD U B, SUTER S, GIANELLA-BORRADORI    et al. A comparison of ceftriaxone and cefuroxime for the treatment of bacterial    meningitis in children. N Engl J Med 1990; 322: 141-7.         [ Links ]74.- KLEIN N C, CUNHA B A. Cefalosporinas de    la tercera generación. Clin Med Nort Am 1995; 79: 693-707.         [ Links ]75.- KLUGMAN K P, MADHI S A. Emergence of    drug resistance impact on bacterial meningitis. Infect Dis Clin North Am 1999;    13: 637-46.         [ Links ]76.- RICHARDS D M, BROGDEN R N. Ceftazidime.    A review of its antibacterial activity, pharmacokinetic properties and therapeutic    use. Drugs 1985; 29: 105-61.         [ Links ]77.- SCHATZ B S, KARAVOKIROS K T, TAEUBEL    M A, ITOKAZU G S. Comparison of cefprozil, cefpodoxime proxetil, loracarbef,    cefixime, and ceftibuten. Ann Pharmacother 1996; 30: 258-68.         [ Links ]78.- DALMAU D, LAYRARGUES G P, FENYVES D,    WILLEMS B, TURGEON F, TURGEON P. Cefotaxime, desacetyl-cefotaxime, and bactericidal    activity in spontaneous bacterial peritonitis. J Infect Dis 1999; 180: 1597-1602.          [ Links ]79.- NIKAIDO W, LIU W, ROSENBERG E Y. Outer    membrane permeability and ß-lactamase stability of dipolar ionic cephalosporins    containing methoxyimino substituents. Antimicrob Agents Chemother 1990; 34:    337-42.         [ Links ]80.- HANCOCK R E W, BELLIDO F. Factors involved    in the enhanced efficacy against gram-negative bacteria of fourth generation    cephalosporins. J Antimicrob Chemother 1992; 29(Suppl A): 1-6.         [ Links ]81.- BELLIDO F, PECHERE J C, HANCOCK REW.    Novel method for measurement of outer membrane permeability to new beta-lactams    in intact Enterobacter cloacae cells. Antimicrob Agents Chemother 1991;    35: 68-72.         [ Links ]82.- NEU H C, CHIN N X, JULES K, LABTHAVIKUL    P. The activity of BMY-28142, a new broad spectrum beta-lactamase stable cephalosporin.    J Antimicrob Chemother 1986; 17: 441-52.         [ Links ]83.- KOBAYASHI S, ARAI S, HAYASHI S, FUJIMOTO    K. ß-lactamase stability of cefpirome (HR 810), a new cephalosporin with    a broad antimicrobial spectrum. Antimicrob Agents Chemother 1986; 30: 713-8.          [ Links ]84.- GARAU J, WILSON W, WOOD M, CARLET J.    Fourth generation cephalosporins: a review of in vitro activity, pharmacokinetics,    pharmacodynamics, and clinical utility. Clin Microb Infect 1997; 3 (Suppl 1):    87-101.         [ Links ]85.- KESSLER R E, FUNG-TOMC J. Susceptibility    of bacterial isolates to beta-lactam antibiotics from U.S. clinical trials over    5-year period. Am J Med 1996; 24 (6 A): 13-9.         [ Links ]86.- PIERARD D, EMMERECHTS K, LAUWERS S. Comparative    in-vitro activity of cefpirome against isolates from intensive care and haematology/oncology    units. Belgian Multicentric Study Group. J Antimicrob Chemother 1998; 41: 443-50.          [ Links ]87.- JONES R N. Resistance patterns among    nosocomial pathogens: trends over the past few years. Chest 2001; 119 (Suppl    2): 397-404.         [ Links ]88.- LORBER B. Changing patterns of infectious    diseases. Am J Med 1988; 84: 569-78.         [ Links ]89.- MOELLERING R C. A novel antimicrobial    agent joins the battle against resistant bacteria. Ann Intern Med 1999; 130:    155-7.         [ Links ]90.- WILSON W R. The role of fourth-generation    cephalosporins in the treatment of serious infectious diseases in hospitalized    patients. Diagn Microbiol Infect Dis 1998; 31: 473-7.         [ Links ]Correspondencia a:        Sergio Mella Montecinos        Laboratorio de Antibióticos,        Departamento de Microbiología,        Facultad de Ciencias Biológicas        Casilla 160-C, Concepción        E-mail: pignatio@ctcinternet.cl  

29.- PODSCHUN R, ULLMAN U. Klebsiella spp.    as nosocomial pathogens: epidemiology, taxonomy, typing methods, and pathogenicity    factors. Clin Microbiol Rev 1998; 11: 589-603.         [ Links ]30.- PITOUT J D D, SANDERS C C, SANDERS W    E. Antimicrobial resistance with focus on ß-lactam resistance in Gram    negative bacilli. Am J Med 1997; 103: 51-9.         [ Links ]31.- HANBERGER H, GARCIA-RODRIGUEZ J A, GOBERNADO    et al. Antibiotic susceptibility among aerobic Gram negative bacilli in intensive    care units in 5 european countries. JAMA 1999; 281: 67-71.         [ Links ]32.- CHARREL R N, PAGES J M, DE MICCO P et    al. Prevalence of outer membrane porin alteration in ß-lactam-antibiotic-resistant    Enterobacter aerogenes. Antimicrob Agents Chemother 1996; 40: 2854-8.          [ Links ]33.- BRADFORD P A, URBAN C, MARIANO N, PROJAN    S J, RAHAL J J, BUSH K. Imipenem resistance in Klebsiella pneumoniae is    associated with the combination of ACT-1, a plasmid-mediated Amp C ß-lactamase,    and the loss of an outer membrane protein. Antimicrob Agents Chemother 1997;    41: 563-9.         [ Links ]34.- QUEENAN A M, TORRES-VIERA C, GOLD H et    al. SME-type carbapenem-hydrolizing class A ß-lactamases from geographically    diverse Serratia marcescens strains. Antimicrob Agents Chemother 2000;    44: 3035-9.         [ Links ]35.- COHEN S P, MC MURRY L M, HOOPER D C,    WOLFSON J S, LEVY S B. Cross-resistance to fluoroquinolones in multiple-antibiotic-resistance    (Mar) Escherichia coli selected by tetracycline resistance: decreased    drug accumulation asociated with membrane changes in addition to Omp F reduction.    Antimicrob Agents Chemother 1989; 33:1318-25.         [ Links ]36.- SANDERS C C. Cefepime: The next generation?    Clin Infect Dis 1993; 17: 369-79         [ Links ]37.- GARAU J. The clinical potential of fourth-generation    cephalosporins. Diagn Microbiol Infect Dis 1998; 31: 479-80.         [ Links ]38.- CURTIS N A C, ORR D C, ROSS G W, BOULTON    M G. Affinities of penicillins and cephalosporins for the penicillin-binding    proteins of Escherichia coli    K-12 and their antibacterial activity. Antimicrob Agents Chemother 1979; 16:    533-9.  39.- BALANT L, DAYER P, AUCKENTHALER R. Clinical    pharmacokinetics of the third generation cephalosporins. Clin Pharmacokinetics    1985; 10: 101-43.         [ Links ]40.- WHEELER W J. Cephalosporins and other    beta-lactam antibiotics. Lloydia. 1977; 40: 519-42.         [ Links ]41.- LOPEZ F, GARRIDO J C. Química    y relación estructura-actividad de los antibióticos cefalosporínicos.    Rev Col Químico Farmacéutico 1989; 41: 5-14.         [ Links ]42.- FU K P, ASWAPOKEE P, HO I, MATTHIJSSEN    C, NEU H C. Pharmacokinetics of cefotaxime. Antimicrob Agents Chemother 1979;16:    592-7.         [ Links ]43.- YUK J H, NIGHTINGALE C H, QUINTILIANI    R. Clinical pharmacokinetics of ceftriaxone. Clin Pharmacokinetic 1989; 17:    223-35.         [ Links ]44.- BRYSKIER A, PROCYK T, LABRO M T. Cefodizime,    a new 2-aminothiazolyl cephalosporin: physicochemical properties, toxicology    and structure-activity relationships. J Antimicrob Chemother 1990; 26 (Suppl    C): 1-8.         [ Links ]45.- CRITCHLEY I A, BASKER M J, EDMONDSON    R A, KNOTT S J. Uptake of catecholic cephalosporin by the iron transport system    of Escherichia coli. J Antimicrob Chemother 1991; 28: 377-88.         [ Links ]46.- CRITCHLEY I A. Catecholic ß-lactams:    facilitated transport. J Antimicrob Chemother 1990; 26: 733-7.         [ Links ]47.- JONES R N, ERWIN M E. In vitro evaluation    of Ro 09-1227, a novel catechol-substituted cephalosporin. Antimicrob Agents    Chemother 1992; 36: 233-8.         [ Links ]48.- JONES R N. In vitro activity of Ro 24-6392,    a novel ester-linked co-drug combining ciprofloxacin and desacetylcefotaxime.    Eur J Clin Microbiol Infect Dis 1990; 9: 435-8.         [ Links ]49.- TOMASZ A. Penicillin-binding proteins    and the antibacterial effectiveness of ß-lactam antibiotics. Rev Infect    Dis 1986 (Suppl 3); 8: 260-78.         [ Links ]50.- HOLM S E. Interaction between ß-lactam    and other antibiotics. Rev Infect Dis 1986 (Suppl 3); 8: 305-14.         [ Links ]51.- MC CULLERS J A, ENGLISH B K, NOVAK R.    Isolation and characterization of vancomycin-tolerant Streptococcus pneumoniae    from the cerebrospinal fluid of a patient who developed recrudescet meningitis.    J Infect Dis 2000; 181: 369-73.         [ Links ]52.- NIKAIDO H. Outer membrane barrier as    a mechanism of antimicrobial resistance. Antimicrob Agents Chemother 1989; 33:    1831-6.         [ Links ]53.- BARRADELL L B, BRYSON H M. Cefepime.    A review of its antibacterial activity, pharmacokinetic properties and therapeutic    use. Drugs 1994; 47: 471-505.         [ Links ]54.- O'CALLAGHAN C H 1979. Description and    classification of the newer cephalosporins and their relationship with the established    compounds. J Antimicrob Chemother 5: 635-71         [ Links ]55.- BRYSKIER A, PROCYK T, TREMBLAY D, LENFANT    B FOURTILLAN J B. The pharmacokinetics of cefodizime following intravenous and    intramuscular administration of a single dose of 1.0 g. J Antimicrob Chemother    1990; 26 (Suppl. C): 59-63.         [ Links ]56.- WILLIAMS J D. Classification of cephalosporins.    Drugs. 1987; 34 (Suppl 2): 15-22.         [ Links ]57.- WISEMAN L R, LAMB H M. Cefpirome. A review    of its antibacterial activity, pharmacokinetic properties and efficacy in the    treatment of severe nosocomial infections and febrile neutropenia. Drugs 1997;    57: 117-40.         [ Links ]58.- PECHERE J C, WILSON W, NEU H. Laboratory    assesment of antibacterial activity of zwitterionic 7-methoxyimino cephalosporins.    J Antimicrob Chemother 1995; 36: 757-71         [ Links ]59.- GIAMARELLOS-BOURBOULIS EJ, GRECKA P,    TSITSIKA A, TYMPANIDOU C, GIAMARELLOU H. In-vitro activity of FK 037 (cefoselis),    a novel 4 (th) generation cephalosporin, cefepime and cefpirome on nosocomial    staphylococci and gram-negative isolates. Diagn Microbiol infect Dis 2000; 36:    185-91.         [ Links ]60.- JONES R N, ERWIN M E, BARRETT M S, JOHNSON    D M, BRIGGS B M. Antimicrobial activity of E-1040, a novel thiadiazolyl cephalosporin    compare with parenteral cephems. Diagn Microbiol infect Dis 1991; 14: 301-9.          [ Links ]61.- IIZAWA Y, OKONOGI K, HAYASHI R, IWAHI    T, YAMAZAKI T, IMADA A. Therapeutic effect of cefozopran (SCE-2787), a new parenteral    cephalosporin in experimental infections in mice. Antimicrob Agents Chemother    1993; 37: 100-5.         [ Links ]62.- WATANABE N A. Newer antipseudomonal cephalosporins.    J Chemother 1996; 8 (Suppl 2): 48-56.         [ Links ]63.- ACTOR P, GUARINI J, URI J et al. Disk    susceptibility studies with cefazolin and cephalotin. Antimicrob Agents Chemother    1974; 5: 63-7.         [ Links ]64.- UWAYDAH M. Cefazolin in the treatment    of acute enteric fever. Antimicrob Agents Chemother 1976; 10: 52-6.         [ Links ]65.- JAMAL W Y, ROTIMI V O, CHUGH T D, PAL    T. Prevalence and susceptibility of Shigella to 11 antibiotics in a Kuwait    teaching hospital. J Chemother 1998; 10: 285-90.         [ Links ]66.- COX CE, SHERRILL M, COCCHETT DM. Evaluation    of cefuroxime axetil, cefaclor, and cephalexin in the treatment of urinary tract    infections in adults. Curr Ther Res 1987; 42: 124-37.         [ Links ]67.- SANDERS C W, GREENBERG R N, MARIER R    L. Cefamandole and cefoxitin. Ann Intern Med 1985; 103: 70-8.          [ Links ]68.- STAPLEY E P, JACKSON M, HERNANDEZ S et    al. Cephamycins, a new family of ß-lactam antibiotics I. Production actinomycetes,    including Streptomyces lactamdurans spp.n. Antimicrob Agents Chemother    1972; 2: 122-31.         [ Links ]69.- COOPER R D G. The carbacephems a new    ß-lactams class. Am J Med 1992; 92 (Suppl 6 A): 25-65.         [ Links ]70.- ZEMELMAN R, BELLO H, DOMINGUEZ M, GONZALEZ    G, MELLA S, GARCIA A. Activity of imipenem, third-generation cephalosporins,    aztreonam, and ciprofloxacin against multi-resistant Gram negative bacilli isolated    from Chilean hospitals. J Antimicrob Chemother 1993; 32: 413-9.         [ Links ]71.- MEDEIROS A A. Evolution and dissemination    of ß-lactamases accelerated by generation of ß-lactam antibiotics.    Clin Infect Dis 1997; 24 (Suppl. 1): 19-45.         [ Links ]72.- PERRY C M, BROGDEN R N. Cefuroxime axetil:    review of its antibacterial activity, pharmacokinetic properties and therapeutic    efficacy. Drugs 1996; 52: 125-58.         [ Links ]73.- SCHAAD U B, SUTER S, GIANELLA-BORRADORI    et al. A comparison of ceftriaxone and cefuroxime for the treatment of bacterial    meningitis in children. N Engl J Med 1990; 322: 141-7.         [ Links ]74.- KLEIN N C, CUNHA B A. Cefalosporinas de    la tercera generación. Clin Med Nort Am 1995; 79: 693-707.         [ Links ]75.- KLUGMAN K P, MADHI S A. Emergence of    drug resistance impact on bacterial meningitis. Infect Dis Clin North Am 1999;    13: 637-46.         [ Links ]76.- RICHARDS D M, BROGDEN R N. Ceftazidime.    A review of its antibacterial activity, pharmacokinetic properties and therapeutic    use. Drugs 1985; 29: 105-61.         [ Links ]77.- SCHATZ B S, KARAVOKIROS K T, TAEUBEL    M A, ITOKAZU G S. Comparison of cefprozil, cefpodoxime proxetil, loracarbef,    cefixime, and ceftibuten. Ann Pharmacother 1996; 30: 258-68.         [ Links ]78.- DALMAU D, LAYRARGUES G P, FENYVES D,    WILLEMS B, TURGEON F, TURGEON P. Cefotaxime, desacetyl-cefotaxime, and bactericidal    activity in spontaneous bacterial peritonitis. J Infect Dis 1999; 180: 1597-1602.          [ Links ]79.- NIKAIDO W, LIU W, ROSENBERG E Y. Outer    membrane permeability and ß-lactamase stability of dipolar ionic cephalosporins    containing methoxyimino substituents. Antimicrob Agents Chemother 1990; 34:    337-42.         [ Links ]80.- HANCOCK R E W, BELLIDO F. Factors involved    in the enhanced efficacy against gram-negative bacteria of fourth generation    cephalosporins. J Antimicrob Chemother 1992; 29(Suppl A): 1-6.         [ Links ]81.- BELLIDO F, PECHERE J C, HANCOCK REW.    Novel method for measurement of outer membrane permeability to new beta-lactams    in intact Enterobacter cloacae cells. Antimicrob Agents Chemother 1991;    35: 68-72.         [ Links ]82.- NEU H C, CHIN N X, JULES K, LABTHAVIKUL    P. The activity of BMY-28142, a new broad spectrum beta-lactamase stable cephalosporin.    J Antimicrob Chemother 1986; 17: 441-52.         [ Links ]83.- KOBAYASHI S, ARAI S, HAYASHI S, FUJIMOTO    K. ß-lactamase stability of cefpirome (HR 810), a new cephalosporin with    a broad antimicrobial spectrum. Antimicrob Agents Chemother 1986; 30: 713-8.          [ Links ]84.- GARAU J, WILSON W, WOOD M, CARLET J.    Fourth generation cephalosporins: a review of in vitro activity, pharmacokinetics,    pharmacodynamics, and clinical utility. Clin Microb Infect 1997; 3 (Suppl 1):    87-101.         [ Links ]85.- KESSLER R E, FUNG-TOMC J. Susceptibility    of bacterial isolates to beta-lactam antibiotics from U.S. clinical trials over    5-year period. Am J Med 1996; 24 (6 A): 13-9.         [ Links ]86.- PIERARD D, EMMERECHTS K, LAUWERS S. Comparative    in-vitro activity of cefpirome against isolates from intensive care and haematology/oncology    units. Belgian Multicentric Study Group. J Antimicrob Chemother 1998; 41: 443-50.          [ Links ]87.- JONES R N. Resistance patterns among    nosocomial pathogens: trends over the past few years. Chest 2001; 119 (Suppl    2): 397-404.         [ Links ]88.- LORBER B. Changing patterns of infectious    diseases. Am J Med 1988; 84: 569-78.         [ Links ]89.- MOELLERING R C. A novel antimicrobial    agent joins the battle against resistant bacteria. Ann Intern Med 1999; 130:    155-7.         [ Links ]90.- WILSON W R. The role of fourth-generation    cephalosporins in the treatment of serious infectious diseases in hospitalized    patients. Diagn Microbiol Infect Dis 1998; 31: 473-7.         [ Links ]Correspondencia a:        Sergio Mella Montecinos        Laboratorio de Antibióticos,        Departamento de Microbiología,        Facultad de Ciencias Biológicas        Casilla 160-C, Concepción        E-mail: pignatio@ctcinternet.cl  

30.- PITOUT J D D, SANDERS C C, SANDERS W    E. Antimicrobial resistance with focus on ß-lactam resistance in Gram    negative bacilli. Am J Med 1997; 103: 51-9.         [ Links ]31.- HANBERGER H, GARCIA-RODRIGUEZ J A, GOBERNADO    et al. Antibiotic susceptibility among aerobic Gram negative bacilli in intensive    care units in 5 european countries. JAMA 1999; 281: 67-71.         [ Links ]32.- CHARREL R N, PAGES J M, DE MICCO P et    al. Prevalence of outer membrane porin alteration in ß-lactam-antibiotic-resistant    Enterobacter aerogenes. Antimicrob Agents Chemother 1996; 40: 2854-8.          [ Links ]33.- BRADFORD P A, URBAN C, MARIANO N, PROJAN    S J, RAHAL J J, BUSH K. Imipenem resistance in Klebsiella pneumoniae is    associated with the combination of ACT-1, a plasmid-mediated Amp C ß-lactamase,    and the loss of an outer membrane protein. Antimicrob Agents Chemother 1997;    41: 563-9.         [ Links ]34.- QUEENAN A M, TORRES-VIERA C, GOLD H et    al. SME-type carbapenem-hydrolizing class A ß-lactamases from geographically    diverse Serratia marcescens strains. Antimicrob Agents Chemother 2000;    44: 3035-9.         [ Links ]35.- COHEN S P, MC MURRY L M, HOOPER D C,    WOLFSON J S, LEVY S B. Cross-resistance to fluoroquinolones in multiple-antibiotic-resistance    (Mar) Escherichia coli selected by tetracycline resistance: decreased    drug accumulation asociated with membrane changes in addition to Omp F reduction.    Antimicrob Agents Chemother 1989; 33:1318-25.         [ Links ]36.- SANDERS C C. Cefepime: The next generation?    Clin Infect Dis 1993; 17: 369-79         [ Links ]37.- GARAU J. The clinical potential of fourth-generation    cephalosporins. Diagn Microbiol Infect Dis 1998; 31: 479-80.         [ Links ]38.- CURTIS N A C, ORR D C, ROSS G W, BOULTON    M G. Affinities of penicillins and cephalosporins for the penicillin-binding    proteins of Escherichia coli    K-12 and their antibacterial activity. Antimicrob Agents Chemother 1979; 16:    533-9.  39.- BALANT L, DAYER P, AUCKENTHALER R. Clinical    pharmacokinetics of the third generation cephalosporins. Clin Pharmacokinetics    1985; 10: 101-43.         [ Links ]40.- WHEELER W J. Cephalosporins and other    beta-lactam antibiotics. Lloydia. 1977; 40: 519-42.         [ Links ]41.- LOPEZ F, GARRIDO J C. Química    y relación estructura-actividad de los antibióticos cefalosporínicos.    Rev Col Químico Farmacéutico 1989; 41: 5-14.         [ Links ]42.- FU K P, ASWAPOKEE P, HO I, MATTHIJSSEN    C, NEU H C. Pharmacokinetics of cefotaxime. Antimicrob Agents Chemother 1979;16:    592-7.         [ Links ]43.- YUK J H, NIGHTINGALE C H, QUINTILIANI    R. Clinical pharmacokinetics of ceftriaxone. Clin Pharmacokinetic 1989; 17:    223-35.         [ Links ]44.- BRYSKIER A, PROCYK T, LABRO M T. Cefodizime,    a new 2-aminothiazolyl cephalosporin: physicochemical properties, toxicology    and structure-activity relationships. J Antimicrob Chemother 1990; 26 (Suppl    C): 1-8.         [ Links ]45.- CRITCHLEY I A, BASKER M J, EDMONDSON    R A, KNOTT S J. Uptake of catecholic cephalosporin by the iron transport system    of Escherichia coli. J Antimicrob Chemother 1991; 28: 377-88.         [ Links ]46.- CRITCHLEY I A. Catecholic ß-lactams:    facilitated transport. J Antimicrob Chemother 1990; 26: 733-7.         [ Links ]47.- JONES R N, ERWIN M E. In vitro evaluation    of Ro 09-1227, a novel catechol-substituted cephalosporin. Antimicrob Agents    Chemother 1992; 36: 233-8.         [ Links ]48.- JONES R N. In vitro activity of Ro 24-6392,    a novel ester-linked co-drug combining ciprofloxacin and desacetylcefotaxime.    Eur J Clin Microbiol Infect Dis 1990; 9: 435-8.         [ Links ]49.- TOMASZ A. Penicillin-binding proteins    and the antibacterial effectiveness of ß-lactam antibiotics. Rev Infect    Dis 1986 (Suppl 3); 8: 260-78.         [ Links ]50.- HOLM S E. Interaction between ß-lactam    and other antibiotics. Rev Infect Dis 1986 (Suppl 3); 8: 305-14.         [ Links ]51.- MC CULLERS J A, ENGLISH B K, NOVAK R.    Isolation and characterization of vancomycin-tolerant Streptococcus pneumoniae    from the cerebrospinal fluid of a patient who developed recrudescet meningitis.    J Infect Dis 2000; 181: 369-73.         [ Links ]52.- NIKAIDO H. Outer membrane barrier as    a mechanism of antimicrobial resistance. Antimicrob Agents Chemother 1989; 33:    1831-6.         [ Links ]53.- BARRADELL L B, BRYSON H M. Cefepime.    A review of its antibacterial activity, pharmacokinetic properties and therapeutic    use. Drugs 1994; 47: 471-505.         [ Links ]54.- O'CALLAGHAN C H 1979. Description and    classification of the newer cephalosporins and their relationship with the established    compounds. J Antimicrob Chemother 5: 635-71         [ Links ]55.- BRYSKIER A, PROCYK T, TREMBLAY D, LENFANT    B FOURTILLAN J B. The pharmacokinetics of cefodizime following intravenous and    intramuscular administration of a single dose of 1.0 g. J Antimicrob Chemother    1990; 26 (Suppl. C): 59-63.         [ Links ]56.- WILLIAMS J D. Classification of cephalosporins.    Drugs. 1987; 34 (Suppl 2): 15-22.         [ Links ]57.- WISEMAN L R, LAMB H M. Cefpirome. A review    of its antibacterial activity, pharmacokinetic properties and efficacy in the    treatment of severe nosocomial infections and febrile neutropenia. Drugs 1997;    57: 117-40.         [ Links ]58.- PECHERE J C, WILSON W, NEU H. Laboratory    assesment of antibacterial activity of zwitterionic 7-methoxyimino cephalosporins.    J Antimicrob Chemother 1995; 36: 757-71         [ Links ]59.- GIAMARELLOS-BOURBOULIS EJ, GRECKA P,    TSITSIKA A, TYMPANIDOU C, GIAMARELLOU H. In-vitro activity of FK 037 (cefoselis),    a novel 4 (th) generation cephalosporin, cefepime and cefpirome on nosocomial    staphylococci and gram-negative isolates. Diagn Microbiol infect Dis 2000; 36:    185-91.         [ Links ]60.- JONES R N, ERWIN M E, BARRETT M S, JOHNSON    D M, BRIGGS B M. Antimicrobial activity of E-1040, a novel thiadiazolyl cephalosporin    compare with parenteral cephems. Diagn Microbiol infect Dis 1991; 14: 301-9.          [ Links ]61.- IIZAWA Y, OKONOGI K, HAYASHI R, IWAHI    T, YAMAZAKI T, IMADA A. Therapeutic effect of cefozopran (SCE-2787), a new parenteral    cephalosporin in experimental infections in mice. Antimicrob Agents Chemother    1993; 37: 100-5.         [ Links ]62.- WATANABE N A. Newer antipseudomonal cephalosporins.    J Chemother 1996; 8 (Suppl 2): 48-56.         [ Links ]63.- ACTOR P, GUARINI J, URI J et al. Disk    susceptibility studies with cefazolin and cephalotin. Antimicrob Agents Chemother    1974; 5: 63-7.         [ Links ]64.- UWAYDAH M. Cefazolin in the treatment    of acute enteric fever. Antimicrob Agents Chemother 1976; 10: 52-6.         [ Links ]65.- JAMAL W Y, ROTIMI V O, CHUGH T D, PAL    T. Prevalence and susceptibility of Shigella to 11 antibiotics in a Kuwait    teaching hospital. J Chemother 1998; 10: 285-90.         [ Links ]66.- COX CE, SHERRILL M, COCCHETT DM. Evaluation    of cefuroxime axetil, cefaclor, and cephalexin in the treatment of urinary tract    infections in adults. Curr Ther Res 1987; 42: 124-37.         [ Links ]67.- SANDERS C W, GREENBERG R N, MARIER R    L. Cefamandole and cefoxitin. Ann Intern Med 1985; 103: 70-8.          [ Links ]68.- STAPLEY E P, JACKSON M, HERNANDEZ S et    al. Cephamycins, a new family of ß-lactam antibiotics I. Production actinomycetes,    including Streptomyces lactamdurans spp.n. Antimicrob Agents Chemother    1972; 2: 122-31.         [ Links ]69.- COOPER R D G. The carbacephems a new    ß-lactams class. Am J Med 1992; 92 (Suppl 6 A): 25-65.         [ Links ]70.- ZEMELMAN R, BELLO H, DOMINGUEZ M, GONZALEZ    G, MELLA S, GARCIA A. Activity of imipenem, third-generation cephalosporins,    aztreonam, and ciprofloxacin against multi-resistant Gram negative bacilli isolated    from Chilean hospitals. J Antimicrob Chemother 1993; 32: 413-9.         [ Links ]71.- MEDEIROS A A. Evolution and dissemination    of ß-lactamases accelerated by generation of ß-lactam antibiotics.    Clin Infect Dis 1997; 24 (Suppl. 1): 19-45.         [ Links ]72.- PERRY C M, BROGDEN R N. Cefuroxime axetil:    review of its antibacterial activity, pharmacokinetic properties and therapeutic    efficacy. Drugs 1996; 52: 125-58.         [ Links ]73.- SCHAAD U B, SUTER S, GIANELLA-BORRADORI    et al. A comparison of ceftriaxone and cefuroxime for the treatment of bacterial    meningitis in children. N Engl J Med 1990; 322: 141-7.         [ Links ]74.- KLEIN N C, CUNHA B A. Cefalosporinas de    la tercera generación. Clin Med Nort Am 1995; 79: 693-707.         [ Links ]75.- KLUGMAN K P, MADHI S A. Emergence of    drug resistance impact on bacterial meningitis. Infect Dis Clin North Am 1999;    13: 637-46.         [ Links ]76.- RICHARDS D M, BROGDEN R N. Ceftazidime.    A review of its antibacterial activity, pharmacokinetic properties and therapeutic    use. Drugs 1985; 29: 105-61.         [ Links ]77.- SCHATZ B S, KARAVOKIROS K T, TAEUBEL    M A, ITOKAZU G S. Comparison of cefprozil, cefpodoxime proxetil, loracarbef,    cefixime, and ceftibuten. Ann Pharmacother 1996; 30: 258-68.         [ Links ]78.- DALMAU D, LAYRARGUES G P, FENYVES D,    WILLEMS B, TURGEON F, TURGEON P. Cefotaxime, desacetyl-cefotaxime, and bactericidal    activity in spontaneous bacterial peritonitis. J Infect Dis 1999; 180: 1597-1602.          [ Links ]79.- NIKAIDO W, LIU W, ROSENBERG E Y. Outer    membrane permeability and ß-lactamase stability of dipolar ionic cephalosporins    containing methoxyimino substituents. Antimicrob Agents Chemother 1990; 34:    337-42.         [ Links ]80.- HANCOCK R E W, BELLIDO F. Factors involved    in the enhanced efficacy against gram-negative bacteria of fourth generation    cephalosporins. J Antimicrob Chemother 1992; 29(Suppl A): 1-6.         [ Links ]81.- BELLIDO F, PECHERE J C, HANCOCK REW.    Novel method for measurement of outer membrane permeability to new beta-lactams    in intact Enterobacter cloacae cells. Antimicrob Agents Chemother 1991;    35: 68-72.         [ Links ]82.- NEU H C, CHIN N X, JULES K, LABTHAVIKUL    P. The activity of BMY-28142, a new broad spectrum beta-lactamase stable cephalosporin.    J Antimicrob Chemother 1986; 17: 441-52.         [ Links ]83.- KOBAYASHI S, ARAI S, HAYASHI S, FUJIMOTO    K. ß-lactamase stability of cefpirome (HR 810), a new cephalosporin with    a broad antimicrobial spectrum. Antimicrob Agents Chemother 1986; 30: 713-8.          [ Links ]84.- GARAU J, WILSON W, WOOD M, CARLET J.    Fourth generation cephalosporins: a review of in vitro activity, pharmacokinetics,    pharmacodynamics, and clinical utility. Clin Microb Infect 1997; 3 (Suppl 1):    87-101.         [ Links ]85.- KESSLER R E, FUNG-TOMC J. Susceptibility    of bacterial isolates to beta-lactam antibiotics from U.S. clinical trials over    5-year period. Am J Med 1996; 24 (6 A): 13-9.         [ Links ]86.- PIERARD D, EMMERECHTS K, LAUWERS S. Comparative    in-vitro activity of cefpirome against isolates from intensive care and haematology/oncology    units. Belgian Multicentric Study Group. J Antimicrob Chemother 1998; 41: 443-50.          [ Links ]87.- JONES R N. Resistance patterns among    nosocomial pathogens: trends over the past few years. Chest 2001; 119 (Suppl    2): 397-404.         [ Links ]88.- LORBER B. Changing patterns of infectious    diseases. Am J Med 1988; 84: 569-78.         [ Links ]89.- MOELLERING R C. A novel antimicrobial    agent joins the battle against resistant bacteria. Ann Intern Med 1999; 130:    155-7.         [ Links ]90.- WILSON W R. The role of fourth-generation    cephalosporins in the treatment of serious infectious diseases in hospitalized    patients. Diagn Microbiol Infect Dis 1998; 31: 473-7.         [ Links ]Correspondencia a:        Sergio Mella Montecinos        Laboratorio de Antibióticos,        Departamento de Microbiología,        Facultad de Ciencias Biológicas        Casilla 160-C, Concepción        E-mail: pignatio@ctcinternet.cl  

31.- HANBERGER H, GARCIA-RODRIGUEZ J A, GOBERNADO    et al. Antibiotic susceptibility among aerobic Gram negative bacilli in intensive    care units in 5 european countries. JAMA 1999; 281: 67-71.         [ Links ]32.- CHARREL R N, PAGES J M, DE MICCO P et    al. Prevalence of outer membrane porin alteration in ß-lactam-antibiotic-resistant    Enterobacter aerogenes. Antimicrob Agents Chemother 1996; 40: 2854-8.          [ Links ]33.- BRADFORD P A, URBAN C, MARIANO N, PROJAN    S J, RAHAL J J, BUSH K. Imipenem resistance in Klebsiella pneumoniae is    associated with the combination of ACT-1, a plasmid-mediated Amp C ß-lactamase,    and the loss of an outer membrane protein. Antimicrob Agents Chemother 1997;    41: 563-9.         [ Links ]34.- QUEENAN A M, TORRES-VIERA C, GOLD H et    al. SME-type carbapenem-hydrolizing class A ß-lactamases from geographically    diverse Serratia marcescens strains. Antimicrob Agents Chemother 2000;    44: 3035-9.         [ Links ]35.- COHEN S P, MC MURRY L M, HOOPER D C,    WOLFSON J S, LEVY S B. Cross-resistance to fluoroquinolones in multiple-antibiotic-resistance    (Mar) Escherichia coli selected by tetracycline resistance: decreased    drug accumulation asociated with membrane changes in addition to Omp F reduction.    Antimicrob Agents Chemother 1989; 33:1318-25.         [ Links ]36.- SANDERS C C. Cefepime: The next generation?    Clin Infect Dis 1993; 17: 369-79         [ Links ]37.- GARAU J. The clinical potential of fourth-generation    cephalosporins. Diagn Microbiol Infect Dis 1998; 31: 479-80.         [ Links ]38.- CURTIS N A C, ORR D C, ROSS G W, BOULTON    M G. Affinities of penicillins and cephalosporins for the penicillin-binding    proteins of Escherichia coli    K-12 and their antibacterial activity. Antimicrob Agents Chemother 1979; 16:    533-9.  39.- BALANT L, DAYER P, AUCKENTHALER R. Clinical    pharmacokinetics of the third generation cephalosporins. Clin Pharmacokinetics    1985; 10: 101-43.         [ Links ]40.- WHEELER W J. Cephalosporins and other    beta-lactam antibiotics. Lloydia. 1977; 40: 519-42.         [ Links ]41.- LOPEZ F, GARRIDO J C. Química    y relación estructura-actividad de los antibióticos cefalosporínicos.    Rev Col Químico Farmacéutico 1989; 41: 5-14.         [ Links ]42.- FU K P, ASWAPOKEE P, HO I, MATTHIJSSEN    C, NEU H C. Pharmacokinetics of cefotaxime. Antimicrob Agents Chemother 1979;16:    592-7.         [ Links ]43.- YUK J H, NIGHTINGALE C H, QUINTILIANI    R. Clinical pharmacokinetics of ceftriaxone. Clin Pharmacokinetic 1989; 17:    223-35.         [ Links ]44.- BRYSKIER A, PROCYK T, LABRO M T. Cefodizime,    a new 2-aminothiazolyl cephalosporin: physicochemical properties, toxicology    and structure-activity relationships. J Antimicrob Chemother 1990; 26 (Suppl    C): 1-8.         [ Links ]45.- CRITCHLEY I A, BASKER M J, EDMONDSON    R A, KNOTT S J. Uptake of catecholic cephalosporin by the iron transport system    of Escherichia coli. J Antimicrob Chemother 1991; 28: 377-88.         [ Links ]46.- CRITCHLEY I A. Catecholic ß-lactams:    facilitated transport. J Antimicrob Chemother 1990; 26: 733-7.         [ Links ]47.- JONES R N, ERWIN M E. In vitro evaluation    of Ro 09-1227, a novel catechol-substituted cephalosporin. Antimicrob Agents    Chemother 1992; 36: 233-8.         [ Links ]48.- JONES R N. In vitro activity of Ro 24-6392,    a novel ester-linked co-drug combining ciprofloxacin and desacetylcefotaxime.    Eur J Clin Microbiol Infect Dis 1990; 9: 435-8.         [ Links ]49.- TOMASZ A. Penicillin-binding proteins    and the antibacterial effectiveness of ß-lactam antibiotics. Rev Infect    Dis 1986 (Suppl 3); 8: 260-78.         [ Links ]50.- HOLM S E. Interaction between ß-lactam    and other antibiotics. Rev Infect Dis 1986 (Suppl 3); 8: 305-14.         [ Links ]51.- MC CULLERS J A, ENGLISH B K, NOVAK R.    Isolation and characterization of vancomycin-tolerant Streptococcus pneumoniae    from the cerebrospinal fluid of a patient who developed recrudescet meningitis.    J Infect Dis 2000; 181: 369-73.         [ Links ]52.- NIKAIDO H. Outer membrane barrier as    a mechanism of antimicrobial resistance. Antimicrob Agents Chemother 1989; 33:    1831-6.         [ Links ]53.- BARRADELL L B, BRYSON H M. Cefepime.    A review of its antibacterial activity, pharmacokinetic properties and therapeutic    use. Drugs 1994; 47: 471-505.         [ Links ]54.- O'CALLAGHAN C H 1979. Description and    classification of the newer cephalosporins and their relationship with the established    compounds. J Antimicrob Chemother 5: 635-71         [ Links ]55.- BRYSKIER A, PROCYK T, TREMBLAY D, LENFANT    B FOURTILLAN J B. The pharmacokinetics of cefodizime following intravenous and    intramuscular administration of a single dose of 1.0 g. J Antimicrob Chemother    1990; 26 (Suppl. C): 59-63.         [ Links ]56.- WILLIAMS J D. Classification of cephalosporins.    Drugs. 1987; 34 (Suppl 2): 15-22.         [ Links ]57.- WISEMAN L R, LAMB H M. Cefpirome. A review    of its antibacterial activity, pharmacokinetic properties and efficacy in the    treatment of severe nosocomial infections and febrile neutropenia. Drugs 1997;    57: 117-40.         [ Links ]58.- PECHERE J C, WILSON W, NEU H. Laboratory    assesment of antibacterial activity of zwitterionic 7-methoxyimino cephalosporins.    J Antimicrob Chemother 1995; 36: 757-71         [ Links ]59.- GIAMARELLOS-BOURBOULIS EJ, GRECKA P,    TSITSIKA A, TYMPANIDOU C, GIAMARELLOU H. In-vitro activity of FK 037 (cefoselis),    a novel 4 (th) generation cephalosporin, cefepime and cefpirome on nosocomial    staphylococci and gram-negative isolates. Diagn Microbiol infect Dis 2000; 36:    185-91.         [ Links ]60.- JONES R N, ERWIN M E, BARRETT M S, JOHNSON    D M, BRIGGS B M. Antimicrobial activity of E-1040, a novel thiadiazolyl cephalosporin    compare with parenteral cephems. Diagn Microbiol infect Dis 1991; 14: 301-9.          [ Links ]61.- IIZAWA Y, OKONOGI K, HAYASHI R, IWAHI    T, YAMAZAKI T, IMADA A. Therapeutic effect of cefozopran (SCE-2787), a new parenteral    cephalosporin in experimental infections in mice. Antimicrob Agents Chemother    1993; 37: 100-5.         [ Links ]62.- WATANABE N A. Newer antipseudomonal cephalosporins.    J Chemother 1996; 8 (Suppl 2): 48-56.         [ Links ]63.- ACTOR P, GUARINI J, URI J et al. Disk    susceptibility studies with cefazolin and cephalotin. Antimicrob Agents Chemother    1974; 5: 63-7.         [ Links ]64.- UWAYDAH M. Cefazolin in the treatment    of acute enteric fever. Antimicrob Agents Chemother 1976; 10: 52-6.         [ Links ]65.- JAMAL W Y, ROTIMI V O, CHUGH T D, PAL    T. Prevalence and susceptibility of Shigella to 11 antibiotics in a Kuwait    teaching hospital. J Chemother 1998; 10: 285-90.         [ Links ]66.- COX CE, SHERRILL M, COCCHETT DM. Evaluation    of cefuroxime axetil, cefaclor, and cephalexin in the treatment of urinary tract    infections in adults. Curr Ther Res 1987; 42: 124-37.         [ Links ]67.- SANDERS C W, GREENBERG R N, MARIER R    L. Cefamandole and cefoxitin. Ann Intern Med 1985; 103: 70-8.          [ Links ]68.- STAPLEY E P, JACKSON M, HERNANDEZ S et    al. Cephamycins, a new family of ß-lactam antibiotics I. Production actinomycetes,    including Streptomyces lactamdurans spp.n. Antimicrob Agents Chemother    1972; 2: 122-31.         [ Links ]69.- COOPER R D G. The carbacephems a new    ß-lactams class. Am J Med 1992; 92 (Suppl 6 A): 25-65.         [ Links ]70.- ZEMELMAN R, BELLO H, DOMINGUEZ M, GONZALEZ    G, MELLA S, GARCIA A. Activity of imipenem, third-generation cephalosporins,    aztreonam, and ciprofloxacin against multi-resistant Gram negative bacilli isolated    from Chilean hospitals. J Antimicrob Chemother 1993; 32: 413-9.         [ Links ]71.- MEDEIROS A A. Evolution and dissemination    of ß-lactamases accelerated by generation of ß-lactam antibiotics.    Clin Infect Dis 1997; 24 (Suppl. 1): 19-45.         [ Links ]72.- PERRY C M, BROGDEN R N. Cefuroxime axetil:    review of its antibacterial activity, pharmacokinetic properties and therapeutic    efficacy. Drugs 1996; 52: 125-58.         [ Links ]73.- SCHAAD U B, SUTER S, GIANELLA-BORRADORI    et al. A comparison of ceftriaxone and cefuroxime for the treatment of bacterial    meningitis in children. N Engl J Med 1990; 322: 141-7.         [ Links ]74.- KLEIN N C, CUNHA B A. Cefalosporinas de    la tercera generación. Clin Med Nort Am 1995; 79: 693-707.         [ Links ]75.- KLUGMAN K P, MADHI S A. Emergence of    drug resistance impact on bacterial meningitis. Infect Dis Clin North Am 1999;    13: 637-46.         [ Links ]76.- RICHARDS D M, BROGDEN R N. Ceftazidime.    A review of its antibacterial activity, pharmacokinetic properties and therapeutic    use. Drugs 1985; 29: 105-61.         [ Links ]77.- SCHATZ B S, KARAVOKIROS K T, TAEUBEL    M A, ITOKAZU G S. Comparison of cefprozil, cefpodoxime proxetil, loracarbef,    cefixime, and ceftibuten. Ann Pharmacother 1996; 30: 258-68.         [ Links ]78.- DALMAU D, LAYRARGUES G P, FENYVES D,    WILLEMS B, TURGEON F, TURGEON P. Cefotaxime, desacetyl-cefotaxime, and bactericidal    activity in spontaneous bacterial peritonitis. J Infect Dis 1999; 180: 1597-1602.          [ Links ]79.- NIKAIDO W, LIU W, ROSENBERG E Y. Outer    membrane permeability and ß-lactamase stability of dipolar ionic cephalosporins    containing methoxyimino substituents. Antimicrob Agents Chemother 1990; 34:    337-42.         [ Links ]80.- HANCOCK R E W, BELLIDO F. Factors involved    in the enhanced efficacy against gram-negative bacteria of fourth generation    cephalosporins. J Antimicrob Chemother 1992; 29(Suppl A): 1-6.         [ Links ]81.- BELLIDO F, PECHERE J C, HANCOCK REW.    Novel method for measurement of outer membrane permeability to new beta-lactams    in intact Enterobacter cloacae cells. Antimicrob Agents Chemother 1991;    35: 68-72.         [ Links ]82.- NEU H C, CHIN N X, JULES K, LABTHAVIKUL    P. The activity of BMY-28142, a new broad spectrum beta-lactamase stable cephalosporin.    J Antimicrob Chemother 1986; 17: 441-52.         [ Links ]83.- KOBAYASHI S, ARAI S, HAYASHI S, FUJIMOTO    K. ß-lactamase stability of cefpirome (HR 810), a new cephalosporin with    a broad antimicrobial spectrum. Antimicrob Agents Chemother 1986; 30: 713-8.          [ Links ]84.- GARAU J, WILSON W, WOOD M, CARLET J.    Fourth generation cephalosporins: a review of in vitro activity, pharmacokinetics,    pharmacodynamics, and clinical utility. Clin Microb Infect 1997; 3 (Suppl 1):    87-101.         [ Links ]85.- KESSLER R E, FUNG-TOMC J. Susceptibility    of bacterial isolates to beta-lactam antibiotics from U.S. clinical trials over    5-year period. Am J Med 1996; 24 (6 A): 13-9.         [ Links ]86.- PIERARD D, EMMERECHTS K, LAUWERS S. Comparative    in-vitro activity of cefpirome against isolates from intensive care and haematology/oncology    units. Belgian Multicentric Study Group. J Antimicrob Chemother 1998; 41: 443-50.          [ Links ]87.- JONES R N. Resistance patterns among    nosocomial pathogens: trends over the past few years. Chest 2001; 119 (Suppl    2): 397-404.         [ Links ]88.- LORBER B. Changing patterns of infectious    diseases. Am J Med 1988; 84: 569-78.         [ Links ]89.- MOELLERING R C. A novel antimicrobial    agent joins the battle against resistant bacteria. Ann Intern Med 1999; 130:    155-7.         [ Links ]90.- WILSON W R. The role of fourth-generation    cephalosporins in the treatment of serious infectious diseases in hospitalized    patients. Diagn Microbiol Infect Dis 1998; 31: 473-7.         [ Links ]Correspondencia a:        Sergio Mella Montecinos        Laboratorio de Antibióticos,        Departamento de Microbiología,        Facultad de Ciencias Biológicas        Casilla 160-C, Concepción        E-mail: pignatio@ctcinternet.cl  

32.- CHARREL R N, PAGES J M, DE MICCO P et    al. Prevalence of outer membrane porin alteration in ß-lactam-antibiotic-resistant    Enterobacter aerogenes. Antimicrob Agents Chemother 1996; 40: 2854-8.          [ Links ]33.- BRADFORD P A, URBAN C, MARIANO N, PROJAN    S J, RAHAL J J, BUSH K. Imipenem resistance in Klebsiella pneumoniae is    associated with the combination of ACT-1, a plasmid-mediated Amp C ß-lactamase,    and the loss of an outer membrane protein. Antimicrob Agents Chemother 1997;    41: 563-9.         [ Links ]34.- QUEENAN A M, TORRES-VIERA C, GOLD H et    al. SME-type carbapenem-hydrolizing class A ß-lactamases from geographically    diverse Serratia marcescens strains. Antimicrob Agents Chemother 2000;    44: 3035-9.         [ Links ]35.- COHEN S P, MC MURRY L M, HOOPER D C,    WOLFSON J S, LEVY S B. Cross-resistance to fluoroquinolones in multiple-antibiotic-resistance    (Mar) Escherichia coli selected by tetracycline resistance: decreased    drug accumulation asociated with membrane changes in addition to Omp F reduction.    Antimicrob Agents Chemother 1989; 33:1318-25.         [ Links ]36.- SANDERS C C. Cefepime: The next generation?    Clin Infect Dis 1993; 17: 369-79         [ Links ]37.- GARAU J. The clinical potential of fourth-generation    cephalosporins. Diagn Microbiol Infect Dis 1998; 31: 479-80.         [ Links ]38.- CURTIS N A C, ORR D C, ROSS G W, BOULTON    M G. Affinities of penicillins and cephalosporins for the penicillin-binding    proteins of Escherichia coli    K-12 and their antibacterial activity. Antimicrob Agents Chemother 1979; 16:    533-9.  39.- BALANT L, DAYER P, AUCKENTHALER R. Clinical    pharmacokinetics of the third generation cephalosporins. Clin Pharmacokinetics    1985; 10: 101-43.         [ Links ]40.- WHEELER W J. Cephalosporins and other    beta-lactam antibiotics. Lloydia. 1977; 40: 519-42.         [ Links ]41.- LOPEZ F, GARRIDO J C. Química    y relación estructura-actividad de los antibióticos cefalosporínicos.    Rev Col Químico Farmacéutico 1989; 41: 5-14.         [ Links ]42.- FU K P, ASWAPOKEE P, HO I, MATTHIJSSEN    C, NEU H C. Pharmacokinetics of cefotaxime. Antimicrob Agents Chemother 1979;16:    592-7.         [ Links ]43.- YUK J H, NIGHTINGALE C H, QUINTILIANI    R. Clinical pharmacokinetics of ceftriaxone. Clin Pharmacokinetic 1989; 17:    223-35.         [ Links ]44.- BRYSKIER A, PROCYK T, LABRO M T. Cefodizime,    a new 2-aminothiazolyl cephalosporin: physicochemical properties, toxicology    and structure-activity relationships. J Antimicrob Chemother 1990; 26 (Suppl    C): 1-8.         [ Links ]45.- CRITCHLEY I A, BASKER M J, EDMONDSON    R A, KNOTT S J. Uptake of catecholic cephalosporin by the iron transport system    of Escherichia coli. J Antimicrob Chemother 1991; 28: 377-88.         [ Links ]46.- CRITCHLEY I A. Catecholic ß-lactams:    facilitated transport. J Antimicrob Chemother 1990; 26: 733-7.         [ Links ]47.- JONES R N, ERWIN M E. In vitro evaluation    of Ro 09-1227, a novel catechol-substituted cephalosporin. Antimicrob Agents    Chemother 1992; 36: 233-8.         [ Links ]48.- JONES R N. In vitro activity of Ro 24-6392,    a novel ester-linked co-drug combining ciprofloxacin and desacetylcefotaxime.    Eur J Clin Microbiol Infect Dis 1990; 9: 435-8.         [ Links ]49.- TOMASZ A. Penicillin-binding proteins    and the antibacterial effectiveness of ß-lactam antibiotics. Rev Infect    Dis 1986 (Suppl 3); 8: 260-78.         [ Links ]50.- HOLM S E. Interaction between ß-lactam    and other antibiotics. Rev Infect Dis 1986 (Suppl 3); 8: 305-14.         [ Links ]51.- MC CULLERS J A, ENGLISH B K, NOVAK R.    Isolation and characterization of vancomycin-tolerant Streptococcus pneumoniae    from the cerebrospinal fluid of a patient who developed recrudescet meningitis.    J Infect Dis 2000; 181: 369-73.         [ Links ]52.- NIKAIDO H. Outer membrane barrier as    a mechanism of antimicrobial resistance. Antimicrob Agents Chemother 1989; 33:    1831-6.         [ Links ]53.- BARRADELL L B, BRYSON H M. Cefepime.    A review of its antibacterial activity, pharmacokinetic properties and therapeutic    use. Drugs 1994; 47: 471-505.         [ Links ]54.- O'CALLAGHAN C H 1979. Description and    classification of the newer cephalosporins and their relationship with the established    compounds. J Antimicrob Chemother 5: 635-71         [ Links ]55.- BRYSKIER A, PROCYK T, TREMBLAY D, LENFANT    B FOURTILLAN J B. The pharmacokinetics of cefodizime following intravenous and    intramuscular administration of a single dose of 1.0 g. J Antimicrob Chemother    1990; 26 (Suppl. C): 59-63.         [ Links ]56.- WILLIAMS J D. Classification of cephalosporins.    Drugs. 1987; 34 (Suppl 2): 15-22.         [ Links ]57.- WISEMAN L R, LAMB H M. Cefpirome. A review    of its antibacterial activity, pharmacokinetic properties and efficacy in the    treatment of severe nosocomial infections and febrile neutropenia. Drugs 1997;    57: 117-40.         [ Links ]58.- PECHERE J C, WILSON W, NEU H. Laboratory    assesment of antibacterial activity of zwitterionic 7-methoxyimino cephalosporins.    J Antimicrob Chemother 1995; 36: 757-71         [ Links ]59.- GIAMARELLOS-BOURBOULIS EJ, GRECKA P,    TSITSIKA A, TYMPANIDOU C, GIAMARELLOU H. In-vitro activity of FK 037 (cefoselis),    a novel 4 (th) generation cephalosporin, cefepime and cefpirome on nosocomial    staphylococci and gram-negative isolates. Diagn Microbiol infect Dis 2000; 36:    185-91.         [ Links ]60.- JONES R N, ERWIN M E, BARRETT M S, JOHNSON    D M, BRIGGS B M. Antimicrobial activity of E-1040, a novel thiadiazolyl cephalosporin    compare with parenteral cephems. Diagn Microbiol infect Dis 1991; 14: 301-9.          [ Links ]61.- IIZAWA Y, OKONOGI K, HAYASHI R, IWAHI    T, YAMAZAKI T, IMADA A. Therapeutic effect of cefozopran (SCE-2787), a new parenteral    cephalosporin in experimental infections in mice. Antimicrob Agents Chemother    1993; 37: 100-5.         [ Links ]62.- WATANABE N A. Newer antipseudomonal cephalosporins.    J Chemother 1996; 8 (Suppl 2): 48-56.         [ Links ]63.- ACTOR P, GUARINI J, URI J et al. Disk    susceptibility studies with cefazolin and cephalotin. Antimicrob Agents Chemother    1974; 5: 63-7.         [ Links ]64.- UWAYDAH M. Cefazolin in the treatment    of acute enteric fever. Antimicrob Agents Chemother 1976; 10: 52-6.         [ Links ]65.- JAMAL W Y, ROTIMI V O, CHUGH T D, PAL    T. Prevalence and susceptibility of Shigella to 11 antibiotics in a Kuwait    teaching hospital. J Chemother 1998; 10: 285-90.         [ Links ]66.- COX CE, SHERRILL M, COCCHETT DM. Evaluation    of cefuroxime axetil, cefaclor, and cephalexin in the treatment of urinary tract    infections in adults. Curr Ther Res 1987; 42: 124-37.         [ Links ]67.- SANDERS C W, GREENBERG R N, MARIER R    L. Cefamandole and cefoxitin. Ann Intern Med 1985; 103: 70-8.          [ Links ]68.- STAPLEY E P, JACKSON M, HERNANDEZ S et    al. Cephamycins, a new family of ß-lactam antibiotics I. Production actinomycetes,    including Streptomyces lactamdurans spp.n. Antimicrob Agents Chemother    1972; 2: 122-31.         [ Links ]69.- COOPER R D G. The carbacephems a new    ß-lactams class. Am J Med 1992; 92 (Suppl 6 A): 25-65.         [ Links ]70.- ZEMELMAN R, BELLO H, DOMINGUEZ M, GONZALEZ    G, MELLA S, GARCIA A. Activity of imipenem, third-generation cephalosporins,    aztreonam, and ciprofloxacin against multi-resistant Gram negative bacilli isolated    from Chilean hospitals. J Antimicrob Chemother 1993; 32: 413-9.         [ Links ]71.- MEDEIROS A A. Evolution and dissemination    of ß-lactamases accelerated by generation of ß-lactam antibiotics.    Clin Infect Dis 1997; 24 (Suppl. 1): 19-45.         [ Links ]72.- PERRY C M, BROGDEN R N. Cefuroxime axetil:    review of its antibacterial activity, pharmacokinetic properties and therapeutic    efficacy. Drugs 1996; 52: 125-58.         [ Links ]73.- SCHAAD U B, SUTER S, GIANELLA-BORRADORI    et al. A comparison of ceftriaxone and cefuroxime for the treatment of bacterial    meningitis in children. N Engl J Med 1990; 322: 141-7.         [ Links ]74.- KLEIN N C, CUNHA B A. Cefalosporinas de    la tercera generación. Clin Med Nort Am 1995; 79: 693-707.         [ Links ]75.- KLUGMAN K P, MADHI S A. Emergence of    drug resistance impact on bacterial meningitis. Infect Dis Clin North Am 1999;    13: 637-46.         [ Links ]76.- RICHARDS D M, BROGDEN R N. Ceftazidime.    A review of its antibacterial activity, pharmacokinetic properties and therapeutic    use. Drugs 1985; 29: 105-61.         [ Links ]77.- SCHATZ B S, KARAVOKIROS K T, TAEUBEL    M A, ITOKAZU G S. Comparison of cefprozil, cefpodoxime proxetil, loracarbef,    cefixime, and ceftibuten. Ann Pharmacother 1996; 30: 258-68.         [ Links ]78.- DALMAU D, LAYRARGUES G P, FENYVES D,    WILLEMS B, TURGEON F, TURGEON P. Cefotaxime, desacetyl-cefotaxime, and bactericidal    activity in spontaneous bacterial peritonitis. J Infect Dis 1999; 180: 1597-1602.          [ Links ]79.- NIKAIDO W, LIU W, ROSENBERG E Y. Outer    membrane permeability and ß-lactamase stability of dipolar ionic cephalosporins    containing methoxyimino substituents. Antimicrob Agents Chemother 1990; 34:    337-42.         [ Links ]80.- HANCOCK R E W, BELLIDO F. Factors involved    in the enhanced efficacy against gram-negative bacteria of fourth generation    cephalosporins. J Antimicrob Chemother 1992; 29(Suppl A): 1-6.         [ Links ]81.- BELLIDO F, PECHERE J C, HANCOCK REW.    Novel method for measurement of outer membrane permeability to new beta-lactams    in intact Enterobacter cloacae cells. Antimicrob Agents Chemother 1991;    35: 68-72.         [ Links ]82.- NEU H C, CHIN N X, JULES K, LABTHAVIKUL    P. The activity of BMY-28142, a new broad spectrum beta-lactamase stable cephalosporin.    J Antimicrob Chemother 1986; 17: 441-52.         [ Links ]83.- KOBAYASHI S, ARAI S, HAYASHI S, FUJIMOTO    K. ß-lactamase stability of cefpirome (HR 810), a new cephalosporin with    a broad antimicrobial spectrum. Antimicrob Agents Chemother 1986; 30: 713-8.          [ Links ]84.- GARAU J, WILSON W, WOOD M, CARLET J.    Fourth generation cephalosporins: a review of in vitro activity, pharmacokinetics,    pharmacodynamics, and clinical utility. Clin Microb Infect 1997; 3 (Suppl 1):    87-101.         [ Links ]85.- KESSLER R E, FUNG-TOMC J. Susceptibility    of bacterial isolates to beta-lactam antibiotics from U.S. clinical trials over    5-year period. Am J Med 1996; 24 (6 A): 13-9.         [ Links ]86.- PIERARD D, EMMERECHTS K, LAUWERS S. Comparative    in-vitro activity of cefpirome against isolates from intensive care and haematology/oncology    units. Belgian Multicentric Study Group. J Antimicrob Chemother 1998; 41: 443-50.          [ Links ]87.- JONES R N. Resistance patterns among    nosocomial pathogens: trends over the past few years. Chest 2001; 119 (Suppl    2): 397-404.         [ Links ]88.- LORBER B. Changing patterns of infectious    diseases. Am J Med 1988; 84: 569-78.         [ Links ]89.- MOELLERING R C. A novel antimicrobial    agent joins the battle against resistant bacteria. Ann Intern Med 1999; 130:    155-7.         [ Links ]90.- WILSON W R. The role of fourth-generation    cephalosporins in the treatment of serious infectious diseases in hospitalized    patients. Diagn Microbiol Infect Dis 1998; 31: 473-7.         [ Links ]Correspondencia a:        Sergio Mella Montecinos        Laboratorio de Antibióticos,        Departamento de Microbiología,        Facultad de Ciencias Biológicas        Casilla 160-C, Concepción        E-mail: pignatio@ctcinternet.cl  

33.- BRADFORD P A, URBAN C, MARIANO N, PROJAN    S J, RAHAL J J, BUSH K. Imipenem resistance in Klebsiella pneumoniae is    associated with the combination of ACT-1, a plasmid-mediated Amp C ß-lactamase,    and the loss of an outer membrane protein. Antimicrob Agents Chemother 1997;    41: 563-9.         [ Links ]34.- QUEENAN A M, TORRES-VIERA C, GOLD H et    al. SME-type carbapenem-hydrolizing class A ß-lactamases from geographically    diverse Serratia marcescens strains. Antimicrob Agents Chemother 2000;    44: 3035-9.         [ Links ]35.- COHEN S P, MC MURRY L M, HOOPER D C,    WOLFSON J S, LEVY S B. Cross-resistance to fluoroquinolones in multiple-antibiotic-resistance    (Mar) Escherichia coli selected by tetracycline resistance: decreased    drug accumulation asociated with membrane changes in addition to Omp F reduction.    Antimicrob Agents Chemother 1989; 33:1318-25.         [ Links ]36.- SANDERS C C. Cefepime: The next generation?    Clin Infect Dis 1993; 17: 369-79         [ Links ]37.- GARAU J. The clinical potential of fourth-generation    cephalosporins. Diagn Microbiol Infect Dis 1998; 31: 479-80.         [ Links ]38.- CURTIS N A C, ORR D C, ROSS G W, BOULTON    M G. Affinities of penicillins and cephalosporins for the penicillin-binding    proteins of Escherichia coli    K-12 and their antibacterial activity. Antimicrob Agents Chemother 1979; 16:    533-9.  39.- BALANT L, DAYER P, AUCKENTHALER R. Clinical    pharmacokinetics of the third generation cephalosporins. Clin Pharmacokinetics    1985; 10: 101-43.         [ Links ]40.- WHEELER W J. Cephalosporins and other    beta-lactam antibiotics. Lloydia. 1977; 40: 519-42.         [ Links ]41.- LOPEZ F, GARRIDO J C. Química    y relación estructura-actividad de los antibióticos cefalosporínicos.    Rev Col Químico Farmacéutico 1989; 41: 5-14.         [ Links ]42.- FU K P, ASWAPOKEE P, HO I, MATTHIJSSEN    C, NEU H C. Pharmacokinetics of cefotaxime. Antimicrob Agents Chemother 1979;16:    592-7.         [ Links ]43.- YUK J H, NIGHTINGALE C H, QUINTILIANI    R. Clinical pharmacokinetics of ceftriaxone. Clin Pharmacokinetic 1989; 17:    223-35.         [ Links ]44.- BRYSKIER A, PROCYK T, LABRO M T. Cefodizime,    a new 2-aminothiazolyl cephalosporin: physicochemical properties, toxicology    and structure-activity relationships. J Antimicrob Chemother 1990; 26 (Suppl    C): 1-8.         [ Links ]45.- CRITCHLEY I A, BASKER M J, EDMONDSON    R A, KNOTT S J. Uptake of catecholic cephalosporin by the iron transport system    of Escherichia coli. J Antimicrob Chemother 1991; 28: 377-88.         [ Links ]46.- CRITCHLEY I A. Catecholic ß-lactams:    facilitated transport. J Antimicrob Chemother 1990; 26: 733-7.         [ Links ]47.- JONES R N, ERWIN M E. In vitro evaluation    of Ro 09-1227, a novel catechol-substituted cephalosporin. Antimicrob Agents    Chemother 1992; 36: 233-8.         [ Links ]48.- JONES R N. In vitro activity of Ro 24-6392,    a novel ester-linked co-drug combining ciprofloxacin and desacetylcefotaxime.    Eur J Clin Microbiol Infect Dis 1990; 9: 435-8.         [ Links ]49.- TOMASZ A. Penicillin-binding proteins    and the antibacterial effectiveness of ß-lactam antibiotics. Rev Infect    Dis 1986 (Suppl 3); 8: 260-78.         [ Links ]50.- HOLM S E. Interaction between ß-lactam    and other antibiotics. Rev Infect Dis 1986 (Suppl 3); 8: 305-14.         [ Links ]51.- MC CULLERS J A, ENGLISH B K, NOVAK R.    Isolation and characterization of vancomycin-tolerant Streptococcus pneumoniae    from the cerebrospinal fluid of a patient who developed recrudescet meningitis.    J Infect Dis 2000; 181: 369-73.         [ Links ]52.- NIKAIDO H. Outer membrane barrier as    a mechanism of antimicrobial resistance. Antimicrob Agents Chemother 1989; 33:    1831-6.         [ Links ]53.- BARRADELL L B, BRYSON H M. Cefepime.    A review of its antibacterial activity, pharmacokinetic properties and therapeutic    use. Drugs 1994; 47: 471-505.         [ Links ]54.- O'CALLAGHAN C H 1979. Description and    classification of the newer cephalosporins and their relationship with the established    compounds. J Antimicrob Chemother 5: 635-71         [ Links ]55.- BRYSKIER A, PROCYK T, TREMBLAY D, LENFANT    B FOURTILLAN J B. The pharmacokinetics of cefodizime following intravenous and    intramuscular administration of a single dose of 1.0 g. J Antimicrob Chemother    1990; 26 (Suppl. C): 59-63.         [ Links ]56.- WILLIAMS J D. Classification of cephalosporins.    Drugs. 1987; 34 (Suppl 2): 15-22.         [ Links ]57.- WISEMAN L R, LAMB H M. Cefpirome. A review    of its antibacterial activity, pharmacokinetic properties and efficacy in the    treatment of severe nosocomial infections and febrile neutropenia. Drugs 1997;    57: 117-40.         [ Links ]58.- PECHERE J C, WILSON W, NEU H. Laboratory    assesment of antibacterial activity of zwitterionic 7-methoxyimino cephalosporins.    J Antimicrob Chemother 1995; 36: 757-71         [ Links ]59.- GIAMARELLOS-BOURBOULIS EJ, GRECKA P,    TSITSIKA A, TYMPANIDOU C, GIAMARELLOU H. In-vitro activity of FK 037 (cefoselis),    a novel 4 (th) generation cephalosporin, cefepime and cefpirome on nosocomial    staphylococci and gram-negative isolates. Diagn Microbiol infect Dis 2000; 36:    185-91.         [ Links ]60.- JONES R N, ERWIN M E, BARRETT M S, JOHNSON    D M, BRIGGS B M. Antimicrobial activity of E-1040, a novel thiadiazolyl cephalosporin    compare with parenteral cephems. Diagn Microbiol infect Dis 1991; 14: 301-9.          [ Links ]61.- IIZAWA Y, OKONOGI K, HAYASHI R, IWAHI    T, YAMAZAKI T, IMADA A. Therapeutic effect of cefozopran (SCE-2787), a new parenteral    cephalosporin in experimental infections in mice. Antimicrob Agents Chemother    1993; 37: 100-5.         [ Links ]62.- WATANABE N A. Newer antipseudomonal cephalosporins.    J Chemother 1996; 8 (Suppl 2): 48-56.         [ Links ]63.- ACTOR P, GUARINI J, URI J et al. Disk    susceptibility studies with cefazolin and cephalotin. Antimicrob Agents Chemother    1974; 5: 63-7.         [ Links ]64.- UWAYDAH M. Cefazolin in the treatment    of acute enteric fever. Antimicrob Agents Chemother 1976; 10: 52-6.         [ Links ]65.- JAMAL W Y, ROTIMI V O, CHUGH T D, PAL    T. Prevalence and susceptibility of Shigella to 11 antibiotics in a Kuwait    teaching hospital. J Chemother 1998; 10: 285-90.         [ Links ]66.- COX CE, SHERRILL M, COCCHETT DM. Evaluation    of cefuroxime axetil, cefaclor, and cephalexin in the treatment of urinary tract    infections in adults. Curr Ther Res 1987; 42: 124-37.         [ Links ]67.- SANDERS C W, GREENBERG R N, MARIER R    L. Cefamandole and cefoxitin. Ann Intern Med 1985; 103: 70-8.          [ Links ]68.- STAPLEY E P, JACKSON M, HERNANDEZ S et    al. Cephamycins, a new family of ß-lactam antibiotics I. Production actinomycetes,    including Streptomyces lactamdurans spp.n. Antimicrob Agents Chemother    1972; 2: 122-31.         [ Links ]69.- COOPER R D G. The carbacephems a new    ß-lactams class. Am J Med 1992; 92 (Suppl 6 A): 25-65.         [ Links ]70.- ZEMELMAN R, BELLO H, DOMINGUEZ M, GONZALEZ    G, MELLA S, GARCIA A. Activity of imipenem, third-generation cephalosporins,    aztreonam, and ciprofloxacin against multi-resistant Gram negative bacilli isolated    from Chilean hospitals. J Antimicrob Chemother 1993; 32: 413-9.         [ Links ]71.- MEDEIROS A A. Evolution and dissemination    of ß-lactamases accelerated by generation of ß-lactam antibiotics.    Clin Infect Dis 1997; 24 (Suppl. 1): 19-45.         [ Links ]72.- PERRY C M, BROGDEN R N. Cefuroxime axetil:    review of its antibacterial activity, pharmacokinetic properties and therapeutic    efficacy. Drugs 1996; 52: 125-58.         [ Links ]73.- SCHAAD U B, SUTER S, GIANELLA-BORRADORI    et al. A comparison of ceftriaxone and cefuroxime for the treatment of bacterial    meningitis in children. N Engl J Med 1990; 322: 141-7.         [ Links ]74.- KLEIN N C, CUNHA B A. Cefalosporinas de    la tercera generación. Clin Med Nort Am 1995; 79: 693-707.         [ Links ]75.- KLUGMAN K P, MADHI S A. Emergence of    drug resistance impact on bacterial meningitis. Infect Dis Clin North Am 1999;    13: 637-46.         [ Links ]76.- RICHARDS D M, BROGDEN R N. Ceftazidime.    A review of its antibacterial activity, pharmacokinetic properties and therapeutic    use. Drugs 1985; 29: 105-61.         [ Links ]77.- SCHATZ B S, KARAVOKIROS K T, TAEUBEL    M A, ITOKAZU G S. Comparison of cefprozil, cefpodoxime proxetil, loracarbef,    cefixime, and ceftibuten. Ann Pharmacother 1996; 30: 258-68.         [ Links ]78.- DALMAU D, LAYRARGUES G P, FENYVES D,    WILLEMS B, TURGEON F, TURGEON P. Cefotaxime, desacetyl-cefotaxime, and bactericidal    activity in spontaneous bacterial peritonitis. J Infect Dis 1999; 180: 1597-1602.          [ Links ]79.- NIKAIDO W, LIU W, ROSENBERG E Y. Outer    membrane permeability and ß-lactamase stability of dipolar ionic cephalosporins    containing methoxyimino substituents. Antimicrob Agents Chemother 1990; 34:    337-42.         [ Links ]80.- HANCOCK R E W, BELLIDO F. Factors involved    in the enhanced efficacy against gram-negative bacteria of fourth generation    cephalosporins. J Antimicrob Chemother 1992; 29(Suppl A): 1-6.         [ Links ]81.- BELLIDO F, PECHERE J C, HANCOCK REW.    Novel method for measurement of outer membrane permeability to new beta-lactams    in intact Enterobacter cloacae cells. Antimicrob Agents Chemother 1991;    35: 68-72.         [ Links ]82.- NEU H C, CHIN N X, JULES K, LABTHAVIKUL    P. The activity of BMY-28142, a new broad spectrum beta-lactamase stable cephalosporin.    J Antimicrob Chemother 1986; 17: 441-52.         [ Links ]83.- KOBAYASHI S, ARAI S, HAYASHI S, FUJIMOTO    K. ß-lactamase stability of cefpirome (HR 810), a new cephalosporin with    a broad antimicrobial spectrum. Antimicrob Agents Chemother 1986; 30: 713-8.          [ Links ]84.- GARAU J, WILSON W, WOOD M, CARLET J.    Fourth generation cephalosporins: a review of in vitro activity, pharmacokinetics,    pharmacodynamics, and clinical utility. Clin Microb Infect 1997; 3 (Suppl 1):    87-101.         [ Links ]85.- KESSLER R E, FUNG-TOMC J. Susceptibility    of bacterial isolates to beta-lactam antibiotics from U.S. clinical trials over    5-year period. Am J Med 1996; 24 (6 A): 13-9.         [ Links ]86.- PIERARD D, EMMERECHTS K, LAUWERS S. Comparative    in-vitro activity of cefpirome against isolates from intensive care and haematology/oncology    units. Belgian Multicentric Study Group. J Antimicrob Chemother 1998; 41: 443-50.          [ Links ]87.- JONES R N. Resistance patterns among    nosocomial pathogens: trends over the past few years. Chest 2001; 119 (Suppl    2): 397-404.         [ Links ]88.- LORBER B. Changing patterns of infectious    diseases. Am J Med 1988; 84: 569-78.         [ Links ]89.- MOELLERING R C. A novel antimicrobial    agent joins the battle against resistant bacteria. Ann Intern Med 1999; 130:    155-7.         [ Links ]90.- WILSON W R. The role of fourth-generation    cephalosporins in the treatment of serious infectious diseases in hospitalized    patients. Diagn Microbiol Infect Dis 1998; 31: 473-7.         [ Links ]Correspondencia a:        Sergio Mella Montecinos        Laboratorio de Antibióticos,        Departamento de Microbiología,        Facultad de Ciencias Biológicas        Casilla 160-C, Concepción        E-mail: pignatio@ctcinternet.cl  

34.- QUEENAN A M, TORRES-VIERA C, GOLD H et    al. SME-type carbapenem-hydrolizing class A ß-lactamases from geographically    diverse Serratia marcescens strains. Antimicrob Agents Chemother 2000;    44: 3035-9.         [ Links ]35.- COHEN S P, MC MURRY L M, HOOPER D C,    WOLFSON J S, LEVY S B. Cross-resistance to fluoroquinolones in multiple-antibiotic-resistance    (Mar) Escherichia coli selected by tetracycline resistance: decreased    drug accumulation asociated with membrane changes in addition to Omp F reduction.    Antimicrob Agents Chemother 1989; 33:1318-25.         [ Links ]36.- SANDERS C C. Cefepime: The next generation?    Clin Infect Dis 1993; 17: 369-79         [ Links ]37.- GARAU J. The clinical potential of fourth-generation    cephalosporins. Diagn Microbiol Infect Dis 1998; 31: 479-80.         [ Links ]38.- CURTIS N A C, ORR D C, ROSS G W, BOULTON    M G. Affinities of penicillins and cephalosporins for the penicillin-binding    proteins of Escherichia coli    K-12 and their antibacterial activity. Antimicrob Agents Chemother 1979; 16:    533-9.  39.- BALANT L, DAYER P, AUCKENTHALER R. Clinical    pharmacokinetics of the third generation cephalosporins. Clin Pharmacokinetics    1985; 10: 101-43.         [ Links ]40.- WHEELER W J. Cephalosporins and other    beta-lactam antibiotics. Lloydia. 1977; 40: 519-42.         [ Links ]41.- LOPEZ F, GARRIDO J C. Química    y relación estructura-actividad de los antibióticos cefalosporínicos.    Rev Col Químico Farmacéutico 1989; 41: 5-14.         [ Links ]42.- FU K P, ASWAPOKEE P, HO I, MATTHIJSSEN    C, NEU H C. Pharmacokinetics of cefotaxime. Antimicrob Agents Chemother 1979;16:    592-7.         [ Links ]43.- YUK J H, NIGHTINGALE C H, QUINTILIANI    R. Clinical pharmacokinetics of ceftriaxone. Clin Pharmacokinetic 1989; 17:    223-35.         [ Links ]44.- BRYSKIER A, PROCYK T, LABRO M T. Cefodizime,    a new 2-aminothiazolyl cephalosporin: physicochemical properties, toxicology    and structure-activity relationships. J Antimicrob Chemother 1990; 26 (Suppl    C): 1-8.         [ Links ]45.- CRITCHLEY I A, BASKER M J, EDMONDSON    R A, KNOTT S J. Uptake of catecholic cephalosporin by the iron transport system    of Escherichia coli. J Antimicrob Chemother 1991; 28: 377-88.         [ Links ]46.- CRITCHLEY I A. Catecholic ß-lactams:    facilitated transport. J Antimicrob Chemother 1990; 26: 733-7.         [ Links ]47.- JONES R N, ERWIN M E. In vitro evaluation    of Ro 09-1227, a novel catechol-substituted cephalosporin. Antimicrob Agents    Chemother 1992; 36: 233-8.         [ Links ]48.- JONES R N. In vitro activity of Ro 24-6392,    a novel ester-linked co-drug combining ciprofloxacin and desacetylcefotaxime.    Eur J Clin Microbiol Infect Dis 1990; 9: 435-8.         [ Links ]49.- TOMASZ A. Penicillin-binding proteins    and the antibacterial effectiveness of ß-lactam antibiotics. Rev Infect    Dis 1986 (Suppl 3); 8: 260-78.         [ Links ]50.- HOLM S E. Interaction between ß-lactam    and other antibiotics. Rev Infect Dis 1986 (Suppl 3); 8: 305-14.         [ Links ]51.- MC CULLERS J A, ENGLISH B K, NOVAK R.    Isolation and characterization of vancomycin-tolerant Streptococcus pneumoniae    from the cerebrospinal fluid of a patient who developed recrudescet meningitis.    J Infect Dis 2000; 181: 369-73.         [ Links ]52.- NIKAIDO H. Outer membrane barrier as    a mechanism of antimicrobial resistance. Antimicrob Agents Chemother 1989; 33:    1831-6.         [ Links ]53.- BARRADELL L B, BRYSON H M. Cefepime.    A review of its antibacterial activity, pharmacokinetic properties and therapeutic    use. Drugs 1994; 47: 471-505.         [ Links ]54.- O'CALLAGHAN C H 1979. Description and    classification of the newer cephalosporins and their relationship with the established    compounds. J Antimicrob Chemother 5: 635-71         [ Links ]55.- BRYSKIER A, PROCYK T, TREMBLAY D, LENFANT    B FOURTILLAN J B. The pharmacokinetics of cefodizime following intravenous and    intramuscular administration of a single dose of 1.0 g. J Antimicrob Chemother    1990; 26 (Suppl. C): 59-63.         [ Links ]56.- WILLIAMS J D. Classification of cephalosporins.    Drugs. 1987; 34 (Suppl 2): 15-22.         [ Links ]57.- WISEMAN L R, LAMB H M. Cefpirome. A review    of its antibacterial activity, pharmacokinetic properties and efficacy in the    treatment of severe nosocomial infections and febrile neutropenia. Drugs 1997;    57: 117-40.         [ Links ]58.- PECHERE J C, WILSON W, NEU H. Laboratory    assesment of antibacterial activity of zwitterionic 7-methoxyimino cephalosporins.    J Antimicrob Chemother 1995; 36: 757-71         [ Links ]59.- GIAMARELLOS-BOURBOULIS EJ, GRECKA P,    TSITSIKA A, TYMPANIDOU C, GIAMARELLOU H. In-vitro activity of FK 037 (cefoselis),    a novel 4 (th) generation cephalosporin, cefepime and cefpirome on nosocomial    staphylococci and gram-negative isolates. Diagn Microbiol infect Dis 2000; 36:    185-91.         [ Links ]60.- JONES R N, ERWIN M E, BARRETT M S, JOHNSON    D M, BRIGGS B M. Antimicrobial activity of E-1040, a novel thiadiazolyl cephalosporin    compare with parenteral cephems. Diagn Microbiol infect Dis 1991; 14: 301-9.          [ Links ]61.- IIZAWA Y, OKONOGI K, HAYASHI R, IWAHI    T, YAMAZAKI T, IMADA A. Therapeutic effect of cefozopran (SCE-2787), a new parenteral    cephalosporin in experimental infections in mice. Antimicrob Agents Chemother    1993; 37: 100-5.         [ Links ]62.- WATANABE N A. Newer antipseudomonal cephalosporins.    J Chemother 1996; 8 (Suppl 2): 48-56.         [ Links ]63.- ACTOR P, GUARINI J, URI J et al. Disk    susceptibility studies with cefazolin and cephalotin. Antimicrob Agents Chemother    1974; 5: 63-7.         [ Links ]64.- UWAYDAH M. Cefazolin in the treatment    of acute enteric fever. Antimicrob Agents Chemother 1976; 10: 52-6.         [ Links ]65.- JAMAL W Y, ROTIMI V O, CHUGH T D, PAL    T. Prevalence and susceptibility of Shigella to 11 antibiotics in a Kuwait    teaching hospital. J Chemother 1998; 10: 285-90.         [ Links ]66.- COX CE, SHERRILL M, COCCHETT DM. Evaluation    of cefuroxime axetil, cefaclor, and cephalexin in the treatment of urinary tract    infections in adults. Curr Ther Res 1987; 42: 124-37.         [ Links ]67.- SANDERS C W, GREENBERG R N, MARIER R    L. Cefamandole and cefoxitin. Ann Intern Med 1985; 103: 70-8.          [ Links ]68.- STAPLEY E P, JACKSON M, HERNANDEZ S et    al. Cephamycins, a new family of ß-lactam antibiotics I. Production actinomycetes,    including Streptomyces lactamdurans spp.n. Antimicrob Agents Chemother    1972; 2: 122-31.         [ Links ]69.- COOPER R D G. The carbacephems a new    ß-lactams class. Am J Med 1992; 92 (Suppl 6 A): 25-65.         [ Links ]70.- ZEMELMAN R, BELLO H, DOMINGUEZ M, GONZALEZ    G, MELLA S, GARCIA A. Activity of imipenem, third-generation cephalosporins,    aztreonam, and ciprofloxacin against multi-resistant Gram negative bacilli isolated    from Chilean hospitals. J Antimicrob Chemother 1993; 32: 413-9.         [ Links ]71.- MEDEIROS A A. Evolution and dissemination    of ß-lactamases accelerated by generation of ß-lactam antibiotics.    Clin Infect Dis 1997; 24 (Suppl. 1): 19-45.         [ Links ]72.- PERRY C M, BROGDEN R N. Cefuroxime axetil:    review of its antibacterial activity, pharmacokinetic properties and therapeutic    efficacy. Drugs 1996; 52: 125-58.         [ Links ]73.- SCHAAD U B, SUTER S, GIANELLA-BORRADORI    et al. A comparison of ceftriaxone and cefuroxime for the treatment of bacterial    meningitis in children. N Engl J Med 1990; 322: 141-7.         [ Links ]74.- KLEIN N C, CUNHA B A. Cefalosporinas de    la tercera generación. Clin Med Nort Am 1995; 79: 693-707.         [ Links ]75.- KLUGMAN K P, MADHI S A. Emergence of    drug resistance impact on bacterial meningitis. Infect Dis Clin North Am 1999;    13: 637-46.         [ Links ]76.- RICHARDS D M, BROGDEN R N. Ceftazidime.    A review of its antibacterial activity, pharmacokinetic properties and therapeutic    use. Drugs 1985; 29: 105-61.         [ Links ]77.- SCHATZ B S, KARAVOKIROS K T, TAEUBEL    M A, ITOKAZU G S. Comparison of cefprozil, cefpodoxime proxetil, loracarbef,    cefixime, and ceftibuten. Ann Pharmacother 1996; 30: 258-68.         [ Links ]78.- DALMAU D, LAYRARGUES G P, FENYVES D,    WILLEMS B, TURGEON F, TURGEON P. Cefotaxime, desacetyl-cefotaxime, and bactericidal    activity in spontaneous bacterial peritonitis. J Infect Dis 1999; 180: 1597-1602.          [ Links ]79.- NIKAIDO W, LIU W, ROSENBERG E Y. Outer    membrane permeability and ß-lactamase stability of dipolar ionic cephalosporins    containing methoxyimino substituents. Antimicrob Agents Chemother 1990; 34:    337-42.         [ Links ]80.- HANCOCK R E W, BELLIDO F. Factors involved    in the enhanced efficacy against gram-negative bacteria of fourth generation    cephalosporins. J Antimicrob Chemother 1992; 29(Suppl A): 1-6.         [ Links ]81.- BELLIDO F, PECHERE J C, HANCOCK REW.    Novel method for measurement of outer membrane permeability to new beta-lactams    in intact Enterobacter cloacae cells. Antimicrob Agents Chemother 1991;    35: 68-72.         [ Links ]82.- NEU H C, CHIN N X, JULES K, LABTHAVIKUL    P. The activity of BMY-28142, a new broad spectrum beta-lactamase stable cephalosporin.    J Antimicrob Chemother 1986; 17: 441-52.         [ Links ]83.- KOBAYASHI S, ARAI S, HAYASHI S, FUJIMOTO    K. ß-lactamase stability of cefpirome (HR 810), a new cephalosporin with    a broad antimicrobial spectrum. Antimicrob Agents Chemother 1986; 30: 713-8.          [ Links ]84.- GARAU J, WILSON W, WOOD M, CARLET J.    Fourth generation cephalosporins: a review of in vitro activity, pharmacokinetics,    pharmacodynamics, and clinical utility. Clin Microb Infect 1997; 3 (Suppl 1):    87-101.         [ Links ]85.- KESSLER R E, FUNG-TOMC J. Susceptibility    of bacterial isolates to beta-lactam antibiotics from U.S. clinical trials over    5-year period. Am J Med 1996; 24 (6 A): 13-9.         [ Links ]86.- PIERARD D, EMMERECHTS K, LAUWERS S. Comparative    in-vitro activity of cefpirome against isolates from intensive care and haematology/oncology    units. Belgian Multicentric Study Group. J Antimicrob Chemother 1998; 41: 443-50.          [ Links ]87.- JONES R N. Resistance patterns among    nosocomial pathogens: trends over the past few years. Chest 2001; 119 (Suppl    2): 397-404.         [ Links ]88.- LORBER B. Changing patterns of infectious    diseases. Am J Med 1988; 84: 569-78.         [ Links ]89.- MOELLERING R C. A novel antimicrobial    agent joins the battle against resistant bacteria. Ann Intern Med 1999; 130:    155-7.         [ Links ]90.- WILSON W R. The role of fourth-generation    cephalosporins in the treatment of serious infectious diseases in hospitalized    patients. Diagn Microbiol Infect Dis 1998; 31: 473-7.         [ Links ]Correspondencia a:        Sergio Mella Montecinos        Laboratorio de Antibióticos,        Departamento de Microbiología,        Facultad de Ciencias Biológicas        Casilla 160-C, Concepción        E-mail: pignatio@ctcinternet.cl  

35.- COHEN S P, MC MURRY L M, HOOPER D C,    WOLFSON J S, LEVY S B. Cross-resistance to fluoroquinolones in multiple-antibiotic-resistance    (Mar) Escherichia coli selected by tetracycline resistance: decreased    drug accumulation asociated with membrane changes in addition to Omp F reduction.    Antimicrob Agents Chemother 1989; 33:1318-25.         [ Links ]36.- SANDERS C C. Cefepime: The next generation?    Clin Infect Dis 1993; 17: 369-79         [ Links ]37.- GARAU J. The clinical potential of fourth-generation    cephalosporins. Diagn Microbiol Infect Dis 1998; 31: 479-80.         [ Links ]38.- CURTIS N A C, ORR D C, ROSS G W, BOULTON    M G. Affinities of penicillins and cephalosporins for the penicillin-binding    proteins of Escherichia coli    K-12 and their antibacterial activity. Antimicrob Agents Chemother 1979; 16:    533-9.  39.- BALANT L, DAYER P, AUCKENTHALER R. Clinical    pharmacokinetics of the third generation cephalosporins. Clin Pharmacokinetics    1985; 10: 101-43.         [ Links ]40.- WHEELER W J. Cephalosporins and other    beta-lactam antibiotics. Lloydia. 1977; 40: 519-42.         [ Links ]41.- LOPEZ F, GARRIDO J C. Química    y relación estructura-actividad de los antibióticos cefalosporínicos.    Rev Col Químico Farmacéutico 1989; 41: 5-14.         [ Links ]42.- FU K P, ASWAPOKEE P, HO I, MATTHIJSSEN    C, NEU H C. Pharmacokinetics of cefotaxime. Antimicrob Agents Chemother 1979;16:    592-7.         [ Links ]43.- YUK J H, NIGHTINGALE C H, QUINTILIANI    R. Clinical pharmacokinetics of ceftriaxone. Clin Pharmacokinetic 1989; 17:    223-35.         [ Links ]44.- BRYSKIER A, PROCYK T, LABRO M T. Cefodizime,    a new 2-aminothiazolyl cephalosporin: physicochemical properties, toxicology    and structure-activity relationships. J Antimicrob Chemother 1990; 26 (Suppl    C): 1-8.         [ Links ]45.- CRITCHLEY I A, BASKER M J, EDMONDSON    R A, KNOTT S J. Uptake of catecholic cephalosporin by the iron transport system    of Escherichia coli. J Antimicrob Chemother 1991; 28: 377-88.         [ Links ]46.- CRITCHLEY I A. Catecholic ß-lactams:    facilitated transport. J Antimicrob Chemother 1990; 26: 733-7.         [ Links ]47.- JONES R N, ERWIN M E. In vitro evaluation    of Ro 09-1227, a novel catechol-substituted cephalosporin. Antimicrob Agents    Chemother 1992; 36: 233-8.         [ Links ]48.- JONES R N. In vitro activity of Ro 24-6392,    a novel ester-linked co-drug combining ciprofloxacin and desacetylcefotaxime.    Eur J Clin Microbiol Infect Dis 1990; 9: 435-8.         [ Links ]49.- TOMASZ A. Penicillin-binding proteins    and the antibacterial effectiveness of ß-lactam antibiotics. Rev Infect    Dis 1986 (Suppl 3); 8: 260-78.         [ Links ]50.- HOLM S E. Interaction between ß-lactam    and other antibiotics. Rev Infect Dis 1986 (Suppl 3); 8: 305-14.         [ Links ]51.- MC CULLERS J A, ENGLISH B K, NOVAK R.    Isolation and characterization of vancomycin-tolerant Streptococcus pneumoniae    from the cerebrospinal fluid of a patient who developed recrudescet meningitis.    J Infect Dis 2000; 181: 369-73.         [ Links ]52.- NIKAIDO H. Outer membrane barrier as    a mechanism of antimicrobial resistance. Antimicrob Agents Chemother 1989; 33:    1831-6.         [ Links ]53.- BARRADELL L B, BRYSON H M. Cefepime.    A review of its antibacterial activity, pharmacokinetic properties and therapeutic    use. Drugs 1994; 47: 471-505.         [ Links ]54.- O'CALLAGHAN C H 1979. Description and    classification of the newer cephalosporins and their relationship with the established    compounds. J Antimicrob Chemother 5: 635-71         [ Links ]55.- BRYSKIER A, PROCYK T, TREMBLAY D, LENFANT    B FOURTILLAN J B. The pharmacokinetics of cefodizime following intravenous and    intramuscular administration of a single dose of 1.0 g. J Antimicrob Chemother    1990; 26 (Suppl. C): 59-63.         [ Links ]56.- WILLIAMS J D. Classification of cephalosporins.    Drugs. 1987; 34 (Suppl 2): 15-22.         [ Links ]57.- WISEMAN L R, LAMB H M. Cefpirome. A review    of its antibacterial activity, pharmacokinetic properties and efficacy in the    treatment of severe nosocomial infections and febrile neutropenia. Drugs 1997;    57: 117-40.         [ Links ]58.- PECHERE J C, WILSON W, NEU H. Laboratory    assesment of antibacterial activity of zwitterionic 7-methoxyimino cephalosporins.    J Antimicrob Chemother 1995; 36: 757-71         [ Links ]59.- GIAMARELLOS-BOURBOULIS EJ, GRECKA P,    TSITSIKA A, TYMPANIDOU C, GIAMARELLOU H. In-vitro activity of FK 037 (cefoselis),    a novel 4 (th) generation cephalosporin, cefepime and cefpirome on nosocomial    staphylococci and gram-negative isolates. Diagn Microbiol infect Dis 2000; 36:    185-91.         [ Links ]60.- JONES R N, ERWIN M E, BARRETT M S, JOHNSON    D M, BRIGGS B M. Antimicrobial activity of E-1040, a novel thiadiazolyl cephalosporin    compare with parenteral cephems. Diagn Microbiol infect Dis 1991; 14: 301-9.          [ Links ]61.- IIZAWA Y, OKONOGI K, HAYASHI R, IWAHI    T, YAMAZAKI T, IMADA A. Therapeutic effect of cefozopran (SCE-2787), a new parenteral    cephalosporin in experimental infections in mice. Antimicrob Agents Chemother    1993; 37: 100-5.         [ Links ]62.- WATANABE N A. Newer antipseudomonal cephalosporins.    J Chemother 1996; 8 (Suppl 2): 48-56.         [ Links ]63.- ACTOR P, GUARINI J, URI J et al. Disk    susceptibility studies with cefazolin and cephalotin. Antimicrob Agents Chemother    1974; 5: 63-7.         [ Links ]64.- UWAYDAH M. Cefazolin in the treatment    of acute enteric fever. Antimicrob Agents Chemother 1976; 10: 52-6.         [ Links ]65.- JAMAL W Y, ROTIMI V O, CHUGH T D, PAL    T. Prevalence and susceptibility of Shigella to 11 antibiotics in a Kuwait    teaching hospital. J Chemother 1998; 10: 285-90.         [ Links ]66.- COX CE, SHERRILL M, COCCHETT DM. Evaluation    of cefuroxime axetil, cefaclor, and cephalexin in the treatment of urinary tract    infections in adults. Curr Ther Res 1987; 42: 124-37.         [ Links ]67.- SANDERS C W, GREENBERG R N, MARIER R    L. Cefamandole and cefoxitin. Ann Intern Med 1985; 103: 70-8.          [ Links ]68.- STAPLEY E P, JACKSON M, HERNANDEZ S et    al. Cephamycins, a new family of ß-lactam antibiotics I. Production actinomycetes,    including Streptomyces lactamdurans spp.n. Antimicrob Agents Chemother    1972; 2: 122-31.         [ Links ]69.- COOPER R D G. The carbacephems a new    ß-lactams class. Am J Med 1992; 92 (Suppl 6 A): 25-65.         [ Links ]70.- ZEMELMAN R, BELLO H, DOMINGUEZ M, GONZALEZ    G, MELLA S, GARCIA A. Activity of imipenem, third-generation cephalosporins,    aztreonam, and ciprofloxacin against multi-resistant Gram negative bacilli isolated    from Chilean hospitals. J Antimicrob Chemother 1993; 32: 413-9.         [ Links ]71.- MEDEIROS A A. Evolution and dissemination    of ß-lactamases accelerated by generation of ß-lactam antibiotics.    Clin Infect Dis 1997; 24 (Suppl. 1): 19-45.         [ Links ]72.- PERRY C M, BROGDEN R N. Cefuroxime axetil:    review of its antibacterial activity, pharmacokinetic properties and therapeutic    efficacy. Drugs 1996; 52: 125-58.         [ Links ]73.- SCHAAD U B, SUTER S, GIANELLA-BORRADORI    et al. A comparison of ceftriaxone and cefuroxime for the treatment of bacterial    meningitis in children. N Engl J Med 1990; 322: 141-7.         [ Links ]74.- KLEIN N C, CUNHA B A. Cefalosporinas de    la tercera generación. Clin Med Nort Am 1995; 79: 693-707.         [ Links ]75.- KLUGMAN K P, MADHI S A. Emergence of    drug resistance impact on bacterial meningitis. Infect Dis Clin North Am 1999;    13: 637-46.         [ Links ]76.- RICHARDS D M, BROGDEN R N. Ceftazidime.    A review of its antibacterial activity, pharmacokinetic properties and therapeutic    use. Drugs 1985; 29: 105-61.         [ Links ]77.- SCHATZ B S, KARAVOKIROS K T, TAEUBEL    M A, ITOKAZU G S. Comparison of cefprozil, cefpodoxime proxetil, loracarbef,    cefixime, and ceftibuten. Ann Pharmacother 1996; 30: 258-68.         [ Links ]78.- DALMAU D, LAYRARGUES G P, FENYVES D,    WILLEMS B, TURGEON F, TURGEON P. Cefotaxime, desacetyl-cefotaxime, and bactericidal    activity in spontaneous bacterial peritonitis. J Infect Dis 1999; 180: 1597-1602.          [ Links ]79.- NIKAIDO W, LIU W, ROSENBERG E Y. Outer    membrane permeability and ß-lactamase stability of dipolar ionic cephalosporins    containing methoxyimino substituents. Antimicrob Agents Chemother 1990; 34:    337-42.         [ Links ]80.- HANCOCK R E W, BELLIDO F. Factors involved    in the enhanced efficacy against gram-negative bacteria of fourth generation    cephalosporins. J Antimicrob Chemother 1992; 29(Suppl A): 1-6.         [ Links ]81.- BELLIDO F, PECHERE J C, HANCOCK REW.    Novel method for measurement of outer membrane permeability to new beta-lactams    in intact Enterobacter cloacae cells. Antimicrob Agents Chemother 1991;    35: 68-72.         [ Links ]82.- NEU H C, CHIN N X, JULES K, LABTHAVIKUL    P. The activity of BMY-28142, a new broad spectrum beta-lactamase stable cephalosporin.    J Antimicrob Chemother 1986; 17: 441-52.         [ Links ]83.- KOBAYASHI S, ARAI S, HAYASHI S, FUJIMOTO    K. ß-lactamase stability of cefpirome (HR 810), a new cephalosporin with    a broad antimicrobial spectrum. Antimicrob Agents Chemother 1986; 30: 713-8.          [ Links ]84.- GARAU J, WILSON W, WOOD M, CARLET J.    Fourth generation cephalosporins: a review of in vitro activity, pharmacokinetics,    pharmacodynamics, and clinical utility. Clin Microb Infect 1997; 3 (Suppl 1):    87-101.         [ Links ]85.- KESSLER R E, FUNG-TOMC J. Susceptibility    of bacterial isolates to beta-lactam antibiotics from U.S. clinical trials over    5-year period. Am J Med 1996; 24 (6 A): 13-9.         [ Links ]86.- PIERARD D, EMMERECHTS K, LAUWERS S. Comparative    in-vitro activity of cefpirome against isolates from intensive care and haematology/oncology    units. Belgian Multicentric Study Group. J Antimicrob Chemother 1998; 41: 443-50.          [ Links ]87.- JONES R N. Resistance patterns among    nosocomial pathogens: trends over the past few years. Chest 2001; 119 (Suppl    2): 397-404.         [ Links ]88.- LORBER B. Changing patterns of infectious    diseases. Am J Med 1988; 84: 569-78.         [ Links ]89.- MOELLERING R C. A novel antimicrobial    agent joins the battle against resistant bacteria. Ann Intern Med 1999; 130:    155-7.         [ Links ]90.- WILSON W R. The role of fourth-generation    cephalosporins in the treatment of serious infectious diseases in hospitalized    patients. Diagn Microbiol Infect Dis 1998; 31: 473-7.         [ Links ]Correspondencia a:        Sergio Mella Montecinos        Laboratorio de Antibióticos,        Departamento de Microbiología,        Facultad de Ciencias Biológicas        Casilla 160-C, Concepción        E-mail: pignatio@ctcinternet.cl  

36.- SANDERS C C. Cefepime: The next generation?    Clin Infect Dis 1993; 17: 369-79         [ Links ]37.- GARAU J. The clinical potential of fourth-generation    cephalosporins. Diagn Microbiol Infect Dis 1998; 31: 479-80.         [ Links ]38.- CURTIS N A C, ORR D C, ROSS G W, BOULTON    M G. Affinities of penicillins and cephalosporins for the penicillin-binding    proteins of Escherichia coli    K-12 and their antibacterial activity. Antimicrob Agents Chemother 1979; 16:    533-9.  39.- BALANT L, DAYER P, AUCKENTHALER R. Clinical    pharmacokinetics of the third generation cephalosporins. Clin Pharmacokinetics    1985; 10: 101-43.         [ Links ]40.- WHEELER W J. Cephalosporins and other    beta-lactam antibiotics. Lloydia. 1977; 40: 519-42.         [ Links ]41.- LOPEZ F, GARRIDO J C. Química    y relación estructura-actividad de los antibióticos cefalosporínicos.    Rev Col Químico Farmacéutico 1989; 41: 5-14.         [ Links ]42.- FU K P, ASWAPOKEE P, HO I, MATTHIJSSEN    C, NEU H C. Pharmacokinetics of cefotaxime. Antimicrob Agents Chemother 1979;16:    592-7.         [ Links ]43.- YUK J H, NIGHTINGALE C H, QUINTILIANI    R. Clinical pharmacokinetics of ceftriaxone. Clin Pharmacokinetic 1989; 17:    223-35.         [ Links ]44.- BRYSKIER A, PROCYK T, LABRO M T. Cefodizime,    a new 2-aminothiazolyl cephalosporin: physicochemical properties, toxicology    and structure-activity relationships. J Antimicrob Chemother 1990; 26 (Suppl    C): 1-8.         [ Links ]45.- CRITCHLEY I A, BASKER M J, EDMONDSON    R A, KNOTT S J. Uptake of catecholic cephalosporin by the iron transport system    of Escherichia coli. J Antimicrob Chemother 1991; 28: 377-88.         [ Links ]46.- CRITCHLEY I A. Catecholic ß-lactams:    facilitated transport. J Antimicrob Chemother 1990; 26: 733-7.         [ Links ]47.- JONES R N, ERWIN M E. In vitro evaluation    of Ro 09-1227, a novel catechol-substituted cephalosporin. Antimicrob Agents    Chemother 1992; 36: 233-8.         [ Links ]48.- JONES R N. In vitro activity of Ro 24-6392,    a novel ester-linked co-drug combining ciprofloxacin and desacetylcefotaxime.    Eur J Clin Microbiol Infect Dis 1990; 9: 435-8.         [ Links ]49.- TOMASZ A. Penicillin-binding proteins    and the antibacterial effectiveness of ß-lactam antibiotics. Rev Infect    Dis 1986 (Suppl 3); 8: 260-78.         [ Links ]50.- HOLM S E. Interaction between ß-lactam    and other antibiotics. Rev Infect Dis 1986 (Suppl 3); 8: 305-14.         [ Links ]51.- MC CULLERS J A, ENGLISH B K, NOVAK R.    Isolation and characterization of vancomycin-tolerant Streptococcus pneumoniae    from the cerebrospinal fluid of a patient who developed recrudescet meningitis.    J Infect Dis 2000; 181: 369-73.         [ Links ]52.- NIKAIDO H. Outer membrane barrier as    a mechanism of antimicrobial resistance. Antimicrob Agents Chemother 1989; 33:    1831-6.         [ Links ]53.- BARRADELL L B, BRYSON H M. Cefepime.    A review of its antibacterial activity, pharmacokinetic properties and therapeutic    use. Drugs 1994; 47: 471-505.         [ Links ]54.- O'CALLAGHAN C H 1979. Description and    classification of the newer cephalosporins and their relationship with the established    compounds. J Antimicrob Chemother 5: 635-71         [ Links ]55.- BRYSKIER A, PROCYK T, TREMBLAY D, LENFANT    B FOURTILLAN J B. The pharmacokinetics of cefodizime following intravenous and    intramuscular administration of a single dose of 1.0 g. J Antimicrob Chemother    1990; 26 (Suppl. C): 59-63.         [ Links ]56.- WILLIAMS J D. Classification of cephalosporins.    Drugs. 1987; 34 (Suppl 2): 15-22.         [ Links ]57.- WISEMAN L R, LAMB H M. Cefpirome. A review    of its antibacterial activity, pharmacokinetic properties and efficacy in the    treatment of severe nosocomial infections and febrile neutropenia. Drugs 1997;    57: 117-40.         [ Links ]58.- PECHERE J C, WILSON W, NEU H. Laboratory    assesment of antibacterial activity of zwitterionic 7-methoxyimino cephalosporins.    J Antimicrob Chemother 1995; 36: 757-71         [ Links ]59.- GIAMARELLOS-BOURBOULIS EJ, GRECKA P,    TSITSIKA A, TYMPANIDOU C, GIAMARELLOU H. In-vitro activity of FK 037 (cefoselis),    a novel 4 (th) generation cephalosporin, cefepime and cefpirome on nosocomial    staphylococci and gram-negative isolates. Diagn Microbiol infect Dis 2000; 36:    185-91.         [ Links ]60.- JONES R N, ERWIN M E, BARRETT M S, JOHNSON    D M, BRIGGS B M. Antimicrobial activity of E-1040, a novel thiadiazolyl cephalosporin    compare with parenteral cephems. Diagn Microbiol infect Dis 1991; 14: 301-9.          [ Links ]61.- IIZAWA Y, OKONOGI K, HAYASHI R, IWAHI    T, YAMAZAKI T, IMADA A. Therapeutic effect of cefozopran (SCE-2787), a new parenteral    cephalosporin in experimental infections in mice. Antimicrob Agents Chemother    1993; 37: 100-5.         [ Links ]62.- WATANABE N A. Newer antipseudomonal cephalosporins.    J Chemother 1996; 8 (Suppl 2): 48-56.         [ Links ]63.- ACTOR P, GUARINI J, URI J et al. Disk    susceptibility studies with cefazolin and cephalotin. Antimicrob Agents Chemother    1974; 5: 63-7.         [ Links ]64.- UWAYDAH M. Cefazolin in the treatment    of acute enteric fever. Antimicrob Agents Chemother 1976; 10: 52-6.         [ Links ]65.- JAMAL W Y, ROTIMI V O, CHUGH T D, PAL    T. Prevalence and susceptibility of Shigella to 11 antibiotics in a Kuwait    teaching hospital. J Chemother 1998; 10: 285-90.         [ Links ]66.- COX CE, SHERRILL M, COCCHETT DM. Evaluation    of cefuroxime axetil, cefaclor, and cephalexin in the treatment of urinary tract    infections in adults. Curr Ther Res 1987; 42: 124-37.         [ Links ]67.- SANDERS C W, GREENBERG R N, MARIER R    L. Cefamandole and cefoxitin. Ann Intern Med 1985; 103: 70-8.          [ Links ]68.- STAPLEY E P, JACKSON M, HERNANDEZ S et    al. Cephamycins, a new family of ß-lactam antibiotics I. Production actinomycetes,    including Streptomyces lactamdurans spp.n. Antimicrob Agents Chemother    1972; 2: 122-31.         [ Links ]69.- COOPER R D G. The carbacephems a new    ß-lactams class. Am J Med 1992; 92 (Suppl 6 A): 25-65.         [ Links ]70.- ZEMELMAN R, BELLO H, DOMINGUEZ M, GONZALEZ    G, MELLA S, GARCIA A. Activity of imipenem, third-generation cephalosporins,    aztreonam, and ciprofloxacin against multi-resistant Gram negative bacilli isolated    from Chilean hospitals. J Antimicrob Chemother 1993; 32: 413-9.         [ Links ]71.- MEDEIROS A A. Evolution and dissemination    of ß-lactamases accelerated by generation of ß-lactam antibiotics.    Clin Infect Dis 1997; 24 (Suppl. 1): 19-45.         [ Links ]72.- PERRY C M, BROGDEN R N. Cefuroxime axetil:    review of its antibacterial activity, pharmacokinetic properties and therapeutic    efficacy. Drugs 1996; 52: 125-58.         [ Links ]73.- SCHAAD U B, SUTER S, GIANELLA-BORRADORI    et al. A comparison of ceftriaxone and cefuroxime for the treatment of bacterial    meningitis in children. N Engl J Med 1990; 322: 141-7.         [ Links ]74.- KLEIN N C, CUNHA B A. Cefalosporinas de    la tercera generación. Clin Med Nort Am 1995; 79: 693-707.         [ Links ]75.- KLUGMAN K P, MADHI S A. Emergence of    drug resistance impact on bacterial meningitis. Infect Dis Clin North Am 1999;    13: 637-46.         [ Links ]76.- RICHARDS D M, BROGDEN R N. Ceftazidime.    A review of its antibacterial activity, pharmacokinetic properties and therapeutic    use. Drugs 1985; 29: 105-61.         [ Links ]77.- SCHATZ B S, KARAVOKIROS K T, TAEUBEL    M A, ITOKAZU G S. Comparison of cefprozil, cefpodoxime proxetil, loracarbef,    cefixime, and ceftibuten. Ann Pharmacother 1996; 30: 258-68.         [ Links ]78.- DALMAU D, LAYRARGUES G P, FENYVES D,    WILLEMS B, TURGEON F, TURGEON P. Cefotaxime, desacetyl-cefotaxime, and bactericidal    activity in spontaneous bacterial peritonitis. J Infect Dis 1999; 180: 1597-1602.          [ Links ]79.- NIKAIDO W, LIU W, ROSENBERG E Y. Outer    membrane permeability and ß-lactamase stability of dipolar ionic cephalosporins    containing methoxyimino substituents. Antimicrob Agents Chemother 1990; 34:    337-42.         [ Links ]80.- HANCOCK R E W, BELLIDO F. Factors involved    in the enhanced efficacy against gram-negative bacteria of fourth generation    cephalosporins. J Antimicrob Chemother 1992; 29(Suppl A): 1-6.         [ Links ]81.- BELLIDO F, PECHERE J C, HANCOCK REW.    Novel method for measurement of outer membrane permeability to new beta-lactams    in intact Enterobacter cloacae cells. Antimicrob Agents Chemother 1991;    35: 68-72.         [ Links ]82.- NEU H C, CHIN N X, JULES K, LABTHAVIKUL    P. The activity of BMY-28142, a new broad spectrum beta-lactamase stable cephalosporin.    J Antimicrob Chemother 1986; 17: 441-52.         [ Links ]83.- KOBAYASHI S, ARAI S, HAYASHI S, FUJIMOTO    K. ß-lactamase stability of cefpirome (HR 810), a new cephalosporin with    a broad antimicrobial spectrum. Antimicrob Agents Chemother 1986; 30: 713-8.          [ Links ]84.- GARAU J, WILSON W, WOOD M, CARLET J.    Fourth generation cephalosporins: a review of in vitro activity, pharmacokinetics,    pharmacodynamics, and clinical utility. Clin Microb Infect 1997; 3 (Suppl 1):    87-101.         [ Links ]85.- KESSLER R E, FUNG-TOMC J. Susceptibility    of bacterial isolates to beta-lactam antibiotics from U.S. clinical trials over    5-year period. Am J Med 1996; 24 (6 A): 13-9.         [ Links ]86.- PIERARD D, EMMERECHTS K, LAUWERS S. Comparative    in-vitro activity of cefpirome against isolates from intensive care and haematology/oncology    units. Belgian Multicentric Study Group. J Antimicrob Chemother 1998; 41: 443-50.          [ Links ]87.- JONES R N. Resistance patterns among    nosocomial pathogens: trends over the past few years. Chest 2001; 119 (Suppl    2): 397-404.         [ Links ]88.- LORBER B. Changing patterns of infectious    diseases. Am J Med 1988; 84: 569-78.         [ Links ]89.- MOELLERING R C. A novel antimicrobial    agent joins the battle against resistant bacteria. Ann Intern Med 1999; 130:    155-7.         [ Links ]90.- WILSON W R. The role of fourth-generation    cephalosporins in the treatment of serious infectious diseases in hospitalized    patients. Diagn Microbiol Infect Dis 1998; 31: 473-7.         [ Links ]Correspondencia a:        Sergio Mella Montecinos        Laboratorio de Antibióticos,        Departamento de Microbiología,        Facultad de Ciencias Biológicas        Casilla 160-C, Concepción        E-mail: pignatio@ctcinternet.cl  

37.- GARAU J. The clinical potential of fourth-generation    cephalosporins. Diagn Microbiol Infect Dis 1998; 31: 479-80.         [ Links ]38.- CURTIS N A C, ORR D C, ROSS G W, BOULTON    M G. Affinities of penicillins and cephalosporins for the penicillin-binding    proteins of Escherichia coli    K-12 and their antibacterial activity. Antimicrob Agents Chemother 1979; 16:    533-9.  39.- BALANT L, DAYER P, AUCKENTHALER R. Clinical    pharmacokinetics of the third generation cephalosporins. Clin Pharmacokinetics    1985; 10: 101-43.         [ Links ]40.- WHEELER W J. Cephalosporins and other    beta-lactam antibiotics. Lloydia. 1977; 40: 519-42.         [ Links ]41.- LOPEZ F, GARRIDO J C. Química    y relación estructura-actividad de los antibióticos cefalosporínicos.    Rev Col Químico Farmacéutico 1989; 41: 5-14.         [ Links ]42.- FU K P, ASWAPOKEE P, HO I, MATTHIJSSEN    C, NEU H C. Pharmacokinetics of cefotaxime. Antimicrob Agents Chemother 1979;16:    592-7.         [ Links ]43.- YUK J H, NIGHTINGALE C H, QUINTILIANI    R. Clinical pharmacokinetics of ceftriaxone. Clin Pharmacokinetic 1989; 17:    223-35.         [ Links ]44.- BRYSKIER A, PROCYK T, LABRO M T. Cefodizime,    a new 2-aminothiazolyl cephalosporin: physicochemical properties, toxicology    and structure-activity relationships. J Antimicrob Chemother 1990; 26 (Suppl    C): 1-8.         [ Links ]45.- CRITCHLEY I A, BASKER M J, EDMONDSON    R A, KNOTT S J. Uptake of catecholic cephalosporin by the iron transport system    of Escherichia coli. J Antimicrob Chemother 1991; 28: 377-88.         [ Links ]46.- CRITCHLEY I A. Catecholic ß-lactams:    facilitated transport. J Antimicrob Chemother 1990; 26: 733-7.         [ Links ]47.- JONES R N, ERWIN M E. In vitro evaluation    of Ro 09-1227, a novel catechol-substituted cephalosporin. Antimicrob Agents    Chemother 1992; 36: 233-8.         [ Links ]48.- JONES R N. In vitro activity of Ro 24-6392,    a novel ester-linked co-drug combining ciprofloxacin and desacetylcefotaxime.    Eur J Clin Microbiol Infect Dis 1990; 9: 435-8.         [ Links ]49.- TOMASZ A. Penicillin-binding proteins    and the antibacterial effectiveness of ß-lactam antibiotics. Rev Infect    Dis 1986 (Suppl 3); 8: 260-78.         [ Links ]50.- HOLM S E. Interaction between ß-lactam    and other antibiotics. Rev Infect Dis 1986 (Suppl 3); 8: 305-14.         [ Links ]51.- MC CULLERS J A, ENGLISH B K, NOVAK R.    Isolation and characterization of vancomycin-tolerant Streptococcus pneumoniae    from the cerebrospinal fluid of a patient who developed recrudescet meningitis.    J Infect Dis 2000; 181: 369-73.         [ Links ]52.- NIKAIDO H. Outer membrane barrier as    a mechanism of antimicrobial resistance. Antimicrob Agents Chemother 1989; 33:    1831-6.         [ Links ]53.- BARRADELL L B, BRYSON H M. Cefepime.    A review of its antibacterial activity, pharmacokinetic properties and therapeutic    use. Drugs 1994; 47: 471-505.         [ Links ]54.- O'CALLAGHAN C H 1979. Description and    classification of the newer cephalosporins and their relationship with the established    compounds. J Antimicrob Chemother 5: 635-71         [ Links ]55.- BRYSKIER A, PROCYK T, TREMBLAY D, LENFANT    B FOURTILLAN J B. The pharmacokinetics of cefodizime following intravenous and    intramuscular administration of a single dose of 1.0 g. J Antimicrob Chemother    1990; 26 (Suppl. C): 59-63.         [ Links ]56.- WILLIAMS J D. Classification of cephalosporins.    Drugs. 1987; 34 (Suppl 2): 15-22.         [ Links ]57.- WISEMAN L R, LAMB H M. Cefpirome. A review    of its antibacterial activity, pharmacokinetic properties and efficacy in the    treatment of severe nosocomial infections and febrile neutropenia. Drugs 1997;    57: 117-40.         [ Links ]58.- PECHERE J C, WILSON W, NEU H. Laboratory    assesment of antibacterial activity of zwitterionic 7-methoxyimino cephalosporins.    J Antimicrob Chemother 1995; 36: 757-71         [ Links ]59.- GIAMARELLOS-BOURBOULIS EJ, GRECKA P,    TSITSIKA A, TYMPANIDOU C, GIAMARELLOU H. In-vitro activity of FK 037 (cefoselis),    a novel 4 (th) generation cephalosporin, cefepime and cefpirome on nosocomial    staphylococci and gram-negative isolates. Diagn Microbiol infect Dis 2000; 36:    185-91.         [ Links ]60.- JONES R N, ERWIN M E, BARRETT M S, JOHNSON    D M, BRIGGS B M. Antimicrobial activity of E-1040, a novel thiadiazolyl cephalosporin    compare with parenteral cephems. Diagn Microbiol infect Dis 1991; 14: 301-9.          [ Links ]61.- IIZAWA Y, OKONOGI K, HAYASHI R, IWAHI    T, YAMAZAKI T, IMADA A. Therapeutic effect of cefozopran (SCE-2787), a new parenteral    cephalosporin in experimental infections in mice. Antimicrob Agents Chemother    1993; 37: 100-5.         [ Links ]62.- WATANABE N A. Newer antipseudomonal cephalosporins.    J Chemother 1996; 8 (Suppl 2): 48-56.         [ Links ]63.- ACTOR P, GUARINI J, URI J et al. Disk    susceptibility studies with cefazolin and cephalotin. Antimicrob Agents Chemother    1974; 5: 63-7.         [ Links ]64.- UWAYDAH M. Cefazolin in the treatment    of acute enteric fever. Antimicrob Agents Chemother 1976; 10: 52-6.         [ Links ]65.- JAMAL W Y, ROTIMI V O, CHUGH T D, PAL    T. Prevalence and susceptibility of Shigella to 11 antibiotics in a Kuwait    teaching hospital. J Chemother 1998; 10: 285-90.         [ Links ]66.- COX CE, SHERRILL M, COCCHETT DM. Evaluation    of cefuroxime axetil, cefaclor, and cephalexin in the treatment of urinary tract    infections in adults. Curr Ther Res 1987; 42: 124-37.         [ Links ]67.- SANDERS C W, GREENBERG R N, MARIER R    L. Cefamandole and cefoxitin. Ann Intern Med 1985; 103: 70-8.          [ Links ]68.- STAPLEY E P, JACKSON M, HERNANDEZ S et    al. Cephamycins, a new family of ß-lactam antibiotics I. Production actinomycetes,    including Streptomyces lactamdurans spp.n. Antimicrob Agents Chemother    1972; 2: 122-31.         [ Links ]69.- COOPER R D G. The carbacephems a new    ß-lactams class. Am J Med 1992; 92 (Suppl 6 A): 25-65.         [ Links ]70.- ZEMELMAN R, BELLO H, DOMINGUEZ M, GONZALEZ    G, MELLA S, GARCIA A. Activity of imipenem, third-generation cephalosporins,    aztreonam, and ciprofloxacin against multi-resistant Gram negative bacilli isolated    from Chilean hospitals. J Antimicrob Chemother 1993; 32: 413-9.         [ Links ]71.- MEDEIROS A A. Evolution and dissemination    of ß-lactamases accelerated by generation of ß-lactam antibiotics.    Clin Infect Dis 1997; 24 (Suppl. 1): 19-45.         [ Links ]72.- PERRY C M, BROGDEN R N. Cefuroxime axetil:    review of its antibacterial activity, pharmacokinetic properties and therapeutic    efficacy. Drugs 1996; 52: 125-58.         [ Links ]73.- SCHAAD U B, SUTER S, GIANELLA-BORRADORI    et al. A comparison of ceftriaxone and cefuroxime for the treatment of bacterial    meningitis in children. N Engl J Med 1990; 322: 141-7.         [ Links ]74.- KLEIN N C, CUNHA B A. Cefalosporinas de    la tercera generación. Clin Med Nort Am 1995; 79: 693-707.         [ Links ]75.- KLUGMAN K P, MADHI S A. Emergence of    drug resistance impact on bacterial meningitis. Infect Dis Clin North Am 1999;    13: 637-46.         [ Links ]76.- RICHARDS D M, BROGDEN R N. Ceftazidime.    A review of its antibacterial activity, pharmacokinetic properties and therapeutic    use. Drugs 1985; 29: 105-61.         [ Links ]77.- SCHATZ B S, KARAVOKIROS K T, TAEUBEL    M A, ITOKAZU G S. Comparison of cefprozil, cefpodoxime proxetil, loracarbef,    cefixime, and ceftibuten. Ann Pharmacother 1996; 30: 258-68.         [ Links ]78.- DALMAU D, LAYRARGUES G P, FENYVES D,    WILLEMS B, TURGEON F, TURGEON P. Cefotaxime, desacetyl-cefotaxime, and bactericidal    activity in spontaneous bacterial peritonitis. J Infect Dis 1999; 180: 1597-1602.          [ Links ]79.- NIKAIDO W, LIU W, ROSENBERG E Y. Outer    membrane permeability and ß-lactamase stability of dipolar ionic cephalosporins    containing methoxyimino substituents. Antimicrob Agents Chemother 1990; 34:    337-42.         [ Links ]80.- HANCOCK R E W, BELLIDO F. Factors involved    in the enhanced efficacy against gram-negative bacteria of fourth generation    cephalosporins. J Antimicrob Chemother 1992; 29(Suppl A): 1-6.         [ Links ]81.- BELLIDO F, PECHERE J C, HANCOCK REW.    Novel method for measurement of outer membrane permeability to new beta-lactams    in intact Enterobacter cloacae cells. Antimicrob Agents Chemother 1991;    35: 68-72.         [ Links ]82.- NEU H C, CHIN N X, JULES K, LABTHAVIKUL    P. The activity of BMY-28142, a new broad spectrum beta-lactamase stable cephalosporin.    J Antimicrob Chemother 1986; 17: 441-52.         [ Links ]83.- KOBAYASHI S, ARAI S, HAYASHI S, FUJIMOTO    K. ß-lactamase stability of cefpirome (HR 810), a new cephalosporin with    a broad antimicrobial spectrum. Antimicrob Agents Chemother 1986; 30: 713-8.          [ Links ]84.- GARAU J, WILSON W, WOOD M, CARLET J.    Fourth generation cephalosporins: a review of in vitro activity, pharmacokinetics,    pharmacodynamics, and clinical utility. Clin Microb Infect 1997; 3 (Suppl 1):    87-101.         [ Links ]85.- KESSLER R E, FUNG-TOMC J. Susceptibility    of bacterial isolates to beta-lactam antibiotics from U.S. clinical trials over    5-year period. Am J Med 1996; 24 (6 A): 13-9.         [ Links ]86.- PIERARD D, EMMERECHTS K, LAUWERS S. Comparative    in-vitro activity of cefpirome against isolates from intensive care and haematology/oncology    units. Belgian Multicentric Study Group. J Antimicrob Chemother 1998; 41: 443-50.          [ Links ]87.- JONES R N. Resistance patterns among    nosocomial pathogens: trends over the past few years. Chest 2001; 119 (Suppl    2): 397-404.         [ Links ]88.- LORBER B. Changing patterns of infectious    diseases. Am J Med 1988; 84: 569-78.         [ Links ]89.- MOELLERING R C. A novel antimicrobial    agent joins the battle against resistant bacteria. Ann Intern Med 1999; 130:    155-7.         [ Links ]90.- WILSON W R. The role of fourth-generation    cephalosporins in the treatment of serious infectious diseases in hospitalized    patients. Diagn Microbiol Infect Dis 1998; 31: 473-7.         [ Links ]Correspondencia a:        Sergio Mella Montecinos        Laboratorio de Antibióticos,        Departamento de Microbiología,        Facultad de Ciencias Biológicas        Casilla 160-C, Concepción        E-mail: pignatio@ctcinternet.cl  

38.- CURTIS N A C, ORR D C, ROSS G W, BOULTON    M G. Affinities of penicillins and cephalosporins for the penicillin-binding    proteins of Escherichia coli    K-12 and their antibacterial activity. Antimicrob Agents Chemother 1979; 16:    533-9. 

39.- BALANT L, DAYER P, AUCKENTHALER R. Clinical    pharmacokinetics of the third generation cephalosporins. Clin Pharmacokinetics    1985; 10: 101-43.         [ Links ]40.- WHEELER W J. Cephalosporins and other    beta-lactam antibiotics. Lloydia. 1977; 40: 519-42.         [ Links ]41.- LOPEZ F, GARRIDO J C. Química    y relación estructura-actividad de los antibióticos cefalosporínicos.    Rev Col Químico Farmacéutico 1989; 41: 5-14.         [ Links ]42.- FU K P, ASWAPOKEE P, HO I, MATTHIJSSEN    C, NEU H C. Pharmacokinetics of cefotaxime. Antimicrob Agents Chemother 1979;16:    592-7.         [ Links ]43.- YUK J H, NIGHTINGALE C H, QUINTILIANI    R. Clinical pharmacokinetics of ceftriaxone. Clin Pharmacokinetic 1989; 17:    223-35.         [ Links ]44.- BRYSKIER A, PROCYK T, LABRO M T. Cefodizime,    a new 2-aminothiazolyl cephalosporin: physicochemical properties, toxicology    and structure-activity relationships. J Antimicrob Chemother 1990; 26 (Suppl    C): 1-8.         [ Links ]45.- CRITCHLEY I A, BASKER M J, EDMONDSON    R A, KNOTT S J. Uptake of catecholic cephalosporin by the iron transport system    of Escherichia coli. J Antimicrob Chemother 1991; 28: 377-88.         [ Links ]46.- CRITCHLEY I A. Catecholic ß-lactams:    facilitated transport. J Antimicrob Chemother 1990; 26: 733-7.         [ Links ]47.- JONES R N, ERWIN M E. In vitro evaluation    of Ro 09-1227, a novel catechol-substituted cephalosporin. Antimicrob Agents    Chemother 1992; 36: 233-8.         [ Links ]48.- JONES R N. In vitro activity of Ro 24-6392,    a novel ester-linked co-drug combining ciprofloxacin and desacetylcefotaxime.    Eur J Clin Microbiol Infect Dis 1990; 9: 435-8.         [ Links ]49.- TOMASZ A. Penicillin-binding proteins    and the antibacterial effectiveness of ß-lactam antibiotics. Rev Infect    Dis 1986 (Suppl 3); 8: 260-78.         [ Links ]50.- HOLM S E. Interaction between ß-lactam    and other antibiotics. Rev Infect Dis 1986 (Suppl 3); 8: 305-14.         [ Links ]51.- MC CULLERS J A, ENGLISH B K, NOVAK R.    Isolation and characterization of vancomycin-tolerant Streptococcus pneumoniae    from the cerebrospinal fluid of a patient who developed recrudescet meningitis.    J Infect Dis 2000; 181: 369-73.         [ Links ]52.- NIKAIDO H. Outer membrane barrier as    a mechanism of antimicrobial resistance. Antimicrob Agents Chemother 1989; 33:    1831-6.         [ Links ]53.- BARRADELL L B, BRYSON H M. Cefepime.    A review of its antibacterial activity, pharmacokinetic properties and therapeutic    use. Drugs 1994; 47: 471-505.         [ Links ]54.- O'CALLAGHAN C H 1979. Description and    classification of the newer cephalosporins and their relationship with the established    compounds. J Antimicrob Chemother 5: 635-71         [ Links ]55.- BRYSKIER A, PROCYK T, TREMBLAY D, LENFANT    B FOURTILLAN J B. The pharmacokinetics of cefodizime following intravenous and    intramuscular administration of a single dose of 1.0 g. J Antimicrob Chemother    1990; 26 (Suppl. C): 59-63.         [ Links ]56.- WILLIAMS J D. Classification of cephalosporins.    Drugs. 1987; 34 (Suppl 2): 15-22.         [ Links ]57.- WISEMAN L R, LAMB H M. Cefpirome. A review    of its antibacterial activity, pharmacokinetic properties and efficacy in the    treatment of severe nosocomial infections and febrile neutropenia. Drugs 1997;    57: 117-40.         [ Links ]58.- PECHERE J C, WILSON W, NEU H. Laboratory    assesment of antibacterial activity of zwitterionic 7-methoxyimino cephalosporins.    J Antimicrob Chemother 1995; 36: 757-71         [ Links ]59.- GIAMARELLOS-BOURBOULIS EJ, GRECKA P,    TSITSIKA A, TYMPANIDOU C, GIAMARELLOU H. In-vitro activity of FK 037 (cefoselis),    a novel 4 (th) generation cephalosporin, cefepime and cefpirome on nosocomial    staphylococci and gram-negative isolates. Diagn Microbiol infect Dis 2000; 36:    185-91.         [ Links ]60.- JONES R N, ERWIN M E, BARRETT M S, JOHNSON    D M, BRIGGS B M. Antimicrobial activity of E-1040, a novel thiadiazolyl cephalosporin    compare with parenteral cephems. Diagn Microbiol infect Dis 1991; 14: 301-9.          [ Links ]61.- IIZAWA Y, OKONOGI K, HAYASHI R, IWAHI    T, YAMAZAKI T, IMADA A. Therapeutic effect of cefozopran (SCE-2787), a new parenteral    cephalosporin in experimental infections in mice. Antimicrob Agents Chemother    1993; 37: 100-5.         [ Links ]62.- WATANABE N A. Newer antipseudomonal cephalosporins.    J Chemother 1996; 8 (Suppl 2): 48-56.         [ Links ]63.- ACTOR P, GUARINI J, URI J et al. Disk    susceptibility studies with cefazolin and cephalotin. Antimicrob Agents Chemother    1974; 5: 63-7.         [ Links ]64.- UWAYDAH M. Cefazolin in the treatment    of acute enteric fever. Antimicrob Agents Chemother 1976; 10: 52-6.         [ Links ]65.- JAMAL W Y, ROTIMI V O, CHUGH T D, PAL    T. Prevalence and susceptibility of Shigella to 11 antibiotics in a Kuwait    teaching hospital. J Chemother 1998; 10: 285-90.         [ Links ]66.- COX CE, SHERRILL M, COCCHETT DM. Evaluation    of cefuroxime axetil, cefaclor, and cephalexin in the treatment of urinary tract    infections in adults. Curr Ther Res 1987; 42: 124-37.         [ Links ]67.- SANDERS C W, GREENBERG R N, MARIER R    L. Cefamandole and cefoxitin. Ann Intern Med 1985; 103: 70-8.          [ Links ]68.- STAPLEY E P, JACKSON M, HERNANDEZ S et    al. Cephamycins, a new family of ß-lactam antibiotics I. Production actinomycetes,    including Streptomyces lactamdurans spp.n. Antimicrob Agents Chemother    1972; 2: 122-31.         [ Links ]69.- COOPER R D G. The carbacephems a new    ß-lactams class. Am J Med 1992; 92 (Suppl 6 A): 25-65.         [ Links ]70.- ZEMELMAN R, BELLO H, DOMINGUEZ M, GONZALEZ    G, MELLA S, GARCIA A. Activity of imipenem, third-generation cephalosporins,    aztreonam, and ciprofloxacin against multi-resistant Gram negative bacilli isolated    from Chilean hospitals. J Antimicrob Chemother 1993; 32: 413-9.         [ Links ]71.- MEDEIROS A A. Evolution and dissemination    of ß-lactamases accelerated by generation of ß-lactam antibiotics.    Clin Infect Dis 1997; 24 (Suppl. 1): 19-45.         [ Links ]72.- PERRY C M, BROGDEN R N. Cefuroxime axetil:    review of its antibacterial activity, pharmacokinetic properties and therapeutic    efficacy. Drugs 1996; 52: 125-58.         [ Links ]73.- SCHAAD U B, SUTER S, GIANELLA-BORRADORI    et al. A comparison of ceftriaxone and cefuroxime for the treatment of bacterial    meningitis in children. N Engl J Med 1990; 322: 141-7.         [ Links ]74.- KLEIN N C, CUNHA B A. Cefalosporinas de    la tercera generación. Clin Med Nort Am 1995; 79: 693-707.         [ Links ]75.- KLUGMAN K P, MADHI S A. Emergence of    drug resistance impact on bacterial meningitis. Infect Dis Clin North Am 1999;    13: 637-46.         [ Links ]76.- RICHARDS D M, BROGDEN R N. Ceftazidime.    A review of its antibacterial activity, pharmacokinetic properties and therapeutic    use. Drugs 1985; 29: 105-61.         [ Links ]77.- SCHATZ B S, KARAVOKIROS K T, TAEUBEL    M A, ITOKAZU G S. Comparison of cefprozil, cefpodoxime proxetil, loracarbef,    cefixime, and ceftibuten. Ann Pharmacother 1996; 30: 258-68.         [ Links ]78.- DALMAU D, LAYRARGUES G P, FENYVES D,    WILLEMS B, TURGEON F, TURGEON P. Cefotaxime, desacetyl-cefotaxime, and bactericidal    activity in spontaneous bacterial peritonitis. J Infect Dis 1999; 180: 1597-1602.          [ Links ]79.- NIKAIDO W, LIU W, ROSENBERG E Y. Outer    membrane permeability and ß-lactamase stability of dipolar ionic cephalosporins    containing methoxyimino substituents. Antimicrob Agents Chemother 1990; 34:    337-42.         [ Links ]80.- HANCOCK R E W, BELLIDO F. Factors involved    in the enhanced efficacy against gram-negative bacteria of fourth generation    cephalosporins. J Antimicrob Chemother 1992; 29(Suppl A): 1-6.         [ Links ]81.- BELLIDO F, PECHERE J C, HANCOCK REW.    Novel method for measurement of outer membrane permeability to new beta-lactams    in intact Enterobacter cloacae cells. Antimicrob Agents Chemother 1991;    35: 68-72.         [ Links ]82.- NEU H C, CHIN N X, JULES K, LABTHAVIKUL    P. The activity of BMY-28142, a new broad spectrum beta-lactamase stable cephalosporin.    J Antimicrob Chemother 1986; 17: 441-52.         [ Links ]83.- KOBAYASHI S, ARAI S, HAYASHI S, FUJIMOTO    K. ß-lactamase stability of cefpirome (HR 810), a new cephalosporin with    a broad antimicrobial spectrum. Antimicrob Agents Chemother 1986; 30: 713-8.          [ Links ]84.- GARAU J, WILSON W, WOOD M, CARLET J.    Fourth generation cephalosporins: a review of in vitro activity, pharmacokinetics,    pharmacodynamics, and clinical utility. Clin Microb Infect 1997; 3 (Suppl 1):    87-101.         [ Links ]85.- KESSLER R E, FUNG-TOMC J. Susceptibility    of bacterial isolates to beta-lactam antibiotics from U.S. clinical trials over    5-year period. Am J Med 1996; 24 (6 A): 13-9.         [ Links ]86.- PIERARD D, EMMERECHTS K, LAUWERS S. Comparative    in-vitro activity of cefpirome against isolates from intensive care and haematology/oncology    units. Belgian Multicentric Study Group. J Antimicrob Chemother 1998; 41: 443-50.          [ Links ]87.- JONES R N. Resistance patterns among    nosocomial pathogens: trends over the past few years. Chest 2001; 119 (Suppl    2): 397-404.         [ Links ]88.- LORBER B. Changing patterns of infectious    diseases. Am J Med 1988; 84: 569-78.         [ Links ]89.- MOELLERING R C. A novel antimicrobial    agent joins the battle against resistant bacteria. Ann Intern Med 1999; 130:    155-7.         [ Links ]90.- WILSON W R. The role of fourth-generation    cephalosporins in the treatment of serious infectious diseases in hospitalized    patients. Diagn Microbiol Infect Dis 1998; 31: 473-7.         [ Links ]Correspondencia a:        Sergio Mella Montecinos        Laboratorio de Antibióticos,        Departamento de Microbiología,        Facultad de Ciencias Biológicas        Casilla 160-C, Concepción        E-mail: pignatio@ctcinternet.cl  

40.- WHEELER W J. Cephalosporins and other    beta-lactam antibiotics. Lloydia. 1977; 40: 519-42.         [ Links ]41.- LOPEZ F, GARRIDO J C. Química    y relación estructura-actividad de los antibióticos cefalosporínicos.    Rev Col Químico Farmacéutico 1989; 41: 5-14.         [ Links ]42.- FU K P, ASWAPOKEE P, HO I, MATTHIJSSEN    C, NEU H C. Pharmacokinetics of cefotaxime. Antimicrob Agents Chemother 1979;16:    592-7.         [ Links ]43.- YUK J H, NIGHTINGALE C H, QUINTILIANI    R. Clinical pharmacokinetics of ceftriaxone. Clin Pharmacokinetic 1989; 17:    223-35.         [ Links ]44.- BRYSKIER A, PROCYK T, LABRO M T. Cefodizime,    a new 2-aminothiazolyl cephalosporin: physicochemical properties, toxicology    and structure-activity relationships. J Antimicrob Chemother 1990; 26 (Suppl    C): 1-8.         [ Links ]45.- CRITCHLEY I A, BASKER M J, EDMONDSON    R A, KNOTT S J. Uptake of catecholic cephalosporin by the iron transport system    of Escherichia coli. J Antimicrob Chemother 1991; 28: 377-88.         [ Links ]46.- CRITCHLEY I A. Catecholic ß-lactams:    facilitated transport. J Antimicrob Chemother 1990; 26: 733-7.         [ Links ]47.- JONES R N, ERWIN M E. In vitro evaluation    of Ro 09-1227, a novel catechol-substituted cephalosporin. Antimicrob Agents    Chemother 1992; 36: 233-8.         [ Links ]48.- JONES R N. In vitro activity of Ro 24-6392,    a novel ester-linked co-drug combining ciprofloxacin and desacetylcefotaxime.    Eur J Clin Microbiol Infect Dis 1990; 9: 435-8.         [ Links ]49.- TOMASZ A. Penicillin-binding proteins    and the antibacterial effectiveness of ß-lactam antibiotics. Rev Infect    Dis 1986 (Suppl 3); 8: 260-78.         [ Links ]50.- HOLM S E. Interaction between ß-lactam    and other antibiotics. Rev Infect Dis 1986 (Suppl 3); 8: 305-14.         [ Links ]51.- MC CULLERS J A, ENGLISH B K, NOVAK R.    Isolation and characterization of vancomycin-tolerant Streptococcus pneumoniae    from the cerebrospinal fluid of a patient who developed recrudescet meningitis.    J Infect Dis 2000; 181: 369-73.         [ Links ]52.- NIKAIDO H. Outer membrane barrier as    a mechanism of antimicrobial resistance. Antimicrob Agents Chemother 1989; 33:    1831-6.         [ Links ]53.- BARRADELL L B, BRYSON H M. Cefepime.    A review of its antibacterial activity, pharmacokinetic properties and therapeutic    use. Drugs 1994; 47: 471-505.         [ Links ]54.- O'CALLAGHAN C H 1979. Description and    classification of the newer cephalosporins and their relationship with the established    compounds. J Antimicrob Chemother 5: 635-71         [ Links ]55.- BRYSKIER A, PROCYK T, TREMBLAY D, LENFANT    B FOURTILLAN J B. The pharmacokinetics of cefodizime following intravenous and    intramuscular administration of a single dose of 1.0 g. J Antimicrob Chemother    1990; 26 (Suppl. C): 59-63.         [ Links ]56.- WILLIAMS J D. Classification of cephalosporins.    Drugs. 1987; 34 (Suppl 2): 15-22.         [ Links ]57.- WISEMAN L R, LAMB H M. Cefpirome. A review    of its antibacterial activity, pharmacokinetic properties and efficacy in the    treatment of severe nosocomial infections and febrile neutropenia. Drugs 1997;    57: 117-40.         [ Links ]58.- PECHERE J C, WILSON W, NEU H. Laboratory    assesment of antibacterial activity of zwitterionic 7-methoxyimino cephalosporins.    J Antimicrob Chemother 1995; 36: 757-71         [ Links ]59.- GIAMARELLOS-BOURBOULIS EJ, GRECKA P,    TSITSIKA A, TYMPANIDOU C, GIAMARELLOU H. In-vitro activity of FK 037 (cefoselis),    a novel 4 (th) generation cephalosporin, cefepime and cefpirome on nosocomial    staphylococci and gram-negative isolates. Diagn Microbiol infect Dis 2000; 36:    185-91.         [ Links ]60.- JONES R N, ERWIN M E, BARRETT M S, JOHNSON    D M, BRIGGS B M. Antimicrobial activity of E-1040, a novel thiadiazolyl cephalosporin    compare with parenteral cephems. Diagn Microbiol infect Dis 1991; 14: 301-9.          [ Links ]61.- IIZAWA Y, OKONOGI K, HAYASHI R, IWAHI    T, YAMAZAKI T, IMADA A. Therapeutic effect of cefozopran (SCE-2787), a new parenteral    cephalosporin in experimental infections in mice. Antimicrob Agents Chemother    1993; 37: 100-5.         [ Links ]62.- WATANABE N A. Newer antipseudomonal cephalosporins.    J Chemother 1996; 8 (Suppl 2): 48-56.         [ Links ]63.- ACTOR P, GUARINI J, URI J et al. Disk    susceptibility studies with cefazolin and cephalotin. Antimicrob Agents Chemother    1974; 5: 63-7.         [ Links ]64.- UWAYDAH M. Cefazolin in the treatment    of acute enteric fever. Antimicrob Agents Chemother 1976; 10: 52-6.         [ Links ]65.- JAMAL W Y, ROTIMI V O, CHUGH T D, PAL    T. Prevalence and susceptibility of Shigella to 11 antibiotics in a Kuwait    teaching hospital. J Chemother 1998; 10: 285-90.         [ Links ]66.- COX CE, SHERRILL M, COCCHETT DM. Evaluation    of cefuroxime axetil, cefaclor, and cephalexin in the treatment of urinary tract    infections in adults. Curr Ther Res 1987; 42: 124-37.         [ Links ]67.- SANDERS C W, GREENBERG R N, MARIER R    L. Cefamandole and cefoxitin. Ann Intern Med 1985; 103: 70-8.          [ Links ]68.- STAPLEY E P, JACKSON M, HERNANDEZ S et    al. Cephamycins, a new family of ß-lactam antibiotics I. Production actinomycetes,    including Streptomyces lactamdurans spp.n. Antimicrob Agents Chemother    1972; 2: 122-31.         [ Links ]69.- COOPER R D G. The carbacephems a new    ß-lactams class. Am J Med 1992; 92 (Suppl 6 A): 25-65.         [ Links ]70.- ZEMELMAN R, BELLO H, DOMINGUEZ M, GONZALEZ    G, MELLA S, GARCIA A. Activity of imipenem, third-generation cephalosporins,    aztreonam, and ciprofloxacin against multi-resistant Gram negative bacilli isolated    from Chilean hospitals. J Antimicrob Chemother 1993; 32: 413-9.         [ Links ]71.- MEDEIROS A A. Evolution and dissemination    of ß-lactamases accelerated by generation of ß-lactam antibiotics.    Clin Infect Dis 1997; 24 (Suppl. 1): 19-45.         [ Links ]72.- PERRY C M, BROGDEN R N. Cefuroxime axetil:    review of its antibacterial activity, pharmacokinetic properties and therapeutic    efficacy. Drugs 1996; 52: 125-58.         [ Links ]73.- SCHAAD U B, SUTER S, GIANELLA-BORRADORI    et al. A comparison of ceftriaxone and cefuroxime for the treatment of bacterial    meningitis in children. N Engl J Med 1990; 322: 141-7.         [ Links ]74.- KLEIN N C, CUNHA B A. Cefalosporinas de    la tercera generación. Clin Med Nort Am 1995; 79: 693-707.         [ Links ]75.- KLUGMAN K P, MADHI S A. Emergence of    drug resistance impact on bacterial meningitis. Infect Dis Clin North Am 1999;    13: 637-46.         [ Links ]76.- RICHARDS D M, BROGDEN R N. Ceftazidime.    A review of its antibacterial activity, pharmacokinetic properties and therapeutic    use. Drugs 1985; 29: 105-61.         [ Links ]77.- SCHATZ B S, KARAVOKIROS K T, TAEUBEL    M A, ITOKAZU G S. Comparison of cefprozil, cefpodoxime proxetil, loracarbef,    cefixime, and ceftibuten. Ann Pharmacother 1996; 30: 258-68.         [ Links ]78.- DALMAU D, LAYRARGUES G P, FENYVES D,    WILLEMS B, TURGEON F, TURGEON P. Cefotaxime, desacetyl-cefotaxime, and bactericidal    activity in spontaneous bacterial peritonitis. J Infect Dis 1999; 180: 1597-1602.          [ Links ]79.- NIKAIDO W, LIU W, ROSENBERG E Y. Outer    membrane permeability and ß-lactamase stability of dipolar ionic cephalosporins    containing methoxyimino substituents. Antimicrob Agents Chemother 1990; 34:    337-42.         [ Links ]80.- HANCOCK R E W, BELLIDO F. Factors involved    in the enhanced efficacy against gram-negative bacteria of fourth generation    cephalosporins. J Antimicrob Chemother 1992; 29(Suppl A): 1-6.         [ Links ]81.- BELLIDO F, PECHERE J C, HANCOCK REW.    Novel method for measurement of outer membrane permeability to new beta-lactams    in intact Enterobacter cloacae cells. Antimicrob Agents Chemother 1991;    35: 68-72.         [ Links ]82.- NEU H C, CHIN N X, JULES K, LABTHAVIKUL    P. The activity of BMY-28142, a new broad spectrum beta-lactamase stable cephalosporin.    J Antimicrob Chemother 1986; 17: 441-52.         [ Links ]83.- KOBAYASHI S, ARAI S, HAYASHI S, FUJIMOTO    K. ß-lactamase stability of cefpirome (HR 810), a new cephalosporin with    a broad antimicrobial spectrum. Antimicrob Agents Chemother 1986; 30: 713-8.          [ Links ]84.- GARAU J, WILSON W, WOOD M, CARLET J.    Fourth generation cephalosporins: a review of in vitro activity, pharmacokinetics,    pharmacodynamics, and clinical utility. Clin Microb Infect 1997; 3 (Suppl 1):    87-101.         [ Links ]85.- KESSLER R E, FUNG-TOMC J. Susceptibility    of bacterial isolates to beta-lactam antibiotics from U.S. clinical trials over    5-year period. Am J Med 1996; 24 (6 A): 13-9.         [ Links ]86.- PIERARD D, EMMERECHTS K, LAUWERS S. Comparative    in-vitro activity of cefpirome against isolates from intensive care and haematology/oncology    units. Belgian Multicentric Study Group. J Antimicrob Chemother 1998; 41: 443-50.          [ Links ]87.- JONES R N. Resistance patterns among    nosocomial pathogens: trends over the past few years. Chest 2001; 119 (Suppl    2): 397-404.         [ Links ]88.- LORBER B. Changing patterns of infectious    diseases. Am J Med 1988; 84: 569-78.         [ Links ]89.- MOELLERING R C. A novel antimicrobial    agent joins the battle against resistant bacteria. Ann Intern Med 1999; 130:    155-7.         [ Links ]90.- WILSON W R. The role of fourth-generation    cephalosporins in the treatment of serious infectious diseases in hospitalized    patients. Diagn Microbiol Infect Dis 1998; 31: 473-7.         [ Links ]Correspondencia a:        Sergio Mella Montecinos        Laboratorio de Antibióticos,        Departamento de Microbiología,        Facultad de Ciencias Biológicas        Casilla 160-C, Concepción        E-mail: pignatio@ctcinternet.cl  

41.- LOPEZ F, GARRIDO J C. Química    y relación estructura-actividad de los antibióticos cefalosporínicos.    Rev Col Químico Farmacéutico 1989; 41: 5-14.         [ Links ]42.- FU K P, ASWAPOKEE P, HO I, MATTHIJSSEN    C, NEU H C. Pharmacokinetics of cefotaxime. Antimicrob Agents Chemother 1979;16:    592-7.         [ Links ]43.- YUK J H, NIGHTINGALE C H, QUINTILIANI    R. Clinical pharmacokinetics of ceftriaxone. Clin Pharmacokinetic 1989; 17:    223-35.         [ Links ]44.- BRYSKIER A, PROCYK T, LABRO M T. Cefodizime,    a new 2-aminothiazolyl cephalosporin: physicochemical properties, toxicology    and structure-activity relationships. J Antimicrob Chemother 1990; 26 (Suppl    C): 1-8.         [ Links ]45.- CRITCHLEY I A, BASKER M J, EDMONDSON    R A, KNOTT S J. Uptake of catecholic cephalosporin by the iron transport system    of Escherichia coli. J Antimicrob Chemother 1991; 28: 377-88.         [ Links ]46.- CRITCHLEY I A. Catecholic ß-lactams:    facilitated transport. J Antimicrob Chemother 1990; 26: 733-7.         [ Links ]47.- JONES R N, ERWIN M E. In vitro evaluation    of Ro 09-1227, a novel catechol-substituted cephalosporin. Antimicrob Agents    Chemother 1992; 36: 233-8.         [ Links ]48.- JONES R N. In vitro activity of Ro 24-6392,    a novel ester-linked co-drug combining ciprofloxacin and desacetylcefotaxime.    Eur J Clin Microbiol Infect Dis 1990; 9: 435-8.         [ Links ]49.- TOMASZ A. Penicillin-binding proteins    and the antibacterial effectiveness of ß-lactam antibiotics. Rev Infect    Dis 1986 (Suppl 3); 8: 260-78.         [ Links ]50.- HOLM S E. Interaction between ß-lactam    and other antibiotics. Rev Infect Dis 1986 (Suppl 3); 8: 305-14.         [ Links ]51.- MC CULLERS J A, ENGLISH B K, NOVAK R.    Isolation and characterization of vancomycin-tolerant Streptococcus pneumoniae    from the cerebrospinal fluid of a patient who developed recrudescet meningitis.    J Infect Dis 2000; 181: 369-73.         [ Links ]52.- NIKAIDO H. Outer membrane barrier as    a mechanism of antimicrobial resistance. Antimicrob Agents Chemother 1989; 33:    1831-6.         [ Links ]53.- BARRADELL L B, BRYSON H M. Cefepime.    A review of its antibacterial activity, pharmacokinetic properties and therapeutic    use. Drugs 1994; 47: 471-505.         [ Links ]54.- O'CALLAGHAN C H 1979. Description and    classification of the newer cephalosporins and their relationship with the established    compounds. J Antimicrob Chemother 5: 635-71         [ Links ]55.- BRYSKIER A, PROCYK T, TREMBLAY D, LENFANT    B FOURTILLAN J B. The pharmacokinetics of cefodizime following intravenous and    intramuscular administration of a single dose of 1.0 g. J Antimicrob Chemother    1990; 26 (Suppl. C): 59-63.         [ Links ]56.- WILLIAMS J D. Classification of cephalosporins.    Drugs. 1987; 34 (Suppl 2): 15-22.         [ Links ]57.- WISEMAN L R, LAMB H M. Cefpirome. A review    of its antibacterial activity, pharmacokinetic properties and efficacy in the    treatment of severe nosocomial infections and febrile neutropenia. Drugs 1997;    57: 117-40.         [ Links ]58.- PECHERE J C, WILSON W, NEU H. Laboratory    assesment of antibacterial activity of zwitterionic 7-methoxyimino cephalosporins.    J Antimicrob Chemother 1995; 36: 757-71         [ Links ]59.- GIAMARELLOS-BOURBOULIS EJ, GRECKA P,    TSITSIKA A, TYMPANIDOU C, GIAMARELLOU H. In-vitro activity of FK 037 (cefoselis),    a novel 4 (th) generation cephalosporin, cefepime and cefpirome on nosocomial    staphylococci and gram-negative isolates. Diagn Microbiol infect Dis 2000; 36:    185-91.         [ Links ]60.- JONES R N, ERWIN M E, BARRETT M S, JOHNSON    D M, BRIGGS B M. Antimicrobial activity of E-1040, a novel thiadiazolyl cephalosporin    compare with parenteral cephems. Diagn Microbiol infect Dis 1991; 14: 301-9.          [ Links ]61.- IIZAWA Y, OKONOGI K, HAYASHI R, IWAHI    T, YAMAZAKI T, IMADA A. Therapeutic effect of cefozopran (SCE-2787), a new parenteral    cephalosporin in experimental infections in mice. Antimicrob Agents Chemother    1993; 37: 100-5.         [ Links ]62.- WATANABE N A. Newer antipseudomonal cephalosporins.    J Chemother 1996; 8 (Suppl 2): 48-56.         [ Links ]63.- ACTOR P, GUARINI J, URI J et al. Disk    susceptibility studies with cefazolin and cephalotin. Antimicrob Agents Chemother    1974; 5: 63-7.         [ Links ]64.- UWAYDAH M. Cefazolin in the treatment    of acute enteric fever. Antimicrob Agents Chemother 1976; 10: 52-6.         [ Links ]65.- JAMAL W Y, ROTIMI V O, CHUGH T D, PAL    T. Prevalence and susceptibility of Shigella to 11 antibiotics in a Kuwait    teaching hospital. J Chemother 1998; 10: 285-90.         [ Links ]66.- COX CE, SHERRILL M, COCCHETT DM. Evaluation    of cefuroxime axetil, cefaclor, and cephalexin in the treatment of urinary tract    infections in adults. Curr Ther Res 1987; 42: 124-37.         [ Links ]67.- SANDERS C W, GREENBERG R N, MARIER R    L. Cefamandole and cefoxitin. Ann Intern Med 1985; 103: 70-8.          [ Links ]68.- STAPLEY E P, JACKSON M, HERNANDEZ S et    al. Cephamycins, a new family of ß-lactam antibiotics I. Production actinomycetes,    including Streptomyces lactamdurans spp.n. Antimicrob Agents Chemother    1972; 2: 122-31.         [ Links ]69.- COOPER R D G. The carbacephems a new    ß-lactams class. Am J Med 1992; 92 (Suppl 6 A): 25-65.         [ Links ]70.- ZEMELMAN R, BELLO H, DOMINGUEZ M, GONZALEZ    G, MELLA S, GARCIA A. Activity of imipenem, third-generation cephalosporins,    aztreonam, and ciprofloxacin against multi-resistant Gram negative bacilli isolated    from Chilean hospitals. J Antimicrob Chemother 1993; 32: 413-9.         [ Links ]71.- MEDEIROS A A. Evolution and dissemination    of ß-lactamases accelerated by generation of ß-lactam antibiotics.    Clin Infect Dis 1997; 24 (Suppl. 1): 19-45.         [ Links ]72.- PERRY C M, BROGDEN R N. Cefuroxime axetil:    review of its antibacterial activity, pharmacokinetic properties and therapeutic    efficacy. Drugs 1996; 52: 125-58.         [ Links ]73.- SCHAAD U B, SUTER S, GIANELLA-BORRADORI    et al. A comparison of ceftriaxone and cefuroxime for the treatment of bacterial    meningitis in children. N Engl J Med 1990; 322: 141-7.         [ Links ]74.- KLEIN N C, CUNHA B A. Cefalosporinas de    la tercera generación. Clin Med Nort Am 1995; 79: 693-707.         [ Links ]75.- KLUGMAN K P, MADHI S A. Emergence of    drug resistance impact on bacterial meningitis. Infect Dis Clin North Am 1999;    13: 637-46.         [ Links ]76.- RICHARDS D M, BROGDEN R N. Ceftazidime.    A review of its antibacterial activity, pharmacokinetic properties and therapeutic    use. Drugs 1985; 29: 105-61.         [ Links ]77.- SCHATZ B S, KARAVOKIROS K T, TAEUBEL    M A, ITOKAZU G S. Comparison of cefprozil, cefpodoxime proxetil, loracarbef,    cefixime, and ceftibuten. Ann Pharmacother 1996; 30: 258-68.         [ Links ]78.- DALMAU D, LAYRARGUES G P, FENYVES D,    WILLEMS B, TURGEON F, TURGEON P. Cefotaxime, desacetyl-cefotaxime, and bactericidal    activity in spontaneous bacterial peritonitis. J Infect Dis 1999; 180: 1597-1602.          [ Links ]79.- NIKAIDO W, LIU W, ROSENBERG E Y. Outer    membrane permeability and ß-lactamase stability of dipolar ionic cephalosporins    containing methoxyimino substituents. Antimicrob Agents Chemother 1990; 34:    337-42.         [ Links ]80.- HANCOCK R E W, BELLIDO F. Factors involved    in the enhanced efficacy against gram-negative bacteria of fourth generation    cephalosporins. J Antimicrob Chemother 1992; 29(Suppl A): 1-6.         [ Links ]81.- BELLIDO F, PECHERE J C, HANCOCK REW.    Novel method for measurement of outer membrane permeability to new beta-lactams    in intact Enterobacter cloacae cells. Antimicrob Agents Chemother 1991;    35: 68-72.         [ Links ]82.- NEU H C, CHIN N X, JULES K, LABTHAVIKUL    P. The activity of BMY-28142, a new broad spectrum beta-lactamase stable cephalosporin.    J Antimicrob Chemother 1986; 17: 441-52.         [ Links ]83.- KOBAYASHI S, ARAI S, HAYASHI S, FUJIMOTO    K. ß-lactamase stability of cefpirome (HR 810), a new cephalosporin with    a broad antimicrobial spectrum. Antimicrob Agents Chemother 1986; 30: 713-8.          [ Links ]84.- GARAU J, WILSON W, WOOD M, CARLET J.    Fourth generation cephalosporins: a review of in vitro activity, pharmacokinetics,    pharmacodynamics, and clinical utility. Clin Microb Infect 1997; 3 (Suppl 1):    87-101.         [ Links ]85.- KESSLER R E, FUNG-TOMC J. Susceptibility    of bacterial isolates to beta-lactam antibiotics from U.S. clinical trials over    5-year period. Am J Med 1996; 24 (6 A): 13-9.         [ Links ]86.- PIERARD D, EMMERECHTS K, LAUWERS S. Comparative    in-vitro activity of cefpirome against isolates from intensive care and haematology/oncology    units. Belgian Multicentric Study Group. J Antimicrob Chemother 1998; 41: 443-50.          [ Links ]87.- JONES R N. Resistance patterns among    nosocomial pathogens: trends over the past few years. Chest 2001; 119 (Suppl    2): 397-404.         [ Links ]88.- LORBER B. Changing patterns of infectious    diseases. Am J Med 1988; 84: 569-78.         [ Links ]89.- MOELLERING R C. A novel antimicrobial    agent joins the battle against resistant bacteria. Ann Intern Med 1999; 130:    155-7.         [ Links ]90.- WILSON W R. The role of fourth-generation    cephalosporins in the treatment of serious infectious diseases in hospitalized    patients. Diagn Microbiol Infect Dis 1998; 31: 473-7.         [ Links ]Correspondencia a:        Sergio Mella Montecinos        Laboratorio de Antibióticos,        Departamento de Microbiología,        Facultad de Ciencias Biológicas        Casilla 160-C, Concepción        E-mail: pignatio@ctcinternet.cl  

42.- FU K P, ASWAPOKEE P, HO I, MATTHIJSSEN    C, NEU H C. Pharmacokinetics of cefotaxime. Antimicrob Agents Chemother 1979;16:    592-7.         [ Links ]43.- YUK J H, NIGHTINGALE C H, QUINTILIANI    R. Clinical pharmacokinetics of ceftriaxone. Clin Pharmacokinetic 1989; 17:    223-35.         [ Links ]44.- BRYSKIER A, PROCYK T, LABRO M T. Cefodizime,    a new 2-aminothiazolyl cephalosporin: physicochemical properties, toxicology    and structure-activity relationships. J Antimicrob Chemother 1990; 26 (Suppl    C): 1-8.         [ Links ]45.- CRITCHLEY I A, BASKER M J, EDMONDSON    R A, KNOTT S J. Uptake of catecholic cephalosporin by the iron transport system    of Escherichia coli. J Antimicrob Chemother 1991; 28: 377-88.         [ Links ]46.- CRITCHLEY I A. Catecholic ß-lactams:    facilitated transport. J Antimicrob Chemother 1990; 26: 733-7.         [ Links ]47.- JONES R N, ERWIN M E. In vitro evaluation    of Ro 09-1227, a novel catechol-substituted cephalosporin. Antimicrob Agents    Chemother 1992; 36: 233-8.         [ Links ]48.- JONES R N. In vitro activity of Ro 24-6392,    a novel ester-linked co-drug combining ciprofloxacin and desacetylcefotaxime.    Eur J Clin Microbiol Infect Dis 1990; 9: 435-8.         [ Links ]49.- TOMASZ A. Penicillin-binding proteins    and the antibacterial effectiveness of ß-lactam antibiotics. Rev Infect    Dis 1986 (Suppl 3); 8: 260-78.         [ Links ]50.- HOLM S E. Interaction between ß-lactam    and other antibiotics. Rev Infect Dis 1986 (Suppl 3); 8: 305-14.         [ Links ]51.- MC CULLERS J A, ENGLISH B K, NOVAK R.    Isolation and characterization of vancomycin-tolerant Streptococcus pneumoniae    from the cerebrospinal fluid of a patient who developed recrudescet meningitis.    J Infect Dis 2000; 181: 369-73.         [ Links ]52.- NIKAIDO H. Outer membrane barrier as    a mechanism of antimicrobial resistance. Antimicrob Agents Chemother 1989; 33:    1831-6.         [ Links ]53.- BARRADELL L B, BRYSON H M. Cefepime.    A review of its antibacterial activity, pharmacokinetic properties and therapeutic    use. Drugs 1994; 47: 471-505.         [ Links ]54.- O'CALLAGHAN C H 1979. Description and    classification of the newer cephalosporins and their relationship with the established    compounds. J Antimicrob Chemother 5: 635-71         [ Links ]55.- BRYSKIER A, PROCYK T, TREMBLAY D, LENFANT    B FOURTILLAN J B. The pharmacokinetics of cefodizime following intravenous and    intramuscular administration of a single dose of 1.0 g. J Antimicrob Chemother    1990; 26 (Suppl. C): 59-63.         [ Links ]56.- WILLIAMS J D. Classification of cephalosporins.    Drugs. 1987; 34 (Suppl 2): 15-22.         [ Links ]57.- WISEMAN L R, LAMB H M. Cefpirome. A review    of its antibacterial activity, pharmacokinetic properties and efficacy in the    treatment of severe nosocomial infections and febrile neutropenia. Drugs 1997;    57: 117-40.         [ Links ]58.- PECHERE J C, WILSON W, NEU H. Laboratory    assesment of antibacterial activity of zwitterionic 7-methoxyimino cephalosporins.    J Antimicrob Chemother 1995; 36: 757-71         [ Links ]59.- GIAMARELLOS-BOURBOULIS EJ, GRECKA P,    TSITSIKA A, TYMPANIDOU C, GIAMARELLOU H. In-vitro activity of FK 037 (cefoselis),    a novel 4 (th) generation cephalosporin, cefepime and cefpirome on nosocomial    staphylococci and gram-negative isolates. Diagn Microbiol infect Dis 2000; 36:    185-91.         [ Links ]60.- JONES R N, ERWIN M E, BARRETT M S, JOHNSON    D M, BRIGGS B M. Antimicrobial activity of E-1040, a novel thiadiazolyl cephalosporin    compare with parenteral cephems. Diagn Microbiol infect Dis 1991; 14: 301-9.          [ Links ]61.- IIZAWA Y, OKONOGI K, HAYASHI R, IWAHI    T, YAMAZAKI T, IMADA A. Therapeutic effect of cefozopran (SCE-2787), a new parenteral    cephalosporin in experimental infections in mice. Antimicrob Agents Chemother    1993; 37: 100-5.         [ Links ]62.- WATANABE N A. Newer antipseudomonal cephalosporins.    J Chemother 1996; 8 (Suppl 2): 48-56.         [ Links ]63.- ACTOR P, GUARINI J, URI J et al. Disk    susceptibility studies with cefazolin and cephalotin. Antimicrob Agents Chemother    1974; 5: 63-7.         [ Links ]64.- UWAYDAH M. Cefazolin in the treatment    of acute enteric fever. Antimicrob Agents Chemother 1976; 10: 52-6.         [ Links ]65.- JAMAL W Y, ROTIMI V O, CHUGH T D, PAL    T. Prevalence and susceptibility of Shigella to 11 antibiotics in a Kuwait    teaching hospital. J Chemother 1998; 10: 285-90.         [ Links ]66.- COX CE, SHERRILL M, COCCHETT DM. Evaluation    of cefuroxime axetil, cefaclor, and cephalexin in the treatment of urinary tract    infections in adults. Curr Ther Res 1987; 42: 124-37.         [ Links ]67.- SANDERS C W, GREENBERG R N, MARIER R    L. Cefamandole and cefoxitin. Ann Intern Med 1985; 103: 70-8.          [ Links ]68.- STAPLEY E P, JACKSON M, HERNANDEZ S et    al. Cephamycins, a new family of ß-lactam antibiotics I. Production actinomycetes,    including Streptomyces lactamdurans spp.n. Antimicrob Agents Chemother    1972; 2: 122-31.         [ Links ]69.- COOPER R D G. The carbacephems a new    ß-lactams class. Am J Med 1992; 92 (Suppl 6 A): 25-65.         [ Links ]70.- ZEMELMAN R, BELLO H, DOMINGUEZ M, GONZALEZ    G, MELLA S, GARCIA A. Activity of imipenem, third-generation cephalosporins,    aztreonam, and ciprofloxacin against multi-resistant Gram negative bacilli isolated    from Chilean hospitals. J Antimicrob Chemother 1993; 32: 413-9.         [ Links ]71.- MEDEIROS A A. Evolution and dissemination    of ß-lactamases accelerated by generation of ß-lactam antibiotics.    Clin Infect Dis 1997; 24 (Suppl. 1): 19-45.         [ Links ]72.- PERRY C M, BROGDEN R N. Cefuroxime axetil:    review of its antibacterial activity, pharmacokinetic properties and therapeutic    efficacy. Drugs 1996; 52: 125-58.         [ Links ]73.- SCHAAD U B, SUTER S, GIANELLA-BORRADORI    et al. A comparison of ceftriaxone and cefuroxime for the treatment of bacterial    meningitis in children. N Engl J Med 1990; 322: 141-7.         [ Links ]74.- KLEIN N C, CUNHA B A. Cefalosporinas de    la tercera generación. Clin Med Nort Am 1995; 79: 693-707.         [ Links ]75.- KLUGMAN K P, MADHI S A. Emergence of    drug resistance impact on bacterial meningitis. Infect Dis Clin North Am 1999;    13: 637-46.         [ Links ]76.- RICHARDS D M, BROGDEN R N. Ceftazidime.    A review of its antibacterial activity, pharmacokinetic properties and therapeutic    use. Drugs 1985; 29: 105-61.         [ Links ]77.- SCHATZ B S, KARAVOKIROS K T, TAEUBEL    M A, ITOKAZU G S. Comparison of cefprozil, cefpodoxime proxetil, loracarbef,    cefixime, and ceftibuten. Ann Pharmacother 1996; 30: 258-68.         [ Links ]78.- DALMAU D, LAYRARGUES G P, FENYVES D,    WILLEMS B, TURGEON F, TURGEON P. Cefotaxime, desacetyl-cefotaxime, and bactericidal    activity in spontaneous bacterial peritonitis. J Infect Dis 1999; 180: 1597-1602.          [ Links ]79.- NIKAIDO W, LIU W, ROSENBERG E Y. Outer    membrane permeability and ß-lactamase stability of dipolar ionic cephalosporins    containing methoxyimino substituents. Antimicrob Agents Chemother 1990; 34:    337-42.         [ Links ]80.- HANCOCK R E W, BELLIDO F. Factors involved    in the enhanced efficacy against gram-negative bacteria of fourth generation    cephalosporins. J Antimicrob Chemother 1992; 29(Suppl A): 1-6.         [ Links ]81.- BELLIDO F, PECHERE J C, HANCOCK REW.    Novel method for measurement of outer membrane permeability to new beta-lactams    in intact Enterobacter cloacae cells. Antimicrob Agents Chemother 1991;    35: 68-72.         [ Links ]82.- NEU H C, CHIN N X, JULES K, LABTHAVIKUL    P. The activity of BMY-28142, a new broad spectrum beta-lactamase stable cephalosporin.    J Antimicrob Chemother 1986; 17: 441-52.         [ Links ]83.- KOBAYASHI S, ARAI S, HAYASHI S, FUJIMOTO    K. ß-lactamase stability of cefpirome (HR 810), a new cephalosporin with    a broad antimicrobial spectrum. Antimicrob Agents Chemother 1986; 30: 713-8.          [ Links ]84.- GARAU J, WILSON W, WOOD M, CARLET J.    Fourth generation cephalosporins: a review of in vitro activity, pharmacokinetics,    pharmacodynamics, and clinical utility. Clin Microb Infect 1997; 3 (Suppl 1):    87-101.         [ Links ]85.- KESSLER R E, FUNG-TOMC J. Susceptibility    of bacterial isolates to beta-lactam antibiotics from U.S. clinical trials over    5-year period. Am J Med 1996; 24 (6 A): 13-9.         [ Links ]86.- PIERARD D, EMMERECHTS K, LAUWERS S. Comparative    in-vitro activity of cefpirome against isolates from intensive care and haematology/oncology    units. Belgian Multicentric Study Group. J Antimicrob Chemother 1998; 41: 443-50.          [ Links ]87.- JONES R N. Resistance patterns among    nosocomial pathogens: trends over the past few years. Chest 2001; 119 (Suppl    2): 397-404.         [ Links ]88.- LORBER B. Changing patterns of infectious    diseases. Am J Med 1988; 84: 569-78.         [ Links ]89.- MOELLERING R C. A novel antimicrobial    agent joins the battle against resistant bacteria. Ann Intern Med 1999; 130:    155-7.         [ Links ]90.- WILSON W R. The role of fourth-generation    cephalosporins in the treatment of serious infectious diseases in hospitalized    patients. Diagn Microbiol Infect Dis 1998; 31: 473-7.         [ Links ]Correspondencia a:        Sergio Mella Montecinos        Laboratorio de Antibióticos,        Departamento de Microbiología,        Facultad de Ciencias Biológicas        Casilla 160-C, Concepción        E-mail: pignatio@ctcinternet.cl  

43.- YUK J H, NIGHTINGALE C H, QUINTILIANI    R. Clinical pharmacokinetics of ceftriaxone. Clin Pharmacokinetic 1989; 17:    223-35.         [ Links ]44.- BRYSKIER A, PROCYK T, LABRO M T. Cefodizime,    a new 2-aminothiazolyl cephalosporin: physicochemical properties, toxicology    and structure-activity relationships. J Antimicrob Chemother 1990; 26 (Suppl    C): 1-8.         [ Links ]45.- CRITCHLEY I A, BASKER M J, EDMONDSON    R A, KNOTT S J. Uptake of catecholic cephalosporin by the iron transport system    of Escherichia coli. J Antimicrob Chemother 1991; 28: 377-88.         [ Links ]46.- CRITCHLEY I A. Catecholic ß-lactams:    facilitated transport. J Antimicrob Chemother 1990; 26: 733-7.         [ Links ]47.- JONES R N, ERWIN M E. In vitro evaluation    of Ro 09-1227, a novel catechol-substituted cephalosporin. Antimicrob Agents    Chemother 1992; 36: 233-8.         [ Links ]48.- JONES R N. In vitro activity of Ro 24-6392,    a novel ester-linked co-drug combining ciprofloxacin and desacetylcefotaxime.    Eur J Clin Microbiol Infect Dis 1990; 9: 435-8.         [ Links ]49.- TOMASZ A. Penicillin-binding proteins    and the antibacterial effectiveness of ß-lactam antibiotics. Rev Infect    Dis 1986 (Suppl 3); 8: 260-78.         [ Links ]50.- HOLM S E. Interaction between ß-lactam    and other antibiotics. Rev Infect Dis 1986 (Suppl 3); 8: 305-14.         [ Links ]51.- MC CULLERS J A, ENGLISH B K, NOVAK R.    Isolation and characterization of vancomycin-tolerant Streptococcus pneumoniae    from the cerebrospinal fluid of a patient who developed recrudescet meningitis.    J Infect Dis 2000; 181: 369-73.         [ Links ]52.- NIKAIDO H. Outer membrane barrier as    a mechanism of antimicrobial resistance. Antimicrob Agents Chemother 1989; 33:    1831-6.         [ Links ]53.- BARRADELL L B, BRYSON H M. Cefepime.    A review of its antibacterial activity, pharmacokinetic properties and therapeutic    use. Drugs 1994; 47: 471-505.         [ Links ]54.- O'CALLAGHAN C H 1979. Description and    classification of the newer cephalosporins and their relationship with the established    compounds. J Antimicrob Chemother 5: 635-71         [ Links ]55.- BRYSKIER A, PROCYK T, TREMBLAY D, LENFANT    B FOURTILLAN J B. The pharmacokinetics of cefodizime following intravenous and    intramuscular administration of a single dose of 1.0 g. J Antimicrob Chemother    1990; 26 (Suppl. C): 59-63.         [ Links ]56.- WILLIAMS J D. Classification of cephalosporins.    Drugs. 1987; 34 (Suppl 2): 15-22.         [ Links ]57.- WISEMAN L R, LAMB H M. Cefpirome. A review    of its antibacterial activity, pharmacokinetic properties and efficacy in the    treatment of severe nosocomial infections and febrile neutropenia. Drugs 1997;    57: 117-40.         [ Links ]58.- PECHERE J C, WILSON W, NEU H. Laboratory    assesment of antibacterial activity of zwitterionic 7-methoxyimino cephalosporins.    J Antimicrob Chemother 1995; 36: 757-71         [ Links ]59.- GIAMARELLOS-BOURBOULIS EJ, GRECKA P,    TSITSIKA A, TYMPANIDOU C, GIAMARELLOU H. In-vitro activity of FK 037 (cefoselis),    a novel 4 (th) generation cephalosporin, cefepime and cefpirome on nosocomial    staphylococci and gram-negative isolates. Diagn Microbiol infect Dis 2000; 36:    185-91.         [ Links ]60.- JONES R N, ERWIN M E, BARRETT M S, JOHNSON    D M, BRIGGS B M. Antimicrobial activity of E-1040, a novel thiadiazolyl cephalosporin    compare with parenteral cephems. Diagn Microbiol infect Dis 1991; 14: 301-9.          [ Links ]61.- IIZAWA Y, OKONOGI K, HAYASHI R, IWAHI    T, YAMAZAKI T, IMADA A. Therapeutic effect of cefozopran (SCE-2787), a new parenteral    cephalosporin in experimental infections in mice. Antimicrob Agents Chemother    1993; 37: 100-5.         [ Links ]62.- WATANABE N A. Newer antipseudomonal cephalosporins.    J Chemother 1996; 8 (Suppl 2): 48-56.         [ Links ]63.- ACTOR P, GUARINI J, URI J et al. Disk    susceptibility studies with cefazolin and cephalotin. Antimicrob Agents Chemother    1974; 5: 63-7.         [ Links ]64.- UWAYDAH M. Cefazolin in the treatment    of acute enteric fever. Antimicrob Agents Chemother 1976; 10: 52-6.         [ Links ]65.- JAMAL W Y, ROTIMI V O, CHUGH T D, PAL    T. Prevalence and susceptibility of Shigella to 11 antibiotics in a Kuwait    teaching hospital. J Chemother 1998; 10: 285-90.         [ Links ]66.- COX CE, SHERRILL M, COCCHETT DM. Evaluation    of cefuroxime axetil, cefaclor, and cephalexin in the treatment of urinary tract    infections in adults. Curr Ther Res 1987; 42: 124-37.         [ Links ]67.- SANDERS C W, GREENBERG R N, MARIER R    L. Cefamandole and cefoxitin. Ann Intern Med 1985; 103: 70-8.          [ Links ]68.- STAPLEY E P, JACKSON M, HERNANDEZ S et    al. Cephamycins, a new family of ß-lactam antibiotics I. Production actinomycetes,    including Streptomyces lactamdurans spp.n. Antimicrob Agents Chemother    1972; 2: 122-31.         [ Links ]69.- COOPER R D G. The carbacephems a new    ß-lactams class. Am J Med 1992; 92 (Suppl 6 A): 25-65.         [ Links ]70.- ZEMELMAN R, BELLO H, DOMINGUEZ M, GONZALEZ    G, MELLA S, GARCIA A. Activity of imipenem, third-generation cephalosporins,    aztreonam, and ciprofloxacin against multi-resistant Gram negative bacilli isolated    from Chilean hospitals. J Antimicrob Chemother 1993; 32: 413-9.         [ Links ]71.- MEDEIROS A A. Evolution and dissemination    of ß-lactamases accelerated by generation of ß-lactam antibiotics.    Clin Infect Dis 1997; 24 (Suppl. 1): 19-45.         [ Links ]72.- PERRY C M, BROGDEN R N. Cefuroxime axetil:    review of its antibacterial activity, pharmacokinetic properties and therapeutic    efficacy. Drugs 1996; 52: 125-58.         [ Links ]73.- SCHAAD U B, SUTER S, GIANELLA-BORRADORI    et al. A comparison of ceftriaxone and cefuroxime for the treatment of bacterial    meningitis in children. N Engl J Med 1990; 322: 141-7.         [ Links ]74.- KLEIN N C, CUNHA B A. Cefalosporinas de    la tercera generación. Clin Med Nort Am 1995; 79: 693-707.         [ Links ]75.- KLUGMAN K P, MADHI S A. Emergence of    drug resistance impact on bacterial meningitis. Infect Dis Clin North Am 1999;    13: 637-46.         [ Links ]76.- RICHARDS D M, BROGDEN R N. Ceftazidime.    A review of its antibacterial activity, pharmacokinetic properties and therapeutic    use. Drugs 1985; 29: 105-61.         [ Links ]77.- SCHATZ B S, KARAVOKIROS K T, TAEUBEL    M A, ITOKAZU G S. Comparison of cefprozil, cefpodoxime proxetil, loracarbef,    cefixime, and ceftibuten. Ann Pharmacother 1996; 30: 258-68.         [ Links ]78.- DALMAU D, LAYRARGUES G P, FENYVES D,    WILLEMS B, TURGEON F, TURGEON P. Cefotaxime, desacetyl-cefotaxime, and bactericidal    activity in spontaneous bacterial peritonitis. J Infect Dis 1999; 180: 1597-1602.          [ Links ]79.- NIKAIDO W, LIU W, ROSENBERG E Y. Outer    membrane permeability and ß-lactamase stability of dipolar ionic cephalosporins    containing methoxyimino substituents. Antimicrob Agents Chemother 1990; 34:    337-42.         [ Links ]80.- HANCOCK R E W, BELLIDO F. Factors involved    in the enhanced efficacy against gram-negative bacteria of fourth generation    cephalosporins. J Antimicrob Chemother 1992; 29(Suppl A): 1-6.         [ Links ]81.- BELLIDO F, PECHERE J C, HANCOCK REW.    Novel method for measurement of outer membrane permeability to new beta-lactams    in intact Enterobacter cloacae cells. Antimicrob Agents Chemother 1991;    35: 68-72.         [ Links ]82.- NEU H C, CHIN N X, JULES K, LABTHAVIKUL    P. The activity of BMY-28142, a new broad spectrum beta-lactamase stable cephalosporin.    J Antimicrob Chemother 1986; 17: 441-52.         [ Links ]83.- KOBAYASHI S, ARAI S, HAYASHI S, FUJIMOTO    K. ß-lactamase stability of cefpirome (HR 810), a new cephalosporin with    a broad antimicrobial spectrum. Antimicrob Agents Chemother 1986; 30: 713-8.          [ Links ]84.- GARAU J, WILSON W, WOOD M, CARLET J.    Fourth generation cephalosporins: a review of in vitro activity, pharmacokinetics,    pharmacodynamics, and clinical utility. Clin Microb Infect 1997; 3 (Suppl 1):    87-101.         [ Links ]85.- KESSLER R E, FUNG-TOMC J. Susceptibility    of bacterial isolates to beta-lactam antibiotics from U.S. clinical trials over    5-year period. Am J Med 1996; 24 (6 A): 13-9.         [ Links ]86.- PIERARD D, EMMERECHTS K, LAUWERS S. Comparative    in-vitro activity of cefpirome against isolates from intensive care and haematology/oncology    units. Belgian Multicentric Study Group. J Antimicrob Chemother 1998; 41: 443-50.          [ Links ]87.- JONES R N. Resistance patterns among    nosocomial pathogens: trends over the past few years. Chest 2001; 119 (Suppl    2): 397-404.         [ Links ]88.- LORBER B. Changing patterns of infectious    diseases. Am J Med 1988; 84: 569-78.         [ Links ]89.- MOELLERING R C. A novel antimicrobial    agent joins the battle against resistant bacteria. Ann Intern Med 1999; 130:    155-7.         [ Links ]90.- WILSON W R. The role of fourth-generation    cephalosporins in the treatment of serious infectious diseases in hospitalized    patients. Diagn Microbiol Infect Dis 1998; 31: 473-7.         [ Links ]Correspondencia a:        Sergio Mella Montecinos        Laboratorio de Antibióticos,        Departamento de Microbiología,        Facultad de Ciencias Biológicas        Casilla 160-C, Concepción        E-mail: pignatio@ctcinternet.cl  

44.- BRYSKIER A, PROCYK T, LABRO M T. Cefodizime,    a new 2-aminothiazolyl cephalosporin: physicochemical properties, toxicology    and structure-activity relationships. J Antimicrob Chemother 1990; 26 (Suppl    C): 1-8.         [ Links ]45.- CRITCHLEY I A, BASKER M J, EDMONDSON    R A, KNOTT S J. Uptake of catecholic cephalosporin by the iron transport system    of Escherichia coli. J Antimicrob Chemother 1991; 28: 377-88.         [ Links ]46.- CRITCHLEY I A. Catecholic ß-lactams:    facilitated transport. J Antimicrob Chemother 1990; 26: 733-7.         [ Links ]47.- JONES R N, ERWIN M E. In vitro evaluation    of Ro 09-1227, a novel catechol-substituted cephalosporin. Antimicrob Agents    Chemother 1992; 36: 233-8.         [ Links ]48.- JONES R N. In vitro activity of Ro 24-6392,    a novel ester-linked co-drug combining ciprofloxacin and desacetylcefotaxime.    Eur J Clin Microbiol Infect Dis 1990; 9: 435-8.         [ Links ]49.- TOMASZ A. Penicillin-binding proteins    and the antibacterial effectiveness of ß-lactam antibiotics. Rev Infect    Dis 1986 (Suppl 3); 8: 260-78.         [ Links ]50.- HOLM S E. Interaction between ß-lactam    and other antibiotics. Rev Infect Dis 1986 (Suppl 3); 8: 305-14.         [ Links ]51.- MC CULLERS J A, ENGLISH B K, NOVAK R.    Isolation and characterization of vancomycin-tolerant Streptococcus pneumoniae    from the cerebrospinal fluid of a patient who developed recrudescet meningitis.    J Infect Dis 2000; 181: 369-73.         [ Links ]52.- NIKAIDO H. Outer membrane barrier as    a mechanism of antimicrobial resistance. Antimicrob Agents Chemother 1989; 33:    1831-6.         [ Links ]53.- BARRADELL L B, BRYSON H M. Cefepime.    A review of its antibacterial activity, pharmacokinetic properties and therapeutic    use. Drugs 1994; 47: 471-505.         [ Links ]54.- O'CALLAGHAN C H 1979. Description and    classification of the newer cephalosporins and their relationship with the established    compounds. J Antimicrob Chemother 5: 635-71         [ Links ]55.- BRYSKIER A, PROCYK T, TREMBLAY D, LENFANT    B FOURTILLAN J B. The pharmacokinetics of cefodizime following intravenous and    intramuscular administration of a single dose of 1.0 g. J Antimicrob Chemother    1990; 26 (Suppl. C): 59-63.         [ Links ]56.- WILLIAMS J D. Classification of cephalosporins.    Drugs. 1987; 34 (Suppl 2): 15-22.         [ Links ]57.- WISEMAN L R, LAMB H M. Cefpirome. A review    of its antibacterial activity, pharmacokinetic properties and efficacy in the    treatment of severe nosocomial infections and febrile neutropenia. Drugs 1997;    57: 117-40.         [ Links ]58.- PECHERE J C, WILSON W, NEU H. Laboratory    assesment of antibacterial activity of zwitterionic 7-methoxyimino cephalosporins.    J Antimicrob Chemother 1995; 36: 757-71         [ Links ]59.- GIAMARELLOS-BOURBOULIS EJ, GRECKA P,    TSITSIKA A, TYMPANIDOU C, GIAMARELLOU H. In-vitro activity of FK 037 (cefoselis),    a novel 4 (th) generation cephalosporin, cefepime and cefpirome on nosocomial    staphylococci and gram-negative isolates. Diagn Microbiol infect Dis 2000; 36:    185-91.         [ Links ]60.- JONES R N, ERWIN M E, BARRETT M S, JOHNSON    D M, BRIGGS B M. Antimicrobial activity of E-1040, a novel thiadiazolyl cephalosporin    compare with parenteral cephems. Diagn Microbiol infect Dis 1991; 14: 301-9.          [ Links ]61.- IIZAWA Y, OKONOGI K, HAYASHI R, IWAHI    T, YAMAZAKI T, IMADA A. Therapeutic effect of cefozopran (SCE-2787), a new parenteral    cephalosporin in experimental infections in mice. Antimicrob Agents Chemother    1993; 37: 100-5.         [ Links ]62.- WATANABE N A. Newer antipseudomonal cephalosporins.    J Chemother 1996; 8 (Suppl 2): 48-56.         [ Links ]63.- ACTOR P, GUARINI J, URI J et al. Disk    susceptibility studies with cefazolin and cephalotin. Antimicrob Agents Chemother    1974; 5: 63-7.         [ Links ]64.- UWAYDAH M. Cefazolin in the treatment    of acute enteric fever. Antimicrob Agents Chemother 1976; 10: 52-6.         [ Links ]65.- JAMAL W Y, ROTIMI V O, CHUGH T D, PAL    T. Prevalence and susceptibility of Shigella to 11 antibiotics in a Kuwait    teaching hospital. J Chemother 1998; 10: 285-90.         [ Links ]66.- COX CE, SHERRILL M, COCCHETT DM. Evaluation    of cefuroxime axetil, cefaclor, and cephalexin in the treatment of urinary tract    infections in adults. Curr Ther Res 1987; 42: 124-37.         [ Links ]67.- SANDERS C W, GREENBERG R N, MARIER R    L. Cefamandole and cefoxitin. Ann Intern Med 1985; 103: 70-8.          [ Links ]68.- STAPLEY E P, JACKSON M, HERNANDEZ S et    al. Cephamycins, a new family of ß-lactam antibiotics I. Production actinomycetes,    including Streptomyces lactamdurans spp.n. Antimicrob Agents Chemother    1972; 2: 122-31.         [ Links ]69.- COOPER R D G. The carbacephems a new    ß-lactams class. Am J Med 1992; 92 (Suppl 6 A): 25-65.         [ Links ]70.- ZEMELMAN R, BELLO H, DOMINGUEZ M, GONZALEZ    G, MELLA S, GARCIA A. Activity of imipenem, third-generation cephalosporins,    aztreonam, and ciprofloxacin against multi-resistant Gram negative bacilli isolated    from Chilean hospitals. J Antimicrob Chemother 1993; 32: 413-9.         [ Links ]71.- MEDEIROS A A. Evolution and dissemination    of ß-lactamases accelerated by generation of ß-lactam antibiotics.    Clin Infect Dis 1997; 24 (Suppl. 1): 19-45.         [ Links ]72.- PERRY C M, BROGDEN R N. Cefuroxime axetil:    review of its antibacterial activity, pharmacokinetic properties and therapeutic    efficacy. Drugs 1996; 52: 125-58.         [ Links ]73.- SCHAAD U B, SUTER S, GIANELLA-BORRADORI    et al. A comparison of ceftriaxone and cefuroxime for the treatment of bacterial    meningitis in children. N Engl J Med 1990; 322: 141-7.         [ Links ]74.- KLEIN N C, CUNHA B A. Cefalosporinas de    la tercera generación. Clin Med Nort Am 1995; 79: 693-707.         [ Links ]75.- KLUGMAN K P, MADHI S A. Emergence of    drug resistance impact on bacterial meningitis. Infect Dis Clin North Am 1999;    13: 637-46.         [ Links ]76.- RICHARDS D M, BROGDEN R N. Ceftazidime.    A review of its antibacterial activity, pharmacokinetic properties and therapeutic    use. Drugs 1985; 29: 105-61.         [ Links ]77.- SCHATZ B S, KARAVOKIROS K T, TAEUBEL    M A, ITOKAZU G S. Comparison of cefprozil, cefpodoxime proxetil, loracarbef,    cefixime, and ceftibuten. Ann Pharmacother 1996; 30: 258-68.         [ Links ]78.- DALMAU D, LAYRARGUES G P, FENYVES D,    WILLEMS B, TURGEON F, TURGEON P. Cefotaxime, desacetyl-cefotaxime, and bactericidal    activity in spontaneous bacterial peritonitis. J Infect Dis 1999; 180: 1597-1602.          [ Links ]79.- NIKAIDO W, LIU W, ROSENBERG E Y. Outer    membrane permeability and ß-lactamase stability of dipolar ionic cephalosporins    containing methoxyimino substituents. Antimicrob Agents Chemother 1990; 34:    337-42.         [ Links ]80.- HANCOCK R E W, BELLIDO F. Factors involved    in the enhanced efficacy against gram-negative bacteria of fourth generation    cephalosporins. J Antimicrob Chemother 1992; 29(Suppl A): 1-6.         [ Links ]81.- BELLIDO F, PECHERE J C, HANCOCK REW.    Novel method for measurement of outer membrane permeability to new beta-lactams    in intact Enterobacter cloacae cells. Antimicrob Agents Chemother 1991;    35: 68-72.         [ Links ]82.- NEU H C, CHIN N X, JULES K, LABTHAVIKUL    P. The activity of BMY-28142, a new broad spectrum beta-lactamase stable cephalosporin.    J Antimicrob Chemother 1986; 17: 441-52.         [ Links ]83.- KOBAYASHI S, ARAI S, HAYASHI S, FUJIMOTO    K. ß-lactamase stability of cefpirome (HR 810), a new cephalosporin with    a broad antimicrobial spectrum. Antimicrob Agents Chemother 1986; 30: 713-8.          [ Links ]84.- GARAU J, WILSON W, WOOD M, CARLET J.    Fourth generation cephalosporins: a review of in vitro activity, pharmacokinetics,    pharmacodynamics, and clinical utility. Clin Microb Infect 1997; 3 (Suppl 1):    87-101.         [ Links ]85.- KESSLER R E, FUNG-TOMC J. Susceptibility    of bacterial isolates to beta-lactam antibiotics from U.S. clinical trials over    5-year period. Am J Med 1996; 24 (6 A): 13-9.         [ Links ]86.- PIERARD D, EMMERECHTS K, LAUWERS S. Comparative    in-vitro activity of cefpirome against isolates from intensive care and haematology/oncology    units. Belgian Multicentric Study Group. J Antimicrob Chemother 1998; 41: 443-50.          [ Links ]87.- JONES R N. Resistance patterns among    nosocomial pathogens: trends over the past few years. Chest 2001; 119 (Suppl    2): 397-404.         [ Links ]88.- LORBER B. Changing patterns of infectious    diseases. Am J Med 1988; 84: 569-78.         [ Links ]89.- MOELLERING R C. A novel antimicrobial    agent joins the battle against resistant bacteria. Ann Intern Med 1999; 130:    155-7.         [ Links ]90.- WILSON W R. The role of fourth-generation    cephalosporins in the treatment of serious infectious diseases in hospitalized    patients. Diagn Microbiol Infect Dis 1998; 31: 473-7.         [ Links ]Correspondencia a:        Sergio Mella Montecinos        Laboratorio de Antibióticos,        Departamento de Microbiología,        Facultad de Ciencias Biológicas        Casilla 160-C, Concepción        E-mail: pignatio@ctcinternet.cl  

45.- CRITCHLEY I A, BASKER M J, EDMONDSON    R A, KNOTT S J. Uptake of catecholic cephalosporin by the iron transport system    of Escherichia coli. J Antimicrob Chemother 1991; 28: 377-88.         [ Links ]46.- CRITCHLEY I A. Catecholic ß-lactams:    facilitated transport. J Antimicrob Chemother 1990; 26: 733-7.         [ Links ]47.- JONES R N, ERWIN M E. In vitro evaluation    of Ro 09-1227, a novel catechol-substituted cephalosporin. Antimicrob Agents    Chemother 1992; 36: 233-8.         [ Links ]48.- JONES R N. In vitro activity of Ro 24-6392,    a novel ester-linked co-drug combining ciprofloxacin and desacetylcefotaxime.    Eur J Clin Microbiol Infect Dis 1990; 9: 435-8.         [ Links ]49.- TOMASZ A. Penicillin-binding proteins    and the antibacterial effectiveness of ß-lactam antibiotics. Rev Infect    Dis 1986 (Suppl 3); 8: 260-78.         [ Links ]50.- HOLM S E. Interaction between ß-lactam    and other antibiotics. Rev Infect Dis 1986 (Suppl 3); 8: 305-14.         [ Links ]51.- MC CULLERS J A, ENGLISH B K, NOVAK R.    Isolation and characterization of vancomycin-tolerant Streptococcus pneumoniae    from the cerebrospinal fluid of a patient who developed recrudescet meningitis.    J Infect Dis 2000; 181: 369-73.         [ Links ]52.- NIKAIDO H. Outer membrane barrier as    a mechanism of antimicrobial resistance. Antimicrob Agents Chemother 1989; 33:    1831-6.         [ Links ]53.- BARRADELL L B, BRYSON H M. Cefepime.    A review of its antibacterial activity, pharmacokinetic properties and therapeutic    use. Drugs 1994; 47: 471-505.         [ Links ]54.- O'CALLAGHAN C H 1979. Description and    classification of the newer cephalosporins and their relationship with the established    compounds. J Antimicrob Chemother 5: 635-71         [ Links ]55.- BRYSKIER A, PROCYK T, TREMBLAY D, LENFANT    B FOURTILLAN J B. The pharmacokinetics of cefodizime following intravenous and    intramuscular administration of a single dose of 1.0 g. J Antimicrob Chemother    1990; 26 (Suppl. C): 59-63.         [ Links ]56.- WILLIAMS J D. Classification of cephalosporins.    Drugs. 1987; 34 (Suppl 2): 15-22.         [ Links ]57.- WISEMAN L R, LAMB H M. Cefpirome. A review    of its antibacterial activity, pharmacokinetic properties and efficacy in the    treatment of severe nosocomial infections and febrile neutropenia. Drugs 1997;    57: 117-40.         [ Links ]58.- PECHERE J C, WILSON W, NEU H. Laboratory    assesment of antibacterial activity of zwitterionic 7-methoxyimino cephalosporins.    J Antimicrob Chemother 1995; 36: 757-71         [ Links ]59.- GIAMARELLOS-BOURBOULIS EJ, GRECKA P,    TSITSIKA A, TYMPANIDOU C, GIAMARELLOU H. In-vitro activity of FK 037 (cefoselis),    a novel 4 (th) generation cephalosporin, cefepime and cefpirome on nosocomial    staphylococci and gram-negative isolates. Diagn Microbiol infect Dis 2000; 36:    185-91.         [ Links ]60.- JONES R N, ERWIN M E, BARRETT M S, JOHNSON    D M, BRIGGS B M. Antimicrobial activity of E-1040, a novel thiadiazolyl cephalosporin    compare with parenteral cephems. Diagn Microbiol infect Dis 1991; 14: 301-9.          [ Links ]61.- IIZAWA Y, OKONOGI K, HAYASHI R, IWAHI    T, YAMAZAKI T, IMADA A. Therapeutic effect of cefozopran (SCE-2787), a new parenteral    cephalosporin in experimental infections in mice. Antimicrob Agents Chemother    1993; 37: 100-5.         [ Links ]62.- WATANABE N A. Newer antipseudomonal cephalosporins.    J Chemother 1996; 8 (Suppl 2): 48-56.         [ Links ]63.- ACTOR P, GUARINI J, URI J et al. Disk    susceptibility studies with cefazolin and cephalotin. Antimicrob Agents Chemother    1974; 5: 63-7.         [ Links ]64.- UWAYDAH M. Cefazolin in the treatment    of acute enteric fever. Antimicrob Agents Chemother 1976; 10: 52-6.         [ Links ]65.- JAMAL W Y, ROTIMI V O, CHUGH T D, PAL    T. Prevalence and susceptibility of Shigella to 11 antibiotics in a Kuwait    teaching hospital. J Chemother 1998; 10: 285-90.         [ Links ]66.- COX CE, SHERRILL M, COCCHETT DM. Evaluation    of cefuroxime axetil, cefaclor, and cephalexin in the treatment of urinary tract    infections in adults. Curr Ther Res 1987; 42: 124-37.         [ Links ]67.- SANDERS C W, GREENBERG R N, MARIER R    L. Cefamandole and cefoxitin. Ann Intern Med 1985; 103: 70-8.          [ Links ]68.- STAPLEY E P, JACKSON M, HERNANDEZ S et    al. Cephamycins, a new family of ß-lactam antibiotics I. Production actinomycetes,    including Streptomyces lactamdurans spp.n. Antimicrob Agents Chemother    1972; 2: 122-31.         [ Links ]69.- COOPER R D G. The carbacephems a new    ß-lactams class. Am J Med 1992; 92 (Suppl 6 A): 25-65.         [ Links ]70.- ZEMELMAN R, BELLO H, DOMINGUEZ M, GONZALEZ    G, MELLA S, GARCIA A. Activity of imipenem, third-generation cephalosporins,    aztreonam, and ciprofloxacin against multi-resistant Gram negative bacilli isolated    from Chilean hospitals. J Antimicrob Chemother 1993; 32: 413-9.         [ Links ]71.- MEDEIROS A A. Evolution and dissemination    of ß-lactamases accelerated by generation of ß-lactam antibiotics.    Clin Infect Dis 1997; 24 (Suppl. 1): 19-45.         [ Links ]72.- PERRY C M, BROGDEN R N. Cefuroxime axetil:    review of its antibacterial activity, pharmacokinetic properties and therapeutic    efficacy. Drugs 1996; 52: 125-58.         [ Links ]73.- SCHAAD U B, SUTER S, GIANELLA-BORRADORI    et al. A comparison of ceftriaxone and cefuroxime for the treatment of bacterial    meningitis in children. N Engl J Med 1990; 322: 141-7.         [ Links ]74.- KLEIN N C, CUNHA B A. Cefalosporinas de    la tercera generación. Clin Med Nort Am 1995; 79: 693-707.         [ Links ]75.- KLUGMAN K P, MADHI S A. Emergence of    drug resistance impact on bacterial meningitis. Infect Dis Clin North Am 1999;    13: 637-46.         [ Links ]76.- RICHARDS D M, BROGDEN R N. Ceftazidime.    A review of its antibacterial activity, pharmacokinetic properties and therapeutic    use. Drugs 1985; 29: 105-61.         [ Links ]77.- SCHATZ B S, KARAVOKIROS K T, TAEUBEL    M A, ITOKAZU G S. Comparison of cefprozil, cefpodoxime proxetil, loracarbef,    cefixime, and ceftibuten. Ann Pharmacother 1996; 30: 258-68.         [ Links ]78.- DALMAU D, LAYRARGUES G P, FENYVES D,    WILLEMS B, TURGEON F, TURGEON P. Cefotaxime, desacetyl-cefotaxime, and bactericidal    activity in spontaneous bacterial peritonitis. J Infect Dis 1999; 180: 1597-1602.          [ Links ]79.- NIKAIDO W, LIU W, ROSENBERG E Y. Outer    membrane permeability and ß-lactamase stability of dipolar ionic cephalosporins    containing methoxyimino substituents. Antimicrob Agents Chemother 1990; 34:    337-42.         [ Links ]80.- HANCOCK R E W, BELLIDO F. Factors involved    in the enhanced efficacy against gram-negative bacteria of fourth generation    cephalosporins. J Antimicrob Chemother 1992; 29(Suppl A): 1-6.         [ Links ]81.- BELLIDO F, PECHERE J C, HANCOCK REW.    Novel method for measurement of outer membrane permeability to new beta-lactams    in intact Enterobacter cloacae cells. Antimicrob Agents Chemother 1991;    35: 68-72.         [ Links ]82.- NEU H C, CHIN N X, JULES K, LABTHAVIKUL    P. The activity of BMY-28142, a new broad spectrum beta-lactamase stable cephalosporin.    J Antimicrob Chemother 1986; 17: 441-52.         [ Links ]83.- KOBAYASHI S, ARAI S, HAYASHI S, FUJIMOTO    K. ß-lactamase stability of cefpirome (HR 810), a new cephalosporin with    a broad antimicrobial spectrum. Antimicrob Agents Chemother 1986; 30: 713-8.          [ Links ]84.- GARAU J, WILSON W, WOOD M, CARLET J.    Fourth generation cephalosporins: a review of in vitro activity, pharmacokinetics,    pharmacodynamics, and clinical utility. Clin Microb Infect 1997; 3 (Suppl 1):    87-101.         [ Links ]85.- KESSLER R E, FUNG-TOMC J. Susceptibility    of bacterial isolates to beta-lactam antibiotics from U.S. clinical trials over    5-year period. Am J Med 1996; 24 (6 A): 13-9.         [ Links ]86.- PIERARD D, EMMERECHTS K, LAUWERS S. Comparative    in-vitro activity of cefpirome against isolates from intensive care and haematology/oncology    units. Belgian Multicentric Study Group. J Antimicrob Chemother 1998; 41: 443-50.          [ Links ]87.- JONES R N. Resistance patterns among    nosocomial pathogens: trends over the past few years. Chest 2001; 119 (Suppl    2): 397-404.         [ Links ]88.- LORBER B. Changing patterns of infectious    diseases. Am J Med 1988; 84: 569-78.         [ Links ]89.- MOELLERING R C. A novel antimicrobial    agent joins the battle against resistant bacteria. Ann Intern Med 1999; 130:    155-7.         [ Links ]90.- WILSON W R. The role of fourth-generation    cephalosporins in the treatment of serious infectious diseases in hospitalized    patients. Diagn Microbiol Infect Dis 1998; 31: 473-7.         [ Links ]Correspondencia a:        Sergio Mella Montecinos        Laboratorio de Antibióticos,        Departamento de Microbiología,        Facultad de Ciencias Biológicas        Casilla 160-C, Concepción        E-mail: pignatio@ctcinternet.cl  

46.- CRITCHLEY I A. Catecholic ß-lactams:    facilitated transport. J Antimicrob Chemother 1990; 26: 733-7.         [ Links ]47.- JONES R N, ERWIN M E. In vitro evaluation    of Ro 09-1227, a novel catechol-substituted cephalosporin. Antimicrob Agents    Chemother 1992; 36: 233-8.         [ Links ]48.- JONES R N. In vitro activity of Ro 24-6392,    a novel ester-linked co-drug combining ciprofloxacin and desacetylcefotaxime.    Eur J Clin Microbiol Infect Dis 1990; 9: 435-8.         [ Links ]49.- TOMASZ A. Penicillin-binding proteins    and the antibacterial effectiveness of ß-lactam antibiotics. Rev Infect    Dis 1986 (Suppl 3); 8: 260-78.         [ Links ]50.- HOLM S E. Interaction between ß-lactam    and other antibiotics. Rev Infect Dis 1986 (Suppl 3); 8: 305-14.         [ Links ]51.- MC CULLERS J A, ENGLISH B K, NOVAK R.    Isolation and characterization of vancomycin-tolerant Streptococcus pneumoniae    from the cerebrospinal fluid of a patient who developed recrudescet meningitis.    J Infect Dis 2000; 181: 369-73.         [ Links ]52.- NIKAIDO H. Outer membrane barrier as    a mechanism of antimicrobial resistance. Antimicrob Agents Chemother 1989; 33:    1831-6.         [ Links ]53.- BARRADELL L B, BRYSON H M. Cefepime.    A review of its antibacterial activity, pharmacokinetic properties and therapeutic    use. Drugs 1994; 47: 471-505.         [ Links ]54.- O'CALLAGHAN C H 1979. Description and    classification of the newer cephalosporins and their relationship with the established    compounds. J Antimicrob Chemother 5: 635-71         [ Links ]55.- BRYSKIER A, PROCYK T, TREMBLAY D, LENFANT    B FOURTILLAN J B. The pharmacokinetics of cefodizime following intravenous and    intramuscular administration of a single dose of 1.0 g. J Antimicrob Chemother    1990; 26 (Suppl. C): 59-63.         [ Links ]56.- WILLIAMS J D. Classification of cephalosporins.    Drugs. 1987; 34 (Suppl 2): 15-22.         [ Links ]57.- WISEMAN L R, LAMB H M. Cefpirome. A review    of its antibacterial activity, pharmacokinetic properties and efficacy in the    treatment of severe nosocomial infections and febrile neutropenia. Drugs 1997;    57: 117-40.         [ Links ]58.- PECHERE J C, WILSON W, NEU H. Laboratory    assesment of antibacterial activity of zwitterionic 7-methoxyimino cephalosporins.    J Antimicrob Chemother 1995; 36: 757-71         [ Links ]59.- GIAMARELLOS-BOURBOULIS EJ, GRECKA P,    TSITSIKA A, TYMPANIDOU C, GIAMARELLOU H. In-vitro activity of FK 037 (cefoselis),    a novel 4 (th) generation cephalosporin, cefepime and cefpirome on nosocomial    staphylococci and gram-negative isolates. Diagn Microbiol infect Dis 2000; 36:    185-91.         [ Links ]60.- JONES R N, ERWIN M E, BARRETT M S, JOHNSON    D M, BRIGGS B M. Antimicrobial activity of E-1040, a novel thiadiazolyl cephalosporin    compare with parenteral cephems. Diagn Microbiol infect Dis 1991; 14: 301-9.          [ Links ]61.- IIZAWA Y, OKONOGI K, HAYASHI R, IWAHI    T, YAMAZAKI T, IMADA A. Therapeutic effect of cefozopran (SCE-2787), a new parenteral    cephalosporin in experimental infections in mice. Antimicrob Agents Chemother    1993; 37: 100-5.         [ Links ]62.- WATANABE N A. Newer antipseudomonal cephalosporins.    J Chemother 1996; 8 (Suppl 2): 48-56.         [ Links ]63.- ACTOR P, GUARINI J, URI J et al. Disk    susceptibility studies with cefazolin and cephalotin. Antimicrob Agents Chemother    1974; 5: 63-7.         [ Links ]64.- UWAYDAH M. Cefazolin in the treatment    of acute enteric fever. Antimicrob Agents Chemother 1976; 10: 52-6.         [ Links ]65.- JAMAL W Y, ROTIMI V O, CHUGH T D, PAL    T. Prevalence and susceptibility of Shigella to 11 antibiotics in a Kuwait    teaching hospital. J Chemother 1998; 10: 285-90.         [ Links ]66.- COX CE, SHERRILL M, COCCHETT DM. Evaluation    of cefuroxime axetil, cefaclor, and cephalexin in the treatment of urinary tract    infections in adults. Curr Ther Res 1987; 42: 124-37.         [ Links ]67.- SANDERS C W, GREENBERG R N, MARIER R    L. Cefamandole and cefoxitin. Ann Intern Med 1985; 103: 70-8.          [ Links ]68.- STAPLEY E P, JACKSON M, HERNANDEZ S et    al. Cephamycins, a new family of ß-lactam antibiotics I. Production actinomycetes,    including Streptomyces lactamdurans spp.n. Antimicrob Agents Chemother    1972; 2: 122-31.         [ Links ]69.- COOPER R D G. The carbacephems a new    ß-lactams class. Am J Med 1992; 92 (Suppl 6 A): 25-65.         [ Links ]70.- ZEMELMAN R, BELLO H, DOMINGUEZ M, GONZALEZ    G, MELLA S, GARCIA A. Activity of imipenem, third-generation cephalosporins,    aztreonam, and ciprofloxacin against multi-resistant Gram negative bacilli isolated    from Chilean hospitals. J Antimicrob Chemother 1993; 32: 413-9.         [ Links ]71.- MEDEIROS A A. Evolution and dissemination    of ß-lactamases accelerated by generation of ß-lactam antibiotics.    Clin Infect Dis 1997; 24 (Suppl. 1): 19-45.         [ Links ]72.- PERRY C M, BROGDEN R N. Cefuroxime axetil:    review of its antibacterial activity, pharmacokinetic properties and therapeutic    efficacy. Drugs 1996; 52: 125-58.         [ Links ]73.- SCHAAD U B, SUTER S, GIANELLA-BORRADORI    et al. A comparison of ceftriaxone and cefuroxime for the treatment of bacterial    meningitis in children. N Engl J Med 1990; 322: 141-7.         [ Links ]74.- KLEIN N C, CUNHA B A. Cefalosporinas de    la tercera generación. Clin Med Nort Am 1995; 79: 693-707.         [ Links ]75.- KLUGMAN K P, MADHI S A. Emergence of    drug resistance impact on bacterial meningitis. Infect Dis Clin North Am 1999;    13: 637-46.         [ Links ]76.- RICHARDS D M, BROGDEN R N. Ceftazidime.    A review of its antibacterial activity, pharmacokinetic properties and therapeutic    use. Drugs 1985; 29: 105-61.         [ Links ]77.- SCHATZ B S, KARAVOKIROS K T, TAEUBEL    M A, ITOKAZU G S. Comparison of cefprozil, cefpodoxime proxetil, loracarbef,    cefixime, and ceftibuten. Ann Pharmacother 1996; 30: 258-68.         [ Links ]78.- DALMAU D, LAYRARGUES G P, FENYVES D,    WILLEMS B, TURGEON F, TURGEON P. Cefotaxime, desacetyl-cefotaxime, and bactericidal    activity in spontaneous bacterial peritonitis. J Infect Dis 1999; 180: 1597-1602.          [ Links ]79.- NIKAIDO W, LIU W, ROSENBERG E Y. Outer    membrane permeability and ß-lactamase stability of dipolar ionic cephalosporins    containing methoxyimino substituents. Antimicrob Agents Chemother 1990; 34:    337-42.         [ Links ]80.- HANCOCK R E W, BELLIDO F. Factors involved    in the enhanced efficacy against gram-negative bacteria of fourth generation    cephalosporins. J Antimicrob Chemother 1992; 29(Suppl A): 1-6.         [ Links ]81.- BELLIDO F, PECHERE J C, HANCOCK REW.    Novel method for measurement of outer membrane permeability to new beta-lactams    in intact Enterobacter cloacae cells. Antimicrob Agents Chemother 1991;    35: 68-72.         [ Links ]82.- NEU H C, CHIN N X, JULES K, LABTHAVIKUL    P. The activity of BMY-28142, a new broad spectrum beta-lactamase stable cephalosporin.    J Antimicrob Chemother 1986; 17: 441-52.         [ Links ]83.- KOBAYASHI S, ARAI S, HAYASHI S, FUJIMOTO    K. ß-lactamase stability of cefpirome (HR 810), a new cephalosporin with    a broad antimicrobial spectrum. Antimicrob Agents Chemother 1986; 30: 713-8.          [ Links ]84.- GARAU J, WILSON W, WOOD M, CARLET J.    Fourth generation cephalosporins: a review of in vitro activity, pharmacokinetics,    pharmacodynamics, and clinical utility. Clin Microb Infect 1997; 3 (Suppl 1):    87-101.         [ Links ]85.- KESSLER R E, FUNG-TOMC J. Susceptibility    of bacterial isolates to beta-lactam antibiotics from U.S. clinical trials over    5-year period. Am J Med 1996; 24 (6 A): 13-9.         [ Links ]86.- PIERARD D, EMMERECHTS K, LAUWERS S. Comparative    in-vitro activity of cefpirome against isolates from intensive care and haematology/oncology    units. Belgian Multicentric Study Group. J Antimicrob Chemother 1998; 41: 443-50.          [ Links ]87.- JONES R N. Resistance patterns among    nosocomial pathogens: trends over the past few years. Chest 2001; 119 (Suppl    2): 397-404.         [ Links ]88.- LORBER B. Changing patterns of infectious    diseases. Am J Med 1988; 84: 569-78.         [ Links ]89.- MOELLERING R C. A novel antimicrobial    agent joins the battle against resistant bacteria. Ann Intern Med 1999; 130:    155-7.         [ Links ]90.- WILSON W R. The role of fourth-generation    cephalosporins in the treatment of serious infectious diseases in hospitalized    patients. Diagn Microbiol Infect Dis 1998; 31: 473-7.         [ Links ]Correspondencia a:        Sergio Mella Montecinos        Laboratorio de Antibióticos,        Departamento de Microbiología,        Facultad de Ciencias Biológicas        Casilla 160-C, Concepción        E-mail: pignatio@ctcinternet.cl  

47.- JONES R N, ERWIN M E. In vitro evaluation    of Ro 09-1227, a novel catechol-substituted cephalosporin. Antimicrob Agents    Chemother 1992; 36: 233-8.         [ Links ]48.- JONES R N. In vitro activity of Ro 24-6392,    a novel ester-linked co-drug combining ciprofloxacin and desacetylcefotaxime.    Eur J Clin Microbiol Infect Dis 1990; 9: 435-8.         [ Links ]49.- TOMASZ A. Penicillin-binding proteins    and the antibacterial effectiveness of ß-lactam antibiotics. Rev Infect    Dis 1986 (Suppl 3); 8: 260-78.         [ Links ]50.- HOLM S E. Interaction between ß-lactam    and other antibiotics. Rev Infect Dis 1986 (Suppl 3); 8: 305-14.         [ Links ]51.- MC CULLERS J A, ENGLISH B K, NOVAK R.    Isolation and characterization of vancomycin-tolerant Streptococcus pneumoniae    from the cerebrospinal fluid of a patient who developed recrudescet meningitis.    J Infect Dis 2000; 181: 369-73.         [ Links ]52.- NIKAIDO H. Outer membrane barrier as    a mechanism of antimicrobial resistance. Antimicrob Agents Chemother 1989; 33:    1831-6.         [ Links ]53.- BARRADELL L B, BRYSON H M. Cefepime.    A review of its antibacterial activity, pharmacokinetic properties and therapeutic    use. Drugs 1994; 47: 471-505.         [ Links ]54.- O'CALLAGHAN C H 1979. Description and    classification of the newer cephalosporins and their relationship with the established    compounds. J Antimicrob Chemother 5: 635-71         [ Links ]55.- BRYSKIER A, PROCYK T, TREMBLAY D, LENFANT    B FOURTILLAN J B. The pharmacokinetics of cefodizime following intravenous and    intramuscular administration of a single dose of 1.0 g. J Antimicrob Chemother    1990; 26 (Suppl. C): 59-63.         [ Links ]56.- WILLIAMS J D. Classification of cephalosporins.    Drugs. 1987; 34 (Suppl 2): 15-22.         [ Links ]57.- WISEMAN L R, LAMB H M. Cefpirome. A review    of its antibacterial activity, pharmacokinetic properties and efficacy in the    treatment of severe nosocomial infections and febrile neutropenia. Drugs 1997;    57: 117-40.         [ Links ]58.- PECHERE J C, WILSON W, NEU H. Laboratory    assesment of antibacterial activity of zwitterionic 7-methoxyimino cephalosporins.    J Antimicrob Chemother 1995; 36: 757-71         [ Links ]59.- GIAMARELLOS-BOURBOULIS EJ, GRECKA P,    TSITSIKA A, TYMPANIDOU C, GIAMARELLOU H. In-vitro activity of FK 037 (cefoselis),    a novel 4 (th) generation cephalosporin, cefepime and cefpirome on nosocomial    staphylococci and gram-negative isolates. Diagn Microbiol infect Dis 2000; 36:    185-91.         [ Links ]60.- JONES R N, ERWIN M E, BARRETT M S, JOHNSON    D M, BRIGGS B M. Antimicrobial activity of E-1040, a novel thiadiazolyl cephalosporin    compare with parenteral cephems. Diagn Microbiol infect Dis 1991; 14: 301-9.          [ Links ]61.- IIZAWA Y, OKONOGI K, HAYASHI R, IWAHI    T, YAMAZAKI T, IMADA A. Therapeutic effect of cefozopran (SCE-2787), a new parenteral    cephalosporin in experimental infections in mice. Antimicrob Agents Chemother    1993; 37: 100-5.         [ Links ]62.- WATANABE N A. Newer antipseudomonal cephalosporins.    J Chemother 1996; 8 (Suppl 2): 48-56.         [ Links ]63.- ACTOR P, GUARINI J, URI J et al. Disk    susceptibility studies with cefazolin and cephalotin. Antimicrob Agents Chemother    1974; 5: 63-7.         [ Links ]64.- UWAYDAH M. Cefazolin in the treatment    of acute enteric fever. Antimicrob Agents Chemother 1976; 10: 52-6.         [ Links ]65.- JAMAL W Y, ROTIMI V O, CHUGH T D, PAL    T. Prevalence and susceptibility of Shigella to 11 antibiotics in a Kuwait    teaching hospital. J Chemother 1998; 10: 285-90.         [ Links ]66.- COX CE, SHERRILL M, COCCHETT DM. Evaluation    of cefuroxime axetil, cefaclor, and cephalexin in the treatment of urinary tract    infections in adults. Curr Ther Res 1987; 42: 124-37.         [ Links ]67.- SANDERS C W, GREENBERG R N, MARIER R    L. Cefamandole and cefoxitin. Ann Intern Med 1985; 103: 70-8.          [ Links ]68.- STAPLEY E P, JACKSON M, HERNANDEZ S et    al. Cephamycins, a new family of ß-lactam antibiotics I. Production actinomycetes,    including Streptomyces lactamdurans spp.n. Antimicrob Agents Chemother    1972; 2: 122-31.         [ Links ]69.- COOPER R D G. The carbacephems a new    ß-lactams class. Am J Med 1992; 92 (Suppl 6 A): 25-65.         [ Links ]70.- ZEMELMAN R, BELLO H, DOMINGUEZ M, GONZALEZ    G, MELLA S, GARCIA A. Activity of imipenem, third-generation cephalosporins,    aztreonam, and ciprofloxacin against multi-resistant Gram negative bacilli isolated    from Chilean hospitals. J Antimicrob Chemother 1993; 32: 413-9.         [ Links ]71.- MEDEIROS A A. Evolution and dissemination    of ß-lactamases accelerated by generation of ß-lactam antibiotics.    Clin Infect Dis 1997; 24 (Suppl. 1): 19-45.         [ Links ]72.- PERRY C M, BROGDEN R N. Cefuroxime axetil:    review of its antibacterial activity, pharmacokinetic properties and therapeutic    efficacy. Drugs 1996; 52: 125-58.         [ Links ]73.- SCHAAD U B, SUTER S, GIANELLA-BORRADORI    et al. A comparison of ceftriaxone and cefuroxime for the treatment of bacterial    meningitis in children. N Engl J Med 1990; 322: 141-7.         [ Links ]74.- KLEIN N C, CUNHA B A. Cefalosporinas de    la tercera generación. Clin Med Nort Am 1995; 79: 693-707.         [ Links ]75.- KLUGMAN K P, MADHI S A. Emergence of    drug resistance impact on bacterial meningitis. Infect Dis Clin North Am 1999;    13: 637-46.         [ Links ]76.- RICHARDS D M, BROGDEN R N. Ceftazidime.    A review of its antibacterial activity, pharmacokinetic properties and therapeutic    use. Drugs 1985; 29: 105-61.         [ Links ]77.- SCHATZ B S, KARAVOKIROS K T, TAEUBEL    M A, ITOKAZU G S. Comparison of cefprozil, cefpodoxime proxetil, loracarbef,    cefixime, and ceftibuten. Ann Pharmacother 1996; 30: 258-68.         [ Links ]78.- DALMAU D, LAYRARGUES G P, FENYVES D,    WILLEMS B, TURGEON F, TURGEON P. Cefotaxime, desacetyl-cefotaxime, and bactericidal    activity in spontaneous bacterial peritonitis. J Infect Dis 1999; 180: 1597-1602.          [ Links ]79.- NIKAIDO W, LIU W, ROSENBERG E Y. Outer    membrane permeability and ß-lactamase stability of dipolar ionic cephalosporins    containing methoxyimino substituents. Antimicrob Agents Chemother 1990; 34:    337-42.         [ Links ]80.- HANCOCK R E W, BELLIDO F. Factors involved    in the enhanced efficacy against gram-negative bacteria of fourth generation    cephalosporins. J Antimicrob Chemother 1992; 29(Suppl A): 1-6.         [ Links ]81.- BELLIDO F, PECHERE J C, HANCOCK REW.    Novel method for measurement of outer membrane permeability to new beta-lactams    in intact Enterobacter cloacae cells. Antimicrob Agents Chemother 1991;    35: 68-72.         [ Links ]82.- NEU H C, CHIN N X, JULES K, LABTHAVIKUL    P. The activity of BMY-28142, a new broad spectrum beta-lactamase stable cephalosporin.    J Antimicrob Chemother 1986; 17: 441-52.         [ Links ]83.- KOBAYASHI S, ARAI S, HAYASHI S, FUJIMOTO    K. ß-lactamase stability of cefpirome (HR 810), a new cephalosporin with    a broad antimicrobial spectrum. Antimicrob Agents Chemother 1986; 30: 713-8.          [ Links ]84.- GARAU J, WILSON W, WOOD M, CARLET J.    Fourth generation cephalosporins: a review of in vitro activity, pharmacokinetics,    pharmacodynamics, and clinical utility. Clin Microb Infect 1997; 3 (Suppl 1):    87-101.         [ Links ]85.- KESSLER R E, FUNG-TOMC J. Susceptibility    of bacterial isolates to beta-lactam antibiotics from U.S. clinical trials over    5-year period. Am J Med 1996; 24 (6 A): 13-9.         [ Links ]86.- PIERARD D, EMMERECHTS K, LAUWERS S. Comparative    in-vitro activity of cefpirome against isolates from intensive care and haematology/oncology    units. Belgian Multicentric Study Group. J Antimicrob Chemother 1998; 41: 443-50.          [ Links ]87.- JONES R N. Resistance patterns among    nosocomial pathogens: trends over the past few years. Chest 2001; 119 (Suppl    2): 397-404.         [ Links ]88.- LORBER B. Changing patterns of infectious    diseases. Am J Med 1988; 84: 569-78.         [ Links ]89.- MOELLERING R C. A novel antimicrobial    agent joins the battle against resistant bacteria. Ann Intern Med 1999; 130:    155-7.         [ Links ]90.- WILSON W R. The role of fourth-generation    cephalosporins in the treatment of serious infectious diseases in hospitalized    patients. Diagn Microbiol Infect Dis 1998; 31: 473-7.         [ Links ]Correspondencia a:        Sergio Mella Montecinos        Laboratorio de Antibióticos,        Departamento de Microbiología,        Facultad de Ciencias Biológicas        Casilla 160-C, Concepción        E-mail: pignatio@ctcinternet.cl  

48.- JONES R N. In vitro activity of Ro 24-6392,    a novel ester-linked co-drug combining ciprofloxacin and desacetylcefotaxime.    Eur J Clin Microbiol Infect Dis 1990; 9: 435-8.         [ Links ]49.- TOMASZ A. Penicillin-binding proteins    and the antibacterial effectiveness of ß-lactam antibiotics. Rev Infect    Dis 1986 (Suppl 3); 8: 260-78.         [ Links ]50.- HOLM S E. Interaction between ß-lactam    and other antibiotics. Rev Infect Dis 1986 (Suppl 3); 8: 305-14.         [ Links ]51.- MC CULLERS J A, ENGLISH B K, NOVAK R.    Isolation and characterization of vancomycin-tolerant Streptococcus pneumoniae    from the cerebrospinal fluid of a patient who developed recrudescet meningitis.    J Infect Dis 2000; 181: 369-73.         [ Links ]52.- NIKAIDO H. Outer membrane barrier as    a mechanism of antimicrobial resistance. Antimicrob Agents Chemother 1989; 33:    1831-6.         [ Links ]53.- BARRADELL L B, BRYSON H M. Cefepime.    A review of its antibacterial activity, pharmacokinetic properties and therapeutic    use. Drugs 1994; 47: 471-505.         [ Links ]54.- O'CALLAGHAN C H 1979. Description and    classification of the newer cephalosporins and their relationship with the established    compounds. J Antimicrob Chemother 5: 635-71         [ Links ]55.- BRYSKIER A, PROCYK T, TREMBLAY D, LENFANT    B FOURTILLAN J B. The pharmacokinetics of cefodizime following intravenous and    intramuscular administration of a single dose of 1.0 g. J Antimicrob Chemother    1990; 26 (Suppl. C): 59-63.         [ Links ]56.- WILLIAMS J D. Classification of cephalosporins.    Drugs. 1987; 34 (Suppl 2): 15-22.         [ Links ]57.- WISEMAN L R, LAMB H M. Cefpirome. A review    of its antibacterial activity, pharmacokinetic properties and efficacy in the    treatment of severe nosocomial infections and febrile neutropenia. Drugs 1997;    57: 117-40.         [ Links ]58.- PECHERE J C, WILSON W, NEU H. Laboratory    assesment of antibacterial activity of zwitterionic 7-methoxyimino cephalosporins.    J Antimicrob Chemother 1995; 36: 757-71         [ Links ]59.- GIAMARELLOS-BOURBOULIS EJ, GRECKA P,    TSITSIKA A, TYMPANIDOU C, GIAMARELLOU H. In-vitro activity of FK 037 (cefoselis),    a novel 4 (th) generation cephalosporin, cefepime and cefpirome on nosocomial    staphylococci and gram-negative isolates. Diagn Microbiol infect Dis 2000; 36:    185-91.         [ Links ]60.- JONES R N, ERWIN M E, BARRETT M S, JOHNSON    D M, BRIGGS B M. Antimicrobial activity of E-1040, a novel thiadiazolyl cephalosporin    compare with parenteral cephems. Diagn Microbiol infect Dis 1991; 14: 301-9.          [ Links ]61.- IIZAWA Y, OKONOGI K, HAYASHI R, IWAHI    T, YAMAZAKI T, IMADA A. Therapeutic effect of cefozopran (SCE-2787), a new parenteral    cephalosporin in experimental infections in mice. Antimicrob Agents Chemother    1993; 37: 100-5.         [ Links ]62.- WATANABE N A. Newer antipseudomonal cephalosporins.    J Chemother 1996; 8 (Suppl 2): 48-56.         [ Links ]63.- ACTOR P, GUARINI J, URI J et al. Disk    susceptibility studies with cefazolin and cephalotin. Antimicrob Agents Chemother    1974; 5: 63-7.         [ Links ]64.- UWAYDAH M. Cefazolin in the treatment    of acute enteric fever. Antimicrob Agents Chemother 1976; 10: 52-6.         [ Links ]65.- JAMAL W Y, ROTIMI V O, CHUGH T D, PAL    T. Prevalence and susceptibility of Shigella to 11 antibiotics in a Kuwait    teaching hospital. J Chemother 1998; 10: 285-90.         [ Links ]66.- COX CE, SHERRILL M, COCCHETT DM. Evaluation    of cefuroxime axetil, cefaclor, and cephalexin in the treatment of urinary tract    infections in adults. Curr Ther Res 1987; 42: 124-37.         [ Links ]67.- SANDERS C W, GREENBERG R N, MARIER R    L. Cefamandole and cefoxitin. Ann Intern Med 1985; 103: 70-8.          [ Links ]68.- STAPLEY E P, JACKSON M, HERNANDEZ S et    al. Cephamycins, a new family of ß-lactam antibiotics I. Production actinomycetes,    including Streptomyces lactamdurans spp.n. Antimicrob Agents Chemother    1972; 2: 122-31.         [ Links ]69.- COOPER R D G. The carbacephems a new    ß-lactams class. Am J Med 1992; 92 (Suppl 6 A): 25-65.         [ Links ]70.- ZEMELMAN R, BELLO H, DOMINGUEZ M, GONZALEZ    G, MELLA S, GARCIA A. Activity of imipenem, third-generation cephalosporins,    aztreonam, and ciprofloxacin against multi-resistant Gram negative bacilli isolated    from Chilean hospitals. J Antimicrob Chemother 1993; 32: 413-9.         [ Links ]71.- MEDEIROS A A. Evolution and dissemination    of ß-lactamases accelerated by generation of ß-lactam antibiotics.    Clin Infect Dis 1997; 24 (Suppl. 1): 19-45.         [ Links ]72.- PERRY C M, BROGDEN R N. Cefuroxime axetil:    review of its antibacterial activity, pharmacokinetic properties and therapeutic    efficacy. Drugs 1996; 52: 125-58.         [ Links ]73.- SCHAAD U B, SUTER S, GIANELLA-BORRADORI    et al. A comparison of ceftriaxone and cefuroxime for the treatment of bacterial    meningitis in children. N Engl J Med 1990; 322: 141-7.         [ Links ]74.- KLEIN N C, CUNHA B A. Cefalosporinas de    la tercera generación. Clin Med Nort Am 1995; 79: 693-707.         [ Links ]75.- KLUGMAN K P, MADHI S A. Emergence of    drug resistance impact on bacterial meningitis. Infect Dis Clin North Am 1999;    13: 637-46.         [ Links ]76.- RICHARDS D M, BROGDEN R N. Ceftazidime.    A review of its antibacterial activity, pharmacokinetic properties and therapeutic    use. Drugs 1985; 29: 105-61.         [ Links ]77.- SCHATZ B S, KARAVOKIROS K T, TAEUBEL    M A, ITOKAZU G S. Comparison of cefprozil, cefpodoxime proxetil, loracarbef,    cefixime, and ceftibuten. Ann Pharmacother 1996; 30: 258-68.         [ Links ]78.- DALMAU D, LAYRARGUES G P, FENYVES D,    WILLEMS B, TURGEON F, TURGEON P. Cefotaxime, desacetyl-cefotaxime, and bactericidal    activity in spontaneous bacterial peritonitis. J Infect Dis 1999; 180: 1597-1602.          [ Links ]79.- NIKAIDO W, LIU W, ROSENBERG E Y. Outer    membrane permeability and ß-lactamase stability of dipolar ionic cephalosporins    containing methoxyimino substituents. Antimicrob Agents Chemother 1990; 34:    337-42.         [ Links ]80.- HANCOCK R E W, BELLIDO F. Factors involved    in the enhanced efficacy against gram-negative bacteria of fourth generation    cephalosporins. J Antimicrob Chemother 1992; 29(Suppl A): 1-6.         [ Links ]81.- BELLIDO F, PECHERE J C, HANCOCK REW.    Novel method for measurement of outer membrane permeability to new beta-lactams    in intact Enterobacter cloacae cells. Antimicrob Agents Chemother 1991;    35: 68-72.         [ Links ]82.- NEU H C, CHIN N X, JULES K, LABTHAVIKUL    P. The activity of BMY-28142, a new broad spectrum beta-lactamase stable cephalosporin.    J Antimicrob Chemother 1986; 17: 441-52.         [ Links ]83.- KOBAYASHI S, ARAI S, HAYASHI S, FUJIMOTO    K. ß-lactamase stability of cefpirome (HR 810), a new cephalosporin with    a broad antimicrobial spectrum. Antimicrob Agents Chemother 1986; 30: 713-8.          [ Links ]84.- GARAU J, WILSON W, WOOD M, CARLET J.    Fourth generation cephalosporins: a review of in vitro activity, pharmacokinetics,    pharmacodynamics, and clinical utility. Clin Microb Infect 1997; 3 (Suppl 1):    87-101.         [ Links ]85.- KESSLER R E, FUNG-TOMC J. Susceptibility    of bacterial isolates to beta-lactam antibiotics from U.S. clinical trials over    5-year period. Am J Med 1996; 24 (6 A): 13-9.         [ Links ]86.- PIERARD D, EMMERECHTS K, LAUWERS S. Comparative    in-vitro activity of cefpirome against isolates from intensive care and haematology/oncology    units. Belgian Multicentric Study Group. J Antimicrob Chemother 1998; 41: 443-50.          [ Links ]87.- JONES R N. Resistance patterns among    nosocomial pathogens: trends over the past few years. Chest 2001; 119 (Suppl    2): 397-404.         [ Links ]88.- LORBER B. Changing patterns of infectious    diseases. Am J Med 1988; 84: 569-78.         [ Links ]89.- MOELLERING R C. A novel antimicrobial    agent joins the battle against resistant bacteria. Ann Intern Med 1999; 130:    155-7.         [ Links ]90.- WILSON W R. The role of fourth-generation    cephalosporins in the treatment of serious infectious diseases in hospitalized    patients. Diagn Microbiol Infect Dis 1998; 31: 473-7.         [ Links ]Correspondencia a:        Sergio Mella Montecinos        Laboratorio de Antibióticos,        Departamento de Microbiología,        Facultad de Ciencias Biológicas        Casilla 160-C, Concepción        E-mail: pignatio@ctcinternet.cl  

49.- TOMASZ A. Penicillin-binding proteins    and the antibacterial effectiveness of ß-lactam antibiotics. Rev Infect    Dis 1986 (Suppl 3); 8: 260-78.         [ Links ]50.- HOLM S E. Interaction between ß-lactam    and other antibiotics. Rev Infect Dis 1986 (Suppl 3); 8: 305-14.         [ Links ]51.- MC CULLERS J A, ENGLISH B K, NOVAK R.    Isolation and characterization of vancomycin-tolerant Streptococcus pneumoniae    from the cerebrospinal fluid of a patient who developed recrudescet meningitis.    J Infect Dis 2000; 181: 369-73.         [ Links ]52.- NIKAIDO H. Outer membrane barrier as    a mechanism of antimicrobial resistance. Antimicrob Agents Chemother 1989; 33:    1831-6.         [ Links ]53.- BARRADELL L B, BRYSON H M. Cefepime.    A review of its antibacterial activity, pharmacokinetic properties and therapeutic    use. Drugs 1994; 47: 471-505.         [ Links ]54.- O'CALLAGHAN C H 1979. Description and    classification of the newer cephalosporins and their relationship with the established    compounds. J Antimicrob Chemother 5: 635-71         [ Links ]55.- BRYSKIER A, PROCYK T, TREMBLAY D, LENFANT    B FOURTILLAN J B. The pharmacokinetics of cefodizime following intravenous and    intramuscular administration of a single dose of 1.0 g. J Antimicrob Chemother    1990; 26 (Suppl. C): 59-63.         [ Links ]56.- WILLIAMS J D. Classification of cephalosporins.    Drugs. 1987; 34 (Suppl 2): 15-22.         [ Links ]57.- WISEMAN L R, LAMB H M. Cefpirome. A review    of its antibacterial activity, pharmacokinetic properties and efficacy in the    treatment of severe nosocomial infections and febrile neutropenia. Drugs 1997;    57: 117-40.         [ Links ]58.- PECHERE J C, WILSON W, NEU H. Laboratory    assesment of antibacterial activity of zwitterionic 7-methoxyimino cephalosporins.    J Antimicrob Chemother 1995; 36: 757-71         [ Links ]59.- GIAMARELLOS-BOURBOULIS EJ, GRECKA P,    TSITSIKA A, TYMPANIDOU C, GIAMARELLOU H. In-vitro activity of FK 037 (cefoselis),    a novel 4 (th) generation cephalosporin, cefepime and cefpirome on nosocomial    staphylococci and gram-negative isolates. Diagn Microbiol infect Dis 2000; 36:    185-91.         [ Links ]60.- JONES R N, ERWIN M E, BARRETT M S, JOHNSON    D M, BRIGGS B M. Antimicrobial activity of E-1040, a novel thiadiazolyl cephalosporin    compare with parenteral cephems. Diagn Microbiol infect Dis 1991; 14: 301-9.          [ Links ]61.- IIZAWA Y, OKONOGI K, HAYASHI R, IWAHI    T, YAMAZAKI T, IMADA A. Therapeutic effect of cefozopran (SCE-2787), a new parenteral    cephalosporin in experimental infections in mice. Antimicrob Agents Chemother    1993; 37: 100-5.         [ Links ]62.- WATANABE N A. Newer antipseudomonal cephalosporins.    J Chemother 1996; 8 (Suppl 2): 48-56.         [ Links ]63.- ACTOR P, GUARINI J, URI J et al. Disk    susceptibility studies with cefazolin and cephalotin. Antimicrob Agents Chemother    1974; 5: 63-7.         [ Links ]64.- UWAYDAH M. Cefazolin in the treatment    of acute enteric fever. Antimicrob Agents Chemother 1976; 10: 52-6.         [ Links ]65.- JAMAL W Y, ROTIMI V O, CHUGH T D, PAL    T. Prevalence and susceptibility of Shigella to 11 antibiotics in a Kuwait    teaching hospital. J Chemother 1998; 10: 285-90.         [ Links ]66.- COX CE, SHERRILL M, COCCHETT DM. Evaluation    of cefuroxime axetil, cefaclor, and cephalexin in the treatment of urinary tract    infections in adults. Curr Ther Res 1987; 42: 124-37.         [ Links ]67.- SANDERS C W, GREENBERG R N, MARIER R    L. Cefamandole and cefoxitin. Ann Intern Med 1985; 103: 70-8.          [ Links ]68.- STAPLEY E P, JACKSON M, HERNANDEZ S et    al. Cephamycins, a new family of ß-lactam antibiotics I. Production actinomycetes,    including Streptomyces lactamdurans spp.n. Antimicrob Agents Chemother    1972; 2: 122-31.         [ Links ]69.- COOPER R D G. The carbacephems a new    ß-lactams class. Am J Med 1992; 92 (Suppl 6 A): 25-65.         [ Links ]70.- ZEMELMAN R, BELLO H, DOMINGUEZ M, GONZALEZ    G, MELLA S, GARCIA A. Activity of imipenem, third-generation cephalosporins,    aztreonam, and ciprofloxacin against multi-resistant Gram negative bacilli isolated    from Chilean hospitals. J Antimicrob Chemother 1993; 32: 413-9.         [ Links ]71.- MEDEIROS A A. Evolution and dissemination    of ß-lactamases accelerated by generation of ß-lactam antibiotics.    Clin Infect Dis 1997; 24 (Suppl. 1): 19-45.         [ Links ]72.- PERRY C M, BROGDEN R N. Cefuroxime axetil:    review of its antibacterial activity, pharmacokinetic properties and therapeutic    efficacy. Drugs 1996; 52: 125-58.         [ Links ]73.- SCHAAD U B, SUTER S, GIANELLA-BORRADORI    et al. A comparison of ceftriaxone and cefuroxime for the treatment of bacterial    meningitis in children. N Engl J Med 1990; 322: 141-7.         [ Links ]74.- KLEIN N C, CUNHA B A. Cefalosporinas de    la tercera generación. Clin Med Nort Am 1995; 79: 693-707.         [ Links ]75.- KLUGMAN K P, MADHI S A. Emergence of    drug resistance impact on bacterial meningitis. Infect Dis Clin North Am 1999;    13: 637-46.         [ Links ]76.- RICHARDS D M, BROGDEN R N. Ceftazidime.    A review of its antibacterial activity, pharmacokinetic properties and therapeutic    use. Drugs 1985; 29: 105-61.         [ Links ]77.- SCHATZ B S, KARAVOKIROS K T, TAEUBEL    M A, ITOKAZU G S. Comparison of cefprozil, cefpodoxime proxetil, loracarbef,    cefixime, and ceftibuten. Ann Pharmacother 1996; 30: 258-68.         [ Links ]78.- DALMAU D, LAYRARGUES G P, FENYVES D,    WILLEMS B, TURGEON F, TURGEON P. Cefotaxime, desacetyl-cefotaxime, and bactericidal    activity in spontaneous bacterial peritonitis. J Infect Dis 1999; 180: 1597-1602.          [ Links ]79.- NIKAIDO W, LIU W, ROSENBERG E Y. Outer    membrane permeability and ß-lactamase stability of dipolar ionic cephalosporins    containing methoxyimino substituents. Antimicrob Agents Chemother 1990; 34:    337-42.         [ Links ]80.- HANCOCK R E W, BELLIDO F. Factors involved    in the enhanced efficacy against gram-negative bacteria of fourth generation    cephalosporins. J Antimicrob Chemother 1992; 29(Suppl A): 1-6.         [ Links ]81.- BELLIDO F, PECHERE J C, HANCOCK REW.    Novel method for measurement of outer membrane permeability to new beta-lactams    in intact Enterobacter cloacae cells. Antimicrob Agents Chemother 1991;    35: 68-72.         [ Links ]82.- NEU H C, CHIN N X, JULES K, LABTHAVIKUL    P. The activity of BMY-28142, a new broad spectrum beta-lactamase stable cephalosporin.    J Antimicrob Chemother 1986; 17: 441-52.         [ Links ]83.- KOBAYASHI S, ARAI S, HAYASHI S, FUJIMOTO    K. ß-lactamase stability of cefpirome (HR 810), a new cephalosporin with    a broad antimicrobial spectrum. Antimicrob Agents Chemother 1986; 30: 713-8.          [ Links ]84.- GARAU J, WILSON W, WOOD M, CARLET J.    Fourth generation cephalosporins: a review of in vitro activity, pharmacokinetics,    pharmacodynamics, and clinical utility. Clin Microb Infect 1997; 3 (Suppl 1):    87-101.         [ Links ]85.- KESSLER R E, FUNG-TOMC J. Susceptibility    of bacterial isolates to beta-lactam antibiotics from U.S. clinical trials over    5-year period. Am J Med 1996; 24 (6 A): 13-9.         [ Links ]86.- PIERARD D, EMMERECHTS K, LAUWERS S. Comparative    in-vitro activity of cefpirome against isolates from intensive care and haematology/oncology    units. Belgian Multicentric Study Group. J Antimicrob Chemother 1998; 41: 443-50.          [ Links ]87.- JONES R N. Resistance patterns among    nosocomial pathogens: trends over the past few years. Chest 2001; 119 (Suppl    2): 397-404.         [ Links ]88.- LORBER B. Changing patterns of infectious    diseases. Am J Med 1988; 84: 569-78.         [ Links ]89.- MOELLERING R C. A novel antimicrobial    agent joins the battle against resistant bacteria. Ann Intern Med 1999; 130:    155-7.         [ Links ]90.- WILSON W R. The role of fourth-generation    cephalosporins in the treatment of serious infectious diseases in hospitalized    patients. Diagn Microbiol Infect Dis 1998; 31: 473-7.         [ Links ]Correspondencia a:        Sergio Mella Montecinos        Laboratorio de Antibióticos,        Departamento de Microbiología,        Facultad de Ciencias Biológicas        Casilla 160-C, Concepción        E-mail: pignatio@ctcinternet.cl  

50.- HOLM S E. Interaction between ß-lactam    and other antibiotics. Rev Infect Dis 1986 (Suppl 3); 8: 305-14.         [ Links ]51.- MC CULLERS J A, ENGLISH B K, NOVAK R.    Isolation and characterization of vancomycin-tolerant Streptococcus pneumoniae    from the cerebrospinal fluid of a patient who developed recrudescet meningitis.    J Infect Dis 2000; 181: 369-73.         [ Links ]52.- NIKAIDO H. Outer membrane barrier as    a mechanism of antimicrobial resistance. Antimicrob Agents Chemother 1989; 33:    1831-6.         [ Links ]53.- BARRADELL L B, BRYSON H M. Cefepime.    A review of its antibacterial activity, pharmacokinetic properties and therapeutic    use. Drugs 1994; 47: 471-505.         [ Links ]54.- O'CALLAGHAN C H 1979. Description and    classification of the newer cephalosporins and their relationship with the established    compounds. J Antimicrob Chemother 5: 635-71         [ Links ]55.- BRYSKIER A, PROCYK T, TREMBLAY D, LENFANT    B FOURTILLAN J B. The pharmacokinetics of cefodizime following intravenous and    intramuscular administration of a single dose of 1.0 g. J Antimicrob Chemother    1990; 26 (Suppl. C): 59-63.         [ Links ]56.- WILLIAMS J D. Classification of cephalosporins.    Drugs. 1987; 34 (Suppl 2): 15-22.         [ Links ]57.- WISEMAN L R, LAMB H M. Cefpirome. A review    of its antibacterial activity, pharmacokinetic properties and efficacy in the    treatment of severe nosocomial infections and febrile neutropenia. Drugs 1997;    57: 117-40.         [ Links ]58.- PECHERE J C, WILSON W, NEU H. Laboratory    assesment of antibacterial activity of zwitterionic 7-methoxyimino cephalosporins.    J Antimicrob Chemother 1995; 36: 757-71         [ Links ]59.- GIAMARELLOS-BOURBOULIS EJ, GRECKA P,    TSITSIKA A, TYMPANIDOU C, GIAMARELLOU H. In-vitro activity of FK 037 (cefoselis),    a novel 4 (th) generation cephalosporin, cefepime and cefpirome on nosocomial    staphylococci and gram-negative isolates. Diagn Microbiol infect Dis 2000; 36:    185-91.         [ Links ]60.- JONES R N, ERWIN M E, BARRETT M S, JOHNSON    D M, BRIGGS B M. Antimicrobial activity of E-1040, a novel thiadiazolyl cephalosporin    compare with parenteral cephems. Diagn Microbiol infect Dis 1991; 14: 301-9.          [ Links ]61.- IIZAWA Y, OKONOGI K, HAYASHI R, IWAHI    T, YAMAZAKI T, IMADA A. Therapeutic effect of cefozopran (SCE-2787), a new parenteral    cephalosporin in experimental infections in mice. Antimicrob Agents Chemother    1993; 37: 100-5.         [ Links ]62.- WATANABE N A. Newer antipseudomonal cephalosporins.    J Chemother 1996; 8 (Suppl 2): 48-56.         [ Links ]63.- ACTOR P, GUARINI J, URI J et al. Disk    susceptibility studies with cefazolin and cephalotin. Antimicrob Agents Chemother    1974; 5: 63-7.         [ Links ]64.- UWAYDAH M. Cefazolin in the treatment    of acute enteric fever. Antimicrob Agents Chemother 1976; 10: 52-6.         [ Links ]65.- JAMAL W Y, ROTIMI V O, CHUGH T D, PAL    T. Prevalence and susceptibility of Shigella to 11 antibiotics in a Kuwait    teaching hospital. J Chemother 1998; 10: 285-90.         [ Links ]66.- COX CE, SHERRILL M, COCCHETT DM. Evaluation    of cefuroxime axetil, cefaclor, and cephalexin in the treatment of urinary tract    infections in adults. Curr Ther Res 1987; 42: 124-37.         [ Links ]67.- SANDERS C W, GREENBERG R N, MARIER R    L. Cefamandole and cefoxitin. Ann Intern Med 1985; 103: 70-8.          [ Links ]68.- STAPLEY E P, JACKSON M, HERNANDEZ S et    al. Cephamycins, a new family of ß-lactam antibiotics I. Production actinomycetes,    including Streptomyces lactamdurans spp.n. Antimicrob Agents Chemother    1972; 2: 122-31.         [ Links ]69.- COOPER R D G. The carbacephems a new    ß-lactams class. Am J Med 1992; 92 (Suppl 6 A): 25-65.         [ Links ]70.- ZEMELMAN R, BELLO H, DOMINGUEZ M, GONZALEZ    G, MELLA S, GARCIA A. Activity of imipenem, third-generation cephalosporins,    aztreonam, and ciprofloxacin against multi-resistant Gram negative bacilli isolated    from Chilean hospitals. J Antimicrob Chemother 1993; 32: 413-9.         [ Links ]71.- MEDEIROS A A. Evolution and dissemination    of ß-lactamases accelerated by generation of ß-lactam antibiotics.    Clin Infect Dis 1997; 24 (Suppl. 1): 19-45.         [ Links ]72.- PERRY C M, BROGDEN R N. Cefuroxime axetil:    review of its antibacterial activity, pharmacokinetic properties and therapeutic    efficacy. Drugs 1996; 52: 125-58.         [ Links ]73.- SCHAAD U B, SUTER S, GIANELLA-BORRADORI    et al. A comparison of ceftriaxone and cefuroxime for the treatment of bacterial    meningitis in children. N Engl J Med 1990; 322: 141-7.         [ Links ]74.- KLEIN N C, CUNHA B A. Cefalosporinas de    la tercera generación. Clin Med Nort Am 1995; 79: 693-707.         [ Links ]75.- KLUGMAN K P, MADHI S A. Emergence of    drug resistance impact on bacterial meningitis. Infect Dis Clin North Am 1999;    13: 637-46.         [ Links ]76.- RICHARDS D M, BROGDEN R N. Ceftazidime.    A review of its antibacterial activity, pharmacokinetic properties and therapeutic    use. Drugs 1985; 29: 105-61.         [ Links ]77.- SCHATZ B S, KARAVOKIROS K T, TAEUBEL    M A, ITOKAZU G S. Comparison of cefprozil, cefpodoxime proxetil, loracarbef,    cefixime, and ceftibuten. Ann Pharmacother 1996; 30: 258-68.         [ Links ]78.- DALMAU D, LAYRARGUES G P, FENYVES D,    WILLEMS B, TURGEON F, TURGEON P. Cefotaxime, desacetyl-cefotaxime, and bactericidal    activity in spontaneous bacterial peritonitis. J Infect Dis 1999; 180: 1597-1602.          [ Links ]79.- NIKAIDO W, LIU W, ROSENBERG E Y. Outer    membrane permeability and ß-lactamase stability of dipolar ionic cephalosporins    containing methoxyimino substituents. Antimicrob Agents Chemother 1990; 34:    337-42.         [ Links ]80.- HANCOCK R E W, BELLIDO F. Factors involved    in the enhanced efficacy against gram-negative bacteria of fourth generation    cephalosporins. J Antimicrob Chemother 1992; 29(Suppl A): 1-6.         [ Links ]81.- BELLIDO F, PECHERE J C, HANCOCK REW.    Novel method for measurement of outer membrane permeability to new beta-lactams    in intact Enterobacter cloacae cells. Antimicrob Agents Chemother 1991;    35: 68-72.         [ Links ]82.- NEU H C, CHIN N X, JULES K, LABTHAVIKUL    P. The activity of BMY-28142, a new broad spectrum beta-lactamase stable cephalosporin.    J Antimicrob Chemother 1986; 17: 441-52.         [ Links ]83.- KOBAYASHI S, ARAI S, HAYASHI S, FUJIMOTO    K. ß-lactamase stability of cefpirome (HR 810), a new cephalosporin with    a broad antimicrobial spectrum. Antimicrob Agents Chemother 1986; 30: 713-8.          [ Links ]84.- GARAU J, WILSON W, WOOD M, CARLET J.    Fourth generation cephalosporins: a review of in vitro activity, pharmacokinetics,    pharmacodynamics, and clinical utility. Clin Microb Infect 1997; 3 (Suppl 1):    87-101.         [ Links ]85.- KESSLER R E, FUNG-TOMC J. Susceptibility    of bacterial isolates to beta-lactam antibiotics from U.S. clinical trials over    5-year period. Am J Med 1996; 24 (6 A): 13-9.         [ Links ]86.- PIERARD D, EMMERECHTS K, LAUWERS S. Comparative    in-vitro activity of cefpirome against isolates from intensive care and haematology/oncology    units. Belgian Multicentric Study Group. J Antimicrob Chemother 1998; 41: 443-50.          [ Links ]87.- JONES R N. Resistance patterns among    nosocomial pathogens: trends over the past few years. Chest 2001; 119 (Suppl    2): 397-404.         [ Links ]88.- LORBER B. Changing patterns of infectious    diseases. Am J Med 1988; 84: 569-78.         [ Links ]89.- MOELLERING R C. A novel antimicrobial    agent joins the battle against resistant bacteria. Ann Intern Med 1999; 130:    155-7.         [ Links ]90.- WILSON W R. The role of fourth-generation    cephalosporins in the treatment of serious infectious diseases in hospitalized    patients. Diagn Microbiol Infect Dis 1998; 31: 473-7.         [ Links ]Correspondencia a:        Sergio Mella Montecinos        Laboratorio de Antibióticos,        Departamento de Microbiología,        Facultad de Ciencias Biológicas        Casilla 160-C, Concepción        E-mail: pignatio@ctcinternet.cl  

51.- MC CULLERS J A, ENGLISH B K, NOVAK R.    Isolation and characterization of vancomycin-tolerant Streptococcus pneumoniae    from the cerebrospinal fluid of a patient who developed recrudescet meningitis.    J Infect Dis 2000; 181: 369-73.         [ Links ]52.- NIKAIDO H. Outer membrane barrier as    a mechanism of antimicrobial resistance. Antimicrob Agents Chemother 1989; 33:    1831-6.         [ Links ]53.- BARRADELL L B, BRYSON H M. Cefepime.    A review of its antibacterial activity, pharmacokinetic properties and therapeutic    use. Drugs 1994; 47: 471-505.         [ Links ]54.- O'CALLAGHAN C H 1979. Description and    classification of the newer cephalosporins and their relationship with the established    compounds. J Antimicrob Chemother 5: 635-71         [ Links ]55.- BRYSKIER A, PROCYK T, TREMBLAY D, LENFANT    B FOURTILLAN J B. The pharmacokinetics of cefodizime following intravenous and    intramuscular administration of a single dose of 1.0 g. J Antimicrob Chemother    1990; 26 (Suppl. C): 59-63.         [ Links ]56.- WILLIAMS J D. Classification of cephalosporins.    Drugs. 1987; 34 (Suppl 2): 15-22.         [ Links ]57.- WISEMAN L R, LAMB H M. Cefpirome. A review    of its antibacterial activity, pharmacokinetic properties and efficacy in the    treatment of severe nosocomial infections and febrile neutropenia. Drugs 1997;    57: 117-40.         [ Links ]58.- PECHERE J C, WILSON W, NEU H. Laboratory    assesment of antibacterial activity of zwitterionic 7-methoxyimino cephalosporins.    J Antimicrob Chemother 1995; 36: 757-71         [ Links ]59.- GIAMARELLOS-BOURBOULIS EJ, GRECKA P,    TSITSIKA A, TYMPANIDOU C, GIAMARELLOU H. In-vitro activity of FK 037 (cefoselis),    a novel 4 (th) generation cephalosporin, cefepime and cefpirome on nosocomial    staphylococci and gram-negative isolates. Diagn Microbiol infect Dis 2000; 36:    185-91.         [ Links ]60.- JONES R N, ERWIN M E, BARRETT M S, JOHNSON    D M, BRIGGS B M. Antimicrobial activity of E-1040, a novel thiadiazolyl cephalosporin    compare with parenteral cephems. Diagn Microbiol infect Dis 1991; 14: 301-9.          [ Links ]61.- IIZAWA Y, OKONOGI K, HAYASHI R, IWAHI    T, YAMAZAKI T, IMADA A. Therapeutic effect of cefozopran (SCE-2787), a new parenteral    cephalosporin in experimental infections in mice. Antimicrob Agents Chemother    1993; 37: 100-5.         [ Links ]62.- WATANABE N A. Newer antipseudomonal cephalosporins.    J Chemother 1996; 8 (Suppl 2): 48-56.         [ Links ]63.- ACTOR P, GUARINI J, URI J et al. Disk    susceptibility studies with cefazolin and cephalotin. Antimicrob Agents Chemother    1974; 5: 63-7.         [ Links ]64.- UWAYDAH M. Cefazolin in the treatment    of acute enteric fever. Antimicrob Agents Chemother 1976; 10: 52-6.         [ Links ]65.- JAMAL W Y, ROTIMI V O, CHUGH T D, PAL    T. Prevalence and susceptibility of Shigella to 11 antibiotics in a Kuwait    teaching hospital. J Chemother 1998; 10: 285-90.         [ Links ]66.- COX CE, SHERRILL M, COCCHETT DM. Evaluation    of cefuroxime axetil, cefaclor, and cephalexin in the treatment of urinary tract    infections in adults. Curr Ther Res 1987; 42: 124-37.         [ Links ]67.- SANDERS C W, GREENBERG R N, MARIER R    L. Cefamandole and cefoxitin. Ann Intern Med 1985; 103: 70-8.          [ Links ]68.- STAPLEY E P, JACKSON M, HERNANDEZ S et    al. Cephamycins, a new family of ß-lactam antibiotics I. Production actinomycetes,    including Streptomyces lactamdurans spp.n. Antimicrob Agents Chemother    1972; 2: 122-31.         [ Links ]69.- COOPER R D G. The carbacephems a new    ß-lactams class. Am J Med 1992; 92 (Suppl 6 A): 25-65.         [ Links ]70.- ZEMELMAN R, BELLO H, DOMINGUEZ M, GONZALEZ    G, MELLA S, GARCIA A. Activity of imipenem, third-generation cephalosporins,    aztreonam, and ciprofloxacin against multi-resistant Gram negative bacilli isolated    from Chilean hospitals. J Antimicrob Chemother 1993; 32: 413-9.         [ Links ]71.- MEDEIROS A A. Evolution and dissemination    of ß-lactamases accelerated by generation of ß-lactam antibiotics.    Clin Infect Dis 1997; 24 (Suppl. 1): 19-45.         [ Links ]72.- PERRY C M, BROGDEN R N. Cefuroxime axetil:    review of its antibacterial activity, pharmacokinetic properties and therapeutic    efficacy. Drugs 1996; 52: 125-58.         [ Links ]73.- SCHAAD U B, SUTER S, GIANELLA-BORRADORI    et al. A comparison of ceftriaxone and cefuroxime for the treatment of bacterial    meningitis in children. N Engl J Med 1990; 322: 141-7.         [ Links ]74.- KLEIN N C, CUNHA B A. Cefalosporinas de    la tercera generación. Clin Med Nort Am 1995; 79: 693-707.         [ Links ]75.- KLUGMAN K P, MADHI S A. Emergence of    drug resistance impact on bacterial meningitis. Infect Dis Clin North Am 1999;    13: 637-46.         [ Links ]76.- RICHARDS D M, BROGDEN R N. Ceftazidime.    A review of its antibacterial activity, pharmacokinetic properties and therapeutic    use. Drugs 1985; 29: 105-61.         [ Links ]77.- SCHATZ B S, KARAVOKIROS K T, TAEUBEL    M A, ITOKAZU G S. Comparison of cefprozil, cefpodoxime proxetil, loracarbef,    cefixime, and ceftibuten. Ann Pharmacother 1996; 30: 258-68.         [ Links ]78.- DALMAU D, LAYRARGUES G P, FENYVES D,    WILLEMS B, TURGEON F, TURGEON P. Cefotaxime, desacetyl-cefotaxime, and bactericidal    activity in spontaneous bacterial peritonitis. J Infect Dis 1999; 180: 1597-1602.          [ Links ]79.- NIKAIDO W, LIU W, ROSENBERG E Y. Outer    membrane permeability and ß-lactamase stability of dipolar ionic cephalosporins    containing methoxyimino substituents. Antimicrob Agents Chemother 1990; 34:    337-42.         [ Links ]80.- HANCOCK R E W, BELLIDO F. Factors involved    in the enhanced efficacy against gram-negative bacteria of fourth generation    cephalosporins. J Antimicrob Chemother 1992; 29(Suppl A): 1-6.         [ Links ]81.- BELLIDO F, PECHERE J C, HANCOCK REW.    Novel method for measurement of outer membrane permeability to new beta-lactams    in intact Enterobacter cloacae cells. Antimicrob Agents Chemother 1991;    35: 68-72.         [ Links ]82.- NEU H C, CHIN N X, JULES K, LABTHAVIKUL    P. The activity of BMY-28142, a new broad spectrum beta-lactamase stable cephalosporin.    J Antimicrob Chemother 1986; 17: 441-52.         [ Links ]83.- KOBAYASHI S, ARAI S, HAYASHI S, FUJIMOTO    K. ß-lactamase stability of cefpirome (HR 810), a new cephalosporin with    a broad antimicrobial spectrum. Antimicrob Agents Chemother 1986; 30: 713-8.          [ Links ]84.- GARAU J, WILSON W, WOOD M, CARLET J.    Fourth generation cephalosporins: a review of in vitro activity, pharmacokinetics,    pharmacodynamics, and clinical utility. Clin Microb Infect 1997; 3 (Suppl 1):    87-101.         [ Links ]85.- KESSLER R E, FUNG-TOMC J. Susceptibility    of bacterial isolates to beta-lactam antibiotics from U.S. clinical trials over    5-year period. Am J Med 1996; 24 (6 A): 13-9.         [ Links ]86.- PIERARD D, EMMERECHTS K, LAUWERS S. Comparative    in-vitro activity of cefpirome against isolates from intensive care and haematology/oncology    units. Belgian Multicentric Study Group. J Antimicrob Chemother 1998; 41: 443-50.          [ Links ]87.- JONES R N. Resistance patterns among    nosocomial pathogens: trends over the past few years. Chest 2001; 119 (Suppl    2): 397-404.         [ Links ]88.- LORBER B. Changing patterns of infectious    diseases. Am J Med 1988; 84: 569-78.         [ Links ]89.- MOELLERING R C. A novel antimicrobial    agent joins the battle against resistant bacteria. Ann Intern Med 1999; 130:    155-7.         [ Links ]90.- WILSON W R. The role of fourth-generation    cephalosporins in the treatment of serious infectious diseases in hospitalized    patients. Diagn Microbiol Infect Dis 1998; 31: 473-7.         [ Links ]Correspondencia a:        Sergio Mella Montecinos        Laboratorio de Antibióticos,        Departamento de Microbiología,        Facultad de Ciencias Biológicas        Casilla 160-C, Concepción        E-mail: pignatio@ctcinternet.cl  

52.- NIKAIDO H. Outer membrane barrier as    a mechanism of antimicrobial resistance. Antimicrob Agents Chemother 1989; 33:    1831-6.         [ Links ]53.- BARRADELL L B, BRYSON H M. Cefepime.    A review of its antibacterial activity, pharmacokinetic properties and therapeutic    use. Drugs 1994; 47: 471-505.         [ Links ]54.- O'CALLAGHAN C H 1979. Description and    classification of the newer cephalosporins and their relationship with the established    compounds. J Antimicrob Chemother 5: 635-71         [ Links ]55.- BRYSKIER A, PROCYK T, TREMBLAY D, LENFANT    B FOURTILLAN J B. The pharmacokinetics of cefodizime following intravenous and    intramuscular administration of a single dose of 1.0 g. J Antimicrob Chemother    1990; 26 (Suppl. C): 59-63.         [ Links ]56.- WILLIAMS J D. Classification of cephalosporins.    Drugs. 1987; 34 (Suppl 2): 15-22.         [ Links ]57.- WISEMAN L R, LAMB H M. Cefpirome. A review    of its antibacterial activity, pharmacokinetic properties and efficacy in the    treatment of severe nosocomial infections and febrile neutropenia. Drugs 1997;    57: 117-40.         [ Links ]58.- PECHERE J C, WILSON W, NEU H. Laboratory    assesment of antibacterial activity of zwitterionic 7-methoxyimino cephalosporins.    J Antimicrob Chemother 1995; 36: 757-71         [ Links ]59.- GIAMARELLOS-BOURBOULIS EJ, GRECKA P,    TSITSIKA A, TYMPANIDOU C, GIAMARELLOU H. In-vitro activity of FK 037 (cefoselis),    a novel 4 (th) generation cephalosporin, cefepime and cefpirome on nosocomial    staphylococci and gram-negative isolates. Diagn Microbiol infect Dis 2000; 36:    185-91.         [ Links ]60.- JONES R N, ERWIN M E, BARRETT M S, JOHNSON    D M, BRIGGS B M. Antimicrobial activity of E-1040, a novel thiadiazolyl cephalosporin    compare with parenteral cephems. Diagn Microbiol infect Dis 1991; 14: 301-9.          [ Links ]61.- IIZAWA Y, OKONOGI K, HAYASHI R, IWAHI    T, YAMAZAKI T, IMADA A. Therapeutic effect of cefozopran (SCE-2787), a new parenteral    cephalosporin in experimental infections in mice. Antimicrob Agents Chemother    1993; 37: 100-5.         [ Links ]62.- WATANABE N A. Newer antipseudomonal cephalosporins.    J Chemother 1996; 8 (Suppl 2): 48-56.         [ Links ]63.- ACTOR P, GUARINI J, URI J et al. Disk    susceptibility studies with cefazolin and cephalotin. Antimicrob Agents Chemother    1974; 5: 63-7.         [ Links ]64.- UWAYDAH M. Cefazolin in the treatment    of acute enteric fever. Antimicrob Agents Chemother 1976; 10: 52-6.         [ Links ]65.- JAMAL W Y, ROTIMI V O, CHUGH T D, PAL    T. Prevalence and susceptibility of Shigella to 11 antibiotics in a Kuwait    teaching hospital. J Chemother 1998; 10: 285-90.         [ Links ]66.- COX CE, SHERRILL M, COCCHETT DM. Evaluation    of cefuroxime axetil, cefaclor, and cephalexin in the treatment of urinary tract    infections in adults. Curr Ther Res 1987; 42: 124-37.         [ Links ]67.- SANDERS C W, GREENBERG R N, MARIER R    L. Cefamandole and cefoxitin. Ann Intern Med 1985; 103: 70-8.          [ Links ]68.- STAPLEY E P, JACKSON M, HERNANDEZ S et    al. Cephamycins, a new family of ß-lactam antibiotics I. Production actinomycetes,    including Streptomyces lactamdurans spp.n. Antimicrob Agents Chemother    1972; 2: 122-31.         [ Links ]69.- COOPER R D G. The carbacephems a new    ß-lactams class. Am J Med 1992; 92 (Suppl 6 A): 25-65.         [ Links ]70.- ZEMELMAN R, BELLO H, DOMINGUEZ M, GONZALEZ    G, MELLA S, GARCIA A. Activity of imipenem, third-generation cephalosporins,    aztreonam, and ciprofloxacin against multi-resistant Gram negative bacilli isolated    from Chilean hospitals. J Antimicrob Chemother 1993; 32: 413-9.         [ Links ]71.- MEDEIROS A A. Evolution and dissemination    of ß-lactamases accelerated by generation of ß-lactam antibiotics.    Clin Infect Dis 1997; 24 (Suppl. 1): 19-45.         [ Links ]72.- PERRY C M, BROGDEN R N. Cefuroxime axetil:    review of its antibacterial activity, pharmacokinetic properties and therapeutic    efficacy. Drugs 1996; 52: 125-58.         [ Links ]73.- SCHAAD U B, SUTER S, GIANELLA-BORRADORI    et al. A comparison of ceftriaxone and cefuroxime for the treatment of bacterial    meningitis in children. N Engl J Med 1990; 322: 141-7.         [ Links ]74.- KLEIN N C, CUNHA B A. Cefalosporinas de    la tercera generación. Clin Med Nort Am 1995; 79: 693-707.         [ Links ]75.- KLUGMAN K P, MADHI S A. Emergence of    drug resistance impact on bacterial meningitis. Infect Dis Clin North Am 1999;    13: 637-46.         [ Links ]76.- RICHARDS D M, BROGDEN R N. Ceftazidime.    A review of its antibacterial activity, pharmacokinetic properties and therapeutic    use. Drugs 1985; 29: 105-61.         [ Links ]77.- SCHATZ B S, KARAVOKIROS K T, TAEUBEL    M A, ITOKAZU G S. Comparison of cefprozil, cefpodoxime proxetil, loracarbef,    cefixime, and ceftibuten. Ann Pharmacother 1996; 30: 258-68.         [ Links ]78.- DALMAU D, LAYRARGUES G P, FENYVES D,    WILLEMS B, TURGEON F, TURGEON P. Cefotaxime, desacetyl-cefotaxime, and bactericidal    activity in spontaneous bacterial peritonitis. J Infect Dis 1999; 180: 1597-1602.          [ Links ]79.- NIKAIDO W, LIU W, ROSENBERG E Y. Outer    membrane permeability and ß-lactamase stability of dipolar ionic cephalosporins    containing methoxyimino substituents. Antimicrob Agents Chemother 1990; 34:    337-42.         [ Links ]80.- HANCOCK R E W, BELLIDO F. Factors involved    in the enhanced efficacy against gram-negative bacteria of fourth generation    cephalosporins. J Antimicrob Chemother 1992; 29(Suppl A): 1-6.         [ Links ]81.- BELLIDO F, PECHERE J C, HANCOCK REW.    Novel method for measurement of outer membrane permeability to new beta-lactams    in intact Enterobacter cloacae cells. Antimicrob Agents Chemother 1991;    35: 68-72.         [ Links ]82.- NEU H C, CHIN N X, JULES K, LABTHAVIKUL    P. The activity of BMY-28142, a new broad spectrum beta-lactamase stable cephalosporin.    J Antimicrob Chemother 1986; 17: 441-52.         [ Links ]83.- KOBAYASHI S, ARAI S, HAYASHI S, FUJIMOTO    K. ß-lactamase stability of cefpirome (HR 810), a new cephalosporin with    a broad antimicrobial spectrum. Antimicrob Agents Chemother 1986; 30: 713-8.          [ Links ]84.- GARAU J, WILSON W, WOOD M, CARLET J.    Fourth generation cephalosporins: a review of in vitro activity, pharmacokinetics,    pharmacodynamics, and clinical utility. Clin Microb Infect 1997; 3 (Suppl 1):    87-101.         [ Links ]85.- KESSLER R E, FUNG-TOMC J. Susceptibility    of bacterial isolates to beta-lactam antibiotics from U.S. clinical trials over    5-year period. Am J Med 1996; 24 (6 A): 13-9.         [ Links ]86.- PIERARD D, EMMERECHTS K, LAUWERS S. Comparative    in-vitro activity of cefpirome against isolates from intensive care and haematology/oncology    units. Belgian Multicentric Study Group. J Antimicrob Chemother 1998; 41: 443-50.          [ Links ]87.- JONES R N. Resistance patterns among    nosocomial pathogens: trends over the past few years. Chest 2001; 119 (Suppl    2): 397-404.         [ Links ]88.- LORBER B. Changing patterns of infectious    diseases. Am J Med 1988; 84: 569-78.         [ Links ]89.- MOELLERING R C. A novel antimicrobial    agent joins the battle against resistant bacteria. Ann Intern Med 1999; 130:    155-7.         [ Links ]90.- WILSON W R. The role of fourth-generation    cephalosporins in the treatment of serious infectious diseases in hospitalized    patients. Diagn Microbiol Infect Dis 1998; 31: 473-7.         [ Links ]Correspondencia a:        Sergio Mella Montecinos        Laboratorio de Antibióticos,        Departamento de Microbiología,        Facultad de Ciencias Biológicas        Casilla 160-C, Concepción        E-mail: pignatio@ctcinternet.cl  

53.- BARRADELL L B, BRYSON H M. Cefepime.    A review of its antibacterial activity, pharmacokinetic properties and therapeutic    use. Drugs 1994; 47: 471-505.         [ Links ]54.- O'CALLAGHAN C H 1979. Description and    classification of the newer cephalosporins and their relationship with the established    compounds. J Antimicrob Chemother 5: 635-71         [ Links ]55.- BRYSKIER A, PROCYK T, TREMBLAY D, LENFANT    B FOURTILLAN J B. The pharmacokinetics of cefodizime following intravenous and    intramuscular administration of a single dose of 1.0 g. J Antimicrob Chemother    1990; 26 (Suppl. C): 59-63.         [ Links ]56.- WILLIAMS J D. Classification of cephalosporins.    Drugs. 1987; 34 (Suppl 2): 15-22.         [ Links ]57.- WISEMAN L R, LAMB H M. Cefpirome. A review    of its antibacterial activity, pharmacokinetic properties and efficacy in the    treatment of severe nosocomial infections and febrile neutropenia. Drugs 1997;    57: 117-40.         [ Links ]58.- PECHERE J C, WILSON W, NEU H. Laboratory    assesment of antibacterial activity of zwitterionic 7-methoxyimino cephalosporins.    J Antimicrob Chemother 1995; 36: 757-71         [ Links ]59.- GIAMARELLOS-BOURBOULIS EJ, GRECKA P,    TSITSIKA A, TYMPANIDOU C, GIAMARELLOU H. In-vitro activity of FK 037 (cefoselis),    a novel 4 (th) generation cephalosporin, cefepime and cefpirome on nosocomial    staphylococci and gram-negative isolates. Diagn Microbiol infect Dis 2000; 36:    185-91.         [ Links ]60.- JONES R N, ERWIN M E, BARRETT M S, JOHNSON    D M, BRIGGS B M. Antimicrobial activity of E-1040, a novel thiadiazolyl cephalosporin    compare with parenteral cephems. Diagn Microbiol infect Dis 1991; 14: 301-9.          [ Links ]61.- IIZAWA Y, OKONOGI K, HAYASHI R, IWAHI    T, YAMAZAKI T, IMADA A. Therapeutic effect of cefozopran (SCE-2787), a new parenteral    cephalosporin in experimental infections in mice. Antimicrob Agents Chemother    1993; 37: 100-5.         [ Links ]62.- WATANABE N A. Newer antipseudomonal cephalosporins.    J Chemother 1996; 8 (Suppl 2): 48-56.         [ Links ]63.- ACTOR P, GUARINI J, URI J et al. Disk    susceptibility studies with cefazolin and cephalotin. Antimicrob Agents Chemother    1974; 5: 63-7.         [ Links ]64.- UWAYDAH M. Cefazolin in the treatment    of acute enteric fever. Antimicrob Agents Chemother 1976; 10: 52-6.         [ Links ]65.- JAMAL W Y, ROTIMI V O, CHUGH T D, PAL    T. Prevalence and susceptibility of Shigella to 11 antibiotics in a Kuwait    teaching hospital. J Chemother 1998; 10: 285-90.         [ Links ]66.- COX CE, SHERRILL M, COCCHETT DM. Evaluation    of cefuroxime axetil, cefaclor, and cephalexin in the treatment of urinary tract    infections in adults. Curr Ther Res 1987; 42: 124-37.         [ Links ]67.- SANDERS C W, GREENBERG R N, MARIER R    L. Cefamandole and cefoxitin. Ann Intern Med 1985; 103: 70-8.          [ Links ]68.- STAPLEY E P, JACKSON M, HERNANDEZ S et    al. Cephamycins, a new family of ß-lactam antibiotics I. Production actinomycetes,    including Streptomyces lactamdurans spp.n. Antimicrob Agents Chemother    1972; 2: 122-31.         [ Links ]69.- COOPER R D G. The carbacephems a new    ß-lactams class. Am J Med 1992; 92 (Suppl 6 A): 25-65.         [ Links ]70.- ZEMELMAN R, BELLO H, DOMINGUEZ M, GONZALEZ    G, MELLA S, GARCIA A. Activity of imipenem, third-generation cephalosporins,    aztreonam, and ciprofloxacin against multi-resistant Gram negative bacilli isolated    from Chilean hospitals. J Antimicrob Chemother 1993; 32: 413-9.         [ Links ]71.- MEDEIROS A A. Evolution and dissemination    of ß-lactamases accelerated by generation of ß-lactam antibiotics.    Clin Infect Dis 1997; 24 (Suppl. 1): 19-45.         [ Links ]72.- PERRY C M, BROGDEN R N. Cefuroxime axetil:    review of its antibacterial activity, pharmacokinetic properties and therapeutic    efficacy. Drugs 1996; 52: 125-58.         [ Links ]73.- SCHAAD U B, SUTER S, GIANELLA-BORRADORI    et al. A comparison of ceftriaxone and cefuroxime for the treatment of bacterial    meningitis in children. N Engl J Med 1990; 322: 141-7.         [ Links ]74.- KLEIN N C, CUNHA B A. Cefalosporinas de    la tercera generación. Clin Med Nort Am 1995; 79: 693-707.         [ Links ]75.- KLUGMAN K P, MADHI S A. Emergence of    drug resistance impact on bacterial meningitis. Infect Dis Clin North Am 1999;    13: 637-46.         [ Links ]76.- RICHARDS D M, BROGDEN R N. Ceftazidime.    A review of its antibacterial activity, pharmacokinetic properties and therapeutic    use. Drugs 1985; 29: 105-61.         [ Links ]77.- SCHATZ B S, KARAVOKIROS K T, TAEUBEL    M A, ITOKAZU G S. Comparison of cefprozil, cefpodoxime proxetil, loracarbef,    cefixime, and ceftibuten. Ann Pharmacother 1996; 30: 258-68.         [ Links ]78.- DALMAU D, LAYRARGUES G P, FENYVES D,    WILLEMS B, TURGEON F, TURGEON P. Cefotaxime, desacetyl-cefotaxime, and bactericidal    activity in spontaneous bacterial peritonitis. J Infect Dis 1999; 180: 1597-1602.          [ Links ]79.- NIKAIDO W, LIU W, ROSENBERG E Y. Outer    membrane permeability and ß-lactamase stability of dipolar ionic cephalosporins    containing methoxyimino substituents. Antimicrob Agents Chemother 1990; 34:    337-42.         [ Links ]80.- HANCOCK R E W, BELLIDO F. Factors involved    in the enhanced efficacy against gram-negative bacteria of fourth generation    cephalosporins. J Antimicrob Chemother 1992; 29(Suppl A): 1-6.         [ Links ]81.- BELLIDO F, PECHERE J C, HANCOCK REW.    Novel method for measurement of outer membrane permeability to new beta-lactams    in intact Enterobacter cloacae cells. Antimicrob Agents Chemother 1991;    35: 68-72.         [ Links ]82.- NEU H C, CHIN N X, JULES K, LABTHAVIKUL    P. The activity of BMY-28142, a new broad spectrum beta-lactamase stable cephalosporin.    J Antimicrob Chemother 1986; 17: 441-52.         [ Links ]83.- KOBAYASHI S, ARAI S, HAYASHI S, FUJIMOTO    K. ß-lactamase stability of cefpirome (HR 810), a new cephalosporin with    a broad antimicrobial spectrum. Antimicrob Agents Chemother 1986; 30: 713-8.          [ Links ]84.- GARAU J, WILSON W, WOOD M, CARLET J.    Fourth generation cephalosporins: a review of in vitro activity, pharmacokinetics,    pharmacodynamics, and clinical utility. Clin Microb Infect 1997; 3 (Suppl 1):    87-101.         [ Links ]85.- KESSLER R E, FUNG-TOMC J. Susceptibility    of bacterial isolates to beta-lactam antibiotics from U.S. clinical trials over    5-year period. Am J Med 1996; 24 (6 A): 13-9.         [ Links ]86.- PIERARD D, EMMERECHTS K, LAUWERS S. Comparative    in-vitro activity of cefpirome against isolates from intensive care and haematology/oncology    units. Belgian Multicentric Study Group. J Antimicrob Chemother 1998; 41: 443-50.          [ Links ]87.- JONES R N. Resistance patterns among    nosocomial pathogens: trends over the past few years. Chest 2001; 119 (Suppl    2): 397-404.         [ Links ]88.- LORBER B. Changing patterns of infectious    diseases. Am J Med 1988; 84: 569-78.         [ Links ]89.- MOELLERING R C. A novel antimicrobial    agent joins the battle against resistant bacteria. Ann Intern Med 1999; 130:    155-7.         [ Links ]90.- WILSON W R. The role of fourth-generation    cephalosporins in the treatment of serious infectious diseases in hospitalized    patients. Diagn Microbiol Infect Dis 1998; 31: 473-7.         [ Links ]Correspondencia a:        Sergio Mella Montecinos        Laboratorio de Antibióticos,        Departamento de Microbiología,        Facultad de Ciencias Biológicas        Casilla 160-C, Concepción        E-mail: pignatio@ctcinternet.cl  

54.- O'CALLAGHAN C H 1979. Description and    classification of the newer cephalosporins and their relationship with the established    compounds. J Antimicrob Chemother 5: 635-71         [ Links ]55.- BRYSKIER A, PROCYK T, TREMBLAY D, LENFANT    B FOURTILLAN J B. The pharmacokinetics of cefodizime following intravenous and    intramuscular administration of a single dose of 1.0 g. J Antimicrob Chemother    1990; 26 (Suppl. C): 59-63.         [ Links ]56.- WILLIAMS J D. Classification of cephalosporins.    Drugs. 1987; 34 (Suppl 2): 15-22.         [ Links ]57.- WISEMAN L R, LAMB H M. Cefpirome. A review    of its antibacterial activity, pharmacokinetic properties and efficacy in the    treatment of severe nosocomial infections and febrile neutropenia. Drugs 1997;    57: 117-40.         [ Links ]58.- PECHERE J C, WILSON W, NEU H. Laboratory    assesment of antibacterial activity of zwitterionic 7-methoxyimino cephalosporins.    J Antimicrob Chemother 1995; 36: 757-71         [ Links ]59.- GIAMARELLOS-BOURBOULIS EJ, GRECKA P,    TSITSIKA A, TYMPANIDOU C, GIAMARELLOU H. In-vitro activity of FK 037 (cefoselis),    a novel 4 (th) generation cephalosporin, cefepime and cefpirome on nosocomial    staphylococci and gram-negative isolates. Diagn Microbiol infect Dis 2000; 36:    185-91.         [ Links ]60.- JONES R N, ERWIN M E, BARRETT M S, JOHNSON    D M, BRIGGS B M. Antimicrobial activity of E-1040, a novel thiadiazolyl cephalosporin    compare with parenteral cephems. Diagn Microbiol infect Dis 1991; 14: 301-9.          [ Links ]61.- IIZAWA Y, OKONOGI K, HAYASHI R, IWAHI    T, YAMAZAKI T, IMADA A. Therapeutic effect of cefozopran (SCE-2787), a new parenteral    cephalosporin in experimental infections in mice. Antimicrob Agents Chemother    1993; 37: 100-5.         [ Links ]62.- WATANABE N A. Newer antipseudomonal cephalosporins.    J Chemother 1996; 8 (Suppl 2): 48-56.         [ Links ]63.- ACTOR P, GUARINI J, URI J et al. Disk    susceptibility studies with cefazolin and cephalotin. Antimicrob Agents Chemother    1974; 5: 63-7.         [ Links ]64.- UWAYDAH M. Cefazolin in the treatment    of acute enteric fever. Antimicrob Agents Chemother 1976; 10: 52-6.         [ Links ]65.- JAMAL W Y, ROTIMI V O, CHUGH T D, PAL    T. Prevalence and susceptibility of Shigella to 11 antibiotics in a Kuwait    teaching hospital. J Chemother 1998; 10: 285-90.         [ Links ]66.- COX CE, SHERRILL M, COCCHETT DM. Evaluation    of cefuroxime axetil, cefaclor, and cephalexin in the treatment of urinary tract    infections in adults. Curr Ther Res 1987; 42: 124-37.         [ Links ]67.- SANDERS C W, GREENBERG R N, MARIER R    L. Cefamandole and cefoxitin. Ann Intern Med 1985; 103: 70-8.          [ Links ]68.- STAPLEY E P, JACKSON M, HERNANDEZ S et    al. Cephamycins, a new family of ß-lactam antibiotics I. Production actinomycetes,    including Streptomyces lactamdurans spp.n. Antimicrob Agents Chemother    1972; 2: 122-31.         [ Links ]69.- COOPER R D G. The carbacephems a new    ß-lactams class. Am J Med 1992; 92 (Suppl 6 A): 25-65.         [ Links ]70.- ZEMELMAN R, BELLO H, DOMINGUEZ M, GONZALEZ    G, MELLA S, GARCIA A. Activity of imipenem, third-generation cephalosporins,    aztreonam, and ciprofloxacin against multi-resistant Gram negative bacilli isolated    from Chilean hospitals. J Antimicrob Chemother 1993; 32: 413-9.         [ Links ]71.- MEDEIROS A A. Evolution and dissemination    of ß-lactamases accelerated by generation of ß-lactam antibiotics.    Clin Infect Dis 1997; 24 (Suppl. 1): 19-45.         [ Links ]72.- PERRY C M, BROGDEN R N. Cefuroxime axetil:    review of its antibacterial activity, pharmacokinetic properties and therapeutic    efficacy. Drugs 1996; 52: 125-58.         [ Links ]73.- SCHAAD U B, SUTER S, GIANELLA-BORRADORI    et al. A comparison of ceftriaxone and cefuroxime for the treatment of bacterial    meningitis in children. N Engl J Med 1990; 322: 141-7.         [ Links ]74.- KLEIN N C, CUNHA B A. Cefalosporinas de    la tercera generación. Clin Med Nort Am 1995; 79: 693-707.         [ Links ]75.- KLUGMAN K P, MADHI S A. Emergence of    drug resistance impact on bacterial meningitis. Infect Dis Clin North Am 1999;    13: 637-46.         [ Links ]76.- RICHARDS D M, BROGDEN R N. Ceftazidime.    A review of its antibacterial activity, pharmacokinetic properties and therapeutic    use. Drugs 1985; 29: 105-61.         [ Links ]77.- SCHATZ B S, KARAVOKIROS K T, TAEUBEL    M A, ITOKAZU G S. Comparison of cefprozil, cefpodoxime proxetil, loracarbef,    cefixime, and ceftibuten. Ann Pharmacother 1996; 30: 258-68.         [ Links ]78.- DALMAU D, LAYRARGUES G P, FENYVES D,    WILLEMS B, TURGEON F, TURGEON P. Cefotaxime, desacetyl-cefotaxime, and bactericidal    activity in spontaneous bacterial peritonitis. J Infect Dis 1999; 180: 1597-1602.          [ Links ]79.- NIKAIDO W, LIU W, ROSENBERG E Y. Outer    membrane permeability and ß-lactamase stability of dipolar ionic cephalosporins    containing methoxyimino substituents. Antimicrob Agents Chemother 1990; 34:    337-42.         [ Links ]80.- HANCOCK R E W, BELLIDO F. Factors involved    in the enhanced efficacy against gram-negative bacteria of fourth generation    cephalosporins. J Antimicrob Chemother 1992; 29(Suppl A): 1-6.         [ Links ]81.- BELLIDO F, PECHERE J C, HANCOCK REW.    Novel method for measurement of outer membrane permeability to new beta-lactams    in intact Enterobacter cloacae cells. Antimicrob Agents Chemother 1991;    35: 68-72.         [ Links ]82.- NEU H C, CHIN N X, JULES K, LABTHAVIKUL    P. The activity of BMY-28142, a new broad spectrum beta-lactamase stable cephalosporin.    J Antimicrob Chemother 1986; 17: 441-52.         [ Links ]83.- KOBAYASHI S, ARAI S, HAYASHI S, FUJIMOTO    K. ß-lactamase stability of cefpirome (HR 810), a new cephalosporin with    a broad antimicrobial spectrum. Antimicrob Agents Chemother 1986; 30: 713-8.          [ Links ]84.- GARAU J, WILSON W, WOOD M, CARLET J.    Fourth generation cephalosporins: a review of in vitro activity, pharmacokinetics,    pharmacodynamics, and clinical utility. Clin Microb Infect 1997; 3 (Suppl 1):    87-101.         [ Links ]85.- KESSLER R E, FUNG-TOMC J. Susceptibility    of bacterial isolates to beta-lactam antibiotics from U.S. clinical trials over    5-year period. Am J Med 1996; 24 (6 A): 13-9.         [ Links ]86.- PIERARD D, EMMERECHTS K, LAUWERS S. Comparative    in-vitro activity of cefpirome against isolates from intensive care and haematology/oncology    units. Belgian Multicentric Study Group. J Antimicrob Chemother 1998; 41: 443-50.          [ Links ]87.- JONES R N. Resistance patterns among    nosocomial pathogens: trends over the past few years. Chest 2001; 119 (Suppl    2): 397-404.         [ Links ]88.- LORBER B. Changing patterns of infectious    diseases. Am J Med 1988; 84: 569-78.         [ Links ]89.- MOELLERING R C. A novel antimicrobial    agent joins the battle against resistant bacteria. Ann Intern Med 1999; 130:    155-7.         [ Links ]90.- WILSON W R. The role of fourth-generation    cephalosporins in the treatment of serious infectious diseases in hospitalized    patients. Diagn Microbiol Infect Dis 1998; 31: 473-7.         [ Links ]Correspondencia a:        Sergio Mella Montecinos        Laboratorio de Antibióticos,        Departamento de Microbiología,        Facultad de Ciencias Biológicas        Casilla 160-C, Concepción        E-mail: pignatio@ctcinternet.cl  

55.- BRYSKIER A, PROCYK T, TREMBLAY D, LENFANT    B FOURTILLAN J B. The pharmacokinetics of cefodizime following intravenous and    intramuscular administration of a single dose of 1.0 g. J Antimicrob Chemother    1990; 26 (Suppl. C): 59-63.         [ Links ]56.- WILLIAMS J D. Classification of cephalosporins.    Drugs. 1987; 34 (Suppl 2): 15-22.         [ Links ]57.- WISEMAN L R, LAMB H M. Cefpirome. A review    of its antibacterial activity, pharmacokinetic properties and efficacy in the    treatment of severe nosocomial infections and febrile neutropenia. Drugs 1997;    57: 117-40.         [ Links ]58.- PECHERE J C, WILSON W, NEU H. Laboratory    assesment of antibacterial activity of zwitterionic 7-methoxyimino cephalosporins.    J Antimicrob Chemother 1995; 36: 757-71         [ Links ]59.- GIAMARELLOS-BOURBOULIS EJ, GRECKA P,    TSITSIKA A, TYMPANIDOU C, GIAMARELLOU H. In-vitro activity of FK 037 (cefoselis),    a novel 4 (th) generation cephalosporin, cefepime and cefpirome on nosocomial    staphylococci and gram-negative isolates. Diagn Microbiol infect Dis 2000; 36:    185-91.         [ Links ]60.- JONES R N, ERWIN M E, BARRETT M S, JOHNSON    D M, BRIGGS B M. Antimicrobial activity of E-1040, a novel thiadiazolyl cephalosporin    compare with parenteral cephems. Diagn Microbiol infect Dis 1991; 14: 301-9.          [ Links ]61.- IIZAWA Y, OKONOGI K, HAYASHI R, IWAHI    T, YAMAZAKI T, IMADA A. Therapeutic effect of cefozopran (SCE-2787), a new parenteral    cephalosporin in experimental infections in mice. Antimicrob Agents Chemother    1993; 37: 100-5.         [ Links ]62.- WATANABE N A. Newer antipseudomonal cephalosporins.    J Chemother 1996; 8 (Suppl 2): 48-56.         [ Links ]63.- ACTOR P, GUARINI J, URI J et al. Disk    susceptibility studies with cefazolin and cephalotin. Antimicrob Agents Chemother    1974; 5: 63-7.         [ Links ]64.- UWAYDAH M. Cefazolin in the treatment    of acute enteric fever. Antimicrob Agents Chemother 1976; 10: 52-6.         [ Links ]65.- JAMAL W Y, ROTIMI V O, CHUGH T D, PAL    T. Prevalence and susceptibility of Shigella to 11 antibiotics in a Kuwait    teaching hospital. J Chemother 1998; 10: 285-90.         [ Links ]66.- COX CE, SHERRILL M, COCCHETT DM. Evaluation    of cefuroxime axetil, cefaclor, and cephalexin in the treatment of urinary tract    infections in adults. Curr Ther Res 1987; 42: 124-37.         [ Links ]67.- SANDERS C W, GREENBERG R N, MARIER R    L. Cefamandole and cefoxitin. Ann Intern Med 1985; 103: 70-8.          [ Links ]68.- STAPLEY E P, JACKSON M, HERNANDEZ S et    al. Cephamycins, a new family of ß-lactam antibiotics I. Production actinomycetes,    including Streptomyces lactamdurans spp.n. Antimicrob Agents Chemother    1972; 2: 122-31.         [ Links ]69.- COOPER R D G. The carbacephems a new    ß-lactams class. Am J Med 1992; 92 (Suppl 6 A): 25-65.         [ Links ]70.- ZEMELMAN R, BELLO H, DOMINGUEZ M, GONZALEZ    G, MELLA S, GARCIA A. Activity of imipenem, third-generation cephalosporins,    aztreonam, and ciprofloxacin against multi-resistant Gram negative bacilli isolated    from Chilean hospitals. J Antimicrob Chemother 1993; 32: 413-9.         [ Links ]71.- MEDEIROS A A. Evolution and dissemination    of ß-lactamases accelerated by generation of ß-lactam antibiotics.    Clin Infect Dis 1997; 24 (Suppl. 1): 19-45.         [ Links ]72.- PERRY C M, BROGDEN R N. Cefuroxime axetil:    review of its antibacterial activity, pharmacokinetic properties and therapeutic    efficacy. Drugs 1996; 52: 125-58.         [ Links ]73.- SCHAAD U B, SUTER S, GIANELLA-BORRADORI    et al. A comparison of ceftriaxone and cefuroxime for the treatment of bacterial    meningitis in children. N Engl J Med 1990; 322: 141-7.         [ Links ]74.- KLEIN N C, CUNHA B A. Cefalosporinas de    la tercera generación. Clin Med Nort Am 1995; 79: 693-707.         [ Links ]75.- KLUGMAN K P, MADHI S A. Emergence of    drug resistance impact on bacterial meningitis. Infect Dis Clin North Am 1999;    13: 637-46.         [ Links ]76.- RICHARDS D M, BROGDEN R N. Ceftazidime.    A review of its antibacterial activity, pharmacokinetic properties and therapeutic    use. Drugs 1985; 29: 105-61.         [ Links ]77.- SCHATZ B S, KARAVOKIROS K T, TAEUBEL    M A, ITOKAZU G S. Comparison of cefprozil, cefpodoxime proxetil, loracarbef,    cefixime, and ceftibuten. Ann Pharmacother 1996; 30: 258-68.         [ Links ]78.- DALMAU D, LAYRARGUES G P, FENYVES D,    WILLEMS B, TURGEON F, TURGEON P. Cefotaxime, desacetyl-cefotaxime, and bactericidal    activity in spontaneous bacterial peritonitis. J Infect Dis 1999; 180: 1597-1602.          [ Links ]79.- NIKAIDO W, LIU W, ROSENBERG E Y. Outer    membrane permeability and ß-lactamase stability of dipolar ionic cephalosporins    containing methoxyimino substituents. Antimicrob Agents Chemother 1990; 34:    337-42.         [ Links ]80.- HANCOCK R E W, BELLIDO F. Factors involved    in the enhanced efficacy against gram-negative bacteria of fourth generation    cephalosporins. J Antimicrob Chemother 1992; 29(Suppl A): 1-6.         [ Links ]81.- BELLIDO F, PECHERE J C, HANCOCK REW.    Novel method for measurement of outer membrane permeability to new beta-lactams    in intact Enterobacter cloacae cells. Antimicrob Agents Chemother 1991;    35: 68-72.         [ Links ]82.- NEU H C, CHIN N X, JULES K, LABTHAVIKUL    P. The activity of BMY-28142, a new broad spectrum beta-lactamase stable cephalosporin.    J Antimicrob Chemother 1986; 17: 441-52.         [ Links ]83.- KOBAYASHI S, ARAI S, HAYASHI S, FUJIMOTO    K. ß-lactamase stability of cefpirome (HR 810), a new cephalosporin with    a broad antimicrobial spectrum. Antimicrob Agents Chemother 1986; 30: 713-8.          [ Links ]84.- GARAU J, WILSON W, WOOD M, CARLET J.    Fourth generation cephalosporins: a review of in vitro activity, pharmacokinetics,    pharmacodynamics, and clinical utility. Clin Microb Infect 1997; 3 (Suppl 1):    87-101.         [ Links ]85.- KESSLER R E, FUNG-TOMC J. Susceptibility    of bacterial isolates to beta-lactam antibiotics from U.S. clinical trials over    5-year period. Am J Med 1996; 24 (6 A): 13-9.         [ Links ]86.- PIERARD D, EMMERECHTS K, LAUWERS S. Comparative    in-vitro activity of cefpirome against isolates from intensive care and haematology/oncology    units. Belgian Multicentric Study Group. J Antimicrob Chemother 1998; 41: 443-50.          [ Links ]87.- JONES R N. Resistance patterns among    nosocomial pathogens: trends over the past few years. Chest 2001; 119 (Suppl    2): 397-404.         [ Links ]88.- LORBER B. Changing patterns of infectious    diseases. Am J Med 1988; 84: 569-78.         [ Links ]89.- MOELLERING R C. A novel antimicrobial    agent joins the battle against resistant bacteria. Ann Intern Med 1999; 130:    155-7.         [ Links ]90.- WILSON W R. The role of fourth-generation    cephalosporins in the treatment of serious infectious diseases in hospitalized    patients. Diagn Microbiol Infect Dis 1998; 31: 473-7.         [ Links ]Correspondencia a:        Sergio Mella Montecinos        Laboratorio de Antibióticos,        Departamento de Microbiología,        Facultad de Ciencias Biológicas        Casilla 160-C, Concepción        E-mail: pignatio@ctcinternet.cl  

56.- WILLIAMS J D. Classification of cephalosporins.    Drugs. 1987; 34 (Suppl 2): 15-22.         [ Links ]57.- WISEMAN L R, LAMB H M. Cefpirome. A review    of its antibacterial activity, pharmacokinetic properties and efficacy in the    treatment of severe nosocomial infections and febrile neutropenia. Drugs 1997;    57: 117-40.         [ Links ]58.- PECHERE J C, WILSON W, NEU H. Laboratory    assesment of antibacterial activity of zwitterionic 7-methoxyimino cephalosporins.    J Antimicrob Chemother 1995; 36: 757-71         [ Links ]59.- GIAMARELLOS-BOURBOULIS EJ, GRECKA P,    TSITSIKA A, TYMPANIDOU C, GIAMARELLOU H. In-vitro activity of FK 037 (cefoselis),    a novel 4 (th) generation cephalosporin, cefepime and cefpirome on nosocomial    staphylococci and gram-negative isolates. Diagn Microbiol infect Dis 2000; 36:    185-91.         [ Links ]60.- JONES R N, ERWIN M E, BARRETT M S, JOHNSON    D M, BRIGGS B M. Antimicrobial activity of E-1040, a novel thiadiazolyl cephalosporin    compare with parenteral cephems. Diagn Microbiol infect Dis 1991; 14: 301-9.          [ Links ]61.- IIZAWA Y, OKONOGI K, HAYASHI R, IWAHI    T, YAMAZAKI T, IMADA A. Therapeutic effect of cefozopran (SCE-2787), a new parenteral    cephalosporin in experimental infections in mice. Antimicrob Agents Chemother    1993; 37: 100-5.         [ Links ]62.- WATANABE N A. Newer antipseudomonal cephalosporins.    J Chemother 1996; 8 (Suppl 2): 48-56.         [ Links ]63.- ACTOR P, GUARINI J, URI J et al. Disk    susceptibility studies with cefazolin and cephalotin. Antimicrob Agents Chemother    1974; 5: 63-7.         [ Links ]64.- UWAYDAH M. Cefazolin in the treatment    of acute enteric fever. Antimicrob Agents Chemother 1976; 10: 52-6.         [ Links ]65.- JAMAL W Y, ROTIMI V O, CHUGH T D, PAL    T. Prevalence and susceptibility of Shigella to 11 antibiotics in a Kuwait    teaching hospital. J Chemother 1998; 10: 285-90.         [ Links ]66.- COX CE, SHERRILL M, COCCHETT DM. Evaluation    of cefuroxime axetil, cefaclor, and cephalexin in the treatment of urinary tract    infections in adults. Curr Ther Res 1987; 42: 124-37.         [ Links ]67.- SANDERS C W, GREENBERG R N, MARIER R    L. Cefamandole and cefoxitin. Ann Intern Med 1985; 103: 70-8.          [ Links ]68.- STAPLEY E P, JACKSON M, HERNANDEZ S et    al. Cephamycins, a new family of ß-lactam antibiotics I. Production actinomycetes,    including Streptomyces lactamdurans spp.n. Antimicrob Agents Chemother    1972; 2: 122-31.         [ Links ]69.- COOPER R D G. The carbacephems a new    ß-lactams class. Am J Med 1992; 92 (Suppl 6 A): 25-65.         [ Links ]70.- ZEMELMAN R, BELLO H, DOMINGUEZ M, GONZALEZ    G, MELLA S, GARCIA A. Activity of imipenem, third-generation cephalosporins,    aztreonam, and ciprofloxacin against multi-resistant Gram negative bacilli isolated    from Chilean hospitals. J Antimicrob Chemother 1993; 32: 413-9.         [ Links ]71.- MEDEIROS A A. Evolution and dissemination    of ß-lactamases accelerated by generation of ß-lactam antibiotics.    Clin Infect Dis 1997; 24 (Suppl. 1): 19-45.         [ Links ]72.- PERRY C M, BROGDEN R N. Cefuroxime axetil:    review of its antibacterial activity, pharmacokinetic properties and therapeutic    efficacy. Drugs 1996; 52: 125-58.         [ Links ]73.- SCHAAD U B, SUTER S, GIANELLA-BORRADORI    et al. A comparison of ceftriaxone and cefuroxime for the treatment of bacterial    meningitis in children. N Engl J Med 1990; 322: 141-7.         [ Links ]74.- KLEIN N C, CUNHA B A. Cefalosporinas de    la tercera generación. Clin Med Nort Am 1995; 79: 693-707.         [ Links ]75.- KLUGMAN K P, MADHI S A. Emergence of    drug resistance impact on bacterial meningitis. Infect Dis Clin North Am 1999;    13: 637-46.         [ Links ]76.- RICHARDS D M, BROGDEN R N. Ceftazidime.    A review of its antibacterial activity, pharmacokinetic properties and therapeutic    use. Drugs 1985; 29: 105-61.         [ Links ]77.- SCHATZ B S, KARAVOKIROS K T, TAEUBEL    M A, ITOKAZU G S. Comparison of cefprozil, cefpodoxime proxetil, loracarbef,    cefixime, and ceftibuten. Ann Pharmacother 1996; 30: 258-68.         [ Links ]78.- DALMAU D, LAYRARGUES G P, FENYVES D,    WILLEMS B, TURGEON F, TURGEON P. Cefotaxime, desacetyl-cefotaxime, and bactericidal    activity in spontaneous bacterial peritonitis. J Infect Dis 1999; 180: 1597-1602.          [ Links ]79.- NIKAIDO W, LIU W, ROSENBERG E Y. Outer    membrane permeability and ß-lactamase stability of dipolar ionic cephalosporins    containing methoxyimino substituents. Antimicrob Agents Chemother 1990; 34:    337-42.         [ Links ]80.- HANCOCK R E W, BELLIDO F. Factors involved    in the enhanced efficacy against gram-negative bacteria of fourth generation    cephalosporins. J Antimicrob Chemother 1992; 29(Suppl A): 1-6.         [ Links ]81.- BELLIDO F, PECHERE J C, HANCOCK REW.    Novel method for measurement of outer membrane permeability to new beta-lactams    in intact Enterobacter cloacae cells. Antimicrob Agents Chemother 1991;    35: 68-72.         [ Links ]82.- NEU H C, CHIN N X, JULES K, LABTHAVIKUL    P. The activity of BMY-28142, a new broad spectrum beta-lactamase stable cephalosporin.    J Antimicrob Chemother 1986; 17: 441-52.         [ Links ]83.- KOBAYASHI S, ARAI S, HAYASHI S, FUJIMOTO    K. ß-lactamase stability of cefpirome (HR 810), a new cephalosporin with    a broad antimicrobial spectrum. Antimicrob Agents Chemother 1986; 30: 713-8.          [ Links ]84.- GARAU J, WILSON W, WOOD M, CARLET J.    Fourth generation cephalosporins: a review of in vitro activity, pharmacokinetics,    pharmacodynamics, and clinical utility. Clin Microb Infect 1997; 3 (Suppl 1):    87-101.         [ Links ]85.- KESSLER R E, FUNG-TOMC J. Susceptibility    of bacterial isolates to beta-lactam antibiotics from U.S. clinical trials over    5-year period. Am J Med 1996; 24 (6 A): 13-9.         [ Links ]86.- PIERARD D, EMMERECHTS K, LAUWERS S. Comparative    in-vitro activity of cefpirome against isolates from intensive care and haematology/oncology    units. Belgian Multicentric Study Group. J Antimicrob Chemother 1998; 41: 443-50.          [ Links ]87.- JONES R N. Resistance patterns among    nosocomial pathogens: trends over the past few years. Chest 2001; 119 (Suppl    2): 397-404.         [ Links ]88.- LORBER B. Changing patterns of infectious    diseases. Am J Med 1988; 84: 569-78.         [ Links ]89.- MOELLERING R C. A novel antimicrobial    agent joins the battle against resistant bacteria. Ann Intern Med 1999; 130:    155-7.         [ Links ]90.- WILSON W R. The role of fourth-generation    cephalosporins in the treatment of serious infectious diseases in hospitalized    patients. Diagn Microbiol Infect Dis 1998; 31: 473-7.         [ Links ]Correspondencia a:        Sergio Mella Montecinos        Laboratorio de Antibióticos,        Departamento de Microbiología,        Facultad de Ciencias Biológicas        Casilla 160-C, Concepción        E-mail: pignatio@ctcinternet.cl  

57.- WISEMAN L R, LAMB H M. Cefpirome. A review    of its antibacterial activity, pharmacokinetic properties and efficacy in the    treatment of severe nosocomial infections and febrile neutropenia. Drugs 1997;    57: 117-40.         [ Links ]58.- PECHERE J C, WILSON W, NEU H. Laboratory    assesment of antibacterial activity of zwitterionic 7-methoxyimino cephalosporins.    J Antimicrob Chemother 1995; 36: 757-71         [ Links ]59.- GIAMARELLOS-BOURBOULIS EJ, GRECKA P,    TSITSIKA A, TYMPANIDOU C, GIAMARELLOU H. In-vitro activity of FK 037 (cefoselis),    a novel 4 (th) generation cephalosporin, cefepime and cefpirome on nosocomial    staphylococci and gram-negative isolates. Diagn Microbiol infect Dis 2000; 36:    185-91.         [ Links ]60.- JONES R N, ERWIN M E, BARRETT M S, JOHNSON    D M, BRIGGS B M. Antimicrobial activity of E-1040, a novel thiadiazolyl cephalosporin    compare with parenteral cephems. Diagn Microbiol infect Dis 1991; 14: 301-9.          [ Links ]61.- IIZAWA Y, OKONOGI K, HAYASHI R, IWAHI    T, YAMAZAKI T, IMADA A. Therapeutic effect of cefozopran (SCE-2787), a new parenteral    cephalosporin in experimental infections in mice. Antimicrob Agents Chemother    1993; 37: 100-5.         [ Links ]62.- WATANABE N A. Newer antipseudomonal cephalosporins.    J Chemother 1996; 8 (Suppl 2): 48-56.         [ Links ]63.- ACTOR P, GUARINI J, URI J et al. Disk    susceptibility studies with cefazolin and cephalotin. Antimicrob Agents Chemother    1974; 5: 63-7.         [ Links ]64.- UWAYDAH M. Cefazolin in the treatment    of acute enteric fever. Antimicrob Agents Chemother 1976; 10: 52-6.         [ Links ]65.- JAMAL W Y, ROTIMI V O, CHUGH T D, PAL    T. Prevalence and susceptibility of Shigella to 11 antibiotics in a Kuwait    teaching hospital. J Chemother 1998; 10: 285-90.         [ Links ]66.- COX CE, SHERRILL M, COCCHETT DM. Evaluation    of cefuroxime axetil, cefaclor, and cephalexin in the treatment of urinary tract    infections in adults. Curr Ther Res 1987; 42: 124-37.         [ Links ]67.- SANDERS C W, GREENBERG R N, MARIER R    L. Cefamandole and cefoxitin. Ann Intern Med 1985; 103: 70-8.          [ Links ]68.- STAPLEY E P, JACKSON M, HERNANDEZ S et    al. Cephamycins, a new family of ß-lactam antibiotics I. Production actinomycetes,    including Streptomyces lactamdurans spp.n. Antimicrob Agents Chemother    1972; 2: 122-31.         [ Links ]69.- COOPER R D G. The carbacephems a new    ß-lactams class. Am J Med 1992; 92 (Suppl 6 A): 25-65.         [ Links ]70.- ZEMELMAN R, BELLO H, DOMINGUEZ M, GONZALEZ    G, MELLA S, GARCIA A. Activity of imipenem, third-generation cephalosporins,    aztreonam, and ciprofloxacin against multi-resistant Gram negative bacilli isolated    from Chilean hospitals. J Antimicrob Chemother 1993; 32: 413-9.         [ Links ]71.- MEDEIROS A A. Evolution and dissemination    of ß-lactamases accelerated by generation of ß-lactam antibiotics.    Clin Infect Dis 1997; 24 (Suppl. 1): 19-45.         [ Links ]72.- PERRY C M, BROGDEN R N. Cefuroxime axetil:    review of its antibacterial activity, pharmacokinetic properties and therapeutic    efficacy. Drugs 1996; 52: 125-58.         [ Links ]73.- SCHAAD U B, SUTER S, GIANELLA-BORRADORI    et al. A comparison of ceftriaxone and cefuroxime for the treatment of bacterial    meningitis in children. N Engl J Med 1990; 322: 141-7.         [ Links ]74.- KLEIN N C, CUNHA B A. Cefalosporinas de    la tercera generación. Clin Med Nort Am 1995; 79: 693-707.         [ Links ]75.- KLUGMAN K P, MADHI S A. Emergence of    drug resistance impact on bacterial meningitis. Infect Dis Clin North Am 1999;    13: 637-46.         [ Links ]76.- RICHARDS D M, BROGDEN R N. Ceftazidime.    A review of its antibacterial activity, pharmacokinetic properties and therapeutic    use. Drugs 1985; 29: 105-61.         [ Links ]77.- SCHATZ B S, KARAVOKIROS K T, TAEUBEL    M A, ITOKAZU G S. Comparison of cefprozil, cefpodoxime proxetil, loracarbef,    cefixime, and ceftibuten. Ann Pharmacother 1996; 30: 258-68.         [ Links ]78.- DALMAU D, LAYRARGUES G P, FENYVES D,    WILLEMS B, TURGEON F, TURGEON P. Cefotaxime, desacetyl-cefotaxime, and bactericidal    activity in spontaneous bacterial peritonitis. J Infect Dis 1999; 180: 1597-1602.          [ Links ]79.- NIKAIDO W, LIU W, ROSENBERG E Y. Outer    membrane permeability and ß-lactamase stability of dipolar ionic cephalosporins    containing methoxyimino substituents. Antimicrob Agents Chemother 1990; 34:    337-42.         [ Links ]80.- HANCOCK R E W, BELLIDO F. Factors involved    in the enhanced efficacy against gram-negative bacteria of fourth generation    cephalosporins. J Antimicrob Chemother 1992; 29(Suppl A): 1-6.         [ Links ]81.- BELLIDO F, PECHERE J C, HANCOCK REW.    Novel method for measurement of outer membrane permeability to new beta-lactams    in intact Enterobacter cloacae cells. Antimicrob Agents Chemother 1991;    35: 68-72.         [ Links ]82.- NEU H C, CHIN N X, JULES K, LABTHAVIKUL    P. The activity of BMY-28142, a new broad spectrum beta-lactamase stable cephalosporin.    J Antimicrob Chemother 1986; 17: 441-52.         [ Links ]83.- KOBAYASHI S, ARAI S, HAYASHI S, FUJIMOTO    K. ß-lactamase stability of cefpirome (HR 810), a new cephalosporin with    a broad antimicrobial spectrum. Antimicrob Agents Chemother 1986; 30: 713-8.          [ Links ]84.- GARAU J, WILSON W, WOOD M, CARLET J.    Fourth generation cephalosporins: a review of in vitro activity, pharmacokinetics,    pharmacodynamics, and clinical utility. Clin Microb Infect 1997; 3 (Suppl 1):    87-101.         [ Links ]85.- KESSLER R E, FUNG-TOMC J. Susceptibility    of bacterial isolates to beta-lactam antibiotics from U.S. clinical trials over    5-year period. Am J Med 1996; 24 (6 A): 13-9.         [ Links ]86.- PIERARD D, EMMERECHTS K, LAUWERS S. Comparative    in-vitro activity of cefpirome against isolates from intensive care and haematology/oncology    units. Belgian Multicentric Study Group. J Antimicrob Chemother 1998; 41: 443-50.          [ Links ]87.- JONES R N. Resistance patterns among    nosocomial pathogens: trends over the past few years. Chest 2001; 119 (Suppl    2): 397-404.         [ Links ]88.- LORBER B. Changing patterns of infectious    diseases. Am J Med 1988; 84: 569-78.         [ Links ]89.- MOELLERING R C. A novel antimicrobial    agent joins the battle against resistant bacteria. Ann Intern Med 1999; 130:    155-7.         [ Links ]90.- WILSON W R. The role of fourth-generation    cephalosporins in the treatment of serious infectious diseases in hospitalized    patients. Diagn Microbiol Infect Dis 1998; 31: 473-7.         [ Links ]Correspondencia a:        Sergio Mella Montecinos        Laboratorio de Antibióticos,        Departamento de Microbiología,        Facultad de Ciencias Biológicas        Casilla 160-C, Concepción        E-mail: pignatio@ctcinternet.cl  

58.- PECHERE J C, WILSON W, NEU H. Laboratory    assesment of antibacterial activity of zwitterionic 7-methoxyimino cephalosporins.    J Antimicrob Chemother 1995; 36: 757-71         [ Links ]59.- GIAMARELLOS-BOURBOULIS EJ, GRECKA P,    TSITSIKA A, TYMPANIDOU C, GIAMARELLOU H. In-vitro activity of FK 037 (cefoselis),    a novel 4 (th) generation cephalosporin, cefepime and cefpirome on nosocomial    staphylococci and gram-negative isolates. Diagn Microbiol infect Dis 2000; 36:    185-91.         [ Links ]60.- JONES R N, ERWIN M E, BARRETT M S, JOHNSON    D M, BRIGGS B M. Antimicrobial activity of E-1040, a novel thiadiazolyl cephalosporin    compare with parenteral cephems. Diagn Microbiol infect Dis 1991; 14: 301-9.          [ Links ]61.- IIZAWA Y, OKONOGI K, HAYASHI R, IWAHI    T, YAMAZAKI T, IMADA A. Therapeutic effect of cefozopran (SCE-2787), a new parenteral    cephalosporin in experimental infections in mice. Antimicrob Agents Chemother    1993; 37: 100-5.         [ Links ]62.- WATANABE N A. Newer antipseudomonal cephalosporins.    J Chemother 1996; 8 (Suppl 2): 48-56.         [ Links ]63.- ACTOR P, GUARINI J, URI J et al. Disk    susceptibility studies with cefazolin and cephalotin. Antimicrob Agents Chemother    1974; 5: 63-7.         [ Links ]64.- UWAYDAH M. Cefazolin in the treatment    of acute enteric fever. Antimicrob Agents Chemother 1976; 10: 52-6.         [ Links ]65.- JAMAL W Y, ROTIMI V O, CHUGH T D, PAL    T. Prevalence and susceptibility of Shigella to 11 antibiotics in a Kuwait    teaching hospital. J Chemother 1998; 10: 285-90.         [ Links ]66.- COX CE, SHERRILL M, COCCHETT DM. Evaluation    of cefuroxime axetil, cefaclor, and cephalexin in the treatment of urinary tract    infections in adults. Curr Ther Res 1987; 42: 124-37.         [ Links ]67.- SANDERS C W, GREENBERG R N, MARIER R    L. Cefamandole and cefoxitin. Ann Intern Med 1985; 103: 70-8.          [ Links ]68.- STAPLEY E P, JACKSON M, HERNANDEZ S et    al. Cephamycins, a new family of ß-lactam antibiotics I. Production actinomycetes,    including Streptomyces lactamdurans spp.n. Antimicrob Agents Chemother    1972; 2: 122-31.         [ Links ]69.- COOPER R D G. The carbacephems a new    ß-lactams class. Am J Med 1992; 92 (Suppl 6 A): 25-65.         [ Links ]70.- ZEMELMAN R, BELLO H, DOMINGUEZ M, GONZALEZ    G, MELLA S, GARCIA A. Activity of imipenem, third-generation cephalosporins,    aztreonam, and ciprofloxacin against multi-resistant Gram negative bacilli isolated    from Chilean hospitals. J Antimicrob Chemother 1993; 32: 413-9.         [ Links ]71.- MEDEIROS A A. Evolution and dissemination    of ß-lactamases accelerated by generation of ß-lactam antibiotics.    Clin Infect Dis 1997; 24 (Suppl. 1): 19-45.         [ Links ]72.- PERRY C M, BROGDEN R N. Cefuroxime axetil:    review of its antibacterial activity, pharmacokinetic properties and therapeutic    efficacy. Drugs 1996; 52: 125-58.         [ Links ]73.- SCHAAD U B, SUTER S, GIANELLA-BORRADORI    et al. A comparison of ceftriaxone and cefuroxime for the treatment of bacterial    meningitis in children. N Engl J Med 1990; 322: 141-7.         [ Links ]74.- KLEIN N C, CUNHA B A. Cefalosporinas de    la tercera generación. Clin Med Nort Am 1995; 79: 693-707.         [ Links ]75.- KLUGMAN K P, MADHI S A. Emergence of    drug resistance impact on bacterial meningitis. Infect Dis Clin North Am 1999;    13: 637-46.         [ Links ]76.- RICHARDS D M, BROGDEN R N. Ceftazidime.    A review of its antibacterial activity, pharmacokinetic properties and therapeutic    use. Drugs 1985; 29: 105-61.         [ Links ]77.- SCHATZ B S, KARAVOKIROS K T, TAEUBEL    M A, ITOKAZU G S. Comparison of cefprozil, cefpodoxime proxetil, loracarbef,    cefixime, and ceftibuten. Ann Pharmacother 1996; 30: 258-68.         [ Links ]78.- DALMAU D, LAYRARGUES G P, FENYVES D,    WILLEMS B, TURGEON F, TURGEON P. Cefotaxime, desacetyl-cefotaxime, and bactericidal    activity in spontaneous bacterial peritonitis. J Infect Dis 1999; 180: 1597-1602.          [ Links ]79.- NIKAIDO W, LIU W, ROSENBERG E Y. Outer    membrane permeability and ß-lactamase stability of dipolar ionic cephalosporins    containing methoxyimino substituents. Antimicrob Agents Chemother 1990; 34:    337-42.         [ Links ]80.- HANCOCK R E W, BELLIDO F. Factors involved    in the enhanced efficacy against gram-negative bacteria of fourth generation    cephalosporins. J Antimicrob Chemother 1992; 29(Suppl A): 1-6.         [ Links ]81.- BELLIDO F, PECHERE J C, HANCOCK REW.    Novel method for measurement of outer membrane permeability to new beta-lactams    in intact Enterobacter cloacae cells. Antimicrob Agents Chemother 1991;    35: 68-72.         [ Links ]82.- NEU H C, CHIN N X, JULES K, LABTHAVIKUL    P. The activity of BMY-28142, a new broad spectrum beta-lactamase stable cephalosporin.    J Antimicrob Chemother 1986; 17: 441-52.         [ Links ]83.- KOBAYASHI S, ARAI S, HAYASHI S, FUJIMOTO    K. ß-lactamase stability of cefpirome (HR 810), a new cephalosporin with    a broad antimicrobial spectrum. Antimicrob Agents Chemother 1986; 30: 713-8.          [ Links ]84.- GARAU J, WILSON W, WOOD M, CARLET J.    Fourth generation cephalosporins: a review of in vitro activity, pharmacokinetics,    pharmacodynamics, and clinical utility. Clin Microb Infect 1997; 3 (Suppl 1):    87-101.         [ Links ]85.- KESSLER R E, FUNG-TOMC J. Susceptibility    of bacterial isolates to beta-lactam antibiotics from U.S. clinical trials over    5-year period. Am J Med 1996; 24 (6 A): 13-9.         [ Links ]86.- PIERARD D, EMMERECHTS K, LAUWERS S. Comparative    in-vitro activity of cefpirome against isolates from intensive care and haematology/oncology    units. Belgian Multicentric Study Group. J Antimicrob Chemother 1998; 41: 443-50.          [ Links ]87.- JONES R N. Resistance patterns among    nosocomial pathogens: trends over the past few years. Chest 2001; 119 (Suppl    2): 397-404.         [ Links ]88.- LORBER B. Changing patterns of infectious    diseases. Am J Med 1988; 84: 569-78.         [ Links ]89.- MOELLERING R C. A novel antimicrobial    agent joins the battle against resistant bacteria. Ann Intern Med 1999; 130:    155-7.         [ Links ]90.- WILSON W R. The role of fourth-generation    cephalosporins in the treatment of serious infectious diseases in hospitalized    patients. Diagn Microbiol Infect Dis 1998; 31: 473-7.         [ Links ]Correspondencia a:        Sergio Mella Montecinos        Laboratorio de Antibióticos,        Departamento de Microbiología,        Facultad de Ciencias Biológicas        Casilla 160-C, Concepción        E-mail: pignatio@ctcinternet.cl  

59.- GIAMARELLOS-BOURBOULIS EJ, GRECKA P,    TSITSIKA A, TYMPANIDOU C, GIAMARELLOU H. In-vitro activity of FK 037 (cefoselis),    a novel 4 (th) generation cephalosporin, cefepime and cefpirome on nosocomial    staphylococci and gram-negative isolates. Diagn Microbiol infect Dis 2000; 36:    185-91.         [ Links ]60.- JONES R N, ERWIN M E, BARRETT M S, JOHNSON    D M, BRIGGS B M. Antimicrobial activity of E-1040, a novel thiadiazolyl cephalosporin    compare with parenteral cephems. Diagn Microbiol infect Dis 1991; 14: 301-9.          [ Links ]61.- IIZAWA Y, OKONOGI K, HAYASHI R, IWAHI    T, YAMAZAKI T, IMADA A. Therapeutic effect of cefozopran (SCE-2787), a new parenteral    cephalosporin in experimental infections in mice. Antimicrob Agents Chemother    1993; 37: 100-5.         [ Links ]62.- WATANABE N A. Newer antipseudomonal cephalosporins.    J Chemother 1996; 8 (Suppl 2): 48-56.         [ Links ]63.- ACTOR P, GUARINI J, URI J et al. Disk    susceptibility studies with cefazolin and cephalotin. Antimicrob Agents Chemother    1974; 5: 63-7.         [ Links ]64.- UWAYDAH M. Cefazolin in the treatment    of acute enteric fever. Antimicrob Agents Chemother 1976; 10: 52-6.         [ Links ]65.- JAMAL W Y, ROTIMI V O, CHUGH T D, PAL    T. Prevalence and susceptibility of Shigella to 11 antibiotics in a Kuwait    teaching hospital. J Chemother 1998; 10: 285-90.         [ Links ]66.- COX CE, SHERRILL M, COCCHETT DM. Evaluation    of cefuroxime axetil, cefaclor, and cephalexin in the treatment of urinary tract    infections in adults. Curr Ther Res 1987; 42: 124-37.         [ Links ]67.- SANDERS C W, GREENBERG R N, MARIER R    L. Cefamandole and cefoxitin. Ann Intern Med 1985; 103: 70-8.          [ Links ]68.- STAPLEY E P, JACKSON M, HERNANDEZ S et    al. Cephamycins, a new family of ß-lactam antibiotics I. Production actinomycetes,    including Streptomyces lactamdurans spp.n. Antimicrob Agents Chemother    1972; 2: 122-31.         [ Links ]69.- COOPER R D G. The carbacephems a new    ß-lactams class. Am J Med 1992; 92 (Suppl 6 A): 25-65.         [ Links ]70.- ZEMELMAN R, BELLO H, DOMINGUEZ M, GONZALEZ    G, MELLA S, GARCIA A. Activity of imipenem, third-generation cephalosporins,    aztreonam, and ciprofloxacin against multi-resistant Gram negative bacilli isolated    from Chilean hospitals. J Antimicrob Chemother 1993; 32: 413-9.         [ Links ]71.- MEDEIROS A A. Evolution and dissemination    of ß-lactamases accelerated by generation of ß-lactam antibiotics.    Clin Infect Dis 1997; 24 (Suppl. 1): 19-45.         [ Links ]72.- PERRY C M, BROGDEN R N. Cefuroxime axetil:    review of its antibacterial activity, pharmacokinetic properties and therapeutic    efficacy. Drugs 1996; 52: 125-58.         [ Links ]73.- SCHAAD U B, SUTER S, GIANELLA-BORRADORI    et al. A comparison of ceftriaxone and cefuroxime for the treatment of bacterial    meningitis in children. N Engl J Med 1990; 322: 141-7.         [ Links ]74.- KLEIN N C, CUNHA B A. Cefalosporinas de    la tercera generación. Clin Med Nort Am 1995; 79: 693-707.         [ Links ]75.- KLUGMAN K P, MADHI S A. Emergence of    drug resistance impact on bacterial meningitis. Infect Dis Clin North Am 1999;    13: 637-46.         [ Links ]76.- RICHARDS D M, BROGDEN R N. Ceftazidime.    A review of its antibacterial activity, pharmacokinetic properties and therapeutic    use. Drugs 1985; 29: 105-61.         [ Links ]77.- SCHATZ B S, KARAVOKIROS K T, TAEUBEL    M A, ITOKAZU G S. Comparison of cefprozil, cefpodoxime proxetil, loracarbef,    cefixime, and ceftibuten. Ann Pharmacother 1996; 30: 258-68.         [ Links ]78.- DALMAU D, LAYRARGUES G P, FENYVES D,    WILLEMS B, TURGEON F, TURGEON P. Cefotaxime, desacetyl-cefotaxime, and bactericidal    activity in spontaneous bacterial peritonitis. J Infect Dis 1999; 180: 1597-1602.          [ Links ]79.- NIKAIDO W, LIU W, ROSENBERG E Y. Outer    membrane permeability and ß-lactamase stability of dipolar ionic cephalosporins    containing methoxyimino substituents. Antimicrob Agents Chemother 1990; 34:    337-42.         [ Links ]80.- HANCOCK R E W, BELLIDO F. Factors involved    in the enhanced efficacy against gram-negative bacteria of fourth generation    cephalosporins. J Antimicrob Chemother 1992; 29(Suppl A): 1-6.         [ Links ]81.- BELLIDO F, PECHERE J C, HANCOCK REW.    Novel method for measurement of outer membrane permeability to new beta-lactams    in intact Enterobacter cloacae cells. Antimicrob Agents Chemother 1991;    35: 68-72.         [ Links ]82.- NEU H C, CHIN N X, JULES K, LABTHAVIKUL    P. The activity of BMY-28142, a new broad spectrum beta-lactamase stable cephalosporin.    J Antimicrob Chemother 1986; 17: 441-52.         [ Links ]83.- KOBAYASHI S, ARAI S, HAYASHI S, FUJIMOTO    K. ß-lactamase stability of cefpirome (HR 810), a new cephalosporin with    a broad antimicrobial spectrum. Antimicrob Agents Chemother 1986; 30: 713-8.          [ Links ]84.- GARAU J, WILSON W, WOOD M, CARLET J.    Fourth generation cephalosporins: a review of in vitro activity, pharmacokinetics,    pharmacodynamics, and clinical utility. Clin Microb Infect 1997; 3 (Suppl 1):    87-101.         [ Links ]85.- KESSLER R E, FUNG-TOMC J. Susceptibility    of bacterial isolates to beta-lactam antibiotics from U.S. clinical trials over    5-year period. Am J Med 1996; 24 (6 A): 13-9.         [ Links ]86.- PIERARD D, EMMERECHTS K, LAUWERS S. Comparative    in-vitro activity of cefpirome against isolates from intensive care and haematology/oncology    units. Belgian Multicentric Study Group. J Antimicrob Chemother 1998; 41: 443-50.          [ Links ]87.- JONES R N. Resistance patterns among    nosocomial pathogens: trends over the past few years. Chest 2001; 119 (Suppl    2): 397-404.         [ Links ]88.- LORBER B. Changing patterns of infectious    diseases. Am J Med 1988; 84: 569-78.         [ Links ]89.- MOELLERING R C. A novel antimicrobial    agent joins the battle against resistant bacteria. Ann Intern Med 1999; 130:    155-7.         [ Links ]90.- WILSON W R. The role of fourth-generation    cephalosporins in the treatment of serious infectious diseases in hospitalized    patients. Diagn Microbiol Infect Dis 1998; 31: 473-7.         [ Links ]Correspondencia a:        Sergio Mella Montecinos        Laboratorio de Antibióticos,        Departamento de Microbiología,        Facultad de Ciencias Biológicas        Casilla 160-C, Concepción        E-mail: pignatio@ctcinternet.cl  

60.- JONES R N, ERWIN M E, BARRETT M S, JOHNSON    D M, BRIGGS B M. Antimicrobial activity of E-1040, a novel thiadiazolyl cephalosporin    compare with parenteral cephems. Diagn Microbiol infect Dis 1991; 14: 301-9.          [ Links ]61.- IIZAWA Y, OKONOGI K, HAYASHI R, IWAHI    T, YAMAZAKI T, IMADA A. Therapeutic effect of cefozopran (SCE-2787), a new parenteral    cephalosporin in experimental infections in mice. Antimicrob Agents Chemother    1993; 37: 100-5.         [ Links ]62.- WATANABE N A. Newer antipseudomonal cephalosporins.    J Chemother 1996; 8 (Suppl 2): 48-56.         [ Links ]63.- ACTOR P, GUARINI J, URI J et al. Disk    susceptibility studies with cefazolin and cephalotin. Antimicrob Agents Chemother    1974; 5: 63-7.         [ Links ]64.- UWAYDAH M. Cefazolin in the treatment    of acute enteric fever. Antimicrob Agents Chemother 1976; 10: 52-6.         [ Links ]65.- JAMAL W Y, ROTIMI V O, CHUGH T D, PAL    T. Prevalence and susceptibility of Shigella to 11 antibiotics in a Kuwait    teaching hospital. J Chemother 1998; 10: 285-90.         [ Links ]66.- COX CE, SHERRILL M, COCCHETT DM. Evaluation    of cefuroxime axetil, cefaclor, and cephalexin in the treatment of urinary tract    infections in adults. Curr Ther Res 1987; 42: 124-37.         [ Links ]67.- SANDERS C W, GREENBERG R N, MARIER R    L. Cefamandole and cefoxitin. Ann Intern Med 1985; 103: 70-8.          [ Links ]68.- STAPLEY E P, JACKSON M, HERNANDEZ S et    al. Cephamycins, a new family of ß-lactam antibiotics I. Production actinomycetes,    including Streptomyces lactamdurans spp.n. Antimicrob Agents Chemother    1972; 2: 122-31.         [ Links ]69.- COOPER R D G. The carbacephems a new    ß-lactams class. Am J Med 1992; 92 (Suppl 6 A): 25-65.         [ Links ]70.- ZEMELMAN R, BELLO H, DOMINGUEZ M, GONZALEZ    G, MELLA S, GARCIA A. Activity of imipenem, third-generation cephalosporins,    aztreonam, and ciprofloxacin against multi-resistant Gram negative bacilli isolated    from Chilean hospitals. J Antimicrob Chemother 1993; 32: 413-9.         [ Links ]71.- MEDEIROS A A. Evolution and dissemination    of ß-lactamases accelerated by generation of ß-lactam antibiotics.    Clin Infect Dis 1997; 24 (Suppl. 1): 19-45.         [ Links ]72.- PERRY C M, BROGDEN R N. Cefuroxime axetil:    review of its antibacterial activity, pharmacokinetic properties and therapeutic    efficacy. Drugs 1996; 52: 125-58.         [ Links ]73.- SCHAAD U B, SUTER S, GIANELLA-BORRADORI    et al. A comparison of ceftriaxone and cefuroxime for the treatment of bacterial    meningitis in children. N Engl J Med 1990; 322: 141-7.         [ Links ]74.- KLEIN N C, CUNHA B A. Cefalosporinas de    la tercera generación. Clin Med Nort Am 1995; 79: 693-707.         [ Links ]75.- KLUGMAN K P, MADHI S A. Emergence of    drug resistance impact on bacterial meningitis. Infect Dis Clin North Am 1999;    13: 637-46.         [ Links ]76.- RICHARDS D M, BROGDEN R N. Ceftazidime.    A review of its antibacterial activity, pharmacokinetic properties and therapeutic    use. Drugs 1985; 29: 105-61.         [ Links ]77.- SCHATZ B S, KARAVOKIROS K T, TAEUBEL    M A, ITOKAZU G S. Comparison of cefprozil, cefpodoxime proxetil, loracarbef,    cefixime, and ceftibuten. Ann Pharmacother 1996; 30: 258-68.         [ Links ]78.- DALMAU D, LAYRARGUES G P, FENYVES D,    WILLEMS B, TURGEON F, TURGEON P. Cefotaxime, desacetyl-cefotaxime, and bactericidal    activity in spontaneous bacterial peritonitis. J Infect Dis 1999; 180: 1597-1602.          [ Links ]79.- NIKAIDO W, LIU W, ROSENBERG E Y. Outer    membrane permeability and ß-lactamase stability of dipolar ionic cephalosporins    containing methoxyimino substituents. Antimicrob Agents Chemother 1990; 34:    337-42.         [ Links ]80.- HANCOCK R E W, BELLIDO F. Factors involved    in the enhanced efficacy against gram-negative bacteria of fourth generation    cephalosporins. J Antimicrob Chemother 1992; 29(Suppl A): 1-6.         [ Links ]81.- BELLIDO F, PECHERE J C, HANCOCK REW.    Novel method for measurement of outer membrane permeability to new beta-lactams    in intact Enterobacter cloacae cells. Antimicrob Agents Chemother 1991;    35: 68-72.         [ Links ]82.- NEU H C, CHIN N X, JULES K, LABTHAVIKUL    P. The activity of BMY-28142, a new broad spectrum beta-lactamase stable cephalosporin.    J Antimicrob Chemother 1986; 17: 441-52.         [ Links ]83.- KOBAYASHI S, ARAI S, HAYASHI S, FUJIMOTO    K. ß-lactamase stability of cefpirome (HR 810), a new cephalosporin with    a broad antimicrobial spectrum. Antimicrob Agents Chemother 1986; 30: 713-8.          [ Links ]84.- GARAU J, WILSON W, WOOD M, CARLET J.    Fourth generation cephalosporins: a review of in vitro activity, pharmacokinetics,    pharmacodynamics, and clinical utility. Clin Microb Infect 1997; 3 (Suppl 1):    87-101.         [ Links ]85.- KESSLER R E, FUNG-TOMC J. Susceptibility    of bacterial isolates to beta-lactam antibiotics from U.S. clinical trials over    5-year period. Am J Med 1996; 24 (6 A): 13-9.         [ Links ]86.- PIERARD D, EMMERECHTS K, LAUWERS S. Comparative    in-vitro activity of cefpirome against isolates from intensive care and haematology/oncology    units. Belgian Multicentric Study Group. J Antimicrob Chemother 1998; 41: 443-50.          [ Links ]87.- JONES R N. Resistance patterns among    nosocomial pathogens: trends over the past few years. Chest 2001; 119 (Suppl    2): 397-404.         [ Links ]88.- LORBER B. Changing patterns of infectious    diseases. Am J Med 1988; 84: 569-78.         [ Links ]89.- MOELLERING R C. A novel antimicrobial    agent joins the battle against resistant bacteria. Ann Intern Med 1999; 130:    155-7.         [ Links ]90.- WILSON W R. The role of fourth-generation    cephalosporins in the treatment of serious infectious diseases in hospitalized    patients. Diagn Microbiol Infect Dis 1998; 31: 473-7.         [ Links ]Correspondencia a:        Sergio Mella Montecinos        Laboratorio de Antibióticos,        Departamento de Microbiología,        Facultad de Ciencias Biológicas        Casilla 160-C, Concepción        E-mail: pignatio@ctcinternet.cl  

61.- IIZAWA Y, OKONOGI K, HAYASHI R, IWAHI    T, YAMAZAKI T, IMADA A. Therapeutic effect of cefozopran (SCE-2787), a new parenteral    cephalosporin in experimental infections in mice. Antimicrob Agents Chemother    1993; 37: 100-5.         [ Links ]62.- WATANABE N A. Newer antipseudomonal cephalosporins.    J Chemother 1996; 8 (Suppl 2): 48-56.         [ Links ]63.- ACTOR P, GUARINI J, URI J et al. Disk    susceptibility studies with cefazolin and cephalotin. Antimicrob Agents Chemother    1974; 5: 63-7.         [ Links ]64.- UWAYDAH M. Cefazolin in the treatment    of acute enteric fever. Antimicrob Agents Chemother 1976; 10: 52-6.         [ Links ]65.- JAMAL W Y, ROTIMI V O, CHUGH T D, PAL    T. Prevalence and susceptibility of Shigella to 11 antibiotics in a Kuwait    teaching hospital. J Chemother 1998; 10: 285-90.         [ Links ]66.- COX CE, SHERRILL M, COCCHETT DM. Evaluation    of cefuroxime axetil, cefaclor, and cephalexin in the treatment of urinary tract    infections in adults. Curr Ther Res 1987; 42: 124-37.         [ Links ]67.- SANDERS C W, GREENBERG R N, MARIER R    L. Cefamandole and cefoxitin. Ann Intern Med 1985; 103: 70-8.          [ Links ]68.- STAPLEY E P, JACKSON M, HERNANDEZ S et    al. Cephamycins, a new family of ß-lactam antibiotics I. Production actinomycetes,    including Streptomyces lactamdurans spp.n. Antimicrob Agents Chemother    1972; 2: 122-31.         [ Links ]69.- COOPER R D G. The carbacephems a new    ß-lactams class. Am J Med 1992; 92 (Suppl 6 A): 25-65.         [ Links ]70.- ZEMELMAN R, BELLO H, DOMINGUEZ M, GONZALEZ    G, MELLA S, GARCIA A. Activity of imipenem, third-generation cephalosporins,    aztreonam, and ciprofloxacin against multi-resistant Gram negative bacilli isolated    from Chilean hospitals. J Antimicrob Chemother 1993; 32: 413-9.         [ Links ]71.- MEDEIROS A A. Evolution and dissemination    of ß-lactamases accelerated by generation of ß-lactam antibiotics.    Clin Infect Dis 1997; 24 (Suppl. 1): 19-45.         [ Links ]72.- PERRY C M, BROGDEN R N. Cefuroxime axetil:    review of its antibacterial activity, pharmacokinetic properties and therapeutic    efficacy. Drugs 1996; 52: 125-58.         [ Links ]73.- SCHAAD U B, SUTER S, GIANELLA-BORRADORI    et al. A comparison of ceftriaxone and cefuroxime for the treatment of bacterial    meningitis in children. N Engl J Med 1990; 322: 141-7.         [ Links ]74.- KLEIN N C, CUNHA B A. Cefalosporinas de    la tercera generación. Clin Med Nort Am 1995; 79: 693-707.         [ Links ]75.- KLUGMAN K P, MADHI S A. Emergence of    drug resistance impact on bacterial meningitis. Infect Dis Clin North Am 1999;    13: 637-46.         [ Links ]76.- RICHARDS D M, BROGDEN R N. Ceftazidime.    A review of its antibacterial activity, pharmacokinetic properties and therapeutic    use. Drugs 1985; 29: 105-61.         [ Links ]77.- SCHATZ B S, KARAVOKIROS K T, TAEUBEL    M A, ITOKAZU G S. Comparison of cefprozil, cefpodoxime proxetil, loracarbef,    cefixime, and ceftibuten. Ann Pharmacother 1996; 30: 258-68.         [ Links ]78.- DALMAU D, LAYRARGUES G P, FENYVES D,    WILLEMS B, TURGEON F, TURGEON P. Cefotaxime, desacetyl-cefotaxime, and bactericidal    activity in spontaneous bacterial peritonitis. J Infect Dis 1999; 180: 1597-1602.          [ Links ]79.- NIKAIDO W, LIU W, ROSENBERG E Y. Outer    membrane permeability and ß-lactamase stability of dipolar ionic cephalosporins    containing methoxyimino substituents. Antimicrob Agents Chemother 1990; 34:    337-42.         [ Links ]80.- HANCOCK R E W, BELLIDO F. Factors involved    in the enhanced efficacy against gram-negative bacteria of fourth generation    cephalosporins. J Antimicrob Chemother 1992; 29(Suppl A): 1-6.         [ Links ]81.- BELLIDO F, PECHERE J C, HANCOCK REW.    Novel method for measurement of outer membrane permeability to new beta-lactams    in intact Enterobacter cloacae cells. Antimicrob Agents Chemother 1991;    35: 68-72.         [ Links ]82.- NEU H C, CHIN N X, JULES K, LABTHAVIKUL    P. The activity of BMY-28142, a new broad spectrum beta-lactamase stable cephalosporin.    J Antimicrob Chemother 1986; 17: 441-52.         [ Links ]83.- KOBAYASHI S, ARAI S, HAYASHI S, FUJIMOTO    K. ß-lactamase stability of cefpirome (HR 810), a new cephalosporin with    a broad antimicrobial spectrum. Antimicrob Agents Chemother 1986; 30: 713-8.          [ Links ]84.- GARAU J, WILSON W, WOOD M, CARLET J.    Fourth generation cephalosporins: a review of in vitro activity, pharmacokinetics,    pharmacodynamics, and clinical utility. Clin Microb Infect 1997; 3 (Suppl 1):    87-101.         [ Links ]85.- KESSLER R E, FUNG-TOMC J. Susceptibility    of bacterial isolates to beta-lactam antibiotics from U.S. clinical trials over    5-year period. Am J Med 1996; 24 (6 A): 13-9.         [ Links ]86.- PIERARD D, EMMERECHTS K, LAUWERS S. Comparative    in-vitro activity of cefpirome against isolates from intensive care and haematology/oncology    units. Belgian Multicentric Study Group. J Antimicrob Chemother 1998; 41: 443-50.          [ Links ]87.- JONES R N. Resistance patterns among    nosocomial pathogens: trends over the past few years. Chest 2001; 119 (Suppl    2): 397-404.         [ Links ]88.- LORBER B. Changing patterns of infectious    diseases. Am J Med 1988; 84: 569-78.         [ Links ]89.- MOELLERING R C. A novel antimicrobial    agent joins the battle against resistant bacteria. Ann Intern Med 1999; 130:    155-7.         [ Links ]90.- WILSON W R. The role of fourth-generation    cephalosporins in the treatment of serious infectious diseases in hospitalized    patients. Diagn Microbiol Infect Dis 1998; 31: 473-7.         [ Links ]Correspondencia a:        Sergio Mella Montecinos        Laboratorio de Antibióticos,        Departamento de Microbiología,        Facultad de Ciencias Biológicas        Casilla 160-C, Concepción        E-mail: pignatio@ctcinternet.cl  

62.- WATANABE N A. Newer antipseudomonal cephalosporins.    J Chemother 1996; 8 (Suppl 2): 48-56.         [ Links ]63.- ACTOR P, GUARINI J, URI J et al. Disk    susceptibility studies with cefazolin and cephalotin. Antimicrob Agents Chemother    1974; 5: 63-7.         [ Links ]64.- UWAYDAH M. Cefazolin in the treatment    of acute enteric fever. Antimicrob Agents Chemother 1976; 10: 52-6.         [ Links ]65.- JAMAL W Y, ROTIMI V O, CHUGH T D, PAL    T. Prevalence and susceptibility of Shigella to 11 antibiotics in a Kuwait    teaching hospital. J Chemother 1998; 10: 285-90.         [ Links ]66.- COX CE, SHERRILL M, COCCHETT DM. Evaluation    of cefuroxime axetil, cefaclor, and cephalexin in the treatment of urinary tract    infections in adults. Curr Ther Res 1987; 42: 124-37.         [ Links ]67.- SANDERS C W, GREENBERG R N, MARIER R    L. Cefamandole and cefoxitin. Ann Intern Med 1985; 103: 70-8.          [ Links ]68.- STAPLEY E P, JACKSON M, HERNANDEZ S et    al. Cephamycins, a new family of ß-lactam antibiotics I. Production actinomycetes,    including Streptomyces lactamdurans spp.n. Antimicrob Agents Chemother    1972; 2: 122-31.         [ Links ]69.- COOPER R D G. The carbacephems a new    ß-lactams class. Am J Med 1992; 92 (Suppl 6 A): 25-65.         [ Links ]70.- ZEMELMAN R, BELLO H, DOMINGUEZ M, GONZALEZ    G, MELLA S, GARCIA A. Activity of imipenem, third-generation cephalosporins,    aztreonam, and ciprofloxacin against multi-resistant Gram negative bacilli isolated    from Chilean hospitals. J Antimicrob Chemother 1993; 32: 413-9.         [ Links ]71.- MEDEIROS A A. Evolution and dissemination    of ß-lactamases accelerated by generation of ß-lactam antibiotics.    Clin Infect Dis 1997; 24 (Suppl. 1): 19-45.         [ Links ]72.- PERRY C M, BROGDEN R N. Cefuroxime axetil:    review of its antibacterial activity, pharmacokinetic properties and therapeutic    efficacy. Drugs 1996; 52: 125-58.         [ Links ]73.- SCHAAD U B, SUTER S, GIANELLA-BORRADORI    et al. A comparison of ceftriaxone and cefuroxime for the treatment of bacterial    meningitis in children. N Engl J Med 1990; 322: 141-7.         [ Links ]74.- KLEIN N C, CUNHA B A. Cefalosporinas de    la tercera generación. Clin Med Nort Am 1995; 79: 693-707.         [ Links ]75.- KLUGMAN K P, MADHI S A. Emergence of    drug resistance impact on bacterial meningitis. Infect Dis Clin North Am 1999;    13: 637-46.         [ Links ]76.- RICHARDS D M, BROGDEN R N. Ceftazidime.    A review of its antibacterial activity, pharmacokinetic properties and therapeutic    use. Drugs 1985; 29: 105-61.         [ Links ]77.- SCHATZ B S, KARAVOKIROS K T, TAEUBEL    M A, ITOKAZU G S. Comparison of cefprozil, cefpodoxime proxetil, loracarbef,    cefixime, and ceftibuten. Ann Pharmacother 1996; 30: 258-68.         [ Links ]78.- DALMAU D, LAYRARGUES G P, FENYVES D,    WILLEMS B, TURGEON F, TURGEON P. Cefotaxime, desacetyl-cefotaxime, and bactericidal    activity in spontaneous bacterial peritonitis. J Infect Dis 1999; 180: 1597-1602.          [ Links ]79.- NIKAIDO W, LIU W, ROSENBERG E Y. Outer    membrane permeability and ß-lactamase stability of dipolar ionic cephalosporins    containing methoxyimino substituents. Antimicrob Agents Chemother 1990; 34:    337-42.         [ Links ]80.- HANCOCK R E W, BELLIDO F. Factors involved    in the enhanced efficacy against gram-negative bacteria of fourth generation    cephalosporins. J Antimicrob Chemother 1992; 29(Suppl A): 1-6.         [ Links ]81.- BELLIDO F, PECHERE J C, HANCOCK REW.    Novel method for measurement of outer membrane permeability to new beta-lactams    in intact Enterobacter cloacae cells. Antimicrob Agents Chemother 1991;    35: 68-72.         [ Links ]82.- NEU H C, CHIN N X, JULES K, LABTHAVIKUL    P. The activity of BMY-28142, a new broad spectrum beta-lactamase stable cephalosporin.    J Antimicrob Chemother 1986; 17: 441-52.         [ Links ]83.- KOBAYASHI S, ARAI S, HAYASHI S, FUJIMOTO    K. ß-lactamase stability of cefpirome (HR 810), a new cephalosporin with    a broad antimicrobial spectrum. Antimicrob Agents Chemother 1986; 30: 713-8.          [ Links ]84.- GARAU J, WILSON W, WOOD M, CARLET J.    Fourth generation cephalosporins: a review of in vitro activity, pharmacokinetics,    pharmacodynamics, and clinical utility. Clin Microb Infect 1997; 3 (Suppl 1):    87-101.         [ Links ]85.- KESSLER R E, FUNG-TOMC J. Susceptibility    of bacterial isolates to beta-lactam antibiotics from U.S. clinical trials over    5-year period. Am J Med 1996; 24 (6 A): 13-9.         [ Links ]86.- PIERARD D, EMMERECHTS K, LAUWERS S. Comparative    in-vitro activity of cefpirome against isolates from intensive care and haematology/oncology    units. Belgian Multicentric Study Group. J Antimicrob Chemother 1998; 41: 443-50.          [ Links ]87.- JONES R N. Resistance patterns among    nosocomial pathogens: trends over the past few years. Chest 2001; 119 (Suppl    2): 397-404.         [ Links ]88.- LORBER B. Changing patterns of infectious    diseases. Am J Med 1988; 84: 569-78.         [ Links ]89.- MOELLERING R C. A novel antimicrobial    agent joins the battle against resistant bacteria. Ann Intern Med 1999; 130:    155-7.         [ Links ]90.- WILSON W R. The role of fourth-generation    cephalosporins in the treatment of serious infectious diseases in hospitalized    patients. Diagn Microbiol Infect Dis 1998; 31: 473-7.         [ Links ]Correspondencia a:        Sergio Mella Montecinos        Laboratorio de Antibióticos,        Departamento de Microbiología,        Facultad de Ciencias Biológicas        Casilla 160-C, Concepción        E-mail: pignatio@ctcinternet.cl  

63.- ACTOR P, GUARINI J, URI J et al. Disk    susceptibility studies with cefazolin and cephalotin. Antimicrob Agents Chemother    1974; 5: 63-7.         [ Links ]64.- UWAYDAH M. Cefazolin in the treatment    of acute enteric fever. Antimicrob Agents Chemother 1976; 10: 52-6.         [ Links ]65.- JAMAL W Y, ROTIMI V O, CHUGH T D, PAL    T. Prevalence and susceptibility of Shigella to 11 antibiotics in a Kuwait    teaching hospital. J Chemother 1998; 10: 285-90.         [ Links ]66.- COX CE, SHERRILL M, COCCHETT DM. Evaluation    of cefuroxime axetil, cefaclor, and cephalexin in the treatment of urinary tract    infections in adults. Curr Ther Res 1987; 42: 124-37.         [ Links ]67.- SANDERS C W, GREENBERG R N, MARIER R    L. Cefamandole and cefoxitin. Ann Intern Med 1985; 103: 70-8.          [ Links ]68.- STAPLEY E P, JACKSON M, HERNANDEZ S et    al. Cephamycins, a new family of ß-lactam antibiotics I. Production actinomycetes,    including Streptomyces lactamdurans spp.n. Antimicrob Agents Chemother    1972; 2: 122-31.         [ Links ]69.- COOPER R D G. The carbacephems a new    ß-lactams class. Am J Med 1992; 92 (Suppl 6 A): 25-65.         [ Links ]70.- ZEMELMAN R, BELLO H, DOMINGUEZ M, GONZALEZ    G, MELLA S, GARCIA A. Activity of imipenem, third-generation cephalosporins,    aztreonam, and ciprofloxacin against multi-resistant Gram negative bacilli isolated    from Chilean hospitals. J Antimicrob Chemother 1993; 32: 413-9.         [ Links ]71.- MEDEIROS A A. Evolution and dissemination    of ß-lactamases accelerated by generation of ß-lactam antibiotics.    Clin Infect Dis 1997; 24 (Suppl. 1): 19-45.         [ Links ]72.- PERRY C M, BROGDEN R N. Cefuroxime axetil:    review of its antibacterial activity, pharmacokinetic properties and therapeutic    efficacy. Drugs 1996; 52: 125-58.         [ Links ]73.- SCHAAD U B, SUTER S, GIANELLA-BORRADORI    et al. A comparison of ceftriaxone and cefuroxime for the treatment of bacterial    meningitis in children. N Engl J Med 1990; 322: 141-7.         [ Links ]74.- KLEIN N C, CUNHA B A. Cefalosporinas de    la tercera generación. Clin Med Nort Am 1995; 79: 693-707.         [ Links ]75.- KLUGMAN K P, MADHI S A. Emergence of    drug resistance impact on bacterial meningitis. Infect Dis Clin North Am 1999;    13: 637-46.         [ Links ]76.- RICHARDS D M, BROGDEN R N. Ceftazidime.    A review of its antibacterial activity, pharmacokinetic properties and therapeutic    use. Drugs 1985; 29: 105-61.         [ Links ]77.- SCHATZ B S, KARAVOKIROS K T, TAEUBEL    M A, ITOKAZU G S. Comparison of cefprozil, cefpodoxime proxetil, loracarbef,    cefixime, and ceftibuten. Ann Pharmacother 1996; 30: 258-68.         [ Links ]78.- DALMAU D, LAYRARGUES G P, FENYVES D,    WILLEMS B, TURGEON F, TURGEON P. Cefotaxime, desacetyl-cefotaxime, and bactericidal    activity in spontaneous bacterial peritonitis. J Infect Dis 1999; 180: 1597-1602.          [ Links ]79.- NIKAIDO W, LIU W, ROSENBERG E Y. Outer    membrane permeability and ß-lactamase stability of dipolar ionic cephalosporins    containing methoxyimino substituents. Antimicrob Agents Chemother 1990; 34:    337-42.         [ Links ]80.- HANCOCK R E W, BELLIDO F. Factors involved    in the enhanced efficacy against gram-negative bacteria of fourth generation    cephalosporins. J Antimicrob Chemother 1992; 29(Suppl A): 1-6.         [ Links ]81.- BELLIDO F, PECHERE J C, HANCOCK REW.    Novel method for measurement of outer membrane permeability to new beta-lactams    in intact Enterobacter cloacae cells. Antimicrob Agents Chemother 1991;    35: 68-72.         [ Links ]82.- NEU H C, CHIN N X, JULES K, LABTHAVIKUL    P. The activity of BMY-28142, a new broad spectrum beta-lactamase stable cephalosporin.    J Antimicrob Chemother 1986; 17: 441-52.         [ Links ]83.- KOBAYASHI S, ARAI S, HAYASHI S, FUJIMOTO    K. ß-lactamase stability of cefpirome (HR 810), a new cephalosporin with    a broad antimicrobial spectrum. Antimicrob Agents Chemother 1986; 30: 713-8.          [ Links ]84.- GARAU J, WILSON W, WOOD M, CARLET J.    Fourth generation cephalosporins: a review of in vitro activity, pharmacokinetics,    pharmacodynamics, and clinical utility. Clin Microb Infect 1997; 3 (Suppl 1):    87-101.         [ Links ]85.- KESSLER R E, FUNG-TOMC J. Susceptibility    of bacterial isolates to beta-lactam antibiotics from U.S. clinical trials over    5-year period. Am J Med 1996; 24 (6 A): 13-9.         [ Links ]86.- PIERARD D, EMMERECHTS K, LAUWERS S. Comparative    in-vitro activity of cefpirome against isolates from intensive care and haematology/oncology    units. Belgian Multicentric Study Group. J Antimicrob Chemother 1998; 41: 443-50.          [ Links ]87.- JONES R N. Resistance patterns among    nosocomial pathogens: trends over the past few years. Chest 2001; 119 (Suppl    2): 397-404.         [ Links ]88.- LORBER B. Changing patterns of infectious    diseases. Am J Med 1988; 84: 569-78.         [ Links ]89.- MOELLERING R C. A novel antimicrobial    agent joins the battle against resistant bacteria. Ann Intern Med 1999; 130:    155-7.         [ Links ]90.- WILSON W R. The role of fourth-generation    cephalosporins in the treatment of serious infectious diseases in hospitalized    patients. Diagn Microbiol Infect Dis 1998; 31: 473-7.         [ Links ]Correspondencia a:        Sergio Mella Montecinos        Laboratorio de Antibióticos,        Departamento de Microbiología,        Facultad de Ciencias Biológicas        Casilla 160-C, Concepción        E-mail: pignatio@ctcinternet.cl  

64.- UWAYDAH M. Cefazolin in the treatment    of acute enteric fever. Antimicrob Agents Chemother 1976; 10: 52-6.         [ Links ]65.- JAMAL W Y, ROTIMI V O, CHUGH T D, PAL    T. Prevalence and susceptibility of Shigella to 11 antibiotics in a Kuwait    teaching hospital. J Chemother 1998; 10: 285-90.         [ Links ]66.- COX CE, SHERRILL M, COCCHETT DM. Evaluation    of cefuroxime axetil, cefaclor, and cephalexin in the treatment of urinary tract    infections in adults. Curr Ther Res 1987; 42: 124-37.         [ Links ]67.- SANDERS C W, GREENBERG R N, MARIER R    L. Cefamandole and cefoxitin. Ann Intern Med 1985; 103: 70-8.          [ Links ]68.- STAPLEY E P, JACKSON M, HERNANDEZ S et    al. Cephamycins, a new family of ß-lactam antibiotics I. Production actinomycetes,    including Streptomyces lactamdurans spp.n. Antimicrob Agents Chemother    1972; 2: 122-31.         [ Links ]69.- COOPER R D G. The carbacephems a new    ß-lactams class. Am J Med 1992; 92 (Suppl 6 A): 25-65.         [ Links ]70.- ZEMELMAN R, BELLO H, DOMINGUEZ M, GONZALEZ    G, MELLA S, GARCIA A. Activity of imipenem, third-generation cephalosporins,    aztreonam, and ciprofloxacin against multi-resistant Gram negative bacilli isolated    from Chilean hospitals. J Antimicrob Chemother 1993; 32: 413-9.         [ Links ]71.- MEDEIROS A A. Evolution and dissemination    of ß-lactamases accelerated by generation of ß-lactam antibiotics.    Clin Infect Dis 1997; 24 (Suppl. 1): 19-45.         [ Links ]72.- PERRY C M, BROGDEN R N. Cefuroxime axetil:    review of its antibacterial activity, pharmacokinetic properties and therapeutic    efficacy. Drugs 1996; 52: 125-58.         [ Links ]73.- SCHAAD U B, SUTER S, GIANELLA-BORRADORI    et al. A comparison of ceftriaxone and cefuroxime for the treatment of bacterial    meningitis in children. N Engl J Med 1990; 322: 141-7.         [ Links ]74.- KLEIN N C, CUNHA B A. Cefalosporinas de    la tercera generación. Clin Med Nort Am 1995; 79: 693-707.         [ Links ]75.- KLUGMAN K P, MADHI S A. Emergence of    drug resistance impact on bacterial meningitis. Infect Dis Clin North Am 1999;    13: 637-46.         [ Links ]76.- RICHARDS D M, BROGDEN R N. Ceftazidime.    A review of its antibacterial activity, pharmacokinetic properties and therapeutic    use. Drugs 1985; 29: 105-61.         [ Links ]77.- SCHATZ B S, KARAVOKIROS K T, TAEUBEL    M A, ITOKAZU G S. Comparison of cefprozil, cefpodoxime proxetil, loracarbef,    cefixime, and ceftibuten. Ann Pharmacother 1996; 30: 258-68.         [ Links ]78.- DALMAU D, LAYRARGUES G P, FENYVES D,    WILLEMS B, TURGEON F, TURGEON P. Cefotaxime, desacetyl-cefotaxime, and bactericidal    activity in spontaneous bacterial peritonitis. J Infect Dis 1999; 180: 1597-1602.          [ Links ]79.- NIKAIDO W, LIU W, ROSENBERG E Y. Outer    membrane permeability and ß-lactamase stability of dipolar ionic cephalosporins    containing methoxyimino substituents. Antimicrob Agents Chemother 1990; 34:    337-42.         [ Links ]80.- HANCOCK R E W, BELLIDO F. Factors involved    in the enhanced efficacy against gram-negative bacteria of fourth generation    cephalosporins. J Antimicrob Chemother 1992; 29(Suppl A): 1-6.         [ Links ]81.- BELLIDO F, PECHERE J C, HANCOCK REW.    Novel method for measurement of outer membrane permeability to new beta-lactams    in intact Enterobacter cloacae cells. Antimicrob Agents Chemother 1991;    35: 68-72.         [ Links ]82.- NEU H C, CHIN N X, JULES K, LABTHAVIKUL    P. The activity of BMY-28142, a new broad spectrum beta-lactamase stable cephalosporin.    J Antimicrob Chemother 1986; 17: 441-52.         [ Links ]83.- KOBAYASHI S, ARAI S, HAYASHI S, FUJIMOTO    K. ß-lactamase stability of cefpirome (HR 810), a new cephalosporin with    a broad antimicrobial spectrum. Antimicrob Agents Chemother 1986; 30: 713-8.          [ Links ]84.- GARAU J, WILSON W, WOOD M, CARLET J.    Fourth generation cephalosporins: a review of in vitro activity, pharmacokinetics,    pharmacodynamics, and clinical utility. Clin Microb Infect 1997; 3 (Suppl 1):    87-101.         [ Links ]85.- KESSLER R E, FUNG-TOMC J. Susceptibility    of bacterial isolates to beta-lactam antibiotics from U.S. clinical trials over    5-year period. Am J Med 1996; 24 (6 A): 13-9.         [ Links ]86.- PIERARD D, EMMERECHTS K, LAUWERS S. Comparative    in-vitro activity of cefpirome against isolates from intensive care and haematology/oncology    units. Belgian Multicentric Study Group. J Antimicrob Chemother 1998; 41: 443-50.          [ Links ]87.- JONES R N. Resistance patterns among    nosocomial pathogens: trends over the past few years. Chest 2001; 119 (Suppl    2): 397-404.         [ Links ]88.- LORBER B. Changing patterns of infectious    diseases. Am J Med 1988; 84: 569-78.         [ Links ]89.- MOELLERING R C. A novel antimicrobial    agent joins the battle against resistant bacteria. Ann Intern Med 1999; 130:    155-7.         [ Links ]90.- WILSON W R. The role of fourth-generation    cephalosporins in the treatment of serious infectious diseases in hospitalized    patients. Diagn Microbiol Infect Dis 1998; 31: 473-7.         [ Links ]Correspondencia a:        Sergio Mella Montecinos        Laboratorio de Antibióticos,        Departamento de Microbiología,        Facultad de Ciencias Biológicas        Casilla 160-C, Concepción        E-mail: pignatio@ctcinternet.cl  

65.- JAMAL W Y, ROTIMI V O, CHUGH T D, PAL    T. Prevalence and susceptibility of Shigella to 11 antibiotics in a Kuwait    teaching hospital. J Chemother 1998; 10: 285-90.         [ Links ]66.- COX CE, SHERRILL M, COCCHETT DM. Evaluation    of cefuroxime axetil, cefaclor, and cephalexin in the treatment of urinary tract    infections in adults. Curr Ther Res 1987; 42: 124-37.         [ Links ]67.- SANDERS C W, GREENBERG R N, MARIER R    L. Cefamandole and cefoxitin. Ann Intern Med 1985; 103: 70-8.          [ Links ]68.- STAPLEY E P, JACKSON M, HERNANDEZ S et    al. Cephamycins, a new family of ß-lactam antibiotics I. Production actinomycetes,    including Streptomyces lactamdurans spp.n. Antimicrob Agents Chemother    1972; 2: 122-31.         [ Links ]69.- COOPER R D G. The carbacephems a new    ß-lactams class. Am J Med 1992; 92 (Suppl 6 A): 25-65.         [ Links ]70.- ZEMELMAN R, BELLO H, DOMINGUEZ M, GONZALEZ    G, MELLA S, GARCIA A. Activity of imipenem, third-generation cephalosporins,    aztreonam, and ciprofloxacin against multi-resistant Gram negative bacilli isolated    from Chilean hospitals. J Antimicrob Chemother 1993; 32: 413-9.         [ Links ]71.- MEDEIROS A A. Evolution and dissemination    of ß-lactamases accelerated by generation of ß-lactam antibiotics.    Clin Infect Dis 1997; 24 (Suppl. 1): 19-45.         [ Links ]72.- PERRY C M, BROGDEN R N. Cefuroxime axetil:    review of its antibacterial activity, pharmacokinetic properties and therapeutic    efficacy. Drugs 1996; 52: 125-58.         [ Links ]73.- SCHAAD U B, SUTER S, GIANELLA-BORRADORI    et al. A comparison of ceftriaxone and cefuroxime for the treatment of bacterial    meningitis in children. N Engl J Med 1990; 322: 141-7.         [ Links ]74.- KLEIN N C, CUNHA B A. Cefalosporinas de    la tercera generación. Clin Med Nort Am 1995; 79: 693-707.         [ Links ]75.- KLUGMAN K P, MADHI S A. Emergence of    drug resistance impact on bacterial meningitis. Infect Dis Clin North Am 1999;    13: 637-46.         [ Links ]76.- RICHARDS D M, BROGDEN R N. Ceftazidime.    A review of its antibacterial activity, pharmacokinetic properties and therapeutic    use. Drugs 1985; 29: 105-61.         [ Links ]77.- SCHATZ B S, KARAVOKIROS K T, TAEUBEL    M A, ITOKAZU G S. Comparison of cefprozil, cefpodoxime proxetil, loracarbef,    cefixime, and ceftibuten. Ann Pharmacother 1996; 30: 258-68.         [ Links ]78.- DALMAU D, LAYRARGUES G P, FENYVES D,    WILLEMS B, TURGEON F, TURGEON P. Cefotaxime, desacetyl-cefotaxime, and bactericidal    activity in spontaneous bacterial peritonitis. J Infect Dis 1999; 180: 1597-1602.          [ Links ]79.- NIKAIDO W, LIU W, ROSENBERG E Y. Outer    membrane permeability and ß-lactamase stability of dipolar ionic cephalosporins    containing methoxyimino substituents. Antimicrob Agents Chemother 1990; 34:    337-42.         [ Links ]80.- HANCOCK R E W, BELLIDO F. Factors involved    in the enhanced efficacy against gram-negative bacteria of fourth generation    cephalosporins. J Antimicrob Chemother 1992; 29(Suppl A): 1-6.         [ Links ]81.- BELLIDO F, PECHERE J C, HANCOCK REW.    Novel method for measurement of outer membrane permeability to new beta-lactams    in intact Enterobacter cloacae cells. Antimicrob Agents Chemother 1991;    35: 68-72.         [ Links ]82.- NEU H C, CHIN N X, JULES K, LABTHAVIKUL    P. The activity of BMY-28142, a new broad spectrum beta-lactamase stable cephalosporin.    J Antimicrob Chemother 1986; 17: 441-52.         [ Links ]83.- KOBAYASHI S, ARAI S, HAYASHI S, FUJIMOTO    K. ß-lactamase stability of cefpirome (HR 810), a new cephalosporin with    a broad antimicrobial spectrum. Antimicrob Agents Chemother 1986; 30: 713-8.          [ Links ]84.- GARAU J, WILSON W, WOOD M, CARLET J.    Fourth generation cephalosporins: a review of in vitro activity, pharmacokinetics,    pharmacodynamics, and clinical utility. Clin Microb Infect 1997; 3 (Suppl 1):    87-101.         [ Links ]85.- KESSLER R E, FUNG-TOMC J. Susceptibility    of bacterial isolates to beta-lactam antibiotics from U.S. clinical trials over    5-year period. Am J Med 1996; 24 (6 A): 13-9.         [ Links ]86.- PIERARD D, EMMERECHTS K, LAUWERS S. Comparative    in-vitro activity of cefpirome against isolates from intensive care and haematology/oncology    units. Belgian Multicentric Study Group. J Antimicrob Chemother 1998; 41: 443-50.          [ Links ]87.- JONES R N. Resistance patterns among    nosocomial pathogens: trends over the past few years. Chest 2001; 119 (Suppl    2): 397-404.         [ Links ]88.- LORBER B. Changing patterns of infectious    diseases. Am J Med 1988; 84: 569-78.         [ Links ]89.- MOELLERING R C. A novel antimicrobial    agent joins the battle against resistant bacteria. Ann Intern Med 1999; 130:    155-7.         [ Links ]90.- WILSON W R. The role of fourth-generation    cephalosporins in the treatment of serious infectious diseases in hospitalized    patients. Diagn Microbiol Infect Dis 1998; 31: 473-7.         [ Links ]Correspondencia a:        Sergio Mella Montecinos        Laboratorio de Antibióticos,        Departamento de Microbiología,        Facultad de Ciencias Biológicas        Casilla 160-C, Concepción        E-mail: pignatio@ctcinternet.cl  

66.- COX CE, SHERRILL M, COCCHETT DM. Evaluation    of cefuroxime axetil, cefaclor, and cephalexin in the treatment of urinary tract    infections in adults. Curr Ther Res 1987; 42: 124-37.         [ Links ]67.- SANDERS C W, GREENBERG R N, MARIER R    L. Cefamandole and cefoxitin. Ann Intern Med 1985; 103: 70-8.          [ Links ]68.- STAPLEY E P, JACKSON M, HERNANDEZ S et    al. Cephamycins, a new family of ß-lactam antibiotics I. Production actinomycetes,    including Streptomyces lactamdurans spp.n. Antimicrob Agents Chemother    1972; 2: 122-31.         [ Links ]69.- COOPER R D G. The carbacephems a new    ß-lactams class. Am J Med 1992; 92 (Suppl 6 A): 25-65.         [ Links ]70.- ZEMELMAN R, BELLO H, DOMINGUEZ M, GONZALEZ    G, MELLA S, GARCIA A. Activity of imipenem, third-generation cephalosporins,    aztreonam, and ciprofloxacin against multi-resistant Gram negative bacilli isolated    from Chilean hospitals. J Antimicrob Chemother 1993; 32: 413-9.         [ Links ]71.- MEDEIROS A A. Evolution and dissemination    of ß-lactamases accelerated by generation of ß-lactam antibiotics.    Clin Infect Dis 1997; 24 (Suppl. 1): 19-45.         [ Links ]72.- PERRY C M, BROGDEN R N. Cefuroxime axetil:    review of its antibacterial activity, pharmacokinetic properties and therapeutic    efficacy. Drugs 1996; 52: 125-58.         [ Links ]73.- SCHAAD U B, SUTER S, GIANELLA-BORRADORI    et al. A comparison of ceftriaxone and cefuroxime for the treatment of bacterial    meningitis in children. N Engl J Med 1990; 322: 141-7.         [ Links ]74.- KLEIN N C, CUNHA B A. Cefalosporinas de    la tercera generación. Clin Med Nort Am 1995; 79: 693-707.         [ Links ]75.- KLUGMAN K P, MADHI S A. Emergence of    drug resistance impact on bacterial meningitis. Infect Dis Clin North Am 1999;    13: 637-46.         [ Links ]76.- RICHARDS D M, BROGDEN R N. Ceftazidime.    A review of its antibacterial activity, pharmacokinetic properties and therapeutic    use. Drugs 1985; 29: 105-61.         [ Links ]77.- SCHATZ B S, KARAVOKIROS K T, TAEUBEL    M A, ITOKAZU G S. Comparison of cefprozil, cefpodoxime proxetil, loracarbef,    cefixime, and ceftibuten. Ann Pharmacother 1996; 30: 258-68.         [ Links ]78.- DALMAU D, LAYRARGUES G P, FENYVES D,    WILLEMS B, TURGEON F, TURGEON P. Cefotaxime, desacetyl-cefotaxime, and bactericidal    activity in spontaneous bacterial peritonitis. J Infect Dis 1999; 180: 1597-1602.          [ Links ]79.- NIKAIDO W, LIU W, ROSENBERG E Y. Outer    membrane permeability and ß-lactamase stability of dipolar ionic cephalosporins    containing methoxyimino substituents. Antimicrob Agents Chemother 1990; 34:    337-42.         [ Links ]80.- HANCOCK R E W, BELLIDO F. Factors involved    in the enhanced efficacy against gram-negative bacteria of fourth generation    cephalosporins. J Antimicrob Chemother 1992; 29(Suppl A): 1-6.         [ Links ]81.- BELLIDO F, PECHERE J C, HANCOCK REW.    Novel method for measurement of outer membrane permeability to new beta-lactams    in intact Enterobacter cloacae cells. Antimicrob Agents Chemother 1991;    35: 68-72.         [ Links ]82.- NEU H C, CHIN N X, JULES K, LABTHAVIKUL    P. The activity of BMY-28142, a new broad spectrum beta-lactamase stable cephalosporin.    J Antimicrob Chemother 1986; 17: 441-52.         [ Links ]83.- KOBAYASHI S, ARAI S, HAYASHI S, FUJIMOTO    K. ß-lactamase stability of cefpirome (HR 810), a new cephalosporin with    a broad antimicrobial spectrum. Antimicrob Agents Chemother 1986; 30: 713-8.          [ Links ]84.- GARAU J, WILSON W, WOOD M, CARLET J.    Fourth generation cephalosporins: a review of in vitro activity, pharmacokinetics,    pharmacodynamics, and clinical utility. Clin Microb Infect 1997; 3 (Suppl 1):    87-101.         [ Links ]85.- KESSLER R E, FUNG-TOMC J. Susceptibility    of bacterial isolates to beta-lactam antibiotics from U.S. clinical trials over    5-year period. Am J Med 1996; 24 (6 A): 13-9.         [ Links ]86.- PIERARD D, EMMERECHTS K, LAUWERS S. Comparative    in-vitro activity of cefpirome against isolates from intensive care and haematology/oncology    units. Belgian Multicentric Study Group. J Antimicrob Chemother 1998; 41: 443-50.          [ Links ]87.- JONES R N. Resistance patterns among    nosocomial pathogens: trends over the past few years. Chest 2001; 119 (Suppl    2): 397-404.         [ Links ]88.- LORBER B. Changing patterns of infectious    diseases. Am J Med 1988; 84: 569-78.         [ Links ]89.- MOELLERING R C. A novel antimicrobial    agent joins the battle against resistant bacteria. Ann Intern Med 1999; 130:    155-7.         [ Links ]90.- WILSON W R. The role of fourth-generation    cephalosporins in the treatment of serious infectious diseases in hospitalized    patients. Diagn Microbiol Infect Dis 1998; 31: 473-7.         [ Links ]Correspondencia a:        Sergio Mella Montecinos        Laboratorio de Antibióticos,        Departamento de Microbiología,        Facultad de Ciencias Biológicas        Casilla 160-C, Concepción        E-mail: pignatio@ctcinternet.cl  

67.- SANDERS C W, GREENBERG R N, MARIER R    L. Cefamandole and cefoxitin. Ann Intern Med 1985; 103: 70-8.          [ Links ]68.- STAPLEY E P, JACKSON M, HERNANDEZ S et    al. Cephamycins, a new family of ß-lactam antibiotics I. Production actinomycetes,    including Streptomyces lactamdurans spp.n. Antimicrob Agents Chemother    1972; 2: 122-31.         [ Links ]69.- COOPER R D G. The carbacephems a new    ß-lactams class. Am J Med 1992; 92 (Suppl 6 A): 25-65.         [ Links ]70.- ZEMELMAN R, BELLO H, DOMINGUEZ M, GONZALEZ    G, MELLA S, GARCIA A. Activity of imipenem, third-generation cephalosporins,    aztreonam, and ciprofloxacin against multi-resistant Gram negative bacilli isolated    from Chilean hospitals. J Antimicrob Chemother 1993; 32: 413-9.         [ Links ]71.- MEDEIROS A A. Evolution and dissemination    of ß-lactamases accelerated by generation of ß-lactam antibiotics.    Clin Infect Dis 1997; 24 (Suppl. 1): 19-45.         [ Links ]72.- PERRY C M, BROGDEN R N. Cefuroxime axetil:    review of its antibacterial activity, pharmacokinetic properties and therapeutic    efficacy. Drugs 1996; 52: 125-58.         [ Links ]73.- SCHAAD U B, SUTER S, GIANELLA-BORRADORI    et al. A comparison of ceftriaxone and cefuroxime for the treatment of bacterial    meningitis in children. N Engl J Med 1990; 322: 141-7.         [ Links ]74.- KLEIN N C, CUNHA B A. Cefalosporinas de    la tercera generación. Clin Med Nort Am 1995; 79: 693-707.         [ Links ]75.- KLUGMAN K P, MADHI S A. Emergence of    drug resistance impact on bacterial meningitis. Infect Dis Clin North Am 1999;    13: 637-46.         [ Links ]76.- RICHARDS D M, BROGDEN R N. Ceftazidime.    A review of its antibacterial activity, pharmacokinetic properties and therapeutic    use. Drugs 1985; 29: 105-61.         [ Links ]77.- SCHATZ B S, KARAVOKIROS K T, TAEUBEL    M A, ITOKAZU G S. Comparison of cefprozil, cefpodoxime proxetil, loracarbef,    cefixime, and ceftibuten. Ann Pharmacother 1996; 30: 258-68.         [ Links ]78.- DALMAU D, LAYRARGUES G P, FENYVES D,    WILLEMS B, TURGEON F, TURGEON P. Cefotaxime, desacetyl-cefotaxime, and bactericidal    activity in spontaneous bacterial peritonitis. J Infect Dis 1999; 180: 1597-1602.          [ Links ]79.- NIKAIDO W, LIU W, ROSENBERG E Y. Outer    membrane permeability and ß-lactamase stability of dipolar ionic cephalosporins    containing methoxyimino substituents. Antimicrob Agents Chemother 1990; 34:    337-42.         [ Links ]80.- HANCOCK R E W, BELLIDO F. Factors involved    in the enhanced efficacy against gram-negative bacteria of fourth generation    cephalosporins. J Antimicrob Chemother 1992; 29(Suppl A): 1-6.         [ Links ]81.- BELLIDO F, PECHERE J C, HANCOCK REW.    Novel method for measurement of outer membrane permeability to new beta-lactams    in intact Enterobacter cloacae cells. Antimicrob Agents Chemother 1991;    35: 68-72.         [ Links ]82.- NEU H C, CHIN N X, JULES K, LABTHAVIKUL    P. The activity of BMY-28142, a new broad spectrum beta-lactamase stable cephalosporin.    J Antimicrob Chemother 1986; 17: 441-52.         [ Links ]83.- KOBAYASHI S, ARAI S, HAYASHI S, FUJIMOTO    K. ß-lactamase stability of cefpirome (HR 810), a new cephalosporin with    a broad antimicrobial spectrum. Antimicrob Agents Chemother 1986; 30: 713-8.          [ Links ]84.- GARAU J, WILSON W, WOOD M, CARLET J.    Fourth generation cephalosporins: a review of in vitro activity, pharmacokinetics,    pharmacodynamics, and clinical utility. Clin Microb Infect 1997; 3 (Suppl 1):    87-101.         [ Links ]85.- KESSLER R E, FUNG-TOMC J. Susceptibility    of bacterial isolates to beta-lactam antibiotics from U.S. clinical trials over    5-year period. Am J Med 1996; 24 (6 A): 13-9.         [ Links ]86.- PIERARD D, EMMERECHTS K, LAUWERS S. Comparative    in-vitro activity of cefpirome against isolates from intensive care and haematology/oncology    units. Belgian Multicentric Study Group. J Antimicrob Chemother 1998; 41: 443-50.          [ Links ]87.- JONES R N. Resistance patterns among    nosocomial pathogens: trends over the past few years. Chest 2001; 119 (Suppl    2): 397-404.         [ Links ]88.- LORBER B. Changing patterns of infectious    diseases. Am J Med 1988; 84: 569-78.         [ Links ]89.- MOELLERING R C. A novel antimicrobial    agent joins the battle against resistant bacteria. Ann Intern Med 1999; 130:    155-7.         [ Links ]90.- WILSON W R. The role of fourth-generation    cephalosporins in the treatment of serious infectious diseases in hospitalized    patients. Diagn Microbiol Infect Dis 1998; 31: 473-7.         [ Links ]Correspondencia a:        Sergio Mella Montecinos        Laboratorio de Antibióticos,        Departamento de Microbiología,        Facultad de Ciencias Biológicas        Casilla 160-C, Concepción        E-mail: pignatio@ctcinternet.cl  

68.- STAPLEY E P, JACKSON M, HERNANDEZ S et    al. Cephamycins, a new family of ß-lactam antibiotics I. Production actinomycetes,    including Streptomyces lactamdurans spp.n. Antimicrob Agents Chemother    1972; 2: 122-31.         [ Links ]69.- COOPER R D G. The carbacephems a new    ß-lactams class. Am J Med 1992; 92 (Suppl 6 A): 25-65.         [ Links ]70.- ZEMELMAN R, BELLO H, DOMINGUEZ M, GONZALEZ    G, MELLA S, GARCIA A. Activity of imipenem, third-generation cephalosporins,    aztreonam, and ciprofloxacin against multi-resistant Gram negative bacilli isolated    from Chilean hospitals. J Antimicrob Chemother 1993; 32: 413-9.         [ Links ]71.- MEDEIROS A A. Evolution and dissemination    of ß-lactamases accelerated by generation of ß-lactam antibiotics.    Clin Infect Dis 1997; 24 (Suppl. 1): 19-45.         [ Links ]72.- PERRY C M, BROGDEN R N. Cefuroxime axetil:    review of its antibacterial activity, pharmacokinetic properties and therapeutic    efficacy. Drugs 1996; 52: 125-58.         [ Links ]73.- SCHAAD U B, SUTER S, GIANELLA-BORRADORI    et al. A comparison of ceftriaxone and cefuroxime for the treatment of bacterial    meningitis in children. N Engl J Med 1990; 322: 141-7.         [ Links ]74.- KLEIN N C, CUNHA B A. Cefalosporinas de    la tercera generación. Clin Med Nort Am 1995; 79: 693-707.         [ Links ]75.- KLUGMAN K P, MADHI S A. Emergence of    drug resistance impact on bacterial meningitis. Infect Dis Clin North Am 1999;    13: 637-46.         [ Links ]76.- RICHARDS D M, BROGDEN R N. Ceftazidime.    A review of its antibacterial activity, pharmacokinetic properties and therapeutic    use. Drugs 1985; 29: 105-61.         [ Links ]77.- SCHATZ B S, KARAVOKIROS K T, TAEUBEL    M A, ITOKAZU G S. Comparison of cefprozil, cefpodoxime proxetil, loracarbef,    cefixime, and ceftibuten. Ann Pharmacother 1996; 30: 258-68.         [ Links ]78.- DALMAU D, LAYRARGUES G P, FENYVES D,    WILLEMS B, TURGEON F, TURGEON P. Cefotaxime, desacetyl-cefotaxime, and bactericidal    activity in spontaneous bacterial peritonitis. J Infect Dis 1999; 180: 1597-1602.          [ Links ]79.- NIKAIDO W, LIU W, ROSENBERG E Y. Outer    membrane permeability and ß-lactamase stability of dipolar ionic cephalosporins    containing methoxyimino substituents. Antimicrob Agents Chemother 1990; 34:    337-42.         [ Links ]80.- HANCOCK R E W, BELLIDO F. Factors involved    in the enhanced efficacy against gram-negative bacteria of fourth generation    cephalosporins. J Antimicrob Chemother 1992; 29(Suppl A): 1-6.         [ Links ]81.- BELLIDO F, PECHERE J C, HANCOCK REW.    Novel method for measurement of outer membrane permeability to new beta-lactams    in intact Enterobacter cloacae cells. Antimicrob Agents Chemother 1991;    35: 68-72.         [ Links ]82.- NEU H C, CHIN N X, JULES K, LABTHAVIKUL    P. The activity of BMY-28142, a new broad spectrum beta-lactamase stable cephalosporin.    J Antimicrob Chemother 1986; 17: 441-52.         [ Links ]83.- KOBAYASHI S, ARAI S, HAYASHI S, FUJIMOTO    K. ß-lactamase stability of cefpirome (HR 810), a new cephalosporin with    a broad antimicrobial spectrum. Antimicrob Agents Chemother 1986; 30: 713-8.          [ Links ]84.- GARAU J, WILSON W, WOOD M, CARLET J.    Fourth generation cephalosporins: a review of in vitro activity, pharmacokinetics,    pharmacodynamics, and clinical utility. Clin Microb Infect 1997; 3 (Suppl 1):    87-101.         [ Links ]85.- KESSLER R E, FUNG-TOMC J. Susceptibility    of bacterial isolates to beta-lactam antibiotics from U.S. clinical trials over    5-year period. Am J Med 1996; 24 (6 A): 13-9.         [ Links ]86.- PIERARD D, EMMERECHTS K, LAUWERS S. Comparative    in-vitro activity of cefpirome against isolates from intensive care and haematology/oncology    units. Belgian Multicentric Study Group. J Antimicrob Chemother 1998; 41: 443-50.          [ Links ]87.- JONES R N. Resistance patterns among    nosocomial pathogens: trends over the past few years. Chest 2001; 119 (Suppl    2): 397-404.         [ Links ]88.- LORBER B. Changing patterns of infectious    diseases. Am J Med 1988; 84: 569-78.         [ Links ]89.- MOELLERING R C. A novel antimicrobial    agent joins the battle against resistant bacteria. Ann Intern Med 1999; 130:    155-7.         [ Links ]90.- WILSON W R. The role of fourth-generation    cephalosporins in the treatment of serious infectious diseases in hospitalized    patients. Diagn Microbiol Infect Dis 1998; 31: 473-7.         [ Links ]Correspondencia a:        Sergio Mella Montecinos        Laboratorio de Antibióticos,        Departamento de Microbiología,        Facultad de Ciencias Biológicas        Casilla 160-C, Concepción        E-mail: pignatio@ctcinternet.cl  

69.- COOPER R D G. The carbacephems a new    ß-lactams class. Am J Med 1992; 92 (Suppl 6 A): 25-65.         [ Links ]70.- ZEMELMAN R, BELLO H, DOMINGUEZ M, GONZALEZ    G, MELLA S, GARCIA A. Activity of imipenem, third-generation cephalosporins,    aztreonam, and ciprofloxacin against multi-resistant Gram negative bacilli isolated    from Chilean hospitals. J Antimicrob Chemother 1993; 32: 413-9.         [ Links ]71.- MEDEIROS A A. Evolution and dissemination    of ß-lactamases accelerated by generation of ß-lactam antibiotics.    Clin Infect Dis 1997; 24 (Suppl. 1): 19-45.         [ Links ]72.- PERRY C M, BROGDEN R N. Cefuroxime axetil:    review of its antibacterial activity, pharmacokinetic properties and therapeutic    efficacy. Drugs 1996; 52: 125-58.         [ Links ]73.- SCHAAD U B, SUTER S, GIANELLA-BORRADORI    et al. A comparison of ceftriaxone and cefuroxime for the treatment of bacterial    meningitis in children. N Engl J Med 1990; 322: 141-7.         [ Links ]74.- KLEIN N C, CUNHA B A. Cefalosporinas de    la tercera generación. Clin Med Nort Am 1995; 79: 693-707.         [ Links ]75.- KLUGMAN K P, MADHI S A. Emergence of    drug resistance impact on bacterial meningitis. Infect Dis Clin North Am 1999;    13: 637-46.         [ Links ]76.- RICHARDS D M, BROGDEN R N. Ceftazidime.    A review of its antibacterial activity, pharmacokinetic properties and therapeutic    use. Drugs 1985; 29: 105-61.         [ Links ]77.- SCHATZ B S, KARAVOKIROS K T, TAEUBEL    M A, ITOKAZU G S. Comparison of cefprozil, cefpodoxime proxetil, loracarbef,    cefixime, and ceftibuten. Ann Pharmacother 1996; 30: 258-68.         [ Links ]78.- DALMAU D, LAYRARGUES G P, FENYVES D,    WILLEMS B, TURGEON F, TURGEON P. Cefotaxime, desacetyl-cefotaxime, and bactericidal    activity in spontaneous bacterial peritonitis. J Infect Dis 1999; 180: 1597-1602.          [ Links ]79.- NIKAIDO W, LIU W, ROSENBERG E Y. Outer    membrane permeability and ß-lactamase stability of dipolar ionic cephalosporins    containing methoxyimino substituents. Antimicrob Agents Chemother 1990; 34:    337-42.         [ Links ]80.- HANCOCK R E W, BELLIDO F. Factors involved    in the enhanced efficacy against gram-negative bacteria of fourth generation    cephalosporins. J Antimicrob Chemother 1992; 29(Suppl A): 1-6.         [ Links ]81.- BELLIDO F, PECHERE J C, HANCOCK REW.    Novel method for measurement of outer membrane permeability to new beta-lactams    in intact Enterobacter cloacae cells. Antimicrob Agents Chemother 1991;    35: 68-72.         [ Links ]82.- NEU H C, CHIN N X, JULES K, LABTHAVIKUL    P. The activity of BMY-28142, a new broad spectrum beta-lactamase stable cephalosporin.    J Antimicrob Chemother 1986; 17: 441-52.         [ Links ]83.- KOBAYASHI S, ARAI S, HAYASHI S, FUJIMOTO    K. ß-lactamase stability of cefpirome (HR 810), a new cephalosporin with    a broad antimicrobial spectrum. Antimicrob Agents Chemother 1986; 30: 713-8.          [ Links ]84.- GARAU J, WILSON W, WOOD M, CARLET J.    Fourth generation cephalosporins: a review of in vitro activity, pharmacokinetics,    pharmacodynamics, and clinical utility. Clin Microb Infect 1997; 3 (Suppl 1):    87-101.         [ Links ]85.- KESSLER R E, FUNG-TOMC J. Susceptibility    of bacterial isolates to beta-lactam antibiotics from U.S. clinical trials over    5-year period. Am J Med 1996; 24 (6 A): 13-9.         [ Links ]86.- PIERARD D, EMMERECHTS K, LAUWERS S. Comparative    in-vitro activity of cefpirome against isolates from intensive care and haematology/oncology    units. Belgian Multicentric Study Group. J Antimicrob Chemother 1998; 41: 443-50.          [ Links ]87.- JONES R N. Resistance patterns among    nosocomial pathogens: trends over the past few years. Chest 2001; 119 (Suppl    2): 397-404.         [ Links ]88.- LORBER B. Changing patterns of infectious    diseases. Am J Med 1988; 84: 569-78.         [ Links ]89.- MOELLERING R C. A novel antimicrobial    agent joins the battle against resistant bacteria. Ann Intern Med 1999; 130:    155-7.         [ Links ]90.- WILSON W R. The role of fourth-generation    cephalosporins in the treatment of serious infectious diseases in hospitalized    patients. Diagn Microbiol Infect Dis 1998; 31: 473-7.         [ Links ]Correspondencia a:        Sergio Mella Montecinos        Laboratorio de Antibióticos,        Departamento de Microbiología,        Facultad de Ciencias Biológicas        Casilla 160-C, Concepción        E-mail: pignatio@ctcinternet.cl  

70.- ZEMELMAN R, BELLO H, DOMINGUEZ M, GONZALEZ    G, MELLA S, GARCIA A. Activity of imipenem, third-generation cephalosporins,    aztreonam, and ciprofloxacin against multi-resistant Gram negative bacilli isolated    from Chilean hospitals. J Antimicrob Chemother 1993; 32: 413-9.         [ Links ]71.- MEDEIROS A A. Evolution and dissemination    of ß-lactamases accelerated by generation of ß-lactam antibiotics.    Clin Infect Dis 1997; 24 (Suppl. 1): 19-45.         [ Links ]72.- PERRY C M, BROGDEN R N. Cefuroxime axetil:    review of its antibacterial activity, pharmacokinetic properties and therapeutic    efficacy. Drugs 1996; 52: 125-58.         [ Links ]73.- SCHAAD U B, SUTER S, GIANELLA-BORRADORI    et al. A comparison of ceftriaxone and cefuroxime for the treatment of bacterial    meningitis in children. N Engl J Med 1990; 322: 141-7.         [ Links ]74.- KLEIN N C, CUNHA B A. Cefalosporinas de    la tercera generación. Clin Med Nort Am 1995; 79: 693-707.         [ Links ]75.- KLUGMAN K P, MADHI S A. Emergence of    drug resistance impact on bacterial meningitis. Infect Dis Clin North Am 1999;    13: 637-46.         [ Links ]76.- RICHARDS D M, BROGDEN R N. Ceftazidime.    A review of its antibacterial activity, pharmacokinetic properties and therapeutic    use. Drugs 1985; 29: 105-61.         [ Links ]77.- SCHATZ B S, KARAVOKIROS K T, TAEUBEL    M A, ITOKAZU G S. Comparison of cefprozil, cefpodoxime proxetil, loracarbef,    cefixime, and ceftibuten. Ann Pharmacother 1996; 30: 258-68.         [ Links ]78.- DALMAU D, LAYRARGUES G P, FENYVES D,    WILLEMS B, TURGEON F, TURGEON P. Cefotaxime, desacetyl-cefotaxime, and bactericidal    activity in spontaneous bacterial peritonitis. J Infect Dis 1999; 180: 1597-1602.          [ Links ]79.- NIKAIDO W, LIU W, ROSENBERG E Y. Outer    membrane permeability and ß-lactamase stability of dipolar ionic cephalosporins    containing methoxyimino substituents. Antimicrob Agents Chemother 1990; 34:    337-42.         [ Links ]80.- HANCOCK R E W, BELLIDO F. Factors involved    in the enhanced efficacy against gram-negative bacteria of fourth generation    cephalosporins. J Antimicrob Chemother 1992; 29(Suppl A): 1-6.         [ Links ]81.- BELLIDO F, PECHERE J C, HANCOCK REW.    Novel method for measurement of outer membrane permeability to new beta-lactams    in intact Enterobacter cloacae cells. Antimicrob Agents Chemother 1991;    35: 68-72.         [ Links ]82.- NEU H C, CHIN N X, JULES K, LABTHAVIKUL    P. The activity of BMY-28142, a new broad spectrum beta-lactamase stable cephalosporin.    J Antimicrob Chemother 1986; 17: 441-52.         [ Links ]83.- KOBAYASHI S, ARAI S, HAYASHI S, FUJIMOTO    K. ß-lactamase stability of cefpirome (HR 810), a new cephalosporin with    a broad antimicrobial spectrum. Antimicrob Agents Chemother 1986; 30: 713-8.          [ Links ]84.- GARAU J, WILSON W, WOOD M, CARLET J.    Fourth generation cephalosporins: a review of in vitro activity, pharmacokinetics,    pharmacodynamics, and clinical utility. Clin Microb Infect 1997; 3 (Suppl 1):    87-101.         [ Links ]85.- KESSLER R E, FUNG-TOMC J. Susceptibility    of bacterial isolates to beta-lactam antibiotics from U.S. clinical trials over    5-year period. Am J Med 1996; 24 (6 A): 13-9.         [ Links ]86.- PIERARD D, EMMERECHTS K, LAUWERS S. Comparative    in-vitro activity of cefpirome against isolates from intensive care and haematology/oncology    units. Belgian Multicentric Study Group. J Antimicrob Chemother 1998; 41: 443-50.          [ Links ]87.- JONES R N. Resistance patterns among    nosocomial pathogens: trends over the past few years. Chest 2001; 119 (Suppl    2): 397-404.         [ Links ]88.- LORBER B. Changing patterns of infectious    diseases. Am J Med 1988; 84: 569-78.         [ Links ]89.- MOELLERING R C. A novel antimicrobial    agent joins the battle against resistant bacteria. Ann Intern Med 1999; 130:    155-7.         [ Links ]90.- WILSON W R. The role of fourth-generation    cephalosporins in the treatment of serious infectious diseases in hospitalized    patients. Diagn Microbiol Infect Dis 1998; 31: 473-7.         [ Links ]Correspondencia a:        Sergio Mella Montecinos        Laboratorio de Antibióticos,        Departamento de Microbiología,        Facultad de Ciencias Biológicas        Casilla 160-C, Concepción        E-mail: pignatio@ctcinternet.cl  

71.- MEDEIROS A A. Evolution and dissemination    of ß-lactamases accelerated by generation of ß-lactam antibiotics.    Clin Infect Dis 1997; 24 (Suppl. 1): 19-45.         [ Links ]72.- PERRY C M, BROGDEN R N. Cefuroxime axetil:    review of its antibacterial activity, pharmacokinetic properties and therapeutic    efficacy. Drugs 1996; 52: 125-58.         [ Links ]73.- SCHAAD U B, SUTER S, GIANELLA-BORRADORI    et al. A comparison of ceftriaxone and cefuroxime for the treatment of bacterial    meningitis in children. N Engl J Med 1990; 322: 141-7.         [ Links ]74.- KLEIN N C, CUNHA B A. Cefalosporinas de    la tercera generación. Clin Med Nort Am 1995; 79: 693-707.         [ Links ]75.- KLUGMAN K P, MADHI S A. Emergence of    drug resistance impact on bacterial meningitis. Infect Dis Clin North Am 1999;    13: 637-46.         [ Links ]76.- RICHARDS D M, BROGDEN R N. Ceftazidime.    A review of its antibacterial activity, pharmacokinetic properties and therapeutic    use. Drugs 1985; 29: 105-61.         [ Links ]77.- SCHATZ B S, KARAVOKIROS K T, TAEUBEL    M A, ITOKAZU G S. Comparison of cefprozil, cefpodoxime proxetil, loracarbef,    cefixime, and ceftibuten. Ann Pharmacother 1996; 30: 258-68.         [ Links ]78.- DALMAU D, LAYRARGUES G P, FENYVES D,    WILLEMS B, TURGEON F, TURGEON P. Cefotaxime, desacetyl-cefotaxime, and bactericidal    activity in spontaneous bacterial peritonitis. J Infect Dis 1999; 180: 1597-1602.          [ Links ]79.- NIKAIDO W, LIU W, ROSENBERG E Y. Outer    membrane permeability and ß-lactamase stability of dipolar ionic cephalosporins    containing methoxyimino substituents. Antimicrob Agents Chemother 1990; 34:    337-42.         [ Links ]80.- HANCOCK R E W, BELLIDO F. Factors involved    in the enhanced efficacy against gram-negative bacteria of fourth generation    cephalosporins. J Antimicrob Chemother 1992; 29(Suppl A): 1-6.         [ Links ]81.- BELLIDO F, PECHERE J C, HANCOCK REW.    Novel method for measurement of outer membrane permeability to new beta-lactams    in intact Enterobacter cloacae cells. Antimicrob Agents Chemother 1991;    35: 68-72.         [ Links ]82.- NEU H C, CHIN N X, JULES K, LABTHAVIKUL    P. The activity of BMY-28142, a new broad spectrum beta-lactamase stable cephalosporin.    J Antimicrob Chemother 1986; 17: 441-52.         [ Links ]83.- KOBAYASHI S, ARAI S, HAYASHI S, FUJIMOTO    K. ß-lactamase stability of cefpirome (HR 810), a new cephalosporin with    a broad antimicrobial spectrum. Antimicrob Agents Chemother 1986; 30: 713-8.          [ Links ]84.- GARAU J, WILSON W, WOOD M, CARLET J.    Fourth generation cephalosporins: a review of in vitro activity, pharmacokinetics,    pharmacodynamics, and clinical utility. Clin Microb Infect 1997; 3 (Suppl 1):    87-101.         [ Links ]85.- KESSLER R E, FUNG-TOMC J. Susceptibility    of bacterial isolates to beta-lactam antibiotics from U.S. clinical trials over    5-year period. Am J Med 1996; 24 (6 A): 13-9.         [ Links ]86.- PIERARD D, EMMERECHTS K, LAUWERS S. Comparative    in-vitro activity of cefpirome against isolates from intensive care and haematology/oncology    units. Belgian Multicentric Study Group. J Antimicrob Chemother 1998; 41: 443-50.          [ Links ]87.- JONES R N. Resistance patterns among    nosocomial pathogens: trends over the past few years. Chest 2001; 119 (Suppl    2): 397-404.         [ Links ]88.- LORBER B. Changing patterns of infectious    diseases. Am J Med 1988; 84: 569-78.         [ Links ]89.- MOELLERING R C. A novel antimicrobial    agent joins the battle against resistant bacteria. Ann Intern Med 1999; 130:    155-7.         [ Links ]90.- WILSON W R. The role of fourth-generation    cephalosporins in the treatment of serious infectious diseases in hospitalized    patients. Diagn Microbiol Infect Dis 1998; 31: 473-7.         [ Links ]Correspondencia a:        Sergio Mella Montecinos        Laboratorio de Antibióticos,        Departamento de Microbiología,        Facultad de Ciencias Biológicas        Casilla 160-C, Concepción        E-mail: pignatio@ctcinternet.cl  

72.- PERRY C M, BROGDEN R N. Cefuroxime axetil:    review of its antibacterial activity, pharmacokinetic properties and therapeutic    efficacy. Drugs 1996; 52: 125-58.         [ Links ]73.- SCHAAD U B, SUTER S, GIANELLA-BORRADORI    et al. A comparison of ceftriaxone and cefuroxime for the treatment of bacterial    meningitis in children. N Engl J Med 1990; 322: 141-7.         [ Links ]74.- KLEIN N C, CUNHA B A. Cefalosporinas de    la tercera generación. Clin Med Nort Am 1995; 79: 693-707.         [ Links ]75.- KLUGMAN K P, MADHI S A. Emergence of    drug resistance impact on bacterial meningitis. Infect Dis Clin North Am 1999;    13: 637-46.         [ Links ]76.- RICHARDS D M, BROGDEN R N. Ceftazidime.    A review of its antibacterial activity, pharmacokinetic properties and therapeutic    use. Drugs 1985; 29: 105-61.         [ Links ]77.- SCHATZ B S, KARAVOKIROS K T, TAEUBEL    M A, ITOKAZU G S. Comparison of cefprozil, cefpodoxime proxetil, loracarbef,    cefixime, and ceftibuten. Ann Pharmacother 1996; 30: 258-68.         [ Links ]78.- DALMAU D, LAYRARGUES G P, FENYVES D,    WILLEMS B, TURGEON F, TURGEON P. Cefotaxime, desacetyl-cefotaxime, and bactericidal    activity in spontaneous bacterial peritonitis. J Infect Dis 1999; 180: 1597-1602.          [ Links ]79.- NIKAIDO W, LIU W, ROSENBERG E Y. Outer    membrane permeability and ß-lactamase stability of dipolar ionic cephalosporins    containing methoxyimino substituents. Antimicrob Agents Chemother 1990; 34:    337-42.         [ Links ]80.- HANCOCK R E W, BELLIDO F. Factors involved    in the enhanced efficacy against gram-negative bacteria of fourth generation    cephalosporins. J Antimicrob Chemother 1992; 29(Suppl A): 1-6.         [ Links ]81.- BELLIDO F, PECHERE J C, HANCOCK REW.    Novel method for measurement of outer membrane permeability to new beta-lactams    in intact Enterobacter cloacae cells. Antimicrob Agents Chemother 1991;    35: 68-72.         [ Links ]82.- NEU H C, CHIN N X, JULES K, LABTHAVIKUL    P. The activity of BMY-28142, a new broad spectrum beta-lactamase stable cephalosporin.    J Antimicrob Chemother 1986; 17: 441-52.         [ Links ]83.- KOBAYASHI S, ARAI S, HAYASHI S, FUJIMOTO    K. ß-lactamase stability of cefpirome (HR 810), a new cephalosporin with    a broad antimicrobial spectrum. Antimicrob Agents Chemother 1986; 30: 713-8.          [ Links ]84.- GARAU J, WILSON W, WOOD M, CARLET J.    Fourth generation cephalosporins: a review of in vitro activity, pharmacokinetics,    pharmacodynamics, and clinical utility. Clin Microb Infect 1997; 3 (Suppl 1):    87-101.         [ Links ]85.- KESSLER R E, FUNG-TOMC J. Susceptibility    of bacterial isolates to beta-lactam antibiotics from U.S. clinical trials over    5-year period. Am J Med 1996; 24 (6 A): 13-9.         [ Links ]86.- PIERARD D, EMMERECHTS K, LAUWERS S. Comparative    in-vitro activity of cefpirome against isolates from intensive care and haematology/oncology    units. Belgian Multicentric Study Group. J Antimicrob Chemother 1998; 41: 443-50.          [ Links ]87.- JONES R N. Resistance patterns among    nosocomial pathogens: trends over the past few years. Chest 2001; 119 (Suppl    2): 397-404.         [ Links ]88.- LORBER B. Changing patterns of infectious    diseases. Am J Med 1988; 84: 569-78.         [ Links ]89.- MOELLERING R C. A novel antimicrobial    agent joins the battle against resistant bacteria. Ann Intern Med 1999; 130:    155-7.         [ Links ]90.- WILSON W R. The role of fourth-generation    cephalosporins in the treatment of serious infectious diseases in hospitalized    patients. Diagn Microbiol Infect Dis 1998; 31: 473-7.         [ Links ]Correspondencia a:        Sergio Mella Montecinos        Laboratorio de Antibióticos,        Departamento de Microbiología,        Facultad de Ciencias Biológicas        Casilla 160-C, Concepción        E-mail: pignatio@ctcinternet.cl  

73.- SCHAAD U B, SUTER S, GIANELLA-BORRADORI    et al. A comparison of ceftriaxone and cefuroxime for the treatment of bacterial    meningitis in children. N Engl J Med 1990; 322: 141-7.         [ Links ]74.- KLEIN N C, CUNHA B A. Cefalosporinas de    la tercera generación. Clin Med Nort Am 1995; 79: 693-707.         [ Links ]75.- KLUGMAN K P, MADHI S A. Emergence of    drug resistance impact on bacterial meningitis. Infect Dis Clin North Am 1999;    13: 637-46.         [ Links ]76.- RICHARDS D M, BROGDEN R N. Ceftazidime.    A review of its antibacterial activity, pharmacokinetic properties and therapeutic    use. Drugs 1985; 29: 105-61.         [ Links ]77.- SCHATZ B S, KARAVOKIROS K T, TAEUBEL    M A, ITOKAZU G S. Comparison of cefprozil, cefpodoxime proxetil, loracarbef,    cefixime, and ceftibuten. Ann Pharmacother 1996; 30: 258-68.         [ Links ]78.- DALMAU D, LAYRARGUES G P, FENYVES D,    WILLEMS B, TURGEON F, TURGEON P. Cefotaxime, desacetyl-cefotaxime, and bactericidal    activity in spontaneous bacterial peritonitis. J Infect Dis 1999; 180: 1597-1602.          [ Links ]79.- NIKAIDO W, LIU W, ROSENBERG E Y. Outer    membrane permeability and ß-lactamase stability of dipolar ionic cephalosporins    containing methoxyimino substituents. Antimicrob Agents Chemother 1990; 34:    337-42.         [ Links ]80.- HANCOCK R E W, BELLIDO F. Factors involved    in the enhanced efficacy against gram-negative bacteria of fourth generation    cephalosporins. J Antimicrob Chemother 1992; 29(Suppl A): 1-6.         [ Links ]81.- BELLIDO F, PECHERE J C, HANCOCK REW.    Novel method for measurement of outer membrane permeability to new beta-lactams    in intact Enterobacter cloacae cells. Antimicrob Agents Chemother 1991;    35: 68-72.         [ Links ]82.- NEU H C, CHIN N X, JULES K, LABTHAVIKUL    P. The activity of BMY-28142, a new broad spectrum beta-lactamase stable cephalosporin.    J Antimicrob Chemother 1986; 17: 441-52.         [ Links ]83.- KOBAYASHI S, ARAI S, HAYASHI S, FUJIMOTO    K. ß-lactamase stability of cefpirome (HR 810), a new cephalosporin with    a broad antimicrobial spectrum. Antimicrob Agents Chemother 1986; 30: 713-8.          [ Links ]84.- GARAU J, WILSON W, WOOD M, CARLET J.    Fourth generation cephalosporins: a review of in vitro activity, pharmacokinetics,    pharmacodynamics, and clinical utility. Clin Microb Infect 1997; 3 (Suppl 1):    87-101.         [ Links ]85.- KESSLER R E, FUNG-TOMC J. Susceptibility    of bacterial isolates to beta-lactam antibiotics from U.S. clinical trials over    5-year period. Am J Med 1996; 24 (6 A): 13-9.         [ Links ]86.- PIERARD D, EMMERECHTS K, LAUWERS S. Comparative    in-vitro activity of cefpirome against isolates from intensive care and haematology/oncology    units. Belgian Multicentric Study Group. J Antimicrob Chemother 1998; 41: 443-50.          [ Links ]87.- JONES R N. Resistance patterns among    nosocomial pathogens: trends over the past few years. Chest 2001; 119 (Suppl    2): 397-404.         [ Links ]88.- LORBER B. Changing patterns of infectious    diseases. Am J Med 1988; 84: 569-78.         [ Links ]89.- MOELLERING R C. A novel antimicrobial    agent joins the battle against resistant bacteria. Ann Intern Med 1999; 130:    155-7.         [ Links ]90.- WILSON W R. The role of fourth-generation    cephalosporins in the treatment of serious infectious diseases in hospitalized    patients. Diagn Microbiol Infect Dis 1998; 31: 473-7.         [ Links ]Correspondencia a:        Sergio Mella Montecinos        Laboratorio de Antibióticos,        Departamento de Microbiología,        Facultad de Ciencias Biológicas        Casilla 160-C, Concepción        E-mail: pignatio@ctcinternet.cl  

74.- KLEIN N C, CUNHA B A. Cefalosporinas de    la tercera generación. Clin Med Nort Am 1995; 79: 693-707.         [ Links ]75.- KLUGMAN K P, MADHI S A. Emergence of    drug resistance impact on bacterial meningitis. Infect Dis Clin North Am 1999;    13: 637-46.         [ Links ]76.- RICHARDS D M, BROGDEN R N. Ceftazidime.    A review of its antibacterial activity, pharmacokinetic properties and therapeutic    use. Drugs 1985; 29: 105-61.         [ Links ]77.- SCHATZ B S, KARAVOKIROS K T, TAEUBEL    M A, ITOKAZU G S. Comparison of cefprozil, cefpodoxime proxetil, loracarbef,    cefixime, and ceftibuten. Ann Pharmacother 1996; 30: 258-68.         [ Links ]78.- DALMAU D, LAYRARGUES G P, FENYVES D,    WILLEMS B, TURGEON F, TURGEON P. Cefotaxime, desacetyl-cefotaxime, and bactericidal    activity in spontaneous bacterial peritonitis. J Infect Dis 1999; 180: 1597-1602.          [ Links ]79.- NIKAIDO W, LIU W, ROSENBERG E Y. Outer    membrane permeability and ß-lactamase stability of dipolar ionic cephalosporins    containing methoxyimino substituents. Antimicrob Agents Chemother 1990; 34:    337-42.         [ Links ]80.- HANCOCK R E W, BELLIDO F. Factors involved    in the enhanced efficacy against gram-negative bacteria of fourth generation    cephalosporins. J Antimicrob Chemother 1992; 29(Suppl A): 1-6.         [ Links ]81.- BELLIDO F, PECHERE J C, HANCOCK REW.    Novel method for measurement of outer membrane permeability to new beta-lactams    in intact Enterobacter cloacae cells. Antimicrob Agents Chemother 1991;    35: 68-72.         [ Links ]82.- NEU H C, CHIN N X, JULES K, LABTHAVIKUL    P. The activity of BMY-28142, a new broad spectrum beta-lactamase stable cephalosporin.    J Antimicrob Chemother 1986; 17: 441-52.         [ Links ]83.- KOBAYASHI S, ARAI S, HAYASHI S, FUJIMOTO    K. ß-lactamase stability of cefpirome (HR 810), a new cephalosporin with    a broad antimicrobial spectrum. Antimicrob Agents Chemother 1986; 30: 713-8.          [ Links ]84.- GARAU J, WILSON W, WOOD M, CARLET J.    Fourth generation cephalosporins: a review of in vitro activity, pharmacokinetics,    pharmacodynamics, and clinical utility. Clin Microb Infect 1997; 3 (Suppl 1):    87-101.         [ Links ]85.- KESSLER R E, FUNG-TOMC J. Susceptibility    of bacterial isolates to beta-lactam antibiotics from U.S. clinical trials over    5-year period. Am J Med 1996; 24 (6 A): 13-9.         [ Links ]86.- PIERARD D, EMMERECHTS K, LAUWERS S. Comparative    in-vitro activity of cefpirome against isolates from intensive care and haematology/oncology    units. Belgian Multicentric Study Group. J Antimicrob Chemother 1998; 41: 443-50.          [ Links ]87.- JONES R N. Resistance patterns among    nosocomial pathogens: trends over the past few years. Chest 2001; 119 (Suppl    2): 397-404.         [ Links ]88.- LORBER B. Changing patterns of infectious    diseases. Am J Med 1988; 84: 569-78.         [ Links ]89.- MOELLERING R C. A novel antimicrobial    agent joins the battle against resistant bacteria. Ann Intern Med 1999; 130:    155-7.         [ Links ]90.- WILSON W R. The role of fourth-generation    cephalosporins in the treatment of serious infectious diseases in hospitalized    patients. Diagn Microbiol Infect Dis 1998; 31: 473-7.         [ Links ]Correspondencia a:        Sergio Mella Montecinos        Laboratorio de Antibióticos,        Departamento de Microbiología,        Facultad de Ciencias Biológicas        Casilla 160-C, Concepción        E-mail: pignatio@ctcinternet.cl  

75.- KLUGMAN K P, MADHI S A. Emergence of    drug resistance impact on bacterial meningitis. Infect Dis Clin North Am 1999;    13: 637-46.         [ Links ]76.- RICHARDS D M, BROGDEN R N. Ceftazidime.    A review of its antibacterial activity, pharmacokinetic properties and therapeutic    use. Drugs 1985; 29: 105-61.         [ Links ]77.- SCHATZ B S, KARAVOKIROS K T, TAEUBEL    M A, ITOKAZU G S. Comparison of cefprozil, cefpodoxime proxetil, loracarbef,    cefixime, and ceftibuten. Ann Pharmacother 1996; 30: 258-68.         [ Links ]78.- DALMAU D, LAYRARGUES G P, FENYVES D,    WILLEMS B, TURGEON F, TURGEON P. Cefotaxime, desacetyl-cefotaxime, and bactericidal    activity in spontaneous bacterial peritonitis. J Infect Dis 1999; 180: 1597-1602.          [ Links ]79.- NIKAIDO W, LIU W, ROSENBERG E Y. Outer    membrane permeability and ß-lactamase stability of dipolar ionic cephalosporins    containing methoxyimino substituents. Antimicrob Agents Chemother 1990; 34:    337-42.         [ Links ]80.- HANCOCK R E W, BELLIDO F. Factors involved    in the enhanced efficacy against gram-negative bacteria of fourth generation    cephalosporins. J Antimicrob Chemother 1992; 29(Suppl A): 1-6.         [ Links ]81.- BELLIDO F, PECHERE J C, HANCOCK REW.    Novel method for measurement of outer membrane permeability to new beta-lactams    in intact Enterobacter cloacae cells. Antimicrob Agents Chemother 1991;    35: 68-72.         [ Links ]82.- NEU H C, CHIN N X, JULES K, LABTHAVIKUL    P. The activity of BMY-28142, a new broad spectrum beta-lactamase stable cephalosporin.    J Antimicrob Chemother 1986; 17: 441-52.         [ Links ]83.- KOBAYASHI S, ARAI S, HAYASHI S, FUJIMOTO    K. ß-lactamase stability of cefpirome (HR 810), a new cephalosporin with    a broad antimicrobial spectrum. Antimicrob Agents Chemother 1986; 30: 713-8.          [ Links ]84.- GARAU J, WILSON W, WOOD M, CARLET J.    Fourth generation cephalosporins: a review of in vitro activity, pharmacokinetics,    pharmacodynamics, and clinical utility. Clin Microb Infect 1997; 3 (Suppl 1):    87-101.         [ Links ]85.- KESSLER R E, FUNG-TOMC J. Susceptibility    of bacterial isolates to beta-lactam antibiotics from U.S. clinical trials over    5-year period. Am J Med 1996; 24 (6 A): 13-9.         [ Links ]86.- PIERARD D, EMMERECHTS K, LAUWERS S. Comparative    in-vitro activity of cefpirome against isolates from intensive care and haematology/oncology    units. Belgian Multicentric Study Group. J Antimicrob Chemother 1998; 41: 443-50.          [ Links ]87.- JONES R N. Resistance patterns among    nosocomial pathogens: trends over the past few years. Chest 2001; 119 (Suppl    2): 397-404.         [ Links ]88.- LORBER B. Changing patterns of infectious    diseases. Am J Med 1988; 84: 569-78.         [ Links ]89.- MOELLERING R C. A novel antimicrobial    agent joins the battle against resistant bacteria. Ann Intern Med 1999; 130:    155-7.         [ Links ]90.- WILSON W R. The role of fourth-generation    cephalosporins in the treatment of serious infectious diseases in hospitalized    patients. Diagn Microbiol Infect Dis 1998; 31: 473-7.         [ Links ]Correspondencia a:        Sergio Mella Montecinos        Laboratorio de Antibióticos,        Departamento de Microbiología,        Facultad de Ciencias Biológicas        Casilla 160-C, Concepción        E-mail: pignatio@ctcinternet.cl  

76.- RICHARDS D M, BROGDEN R N. Ceftazidime.    A review of its antibacterial activity, pharmacokinetic properties and therapeutic    use. Drugs 1985; 29: 105-61.         [ Links ]77.- SCHATZ B S, KARAVOKIROS K T, TAEUBEL    M A, ITOKAZU G S. Comparison of cefprozil, cefpodoxime proxetil, loracarbef,    cefixime, and ceftibuten. Ann Pharmacother 1996; 30: 258-68.         [ Links ]78.- DALMAU D, LAYRARGUES G P, FENYVES D,    WILLEMS B, TURGEON F, TURGEON P. Cefotaxime, desacetyl-cefotaxime, and bactericidal    activity in spontaneous bacterial peritonitis. J Infect Dis 1999; 180: 1597-1602.          [ Links ]79.- NIKAIDO W, LIU W, ROSENBERG E Y. Outer    membrane permeability and ß-lactamase stability of dipolar ionic cephalosporins    containing methoxyimino substituents. Antimicrob Agents Chemother 1990; 34:    337-42.         [ Links ]80.- HANCOCK R E W, BELLIDO F. Factors involved    in the enhanced efficacy against gram-negative bacteria of fourth generation    cephalosporins. J Antimicrob Chemother 1992; 29(Suppl A): 1-6.         [ Links ]81.- BELLIDO F, PECHERE J C, HANCOCK REW.    Novel method for measurement of outer membrane permeability to new beta-lactams    in intact Enterobacter cloacae cells. Antimicrob Agents Chemother 1991;    35: 68-72.         [ Links ]82.- NEU H C, CHIN N X, JULES K, LABTHAVIKUL    P. The activity of BMY-28142, a new broad spectrum beta-lactamase stable cephalosporin.    J Antimicrob Chemother 1986; 17: 441-52.         [ Links ]83.- KOBAYASHI S, ARAI S, HAYASHI S, FUJIMOTO    K. ß-lactamase stability of cefpirome (HR 810), a new cephalosporin with    a broad antimicrobial spectrum. Antimicrob Agents Chemother 1986; 30: 713-8.          [ Links ]84.- GARAU J, WILSON W, WOOD M, CARLET J.    Fourth generation cephalosporins: a review of in vitro activity, pharmacokinetics,    pharmacodynamics, and clinical utility. Clin Microb Infect 1997; 3 (Suppl 1):    87-101.         [ Links ]85.- KESSLER R E, FUNG-TOMC J. Susceptibility    of bacterial isolates to beta-lactam antibiotics from U.S. clinical trials over    5-year period. Am J Med 1996; 24 (6 A): 13-9.         [ Links ]86.- PIERARD D, EMMERECHTS K, LAUWERS S. Comparative    in-vitro activity of cefpirome against isolates from intensive care and haematology/oncology    units. Belgian Multicentric Study Group. J Antimicrob Chemother 1998; 41: 443-50.          [ Links ]87.- JONES R N. Resistance patterns among    nosocomial pathogens: trends over the past few years. Chest 2001; 119 (Suppl    2): 397-404.         [ Links ]88.- LORBER B. Changing patterns of infectious    diseases. Am J Med 1988; 84: 569-78.         [ Links ]89.- MOELLERING R C. A novel antimicrobial    agent joins the battle against resistant bacteria. Ann Intern Med 1999; 130:    155-7.         [ Links ]90.- WILSON W R. The role of fourth-generation    cephalosporins in the treatment of serious infectious diseases in hospitalized    patients. Diagn Microbiol Infect Dis 1998; 31: 473-7.         [ Links ]Correspondencia a:        Sergio Mella Montecinos        Laboratorio de Antibióticos,        Departamento de Microbiología,        Facultad de Ciencias Biológicas        Casilla 160-C, Concepción        E-mail: pignatio@ctcinternet.cl  

77.- SCHATZ B S, KARAVOKIROS K T, TAEUBEL    M A, ITOKAZU G S. Comparison of cefprozil, cefpodoxime proxetil, loracarbef,    cefixime, and ceftibuten. Ann Pharmacother 1996; 30: 258-68.         [ Links ]78.- DALMAU D, LAYRARGUES G P, FENYVES D,    WILLEMS B, TURGEON F, TURGEON P. Cefotaxime, desacetyl-cefotaxime, and bactericidal    activity in spontaneous bacterial peritonitis. J Infect Dis 1999; 180: 1597-1602.          [ Links ]79.- NIKAIDO W, LIU W, ROSENBERG E Y. Outer    membrane permeability and ß-lactamase stability of dipolar ionic cephalosporins    containing methoxyimino substituents. Antimicrob Agents Chemother 1990; 34:    337-42.         [ Links ]80.- HANCOCK R E W, BELLIDO F. Factors involved    in the enhanced efficacy against gram-negative bacteria of fourth generation    cephalosporins. J Antimicrob Chemother 1992; 29(Suppl A): 1-6.         [ Links ]81.- BELLIDO F, PECHERE J C, HANCOCK REW.    Novel method for measurement of outer membrane permeability to new beta-lactams    in intact Enterobacter cloacae cells. Antimicrob Agents Chemother 1991;    35: 68-72.         [ Links ]82.- NEU H C, CHIN N X, JULES K, LABTHAVIKUL    P. The activity of BMY-28142, a new broad spectrum beta-lactamase stable cephalosporin.    J Antimicrob Chemother 1986; 17: 441-52.         [ Links ]83.- KOBAYASHI S, ARAI S, HAYASHI S, FUJIMOTO    K. ß-lactamase stability of cefpirome (HR 810), a new cephalosporin with    a broad antimicrobial spectrum. Antimicrob Agents Chemother 1986; 30: 713-8.          [ Links ]84.- GARAU J, WILSON W, WOOD M, CARLET J.    Fourth generation cephalosporins: a review of in vitro activity, pharmacokinetics,    pharmacodynamics, and clinical utility. Clin Microb Infect 1997; 3 (Suppl 1):    87-101.         [ Links ]85.- KESSLER R E, FUNG-TOMC J. Susceptibility    of bacterial isolates to beta-lactam antibiotics from U.S. clinical trials over    5-year period. Am J Med 1996; 24 (6 A): 13-9.         [ Links ]86.- PIERARD D, EMMERECHTS K, LAUWERS S. Comparative    in-vitro activity of cefpirome against isolates from intensive care and haematology/oncology    units. Belgian Multicentric Study Group. J Antimicrob Chemother 1998; 41: 443-50.          [ Links ]87.- JONES R N. Resistance patterns among    nosocomial pathogens: trends over the past few years. Chest 2001; 119 (Suppl    2): 397-404.         [ Links ]88.- LORBER B. Changing patterns of infectious    diseases. Am J Med 1988; 84: 569-78.         [ Links ]89.- MOELLERING R C. A novel antimicrobial    agent joins the battle against resistant bacteria. Ann Intern Med 1999; 130:    155-7.         [ Links ]90.- WILSON W R. The role of fourth-generation    cephalosporins in the treatment of serious infectious diseases in hospitalized    patients. Diagn Microbiol Infect Dis 1998; 31: 473-7.         [ Links ]Correspondencia a:        Sergio Mella Montecinos        Laboratorio de Antibióticos,        Departamento de Microbiología,        Facultad de Ciencias Biológicas        Casilla 160-C, Concepción        E-mail: pignatio@ctcinternet.cl  

78.- DALMAU D, LAYRARGUES G P, FENYVES D,    WILLEMS B, TURGEON F, TURGEON P. Cefotaxime, desacetyl-cefotaxime, and bactericidal    activity in spontaneous bacterial peritonitis. J Infect Dis 1999; 180: 1597-1602.          [ Links ]79.- NIKAIDO W, LIU W, ROSENBERG E Y. Outer    membrane permeability and ß-lactamase stability of dipolar ionic cephalosporins    containing methoxyimino substituents. Antimicrob Agents Chemother 1990; 34:    337-42.         [ Links ]80.- HANCOCK R E W, BELLIDO F. Factors involved    in the enhanced efficacy against gram-negative bacteria of fourth generation    cephalosporins. J Antimicrob Chemother 1992; 29(Suppl A): 1-6.         [ Links ]81.- BELLIDO F, PECHERE J C, HANCOCK REW.    Novel method for measurement of outer membrane permeability to new beta-lactams    in intact Enterobacter cloacae cells. Antimicrob Agents Chemother 1991;    35: 68-72.         [ Links ]82.- NEU H C, CHIN N X, JULES K, LABTHAVIKUL    P. The activity of BMY-28142, a new broad spectrum beta-lactamase stable cephalosporin.    J Antimicrob Chemother 1986; 17: 441-52.         [ Links ]83.- KOBAYASHI S, ARAI S, HAYASHI S, FUJIMOTO    K. ß-lactamase stability of cefpirome (HR 810), a new cephalosporin with    a broad antimicrobial spectrum. Antimicrob Agents Chemother 1986; 30: 713-8.          [ Links ]84.- GARAU J, WILSON W, WOOD M, CARLET J.    Fourth generation cephalosporins: a review of in vitro activity, pharmacokinetics,    pharmacodynamics, and clinical utility. Clin Microb Infect 1997; 3 (Suppl 1):    87-101.         [ Links ]85.- KESSLER R E, FUNG-TOMC J. Susceptibility    of bacterial isolates to beta-lactam antibiotics from U.S. clinical trials over    5-year period. Am J Med 1996; 24 (6 A): 13-9.         [ Links ]86.- PIERARD D, EMMERECHTS K, LAUWERS S. Comparative    in-vitro activity of cefpirome against isolates from intensive care and haematology/oncology    units. Belgian Multicentric Study Group. J Antimicrob Chemother 1998; 41: 443-50.          [ Links ]87.- JONES R N. Resistance patterns among    nosocomial pathogens: trends over the past few years. Chest 2001; 119 (Suppl    2): 397-404.         [ Links ]88.- LORBER B. Changing patterns of infectious    diseases. Am J Med 1988; 84: 569-78.         [ Links ]89.- MOELLERING R C. A novel antimicrobial    agent joins the battle against resistant bacteria. Ann Intern Med 1999; 130:    155-7.         [ Links ]90.- WILSON W R. The role of fourth-generation    cephalosporins in the treatment of serious infectious diseases in hospitalized    patients. Diagn Microbiol Infect Dis 1998; 31: 473-7.         [ Links ]Correspondencia a:        Sergio Mella Montecinos        Laboratorio de Antibióticos,        Departamento de Microbiología,        Facultad de Ciencias Biológicas        Casilla 160-C, Concepción        E-mail: pignatio@ctcinternet.cl  

79.- NIKAIDO W, LIU W, ROSENBERG E Y. Outer    membrane permeability and ß-lactamase stability of dipolar ionic cephalosporins    containing methoxyimino substituents. Antimicrob Agents Chemother 1990; 34:    337-42.         [ Links ]80.- HANCOCK R E W, BELLIDO F. Factors involved    in the enhanced efficacy against gram-negative bacteria of fourth generation    cephalosporins. J Antimicrob Chemother 1992; 29(Suppl A): 1-6.         [ Links ]81.- BELLIDO F, PECHERE J C, HANCOCK REW.    Novel method for measurement of outer membrane permeability to new beta-lactams    in intact Enterobacter cloacae cells. Antimicrob Agents Chemother 1991;    35: 68-72.         [ Links ]82.- NEU H C, CHIN N X, JULES K, LABTHAVIKUL    P. The activity of BMY-28142, a new broad spectrum beta-lactamase stable cephalosporin.    J Antimicrob Chemother 1986; 17: 441-52.         [ Links ]83.- KOBAYASHI S, ARAI S, HAYASHI S, FUJIMOTO    K. ß-lactamase stability of cefpirome (HR 810), a new cephalosporin with    a broad antimicrobial spectrum. Antimicrob Agents Chemother 1986; 30: 713-8.          [ Links ]84.- GARAU J, WILSON W, WOOD M, CARLET J.    Fourth generation cephalosporins: a review of in vitro activity, pharmacokinetics,    pharmacodynamics, and clinical utility. Clin Microb Infect 1997; 3 (Suppl 1):    87-101.         [ Links ]85.- KESSLER R E, FUNG-TOMC J. Susceptibility    of bacterial isolates to beta-lactam antibiotics from U.S. clinical trials over    5-year period. Am J Med 1996; 24 (6 A): 13-9.         [ Links ]86.- PIERARD D, EMMERECHTS K, LAUWERS S. Comparative    in-vitro activity of cefpirome against isolates from intensive care and haematology/oncology    units. Belgian Multicentric Study Group. J Antimicrob Chemother 1998; 41: 443-50.          [ Links ]87.- JONES R N. Resistance patterns among    nosocomial pathogens: trends over the past few years. Chest 2001; 119 (Suppl    2): 397-404.         [ Links ]88.- LORBER B. Changing patterns of infectious    diseases. Am J Med 1988; 84: 569-78.         [ Links ]89.- MOELLERING R C. A novel antimicrobial    agent joins the battle against resistant bacteria. Ann Intern Med 1999; 130:    155-7.         [ Links ]90.- WILSON W R. The role of fourth-generation    cephalosporins in the treatment of serious infectious diseases in hospitalized    patients. Diagn Microbiol Infect Dis 1998; 31: 473-7.         [ Links ]Correspondencia a:        Sergio Mella Montecinos        Laboratorio de Antibióticos,        Departamento de Microbiología,        Facultad de Ciencias Biológicas        Casilla 160-C, Concepción        E-mail: pignatio@ctcinternet.cl  

80.- HANCOCK R E W, BELLIDO F. Factors involved    in the enhanced efficacy against gram-negative bacteria of fourth generation    cephalosporins. J Antimicrob Chemother 1992; 29(Suppl A): 1-6.         [ Links ]81.- BELLIDO F, PECHERE J C, HANCOCK REW.    Novel method for measurement of outer membrane permeability to new beta-lactams    in intact Enterobacter cloacae cells. Antimicrob Agents Chemother 1991;    35: 68-72.         [ Links ]82.- NEU H C, CHIN N X, JULES K, LABTHAVIKUL    P. The activity of BMY-28142, a new broad spectrum beta-lactamase stable cephalosporin.    J Antimicrob Chemother 1986; 17: 441-52.         [ Links ]83.- KOBAYASHI S, ARAI S, HAYASHI S, FUJIMOTO    K. ß-lactamase stability of cefpirome (HR 810), a new cephalosporin with    a broad antimicrobial spectrum. Antimicrob Agents Chemother 1986; 30: 713-8.          [ Links ]84.- GARAU J, WILSON W, WOOD M, CARLET J.    Fourth generation cephalosporins: a review of in vitro activity, pharmacokinetics,    pharmacodynamics, and clinical utility. Clin Microb Infect 1997; 3 (Suppl 1):    87-101.         [ Links ]85.- KESSLER R E, FUNG-TOMC J. Susceptibility    of bacterial isolates to beta-lactam antibiotics from U.S. clinical trials over    5-year period. Am J Med 1996; 24 (6 A): 13-9.         [ Links ]86.- PIERARD D, EMMERECHTS K, LAUWERS S. Comparative    in-vitro activity of cefpirome against isolates from intensive care and haematology/oncology    units. Belgian Multicentric Study Group. J Antimicrob Chemother 1998; 41: 443-50.          [ Links ]87.- JONES R N. Resistance patterns among    nosocomial pathogens: trends over the past few years. Chest 2001; 119 (Suppl    2): 397-404.         [ Links ]88.- LORBER B. Changing patterns of infectious    diseases. Am J Med 1988; 84: 569-78.         [ Links ]89.- MOELLERING R C. A novel antimicrobial    agent joins the battle against resistant bacteria. Ann Intern Med 1999; 130:    155-7.         [ Links ]90.- WILSON W R. The role of fourth-generation    cephalosporins in the treatment of serious infectious diseases in hospitalized    patients. Diagn Microbiol Infect Dis 1998; 31: 473-7.         [ Links ]Correspondencia a:        Sergio Mella Montecinos        Laboratorio de Antibióticos,        Departamento de Microbiología,        Facultad de Ciencias Biológicas        Casilla 160-C, Concepción        E-mail: pignatio@ctcinternet.cl  

81.- BELLIDO F, PECHERE J C, HANCOCK REW.    Novel method for measurement of outer membrane permeability to new beta-lactams    in intact Enterobacter cloacae cells. Antimicrob Agents Chemother 1991;    35: 68-72.         [ Links ]82.- NEU H C, CHIN N X, JULES K, LABTHAVIKUL    P. The activity of BMY-28142, a new broad spectrum beta-lactamase stable cephalosporin.    J Antimicrob Chemother 1986; 17: 441-52.         [ Links ]83.- KOBAYASHI S, ARAI S, HAYASHI S, FUJIMOTO    K. ß-lactamase stability of cefpirome (HR 810), a new cephalosporin with    a broad antimicrobial spectrum. Antimicrob Agents Chemother 1986; 30: 713-8.          [ Links ]84.- GARAU J, WILSON W, WOOD M, CARLET J.    Fourth generation cephalosporins: a review of in vitro activity, pharmacokinetics,    pharmacodynamics, and clinical utility. Clin Microb Infect 1997; 3 (Suppl 1):    87-101.         [ Links ]85.- KESSLER R E, FUNG-TOMC J. Susceptibility    of bacterial isolates to beta-lactam antibiotics from U.S. clinical trials over    5-year period. Am J Med 1996; 24 (6 A): 13-9.         [ Links ]86.- PIERARD D, EMMERECHTS K, LAUWERS S. Comparative    in-vitro activity of cefpirome against isolates from intensive care and haematology/oncology    units. Belgian Multicentric Study Group. J Antimicrob Chemother 1998; 41: 443-50.          [ Links ]87.- JONES R N. Resistance patterns among    nosocomial pathogens: trends over the past few years. Chest 2001; 119 (Suppl    2): 397-404.         [ Links ]88.- LORBER B. Changing patterns of infectious    diseases. Am J Med 1988; 84: 569-78.         [ Links ]89.- MOELLERING R C. A novel antimicrobial    agent joins the battle against resistant bacteria. Ann Intern Med 1999; 130:    155-7.         [ Links ]90.- WILSON W R. The role of fourth-generation    cephalosporins in the treatment of serious infectious diseases in hospitalized    patients. Diagn Microbiol Infect Dis 1998; 31: 473-7.         [ Links ]Correspondencia a:        Sergio Mella Montecinos        Laboratorio de Antibióticos,        Departamento de Microbiología,        Facultad de Ciencias Biológicas        Casilla 160-C, Concepción        E-mail: pignatio@ctcinternet.cl  

82.- NEU H C, CHIN N X, JULES K, LABTHAVIKUL    P. The activity of BMY-28142, a new broad spectrum beta-lactamase stable cephalosporin.    J Antimicrob Chemother 1986; 17: 441-52.         [ Links ]83.- KOBAYASHI S, ARAI S, HAYASHI S, FUJIMOTO    K. ß-lactamase stability of cefpirome (HR 810), a new cephalosporin with    a broad antimicrobial spectrum. Antimicrob Agents Chemother 1986; 30: 713-8.          [ Links ]84.- GARAU J, WILSON W, WOOD M, CARLET J.    Fourth generation cephalosporins: a review of in vitro activity, pharmacokinetics,    pharmacodynamics, and clinical utility. Clin Microb Infect 1997; 3 (Suppl 1):    87-101.         [ Links ]85.- KESSLER R E, FUNG-TOMC J. Susceptibility    of bacterial isolates to beta-lactam antibiotics from U.S. clinical trials over    5-year period. Am J Med 1996; 24 (6 A): 13-9.         [ Links ]86.- PIERARD D, EMMERECHTS K, LAUWERS S. Comparative    in-vitro activity of cefpirome against isolates from intensive care and haematology/oncology    units. Belgian Multicentric Study Group. J Antimicrob Chemother 1998; 41: 443-50.          [ Links ]87.- JONES R N. Resistance patterns among    nosocomial pathogens: trends over the past few years. Chest 2001; 119 (Suppl    2): 397-404.         [ Links ]88.- LORBER B. Changing patterns of infectious    diseases. Am J Med 1988; 84: 569-78.         [ Links ]89.- MOELLERING R C. A novel antimicrobial    agent joins the battle against resistant bacteria. Ann Intern Med 1999; 130:    155-7.         [ Links ]90.- WILSON W R. The role of fourth-generation    cephalosporins in the treatment of serious infectious diseases in hospitalized    patients. Diagn Microbiol Infect Dis 1998; 31: 473-7.         [ Links ]Correspondencia a:        Sergio Mella Montecinos        Laboratorio de Antibióticos,        Departamento de Microbiología,        Facultad de Ciencias Biológicas        Casilla 160-C, Concepción        E-mail: pignatio@ctcinternet.cl  

83.- KOBAYASHI S, ARAI S, HAYASHI S, FUJIMOTO    K. ß-lactamase stability of cefpirome (HR 810), a new cephalosporin with    a broad antimicrobial spectrum. Antimicrob Agents Chemother 1986; 30: 713-8.          [ Links ]84.- GARAU J, WILSON W, WOOD M, CARLET J.    Fourth generation cephalosporins: a review of in vitro activity, pharmacokinetics,    pharmacodynamics, and clinical utility. Clin Microb Infect 1997; 3 (Suppl 1):    87-101.         [ Links ]85.- KESSLER R E, FUNG-TOMC J. Susceptibility    of bacterial isolates to beta-lactam antibiotics from U.S. clinical trials over    5-year period. Am J Med 1996; 24 (6 A): 13-9.         [ Links ]86.- PIERARD D, EMMERECHTS K, LAUWERS S. Comparative    in-vitro activity of cefpirome against isolates from intensive care and haematology/oncology    units. Belgian Multicentric Study Group. J Antimicrob Chemother 1998; 41: 443-50.          [ Links ]87.- JONES R N. Resistance patterns among    nosocomial pathogens: trends over the past few years. Chest 2001; 119 (Suppl    2): 397-404.         [ Links ]88.- LORBER B. Changing patterns of infectious    diseases. Am J Med 1988; 84: 569-78.         [ Links ]89.- MOELLERING R C. A novel antimicrobial    agent joins the battle against resistant bacteria. Ann Intern Med 1999; 130:    155-7.         [ Links ]90.- WILSON W R. The role of fourth-generation    cephalosporins in the treatment of serious infectious diseases in hospitalized    patients. Diagn Microbiol Infect Dis 1998; 31: 473-7.         [ Links ]Correspondencia a:        Sergio Mella Montecinos        Laboratorio de Antibióticos,        Departamento de Microbiología,        Facultad de Ciencias Biológicas        Casilla 160-C, Concepción        E-mail: pignatio@ctcinternet.cl  

84.- GARAU J, WILSON W, WOOD M, CARLET J.    Fourth generation cephalosporins: a review of in vitro activity, pharmacokinetics,    pharmacodynamics, and clinical utility. Clin Microb Infect 1997; 3 (Suppl 1):    87-101.         [ Links ]85.- KESSLER R E, FUNG-TOMC J. Susceptibility    of bacterial isolates to beta-lactam antibiotics from U.S. clinical trials over    5-year period. Am J Med 1996; 24 (6 A): 13-9.         [ Links ]86.- PIERARD D, EMMERECHTS K, LAUWERS S. Comparative    in-vitro activity of cefpirome against isolates from intensive care and haematology/oncology    units. Belgian Multicentric Study Group. J Antimicrob Chemother 1998; 41: 443-50.          [ Links ]87.- JONES R N. Resistance patterns among    nosocomial pathogens: trends over the past few years. Chest 2001; 119 (Suppl    2): 397-404.         [ Links ]88.- LORBER B. Changing patterns of infectious    diseases. Am J Med 1988; 84: 569-78.         [ Links ]89.- MOELLERING R C. A novel antimicrobial    agent joins the battle against resistant bacteria. Ann Intern Med 1999; 130:    155-7.         [ Links ]90.- WILSON W R. The role of fourth-generation    cephalosporins in the treatment of serious infectious diseases in hospitalized    patients. Diagn Microbiol Infect Dis 1998; 31: 473-7.         [ Links ]Correspondencia a:        Sergio Mella Montecinos        Laboratorio de Antibióticos,        Departamento de Microbiología,        Facultad de Ciencias Biológicas        Casilla 160-C, Concepción        E-mail: pignatio@ctcinternet.cl  

85.- KESSLER R E, FUNG-TOMC J. Susceptibility    of bacterial isolates to beta-lactam antibiotics from U.S. clinical trials over    5-year period. Am J Med 1996; 24 (6 A): 13-9.         [ Links ]86.- PIERARD D, EMMERECHTS K, LAUWERS S. Comparative    in-vitro activity of cefpirome against isolates from intensive care and haematology/oncology    units. Belgian Multicentric Study Group. J Antimicrob Chemother 1998; 41: 443-50.          [ Links ]87.- JONES R N. Resistance patterns among    nosocomial pathogens: trends over the past few years. Chest 2001; 119 (Suppl    2): 397-404.         [ Links ]88.- LORBER B. Changing patterns of infectious    diseases. Am J Med 1988; 84: 569-78.         [ Links ]89.- MOELLERING R C. A novel antimicrobial    agent joins the battle against resistant bacteria. Ann Intern Med 1999; 130:    155-7.         [ Links ]90.- WILSON W R. The role of fourth-generation    cephalosporins in the treatment of serious infectious diseases in hospitalized    patients. Diagn Microbiol Infect Dis 1998; 31: 473-7.         [ Links ]Correspondencia a:        Sergio Mella Montecinos        Laboratorio de Antibióticos,        Departamento de Microbiología,        Facultad de Ciencias Biológicas        Casilla 160-C, Concepción        E-mail: pignatio@ctcinternet.cl  

86.- PIERARD D, EMMERECHTS K, LAUWERS S. Comparative    in-vitro activity of cefpirome against isolates from intensive care and haematology/oncology    units. Belgian Multicentric Study Group. J Antimicrob Chemother 1998; 41: 443-50.          [ Links ]87.- JONES R N. Resistance patterns among    nosocomial pathogens: trends over the past few years. Chest 2001; 119 (Suppl    2): 397-404.         [ Links ]88.- LORBER B. Changing patterns of infectious    diseases. Am J Med 1988; 84: 569-78.         [ Links ]89.- MOELLERING R C. A novel antimicrobial    agent joins the battle against resistant bacteria. Ann Intern Med 1999; 130:    155-7.         [ Links ]90.- WILSON W R. The role of fourth-generation    cephalosporins in the treatment of serious infectious diseases in hospitalized    patients. Diagn Microbiol Infect Dis 1998; 31: 473-7.         [ Links ]Correspondencia a:        Sergio Mella Montecinos        Laboratorio de Antibióticos,        Departamento de Microbiología,        Facultad de Ciencias Biológicas        Casilla 160-C, Concepción        E-mail: pignatio@ctcinternet.cl  

87.- JONES R N. Resistance patterns among    nosocomial pathogens: trends over the past few years. Chest 2001; 119 (Suppl    2): 397-404.         [ Links ]88.- LORBER B. Changing patterns of infectious    diseases. Am J Med 1988; 84: 569-78.         [ Links ]89.- MOELLERING R C. A novel antimicrobial    agent joins the battle against resistant bacteria. Ann Intern Med 1999; 130:    155-7.         [ Links ]90.- WILSON W R. The role of fourth-generation    cephalosporins in the treatment of serious infectious diseases in hospitalized    patients. Diagn Microbiol Infect Dis 1998; 31: 473-7.         [ Links ]Correspondencia a:        Sergio Mella Montecinos        Laboratorio de Antibióticos,        Departamento de Microbiología,        Facultad de Ciencias Biológicas        Casilla 160-C, Concepción        E-mail: pignatio@ctcinternet.cl  

88.- LORBER B. Changing patterns of infectious    diseases. Am J Med 1988; 84: 569-78.         [ Links ]89.- MOELLERING R C. A novel antimicrobial    agent joins the battle against resistant bacteria. Ann Intern Med 1999; 130:    155-7.         [ Links ]90.- WILSON W R. The role of fourth-generation    cephalosporins in the treatment of serious infectious diseases in hospitalized    patients. Diagn Microbiol Infect Dis 1998; 31: 473-7.         [ Links ]Correspondencia a:        Sergio Mella Montecinos        Laboratorio de Antibióticos,        Departamento de Microbiología,        Facultad de Ciencias Biológicas        Casilla 160-C, Concepción        E-mail: pignatio@ctcinternet.cl  

89.- MOELLERING R C. A novel antimicrobial    agent joins the battle against resistant bacteria. Ann Intern Med 1999; 130:    155-7.         [ Links ]90.- WILSON W R. The role of fourth-generation    cephalosporins in the treatment of serious infectious diseases in hospitalized    patients. Diagn Microbiol Infect Dis 1998; 31: 473-7.         [ Links ]Correspondencia a:        Sergio Mella Montecinos        Laboratorio de Antibióticos,        Departamento de Microbiología,        Facultad de Ciencias Biológicas        Casilla 160-C, Concepción        E-mail: pignatio@ctcinternet.cl  

90.- WILSON W R. The role of fourth-generation    cephalosporins in the treatment of serious infectious diseases in hospitalized    patients. Diagn Microbiol Infect Dis 1998; 31: 473-7.         [ Links ]Correspondencia a:        Sergio Mella Montecinos        Laboratorio de Antibióticos,        Departamento de Microbiología,        Facultad de Ciencias Biológicas        Casilla 160-C, Concepción        E-mail: pignatio@ctcinternet.cl  

Correspondencia a:        Sergio Mella Montecinos        Laboratorio de Antibióticos,        Departamento de Microbiología,        Facultad de Ciencias Biológicas        Casilla 160-C, Concepción        E-mail: pignatio@ctcinternet.cl 